<SEC-DOCUMENT>0000719135-23-000018.txt : 20230316
<SEC-HEADER>0000719135-23-000018.hdr.sgml : 20230316
<ACCEPTANCE-DATETIME>20230316160727
ACCESSION NUMBER:		0000719135-23-000018
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230316
DATE AS OF CHANGE:		20230316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apyx Medical Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		23738810

	BUSINESS ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760
		BUSINESS PHONE:		7273842323

	MAIL ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL Corp
		DATE OF NAME CHANGE:	20150319

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>apyx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:45c174b4-24e6-4af0-9ca8-997a51f8c128,g:9f6ae534-5ac4-415d-9362-3e1615bb09a1,d:73dfbc4a18db4511aef7bcb1e0418d6c--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:apyx="http://apyxmedical.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>apyx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityCentralIndexKey" id="f-30">0000719135</ix:nonNumeric><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="f-32">FY</ix:nonNumeric><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="f-33">2022</ix:nonNumeric><ix:nonNumeric contextRef="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-617">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="apyx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e23c6c6eda44beb4d3b5fec9263660_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ife4bcfcbe5424292ba030a02e7623b76_I20230315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia7082c9220d542aea74c20a8d84ddd01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e0b82b58654112a567e39aa1802734_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bae49cc66e64b74871c5922613110b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0719a3bd71c14176a650c4eb12985506_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a6edda2d6904896afa5d78839163c76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib406169147a6431dbc30a2558b1f5e27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i295652f4d94541d6bfe4a8724a96ea47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23cc21664d6348d5bb8761b3ca26250d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f0820c833a4d97a42d7bf8f8ef0251_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87632d688d4749c9803b3fcc53b01ce8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b220174f25b49019af92cabbeeaab3c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa2eb62abf14f7192ce12f735e12a77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758630662d83465d81b8137958c8cefc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a54ae736e074ebfb7dd790dda19e87f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee3b5a980ce4da3a2b821cfef923265_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i160d1cf15ee840e19f82d1cb22f0d5e8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387665639f6d4372866cc35427b6f229_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76906bbc37b643fb86fb3fd07b5d57d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id796f312650b4349a1f87ceaf7050569_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7ebb24b75346f1927c12e624da2d6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08c1ccf4264f41de9fa4a85ef430cc4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d05d6cf479e4b08b903d62cabfaf1b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d0bcee5be54a1bb6f172bf7c4ee059_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f94b6a4a7043f7b1bba426285e2789_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id973048cfe784ebca10458b24c0549da_D20221122-20221122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apyx:ShelfRegistrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4f6946432a43cc9388c670091e059e_D20221122-20221122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apyx:AtTheMarketFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9623247cdf6a40419d4a2b011f00d8ed_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i498926f26c67490999cf1e6f231404e1_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd920217a5774a4a8e99a083c1cb188c_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie91aea3453ae4206b00854b54ccdde12_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fbd4462461f48afb157563bd14c45a5_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i982284b9ef6f4f6f9d69822b5e02cff9_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-14</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf73cd58c774543acd7ca829d302f18_D20230119-20230119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-19</xbrli:startDate><xbrli:endDate>2023-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic3257cbd5e38423bac3cb15f13f803cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ApyxSYMedicalDevicesNingboCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7654b3f92f4f47c7a70f057fb31c8385_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieabcc8e7335642cb80a3d0784277b499_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7cfe454f7084225b0b55f3a129f958b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1b946daaf54d3297203c790f0eaf01_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9f29492d5a4b14a57cb6b526e5dfe3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b3e3ec5679411f8dd7d36415a88d70_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5b5a0b0ccd476e8cc706006cc8fa2e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ecb32d40a164cc78a526b05c7c1ff9f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c33358a7584267bc50bbb56019e99c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3bf0f938d834033b089a461be19a891_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:RenuvionJPlasmaGeneratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa934ffbea294e0fac514a7ff600cbbd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:MountingFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80078dd0c8b24caca7d3320de6bd5594_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:AccessoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b00095642c4b108229e13776c6580c_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd4fe74bd604c1db72d55317651b6d4_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa166e3072441a1a7435fde8c995859_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab43910064884237bbdef4ac6cc8ff44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3f56438b0549d9bb1816cb85ae9d4f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bcfaba8f0c645ee95bc37c4c4f557bc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3682736d9142f6ac1dda33e04b7f44_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33cd0694a0974259aa4da54d953aa393_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e47e5bd233347f190ad5ea24579801f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e0bc92d62a40c4b1273fbafc570bd2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5ca601b6594ace8b084574b85670b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56987d7ae3fb47dfaaf61b0612cb8a6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf70880d8834a4ea7a3ff7705a7d5e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf54c2e8062e464a943af7a1cc6f702e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292d860f0b124b10b47265b193979452_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bcfa1867b9c4a31a3709fe8a05bbe58_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb15fe17f8554f4bb5cb43cfef473c00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10b4e8b0d165454996fdf3396b1c0d64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id12249f705534e21b3e97868de6b1157_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90034014d4ac40d6b47f2c9dfd2b0b6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2d3c40f1484004855a884bc75b810d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c1dff9d0dbb4b90aef7333e20bb5fb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b3ec8b01964331aded480dad14486f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68358e6c1c414942ab2b1cacdda282a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i243c730de3e94d3283669d4a2661af4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce8494d2834491ab35f3664a41429db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa25d872e0d140a98af126a2c508757b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>apyx:lease</xbrli:measure></xbrli:unit><xbrli:context id="ie2aaebfd6e5041e3b8fade9ae7be2f4c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad2fb842f9454872b733d0f3ea008372_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if873b957ef9a452fbbc6e871b2410716_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c65c91210b4634aa8886aa2c04c687_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be8be05786644b587f7269db8612ba8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bd31e839574eb0b58cd8ec4b423216_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bafa9f247264d98b3a5973a8aa85489_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81985ec077fa472193067684bf28ef76_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3517b2fe5b464ec5ab2cb6fedcd9c77d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20512693f6584e7d82c03a312e6156ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aae6976833242b1b30c6676851c9194_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b182548e09413c8f592eb9c29abd89_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a58968298ce4c70ab56e29d0ce9450d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ef0e96305c24e7297840166aa515f96_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a0b18b016bd448eabc6ee7bdd802e0b_D20230101-20230316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978115ab316f4e03b88b250dc52320f6_I20230316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8015e0424ea1487ba240da801ce050f6_I20230316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870ddbfe09ce44fab9950cf2896a4dfe_I20230316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba71a7789d3e40e99df5af434f95f621_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:LargestCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1a97606daa4ceba9e7e3f4025e9194_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:TwoLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">apyx:AccountsReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445e51d03e01407ab9b5e970e37bb25c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:TwoLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">apyx:AccountsReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4cb62a47674f069376423c04bbf511_I20011231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2001ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2001-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce22e9e74ae4aad81ea9bf903e52593_I20071030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2003ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853b05ef16534eea839dc217dc64ae1e_I20120731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandTwelveShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2118a02b53544ed902dfa41da2fb932_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandTwelveShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dd72154e8a84a13ba2ec410056e0cc3_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a40b61b75e4a1da2703881874d03b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb85bfecc9fe411fbf5543ebcc203676_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2017ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if744468335d24182b13e02e0c5cbee45_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2017ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac91df8b60954d69a9e1632838aa1f72_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2019ShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib635cac0c9b846c38ee05d5e5de8a30e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2019ShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b00dca027564cc4a6278d01e014e129_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2021ShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i627345abf94741d0b8653a012a895db1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2021ShareIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idba9e20874ac40928de8555b5779b796_I20230111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54189c6eb13741cab646fd61dc525b97_D20230111-20230111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-11</xbrli:startDate><xbrli:endDate>2023-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05944548e154442b75796c157713f6b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d89fb15b914a8b9464e4d4f665063b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>apyx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i94da9825cefa47e085dc8967533353fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec7daf90e27a450094b575521306a713_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3fd74d3ecc94c9d852ed481d8155c2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb3893cd8fd491f9f46c1f269d3f5e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd72b9e18204c609c5668ac31713394_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide55cc7e04aa4a9dbf8cb858b7ceafaa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b469a871d414d41b9f05c65d751b0f2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868b6761ce074d338f4b5ce301df99d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee6627e384748dd93f7c235043736aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d35bf44ac044d9b818e2795485ffad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf38b5907d248938c29ae1623e0a4ae_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="numberofmonthlypayment"><xbrli:measure>apyx:numberOfMonthlyPayment</xbrli:measure></xbrli:unit><xbrli:context id="i6462edbcc6f3498fb5595ceca9c9b20c_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd50214c28b1419d87380a2edcf8c85e_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8c189ae54b4398bbe43a8016d14d18_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ace2066c844d0eb08a5d4455fd34f1_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37bf520b9b2c4b23b71810b3dd058fcf_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d6f70a7eab414799e5833f411483ba_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ebe1df213944e88b24cf4d7fc508cf9_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic06bbd8e6458436597927a368cb238b8_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if422168e879e462b8d0dc783bdd44842_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67955df49b104c96886c90aa72882ab9_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b8d9c682c84508b0bc8b27676bfeda_I20230314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-14</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_1"></div><div style="min-height:31.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.136%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the fiscal year ended </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">or</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from _____ to _____</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityFileNumber" id="f-6">0-12183</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:114pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="apyx-20221231_g1.jpg" alt="apyx-20221231_g1.jpg" style="height:145px;margin-bottom:5pt;vertical-align:text-bottom;width:223px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityRegistrantName" id="f-7">APYX MEDICAL CORPORATION</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="f-9">11-2644611</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="f-10">5115 Ulmerton Road</ix:nonNumeric>, <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="f-11">Clearwater</ix:nonNumeric>, <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="f-12">FL</ix:nonNumeric> <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="f-13">33760</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:CityAreaCode" id="f-14">727</ix:nonNumeric>) <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:LocalPhoneNumber" id="f-15">384-2323</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Issuer&#8217;s telephone number)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:31.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each Exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:Security12bTitle" id="f-16">Common Stock, $.001 Par Value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:TradingSymbol" id="f-17">APYX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered under Section 12(g) of the Exchange Act: None</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act (Check one):</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#253;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#253;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has &#64257;led a report on and attestation to its management&#8217;s assessment of the e&#64256;ectiveness of its internal control over &#64257;nancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting &#64257;rm that prepared or issued its audit report.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="f-26">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">&#253;</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The aggregate market value of the common stock held by non-affiliates and non-voting equity held by non-affiliates computed by reference to the price at which the common stock was last sold, or the average bid and asked prices of such common stock as of June 30, 2022, the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="ie8e23c6c6eda44beb4d3b5fec9263660_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-28">202.1</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March 15</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, 20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">23, <ix:nonFraction unitRef="shares" contextRef="ife4bcfcbe5424292ba030a02e7623b76_I20230315" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-29">34,597,822</ix:nonFraction> sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">s of the registrant&#8217;s $.001 par value common stock were outstanding.</span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO ANNUAL REPORT ON FORM 10-K</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022 </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_16">Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_19">12</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_22">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_25">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_25">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_28">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_31">22</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_37">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_40">Reserved</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_40">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_43">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_46">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_46">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_49">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_49">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_130">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_130">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_133">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_133">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_136">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_136">68</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_142">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_142">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_145">Executive Compensation Discussion and Analysis</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_145">76</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_148">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_148">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_151">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_151">90</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_154">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_154">90</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_160">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_160">91</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_10"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Notes Regarding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included or incorporated by reference into this report, and from time to time may make in our public filings, press releases or other public statements, certain statements that may constitute forward-looking statements. These include without limitation those under &#8220;Business&#8221; in Part I, Item 1, &#8220;Risk Factors&#8221; in Part I, Item 1A, &#8220;Legal Proceedings&#8221; in Part I, Item 3 and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7. In addition, our management my make forward-looking statements to analysts, investors, representatives of the media and others. These forward-looking statements are not historical facts and represent only our beliefs regarding future events, many of which, by their nature, are inherently uncertain and beyond our control. We may, in some cases, use words such as &#8220;project&#8221;, &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;estimate&#8221;, &#8220;intend&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;potentially&#8221;, &#8220;may&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results to differ materially from those contained in any forward- looking statements made by us. Any such forward-looking statements are qualified by reference to the following cautionary statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements in this report are subject to a number of risks and uncertainties, some of which are beyond our control, including, among other things: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general economic, business or demographic conditions or trends in the U.S. or throughout the world or changes in the political environment, including changes in GDP, military and trade wars, interest rates, economic recession and inflation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain sufficient liquidity, meet current debt covenants, and preserve working capital in order to maintain operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to conclude a sufficient number of attractive growth projects, deploy growth capital in amounts consistent with our objectives in the prosecution of those and achieve targeted risk-adjusted returns on any growth project, including the continued commercialization of our Helium Plasma Technology;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory environment, including our ability to gain requisite approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and other governmental and regulatory bodies, both domestically and internationally, including the effects of the recent FDA Medical Device Safety Communication regarding an emerging safety signal of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to estimate compliance costs, comply with any changes thereto, rates implemented by regulators, and our relationships and rights under, and contracts with, governmental agencies and authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions or other extraordinary or force majeure events and the ability to insure against losses resulting from such events or disruptions, including disruptions caused by COVID-19 or other global pandemics;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sudden or extreme volatility in commodity prices and availability, including supply chain disruptions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in competitive dynamics affecting our business and the medical device industry as a whole;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">technological innovations leading to increased competition in the medical device industry;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in healthcare policy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to make alternate arrangements to account for any disruptions or shutdowns that may affect suppliers&#8217; facilities or the operations upon which our business is dependent;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued aggressive EPA state regulation of Ethylene oxide sterilization (EtO) commercial plants resulting in additional plant closures, leading to a reduced availability of our handpieces, which are commercially sterilized;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement operating and internal growth strategies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">environmental risks, including the impact of climate change and weather conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of weather events, including potentially hurricanes, tornadoes and/or seasonal extremes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unplanned outages and/or failures of technical and mechanical systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity breaches impacting critical systems or data;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">work interruptions or other labor stoppages;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our actual results, performance, prospects or opportunities could differ materially from those expressed in or implied by the forward-looking statements. A description of risks that could cause our actual results to differ appears under the caption &#8220;Risk Factors&#8221; in Part I, Item 1A and elsewhere in this report. It is not possible to predict or identify all risk factors and you should not consider that description to be a complete discussion of all potential risks or uncertainties that could cause actual results to differ.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements. The forward-looking events discussed in this report may not occur. These forward-looking statements are made as of the date of this report. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should, however, consult further disclosures we may make in future filings with the Securities and Exchange Commission. Past performance is not an indicator of future results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_16"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company&#8221;, &#8220;Apyx Medical&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including our Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Our primary focus is on the cosmetic surgery market where Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (&#8220;OEM&#8221;) agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our plan to accelerate and fully fund the development of our advanced energy business, with a focus in the cosmetic  surgery market, we sold our Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, we had and still have, some significant non-recurring discretionary expenditures associated with completing our multi-year marketing initiatives related to our dermal resurfacing and skin laxity clearances. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Safety Communication that warns consumers and health care providers against the use of our Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, we experienced slowed demand for the adoption of our Helium Plasma Technology. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for certain skin contraction procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, and July 21, 2022, the FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#174; Dermal handpiece, and the expanded indications for the Renuvion&#174; APR handpieces. The 510(k) clearance for the Renuvion&#174; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. The 510(k) clearance for the Renuvion&#174; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2023, we announced we had submitted a 510(k) premarket notification (&#8220;510(k) submission&#8221;) for the Renuvion APR Handpiece to the FDA, supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion&#8217;s indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expected that receiving the two clearances in 2022 would materially mitigate the financial effects of the Safety Communication in future periods, we continue to experience reduced demand for the adoption and utilization of our technology and we believe that this may have an adverse effect in future periods.  In 2023, we expect to deliver growth in global sales of our Advanced Energy products, fueled by strong execution on our commercial and regulatory objectives and improving generator demand trends as we move through fiscal 2023. We remain focused on maximizing our resources through prudent expense management and have recently implemented activities to eliminate certain operating expenses to improve cash flow, while preserving our capabilities as an organization. We also continue to actively evaluate all potential options to enhance our liquidity and financial condition.  </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of our sale of the Core business segment to Symmetry Surgical during 2018, we have incurred recurring net losses and cash outflows from operations and we anticipate that losses will continue in the near term. For the year ended December 31, 2022, we incurred an operating loss of $23.6&#160;million and used $20.3&#160;million of cash in operations. As of December 31, 2022, we had cash and cash equivalents of $10.2&#160;million. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of our consolidated financial statements, including in Part II, Item 8 of this Form 10-K.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date we have not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement see Note 20 of Notes to Consolidated Financial Statements in Part II, Item 8 of this report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. Upon the closing of the sale of the Property, we will enter into a lease agreement with the Purchaser, pursuant to which the Property will be leased back to us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement see Note 20 of Notes to Consolidated Financial Statements in Part II, Item 8 of this report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the our tax refunds were approved for substantially the amount recorded in our Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to focus our efforts to increase the adoption of our Advanced Energy technology and utilization of our handpieces by surgeons in the U.S. and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 60 countries. As of December 31, 2022, we had a direct sales force of 35 field-based selling professionals and utilized 3 independent sales agencies. We also had 4 sales managers. This selling organization is focused on the use of Renuvion&#174; and J-Plasma&#174; in the cosmetic and hospital surgical markets, supported by our global medical affairs team. This global team of clinical support specialists focuses on supporting our users to ensure optimal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcomes for their patients. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174; into surgeons' practices.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the global supply chain instability and inflationary cost increases, we continue to take action to minimize, as much as possible, any potential adverse impacts by working closely with our suppliers to closely monitor the availability of raw material components (i.e. semiconductors and plastics), lead times, and freight carrier availability. We expect global supply chain instability will continue to have an impact on our business, but to date that has not been material to our financial performance. The consequences of global supply chain instability, inflationary cost increases and the pandemic, and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly encourage investors to visit our website: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.apyxmedical.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to view the most current news and to review our filings with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Subsidiaries</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apyx Bulgaria, EOOD is a wholly owned limited liability company incorporated under Bulgarian law, located in Sofia, Bulgaria. It is engaged in the business of development and manufacturing of our advanced energy&#160;generators, as well as the manufacturing of our disposable handpieces and accessories, and development and manufacturing of OEM generators and related accessories. The facility also distributes products directly to customers in certain international markets and provides warranty and repair services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cosmetic surgery market is a special segment of the medical field which is involved in the restoration, reconstruction, or alteration of the human body so as to enhance the body&#8217;s appearance. The market for cosmetic surgery includes surgical, minimally invasive, and nonsurgical cosmetic procedures. This market is expected to have steady growth year-over-year and this growth is driven by social and cultural factors such as the influence of social media, peer pressure for appearance and beauty, and increasing disposable income. According to the recent International Society of Aesthetic Plastic Surgery (&#8220;ISAPS&#8221;) 2021 Global Survey report, liposicution procedures grew 24.8% year-over-year, and is now the number one aesthetic surgical procedure globally. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have sustainable, competitive advantages in the cosmetic surgery market for several reasons: our long history of developing unique energy devices to meet the needs of physicians, our unique Helium Plasma Technology,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our outstanding product quality supported by strong engineering and research and development capabilities, and the clinical support that our expanding global medical affairs team provides to our customers. We feel that our products and our strategy as a customer-centric aesthetic medical device manufacturer have, and will continue to improve, the lives of doctors and their patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our intellectual property that we have developed or acquired over the years including patents, trade secrets, technical innovations and various licensing agreements to provide our future growth and build our competitive position. We have been issued 40 patents in the United States and 28 foreign patents. We have 22 pending patent applications in the United States and 58 pending foreign applications. We have 9 U.S. registered trademarks, 5 international registered trademarks, and 4 pending international trademark applications. As we continue to expand our intellectual property portfolio, we believe it is critical for us to continue to invest in filing patent applications to protect our technology, inventions and improvements. However, we can </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">give no assurance that competitors will not infringe on our patent rights or otherwise create similar or non-infringing competing products that are technically patentable in their own right.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Suppliers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to producing the most technically advanced and highest quality products of their kind available on the market. We manufacture the majority of our products on our premises in Clearwater, Florida and at our facility located in Sofia, Bulgaria, both of which are certified under the ISO13485:2016 international quality standards and are subject to continuing regulation and routine inspections by the FDA and other regulatory agencies to ensure compliance with regulations relating to our quality management system, medical device complaint reporting, and adherence to FDA and other country restrictions on promotion and advertising. In addition, we are subject to regulations under the Occupational Safety and Health Act, the Environmental Protection Act and other federal, state and local regulations, as well as international laws and regulations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work closely with our suppliers to ensure that our raw material inventory (i.e., semiconductors and plastics) needs are met, while maintaining high quality and reliability. To date, we have experienced some delays in locating and obtaining the materials necessary to fulfill our production requirements, but such delays have not caused a meaningful backlog of sales orders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, it is possible that a prolonged disruption to the global supply chain could cause a backlog of sales orders in the future. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work to find other sources of supply, where feasible, and have </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expedited</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the shipments of certain raw material items to adequately maintain our production and safety stock levels, resulting in higher shipping costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also experienced some impact on the purchase prices of our raw materials due to inflation, global inventory shortages. and increased demand across the manufacturing sector.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain collaborative arrangements with three foreign suppliers, including our contract component manufacturer located in Ningbo, China, under which we request the development of certain products which we purchase pursuant to purchase orders. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purchase order commitments are never more than one year in duration and are supported by our sales forecasts. To our knowledge, none of the products that we source are through entities manufacturing in the Xinjiang province.   </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During late 2019, we entered into a joint venture with our Chinese supplier to establish a foundation for the manufacturing and sale of our Advanced Energy products into the Chinese market. As of the date of this report, the joint venture has not commenced its principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Backlog</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of unshipped factory orders is not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sustainability</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have created a strong environmental, social and governance (&#8220;ESG&#8221;) structure by introducing a cross-functional ESG team which has been working with senior management, our board, and other stakeholders to develop an ESG framework that is aligned with our corporate mission, vision and values. Our ESG initiatives are sponsored by our CEO and CFO, and includes a steering committee comprised of all members of the executive management team as well as some mid-level managers in certain areas such as R&amp;D, Regulatory and Quality. In July 2022, we published our first ESG report aligned with the Sustainability Accounting Standards Board (&#8220;SASB&#8221;) Medical Equipment industry standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part of our culture is to give back and support the communities and people around us.  In 2022, we engaged in both employee volunteer and financial support in the areas of education and the environment.  Such initiatives included the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Week-long high school internship\shadowing program for students interested in the field of engineering;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hosting a group of 25 local students participating in their school&#8217;s STEM program at our manufacturing facility </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employee participation in a local beach clean up event</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Donation of supplies to a local elementary school and to support those impacted by Hurricane Ian</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Local food drive donations as well as gifts for less fortunate children during the holidays</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Several financial contributions and sponsorships to various non-profit organizations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Human Capital Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had 276 full-time employees world-wide, of whom 4 were executive officers, 47 were supervisory personnel, 36 were sales personnel and 189 were technical support, administrative and production employees. None of our current employees are covered by a collective bargaining agreement and we have never experienced a work stoppage. During 2022, our voluntary employee turnover rate was approximately 13.6%.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Equity and Inclusion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">We have worked to create a culture that fosters employee engagement, where diverse talent is productive and passionate about the work they do.  We continuously focus our efforts on cultivating and enhancing our working culture that embraces equality, diversity and inclusion. Currently, over half of our global workforce is represented by women, including half of our executive management team.  In addition, in the U.S., approximately 36% of our employees are from minority ethnic\racial groups.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recruitment, Training and Development</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of our growth strategy largely depends on our ability to hire, train, and retain our workforce. Our recruitment practices include cross-functional departmental interviewing, allowing for the best fit not just for a specific department, but the Company as a whole.  We also ensure all of our employees are fully trained and competent for the role for which they were hired. In addition, we train our sales professionals to thoroughly understand our Helium Plasma Technology and the marketplace in which we compete, including how our technologies can increase our customer's revenue and the results they are able to achieve for their patients. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs are designed to align the compensation of our employees with our performance, and to provide the proper incentives to attract, retain and motivate them to achieve superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance, specifically:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We offer wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our compensation practices are fair and equitable across all levels of the organization, from our Executive Officers to our hourly employees;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We work with both local and nationally recognized outside compensation and benefits consulting firms to independently evaluate the effectiveness of our executive and non-executive compensation and benefit programs and to provide benchmarking against our peers within our industry; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may provide our non-hourly U.S-based employees long term incentives in the form of stock options to help foster a culture of ownership, and empower individuals to drive continuous improvements to increase stockholder value; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Annual increases and incentive compensation are based on merit, which is communicated to employees at the time of hiring and documented through our talent management process as part of our annual review procedures and upon internal transfer and/or promotion; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All employees are eligible for health insurance, paid and unpaid leaves, a retirement plan, and life and disability/accident coverage. We also offer a variety of voluntary benefits that allow employees to select the options that meet their needs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Culture </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#243f60;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a solution focused company in the cosmetic surgery market and the broader medical technology sector, and endeavor to provide unique and creative solutions for the ever-changing needs of our physician customers and their patients.</span><span style="color:#243f60;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission and vision are to be the world&#8217;s leading innovator in unique energy solutions that continually reshape what&#8217;s possible in cosmetic and medical procedures through innovative solutions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shared values of transforming physicians&#8217; and their patients&#8217; lives, acting with integrity, and driving innovation, form the core of our company's culture. We articulate the qualities associated with these behaviors through our three Core Values:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Trailblazers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We are passionate about the work we do. We energetically pursue our goals, aim higher, and reach further. When we encounter setbacks, we see opportunities for innovation and improvement. When we clear a business hurdle, we celebrate, and then raise the bar.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;padding-left:14.5pt">Challengers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">We speak up and are not afraid to question, to reimagine, to think differently. We innovate to break the status quo, and create new possibilities, for our customers and for our company.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Team Players</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We respect everyone&#8217;s contribution and are absolutely committed to elevating our fellow team members, and our customers and their patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Health and Safety  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health and safety of our employees is our highest priority, and this is consistent with our operating philosophy. We provide a safe and healthy workplace for employees consistent with the requirements of the Occupational Safety and Health Act (&#8220;OSHA&#8221;). We aim to prevent any employee, visitor, customer, or person from being subjected to any health or safety risks. We provide annual training and expect our employees to diligently work towards the maintenance of safe and healthy working conditions, adhere to proper operating practices and procedures designed to prevent injury and illness, and conscientiously observe all safety regulations. Our commitment to the safety and well-being of our employees is shown through safety walkthroughs by our Safety Committee, as well as having an open-door policy, allowing employees to feel comfortable bringing up any safety concerns to management or Human Resources.  Identified concerns and potential hazards are addressed immediately, which is evidenced by our low safety incident rate quarter over quarter. In 2022, we had no lost time accidents.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Two Business Segments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. &#8220;Corporate &amp; Other&#8221; includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regards to these operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur OEM segment contributed 17.3% of our consolidated total revenue and our Advanced Energy segment contributed 82.7% of our consolidated total revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advanced Energy Segment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product portfolio consists of our Helium Plasma Technology that is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Our primary focus is on the cosmetic surgery market where Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. This technology has FDA clearance, CE mark, and clearance for sale in multiple other countries and is generally indicated for the cutting, coagulation and ablation of soft tissue. The system consists of an electrosurgical generator unit (&#8220;ESU&#8221;), a handpiece and a supply of helium gas. The proprietary radiofrequency (&#8220;RF&#8221;) energy is delivered to the handpiece by the ESU and used to energize an electrode. When helium gas passes over the energized electrode, helium plasma is generated which allows for conduction of the RF energy from the electrode to the patient in the form of a precise helium plasma beam. The energy delivered to the patient via the helium plasma beam is unique in that it allows for the application of heat to tissue in a way that is not possible with traditional monopolar or bipolar technologies. This technology has been the subject of over ninety peer-reviewed journal articles, book chapters, abstracts, and posters. It also continues to be the subject of numerous presentations at traditional and cosmetic surgery conferences around the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This technology initially received FDA clearance in 2012 and a CE mark in December 2014, which enables us to sell the product in the European Union. In 2014, we created and trained a direct sales force dedicated to sell this technology. In 2015, we continued the commercialization process for our Helium Plasma Technology with a multi-faceted strategy designed to accelerate adoption of the product. This strategy primarily involved deployment of a dedicated sales force, developing product line extensions and expanding the specialties in which this technology can become the &#8220;standard of care&#8221; for certain procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we continued our full-scale, global, commercialization efforts for Renuvion&#174; in the cosmetic and plastic surgery markets. As of December 31, 2022, we had a direct sales force of 35 field-based selling professionals and utilized 3 independent sales agencies. We also had 4 sales managers. This selling organization is focused on the use of Renuvion&#174; in the cosmetic surgery market, supported by our global medical affairs team.  This global team of clinical support specialists focuses on supporting our users to ensure optimal outcomes for their patients. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174; into physicians&#8217; practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2015 through 2022, we launched numerous new extensions to our Helium Plasma product lines in an effort to target new surgical procedures, users, and markets. Most notably, throughout 2021, we continued our launch of our Renuvion&#174; Apyx Plasma RF handpieces (&#8220;APR&#8221;) around the world. These handpieces were designed with improved ergonomics and usability for our Renuvion&#174; customers. As a result of our sales, marketing and product development initiatives, we have significantly increased the number of physicians using our Helium Plasma Technology by expanding usage to include the cosmetic surgery market in the U.S., and the cosmetic surgery market as well as the surgical oncology market outside the U.S. In late January 2023, we launched our recently FDA approved Apyx One Console in the US.  This is a multi-functional generator incorporating an advanced 3-in-1 energy system that enables plastic and cosmetic surgeons to utilize Renuvion technology, together with full monopolar and bipolar energy.  <br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key features of the Apyx One Console include adaptive and intuitive touch screens, procedural presets by body part, cloud connectivity, data sharing and logging, remote upgrade capabilities and system diagnostics, and an advanced gas system that measures and monitors gas volume and usage. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to assist us in leveraging our Helium Plasma Technology&#8217;s precision and effectiveness in multiple surgical specialties, we continue to utilize our Medical Advisory Board which currently consists of 5 members representing the plastic surgery, fascial plastic surgery, and cosmetic procedure specialties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial strategy in the U.S. and outside the U.S. is primarily focused on advancing the usage of Renuvion&#174; in the cosmetic surgery market. In some of our international markets, we continue to provide support to our customers who have adopted our J-Plasma&#174; technology for the hospital surgical market. We continue to develop a clinical and regulatory strategy, and corresponding marketing campaigns, to support our market focus. We also continue to expand the reach of our global medical affairs team in order to provide clinical support to our customers in all markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to make substantial investments in the development and marketing of our Renuvion&#174; technology for the long-term benefit of the Company and its stakeholders, and this may adversely affect our short-term operating performance and cash flows, particularly over the next 12 to 18 months. While we believe that these investments have the potential to generate additional revenues and profits in the future, there can be no assurance that our Helium Plasma Technology will continue to be successful or that such future revenues and profitability will be realized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we primarily sell our Renuvion&#174; products through our direct sales force to physicians, cosmetic surgery offices and surgical centers.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., all of our products are sold primarily through our distributor network.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Advanced Energy Products consist of our Helium Plasma Technology lines (Renuvion&#174; and J-Plasma&#174;). These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. RF energy is delivered to the handpiece by the generator and used to energize an electrode. When helium gas passes over the energized electrode, helium plasma is generated which allows for conduction of the RF energy from the electrode to the patient in the form of a precise helium plasma beam. The energy delivered to the patient via the helium plasma beam is unique in that it allows for the application of heat to tissue in a way that is not possible with traditional monopolar or bipolar technologies. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Helium Plasma Generator</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we did a limited launch of our Apyx Once Console in the U.S. in the fourth quarter of 2022, full commercial launch of the generator in the U.S. started in January 2023. Internationally, during 2022, we continued our launch of the Renuvion&#174; System 3 generator, to markets outside the U.S. This high frequency electrosurgical generator can be used for delivery of RF energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. This new generator was built for use with our Renuvion&#174; APR handpieces, and features enhanced capabilities such as a joule counter, capable of displaying energy delivered to the patient, and new Auto-Bipolar functionality, which expands the surgical capabilities of the system. These new product releases continue to expand the procedure base for our Helium Plasma Technology by providing surgeons with the tools they need to access additional anatomic locations and perform specific procedures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disposables Portfolio</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a variety of different hand pieces for open and laparoscopic procedures. The helium-based plasma generated from these devices has been shown to provide increased precision and control and cause less thermal damage to tissue than CO2 laser, argon plasma and RF energy products currently available on the market. The technology has a general indication and can be used for cutting, coagulating and ablating soft tissue. The advantages of helium plasma continue to be studied throughout the medical and scientific communities. We believe that cosmetic surgery applications are the primary area of opportunity for this technology. In 2020, we completed the launch of our new generation APR handpieces in the U.S. market. During 2021, we began to launch these new handpieces in our international markets, designed specifically for minimally invasive use, with improved ergonomics and safety features. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we are the only company with helium-based plasma products and two specific indications from the FDA. While the FDA Safety Notice did impact our sales, and there are RF-based competitors, argon plasma competitors, and CO2 laser competitors for our target market, we still believe our competitive position did not change in 2022.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA and Other Government Regulations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business is subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation and enforcement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to costly and complex U.S. and foreign laws and governmental regulations, and any adverse regulatory action may materially adversely affect the our financial condition and business operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the drug, device, and cosmetic industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise of broad regulatory powers by the FDA continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar trends are also evident in major markets outside of the U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new medical device regulatory framework and the new privacy regulations in Europe and in other countries are examples of such increased regulation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the European Union enacted the European Union Medical Device Regulation in May 2017 with an effective date of May 2021, which imposes stricter requirements for the marketing and sale of medical devices, including in the areas of clinical evaluation requirements, quality systems, labeling and post-market surveillance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as a result of the exit of the United Kingdom from the European Union (Brexit), new medical device regulations were released by the United Kingdom, which became effective January 1, 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A gap analysis against the prior Medical Device Directive (&#8220;MDD&#8221;), a compliance plan was implemented, and the plan is being executed for both the European Union and United Kingdom regulations to ensure compliance and minimize business disruption.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the Company&#8217;s may deem it advisable to initiate product recalls.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and regulatory agencies around the globe are also increasing their enforcement activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our medical devices are ineffective or pose an unreasonable health risk, the FDA could ban such products, detain or seize adulterated or misbranded products, order a recall, repair, replacement, or refund of such products, refuse to grant pending applications for marketing authorization or require certificates of foreign governments for exports, and/or require us to notify health professionals and others that the products present unreasonable risks of substantial harm to the public health. The FDA may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis or enjoin and/or restrain certain conduct resulting in violations of applicable law. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future clearances or approvals, and could result in a substantial modification to our business practices and operations. Equivalent enforcement mechanisms exist in different countries in which we conduct business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2022, the FDA posted a Safety Communication that warns consumers and health care providers against the use of our Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, we experienced slowed demand for the adoption of our Helium Plasma Technology. Throughout 2022, and continuing into 2023, we have been working closely with the FDA to gain clearances for the use of our products in various surgical applications, demonstrating our commitment to both safety and efficacy, supported by both clinical study and real-world data. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The costs of human healthcare have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the U.S., attention has been focused by states, regulatory agencies and congress on device prices and profits and programs that encourage doctors to recommend, use or purchase particular medical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">devices. Laws and regulations have been enacted to require adherence to strict compliance standards and prevent fraud and abuse in the healthcare industry. There is increased focus on interactions and financial relationships between healthcare companies and healthcare providers. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various transparency laws and regulations require disclosures of payments and other transfers of value made to physicians and teaching hospitals and, beginning with disclosures in 2022, to certain non-physician practitioners. Payers have become a more potent force in the marketplace and increased attention is being paid to medical device pricing, appropriate drug and medical device utilization and the quality and costs of healthcare generally.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, most of the Company&#8217;s products are not reimbursable by payers (including the US. Government) which alleviates some of the burden of reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nevertheless, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are committed to following all legal requirements, as well as company policies and procedures as it relates to our interactions with healthcare professionals. At all times, we will provide information to healthcare professionals that is truthful, not misleading, and consistent with our product labeling and supported by our data.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Medical Device Single Audit Program (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MDSAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">       </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The International Medical Device Regulators Forum (&#8220;IMDRF&#8221;) recognized that a global approach to auditing and monitoring the manufacturing of medical devices could improve their safety and oversight on an international scale. The IMDRF established a work group that developed specific documents to advance a MDSAP. The Medical Device Single Audit Program allowed MDSAP recognized Auditing Organizations to conduct a single regulatory audit of a medical device manufacturer to satisfy the relevant requirements of the regulatory authorities participating in the program. Today the regulatory authority members include the US, Australia, Brazil, Canada and Japan, official observers European Union and United Kingdom, and affiliates Argentina, Israel, South Korea, and Singapore. In February 2022, we underwent a successful annual MDSAP audit by our registrar GMED SAS. There were no observations related to safety or efficacy of our products noted during this MDSAP audit. The FDA accepts MDSAP audit reports as a substitute for routine Agency inspections.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Supply Chain Impact</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Company relies on global supply chains, and production and distribution processes, that are complex, are subject to increasing regulatory requirements, and may be faced with unexpected changes that may affect sourcing, supply and pricing of materials used in the Company&#8217;s products. These processes also are subject to complex and lengthy regulatory approvals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OEM Segment </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage our expertise in the design, development and manufacturing of electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for large, well-known medical device manufacturers through original equipment manufacturing (&#8220;OEM&#8221;) agreements, as well as start-up companies with the need for our energy-based designs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement with Symmetry Surgical in 2018, we entered into a Manufacturing and Supply Agreement for a ten-year term, whereby we will manufacture certain products and sell to them at agreed upon prices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue, costs and expenses resulting from this agreement are reported in our Consolidated Statements of Operations as a component of income or loss from operations of our OEM reporting segment. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_19"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. Risk Factors </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risks and uncertainties in the ordinary course of business, important risk factors that may affect us are discussed below. Additional risks not presently known to us, or that we currently believe are immaterial, may also significantly impact or impair our business operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Compliance Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Approval and Monitoring</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most countries where we sell medical devices subject our technologies to their own approval and other regulatory requirements regarding performance, safety, and quality. The global regulatory environment is increasingly unpredictable and stringent. Countries that did not have regulatory requirements for medical devices have established such requirements in recent years, and other countries have expanded, or plan to expand, their existing regulations. While there are efforts at some harmonization of global regulations, requirements continue to differ significantly among countries. We expect that as this global regulatory environment continues to evolve, it could impact the cost, the time needed to approve, and ultimately, our ability to maintain existing approvals or obtain future approvals for our products. Regulations of the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and other regulatory agencies in and outside the U.S. impose significant compliance and monitoring obligations on our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to costly and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the regulatory process for obtaining marketing clearance or approval for new products and new indications for existing products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations, and trial endpoints. Unfavorable or inconsistent clinical data from existing or future clinical trials, or the market&#8217;s or the FDA&#8217;s perception of these clinical data, may adversely impact our ability to obtain product approvals, our position in, and share of, the markets in which we participate. We cannot guarantee that we will be able to obtain or maintain marketing clearance for our new products or enhancements or modifications to existing products, and the failure to maintain approvals or obtain approval or clearance could have a material adverse effect on our business, results of operations, financial condition and cash flows. Even if we are able to obtain approval or clearance, it may:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant amount of time; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of considerable resources; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve rigorous clinical and pre-clinical testing, as well as increased post-market surveillance; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve modifications, repairs, corrections, or replacements of our products; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the proposed intended uses of our products. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2022, the FDA posted a Communication that warns consumers and health care providers against the use of our Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. We continue to work with the FDA towards securing 510(k) clearance for additional indications. We continue to evaluate what effects, if any, the Communication will continue to have on our results of operations, cash flows and financial position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for certain skin contraction procedures. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, and July 21, 2022, the FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#174; Dermal handpiece, and the expanded indications for the Renuvion&#174; APR handpieces. The 510(k) clearance for the Renuvion&#174; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. The 510(k) clearance for the Renuvion&#174; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2023, we announced we had submitted a 510(k) premarket notification (&#8220;510(k) submission&#8221;) for the Renuvion APR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Handpiece</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supported</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">real-world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evidence.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This 510(k) submission is intended to expand Renuvion&#8217;s indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction. There can be no assurance that we will receive such FDA clearance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, we continue to experience reduced demand for the adoption and utilization of our technology and we believe that this may have an adverse effect in future periods.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before and after a product is commercially released, we have ongoing responsibilities under the FDA, Health Canada, Australia, Brazil, EU, and other applicable world-wide government agency regulations. For instance, many of our processes and facilities, as well as those of our suppliers, are also subject to periodic audits to determine compliance with applicable regulations. The results of these audits can include major inspectional observations, warning letters, or other forms of enforcement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our medical products are ineffective or pose an unreasonable health risk, they could ban such medical products, determine that our products are adulterated or misbranded, order a recall, repair, replacement, correction, or refund of such products, refuse to grant pending pre-market clearances or approvals, refuse to issue export certificates for foreign governments, or require us to notify health professionals and others that the devices present unreasonable risks of substantial harm to the public health. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other non-U.S. government agencies may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis. The FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future pre-market clearances or approvals, and could result in a substantial modification to our business practices and operations. These potential consequences, as well as any adverse outcome from government investigations, could have a material adverse effect on our business, results of operations, financial condition, and cash flows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA has taken the position  that device manufacturers are prohibited from promoting their products other than for the uses and indications set forth in the cleared product labeling. Any failure to comply could subject us to significant civil or criminal exposure, administrative obligations and costs, other potential penalties from, and/or agreements with, the federal government. Governmental regulations worldwide have, and may continue to become, increasingly stringent and customary. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, a single regulatory approval process exists, and conformity with the legal requirements is represented by the CE Mark. To obtain a CE Mark, defined products must meet minimum standards of performance, safety, and quality (i.e., the essential requirements), and then, according to their classification, comply with one or more of a selection of conformity assessment routes. The competent authorities of the EU countries separately regulate the clinical research for medical devices and the market surveillance of products once they are placed on the market. A new Regulation (EU) 2017/745 on medical devices, or &#8220;EU MDR&#8221;, came into effect in May 2017, which imposes significant additional premarket and postmarket requirements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The EU MDR represents the first major changes to the EU medical device regulatory environment, has significantly raised the compliance bar for the medical device industry, and will cause significant changes to the regulatory obligations of manufacturers, importers and distributors involved in the medical device distribution chain. Classification has changed for some product categories, and strict new requirements have been imposed on clinical data, risk management, post market surveillance, and supplier management.  Penalties for regulatory non-compliance could be severe, including fines and revocation or suspension of a company&#8217;s business license, and criminal sanctions. The regulation initially provided a three-year implementation period to May 2020, but that timeline was delayed to May 2021 due to COVID-19 and its impact on audits and technical file review by Notified Bodies. After that time, medical devices marketed in the EU will require certification according to these new requirements, except for devices with valid CE certificates, issued pursuant to the Medical Device Directives before May 2020, which can be placed in the market until May 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outside of the EU, regulations vary significantly from country to country and are becoming increasingly stringent and country specific. Territories and countries around the world continue to develop their own unique regulatory requirements, and these individual governments are passing laws that enforce these new regulations, including imposing fees, to register products in their country.  The time and effort required to obtain approval to market products may be longer or shorter than that required in the U.S. or the EU. Certain European countries outside of the EU, and other countries around the world do not recognize the CE mark certification or FDA clearance/approval and have their own regulatory requirements to register and sell products in these territories. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry continues to be the subject of intense scrutiny and stringent regulation and the demand for green, sustainable products is rapidly increasing.  There are increasing requirements for efficient and accurate processes for hazardous substance handling, supplier disclosures, and regulatory reporting in order to comply with numerous global health and environmental regulatory requirements and restrictions, including but not limited to: </span></div><div style="margin-bottom:3.75pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">Restriction on Hazardous Substances (&#8220;RoHS&#8221;) Directive </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Packaging and Packing Waste Directive</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">REACH Regulation</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Proposition 65</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Hazardous Air Pollutants: Ethylene Oxide</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with existing and future environmental regulations may have an impact on the manufacturing and sterilization of our medical devices.  Environmental regulations in the U.S. and EU limit or prohibit the use of certain chemicals, substances and materials in the manufacture of our medical devices such as Prop 65 in California and others in the EU such as REACH, RoHS, and WEEE Directive.  With the current global concerns over climate change and the tangible effects human beings are having on the environment, there is no doubt that the amount of environmental legislation is primed to increase still further, with the EU being at the forefront of this movement. </span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethylene oxide (&#8220;EtO&#8221;) is used to sterilize approximately 50% of medical devices in the U.S.  While some alternative methods currently exist, potential device incompatibility issues exist with these alternatives.  The U.S. Environmental Protection Agency (EPA) classified EtO as a carcinogen after linking it to cases of breast cancer, lymphoma and leukemia. Currently, shortages due to current closures are not expected, but any additional commercial sterilization facility closures could result in shortages for certain devices.  Our devices are not currently impacted by these closures, however, it is unknown if the current EtO facilities utilized by Apyx Medical could be impacted in the future.</span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is closely monitoring the supply chain effects of closures and potential closures of certain facilities that use EtO to sterilize medical devices prior to their use, and, is concerned about the future availability of sterile medical devices and the potential for medical device shortages that might impact patient care. However, they do not have oversight authority over EtO emissions, which is within the purview of the EPA.</span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and those of certain third-party suppliers involve the use of substances subject to these laws and regulations, primarily those used in manufacturing and sterilization processes. If we or our suppliers violate these environmental laws and regulations, facilities could be shut down and violators could be fined, criminally charged or otherwise sanctioned. Furthermore, environmental laws outside of the U.S. are becoming more stringent, resulting in increased costs and compliance burdens. In addition, certain environmental laws assess liability on current or previous owners or operators of real property for the costs of investigation, removal or remediation of hazardous substances or materials at their properties or at properties which they have disposed of hazardous substances. In addition to cleanup actions brought by governmental authorities, private parties could bring personal injury or other claims due to the presence of, or exposure to, hazardous substances. The ultimate cost of site cleanup and timing of future cash outflows is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The costs of complying with current or future environmental protection and health and safety laws and regulations, or liabilities arising from past or future releases of, or exposures to, hazardous substances, may exceed our estimates, or have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Corruption Regulation</span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we grow our international presence and global operations, we will be increasingly exposed to statutes, anti-corruption trade policies, economic sanctions and other restrictions imposed by the United States and other foreign governments and organizations, including the U.S. Foreign Corrupt Practices Act, or the FCPA, and other federal statutes and regulations, including those established by the Office of Foreign Assets Control, or OFAC. In addition, other foreign statutes, such as the U.K. Bribery Act of 2010, or the Bribery Act, prohibits both domestic and international bribery, as well as bribery across both private and public sectors. </span></div><div style="margin-bottom:3.75pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented policies and procedures designed to ensure compliance by our directors, officers, employees, representatives, consultants and agents with the FCPA, OFAC restrictions, the Bribery Act and other export control, anti-corruption, anti-money-laundering and anti-terrorism laws and regulations, and require training of our employees, management team and our global distributors on an annual basis. However, there can be no assurance that our policies and procedures are or will be sufficient to prevent violations from occurring.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the FCPA, OFAC restrictions, the Bribery Act or other export control, anti-corruption, anti-money laundering and anti-terrorism laws or regulations may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could have a material adverse effect on our reputation, financial condition, and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture the majority of our products at our Clearwater, Florida and Sofia, Bulgaria facilities. Components, labor-intensive assemblies and sub-assemblies, and sterilization services are outsourced to third parties and produced to our specifications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also dependent on OEM customers who have no legal obligation to purchase products from us. Should such customers fail to give us purchase orders for products after development, our future business could be negatively affected. Furthermore, no assurance can be given that such customers will give sufficient high priority to our products. Finally, disagreements or disputes may arise between us and our customers, which could adversely affect production and sales of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have had a history of operating losses that have impacted our overall cash flows and may impact our ability to continue as a going concern. We anticipate that we may need to adjust our operating expenditures to be commensurate with our expected levels of revenue and/or raise additional capital to finance operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to our recurring net losses and the continued impact of the FDA Safety Communication on demand for the adoption and utilization of our technology, we may need to raise additional capital to fund our future operations. Our cash needs will depend on numerous factors, including our revenues, successful completion of our FDA product clearance activities, our continued ability to commercialize our advanced energy products, and our ability to reduce and control costs. If we are unable to secure such additional financing on terms that are acceptable to us, it will have a material adverse effect on our business, and we may have to limit operations in a manner inconsistent with our growth strategy. If additional funds are raised through the issuance of equity securities, it will be dilutive to our stockholders and could result in a decrease in our stock price. If we are unable to obtain the requisite amount of financing needed to fund our planned operations, it would have a material adverse effect on our business and ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:109%">Our indebtedness levels could impact our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to make payments on, and to refinance, our indebtedness will depend on our ability to generate cash from operations or other financings. Our ability to generate cash is subject to general economic, financial, competitive, regulatory, and other factors that are beyond our control. We may not generate sufficient funds to service our debt, meet our required debt covenants, or meet our business needs, such as funding working capital or the expansion of our operations. If we are unable to do so, we may be forced to take disadvantageous actions, including issuing additional shares of our stock, reducing spending on marketing, product development, reducing financing in the future for working capital, capital expenditures and general corporate purposes, or dedicating an unsustainable level of our cash flows from operations to the payment of principal and interest on our indebtedness. The creditors who hold our debt could also accelerate amounts due in the event that we trigger a default.  Any inability to generate sufficient cash flow or to refinance our indebtedness on favorable terms could have a material adverse effect on our financial condition.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:109%">The aesthetic equipment market is characterized by rapid innovation.  To compete effectively, we must develop and/or acquire new products, seek regulatory clearance, ensure adequate product supply, execute successful marketing, and identify new markets for our technology. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our industry is subject to continuous technological development and product innovation. If we do not continue to innovate and develop new products and applications, our competitive position will likely deteriorate as other companies successfully design and commercialize new products and applications or enhancements to our current products.  To grow in the future, we must continue to develop and/or acquire new and innovative aesthetic products and applications, identify new markets, and successfully launch the newly acquired or developed product offerings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development activities are an essential component of our efforts to develop new and innovative products. New and improved products play a critical role in our sales growth. We continue to place emphasis on the development of proprietary products, such as our Renuvion&#174;/J-Plasma&#174; technology, and product improvements to complement and expand our existing product lines. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and areas of development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we expect to continue making future investments to enable us to develop and market new technologies and products to further our strategic objectives and strengthen our existing business. We cannot guarantee that any of our previous or future investments in both facilities will be successful or that our new products will gain market acceptance. This would have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are successful in developing new, or enhancing our existing products, there are various circumstances that could prevent their successful commercialization.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize our products will depend on a number of factors, any of which could delay or prevent commercialization, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain the necessary regulatory clearances or approvals for expanded indications, new products, or product modifications;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical trials;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our product is determined to be ineffective or unsafe following approval, and is removed from the market or we are required to perform additional research and development to further prove the safety and effectiveness of the product before re-entry into the market;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if  the regulatory approvals/clearances of our new products are delayed or denied, or we are required to conduct further research and development of our products prior to receiving regulatory approval;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to build and maintain a sales and marketing group to successfully launch and sell our new products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we experience sudden or extreme volatility in commodity prices and availability, including supply chain disruptions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we are required to allocate available funds to litigation matters;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the needs of our physicians or their patients are not sufficiently met;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we are unable to manufacture the quantity of products needed, in accordance with quality manufacturing standards, to meet market demand;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from other products or technologies prevents or reduces market acceptance of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we do not have, and cannot obtain, the intellectual property rights needed to manufacture or market our products without infringing on another company&#8217;s patents; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we are unsuccessful in defending against patent infringement, or other intellectual property rights claims, that could be brought against us, our products or technologies;</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to successfully commercialize our products will have a material and adverse effect on the future growth of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our patents or other proprietary rights, or if we infringe on the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been issued 40 patents in the United States and 28 foreign patents. We have 22 pending patent applications in the United States and 58 pending foreign applications. Our intellectual property portfolio for our J-Plasma&#174;/Renuvion&#174; products continues to grow on an annual basis. We intend to continue to seek legal protection, primarily through patents, for our proprietary technology. Seeking patent protection is a lengthy and costly process and there can be no assurance that patents will be issued from any pending applications, or that any claims allowed from existing or pending patents will be sufficiently broad or strong to protect our proprietary technology. There is also no guarantee that any patents we hold will not be challenged, invalidated or circumvented, or that the patent rights granted will provide competitive advantages to us. Our competitors have developed, and may continue to develop and obtain, patents for technologies that are similar or superior to our technologies. In addition, the laws of foreign jurisdictions in which we develop, manufacture or sell our products may not protect our intellectual property rights to the same extent as the laws of the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse outcomes in current or future legal disputes regarding patent and other intellectual property rights could result in the loss of our intellectual property rights, subject us to significant liabilities to third parties, require us to seek licenses from third parties on terms that may not be reasonable or favorable to us, prevent us from manufacturing, importing or selling our products, or compel us to redesign our products to avoid infringing third parties&#8217; intellectual property. As a result, our product offerings may be delayed, and we may be unable to meet customers&#8217; requirements in a timely manner. Regardless of the merit of any related legal proceeding, we have incurred in the past, and may be required to incur in the future, substantial costs to prosecute, enforce or defend our intellectual property rights. Even in the absence of infringement by our products on third parties&#8217; intellectual property rights, or litigation related to trade secrets, we have elected in the past, and may in the future, elect to enter into settlements to avoid the costs and risks of protracted litigation and the diversion of resources and management&#8217;s attention. If the terms of settlements entered into with certain of our competitors are not observed or enforced, we may suffer further costs and risks. Any of these circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent, copyright, and trademark protection, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our consultants, vendors, and our former or current employees.  Despite these efforts, however, any of these parties may breach those agreements and disclose our trade secrets and other unpatented or unregistered proprietary information, and once disclosed, we are likely to lose trade secret protection. Monitoring unauthorized uses and disclosures of our trade secrets is difficult, and we cannot be certain that the steps we have taken to protect our intellectual property will be effective. In addition, our remedies may not be sufficient to cover our losses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been, and may in the future, become subject to litigation proceedings that could materially and adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business, including claims by current or former employees, distributors and competitors, and with respect to our products and product liability claims, lawsuits and proceedings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of legal actions relating to the use of our technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. In the opinion of management, the Company has meritorious defenses, and such claims are adequately covered by insurance, or are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of our policy, or if our insurance carriers disclaim coverage, or if we are unable to continue to obtain coverage on commercially reasonable terms, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated financial position, results of operations and cash flows (see below </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3:  Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on certain suppliers, subcontractors, and manufacturers for raw materials and other products and are vulnerable to fluctuations in the availability and price of such products and services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in the price, availability and quality of the raw materials (including plastics and other petroleum-based materials, along with semi-conductors and precious metals) and subcontracting services we use in our manufacturing could have a negative effect on our cost of sales and our ability to meet the demands of our customers. Inability to meet the demands of our customers could result in the loss of future sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the costs to manufacture our products depend in part on the market prices of the raw materials used to produce them. We may not be able to pass along to our customers all or a portion of our higher costs of raw materials due to competitive and market pressures, which could decrease our earnings and profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborative arrangements with three key foreign suppliers under which we request the development of certain items and components, which we purchase pursuant to purchase orders. Our purchase order commitments are never more than one year in duration and are supported by our sales forecasts. The majority of our raw materials are purchased from sole-source suppliers. While we believe we could ultimately procure other sources for these components, should we experience any significant disruptions in this key supply chain, there are no assurances that we could do so in a timely manner which could render us unable to meet the demands of our customers, resulting in a material and adverse effect on our business and results of operations.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facilities are located in Clearwater, Florida and Sofia, Bulgaria and could be affected due to multiple weather risks, including risks to our Florida facility from hurricanes and similar phenomena.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facilities are located in Clearwater, Florida and Sofia, Bulgaria and could be affected by multiple weather risks, most notably hurricanes in Clearwater, Florida. Although we carry property and casualty insurance and business interruption insurance, future possible disruptions of operations or damage to property, plant and equipment due to hurricanes or other weather risks could result in impaired production and affect our ability to meet our commitments to our customers and impair important business relationships, the loss of which could adversely affect our operations and profitability. We do, however, maintain a backup power source at our Clearwater facility, are working to establish deeper redundancies between both facilities, and have a disaster recovery plan in place to help mitigate this risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Management and Product Liability </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends on the quality of our products, and we have global processes, procedures and programs that are intended to help us maintain the highest possible level of quality.  We operate in an industry susceptible to significant product liability claims; these claims may be brought by individuals seeking relief on their own behalf or purporting to represent a class.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality problems and product liability claims could lead to recalls or safety alerts, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div><span><br/></span></div><div style="margin-bottom:3.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality is extremely important to us and our customers due to the impact on patients, and the serious and potentially costly consequences of product failure. Our business exposes us to potential product liability risks that are inherent in the design, manufacture, and marketing of medical devices. If they were to occur, component failures, manufacturing nonconformances, design defects, off-label use, or inadequate disclosure of product-related risks or product related information, could result in an unsafe condition, injury to, or even death of, a patient. These problems could lead to recall or issuance of safety notices relating to our products and could result in product liability claims and lawsuits, including class actions. Further, we may be exposed to unpredictable or accelerated changes in demand for certain of our products in connection with COVID-19, and its related impacts could impact production of products that could increase the risk of regulatory enforcement actions, product defects or related claims, as well as adversely impact our customer relationships and reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The energy-based medical device industry in the aesthetics market is highly competitive and we may be unable to compete effectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The energy-based medical device industry for the aesthetics market is highly competitive. Many competitors in this industry are well-established, do a substantially greater amount of business, and have greater financial resources and facilities than we do.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested and continue to invest, substantial resources to develop and monetize our Renuvion&#174; technology into the cosmetic surgery market. We believe we must continue to innovate and develop new applications for our products and obtain new indications for use in order to differentiate ourselves and stay competitive. If we are unable to gain acceptance of our technology in the marketplace, or obtain new indications for use, our business and results of operations and cash flows may be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part of our strategy depends on developing strong working relationships with key plastic surgeons, cosmetic physicians and other healthcare professionals.  The guidance we get from these relationships is important from both a commercialization strategy and product development standpoint.  Without establishing and maintaining these relationships globally, the development and commercialization of our products could suffer which could have a material adverse impact on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If there is not sufficient consumer demand for the procedures performed with our products, surgeon demand for our products could be inhibited, resulting in unfavorable operating results and reduced growth potential. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued expansion of the global market for aesthetic procedures is a material assumption of our business strategy. The procedures performed using our products are elective procedures not reimbursable through government or private health insurance, with the costs borne by the patient. The decision to utilize our products may therefore be influenced by a number of factors, including:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consumer disposable income and access to consumer credit, which as a result of an unstable economy, may be &#160;&#160;&#160;&#160;significantly impacted; </span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, safety and effectiveness of alternative treatments;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of our direct to consumer sales and marketing efforts; and</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the education of our customers and their patients on the benefits and uses of our products, compared to competitors&#8217; products and technologies. </span></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, as a result of these factors, there is not sufficient demand for the procedures performed with our products, customer demand could be reduced, which could have a material adverse effect on our business, financial condition, revenue and result of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our stock has been and may continue to be highly volatile.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on The NASDAQ Stock Market LLC under the ticker symbol &#8220;APYX&#8221;. The market price of our stock has been, and may continue to be, highly volatile and announcements by us or by third parties may have a significant impact on our stock price. These announcements may include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our listing status on the The NASDAQ Stock Market LLC;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our operating results falling below the expectations of public market analysts and investors;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments in our relationships with or developments affecting our major customers;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negative regulatory action or regulatory non-approval with respect to our new products;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">government regulation, governmental investigations, or audits related to us or to our products;</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments related to our patents or other proprietary rights or those of our competitors and</span></div><div style="padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the position of securities analysts with respect to our stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market has from time-to-time experienced extreme price and volume fluctuations, which have particularly affected the market prices for the medical technology sector companies, and which have often been unrelated to their operating performance. These broad market fluctuations may adversely affect the market price of our common stock. In addition, future sales by our security holders may lower the price of our common stock, which could result in losses to our stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no present intention to pay dividends on our common stock and, even if we change that policy, we may be unable to pay dividends on it. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not anticipate paying any dividends on our common stock in the foreseeable future, and we are subject to restrictions on our ability to pay dividends pursuant to our credit agreement executed in February 2023. We currently intend to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retain future earnings, if any, to finance operations and invest in our business. Any declaration and payment of future dividends to holders of our common stock will be at the discretion of our board of directors and will depend on many factors, including our financial condition, earnings, capital requirements, level of indebtedness, statutory and contractual restrictions applying to the payment of dividends, and other considerations that our board of directors deems relevant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we change that policy and commence paying dividends, we will not be obligated to continue paying those dividends, and our stockholders will not be guaranteed, or have contractual or other rights, to receive dividends. If we commence paying dividends in the future, our board of directors may decide, at its discretion, at any time, to decrease the number of dividends, otherwise modify or repeal the dividend policy or discontinue entirely the payment of dividends. Under Delaware law, our board of directors may not authorize the payment of a dividend unless it is paid out of our statutory surplus.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of equity through our shelf registration, as well as the exercise of options issued by us will dilute the ownership interest of existing stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, our outstanding stock options to our employees, officers, directors and consultants amounted to  6,520,444 shares of our common stock, representing approximately 18.8% of our outstanding common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of additional equity through our shelf registration or through the exercise of some or all of our stock options will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon such conversion or exercise could adversely affect prevailing market prices of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may, in the future, identify deficiencies in internal controls over financial reporting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have concluded that, as of December 31, 2022, our disclosure and reporting controls were effective as included in Part II, Item 9A of this Form 10-K, there can be no assurance that future control deficiencies or material weaknesses will not be identified.  If we do identify additional material weaknesses in our internal controls over financial reporting in the future, our ability to analyze, record and report financial information free of material misstatements, and to prepare our financial statements within the time periods specified by the rules and forms of the SEC, may likely be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our management team and other key personnel, and we may lose key personnel or fail to attract, train, and retain other talented personnel.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on the skills, working relationships, and continued services of key personnel, including our experienced management team.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to achieve our strategic operating objectives depends on our ability to identify, hire, train, and retain qualified individuals throughout the organization. We compete with other companies both within and outside of our industry for talented personnel, and we may lose key personnel or fail to attract, train, develop, and retain other talented personnel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such loss or failure could adversely affect our sales, operating results, and financial condition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are at risk of being the victim of a cyber-attack or a security breach that may expose confidential customer, product and Company data or compromise our internal IT infrastructure.  This could lead to liabilities resulting from failure to comply with US and foreign data security and privacy regulations and negative impacts to our business operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We store in our computer systems and network various elements of data and information related to our customers, products and company that could be compromised as the result of a cyber-attack or security breach.   If an individual or group of individuals, including a Company employee, were to compromise confidential information, or if customer confidential information is inappropriately disclosed due to a security breach of our computer systems, system failures or otherwise, we may face substantial liabilities or incur penalties in connection with any violation of applicable privacy laws or regulations.   We also rely heavily on our internal systems, network and data.  To date, we have not had any breaches against our systems and network, and we obtain cyber security insurance coverage on an annual basis.  However, our inability to properly scale IT security levels as our business grows, or any future attacks on our IT infrastructure could have a significant impact on our daily manufacturing and customer service functions which could result in a material adverse impact on our financial results, potentially in excess of our current coverage limits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is dependent on the security of our IT networks and those of our customers. Internal or external attacks on any of those could disrupt the normal operations of our engagements and impede our ability to provide critical services to our customers, thereby subjecting us to liability under our contracts. Additionally, our business involves the use, storage and transmission of information about our employees, our customers and clients of our customers. While we take measures to protect the security of, and unauthorized access to, our systems, as well as the privacy of personal and proprietary information, it is possible that our security controls over our systems, as well as other security practices we follow or those systems of our customers into which we operate and rely upon, may not prevent the improper access to or disclosure of personally identifiable or proprietary information. Such disclosure could harm our reputation and subject us to liability under our contracts and laws that protect personal data, resulting in increased costs or loss of revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data privacy is subject to frequently changing rules and regulations, which sometimes conflict among the various jurisdictions and countries in which we operate and continue to develop in ways which we cannot predict. We are subject to U.S. federal and state laws regarding data privacy and security including Section 5 of the Federal Trade Commission Act, or FTC Act. We are also subject to foreign data privacy and security laws, including the Global Data Protection Regulation, or GDPR, the European Union-wide legal framework to govern data collection, use and sharing and related consumer privacy rights. The GDPR includes significant penalties for non-compliance. Our failure to adhere to, or successfully implement processes in response to, changing regulatory requirements in this area could result in legal liability or impairment to our reputation in the marketplace, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse global and regional economic conditions could materially adversely affect the Company&#8217;s business, results of operations and financial condition. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy, tighter credit, higher interest rates, high unemployment and currency fluctuations can adversely impact consumer confidence and spending and materially adversely affect demand for the Company&#8217;s products and services. In addition, uncertainty about, or a decline in, global or regional economic conditions could have a significant impact on the Company&#8217;s suppliers, contract manufacturers, freight carriers, and distributors, resulting in delayed or limited availability of components, higher component costs, and higher freight costs.  These and other economic factors could materially adversely affect the Company&#8217;s business, results of operations, financial condition and stock price.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s business can be impacted by political events, trade and other international disputes, war, terrorism, natural disasters, public health issues, industrial accidents and other business interruptions. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Political events, trade and other international disputes, war, terrorism, natural disasters, public health issues, industrial accidents and other business interruptions can harm or disrupt international commerce and the global economy, and could have a material adverse effect on the Company and its customers, suppliers, contract manufacturers, freight carriers, and distributors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. trade policies could significantly increase the cost of imported goods into the United States, which may materially reduce our sales or profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in U.S. trade policy could trigger retaliatory actions by affected countries, resulting in "trade wars," in increased costs for goods imported into the United States, which may reduce customer demand for these products if the parties having to pay those tariffs increase their prices, or in trading partners limiting their trade with the United States. If these consequences are realized, the volume of economic activity in the United States, may be materially reduced. Such a reduction may materially and adversely affect our sales volumes. Further, the realization of these matters may increase our cost of goods and, if those costs cannot be passed on to our customers, our business and profits may be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_22"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. Unresolved Staff Comments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. Properties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own and maintain an approximately 60,000 square foot facility which consists of office, warehousing, manufacturing and research space located at 5115 Ulmerton Rd., Clearwater, Florida. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Bulgaria EOOD leases approximately 27,000 square feet of office, warehousing and manufacturing facilities located in Sofia, Bulgaria. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_28"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 of Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_34"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock currently is traded on the NASDAQ Stock Market LLC. As of March&#160;15, 2023, we had approximately 600 stockholders of record. Since many stockholders choose to hold their shares under the name of their brokerage firm, we estimate that the actual number of stockholders was over 3,500 stockholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price of Outstanding Options, Warrants and Rights<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a))<br/>(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,460,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Represents inducement grants for new hires</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common stock and we currently do not anticipate paying cash dividends in the foreseeable future. We currently expect to retain any future earnings to fund the operation and expansion of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Five Year Performance Graph </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following line graph compares the cumulative total return of our common shares with the cumulative total return of the Russell 2000 Stock Index and the Russell 3000 Stock Index. The line graph assumes, in each case, an initial investment of $100 on December&#160;31, 2018, based on the market prices at the end of each fiscal year through and including December&#160;31, 2022, and reinvestment of dividends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="apyx-20221231_g2.jpg" alt="apyx-20221231_g2.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apyx Medical Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell 2000 Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell 3000 Index</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_40"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. Reserved </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following discussion and analysis in conjunction with our consolidated financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Level Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including our Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Safety Communication that warns consumers and health care providers against the use of our Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, we experienced slowed demand for the adoption of our Helium Plasma Technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for certain skin contraction procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, and July 21, 2022, the FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#174; Dermal handpiece, and the expanded indications for the Renuvion&#174; APR handpieces. The 510(k) clearance for the Renuvion&#174; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. The 510(k) clearance for the Renuvion&#174; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 1, 2023, we announced we had submitted a 510(k) premarket notification (&#8220;510(k) submission&#8221;) for the Renuvion APR Handpiece to the FDA, supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion&#8217;s indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, we continue to experience reduced demand for the adoption and utilization of our technology and we believe that this may have an adverse effect in future periods.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of our plan to accelerate and fully fund the development of our advanced energy business, with a focus in the cosmetic  surgery market, we sold our Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, we had and still have, some significant non-recurring discretionary expenditures associated with completing our multi-year marketing initiatives related to our dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">years, exclusive of our sale of the Core business segment to Symmetry Surgical during 2018, we have incurred recurring net losses and cash outflows from operations and we anticipate that losses will continue in the near term. For the year ended December 31, 2022, we incurred an operating loss of $23.6&#160;million and used $20.3&#160;million of cash in operations. As of December 31, 2022, we had cash and cash equivalents of $10.2&#160;million. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date we have not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement see Note 20 in Item 8 of this report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. Upon the closing of the sale of the Property, we will enter into a lease agreement with the Purchaser, pursuant to which the Property will be leased back to us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement see Note 20 in Item 8 of this report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for substantially the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Impact of COVID-19, Supply Chain Disruptions and Other Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the COVID-19 outbreak has subsided substantially in the U.S. but continues to result in reduced activity levels outside of the U.S., such as continued restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes or places of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the global supply chain instability and inflationary cost increases, we continue to take action to minimize, as much as possible, any potential adverse impacts by working closely with our suppliers to closely monitor the availability of raw </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material components (i.e., semiconductors and plastics), lead times, and freight carrier availability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect global supply chain instability will continue to have an impact on our business, but to date that has not been material to our financial performance. The consequences of global supply chain instability, inflationary cost increases aand the pandemic, and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we hosted over 30 Physician Mentor Programs, or &#8220;PMPs,&#8221; and our efforts to expand our presence and educational programming at industry conferences and trade shows proceeded as expected.  In April 2022, we hosted our first in-person Users&#8217; Meeting and had over 200 people in attendance.  This program consisted of presentations from key Renuvion&#174; users around the world on various applications for the product.  All of the content was recorded and made available on our website portal for reference by all of our users around the world.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued virtual educational events have also included case studies to illustrate how our leading clinician customers have adopted Renuvion&#174;, their strategies for marketing and selling to new patients, and their thoughts on pricing and return on investment. We also engaged with clinician customers outside the U.S. including hosting multiple continuing education training sessions on Renuvion&#174; with our current international distributors and conducting multiple calls with groups of international prospects interested in learning about our Renuvion&#174; technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2022, we continued to drive sales in our Advanced Energy business by increasing the adoption and utilization of our handpieces in the U.S. cosmetic surgery market and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 60 countries.  As of December&#160;31, 2022, we had a direct sales force of 35 field-based selling professionals and utilized 3 independent sales agencies. We also had 4 sales managers. This selling organization is focused on the use of Renuvion&#174; and J-Plasma&#174; in the cosmetic and hospital surgical markets, supported by our global medical affairs team. This global team of clinical support specialists focuses on supporting our users to ensure optimal outcomes for their patients. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174; into surgeons' practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our continued investment and focus on the following strategic initiatives in 2022 and beyond will position the Company for long-term growth in the cosmetic surgery market:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To formalize our regulatory strategy to pursue specific clinical indications that will enable us to sell our Renuvion&#174; products for targeted procedures</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To secure new clinical evidence demonstrating the safety and efficacy of our Helium Plasma Technology</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To provide enhanced physician and practice support for our cosmetic surgery customers</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To improve our manufacturing capabilities and efficiencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regards to our operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate &amp; Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly encourage investors to visit our website: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.apyxmedical.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to view the most current news and to review our filings with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Reportable Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Energy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OEM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,517&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,517&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by 8.3% or approximately $4.0 million for the year ended December&#160;31, 2022 when compared with 2021. Advanced Energy segment sales decreased 14.4% or approximately $6.2 million for the year ended December&#160;31, 2022 when compared with 2021. The Advanced Energy sales decrease is due to global decreases in utilization based demand for our handpieces and the adoption of our generator technology following the FDA Safety Communication on March 14, 2022. The Advanced Energy sales decrease was partially offset by an increase in global utilization based demand for our handpieces and adoption of our generator technology in international markets for most of the first quarter before the FDA Safety Communication.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OEM product line consists of proprietary products designed specifically for third party equipment manufacturers. Revenue for this product line increased 39.3%, or approximately $2.2 million, when compared to 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in OEM sales was due to increases in sales volume to existing customers, including Symmetry Surgical, under our 10-year generator manufacturing and supply agreement, as well as incremental new sales upon the commencement of the supply arrangement related to the completion of the development portion of some of our OEM development agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 29.9% and 32.0% of total revenues for the years ended December&#160;31, 2022 and 2021, respectively. Management estimates our products have been sold in more than 60 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margin as a percentage of sales decreased by 3.8% during the year ended December&#160;31, 2022 compared with 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The de</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">crease in gross profit margins for the year ended December 31, 2022 from the prior year is primarily attributable to changes in the sales mix between our two segments, with our OEM segment comprising a higher percentage of total sales, product mix within our Advanced Energy Segment and higher material and inbound shipping costs to manufacture our inventory. These decreases were partially offset by geographic mix within our Advanced Energy segment, with domestic sales comprising a higher percentage of total sales and the mix of newer product models </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we obtain registrations, allowing these products to be introduced into the markets we serve.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures for research and development related activities increased by 5.2% or approximately $0.2 million for the year ended December&#160;31, 2022, compared with 2021. This increase was primarily due to increases in payroll and related benefits of R&amp;D personnel ($0.3 million) partially offset by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lower spending on ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r two investigational device exemption (IDE) clinical studies and other product development initiatives ($0.1 million).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services expenses increased 19.2%, or approximately $1.5 million for the year ended December&#160;31, 2022, compared with 2021. This increase was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily attributable to increases in legal expenses ($0.4 million), primarily associated with the estimated loss recorded for the class action lawsuit, Board of Directors option expense ($0.4 million), marketing consulting expense ($0.3 million), accounting and auditing fees ($0.2 million), physician consulting fees ($0.2 million), and employee recruitment expense ($0.2 million). These increases were partially offset by a decrease in stock compensation expense for our partner physicians ($0.2 million).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and related costs</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and related expenses increased 6.3% or approximately $1.1 million for the year ended December&#160;31, 2022, compared to 2021. The increase was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily driven by higher compensation and benefits ($1.7 million) and stock compensation expense ($1.2 million) as compared to the same period in the prior year. These increases are partially offset by a decrease in bonus expense ($1.8 million) as we determined we did not meet our 2022 bonus objectives, and accordingly, we have recorded no annual bonus expense in 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense increased by 10.0% or approximately $1.9 million for the year ended December&#160;31, 2022, compared with 2021.&#160;The change is p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rimarily driven by higher insurance expense, including product liability claims on our policies ($1.9 million), travel and entertainment expense ($1.1 million), advertising expense, including trade show fees and related costs ($1.0 million), employee training and other meeting expenses ($0.7 million),  bad debt expense ($0.2 million), and other public company related costs ($0.1 million). These increases were partially offset by decreases in commissions on Advanced Energy sales ($2.5 million), OEM product recall costs ($0.2 million) as we experienced no product recalls in 2022, lower technology costs ($0.2 million) and lower regulatory registration expenses ($0.2 million).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.596%"><tr><td style="width:1.0%"></td><td style="width:73.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, compared with 2021. This increase is due to higher yields on our investments in money market funds and U.S. Treasury securities included in cash and cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Loss) Income, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.596%"><tr><td style="width:1.0%"></td><td style="width:73.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (losses), net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (losses), net increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">236.5%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, compared with 2021. This increase was primarily attributable to the release of a portion of our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> joint and several payroll liability due to the lapse of the statute of limitations on a portion of the liability ($0.6 million) and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the wind down of the supply arrangement with Symmetry in the Core business segment ($0.3 million).</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was approximately $0.4 million, with effective tax rates of (1.6)% and (2.6)%, respectively, for the years ended December 31, 2022 and 2021. For each of the years ended December 31, 2022 and 2021, the effective tax rate differs from the statutory rate primarily due to the valuation allowance on our Federal and State net operating losses (NOLs) combined with interest and penalties on our uncertain tax positions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash and cash equivalents as compared to approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  in cash and cash equivalents at December&#160;31, 2021.  Our working capital at December&#160;31, 2022 was approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $47.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at December&#160;31, 2021. The decrease in working capital at December&#160;31, 2022 was primarily due to the net loss incurred by the Company in 2022 following the Safety Communication on March 14, 2022, excluding non-cash activity, comprised primarily of stock-based compensation expense. Following the Safety Communication we had cash outflows of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.6 million related to growth in inventory due to existing non-cancellable purchase orders when the Safety Communication was issued and management's decision to continue to build inventory with these materials through the uncertainty. The lower sales as a result of the Safety Communication also resulted in operating cash inflows of $1.9 million related to lower accounts receivable balances on the lower sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, net cash used in operating activities was approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which principally funded our los</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s from operations of $23.6 million, compared with net cash used in operating activities of approximately $10.4 million in 2021. As discussed in the Executive Level Overview, our operating loss, cash used in operations and current cash and cash equivalents balance of $10.2 million raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date we have not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit agreement see Note 20 in Item 8 of this report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement see Note 20 in Item 8 of this report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LLC (the &#8220;Purchaser&#8221;), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. Upon the closing of the sale of the Property, we will enter into a lease agreement with the Purchaser, pursuant to which the Property will be leased back to us. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement see Note 20 in Item 8 of this report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for substantially the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. As of the date of this report, we are awaiting receipt of the tax refunds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that the actions already taken, and additional actions that we intend to take to manage operating expenditures, will enable us to meet our obligations for a period of at least one year from the date of issuance of our audited consolidated financial statements. As a result, we believe our plans alleviate substantial doubt about our ability to continue as a going concern. Our audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the years ended December&#160;31, 2022 and 2021, were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, related to purchases of property and equipment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had purchase commitments for inventories totaling approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all of which is expected to be purchased by the end of 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model, which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the estimates of expected life and volatility used in the calculations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. The SEC allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable Allowance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze specific unremitted customer balances for known collectability issues, review historical bad debt experience, customer credit worthiness and economic trends, and we make estimates in connection with establishing the allowance for doubtful accounts, including the future impacts of current trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory Obsolescence Allowance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of historical losses and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on our net deferred tax assets. Exclusive of the carryback provisions of the CARES Act and the associated income tax benefit recognized in 2020, we do not anticipate recording an income tax benefit related to our deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent our results of operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has not fully determined the timing of when it will generate taxable income in the U.S., we continued to record a valuation allowance on the net deferred tax assets balance as of December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained based on the technical merit of the position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve.  Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty.  Inflation has not, to date, materially impacted our operations or financial performance.  However, as these trends continue for raw materials, freight, and labor costs, our future financial performance could be adversely impacted.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We have no off-balance sheet arrangements at this time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_46"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not required.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. Financial Statements and Supplementary Data </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL INFORMATION</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:93.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:AuditorFirmId" id="f-34">49</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_52">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">Consolidated Balance Sheets at December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">2 </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58">Consolidated Statements of Operations for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58">21</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">Consolidated Statements of Changes in Equity for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61"> and 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">02</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">41</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64">Consolidated Statements of Cash Flows for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64">21</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_67">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_67">43</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_52"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stockholders and the Board of Directors</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apyx Medical Corporation</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Apyx Medical Corporation and its subsidiaries (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, changes in equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Audit Matter</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Going Concern </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 1 to the consolidated financial statements, the Company disclosed certain adverse conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of the consolidated financial statements. The Company further disclosed certain plans identified by management, which involve the use of significant judgment, that management believes it can implement that alleviate the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We identified the Company&#8217;s ability to continue as a going concern as a critical audit matter because of certain significant assumptions management made in concluding management&#8217;s plans alleviate the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern, including the reasonableness of the assumptions underlying management&#8217;s cash flow forecast for a period of one year from the date of issuance of the consolidated financial statements. Auditing management&#8217;s assumptions involved a high degree of auditor judgment and an increase in audit effort, including the use of an internal specialist, due to the impact these assumptions have on the conclusion that management&#8217;s plans alleviate the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit procedures related to the Company&#8217;s ability to continue as a going concern included the following, among others: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">We obtained management&#8217;s going concern assessment and evaluated the reasonableness of the conclusion that management&#8217;s plans alleviate the conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern by considering both the likelihood that management could implement its plans and how the implementation of those plans impacted the identified adverse conditions. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">We evaluated management&#8217;s cash flow forecast by performing the following procedures, among others:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.46pt">We evaluated the reasonableness of the forecasted nature, amount and timing of operating expenditures expected to be reduced or delayed over the course of a year from the date of issuance of the consolidated financial statements based on our understanding of the Company&#8217;s operations, cost structure, historical expenditures and actions taken to date by management.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.46pt">We evaluated the Company&#8217;s ability to comply with its debt covenants under the Company&#8217;s new credit agreement, which was executed in February 2023. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.46pt">We obtained and read correspondence between the Internal Revenue Service and the Company evidencing approval of the amount of the Company&#8217;s income tax receivable.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.46pt">We obtained and read the purchase and sale agreement between the Company and a third party for the sale and leaseback of the Company&#8217;s building. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.46pt">We considered the Company&#8217;s current shelf registration and the embedded at-the-market facility by evaluating management&#8217;s intent and ability to execute on a public offering.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">With the assistance of an internal specialist, we evaluated the accuracy and completeness of the Company&#8217;s financial statement disclosure and their compliance with accounting principles generally accepted in the United States of America.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:AuditorName" id="f-35">RSM US LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="dei:AuditorLocation" id="f-36">Orlando, Florida</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 16, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-37">10,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-38">30,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Trade accounts receivable, net of allowance of $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-39">668</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="f-40">430</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">13,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-43">7,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-44">7,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-45">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-46">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net of provision for obsolescence of $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="f-47">457</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="f-48">263</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-49">11,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-50">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">42,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">60,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-55">6,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-56">6,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-57">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-58">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-59">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-60">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-63">51,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-64">68,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">2,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">2,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">8,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">10,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-69">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-70">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-71">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-72">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">11,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">13,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-75">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-77">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-78">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-81">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-82">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-83">13,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-84">14,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 17)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-85"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-86"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-87"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-88">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-89"><ix:nonFraction unitRef="shares" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-90">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-91"><ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-93"><ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-94">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-97"><ix:nonFraction unitRef="usdPerShare" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-98">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-100">75,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-102">34,597,822</ix:nonFraction></ix:nonFraction> issued and outstanding as of December&#160;31, 2022, and <ix:nonFraction unitRef="shares" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-103"><ix:nonFraction unitRef="shares" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-104">34,409,912</ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-105">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-106">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-107">73,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-108">66,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-109">35,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-110">12,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">37,582</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">53,704</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-113">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-114">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-115">37,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-116">54,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">51,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-118">68,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-119">44,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-120">48,517</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-121">15,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-122">14,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-123">29,131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-124">33,601</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-125">4,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">4,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-127">9,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-128">7,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:SalariesAndWages" format="ixt:num-dot-decimal" scale="3" id="f-129">18,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:SalariesAndWages" format="ixt:num-dot-decimal" scale="3" id="f-130">17,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">20,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">18,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-133">52,693</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">48,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">23,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">14,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-137">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-138">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-139">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-140">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (losses), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-141">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-142">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income (loss), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-143">651</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-144">372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-145">22,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-146">14,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-147">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-148">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">23,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">15,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-151">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-152">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">23,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">15,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="f-155"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="f-156">0.67</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="f-157"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="f-158">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-159"><ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-160">34,516</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-161"><ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-162">34,332</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.457%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total  Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bae49cc66e64b74871c5922613110b0_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-163">34,289</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bae49cc66e64b74871c5922613110b0_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-164">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0719a3bd71c14176a650c4eb12985506_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-165">61,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a6edda2d6904896afa5d78839163c76_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-166">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib406169147a6431dbc30a2558b1f5e27_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-167">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-168">63,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23cc21664d6348d5bb8761b3ca26250d_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="f-169">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="f-170">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57f0820c833a4d97a42d7bf8f8ef0251_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-171">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87632d688d4749c9803b3fcc53b01ce8_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-172">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-173">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87632d688d4749c9803b3fcc53b01ce8_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-174">5,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-175">5,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57f0820c833a4d97a42d7bf8f8ef0251_D20210101-20211231" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="f-176">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b220174f25b49019af92cabbeeaab3c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-177">15,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23cc21664d6348d5bb8761b3ca26250d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-178">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-179">15,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fa2eb62abf14f7192ce12f735e12a77_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-180">34,410</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa2eb62abf14f7192ce12f735e12a77_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-181">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758630662d83465d81b8137958c8cefc_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-182">66,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a54ae736e074ebfb7dd790dda19e87f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-183">12,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee3b5a980ce4da3a2b821cfef923265_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-184">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-185">54,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i160d1cf15ee840e19f82d1cb22f0d5e8_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-186">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160d1cf15ee840e19f82d1cb22f0d5e8_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-187">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387665639f6d4372866cc35427b6f229_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-188">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-189">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387665639f6d4372866cc35427b6f229_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-190">6,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-191">6,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i160d1cf15ee840e19f82d1cb22f0d5e8_D20220101-20221231" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="f-192">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76906bbc37b643fb86fb3fd07b5d57d4_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-193">23,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id796f312650b4349a1f87ceaf7050569_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-194">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">23,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e7ebb24b75346f1927c12e624da2d6f_I20221231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-196">34,598</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7ebb24b75346f1927c12e624da2d6f_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-197">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c1ccf4264f41de9fa4a85ef430cc4f_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-198">73,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d05d6cf479e4b08b903d62cabfaf1b2_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-199">35,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d0bcee5be54a1bb6f172bf7c4ee059_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-200">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-201">37,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands) </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.744%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-202">23,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">15,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-204">890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-205">903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for inventory obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="f-206">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="f-207">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="apyx:ProductWarrantyExpenseNet" scale="3" id="f-208">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:ProductWarrantyExpenseNet" scale="3" id="f-209">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-210">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-211">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-212">6,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-213">5,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-214">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-215">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in current assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-216">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-217">4,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="f-218">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="f-219">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-220">523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-221">1,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-222">5,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-223">2,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-224">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-225">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-226">1,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-227">3,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-228">20,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-229">10,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-230">1,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-231">723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-232">1,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-233">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="f-234">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="f-235">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:RepaymentOfFinanceLeaseLiabilities" scale="3" id="f-236">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:RepaymentOfFinanceLeaseLiabilities" scale="3" id="f-237">238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="f-239">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-240">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-241">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-242">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-243">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-244">20,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-245">11,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-246">30,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-247">41,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-248">10,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-249">30,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-250">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-251">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-252">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-253">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:CapitalizationOfLeaseRecongizedNonCash" scale="3" id="f-254">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:CapitalizationOfLeaseRecongizedNonCash" format="ixt:fixed-zero" scale="3" id="f-255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:CapitalizationOfLeaseRecognizedExecution" scale="3" id="f-256">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:CapitalizationOfLeaseRecognizedExecution" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:CapitalizationOfLeaseDerecognizedExecution" scale="3" id="f-258">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:CapitalizationOfLeaseDerecognizedExecution" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Transfer of right-of-use assets to property and equipment on exercise of purchase option</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:NonCashTransferOfOtherAssetsToFixedAssets" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:NonCashTransferOfOtherAssetsToFixedAssets" scale="3" id="f-261">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_67"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-262" continuedAt="i8d7c4f5fa94f425dbf73dae07b356073" escape="true">DESCRIPTION OF BUSINESS&#160;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><ix:continuation id="i8d7c4f5fa94f425dbf73dae07b356073" continuedAt="i6d9bdce949564917af3a1d946a323e6b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its plan to accelerate and fully fund the development of its advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, the Company sold its Core business in 2018 for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i00f94b6a4a7043f7b1bba426285e2789_D20180101-20181231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-263">97</ix:nonFraction>&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Safety Communication that warns consumers and health care providers against the use of the Company&#8217;s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#174; Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for certain skin contraction procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, and July 21, 2022, the FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#174; Dermal handpiece, and the expanded indications for the Renuvion&#174; APR handpieces. The 510(k) clearance for the Renuvion&#174; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.  The 510(k) clearance for the Renuvion&#174; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2023, we announced we had submitted a 510(k) premarket notification (&#8220;510(k) submission&#8221;) for the Renuvion APR Handpiece to the FDA, supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion&#8217;s indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While management expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, the Company continues to experience reduced demand for the adoption and utilization of its technology and management believes that this may have an adverse effect in future periods.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Financial Accounting Standards Board&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="i6d9bdce949564917af3a1d946a323e6b" continuedAt="iea2816a978bd4f6a9b4380f640d27ff8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company as of the date the condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#8217;s sale of the Core business segment to Symmetry Surgical during 2018, it has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-264">23.6</ix:nonFraction>&#160;million and used $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-265">20.3</ix:nonFraction>&#160;million of cash in operations. As of December 31, 2022, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-266">10.2</ix:nonFraction>&#160;million. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $<ix:nonFraction unitRef="usd" contextRef="id973048cfe784ebca10458b24c0549da_D20221122-20221122" decimals="-6" name="apyx:SecuritiesRegisteredNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-267">100</ix:nonFraction>&#160;million. The shelf registration included an embedded ATM facility for up to $<ix:nonFraction unitRef="usd" contextRef="i1c4f6946432a43cc9388c670091e059e_D20221122-20221122" decimals="-6" name="apyx:SecuritiesRegisteredNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-268">40</ix:nonFraction>&#160;million. To date the Company has not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $<ix:nonFraction unitRef="usd" contextRef="i9623247cdf6a40419d4a2b011f00d8ed_I20230217" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-269">35</ix:nonFraction>&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $<ix:nonFraction unitRef="usd" contextRef="i498926f26c67490999cf1e6f231404e1_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-270">25</ix:nonFraction>&#160;million, comprised of (i) an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="icd920217a5774a4a8e99a083c1cb188c_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-271">10</ix:nonFraction>&#160;million, (ii) a second tranche of $<ix:nonFraction unitRef="usd" contextRef="ie91aea3453ae4206b00854b54ccdde12_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-272">5</ix:nonFraction>&#160;million, and (iii) a third tranche of $<ix:nonFraction unitRef="usd" contextRef="i4fbd4462461f48afb157563bd14c45a5_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-273">10</ix:nonFraction>&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i982284b9ef6f4f6f9d69822b5e02cff9_I20230217" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-274">10</ix:nonFraction>&#160;million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement see Note 20.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, the Company&#8217;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of the Company's facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" decimals="-4" name="apyx:SaleLeasebackPurchaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-275">7,650,000</ix:nonFraction>. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. Upon the closing of the sale of the Property, the Company will enter into a lease agreement with the Purchaser, pursuant to which the Property will be leased back to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement see Note 20.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for substantially the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company's U.S. headcount by <ix:nonFraction unitRef="number" contextRef="i4bf73cd58c774543acd7ca829d302f18_D20230119-20230119" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-276">14</ix:nonFraction>%. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="iea2816a978bd4f6a9b4380f640d27ff8">Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations for a period of at least one year from the date of issuance of these audited consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company's ability to continue as a going concern. These audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-277" continuedAt="i446859074396467f9ffa76ab4b06ac88" escape="true">SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i446859074396467f9ffa76ab4b06ac88" continuedAt="i53b8bf69b1f34e879f5ae657894db7d9">&#160;</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i53b8bf69b1f34e879f5ae657894db7d9" continuedAt="i8f4111a9710b4477abd8a0c66c403b69"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="f-278" continuedAt="ic3c4d4ca91544d5d8f37a4a67832eb99" escape="true">Consolidated Financial Statements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic3c4d4ca91544d5d8f37a4a67832eb99">The accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its <ix:nonFraction unitRef="number" contextRef="ic3257cbd5e38423bac3cb15f13f803cc_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-279">51</ix:nonFraction>% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, &#8220;Apyx,&#8221; or the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated in consolidation.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:UseOfEstimates" id="f-280" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-281" continuedAt="icbdc55a1a8e3458f8331b153552a94e0" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="icbdc55a1a8e3458f8331b153552a94e0">Holdings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December&#160;31, 2022 and 2021, all of the Company&#8217;s investments are in money market funds or in Treasury Bills with original maturities of three months or less and are included in cash and cash equivalents.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-282" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-283" continuedAt="i3c4a0173eee24c4db416db8aa22d4c99" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's standard credit terms for billings range from net 30 days to net 120 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3c4a0173eee24c4db416db8aa22d4c99">The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#8217; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available.</ix:continuation> Management believes that the allowances for doubtful accounts of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-284">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-285">0.4</ix:nonFraction>&#160;million at December&#160;31, 2022 and 2021, respectively, are adequate to provide for probable bad debts.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="f-286" continuedAt="i7c95aab8a86d4f4ab1f336f89cfd62bb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. </span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="i8f4111a9710b4477abd8a0c66c403b69" continuedAt="i14fa25bf050f47e3be3e1faf7452fffd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7c95aab8a86d4f4ab1f336f89cfd62bb">The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-287" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, <ix:nonNumeric contextRef="i7654b3f92f4f47c7a70f057fb31c8385_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-288">39</ix:nonNumeric> years; machinery and equipment, <ix:nonNumeric contextRef="ieabcc8e7335642cb80a3d0784277b499_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-289">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ie7cfe454f7084225b0b55f3a129f958b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-290">10</ix:nonNumeric> years; furniture and fixtures, <ix:nonNumeric contextRef="i2b1b946daaf54d3297203c790f0eaf01_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-291">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i6a9f29492d5a4b14a57cb6b526e5dfe3_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-292">10</ix:nonNumeric> years;  computer equipment and software, <ix:nonNumeric contextRef="ia0b3e3ec5679411f8dd7d36415a88d70_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-293">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i2a5b5a0b0ccd476e8cc706006cc8fa2e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-294">5</ix:nonNumeric> years; and molds, <ix:nonNumeric contextRef="i5ecb32d40a164cc78a526b05c7c1ff9f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-295">7</ix:nonNumeric>-<ix:nonNumeric contextRef="id3c33358a7584267bc50bbb56019e99c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-296">15</ix:nonNumeric> years.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-297" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#8217; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2022 and 2021, the Company believes the remaining carrying values of its long-lived assets are recoverable.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:StandardProductWarrantyPolicy" id="f-298" continuedAt="i7b414fcba050420b9a8662b09f91f381" escape="true">Product Warranties</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b414fcba050420b9a8662b09f91f381">The Company provides a <ix:nonNumeric contextRef="if3bf0f938d834033b089a461be19a891_D20220101-20221231" name="apyx:ProductWarranty" format="ixt-sec:durwordsen" id="f-299">four year</ix:nonNumeric> limited warranty on end-user sales of its Renuvion&#174;/J-Plasma&#174; generators, a <ix:nonNumeric contextRef="ifa934ffbea294e0fac514a7ff600cbbd_D20220101-20221231" name="apyx:ProductWarranty" format="ixt-sec:durwordsen" id="f-300">two year</ix:nonNumeric> warranty on mounting fixtures, and a <ix:nonNumeric contextRef="i80078dd0c8b24caca7d3320de6bd5594_D20220101-20221231" name="apyx:ProductWarranty" format="ixt-sec:durwordsen" id="f-301">one-year</ix:nonNumeric> warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-302" continuedAt="id61f9eea2dfd4db2be244a52dcbb6f16" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#174;/J-Plasma&#174;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Product returns are only accepted at the Company's discretion and in accordance with its &#8220;Returned Goods Policy&#8221;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="i14fa25bf050f47e3be3e1faf7452fffd" continuedAt="ib34e9ae2fa964c3dad1bae7f2a4ea703"><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><ix:continuation id="id61f9eea2dfd4db2be244a52dcbb6f16" continuedAt="i608c042fcca34c1686a88f119edcd0e0"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.</span></ix:continuation></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i608c042fcca34c1686a88f119edcd0e0" continuedAt="i22a8f3d849a54b86aaceea8c0d0f11a2">&#8226;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"><ix:continuation id="i22a8f3d849a54b86aaceea8c0d0f11a2">In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. Recognition of the deferred billings and costs occurs as the Company performs on the accompanying supply arrangements.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-303" continuedAt="i46f584e3aa3946568d0e072108b11987" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i46f584e3aa3946568d0e072108b11987">Advertising costs are expensed as incurred.</ix:continuation> The amounts of advertising costs, including trade shows, were approximately $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-304">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-305">1.3</ix:nonFraction> million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-306" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the grant date fair value of such awards. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:LegalCostsPolicyTextBlock" id="f-307" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-308" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (Loss) Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-309" continuedAt="if3d0c2f7d4b94a37a0924fbdf6c3f2fa" escape="true">Research and Development Costs</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if3d0c2f7d4b94a37a0924fbdf6c3f2fa">Research and development expenses are charged to operations as incurred.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-310" continuedAt="i511c15bb09f746f487c4a6716eb5a0e7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="ib34e9ae2fa964c3dad1bae7f2a4ea703" continuedAt="i3427b1e230f2401189f33931f78f469e"><ix:continuation id="i511c15bb09f746f487c4a6716eb5a0e7" continuedAt="idbaf25a4c4014102882a78c97b0eacc3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planning strategies.  As of December 31, 2022 and 2021, the Company recorded a valuation allowance on the net deferred tax assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2022. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idbaf25a4c4014102882a78c97b0eacc3">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-311" continuedAt="i3c0fe3d4a52841f094b96acb44138a5a" escape="true">Foreign Currency Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3c0fe3d4a52841f094b96acb44138a5a">The functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2022 and 2021.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-312" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior year to conform to the current year presentation. These reclassifications had no impact on previously reported net income, retained earnings or operating cash flows for the periods presented.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_76"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. &#160;&#160;&#160;&#160;<ix:continuation id="i3427b1e230f2401189f33931f78f469e" continuedAt="i564240199ec94427baf01fce2e5ac794">RECENT ACCOUNTING PRONOUNCEMENTS</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i564240199ec94427baf01fce2e5ac794"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-313" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">and Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 842) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-314" continuedAt="i58a3a7fffdd34a919e844ebe166dec18" escape="true">DISPOSITION OF THE CORE BUSINESS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i58a3a7fffdd34a919e844ebe166dec18"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 30, 2018, the Company closed on a definitive asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the Company&#8217;s electrosurgical &#8220;Core&#8221; business segment and related intellectual property, including the Bovie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> brand and trademarks, to Symmetry for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie2b00095642c4b108229e13776c6580c_D20180830-20180830" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="f-315">97</ix:nonFraction> million in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a <ix:nonNumeric contextRef="i8fd4fe74bd604c1db72d55317651b6d4_D20180830-20180830" name="apyx:AssetPurchaseAgreementTerm" format="ixt-sec:durwordsen" id="f-316">four-year</ix:nonNumeric> term, which expired August 30, 2022, whereby it manufactured certain Core pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ducts and sold them to Symmetry at agreed upon prices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Any activity resulting from this agreement is netted and reported in the Consolidated Statements of Operations as other income (loss). Core activity for 2022 amounted to $<ix:nonFraction unitRef="usd" contextRef="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="f-317">0.6</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="f-318">0.6</ix:nonFraction>&#160;million and other related expenses of $<ix:nonFraction unitRef="usd" contextRef="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-319">0.1</ix:nonFraction>&#160;million for net other loss of $<ix:nonFraction unitRef="usd" contextRef="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-320">0.1</ix:nonFraction>&#160;million.  Core activity for 2021 amounted to $<ix:nonFraction unitRef="usd" contextRef="iefa166e3072441a1a7435fde8c995859_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="f-321">6.5</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="iefa166e3072441a1a7435fde8c995859_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="f-322">5.5</ix:nonFraction>&#160;million and other related expenses of $<ix:nonFraction unitRef="usd" contextRef="iefa166e3072441a1a7435fde8c995859_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="6" id="f-323">1.5</ix:nonFraction>&#160;million for net other loss of $<ix:nonFraction unitRef="usd" contextRef="iefa166e3072441a1a7435fde8c995859_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-324">0.4</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:MinorityInterestDisclosureTextBlock" id="f-325" continuedAt="i4753de301ffc4c539f1c586817eaed2d" escape="true">INTEREST IN JOINT VENTURE INVESTMENT</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4753de301ffc4c539f1c586817eaed2d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier (the &#8220;China JV&#8221;) whereby the Company has a <ix:nonFraction unitRef="number" contextRef="iab43910064884237bbdef4ac6cc8ff44_I20191231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-326">51</ix:nonFraction>% interest. The China JV has been consolidated in these consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $<ix:nonFraction unitRef="usd" contextRef="i0a3f56438b0549d9bb1816cb85ae9d4f_I20191231" decimals="-3" name="apyx:NoncontrollingInterestRequiredCapitalContribution" format="ixt:num-dot-decimal" scale="0" id="f-327">357,000</ix:nonFraction>, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i0bcfaba8f0c645ee95bc37c4c4f557bc_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="f-328">203,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6c3682736d9142f6ac1dda33e04b7f44_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="f-329">154,000</ix:nonFraction>, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="apyx:NoncontrollingInterestTableTextBlock" id="f-330" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Changes in the Company&#8217;s ownership investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:54.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.700%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33cd0694a0974259aa4da54d953aa393_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-331">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e47e5bd233347f190ad5ea24579801f_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-332">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e0bc92d62a40c4b1273fbafc570bd2_D20220101-20221231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:fixed-zero" scale="3" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcfaba8f0c645ee95bc37c4c4f557bc_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="f-334">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28e0bc92d62a40c4b1273fbafc570bd2_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-335">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bcfaba8f0c645ee95bc37c4c4f557bc_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-336">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5ca601b6594ace8b084574b85670b1_I20221231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-337">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33cd0694a0974259aa4da54d953aa393_I20211231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-338">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="f-339" continuedAt="i0240d25479a5428a8e4b8c746d9d6279" escape="true">INVENTORIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0240d25479a5428a8e4b8c746d9d6279"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-340" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-341">4,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-342">3,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-343">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-344">1,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-345">5,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-346">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-347">12,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-348">7,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="f-349">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="f-350">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-351">11,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-352">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_88"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-353" continuedAt="i79f3f8753f3d4bbfa80c93a36e59e908" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i79f3f8753f3d4bbfa80c93a36e59e908"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-354" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56987d7ae3fb47dfaaf61b0612cb8a6b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-355">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf70880d8834a4ea7a3ff7705a7d5e7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-356">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf54c2e8062e464a943af7a1cc6f702e_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-357">4,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292d860f0b124b10b47265b193979452_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-358">4,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcfa1867b9c4a31a3709fe8a05bbe58_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-359">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb15fe17f8554f4bb5cb43cfef473c00_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-360">2,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b4e8b0d165454996fdf3396b1c0d64_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-361">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12249f705534e21b3e97868de6b1157_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-362">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90034014d4ac40d6b47f2c9dfd2b0b6d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-363">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2d3c40f1484004855a884bc75b810d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-364">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1dff9d0dbb4b90aef7333e20bb5fb3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-365">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b3ec8b01964331aded480dad14486f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-366">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68358e6c1c414942ab2b1cacdda282a7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-367">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i243c730de3e94d3283669d4a2661af4b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-368">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-369">11,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-370">11,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-371">5,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-372">5,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" format="ixt:num-dot-decimal" scale="3" id="f-373">6,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" format="ixt:num-dot-decimal" scale="3" id="f-374">5,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="f-375">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="f-376">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-377">6,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-378">6,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-379"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-380">0.7</ix:nonFraction></ix:nonFraction>&#160;million for the years ended December&#160;31, 2022 and 2021. Depreciation expense is included within cost of goods sold and selling, general and administrative expense in the Consolidated Statements of Operations.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-381" continuedAt="i6b80f490616b46faa81c5217051d5ba3" escape="true"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-382" continuedAt="i7cca6c71981249ec994772e2b27b2007" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6b80f490616b46faa81c5217051d5ba3" continuedAt="i2819030a312f4727b9777002666472a9"><ix:continuation id="i7cca6c71981249ec994772e2b27b2007" continuedAt="id51ff9f66a8148f18daf3b7b19fcb579"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company&#8217;s lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate, which is indicative of its collateralized borrowing rate. We utilized rates of <ix:nonFraction unitRef="number" contextRef="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231" decimals="4" name="apyx:LesseeDiscountRateIncrementalBorrowingRate" scale="-2" id="f-383">1.83</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231" decimals="4" name="apyx:LesseeDiscountRateIncrementalBorrowingRate" scale="-2" id="f-384">6.49</ix:nonFraction>% for our outstanding leases at December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the year ended December 31, 2022, the Company&#8217;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the year ended December 31, 2022, the Company entered into a <ix:nonNumeric contextRef="i7ce8494d2834491ab35f3664a41429db_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-385">one year</ix:nonNumeric> extension on <ix:nonFraction unitRef="lease" contextRef="ifa25d872e0d140a98af126a2c508757b_D20220101-20221231" decimals="INF" name="apyx:LesseeOperatingLeaseNumberOfLeasesExtended" format="ixt-sec:numwordsen" scale="0" id="f-386">one</ix:nonFraction> of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the year ended December 31, 2022, the Company entered into a <ix:nonNumeric contextRef="ie2aaebfd6e5041e3b8fade9ae7be2f4c_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-387">five year</ix:nonNumeric> extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the year ended December 31, 2022, the Company entered into a <ix:nonNumeric contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durmonth" id="f-388">63</ix:nonNumeric> month lease for computer equipment. These finance leases have terms expiring through July 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="f-389" continuedAt="i7d4070337e584e54a0627d156e0ef39a" escape="true">Information about the Company&#8217;s lease costs are as follows:</ix:nonNumeric></span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2819030a312f4727b9777002666472a9"><ix:continuation id="id51ff9f66a8148f18daf3b7b19fcb579"><ix:continuation id="i7d4070337e584e54a0627d156e0ef39a"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-390">213</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-391">134</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-392">138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-393">216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-394">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-395">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-396">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-397">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-398">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-399">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash information related to our leases are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2021<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-400">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:FinanceLeasePayments" scale="3" id="f-401">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-402">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:FinanceLeasePayments" scale="3" id="f-403">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2021<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-404">4.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-405">3.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-406">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-407">0.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-408">2.54</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-409">2.60</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-410">3.98</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-411">4.00</ix:nonFraction>%</span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-412" escape="true"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-413" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-414">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-415">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-416">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-417">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-418">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-419">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-420">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-421">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-422">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-423">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-424">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-425">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-426">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-427">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-428">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-429">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-430">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-431">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-432">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-433">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-434" continuedAt="i4f5843ce47a042c3b5b5716e6c1784dc" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4f5843ce47a042c3b5b5716e6c1784dc"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="f-435" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:67.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="f-436">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="f-437">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-439">2,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="f-440">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" format="ixt:num-dot-decimal" scale="3" id="f-441">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="f-442">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="f-443">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" format="ixt:num-dot-decimal" scale="3" id="f-444">1,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" scale="3" id="f-445">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-446">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-447">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="f-448">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="apyx:JointAndSeveralPayrollLiability" format="ixt:num-dot-decimal" scale="3" id="f-449">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="apyx:ShortTermContractLiabilities" scale="3" id="f-450">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="apyx:ShortTermContractLiabilities" scale="3" id="f-451">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="apyx:UncertainTaxPositionsLiability" format="ixt:num-dot-decimal" scale="3" id="f-452">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="apyx:UncertainTaxPositionsLiability" format="ixt:num-dot-decimal" scale="3" id="f-453">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="f-454">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="f-455">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="f-456">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="f-457">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-458">8,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-459">10,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ProductWarrantyDisclosureTextBlock" id="f-460" continuedAt="i106d150a9c8d4325965d9e659efcabaa" escape="true">PRODUCT WARRANTIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i106d150a9c8d4325965d9e659efcabaa"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="f-461" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product warranty activity consisted of the following for the years ended:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:67.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="f-462">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="f-463">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualWarrantiesIssued" scale="3" id="f-464">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualWarrantiesIssued" scale="3" id="f-465">318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimate to fulfill prior-year warranty obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StandardProductWarrantyAccrualPreexistingIncreaseDecrease" scale="3" id="f-466">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualPreexistingIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualPayments" scale="3" id="f-468">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrualPayments" scale="3" id="f-469">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="f-470">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="f-471">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="apyx:JointandSeveralPayrollLiabilityTextBlock" id="f-472" continuedAt="if0d05850e524436ea224d9ae354e9f22" escape="true">JOINT AND SEVERAL PAYROLL LIABILITY</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if0d05850e524436ea224d9ae354e9f22">During 2018 and 2019, the Company improperly calculated and reported the amount of income to certain employees, and did not collect and remit the correct amount of its employees' portion of income and payroll taxes, related to stock option exercises as required by the IRS. Due to IRS statutory requirements, the Company has joint and several liability for the full amount that was not withheld and remitted to the proper taxing authorities. During 2022, the Company was relieved of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="apyx:JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" format="ixt:num-dot-decimal" scale="0" id="f-473">650,000</ix:nonFraction> of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. This adjustment is included in other income (losses), net in the accompany Consolidated Statement of Operations for the year ended December 31, 2022. This amount of the liability was approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="apyx:JointAndSeveralPayrollLiability" format="ixt:num-dot-decimal" scale="6" id="f-474">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-5" name="apyx:JointAndSeveralPayrollLiability" format="ixt:num-dot-decimal" scale="6" id="f-475">1.0</ix:nonFraction>&#160;million at December&#160;31, 2022 and 2021, respectively. The Company will be relieved of the remainder of the liability as the statute of limitations on the liability expires, which the Company expects to occur during April 2023, or once the Company can establish that its employees have in fact paid these obligations.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-476" continuedAt="i2372bd46955d45cf97b2a13dc21890ec" escape="true">CONTRACT ASSETS AND LIABILITIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2372bd46955d45cf97b2a13dc21890ec"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers may result in the Company having contract assets and liabilities. These contract assets and liabilities arise primarily from OEM development and supply agreements where the development of the goods does not represent a performance obligation on a standalone basis. The Company defers the development fees billed to customers, and the associated costs, and recognizes them as it completes performance obligations on the supply portion of the agreement. Other contract liabilities may be recognized when a customer prepays for goods or services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, respectively, the Company had recorded approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-477">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-478">1.9</ix:nonFraction>&#160;million of contract liabilities and $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-479">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="f-480">0.5</ix:nonFraction>&#160;million of contract assets related to customer prepayments and the deferral of revenues and expenses under these agreements. At December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-481">0.9</ix:nonFraction>&#160;million of the contract liabilities and $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-482">0.1</ix:nonFraction>&#160;million of the contract assets are presented as current in the accompanying Consolidated Balance Sheet within accrued expenses and other current liabilities and prepaid expenses and other current assets, respectively. At December&#160;31, 2021,  $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-483">0.5</ix:nonFraction>&#160;million of the contract liabilities and $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-484">0.1</ix:nonFraction>&#160;million of the contract assets are presented as current in the accompanying Consolidated Balance Sheet within accrued expenses and other current liabilities and prepaid expenses and other current assets, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-485">0.2</ix:nonFraction>&#160;million of contract liabilities and $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-5" name="apyx:ContractWithCustomerAssetRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-486">0.1</ix:nonFraction>&#160;million of contract assets that existed as of December&#160;31, 2021 in sales and cost of sales, respectively, in the accompanying Consolidated Statement of Operations for the year ended December&#160;31, 2022. During 2021, the Company did not recognize any significant contract liabilities or contract assets that existed as of December&#160;31, 2020 in sales or cost of sales in the accompanying Consolidated Statement of Operations for the year ended December&#160;31, 2021.</span></div></ix:continuation><div style="padding-left:27pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_106"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="f-487" continuedAt="ic62c31873ba94f69b4285b302803105b" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic62c31873ba94f69b4285b302803105b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-488" continuedAt="ia2d38a265f344eeeb2f901c939d6a5c3" escape="true">The following table provides the computation of basic and diluted earnings (loss) per share.</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ia2d38a265f344eeeb2f901c939d6a5c3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerators:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-489">23,184</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-490">15,172</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-491"><ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-492">34,516</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-493"><ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-494">34,332</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-495"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-496">0.67</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-497"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-498">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad2fb842f9454872b733d0f3ea008372_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-499">6,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if873b957ef9a452fbbc6e871b2410716_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-500">5,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-501" continuedAt="i9d9d2f9f25bc4c95906637f24a0c592f" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9d9d2f9f25bc4c95906637f24a0c592f" continuedAt="i9dadad749ebf46ccb405e77551612b83"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-502" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense are as follows:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-503">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-504">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-505">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-506">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-507">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-508">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-509">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-510">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-511">4,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-512">2,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-513">1,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-514">613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-515">5,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-516">3,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="apyx:IncomeTaxExpenseBenefitValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-517">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="apyx:IncomeTaxExpenseBenefitValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-518">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-519">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-520">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-521" continuedAt="i3ab7eaa522824b6ba95055c5fe177722" escape="true">Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="i9dadad749ebf46ccb405e77551612b83" continuedAt="icfeee8ea1a78455c8cb9708732c86b27"><div style="margin-top:5pt"><ix:continuation id="i3ab7eaa522824b6ba95055c5fe177722"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-522">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-523">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-524">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-525">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-526">22.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-527">21.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-528">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-529">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" sign="-" name="apyx:EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" scale="-2" id="f-530">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" sign="-" name="apyx:EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" scale="-2" id="f-531">3.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-532">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-533">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-534">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-535">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="f-536">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="f-537">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-538" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of the Company&#8217;s deferred tax assets (liabilities) are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-539">7,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-540">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-541">2,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-542">1,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="f-543">982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance deductibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="apyx:DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" scale="3" id="f-545">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="apyx:DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" scale="3" id="f-546">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory 263A adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="f-547">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="f-549">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="f-550">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" format="ixt:fixed-zero" scale="3" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" scale="3" id="f-552">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-553">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-554">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-555">12,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-556">7,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-557">12,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-558">6,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-559">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-560">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-561">205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-562">205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-563">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="f-564">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-565">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-566">430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all positive and negative evidence regarding the realization of deferred tax assets, including past operating results and future sources of taxable income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the earnings of Apyx Bulgaria, EOOD to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. It has not recorded a deferred tax liability related to the U.S. Federal and State income taxes and foreign withholding taxes on the undistributed earnings of Apyx Bulgaria, EOOD indefinitely invested outside the United States. If it decides to repatriate the foreign earnings, the Company will need to adjust its income tax provision in the period it determines that the earnings will no longer be indefinitely invested outside the United States.&#160; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. As of December 31, 2022 and 2021, the Company has recorded a liability of approximately $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-569"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-570">1.3</ix:nonFraction></ix:nonFraction> million related to uncertain tax positions and accrued approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-571">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="f-572">0.6</ix:nonFraction>&#160;million, respectively, of interest and penalties on these positions. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="icfeee8ea1a78455c8cb9708732c86b27" continuedAt="i7d09f2b5c62242398c33237a94f39539"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-573" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.093%"><tr><td style="width:1.0%"></td><td style="width:58.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Tax Benefits</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of year balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-574">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-575">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions of tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions of tax positions related to the prior year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Decreases for tax positions related to prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of year balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-582">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-583">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal and state income tax examination.  The Company&#8217;s 2019 through 2021 U.S. federal income tax returns are subject to examination by the Internal Revenue Service (&#8220;IRS&#8221;).  The Company&#8217;s state income tax returns are subject to examination for the 2018 through 2021 tax years.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7d09f2b5c62242398c33237a94f39539">During 2022, the Company was notified by the IRS that it is examining the Company&#8217;s 2018, 2019 and 2020 federal income tax returns. During January 2023, the Company was notified that the examination process was complete and that the Company's tax refunds were approved for substantially the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. In the examination, the Company's uncertain tax positions were accepted by the IRS as submitted on our income tax returns and the Company reversed its uncertain tax position in January 2023.</ix:continuation> </span></div><div><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-584" continuedAt="ied43fe4f001f4e1f9019829c5df64c12" escape="true">RETIREMENT PLAN</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ied43fe4f001f4e1f9019829c5df64c12"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a tax-qualified profit-sharing retirement plan under section 401(k) of the Internal Revenue Code for the benefit of eligible employees with an accumulation of funds for retirement on a tax-deferred basis and provides for annual discretionary contribution to individual trust funds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All employees are eligible to participate upon completing <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="apyx:DefinedContributionPlanRequisiteServicePeriod" format="ixt-sec:durwordsen" id="f-585">three months</ix:nonNumeric> of service. The employees may make voluntary contributions to the plan up to the maximum percentage allowed by the Internal Revenue Code. Vesting in employee matching contributions is graded and depends on the years of service. After <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="apyx:DefinedContributionPlanEmployersMatchingContributionVestingPeriod" format="ixt-sec:durwordsen" id="f-586">three years</ix:nonNumeric> from their date of hire, the employees are <ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="apyx:DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" scale="-2" id="f-587">100</ix:nonFraction>% vested. The Company makes matching contributions of <ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-588">50</ix:nonFraction>% of the employee contributions up to a total of <ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-589">3</ix:nonFraction>% of participant payroll. Matching contributions made by the Company totaled approximately $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-590">0.4</ix:nonFraction>&#160;million for each of the years ended December&#160;31, 2022 and 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_115"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-591" continuedAt="icda97e1bf7b6469684757630487eac56" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="icda97e1bf7b6469684757630487eac56"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Tor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">omanova, Mr. Shilev&#8217;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company&#8217;s China joint venture is also a supplie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r of the Company. For the years ended December&#160;31, 2022 and 2021, the Company made purchases from this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="i15c65c91210b4634aa8886aa2c04c687_D20220101-20221231" decimals="-5" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="6" id="f-592">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2be8be05786644b587f7269db8612ba8_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="6" id="f-593">1.3</ix:nonFraction>&#160;million, respectively. At December&#160;31, 2022 and 2021, the Company had net receivables from and payables to this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="ie1bd31e839574eb0b58cd8ec4b423216_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-594">8,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0bafa9f247264d98b3a5973a8aa85489_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-595">1,000</ix:nonFraction>, respective</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_118"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-596" continuedAt="i1cd91b0e773a4edb87ac73d3c02770bc" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1cd91b0e773a4edb87ac73d3c02770bc" continuedAt="ie11b5b9e48fa4525acefa1c1f45d8f6d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="ie11b5b9e48fa4525acefa1c1f45d8f6d" continuedAt="iea6229319b284723bac39ca3c980cfb5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $<ix:nonFraction unitRef="usd" contextRef="i81985ec077fa472193067684bf28ef76_I20220331" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="f-597">250,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i3517b2fe5b464ec5ab2cb6fedcd9c77d_I20220331" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="f-598">1,000,000</ix:nonFraction>. The Company has recorded an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="i20512693f6584e7d82c03a312e6156ee_I20221231" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-599">250,000</ix:nonFraction> in professional services in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed with the U.S. Securities and Exchange Commission on the Company&#8217;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#8220;Goodwin&#8221;), the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, and Tara Semb (&#8220;Semb&#8221;), the Company&#8217;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#8217;s Advanced Energy products and the impact such usage would have on the Company&#8217;s business, operations and prospects. The Complaint seeks an unspecified amount of damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $<ix:nonFraction unitRef="usd" contextRef="i9aae6976833242b1b30c6676851c9194_I20221231" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="f-600">475,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i92b182548e09413c8f592eb9c29abd89_I20221231" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="f-601">2,500,000</ix:nonFraction>. The Company has recorded an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="i1a58968298ce4c70ab56e29d0ce9450d_I20221231" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-602">475,000</ix:nonFraction> in professional services in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of <ix:nonFraction unitRef="lease" contextRef="i6ef0e96305c24e7297840166aa515f96_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-603">two</ix:nonFraction> related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the <ix:nonFraction unitRef="lease" contextRef="i9a0b18b016bd448eabc6ee7bdd802e0b_D20230101-20230316" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="f-604">ten</ix:nonFraction> individual plaintiff&#8217;s allegations could be subject to separate deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $<ix:nonFraction unitRef="usd" contextRef="i978115ab316f4e03b88b250dc52320f6_I20230316" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="f-605">1,450,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i8015e0424ea1487ba240da801ce050f6_I20230316" decimals="-3" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="0" id="f-606">2,400,000</ix:nonFraction>. The Company has recorded an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="i870ddbfe09ce44fab9950cf2896a4dfe_I20230316" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-607">1,450,000</ix:nonFraction> in selling, general and administrative expenses associated with the insurance deductibles in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="iea6229319b284723bac39ca3c980cfb5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company has purchase commitments for inventories totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-608">4.1</ix:nonFraction>&#160;million, all of which is expected to be purchased by the end of 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant sales concentrations for the year ended December 31, 2022. Sales to one customer within the Advanced Energy segment represented <ix:nonFraction unitRef="number" contextRef="iba71a7789d3e40e99df5af434f95f621_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-609">11</ix:nonFraction>% of total sales for the year ended December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from one customer and two customers within the Advanced Energy segment represented <ix:nonFraction unitRef="number" contextRef="ibb1a97606daa4ceba9e7e3f4025e9194_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-610">13</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i445e51d03e01407ab9b5e970e37bb25c_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-611">22</ix:nonFraction>%, respectively, of trade accounts receivable at December 31, 2022 and December 31, 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_121"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 18. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-612" continuedAt="ia3c45da721a84808b6c4502b25186f40" escape="true">STOCK OPTIONS&#160;</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia3c45da721a84808b6c4502b25186f40" continuedAt="icbdbab81f6af481bae15b86a1ea97271"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2007, the Company&#8217;s stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan (the &#8220;Plan&#8221;) to increase the maximum aggregate number of shares of common stock reserved for issuance under the Plan from <ix:nonFraction unitRef="shares" contextRef="i8f4cb62a47674f069376423c04bbf511_I20011231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="6" id="f-613">1.2</ix:nonFraction> million shares (already reserved against outstanding options) to <ix:nonFraction unitRef="shares" contextRef="i8ce22e9e74ae4aad81ea9bf903e52593_I20071030" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="6" id="f-614">1.7</ix:nonFraction> million shares. Except for the increase in the number of shares covered by the Plan, the Plan remained otherwise unchanged. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance <ix:nonFraction unitRef="shares" contextRef="i8f4cb62a47674f069376423c04bbf511_I20011231" decimals="-5" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="6" id="f-615">1.2</ix:nonFraction> million stock options. Stock options to employees typically have a <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-616">ten-year</ix:nonNumeric> life and currently vest over periods between <span style="-sec-ix-hidden:f-617">one</span> and <ix:nonNumeric contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-618">seven years</ix:nonNumeric>. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, the Company&#8217;s stockholders approved the 2012 Share Incentive Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="i853b05ef16534eea839dc217dc64ae1e_I20120731" decimals="0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-619">750,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately <ix:nonFraction unitRef="shares" contextRef="ic2118a02b53544ed902dfa41da2fb932_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-620">170,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, the Company&#8217;s stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="i5dd72154e8a84a13ba2ec410056e0cc3_I20150731" decimals="0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-621">2,000,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately <ix:nonFraction unitRef="shares" contextRef="i13a40b61b75e4a1da2703881874d03b7_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-622">40,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company&#8217;s stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="icb85bfecc9fe411fbf5543ebcc203676_I20170831" decimals="0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-623">3,000,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately <ix:nonFraction unitRef="shares" contextRef="if744468335d24182b13e02e0c5cbee45_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-624">30,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company&#8217;s stockholders approved the 2019 Share Incentive Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="iac91df8b60954d69a9e1632838aa1f72_I20190831" decimals="0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-625">2,000,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022, all <ix:nonFraction unitRef="shares" contextRef="ib635cac0c9b846c38ee05d5e5de8a30e_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-626">200,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company&#8217;s stockholders approved the 2021 Share Incentive Plan covering a total of <ix:nonFraction unitRef="shares" contextRef="i4b00dca027564cc4a6278d01e014e129_I20210831" decimals="0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-627">1,375,000</ix:nonFraction> shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022, all <ix:nonFraction unitRef="shares" contextRef="i627345abf94741d0b8653a012a895db1_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-628">1,375,000</ix:nonFraction> are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2023, the Company granted employees appro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ximately <ix:nonFraction unitRef="shares" contextRef="idba9e20874ac40928de8555b5779b796_I20230111" decimals="0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-629">1,400,000</ix:nonFraction> options to purchase common shares of the Company's stock. All options granted were pursuant to the plans noted above. The options ves</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t over a period of <ix:nonNumeric contextRef="i54189c6eb13741cab646fd61dc525b97_D20230111-20230111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-630">three years</ix:nonNumeric>. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-631" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the Company&#8217;s stock options is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-632">4,938,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-633">5.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-634">894,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-635">9.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-636">232,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-637">6.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-638">203,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-639">8.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-640">5,397,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-641">5.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-642">1,692,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-643">10.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-644">316,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-645">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-646">253,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-647">9.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-648">6,520,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-649">7.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><ix:continuation id="icbdbab81f6af481bae15b86a1ea97271" continuedAt="i3099becc75524164b1777ab03680a286"><div style="text-align:center"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="f-650" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-651">1,802,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75e0b82b58654112a567e39aa1802734_I20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-652">5.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-653">1,692,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-654">6.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-655">1,028,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="f-656">5.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-657">238,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="f-658">6.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-659">2,227,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-660">6.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. Options are valued using the Black-Scholes model. For employee grants, the Company calculates expected life via the simplified method as it does not have sufficient history to determine actual expected life. For non-employee grants, the Company calculates expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior. <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-661" continuedAt="i44d7c12e6ac24ffc81d9d5780bca9476" escape="true">Inputs used in the valuation models are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i44d7c12e6ac24ffc81d9d5780bca9476"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:60.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.121%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Grants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-662">5.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-663">10.96</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if05944548e154442b75796c157713f6b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-664">9.29</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id4d89fb15b914a8b9464e4d4f665063b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-665">11.51</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-666">1.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-667">3.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if05944548e154442b75796c157713f6b_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-668">0.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4d89fb15b914a8b9464e4d4f665063b_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-669">0.8</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-670">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-671">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-672">69.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-673">78.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-674">68.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-675">70.8</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-676">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-677">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if05944548e154442b75796c157713f6b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-678">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4d89fb15b914a8b9464e4d4f665063b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-679">6</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-680">6,697,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-681">5,088,000</ix:nonFraction> in stock-based compensation expense during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is &#8220;in-the-money&#8221;. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation at December 31, 2022 is based on the $<ix:nonFraction unitRef="usdPerShare" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="2" name="apyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" scale="0" id="f-682">2.34</ix:nonFraction> closing stock price of the Company's common stock on December&#160;30, 2022, the last trading day of 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-683">6,074,922</ix:nonFraction> stock options outstanding and expected to vest with an aggregate intrinsic value of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-684">160,000</ix:nonFraction>. These options have a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-685">6.91</ix:nonFraction> and a weighted average remaining contractual term of approximately <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-686">6</ix:nonNumeric> years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-687">4,292,836</ix:nonFraction> stock options outstanding and exercisable with an aggregate intrinsic value of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-688">160,000</ix:nonFraction>. These options have a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-689">5.60</ix:nonFraction> and a weighted average remaining contractual term of approximately <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-690">6</ix:nonNumeric> years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of in the money options exercised during the years ended December&#160;31, 2022 and 2021, was approximately $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-691">900,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-692">1,600,000</ix:nonFraction>, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options or other consideration paid. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options granted during the years ended December&#160;31, 2022 and 2021, was approximately $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" format="ixt:num-dot-decimal" scale="0" id="f-693">11,350,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" format="ixt:num-dot-decimal" scale="0" id="f-694">5,150,000</ix:nonFraction>, respectively. The weighted average fair value of options granted during the years ended December&#160;31, 2022 and 2021, was $<ix:nonFraction unitRef="usdPerShare" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-695">6.71</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-696">5.76</ix:nonFraction>, respectively. The total fair value of options vested during the years ended December&#160;31, 2022 and 2021, was approximately $<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="0" id="f-697">5,260,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="0" id="f-698">4,270,000</ix:nonFraction>, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows employees to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. During the years ended December&#160;31, 2022 and 2021, the Company received <ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" format="ixt:num-dot-decimal" scale="0" id="f-699">125,596</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" format="ixt:num-dot-decimal" scale="0" id="f-700">111,831</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" format="ixt:num-dot-decimal" scale="0" id="f-701">81,737</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="0" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" format="ixt:num-dot-decimal" scale="0" id="f-702">107,357</ix:nonFraction> options, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3099becc75524164b1777ab03680a286">As of December&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="0" id="f-703">8,430,000</ix:nonFraction> of total unrecognized stock-based compensation expense, related to unvested stock options granted under the plans above. This expense is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-704">1</ix:nonNumeric> year.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_124"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 19. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-705" continuedAt="ifcaa5495d6bc4d4286412968f907602b" escape="true">GEOGRAPHIC AND SEGMENT INFORMATION</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifcaa5495d6bc4d4286412968f907602b" continuedAt="i285bc56257ff444e9d9a2f3f2ea19855">&#160;</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i285bc56257ff444e9d9a2f3f2ea19855"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reportable segments are disclosed as principally organized and managed as</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="segment" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-706">two</ix:nonFraction> operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-707" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da9825cefa47e085dc8967533353fa_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-708">36,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7daf90e27a450094b575521306a713_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-709">7,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-710">44,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94da9825cefa47e085dc8967533353fa_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-711">4,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7daf90e27a450094b575521306a713_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-712">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-713">21,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-714">23,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-715">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-716">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da9825cefa47e085dc8967533353fa_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-718">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-719">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-720"><ix:nonFraction unitRef="usd" contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-721">509</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-722">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94da9825cefa47e085dc8967533353fa_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7daf90e27a450094b575521306a713_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-725">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-726">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3fd74d3ecc94c9d852ed481d8155c2d_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-727">42,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb3893cd8fd491f9f46c1f269d3f5e4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-728">5,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-729">48,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3fd74d3ecc94c9d852ed481d8155c2d_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-730">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb3893cd8fd491f9f46c1f269d3f5e4_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-731">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-732">18,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-733">14,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-734">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="f-735">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-736">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-737">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-738">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="f-739">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3fd74d3ecc94c9d852ed481d8155c2d_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb3893cd8fd491f9f46c1f269d3f5e4_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-741">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-742">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-743">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales in 2022 and 2021, were <ix:nonFraction unitRef="number" contextRef="i0dd72b9e18204c609c5668ac31713394_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-744">29.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ide55cc7e04aa4a9dbf8cb858b7ceafaa_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-745">32.0</ix:nonFraction>% of sales, respectively. <ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="f-746" continuedAt="i9ea06462663344faa424056a706291cc" escape="true">Revenue by geographic region, based on the "ship to" location on the invoice are as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i9ea06462663344faa424056a706291cc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b469a871d414d41b9f05c65d751b0f2_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-747">31,208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868b6761ce074d338f4b5ce301df99d1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-748">32,980</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee6627e384748dd93f7c235043736aa_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-749">13,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d35bf44ac044d9b818e2795485ffad_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-750">15,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-751">44,510</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-752">48,517</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 20. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="f-753" continuedAt="i00956b3c05fc4a2398c051f0b164a3c1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i00956b3c05fc4a2398c051f0b164a3c1" continuedAt="i08fd29ae9861485fb4e7ea6734a9f3fb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Execution of Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;), by and among the Company (as borrower) and Apyx China Holding Corp., the Company&#8217;s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $<ix:nonFraction unitRef="usd" contextRef="i9623247cdf6a40419d4a2b011f00d8ed_I20230217" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-754">35</ix:nonFraction>&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $<ix:nonFraction unitRef="usd" contextRef="i498926f26c67490999cf1e6f231404e1_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-755">25</ix:nonFraction>&#160;million, comprised of (i) an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="icd920217a5774a4a8e99a083c1cb188c_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-756">10</ix:nonFraction>&#160;million, (ii) a second tranche of $<ix:nonFraction unitRef="usd" contextRef="ie91aea3453ae4206b00854b54ccdde12_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-757">5</ix:nonFraction>&#160;million, and (iii) a third tranche of $<ix:nonFraction unitRef="usd" contextRef="i4fbd4462461f48afb157563bd14c45a5_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-758">10</ix:nonFraction>&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i982284b9ef6f4f6f9d69822b5e02cff9_I20230217" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-759">10</ix:nonFraction>&#160;million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.  The Credit Agreement matures on February 1, 2028.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Term Loans </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The initial tranche of $<ix:nonFraction unitRef="usd" contextRef="icd920217a5774a4a8e99a083c1cb188c_I20230217" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-760">10</ix:nonFraction>&#160;million was fully funded on February 17, 2023, with approximately $<ix:nonFraction unitRef="usd" contextRef="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-761">2</ix:nonFraction>&#160;million of the proceeds used to pay for transaction fees and other costs incurred in connection with the Credit Agreement. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company&#8217;s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets. The net proceeds of these term loans are to be used for working capital and general corporate purposes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each term loan bears interest at a floating rate based on an Adjusted Term SOFR (as defined in the Credit Agreement), subject to a floor of <ix:nonFraction unitRef="number" contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217" decimals="3" name="apyx:DebtInstrumentInterestRateFloorPercent" scale="-2" id="f-762">2.5</ix:nonFraction>%, plus <ix:nonFraction unitRef="number" contextRef="iaaf38b5907d248938c29ae1623e0a4ae_D20230217-20230217" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-763">7.35</ix:nonFraction>%. The first twenty-four (<ix:nonNumeric contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217" name="apyx:DebtInstrumentPeriodOfInterestOnly" format="ixt-sec:durmonth" id="f-764">24</ix:nonNumeric>) months of the term loans constitute an interest-only period (with a possible twelve (<ix:nonNumeric contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217" name="apyx:DebtInstrumentExtensionPeriod" format="ixt-sec:durmonth" id="f-765">12</ix:nonNumeric>) month extension), with interest payable monthly on the first day of each month. Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (<ix:nonFraction unitRef="numberofmonthlypayment" contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217" decimals="INF" name="apyx:DebtInstrumentNumberOfMonthlyPayments" scale="0" id="f-766">36</ix:nonFraction>) equal monthly payments (or twenty-four (<ix:nonFraction unitRef="numberofmonthlypayment" contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217" decimals="INF" name="apyx:DebtInstrumentNumberOfMonthlyPaymentsExtension" scale="0" id="f-767">24</ix:nonFraction>) with the extension of the interest-only period). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment obligations, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of <ix:nonFraction unitRef="number" contextRef="i6462edbcc6f3498fb5595ceca9c9b20c_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentPrepaymentFeePercent" scale="-2" id="f-768">3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="idd50214c28b1419d87380a2edcf8c85e_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentPrepaymentFeePercent" scale="-2" id="f-769">2</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="ifd8c189ae54b4398bbe43a8016d14d18_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentPrepaymentFeePercent" scale="-2" id="f-770">1</ix:nonFraction>% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of <ix:nonFraction unitRef="number" contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentExitFee" scale="-2" id="f-771">4</ix:nonFraction>% of the total amount funded thereunder. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Revolving Facility </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. The proceeds of the revolving facility may be used for working capital needs and general corporate purposes.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans made under the revolving facility bear interest at a floating rate based on an Adjusted Term SOFR (as defined in the Credit Agreement), subject to a floor of <ix:nonFraction unitRef="number" contextRef="i84ace2066c844d0eb08a5d4455fd34f1_D20230217-20230217" decimals="3" name="apyx:DebtInstrumentInterestRateFloorPercent" scale="-2" id="f-772">2.5</ix:nonFraction>%, plus <ix:nonFraction unitRef="number" contextRef="i37bf520b9b2c4b23b71810b3dd058fcf_D20230217-20230217" decimals="2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-773">4</ix:nonFraction>%. The Company is obligated to pay a fee equal to <ix:nonFraction unitRef="number" contextRef="i84ace2066c844d0eb08a5d4455fd34f1_D20230217-20230217" decimals="3" name="apyx:DebtInstrumentAnnualFeePercent" scale="-2" id="f-774">0.5</ix:nonFraction>% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee pursuant to the terms of the Credit Agreement. Terminations and reductions of the commitments are subject to fees of <ix:nonFraction unitRef="number" contextRef="i29d6f70a7eab414799e5833f411483ba_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentTerminationFees" scale="-2" id="f-775">3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i0ebe1df213944e88b24cf4d7fc508cf9_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentTerminationFees" scale="-2" id="f-776">2</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="ic06bbd8e6458436597927a368cb238b8_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentTerminationFees" scale="-2" id="f-777">1</ix:nonFraction>% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is required to maintain a minimum balance of <ix:nonFraction unitRef="number" contextRef="i29d6f70a7eab414799e5833f411483ba_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" scale="-2" id="f-778">30</ix:nonFraction>% of the lesser of the borrowing base or $<ix:nonFraction unitRef="usd" contextRef="if422168e879e462b8d0dc783bdd44842_I20230217" decimals="-6" name="apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-779">10</ix:nonFraction>&#160;million under the revolving facility.  If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Collateral </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i08fd29ae9861485fb4e7ea6734a9f3fb" continuedAt="i8fc0269314744568abb91ff1d4418633"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Covenants </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions set forth in the Credit Agreement. The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $<ix:nonFraction unitRef="usd" contextRef="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217" decimals="-6" name="apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" format="ixt:num-dot-decimal" scale="6" id="f-780">49</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217" decimals="-6" name="apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-781">60</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217" decimals="-6" name="apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" format="ixt:num-dot-decimal" scale="6" id="f-782">70</ix:nonFraction>&#160;million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $<ix:nonFraction unitRef="usd" contextRef="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217" decimals="-6" name="apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance" format="ixt:num-dot-decimal" scale="6" id="f-783">10</ix:nonFraction>&#160;million in cash and cash equivalents during the duration of the Credit Agreement&#8217;s term. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Events of Default</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement also contains customary Events of Default (as defined in the Credit Agreement) that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to <ix:nonFraction unitRef="number" contextRef="i67955df49b104c96886c90aa72882ab9_D20230217-20230217" decimals="2" name="apyx:DebtInstrumentDefaultApplicableInterestRate" scale="-2" id="f-784">2</ix:nonFraction>% in excess of the applicable interest rate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Issuance of Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Company&#8217;s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-785">250,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-786">0.001</ix:nonFraction>, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-787">3.40</ix:nonFraction> per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale Leaseback of Clearwater, FL Real Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company's unencumbered real property. On February 27, 2023 the Company&#8217;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 14, 2023, Apyx Medical Corporation (the &#8220;Company&#8221;) entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of the Company&#8217;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" decimals="-4" name="apyx:SaleLeasebackPurchaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-788">7,650,000</ix:nonFraction>. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser within thirty (<ix:nonNumeric contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" name="apyx:SaleLeasebackDueDiligencePeriod" format="ixt-sec:durday" id="f-789">30</ix:nonNumeric>) days from the date of execution, during which time the Purchaser retains the right to cancel the Purchase Agreement. The closing shall occur five (<ix:nonNumeric contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" name="apyx:SaleLeasebackCompletionPeriodAfterDueDiligence" format="ixt-sec:duryear" id="f-790">5</ix:nonNumeric>) days following the expiration of the due diligence period. Upon execution of the Purchase Agreement, the Purchaser paid a down payment of $<ix:nonFraction unitRef="usd" contextRef="i76b8d9c682c84508b0bc8b27676bfeda_I20230314" decimals="-3" name="apyx:SaleLeasebackEscrow" format="ixt:num-dot-decimal" scale="0" id="f-791">400,000</ix:nonFraction> into escrow, which shall be held in accordance with the Purchase Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the terms of the Purchase Agreement, the transaction is not conditioned upon Purchaser obtaining any form of financing. The Purchase Agreement contains customary representations, warranties and covenants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the &#8220;Lease&#8221;) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (<ix:nonNumeric contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" name="apyx:SaleLeasebackTermOfLease" format="ixt-sec:duryear" id="f-792">10</ix:nonNumeric>) years commencing from the closing (the &#8220;Initial Term&#8221;), and a renewal term of five (<ix:nonNumeric contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" name="apyx:SaleLeasebackRenewalTerm" format="ixt-sec:duryear" id="f-793">5</ix:nonNumeric>) years, exercisable at the Company&#8217;s option. The annual fixed rent will be $<ix:nonFraction unitRef="usd" contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" decimals="-2" name="apyx:SaleLeasebackAnnualRentPayment" format="ixt:num-dot-decimal" scale="0" id="f-794">619,500</ix:nonFraction> for the first year of the Initial Term, and will be subject to a <ix:nonFraction unitRef="number" contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" decimals="2" name="apyx:SaleLeasebackAnnualRentIncrease" scale="-2" id="f-795">4</ix:nonFraction>% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a <ix:nonFraction unitRef="number" contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" decimals="2" name="apyx:SaleLeasebackManagementFeeOnRentPayment" scale="-2" id="f-796">3</ix:nonFraction>% management fee on rent payments throughout the Initial Term and optional renewal term. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i8fc0269314744568abb91ff1d4418633"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The net cash proceeds the Company expects to receive following closing is approximately $<ix:nonFraction unitRef="usd" contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314" decimals="-5" name="apyx:SaleLeasebackNetCashProceeds" format="ixt:num-dot-decimal" scale="0" id="f-797">6,700,000</ix:nonFraction> after taxes, expenses, and fees. This estimate is subject to the consummation of the transaction and the finalization of the Company&#8217;s obligations associated with the sale. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the &#8220;Stein Suit&#8221;) against individual members of the Company&#8217;s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the &#8220;Pritchard Case&#8221;).  The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing.  The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously.  The outcome of the action is not within the Company&#8217;s control and may not be known for a prolonged period of time.  In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company&#8217;s financial condition, results of operations and cash flows.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_130"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_133"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of December 31, 2022, the Company's disclosure controls and procedures were effective.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f) and 15d-15(f) under the Exchange Act). The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, management carried out an evaluation of the effectiveness of the Company's internal control over financial reporting as of December 31, 2022, based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission Internal Control Integrated Framework (2013). Based on that evaluation, management concluded that the Company's internal control over financial reporting was effective as of December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has not been any change in our internal control over financial reporting (as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our year ended December 31, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_136"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_139"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BACKGROUND AND EXPERIENCE OF DIRECTORS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable the Board of Directors (&#8220;Board&#8221;) to satisfy its oversight responsibilities effectively in light of the Company&#8217;s business and structure, the Governance and Nominating Committee focused primarily on each person&#8217;s background and experience as reflected in the information discussed in each of the directors&#8217; individual biographies set forth immediately below. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. As more specifically described in such person&#8217;s individual biographies set forth below, our directors possess relevant and industry-specific experience and knowledge in the medical, engineering and business fields, as the case may be, which we believe enhances the Board&#8217;s ability to oversee, evaluate and direct our overall corporate strategy. The Governance and Nominating Committee annually reviews and makes recommendations to the Board regarding the composition and size of the Board so that the Board consists of members with the proper expertise, skills, attributes and personal and professional backgrounds needed by the Board, consistent with applicable regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Governance and Nominating Committee believes that all directors, including nominees, should possess the highest personal and professional ethics, integrity and values and be committed to representing the long-term interests of our stockholders. The Governance and Nominating Committee will consider criteria including the nominee&#8217;s current or recent experience as a senior executive officer, whether the nominee is independent, as that term is defined in existing independence requirements of The NASDAQ Stock Market LLC, the business, scientific or engineering experience currently desired on the Board, geography, the nominee&#8217;s industry experience and the nominee&#8217;s general ability to enhance the overall composition of the Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Governance and Nominating Committee does not have a formal policy on diversity; however, in recommending directors, the Board and the Committee consider the specific background and experience of the Board members and other personal attributes in an effort to provide a diverse mix of capabilities, contributions and viewpoints which the Board believes enables it to function effectively as the Board of Directors of a company with our size and nature of business. Moreover, our corporate governance guidelines commit the Company to maintaining a Board with a strong and diverse membership as set forth below.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors serve for one-year terms and are elected at the annual stockholders&#8217; meeting. Set forth below is information regarding the executive officers, directors and key employees of Apyx Medical Corporation as of March&#160;16, 2023.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew Makrides</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1982</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lawrence J. Waldman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lead Independent Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Geraghty</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Andres</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice-Chairman of the Board</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig Swandal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnie Baylor-Henry</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy Levine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Board Diversity Matrix</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The matrix below reflects our Board&#8217;s gender and racial characteristics and LGBTQ+ status, based on the self-identification of our directors. Each of the categories listed below has the meaning as it is used in Nasdaq Rule 5605(f). </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.950%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="54" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board Diversity Matrix (as of December 31, 2022 and 2021)</span></td></tr><tr><td colspan="54" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Number of Directors                               8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Makrides</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwin</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Waldman</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Andres</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Geraghty</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swandal</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Baylor-Henry</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Levine</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="54" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gender Identity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Male</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Female</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Did Not Disclose Gender</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="54" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Demographic Background</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">African American or Black</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alaskan Native or Native American</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asian</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hispanic or Latinx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Native Hawaiian or Pacific Islander</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">White</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Did Not Disclose Demographic Background</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Knowledge, Skills and Experience Matrix</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The matrix below summarizes certain of the key experiences, qualifications, skills, and attributes that our directors bring to the Board to enable effective oversight. This matrix is intended only to provide a summary of our directors&#8217; qualifications and is not a complete listing of each director&#8217;s strengths and contributions to the Board. Additional information on each director is set forth in their respective biography. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.950%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="54" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Knowledge, Skills and Experience Matrix</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Makrides</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwin</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Waldman</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Andres</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Geraghty</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swandal</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Baylor-Henry</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Levine</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Public Company Board Experience</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk Management</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Governance\Ethics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal\Regulatory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HR\Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Executive Experience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Strategic Planning\Oversight</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and Marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Device Industry</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Makrides</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Esq. age 81, Chairman of the Board of Directors since December 1982, received a Bachelor of Arts degree in Psychology from Hofstra University and a Juris Doctor Degree from Brooklyn Law School. He is a member of the Bar of the State of New York and practiced law from 1968 until joining Apyx Medical Corporation as a co-founder and Executive Vice President and director, in 1982. Mr. Makrides became President of the Company in 1985 and the CEO in December 1998 and served as such until March 18, 2011 at which point he relinquished his position as President, but remained CEO until December 2013. Mr. Makrides employment contract expired December 31, 2016. Mr. Makrides has over 30 years of executive experience in the medical device industry. The Company believes Mr. Makrides is qualified to serve as Chairman because of his over 30 years of experience in the medical device industry as well as with his previous tenure with the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Charles D. Goodwin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 57, Chief Executive Officer and a Director of Apyx Medical since December 2017, is an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accomplished senior executive with over 25 years of experience in the healthcare industry. Before joining Apyx Medical in December 2017, Mr. Goodwin was the Chief Executive Officer of MIS Implants Technologies, Inc., a privately held company specializing in dental implants. Prior to this position, Mr. Goodwin spent more than 11 years with Olympus/Gyrus ACMI in a variety of commercial and leadership roles of increasing responsibility. Mr. Goodwin began as a regional sales director for Gyrus in 2002 and was later promoted to Vice President of Sales, overseeing the Company&#8217;s strong commercial ramp and assisting Gyrus&#8217; executive leadership team in the successful acquisition of American Cytoscope Makers, or &#8220;ACMI&#8221;, for $500 million in 2005. As President of Gyrus ACMI&#8217;s surgical division, Mr. Goodwin developed the company&#8217;s global distribution network and achieved average annual sales growth of 35% for three consecutive years, resulting in a promotion to President of Worldwide Sales in 2007. As President of Worldwide Sales for Gyrus ACMI, Mr. Goodwin was responsible for a global business with approximately 700 employees and was a key contributor to the successful sale of Gyrus ACMI to Olympus for $2.2 billion in 2008. Mr. Goodwin served as Group Vice President of Olympus Corporation&#8217;s global surgical energy group, where he was responsible for commercial strategy, R&amp;D and operations for a business with more than 500 employees worldwide. Mr. Goodwin held this position for five years before joining MIS Implants Technologies, Inc. in 2014. In March, 2022 Mr. Goodwin joined the Board of ZSX Medical, LLC, a clinical stage medical device company improving minimally-invasive surgery. Mr. Goodwin holds a B.A. in Finance and Economics from Eastern Washington University. The Company believes Mr. Goodwin is qualified to serve as a Director given his over 25 years of experience in the medical device industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tara Semb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 53, Chief Financial Officer, Treasurer and Secretary since January 2019. Prior to joining Apyx Medical, Ms. Semb was the Chief Financial Officer for AVAIL Vapor LLC, a manufacturer and retailer of e-liquid for use in electronic vapor devices, from 2015 until 2018. Ms. Semb previously worked for Amsted Industries, a diversified global manufacturer of industrial components, in multiple positions of increasing responsibility from 2006 until 2015, culminating in her promotion to Director of Finance for the company&#8217;s rail bearings division in 2013. Before joining Amsted Industries as Director of Internal Audit in 2006, she held financial and operational roles at Blyth Industries, a manufacturer and seller of candles and home fragrance products, and Anixter International, a global distributor of network &amp; security solutions. She began her career in 1991 as an auditor at Price Waterhouse. Ms. Semb holds a Bachelor of Science degree in Accounting from the University of Illinois, as well as an MBA from Washington University in St. Louis. She is a Certified Public Accountant (CPA).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Todd Hornsby</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 47, Executive Vice President since January 2019, has responsibility for global Commercial operations. He is an accomplished Senior Executive with more than 20 years of success in the medical device and biotech industries. Throughout his career, Todd has held various leadership positions and has extensive experience in sales, sales management, and with building strong teams and launching new technologies. Since joining Apyx&#8482; Medical in August 2014, Todd has focused primarily on the commercialization of Apyx&#8217;s Renuvion / J-Plasma advanced energy system. Prior to joining Apyx, Todd held roles of increasing seniority and responsibility at CryoLife, Inc. During his tenure, Todd directed the US Sales team, with a diversified product portfolio of biological heart valves and vascular grafts, surgical adhesives and hemostatic agents, dialysis access and CHF chronic heart failure products. Todd also directed successful integrations of three acquisitions into the US sales channel. Early in his medical device career, Todd held positions with Ethicon - Endo Surgery and Medex Medical. Todd holds a BA in Psychology from Hope College. He is also the recipient of many awards for sales achievement and growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Moshe Citronowicz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 70, Senior Vice President since 2012, came to the United States in 1978 and has worked in a variety of manufacturing and high technology industries. In October 1993, Mr. Citronowicz joined the Company as Vice President of Operations and served as our Chief Operating Officer until November 2011. Currently, he is serving as the Senior Vice President. Mr. Citronowicz&#8217;s employment contract extends to December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lawrence J. Waldman, CPA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, age 76, Director since March 2011, Lead Independent Director, and Audit Committee Chair. Mr. Waldman has over thirty-five years of experience in public accounting. Mr. Waldman currently serves as a senior advisor to First Long Island Investors, LLC, an investment and wealth management firm since May 2016. Prior to that Mr. Waldman served as an advisor to the accounting firm of EisnerAmper LLP, where he was previously the Partner-in-Charge of Commercial Audit Practice Development for Long Island since September 2011. Prior to joining EisnerAmper LLP, Mr. Waldman was the Partner-in-Charge of Commercial Audit Practice Development for Holtz Rubenstein Reminick, LLP from July 2006 to August 2011. Mr. Waldman was the Managing Partner of the Long Island office of KPMG LLP from 1994 through 2006, the accounting firm where he began his career in 1972. Mr. Waldman was elected to the Board of Directors of Comtech Telecommunications Corp. in August, 2015 and since December 2015, serves as Chair of its Audit Committee, and since December 17, 2021 serves as its Lead Independent Director. In October 2016, Mr. Waldman was appointed and subsequently in December 2016 elected to the Board of Directors of CVD Equipment Corporation, and serves as the Chair of the Audit Committee and as Lead Independent Director. In January 2021, Mr. Waldman was appointed to serve as non-Executive Chairman of the Board of CVD Equipment Corporation. Mr. Waldman also served through October 2018 as a member of the Board of Directors of Northstar/ RXR Metro Income Fund, a non-traded Real Estate Investment Trust, where he </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">also had served as a member of its Audit Committee starting in 2014. Mr. Waldman is also the Chair of the Supervisory Committee of Bethpage Federal Credit Union. Mr. Waldman also served as a member of the State University of New York&#8217;s Board of Trustees and as Chair of its Audit Committee. He previously served as the Chairman of the Board of Trustees of the Long Island Power Authority and as Chair and a member of the Finance and Audit Committee of its Board of Trustees. Mr. Waldman meets the definition of a financial expert as defined by the SEC and The NASDAQ Stock Market LLC. The Company believes Mr. Waldman is qualified to serve as Director, Audit Committee Chair and Lead Independent Director because of his over 35 years of experience in public accounting and his positions on various boards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Geraghty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 75, Director since March 2010 and Compensation Committee Chair. Mr. Geraghty was previously employed as the President of Global Sales at Optos, Inc., a developer and manufacturer of retinal imaging devices for screening, detection and diagnosis of eye related conditions. From 2005 through 2008, he was the President of International Sales at Gyrus Acmi where he first started in 2000 as Senior Vice President of Sales for Gyrus Medical. Prior to this, Mr. Geraghty was the Vice President of Sales and Marketing for Everest Medical, Inc. and before that was the Director of Marketing for Advanced Products at Arthrocare Corporation. Mr. Geraghty specializes in building independent direct sales teams in the medical device industry and has extensive domestic and international sales and marketing experience. He received his bachelor&#8217;s degree from St. Mary&#8217;s University and graduate degree in Executive Sales Management from the University of Minnesota. The Company believes Mr. Geraghty is qualified to serve as Director and Compensation Committee Chair because of his extensive domestic and international sales, marketing, and management experience.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Craig Swandal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 62, Director since March 2018. Mr. Swandal has over 30 years of experience at public and privately-held medical technology and electronics manufacturing companies. He began his career in 1981 at Unisys Corporation, a manufacturer of main frame computer systems, where he held a variety of manufacturing positions of increasing responsibility. In 1995 he joined Silent Knight, a manufacturer of industrial fire and security systems, as a Manufacturing Manager and was promoted to Vice President of Operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2001, Mr. Swandal joined Gyrus, a manufacturer of surgical devices, where he was responsible for the company&#8217;s manufacturing operations as Director of Operations and later Vice President of Operations. Following Gyrus&#8217;s acquisition of ACMI in 2005, Mr. Swandal was promoted to Senior Vice President and was responsible for the global operations of the combined company. He developed and executed Gyrus ACMI&#8217;s strategy to consolidate its manufacturing, distribution, customer service and service and repair operations and was a member of the leadership team that successfully sold the company to Olympus Corporation for $2.2 billion in 2008. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the acquisition of Gyrus ACMI, Mr. Swandal served on the executive leadership teams of several companies, including ATS Medical, ACELL and Tendyne, where he was focused on operational development and currently holds a position. He is currently the Principal of Lead 2 Change Consulting, where he assists companies in identifying and implementing new manufacturing initiatives. Mr. Swandal serves as a member of the Board of Managers for Tiumed LLC a nontraded medical device start up. Mr. Swandal holds a Bachelor&#8217;s degree in Organizational Management and Communications from Concordia University, as well as a mini Master of Business Administration in Medical Technology from the University of St Thomas. The Company believes Mr. Swandal is qualified to serve as Director because of his extensive experience in manufacturing operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Andres</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 65, Vice Chairman of the Board of Directors and Governance and Nominating Committee Chair since July 2014, has over thirty years of experience in the medical device industry. Since April, 2004, Mr. Andres has been a private consultant, doing business through John C. Andres, LLC, specializing in patent/business strategy development and execution. He also is a partner of Hawk Healthcare, LLC, which provides strategic transaction management to private individuals and companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Mr. Andres joined the Board of Directors of Adaptilens, LLC, which is developing an accommodating intraocular lens. In 2017, Mr. Andres joined the Board of Directors of Longeviti Neuro Solutions, LLC which develops and sells cranial implant products for cranial reconstruction. In 2004, Mr. Andres helped found K2M, Inc. (KTWO) and from 2004 until 2010 served as a member of the Board of Directors of K2M, Inc. Prior to 2004, Mr. Andres held various legal and strategic business development positions at the Surgical Division of Tyco Healthcare Group, LLP, now Medtronic (NYSE: MDT) and its predecessor, United States Surgical Corporation. Before joining U.S. Surgical, Mr. Andres worked at the New York law firm of Morgan &amp; Finnegan. He received his Associate of Applied Science degree from Rochester Institute of Technology, his Bachelor of Arts degree from Lehigh University and his Juris Doctor from Pace University School of Law. The Company believes Mr. Andres is qualified to serve as a director because of his extensive experience in patent and business strategy development and execution in the medical device industry.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Minnie Baylor-Henry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 75, Director and Regulatory Compliance Committee Chair since August 2019. Ms. Baylor-Henry has over 25 years of regulatory affairs experience. She is the President of B-Henry &amp; Associates, LLC, a consulting firm that she founded to provide regulatory strategic support to life sciences companies. Prior to starting her consulting company, she held various executive level positions over a 15-year period at Johnson &amp; Johnson (J&amp;J). Before retiring from J&amp;J in 2015, she was the Worldwide Vice President of Regulatory Affairs-Medical Devices. During her time at J&amp;J, she also had served as the Vice President-Medical &amp; Regulatory Affairs in the Over-the Counter Group, as well as Senior Director, Regulatory Affairs- Pharmaceuticals. Ms. Baylor-Henry also worked for Deloitte &amp; Touche (2008-2010) as the National Director Regulatory Affairs- Life Sciences. Prior to joining the private sector, she worked for the US Food &amp; Drug Administration (1991-1999) in many roles, including serving as the Director of the Division of Drug, Marketing, Advertising &amp; Communications and the FDA&#8217;s National Health Fraud Coordinator.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Ms. Baylor-Henry joined the Board of Directors of scPharmaceuticals, a publicly-held company focused on developing technologies that enable subcutaneous administration of therapies and in 20 she stepped down from the Board of Directors of PolarityTE, a publicly- held regenerative medicine company. She joined the Board of Directors of Paratek Pharmaceuticals, a publicly-held company focused on solutions for patients with infectious diseases in 2021. In March, 2022, she joined the Board of Directors of Lantheus Holdings, LLC, an innovative diagnostics and targeted therapeutics company. Ms. Baylor-Henry received her pharmacy degree from Howard University&#8217;s College of Pharmacy and a law degree from Catholic University&#8217;s Columbus School of Law. The Company believes Ms. Baylor-Henry is qualified to serve as Director and Regulatory and Compliance Committee Chair because of her extensive experience in global and regulatory management and compliance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Wendy Levine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, age 50, Director, has over 25 years of healthcare marketing and advertising experience across the pharmaceutical, biotech, medical device and vaccine sectors. She is currently Group President and head of the advertising business at 21GRAMS, part of Real Chemistry, a global health innovation company that she founded with her partners in 2018. From 2003 to 2007, Ms. Levine worked at Johnson &amp; Johnson, where she served as Group Product Director in the Specialty Pharmaceuticals Business Unit and then as Director, Stakeholder Marketing in the Medical Device Business Unit. From 2007 to 2009, Ms. Levine held the position of Senior Director of Marketing for the influenza portfolio at Novartis Vaccines. From 2009 to 2014, a love for advertising brought her to the agency world, where she rose through the ranks within account management at The Bloc. From 2014 to 2015, Ms. Levine held the role of EVP, Managing Director at McCann Health. From 2015 to 2017, she worked as Director of Client Services at GSW. Ms. Levine received her bachelor&#8217;s degree in interdisciplinary studies (economics and Western European culture) from the University of Pittsburgh and a master&#8217;s degree in education from Beaver College (Arcadia University).  The Company believes Ms. Levine is qualified to serve as Director because of her extensive experience in marketing and advertising.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Involvement in Certain Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Board Members</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board currently has seven independent members, Andrew Makrides, John Andres, Michael Geraghty, Lawrence J. Waldman, Craig Swandal, Minnie Baylor-Henry and Wendy Levine, each of whom meets the existing independence requirements of The NASDAQ Stock Market LLC and the Securities and Exchange Commission.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Leadership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent directors appointed Lawrence J. Waldman as the Lead Independent Director. The Lead Independent Director is appointed by the Board and is responsible for coordinating the activities of the independent directors and coordinating with the Chief Executive Officer of the Company to set agendas for Board meetings and chair executive sessions of the independent directors. The Lead Independent Director is also responsible for meeting, from time to time, with the Company&#8217;s Compensation Committee to discuss the Chief Executive Officer&#8217;s performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Corporate Governance Policies also contain several features which the Company believes will ensure that the Board maintains effective and independent oversight of management, including the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Executive sessions without management and non-independent directors present are a standing Board agenda item. Executive sessions of the independent directors are held at any time requested by an independent director and, in any event, are held in connection with all regularly scheduled Board meetings.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The Board regularly meets in executive session with the CEO without other members of management present.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">All Board committee members are independent directors. The committee chairs have authority to hold executive sessions without management and non-independent directors present.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has no formal policy with respect to separation of the positions of Chairman and CEO or with respect to whether the Chairman should be a member of management or an independent director, and believes that these are matters that should be discussed and determined by the Board from time to time. The Chief Executive Officer of the Company, Charles D. Goodwin, is tasked with the responsibility of implementing our corporate strategy. We believe Mr. Goodwin is best suited for leading discussions, at the Board level, regarding performance relative to our corporate strategy and this discussion accounts for a significant portion of the time devoted at our Board meetings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Evaluations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has adopted a policy to evaluate its performance and effectiveness as well as that of the four standing committees on an annual basis. The purpose of the evaluation is to track progress in certain areas targeted for improvement from year to year and to identify ways to enhance the Board&#8217;s effectiveness. As part of the evaluation, each Director may complete a written questionnaire developed by the Governance and Nominating Committee to provide feedback on the effectiveness of the Board, the Committees, as well as each individual Director&#8217;s own contributions. The collective ratings and comments of the Directors are compiled and then presented to the Governance and Nominating Committee and to the full Board for discussion and action as necessary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board believes that risk management is an important component of the Company&#8217;s corporate strategy. While we assess specific risks at our committee levels, the Board, as a whole, oversees our risk management process, and discusses and reviews with management major policies with respect to risk assessment and risk management. The Board is regularly informed through its interactions with management and committee reports about risks we face in the course of our business.&#160;Our Audit Committee also takes an active role in risk assessment and risk management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee assists the Board in its general oversight of our financial reporting, internal controls, and audit functions, and is directly responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. The Audit Committee reviews and discusses with management and our independent accountants the annual audited and quarterly financial statements (including the disclosures under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and matters required to be discussed by the applicable requirements of the PCAOB), reviews the integrity of the financial reporting processes, both internal and external, reviews the qualifications, performance and independence of our independent accountants, and prepares the Audit Committee Report included in its Annual Report in accordance with rules and regulations of the Securities and Exchange Commission. The Audit Committee has the power to investigate any matter brought to its attention within the scope of its duties. It also has the authority to retain counsel and advisors to fulfill its responsibilities and duties. The Audit Committee also acts as a qualified legal compliance committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The meetings of the Committee are designed to facilitate and encourage communication among the Committee, the Company and the Company&#8217;s independent auditor. The Committee discussed with the Company&#8217;s Independent Auditor the overall scope and plans for their respective audits. The Committee meets with the independent auditor, with and without management present, to discuss the results of their examinations; their evaluations of the Company&#8217;s internal controls; and the overall quality of the Company&#8217;s financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, our Audit Committee consisted of four independent members of the Board of Directors, Lawrence J. Waldman, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John Andres, Michael Geraghty and Craig Swandal. As a smaller reporting company, we are required to have at least two independent members comprising our Audit Committee in accordance with Rule 10A-3 of the Securities Exchange Act of 1934 and the rules of The NASDAQ Stock Market LLC. During 2022, Mr. Waldman served as the Audit Committee Chairperson and financial expert. The Audit Committee meets as often as it determines necessary but not less frequently than once every fiscal quarter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance and Nominating Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Governance and Nominating Committee is responsible for matters relating to the corporate governance of our company and the nomination of members of the board and committees thereof. The Governance and Nominating Committee also provides oversight to the Company over its Environmental, Social and Governance (&#8220;ESG&#8221;) initiatives. During 2022, our Governance and Nominating Committee consisted of three independent members of the Board of Directors, John Andres who serves as Chairperson, Lawrence J. Waldman and Michael Geraghty. The Governance and Nominating Committee meets as often as it determines necessary, but not less than once a year. During March 2022, the Board appointed Minnie Baylor-Henry as a member of the Governance and Nominating Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee is responsible for overseeing our compensation and employee benefit plans (including those involving the issuance of our equity securities) and practices, including formulating, evaluating and approving the compensation of our executive officers and reviewing and recommending to the full Board of Directors the compensation of our Chief Executive Officer. During 2022, our Compensation Committee consisted of four independent members of the Board of Directors, Michael Geraghty who served as Chairperson, John Andres, Lawrence J. Waldman and Wendy Levine. The Compensation Committee meets as often as it determines necessary, but not less than once a year. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Regulatory Compliance Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Regulatory Compliance Committee, formed in the third quarter of 2019, is responsible for matters relating to the Company&#8217;s overall non-financial regulatory and compliance strategies and systems. Specifically, the Committee provides oversight of management&#8217;s efforts to comply with the requirements for a medical device company operating in a highly regulated environment with respect to healthcare compliance, product quality and safety, and other areas as directed by the Board. During 2022, our Regulatory Compliance Committee consisted of four independent members of the Board of Directors, Minnie Baylor-Henry who serves as Chairperson, John Andres, Craig Swandal and Wendy Levine. The Regulatory Compliance Committee meets as often as it determines necessary, but not less than once a year.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below indicates the current membership of each committee and how many times the Board and each committee met and/or acted by written consent in 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:22.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.390%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Audit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governance<br/>and<br/>Nominating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Compliance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew Makrides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Andres</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice Chair</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Geraghty</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lawrence J. Waldman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig Swandal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnie Baylor-Henry</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy Levine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Meetings*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">*   Includes formal meetings and acts of written consent</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">** Mr. Waldman has also been designated the Audit Committee&#8217;s financial expert as well as the Board&#8217;s Lead Independent Director.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made minor revisions to our Code of Ethics (&#8220;the Code&#8221;) in the first quarter of 2021. We also have made available a whistleblower hotline that provides a mechanism for reporting breaches of the Code in an anonymous manner.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Review and acknowledgement of the Code is required of all new employees as part of the on-boarding process, and of all existing employees on an annual basis.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the code of ethics, which expressly includes the fiduciary responsibilities of the CEO and CFO, is available on our website at </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https://apyxmedical.com/code-of-ethics-and-conduct/</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Social and Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Governance and Nominating Committee provides oversight to the Company over its ESG initiatives. The Chairman of that Committee has been actively involved in our work to date with our ESG efforts and continues to lead in providing suggestions as to what else can be done to further enhance our initiatives in this area, including a continued focus on Board diversity from the perspective of gender, ethnic\racial background, and relevant professional and educational experience.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ESG initiatives are sponsored by our CEO and CFO, and consists of a steering committee that includes all members of the executive management team as well as some mid-level managers in certain areas such as R&amp;D, Regulatory and Quality. In July 2022, we published our first ESG report aligned with the Sustainability Accounting Standards Board (SASB) Medical Equipment industry standards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have created a strong environmental, social and governance (&#8220;ESG&#8221;) structure by introducing a cross-functional ESG team which has been working with senior management, our board, and other stakeholders to develop an ESG framework that is aligned with our corporate mission, vision and values. Our ESG initiatives are sponsored by our CEO and CFO, and includes a steering committee comprised of all members of the executive management team as well as some mid-level managers in certain areas such as R&amp;D, Regulatory and Quality. In July 2022, we published our first ESG report aligned with the Sustainability Accounting Standards Board (&#8220;SASB&#8221;) Medical Equipment industry standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part of our culture is to give back and support the communities and people around us.  In 2022, we engaged in both employee volunteer and financial support in the areas of education and the environment.  Such initiatives included the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Week-long high school internship\shadowing program for students interested in the field of engineering;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hosting a group of 25 local students participating in their school&#8217;s STEM program at our manufacturing facility </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employee participation in a local beach clean up event</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Donation of supplies to a local elementary school and to support those impacted by Hurricane Ian</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Local food drive donations as well as gifts for less fortunate children during the holidays</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Several financial contributions and sponsorships to various non-profit organizations</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. Executive Compensation Discussion and Analysis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Compensation Discussion &amp; Analysis (&#8220;CD&amp;A&#8221;) explains our executive compensation program for our named executive officers (&#8220;NEOs&#8221;) listed below. This CD&amp;A also describes the Compensation Committee&#8217;s process for making pay decisions, as well as its rationale for specific decisions related to the fiscal year ended December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Apyx Medical qualifies as a &#8220;smaller reporting company&#8221; as defined by the SEC, which allows us to take advantage of scaled-back disclosure requirements, we are including more extensive narrative about our executive compensation program in an effort to be more transparent. We are also committed to keeping an open dialogue with our stockholders to help ensure that we have a regular pulse on investor perspectives and, as we continue to grow, we intend to further enhance our outreach efforts during 2023 and into the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.666%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, CEO and Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Business Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While 2022 ultimately proved to be a challenging year, our team made important progress under difficult circumstances. We believe we are incrementally better positioned in 2023, with an expanding portfolio of 510(k) clearances for our targeted clinical indications, recently implemented activities to reduce operating expenses while preserving our capabilities as an organization, and additional financing secured to strengthen our balance sheet and enhance our financial flexibility. Below are key financial and strategic highlights:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Total revenue of $44.5 million, representing a decline of  8.3% year-over-year</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Advanced Energy revenue of $36.8 million, representing a decline of approximately 14.4% year-over-year</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Loss from operations of $23.6 million, vs. $14.4 million in 2021</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Safety Communication that warns consumers and health care providers against the use of the Company&#8217;s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company began to experience some slowed demand for the adoption of its Helium Plasma Technology primarily in the U.S. The Company continues to evaluate the full effects the Safety Communication will have on the results of its operations, cash flows and financial position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 4, 2022, the Company announced that it had submitted a 510(k) premarket notification to the FDA for the use of the Renuvion to improve the appearance of lax (loose) skin in the neck and submental region.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2023, we announced we had submitted a 510(k) premarket notification (&#8220;510(k) submission&#8221;) for the Renuvion APR Handpiece to the FDA, supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion&#8217;s indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHAT GUIDES OUR PROGRAM</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Compensation Philosophy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of our compensation program for employees, including our compensation program for executive officers, is to attract, retain and motivate qualified individuals and reward them in a manner that is fair to all stockholders. We strive to provide incentives for every employee that reward them for their contribution to the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.509%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Performance-Driven and Stockholder-Aligned</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A portion of a NEO&#8217;s total compensation should be variable (&#8220;at-risk&#8221;) and linked to the achievement of specific short- and long-term performance objectives and designed to drive stockholder value creation.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Competitively-Positioned</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Target compensation should be competitive with that being offered to individuals in comparable roles at other companies with which we compete for talent to ensure that we employ the best people to lead our success.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Responsibly-Governed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Decisions about compensation should be guided by best-practice governance standards and rigorous processes that encourage prudent decision-making.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elements of Pay</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With these objectives in mind, our Board has built executive and non-executive compensation programs that consist of three principal elements - base salary, performance bonuses and grants of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Pay Element</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">How It&#8217;s Paid</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purpose</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Base Salary</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (Fixed)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provide a competitive base salary rate relative to similar positions in the market and enable the Company to attract and retain critical executive talent.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Performance Bonuses (Annual Incentives) </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash (Variable)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Reward executive officers for delivering on annual financial and/or strategic objectives that contribute to the creation of stockholder value.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-Term Incentives </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity (Variable)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Provide incentives for executive officers to execute on longer-term financial goals that drive the creation of stockholder value, support the Company&#8217;s retention strategy, and provide alignment with the interests of our stockholders.</span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">The Decision-Making Process</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Role of the Compensation Committee.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Compensation Committee oversees the executive compensation program for our NEOs. The Compensation Committee is comprised of independent, non-employee members of the Board. The Compensation Committee works very closely with its independent consultant and management to examine the effectiveness of the Company&#8217;s executive compensation program throughout the year. Details of the Compensation Committee&#8217;s authority and responsibilities are specified in its charter, which may be accessed at apyxmedical.com. The Compensation Committee makes all final compensation and equity award decisions regarding our NEOs, except for the CEO, whose compensation is determined by the independent members of the full Board, based upon recommendations of the Compensation Committee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Role of Management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Members of our management team attend regular meetings where executive compensation, Company and individual performance, and competitive compensation levels and practices are discussed and evaluated. Only the Compensation Committee members are allowed to vote on decisions regarding NEO compensation. The CEO reviews his recommendations pertaining to other executives (non-NEO) pay with the Compensation Committee providing transparency and oversight. Decisions on non-NEO pay are made by the CEO. The CEO does not participate in the deliberations of the Compensation Committee regarding his own compensation. Independent members of the Board make all final determinations regarding CEO compensation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Role of the Independent Consultant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Compensation Committee engages an independent compensation consultant to provide expertise on competitive pay practices, program design, and an objective assessment of any inherent risks of any programs. Pursuant to authority granted to it under its charter, the Compensation Committee has hired Pearl Meyer &amp; Partners, LLC (&#8220;Pearl Meyer&#8221;) as its independent consultant. Pearl Meyer reports directly to the Compensation Committee and does not provide any additional services to management. The Compensation Committee has conducted an independence assessment of Pearl Meyer in accordance with SEC rules.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Role of Peer Group Companies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Compensation Committee strives to set a competitive level of total compensation for each NEO as compared with executive officers in similar positions at comparable companies, which we define as our compensation peer group. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee looks to its independent compensation consultant to provide and analyze competitive market data for each NEO, comparing each of their individual components of compensation and total compensation to market. In addition to the peer group, Pearl Meyer may reference industry-specific, size-adjusted market survey data where appropriate. We continue to consult with Pearl Meyer on our compensation strategy on an ongoing basis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our last competitive assessment, Pearl Meyer recommended and the Compensation Committee approved an update to our peer group. Pearl Meyer developed a set of objective filtering and selection criteria to identify US-based, publicly traded companies in the health care equipment, supplies or technology space that were comparable to Apyx at the time in terms of both revenue and market capitalization. The Company's current compensation peer group was composed of the following companies and was unchanged in 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avedro, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GenMark Diagnostics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OrthoPediatrics Corp.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioLife Solutions, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iCAD, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sensus Healthcare, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corindus Vascular Robotics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRadimed Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TransEnterix, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cutera, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Misonix, Inc.</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TransMedics Group, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ekso Bionics Holdings, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuronetics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah Medical Products Inc.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the survey confirmed that, consistent with our desired philosophy, our compensation arrangements were competitive with the marketplace, with some variation by individual.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Executive Compensation Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay base salaries to our Executive Officers in order to provide a consistent, minimum level of pay that sustained individual performance warrants. We also believe that a competitive annual base salary is important to attract and retain an appropriate caliber of talent for each position over time.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base salaries of our Executive Officers are determined by our Compensation Committee and approved by the Board of Directors. All salary decisions are based on each Executive Officer&#8217;s level of responsibility, experience and recent and past performance, as determined by the Compensation Committee. The Compensation Committee benchmarks base salaries using a major independent consulting firm and using their recommendations and other information the Committee evaluates and establishes the base compensation for our executives. </span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.754%"><tr><td style="width:1.0%"></td><td style="width:42.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</span></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Bonus</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance-based cash incentive bonus is designed to provide an opportunity for our senior executives, including our NEOs, to earn an annual incentive, paid in cash, based on the achievement of certain financial targets and/or strategic priorities. An executive&#8217;s incentive target is a percentage of their base salary. The Compensation Committee assessed our performance against certain financial metrics during 2022 with payouts measured on a scale of zero to 125% of target. The table below discloses the annual incentive targets for each NEO for 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:31.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Base Salary <br/>($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bonus Target <br/>(% of Base Salary)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bonus at Target <br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we used Total Revenue, Operating Income/(loss) and Total Operating Cash Burn as the financial performance metrics for determining annual performance bonuses because we believe it is important to focus on driving our top line revenue growth, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">while focusing on continued improvements to our gross product margins and efficiently investing in our operations to drive towards longer-term, bottom-line profitability. This ultimately results in our ability to maintain acceptable levels of cash burn, setting a path to generating positive cash flow through our overall business performance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Annual Incentive Plan Payouts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the actual financial performance results, the funding for performance bonuses was set at 0% of each NEO&#8217;s applicable target. The Committee retains discretion to further adjust the award upward or downward based on its assessment of individual performance. The following table lists the actual awards earned by the NEOs in 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:27.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bonus Target <br/>(% of Base Salary)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bonus Target<br/>($)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Actual Award Payout<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that equity ownership in our Company is important to provide our Executive Officers and key employees with long-term incentives to better align interests of executives with the interests of stockholders and build value for our stockholders. In addition, equity compensation is designed to attract and retain the executive management team and other key employees throughout the organization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Board approved equity awards to the NEOs. These equity awards were granted using incentive stock options to the extent permitted by the IRS. Stock options are intended to align the interests of award recipients with those of stockholders, since options deliver value only if Apyx&#8217;s stock price appreciates after they are granted. This characteristic ensures that the Executive Officers and key employees have a meaningful portion of their compensation tied to future stock price increases and rewards management for long-term strategic planning through the resulting enhancement of the stock price. The 2022 awards for each NEO were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.906%"><tr><td style="width:1.0%"></td><td style="width:59.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.709%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options <br/>(# of options)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,000</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock options vest one-third per year on the anniversary date of the grant over a 3-year period, expire on the 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> anniversary of the grant date, and have an exercise price of $10.96 per share. Stock options are subject to the award recipient&#8217;s continued employment through each vesting date.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option awards to Executive Officers and key employees are entirely discretionary. The CEO recommends to the Compensation Committee awards for individuals other than himself. The Compensation Committee considers this recommendation along with the prior contribution of these individuals and their expected future contributions to our growth. The Committee formulates and presents its recommended allocation of stock option awards to the Board of Directors for approval. The Compensation Committee then would make an independent determination on CEO stock option awards, again formulating and presenting its recommendation for the allocation of stock option awards to the Board of Directors for approval. The Board of Directors approves, rejects, or, if necessary, modifies the Committee&#8217;s recommendations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Perquisites and Other Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Officers are eligible for the same health and welfare programs and benefits as the rest of our employees in their respective locations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Officers are entitled to participate in and receive employer contributions to Apyx's 401(k) Savings Plan. For more information on employer contributions to the 401(k) Savings Plan see the Summary Compensation Table and its footnotes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax and Accounting Considerations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly consider the various tax and accounting implications of our compensation plans. Section 162(m) of the Code generally prohibits any publicly held corporation from taking a federal income tax deduction for compensation paid in excess of $1 million in any taxable year to the CEO and the other &#8220;covered employees&#8221; as defined in the rule. Under the tax laws in effect before 2018, compensation that qualified as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code was deductible without regard to this limitation. Effective for tax years beginning after December 31, 2017, the Tax Cuts and Jobs Act of 2017 generally eliminated the performance-based exemption, subject to a special rule that grandfathers certain awards and agreements that were in effect on November 2, 2017. While considering tax deductibility as only one of several considerations in determining compensation, the Committee believes that the tax deduction limitation should not compromise its ability to structure compensation programs that provide benefits to the Company that outweigh the potential benefit of a tax deduction and, therefore, may approve compensation that is not deductible for tax purposes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting considerations also play an important role in the design of our executive compensation program. Accounting rules, such as FASB ASC Topic 718-10-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> require us to expense the cost of our stock option grants which reduces the amount of our reported profits. Because of option expensing and the impact of dilution on our stockholders, we pay close attention to the number and value of the shares underlying stock options we grant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Executive Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the compensation paid to each of our Executive Officers for the years ended December&#160;31, 2022 and 2021 for services to our Company in all capacities:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:13.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.143%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="57" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards<br/>($) (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Equity Incentive Plan Compensation Earnings<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in Pension Value and Nonqualified Deferred Compensation Earnings<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Compensation<br/>($) (2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">482,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,170,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CEO and Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">701,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,594,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Executive Vice President</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">879,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,017,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CFO, Treasurer and Secretary</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">These columns represent the grant date fair value of the awards as calculated in accordance with FASB ASC 718 (Stock Compensation). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The amounts for 2022 include compensation under the following plans and programs:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.339%"><tr><td style="width:1.0%"></td><td style="width:34.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.027%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C.D.<br/>Goodwin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">M.<br/>Citronowicz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">T.<br/>Hornsby</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">T.<br/>Semb</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance premiums</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term disability premiums</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurance premiums</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer 401(k) contribution</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,943&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in the table above are pro-rated where applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements and Potential Payments Upon Termination or Change in Control</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we were obligated under four employment agreements.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.52pt">Employment contracts provide for the Executives to remain employed by the Company until such time as their employment is terminated pursuant to the terms of their Employment Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Charles D. Goodwin Employment Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 17, 2020, the Company entered into an Amended and Restated Employment Agreement, effective as of September 17, 2020, with Charles D. Goodwin II, the Company&#8217;s President and Chief Executive Officer (the &#8220;Goodwin Agreement&#8221;). The Goodwin Agreement amends and restates Mr. Goodwin&#8217;s original employment agreement, dated as of December 15, 2017, in its entirety. The term of Mr. Goodwin&#8217;s employment under the Goodwin Agreement commenced as of the effective date thereof and shall continue until terminated in accordance with the terms of the Goodwin Agreement. Under the Goodwin Agreement, Mr. Goodwin will receive an initial annual base salary of $450,000, which shall be reviewed from time to time and may be increased, but not decreased, by the Compensation Committee of the Board of Directors (the &#8220;Committee&#8221;) in its sole and exclusive discretion. Mr. Goodwin shall be entitled to participate in (i) any bonus or incentive plan available to the Company&#8217;s executives generally, on such terms as the Committee may determine in its discretion, and (ii) the equity-based incentive plans of the Company, pursuant to which he may receive awards thereunder, as determined by the Company&#8217;s Board of Directors in its sole discretion from time to time and subject to the terms and conditions of such plans and any applicable award agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Goodwin&#8217;s employment is terminated as a result of death or disability, Mr. Goodwin or his estate shall be entitled to receive (i) any unpaid base salary earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, and, (iv) if Mr. Goodwin is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Mr. Goodwin becomes eligible for medical and dental benefits through another employer. In addition, Mr. Goodwin&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Goodwin&#8217;s options (i) that were exercisable as of the effective date of the Goodwin Agreement and (ii) that would have become exercisable on the next anniversary of the effective date following the date of termination shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Goodwin&#8217;s employment is terminated by the Company for cause or by Mr. Goodwin without good reason, Mr. Goodwin shall be entitled to receive any unpaid base salary earned and accrued prior to the date of termination, and reimbursement for expenses incurred prior to the date of termination. In addition, in the event Mr. Goodwin&#8217;s employment is terminated by Mr. Goodwin without good reason, Mr. Goodwin&#8217;s stock option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Goodwin&#8217;s options which were exercisable as of the date of termination shall remain exercisable for a period of 3 months following the date of termination.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Goodwin&#8217;s employment is terminated by Mr. Goodwin for good reason, by the Company without cause, or in connection with a change of control (as defined in the Goodwin Agreement), Mr. Goodwin shall be entitled to receive (i) any unpaid base salary and other benefits earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, (iv) continued payment of his base salary for the twelve (12) month period following the date of termination, and (v) if Mr. Goodwin is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Mr. Goodwin becomes eligible for medical and dental benefits through another employer. In addition, Mr. Goodwin&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Goodwin&#8217;s options that (i) were exercisable as of the date of termination and (ii) would have become exercisable on the next anniversary of the effective date following the date of termination, shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Goodwin Agreement contains customary non-competition, non-solicitation, and confidentiality provisions in favor of the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tara Semb Employment Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 16, 2020, the Company entered into an Amended and Restated Employment Agreement, effective as of September 16, 2020, with Tara Harris Semb, the Company&#8217;s Chief Financial Officer, Secretary and Treasurer (the &#8220;Semb Agreement&#8221;). The Semb Agreement amends and restates Ms. Semb&#8217;s original employment agreement, dated as of January 2, 2019, in its entirety. The term of Ms. Semb&#8217;s employment under the Semb Agreement commenced as of the effective date thereof and shall continue until terminated in accordance with the terms of the Semb Agreement. Under the Semb Agreement, Ms. Semb will receive an initial annual base salary of $328,000, which shall be reviewed from time to time and may be increased, but not decreased, by the Committee in its sole and exclusive discretion. Ms. Semb shall be entitled to participate in any bonus or incentive plan available to the Company&#8217;s executives generally, on such terms as the Committee may determine in its discretion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Ms. Semb&#8217;s employment is terminated as a result of death or disability, Ms. Semb or her estate shall be entitled to receive (i) any unpaid base salary earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, and, (iv) if Ms. Semb is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Ms. Semb becomes eligible for medical and dental benefits through another employer. In addition, Ms. Semb&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Ms. Semb&#8217;s options (i) that were exercisable as of the effective date of the Semb Agreement and (ii) that would have become exercisable on the next anniversary of the effective date following the date of termination shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Ms. Semb&#8217;s employment is terminated for by the Company for cause or by Ms. Semb without good reason, Ms. Semb shall be entitled to receive any unpaid base salary earned and accrued prior to the date of termination, and reimbursement for expenses incurred prior to the date of termination. In addition, in the event Ms. Semb&#8217;s employment is terminated by Ms. Semb without good reason, Ms. Semb&#8217;s stock option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Ms. Semb&#8217;s options which were exercisable as of the date of termination shall remain exercisable for a period of 3 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Ms. Semb&#8217;s employment is terminated by Ms. Semb for good reason, by the Company without cause, or in connection with a change of control (as defined in the Semb Agreement), Ms. Semb shall be entitled to receive (i) any unpaid base salary and other benefits earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, (iv) continued payment of her base salary for the twelve (12) month period following the date of termination, and (v) if Ms. Semb is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Ms. Semb becomes eligible for medical and dental benefits through another employer. In addition, Ms. Semb&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Ms. Semb&#8217;s options that (i) were exercisable as of the date of termination and (ii) would have become exercisable on the next anniversary of the effective date following the date of termination, shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Semb Agreement contains customary non-competition, non-solicitation, and confidentiality provisions in favor of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Todd Hornsby Employment Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 17, 2020, the Company entered into an Amended and Restated Employment Agreement, effective as of September 17, 2020, with Todd Hornsby, the Company&#8217;s Executive Vice President (the &#8220;Hornsby Agreement&#8221;). The Hornsby Agreement amends and restates Mr. Hornsby&#8217;s original employment agreement, dated as of January 1, 2018, in its entirety. The term of Mr. Hornsby&#8217;s employment under the Hornsby Agreement commenced as of the effective date thereof and shall continue until terminated in accordance with the terms of the Hornsby Agreement. Under the Hornsby Agreement, Mr. Hornsby will receive an initial annual base salary of $347,000, which shall be reviewed from time to time and may be increased, but not decreased, by the Committee in its sole and exclusive discretion. Mr. Hornsby shall be entitled to participate in (i) any bonus or incentive plan available to the Company&#8217;s executives generally, on such terms as the Committee may determine in its discretion, and (ii) the equity-based incentive plans of the Company, pursuant to which he may receive awards thereunder, as determined by the Company&#8217;s Board of Directors in its sole discretion from time to time and subject to the terms and conditions of such plans and any applicable award agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Hornsby&#8217;s employment is terminated as a result of death or disability, Mr. Hornsby or his estate shall be entitled to receive (i) any unpaid base salary earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, and, (iv) if Mr. Hornsby is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Mr. Hornsby becomes eligible for medical and dental benefits through another employer. In addition, Mr. Hornsby&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Hornsby&#8217;s options (i) that were exercisable as of the effective date of the Hornsby Agreement and (ii) that would have become exercisable on the next anniversary of the effective date following the date of termination shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Hornsby&#8217;s employment is terminated by the Company for cause or by Mr. Hornsby without good reason, Mr. Hornsby shall be entitled to receive any unpaid base salary earned and accrued prior to the date of termination, and reimbursement for expenses incurred prior to the date of termination. In addition, in the event Mr. Hornsby&#8217;s employment is terminated by Mr. Hornsby without good reason, Mr. Hornsby&#8217;s stock option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Hornsby&#8217;s options which were exercisable as of the date of termination shall remain exercisable for a period of 3 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event Mr. Hornsby&#8217;s employment is terminated by Mr. Hornsby for good reason, by the Company without cause, or in connection with a change of control (as defined in the Hornsby Agreement), Mr. Hornsby shall be entitled to receive (i) any unpaid base salary and other benefits earned and accrued prior to the date of termination, (ii) reimbursement for expenses incurred prior to the date of termination, (iii) a pro rata bonus for the year of termination, (iv) continued payment of his base salary for the twelve (12) month period following the date of termination, and (v) if Mr. Hornsby is eligible for and elects continuation benefits under COBRA, the Company will pay the employer portion of the COBRA coverage premium for the shorter of (x) the 12-month period following the date of termination, or (y) the time at which Mr. Hornsby becomes eligible for medical and dental benefits through another employer. In addition, Mr. Hornsby&#8217;s outstanding option grants shall continue to be treated in accordance with the terms of the applicable plan and award agreement, provided that the portion of Mr. Hornsby&#8217;s options that (i) were exercisable as of the date of termination and (ii) would have become exercisable on the next anniversary of the effective date following the date of termination, shall become and remain exercisable for a period of 12 months following the date of termination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Hornsby Agreement contains customary non-competition, non-solicitation, and confidentiality provisions in favor of the Company.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moshe Citronowicz Employment Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Citronowicz employment agreement contains an automatic extension for a period of one year after the initial term unless we provide Mr. Citronowicz with appropriate 60 days written notice pursuant to the his contract. Mr. Citronowicz&#8217;s employment agreement provides, among other things, that the Mr. Citronowicz may be terminated as follows: </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Upon the death of the Mr. Citronowicz, in which case Mr. Citronowicz&#8217;sestate shall be paid the basic annual compensation due to Mr. Citronowicz pro-rated through the date of death.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">By the resignation of Mr. Citronowicz at any time upon at least thirty (30) days prior written notice to Apyx in which case Apyx shall be obligated to pay Mr. Citronowicz the basic annual compensation due him pro-rated to the effective date of termination.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">By Apyx, &#8220;for cause&#8221; if during the term of the employment agreement Mr. Citronowicz violates the non-competition provisions of his employment agreement, or is found guilty in a court of law of any crime of moral turpitude in which case the contract would be terminated and provisions for future compensation forfeited.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">By Apyx, without cause, with the majority approval of the Board of Directors, for Mr. Citronowicz at any time upon at least thirty (30) days prior written notice to Mr. Citronowicz. In this case Apyx shall be obligated to pay Mr. Citronowicz compensation in effect at such time, including all bonuses, accrued or prorated and expenses up to the date of termination. Thereafter, Apyx shall pay Mr. Citronowicz three times the salary in effect at the time of termination payable in one lump sum.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">If Apyx fails to meet its obligations to Mr. Citronowicz on a timely basis, or if there is a change in the control of Apyx, the executive may elect to terminate Mr. Citronowicz&#8217;s employment agreement. Upon any such termination or breach of any of its obligations under the employment agreement, Apyx shall pay Mr. Citronowicz a lump sum severance equal to three times the annual salary and bonus in effect the month preceding such termination or breach as well as any other sums which may be due under the terms of the employment agreement up to the date of termination. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other employment contracts that have non-cancelable terms in excess of one year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information with respect to each unexercised stock option held by our Executive Officers as of December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>(# Exercisable)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"># of Securities Underlying Unexercised Options <br/>(# Unexercisable)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Option<br/>Exercise Price<br/>($/Sh)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option Expiration<br/>Range After Grant Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/15/2027</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/19/2032</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/19/2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/27/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/19/2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/19/2032</span></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2003, the Board of Directors adopted, and our stockholders approved Apyx's 2003 Executive and Employee Stock Option Plan covering a total of 1,200,000 shares of common stock issuable upon exercise of options to be granted under the Plan.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2007, our stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan to increase the maximum aggregate number of shares of common stock reserved for issuance under the 2003 Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares, or an increase of 500,000 shares of common stock for future issuance pursuant to the terms of the plan. Except for the increase in the number of shares covered by the plan, the plan remains otherwise unchanged from its present status. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, the Company&#8217;s stockholders approved the 2012 Share Incentive Plan covering a total of 750,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 170,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, the Company&#8217;s stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 40,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company&#8217;s stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of 3,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 30,000 are available to be issued in this plan.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company&#8217;s stockholders approved the 2019 Share Incentive Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 200,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company&#8217;s stockholders approved the 2021 Share Incentive Plan covering a total of 1,375,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December 31, 2022, all 1,375,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in the pricing of any options previously or currently awarded.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of the Board of Directors is responsible for determining the compensation of executive officers of the Company, as well as compensation awarded pursuant to the Company&#8217;s equity incentive plans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, our Compensation Committee consisted of four independent members of the Board of Directors, Michael Geraghty (Chairperson), John Andres, Lawrence J. Waldman and Wendy Levine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No member of the Compensation Committee is or has been an officer or employee of the Company or any of its subsidiaries. In addition, no member of the Compensation Committee had any relationships with the Company or any other entity that require disclosure under the proxy rules and regulations promulgated by the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPENSATION COMMITTEE REPORT</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis contained in this Annual Report on Form 10-K with management. Based on our Compensation Committee&#8217;s review of and the discussions with management with respect to the Compensation Discussion and Analysis, our Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in our Proxy Statement and in this Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 for filing with the SEC. During 2022, our Compensation Committee consisted of three independent members of the Board of Directors, Michael Geraghty, who served as Chairperson, John Andres, Lawrence J. Waldman and Wendy Levine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_148"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity Compensation Plan Information&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;ITEM 5. Market for Registrant&#8217;s Common Equity and Related Stockholder Matters&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Ownership of Certain Beneficial Owners </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information as of March&#160;15, 2023, with respect to the beneficial ownership of the Company&#8217;s common stock by its executive officers, directors, all persons known by the Company to be the beneficial owners of more than 5% of its outstanding shares and by all officers and directors as a group. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.560%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and Address</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Owned (i)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nature of Ownership</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Ownership (i)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Archon Capital Management, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,452,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1100 19th Avenue E</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seattle, WA 98122</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RTW Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,398,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 West 55th St. 16th Floor</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York, NY 10019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">William Weeks Vanderfelt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,158,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coralis 44, Azzuri Village 44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Roches Noires, 31201 Mauritius</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PURA VIDA INVESTMENTS, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,287,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512 West 22nd Street, 7th Floor</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York, NY 10011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cowen Financial Products, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,775,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">599 Lexington Ave.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York, NY 10022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,669,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.560%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moshe Citronowicz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Andrew Makrides</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Todd Hornsby</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">422,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(v)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vi)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lawrence Waldman</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(vii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michael E. Geraghty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(viii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">John Andres</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ix)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Craig Swandal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(x)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minnie Baylor-Henry</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(xi)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wendy Levine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(xii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beneficial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5115 Ulmerton Rd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clearwater, FL 33760</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officers and Directors as a group (10 persons)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i) Based on 34,597,822 outstanding shares of Common Stock as of March 15, 2023, of which officers and directors owned a total of 1,241,379 shares at March 15, 2023. We have calculated the percentage ownership in the table above on the basis of the number of outstanding securities plus, for each person or group, any securities that person or group has current or future right to acquire pursuant to options, warrants, conversion privileges or other rights based on the 13G and 13D SEC filings at March 15, 2023 (and exercisable within 60 days thereafter).</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii) Includes 28,250 shares and 1,641,000 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iii) Includes 456,504 shares and 299,000 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iv) Includes 624,389 shares and 87,855 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(v) Includes 0 shares and 422,668 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(vi) Includes 0 shares and 255,000 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(vii) Includes 37,563 shares and 173,355 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(viii) Includes 17,500 shares and 144,355 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ix) Includes 0 shares and 134,355 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(x) Includes 77,173 shares and 22,682 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(xi) Includes 0 shares and 78,978 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(xii) Includes 0 shares and 29,855 vested options (and exercisable within 60 days thereafter).</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 16(a) Beneficial Ownership Reporting Compliance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16(a) of the Securities Exchange Act of 1934 requires our officers and directors and persons who own more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Co</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mmission. Officers, directors and greater than ten-percent shareholders (the &#8220;Reporting Persons&#8221;) are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Company&#8217;s knowledge, based solely on its review of the copies of such reports received or written representations from certain Reporting Persons that no other reports were required, the Company believes that during its fiscal year ended December&#160;31, 2022 all filing requirements applicable to the Reporting Persons were timely met, with the exception of one delinquent filing for Mr. Swandal who inadvertently failed to timely file a Form 4 showing a single transaction.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_151"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. Certain Relationships and Related Transactions and Director Independence</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships and Related Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Board Members</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board currently has seven independent members, Andrew Makrides, John Andres, Michael Geraghty, Lawrence J. Waldman, Craig Swandal, Minnie Baylor-Henry and Wendy Levine who meet the existing independence requirements of The NASDAQ Stock Market LLC and the Securities and Exchange Commission.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. Principal Accountant Fees and Services </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the aggregate fees billed to us and expected to be billed to us by RSM US LLP, our principal accountant for 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit related fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fees billed</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Audit fees consist of billed and unbilled fees for professional services rendered for the audit of Apyx's annual financial statements and reviews of its interim consolidated financial statements included in quarterly reports and other services related to statutory and regulatory filings or engagements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Audit related fees consist of billed and unbilled fees for assurance and related services that are reasonably related to the performance of the audit or reviews of Apyx's consolidated financial statements and are not reported under &#8220;Audit Fees&#8221;.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">Tax fees consist of billed and unbilled fees for professional services rendered for tax compliance and tax advice (domestic and international). These services include assistance regarding federal and international tax compliance and planning associated with transfer pricing and research and development activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:25.52pt">All other fees consist of fees for products and services other than the services reported above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_160"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. Exhibits and Financial Statement Schedules</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)(1)</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LISTING OF FINANCIAL STATEMENTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following consolidated financial statements of the Company are included in Item 8 of this Report:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">Consolidated Balance Sheets at December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_55">39</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58">Consolidated Statements of Operations for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58">1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_58">40</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">Consolidated Statement of Changes in Equity for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_61">41</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64">Consolidated Statements of Cash Flows for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64">21</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_64">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_67">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_67">43</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)(2)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENT SCHEDULES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto included in this Report.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_163"></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3) EXHIBITS</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Articles of Incorporation of the Registrant (Incorporated by reference to </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Exhibit 3.1 to </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">By laws of the Registrant (Incorporated by reference to </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">Exhibit 3.2 to </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q310-q.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by reference to Exhibit 3.5 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 3, 2017)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx201805038-k.htm">Certificate of Elimination of the Series A 6% Convertible Preferred Stock and Series B Convertible Preferred Stock</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on May 3, 2018)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000086/bvx_20181228x8-k.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 28, 2018)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000029/apyxdescriptionofsecurit.htm">Description of the Registrant&#8217;s Securities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by the reference to Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.1**</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000070/sembemploymentagreement.htm">Tara Semb Amended and Restated Employment Agreement, dated September 16, 2020 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on September 18, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.2**</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000070/amendedrestatedgoodwinem.htm">Charles D. Goodwin II Amended and Restated Employment Agreement, dated September 17, 2020 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on September 18, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.3**</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000070/toddhornsbyagreement.htm">Todd Hornsby Amended and Restated Employment Agreement, dated September 17, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K filed on September 18, 2020)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/719135/000071913523000009/creditagreement.htm">Credit, Security and Guaranty Agreement, dated February 17, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on February 24, 2023) </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/719135/000071913523000009/feeletter.htm">Fee Letter, dated February 17, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on February 24, 2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/719135/000071913523000009/warranttopurchasestock.htm">Warrant to Purchase Stock, dated February 17, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K filed on February 24, 2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000719135/000071913523000012/apyx-20230314.htm">Purchase and Sale Agreement, dated March 14, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on March 15, 2023)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000719135/000071913520000029/apyxmedicalcodeofbusines.htm">Code of Ethics</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Incorporated by the reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2020)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="listofsubsidiaries.htm">List of Subsidiaries</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rsm2022consent.htm">Consent of RSM US LLP</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2022q410-kexhibit311.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2022q410-kexhibit312.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2022q410-kexhibit321.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2022q410-kexhibit322.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB***</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE***</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Presentation Document</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Management contract or compensatory arrangement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration&#160;statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i73dfbc4a18db4511aef7bcb1e0418d6c_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73dfbc4a18db4511aef7bcb1e0418d6c_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Clearwater, Florida on&#160;March&#160;16, 2023.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apyx Medical Corporation</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasurer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ ANDREW MAKRIDES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew Makrides</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ CHARLES D. GOODWIN II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ TARA SEMB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ JOHN ANDRES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Andres</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ LAWRENCE J. WALDMAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lawrence J. Waldman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ MICHAEL GERAGHTY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Geraghty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ CRAIG SWANDAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Craig Swandal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ MINNIE BAYLOR-HENRY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minnie Baylor-Henry</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ WENDY LEVINE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy Levine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>listofsubsidiaries.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iebe3ebf226cc458b9a8cf5cdac434974_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBSIDIARIES OF REGISTRANT</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SUBSIDIARY NAME</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apyx Bulgaria EOOD</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apyx China Holding Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apyx SY Medical Devices (NINGBO) Co., LTD.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>rsm2022consent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i219090f9c1a14c8e8732a54e6d6bb0f5_38"></div><div style="min-height:144pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consent of Independent Registered Public Accounting Firm</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in the Registration Statement on Forms&#160;S-8&#160;(No.&#160;333-258908, No. 333-233994, No. 333-222657, No. 333-207206 and No. 333-195624) and Form S-3 (No. 333-268532) of Apyx Medical Corporation of our report dated March 16, 2023, relating to the consolidated financial statements of Apyx Medical Corporation, appearing in this Annual Report on Form 10-K of Apyx Medical Corporation for the year ended December 31, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; RSM US LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orlando, Florida</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2023 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font><br></font></div><div style="height:90.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a2022q410-kexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4b47fb9389544ea5b23120ad7e840170_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 16, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a2022q410-kexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia6d0dc575d1a49c08473bcc5492e4fb7_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tara Semb, the Registrant's Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form 10-K of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 16, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:42.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a2022q410-kexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i11f0bc075f3a4e7e8bca286bbfeae1b0_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report on Form 10-K of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 16, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>a2022q410-kexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i27ce9e82e22c41afbc9566f4d14b01f3_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report on Form 10-K of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 16, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>apyx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:45c174b4-24e6-4af0-9ca8-997a51f8c128,g:9f6ae534-5ac4-415d-9362-3e1615bb09a1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:apyx="http://apyxmedical.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://apyxmedical.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://apyxmedical.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://apyxmedical.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>0000008 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>0000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSITIONOFTHECOREBUSINESS" roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS">
        <link:definition>0000011 - Disclosure - DISPOSITION OF THE CORE BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENT" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT">
        <link:definition>0000012 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://apyxmedical.com/role/INVENTORIES">
        <link:definition>0000013 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000014 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://apyxmedical.com/role/LEASES">
        <link:definition>0000015 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>0000016 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PRODUCTWARRANTIES" roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIES">
        <link:definition>0000017 - Disclosure - PRODUCT WARRANTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="JOINTANDSEVERALPAYROLLLIABILITY" roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY">
        <link:definition>0000018 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTASSETSANDLIABILITIES" roleURI="http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIES">
        <link:definition>0000019 - Disclosure - CONTRACT ASSETS AND LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>0000020 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://apyxmedical.com/role/INCOMETAXES">
        <link:definition>0000021 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RETIREMENTPLAN" roleURI="http://apyxmedical.com/role/RETIREMENTPLAN">
        <link:definition>0000022 - Disclosure - RETIREMENT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000023 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000024 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONS" roleURI="http://apyxmedical.com/role/STOCKOPTIONS">
        <link:definition>0000025 - Disclosure - STOCK OPTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATION" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION">
        <link:definition>0000026 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://apyxmedical.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000027 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTTables" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables">
        <link:definition>0000029 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://apyxmedical.com/role/INVENTORIESTables">
        <link:definition>0000030 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>0000031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://apyxmedical.com/role/LEASESTables">
        <link:definition>0000032 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PRODUCTWARRANTIESTables" roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESTables">
        <link:definition>0000034 - Disclosure - PRODUCT WARRANTIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>0000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://apyxmedical.com/role/INCOMETAXESTables">
        <link:definition>0000036 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSTables" roleURI="http://apyxmedical.com/role/STOCKOPTIONSTables">
        <link:definition>0000037 - Disclosure - STOCK OPTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONTables" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables">
        <link:definition>0000038 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>0000039 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>0000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSITIONOFTHECOREBUSINESSDetails" roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails">
        <link:definition>0000041 - Disclosure - DISPOSITION OF THE CORE BUSINESS - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails">
        <link:definition>0000042 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails">
        <link:definition>0000043 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESDetails" roleURI="http://apyxmedical.com/role/INVENTORIESDetails">
        <link:definition>0000044 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>0000045 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails">
        <link:definition>0000046 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostDetails" roleURI="http://apyxmedical.com/role/LEASESLeaseCostDetails">
        <link:definition>0000047 - Disclosure - LEASES - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESCashandNonCashInformationDetails" roleURI="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails">
        <link:definition>0000048 - Disclosure - LEASES - Cash and Non-Cash Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseTermsandDiscountRatesDetails" roleURI="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails">
        <link:definition>0000049 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails" roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000050 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>0000050 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>0000051 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PRODUCTWARRANTIESDetails" roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails">
        <link:definition>0000052 - Disclosure - PRODUCT WARRANTIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="JOINTANDSEVERALPAYROLLLIABILITYDetails" roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails">
        <link:definition>0000053 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTASSETSANDLIABILITIESDetails" roleURI="http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails">
        <link:definition>0000054 - Disclosure - CONTRACT ASSETS AND LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>0000055 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails">
        <link:definition>0000056 - Disclosure - INCOME TAXES - Components of Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails">
        <link:definition>0000057 - Disclosure - INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>0000058 - Disclosure - INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>0000059 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>0000060 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RETIREMENTPLANNarrativeDetails" roleURI="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails">
        <link:definition>0000061 - Disclosure - RETIREMENT PLAN - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>0000062 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>0000063 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSNarrativeDetails" roleURI="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails">
        <link:definition>0000064 - Disclosure - STOCK OPTIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSSummaryofStockOptionsDetails" roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails">
        <link:definition>0000065 - Disclosure - STOCK OPTIONS - Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails">
        <link:definition>0000066 - Disclosure - STOCK OPTIONS - Summary of Nonvested Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" roleURI="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails">
        <link:definition>0000067 - Disclosure - STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000068 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
        <link:definition>0000069 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
        <link:definition>0000070 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>0000071 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodDomain" abstract="true" name="DebtInstrumentPrepaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackManagementFeeOnRentPayment" abstract="false" name="SaleLeasebackManagementFeeOnRentPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_TwoThousandTwelveShareIncentivePlanMember" abstract="false" name="TwoThousandTwelveShareIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackPurchaseAgreement" abstract="false" name="SaleLeasebackPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_A2021ShareIncentivePlanMember" abstract="true" name="A2021ShareIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentExtensionPeriod" abstract="false" name="DebtInstrumentExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_ShelfRegistrationMember" abstract="true" name="ShelfRegistrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" abstract="true" name="A2003ExecutiveandEmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_ProvisionForInventoryObsolescence" abstract="false" name="ProvisionForInventoryObsolescence" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" abstract="false" name="DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_OperatingLeaseCostsAbstract" abstract="true" name="OperatingLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="apyx_SaleLeasebackAnnualRentPayment" abstract="false" name="SaleLeasebackAnnualRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_RepaymentOfFinanceLeaseLiabilities" abstract="false" name="RepaymentOfFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DefinedContributionPlanRequisiteServicePeriod" abstract="false" name="DefinedContributionPlanRequisiteServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" abstract="false" name="DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" abstract="false" name="DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_AccessoriesMember" abstract="true" name="AccessoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" abstract="false" name="DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" abstract="false" name="DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ContractWithInternationalDistributorMember" abstract="true" name="ContractWithInternationalDistributorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" abstract="false" name="TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_LesseeDiscountRateIncrementalBorrowingRate" abstract="false" name="LesseeDiscountRateIncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" abstract="true" name="A2001ExecutiveandEmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" abstract="false" name="JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" abstract="false" name="DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AssetPurchaseAgreementTerm" abstract="false" name="AssetPurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodAxis" abstract="true" name="DebtInstrumentPrepaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="apyx_ProvisionForObsolescenceInventory" abstract="false" name="ProvisionForObsolescenceInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_RenuvionJPlasmaGeneratorsMember" abstract="true" name="RenuvionJPlasmaGeneratorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SymmetrySurgicalInc.Member" abstract="true" name="SymmetrySurgicalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackCompletionPeriodAfterDueDiligence" abstract="false" name="SaleLeasebackCompletionPeriodAfterDueDiligence" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_AtTheMarketFacilityMember" abstract="true" name="AtTheMarketFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentExitFee" abstract="false" name="DebtInstrumentExitFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_CapitalizationOfLeaseDerecognizedExecution" abstract="false" name="CapitalizationOfLeaseDerecognizedExecution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_JointandSeveralPayrollLiabilityTextBlock" abstract="false" name="JointandSeveralPayrollLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="apyx_NoncontrollingInterestRequiredCapitalContribution" abstract="false" name="NoncontrollingInterestRequiredCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentNumberOfMonthlyPayments" abstract="false" name="DebtInstrumentNumberOfMonthlyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwaps" abstract="false" name="StockIssuedDuringPeriodSharesStockSwaps" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_ContractWithCustomerAssetRevenueRecognized" abstract="false" name="ContractWithCustomerAssetRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ShortTermContractLiabilities" abstract="false" name="ShortTermContractLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SuitAgainstGoodwinAndSimbMember" abstract="true" name="SuitAgainstGoodwinAndSimbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_CapitalizationOfLeaseRecognizedExecution" abstract="false" name="CapitalizationOfLeaseRecognizedExecution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="apyx_FinanceLeasePayments" abstract="false" name="FinanceLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentPeriodOfInterestOnly" abstract="false" name="DebtInstrumentPeriodOfInterestOnly" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_SaleLeasebackAnnualRentIncrease" abstract="false" name="SaleLeasebackAnnualRentIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" abstract="false" name="DefinedContributionPlanEmployersMatchingContributionVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_DebtInstrumentDefaultApplicableInterestRate" abstract="false" name="DebtInstrumentDefaultApplicableInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackNetCashProceeds" abstract="false" name="SaleLeasebackNetCashProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ChineseSupplierMember" abstract="true" name="ChineseSupplierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_TwoLargestCustomersMember" abstract="true" name="TwoLargestCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_JointAndSeveralPayrollLiability" abstract="false" name="JointAndSeveralPayrollLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="apyx_ProductWarrantyExpenseNet" abstract="false" name="ProductWarrantyExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AccountsReceivableBenchmarkMember" abstract="true" name="AccountsReceivableBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationFees" abstract="false" name="DebtInstrumentTerminationFees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodOneMember" abstract="true" name="DebtInstrumentTerminationPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_StockSwapToAcquireOptionsShares" abstract="false" name="StockSwapToAcquireOptionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTrancheThreeMember" abstract="true" name="DebtInstrumentCovenantTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SecuritiesRegisteredNewIssues" abstract="false" name="SecuritiesRegisteredNewIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_LargestCustomerMember" abstract="true" name="LargestCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" abstract="true" name="ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodAxis" abstract="true" name="DebtInstrumentTerminationPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" abstract="false" name="ProceedsFromStockOptionsExercisedAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_MountingFixturesMember" abstract="true" name="MountingFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" abstract="false" name="StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_LesseeOperatingLeaseNumberOfLeasesExtended" abstract="false" name="LesseeOperatingLeaseNumberOfLeasesExtended" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="apyx_CapitalizationOfLeaseRecongizedNonCash" abstract="false" name="CapitalizationOfLeaseRecongizedNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentInterestRateFloorPercent" abstract="false" name="DebtInstrumentInterestRateFloorPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" abstract="true" name="A2017ExecutiveandEmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" abstract="true" name="AdjustedTermSecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantsDomain" abstract="true" name="DebtInstrumentCovenantsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackDueDiligencePeriod" abstract="false" name="SaleLeasebackDueDiligencePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_ComputerEquipmentandSoftwareMember" abstract="true" name="ComputerEquipmentandSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodOneMember" abstract="true" name="DebtInstrumentPrepaymentPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_ProductWarranty" abstract="false" name="ProductWarranty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentFeePercent" abstract="false" name="DebtInstrumentPrepaymentFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_A2019ShareIncentivePlanMember" abstract="true" name="A2019ShareIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_ApyxSYMedicalDevicesNingboCoLtdMember" abstract="true" name="ApyxSYMedicalDevicesNingboCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SuitsFiledIn2022Member" abstract="true" name="SuitsFiledIn2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_OtherAccruedExpensesAndLiabilitiesCurrent" abstract="false" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="apyx_UncertainTaxPositionsLiability" abstract="false" name="UncertainTaxPositionsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodTwoMember" abstract="true" name="DebtInstrumentTerminationPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentAnnualFeePercent" abstract="false" name="DebtInstrumentAnnualFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodDomain" abstract="true" name="DebtInstrumentTerminationPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackRenewalTerm" abstract="false" name="SaleLeasebackRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_SaleLeasebackTermOfLease" abstract="false" name="SaleLeasebackTermOfLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" abstract="false" name="DebtInstrumentNumberOfMonthlyPaymentsExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantsAxis" abstract="true" name="DebtInstrumentCovenantsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodThreeMember" abstract="true" name="DebtInstrumentPrepaymentPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTrancheTwoMember" abstract="true" name="DebtInstrumentCovenantTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_SaleLeasebackEscrow" abstract="false" name="SaleLeasebackEscrow" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" abstract="false" name="DebtInstrumentCovenantCashAndCashEquivalentsBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" abstract="false" name="Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AdvancedEnergyMember" abstract="true" name="AdvancedEnergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_NoncontrollingInterestTableTextBlock" abstract="false" name="NoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="apyx_OEMMember" abstract="false" name="OEMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentCovenantTrancheOneMember" abstract="true" name="DebtInstrumentCovenantTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentPrepaymentPeriodTwoMember" abstract="true" name="DebtInstrumentPrepaymentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_DebtInstrumentTerminationPeriodThreeMember" abstract="true" name="DebtInstrumentTerminationPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_NonCashTransferOfOtherAssetsToFixedAssets" abstract="false" name="NonCashTransferOfOtherAssetsToFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_FinanceLeaseCostsAbstract" abstract="true" name="FinanceLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="apyx_IncomeTaxExpenseBenefitValuationAllowance" abstract="false" name="IncomeTaxExpenseBenefitValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>apyx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:45c174b4-24e6-4af0-9ca8-997a51f8c128,g:9f6ae534-5ac4-415d-9362-3e1615bb09a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d139e283-668d-4163-9ff3-2b972409af9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fab06f77-7e9f-47bc-9d09-63c4aca23f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d139e283-668d-4163-9ff3-2b972409af9d" xlink:to="loc_us-gaap_AssetsCurrent_fab06f77-7e9f-47bc-9d09-63c4aca23f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_90819a1a-d886-4aee-8dc9-3fd0a8c917b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d139e283-668d-4163-9ff3-2b972409af9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_90819a1a-d886-4aee-8dc9-3fd0a8c917b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ed10024-8678-41bb-ba17-e65b7da5ef87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d139e283-668d-4163-9ff3-2b972409af9d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ed10024-8678-41bb-ba17-e65b7da5ef87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_3bf077a6-5823-4f79-9282-10d7d96ec147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d139e283-668d-4163-9ff3-2b972409af9d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_3bf077a6-5823-4f79-9282-10d7d96ec147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_36470d84-4c6d-45b6-9244-4907d94f9e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d139e283-668d-4163-9ff3-2b972409af9d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_36470d84-4c6d-45b6-9244-4907d94f9e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_af9bdbba-43ab-4625-b4d1-f883e0fe3982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2346e2c4-24a6-4575-9e1c-c04867446e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_af9bdbba-43ab-4625-b4d1-f883e0fe3982" xlink:to="loc_us-gaap_AccountsPayableCurrent_2346e2c4-24a6-4575-9e1c-c04867446e4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_64b6d7e9-94b9-49df-996f-ea5f534a043b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_af9bdbba-43ab-4625-b4d1-f883e0fe3982" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_64b6d7e9-94b9-49df-996f-ea5f534a043b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6562b925-cbc9-47c4-846b-ebfcecc8bebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_af9bdbba-43ab-4625-b4d1-f883e0fe3982" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6562b925-cbc9-47c4-846b-ebfcecc8bebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_4d9e3e71-80be-419d-990d-b83c1617a19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_af9bdbba-43ab-4625-b4d1-f883e0fe3982" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_4d9e3e71-80be-419d-990d-b83c1617a19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_199039e6-90a7-433d-85cc-7acfebc6ee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7ce6c8c3-680f-4886-9f5c-da7685cf4f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_199039e6-90a7-433d-85cc-7acfebc6ee0a" xlink:to="loc_us-gaap_Liabilities_7ce6c8c3-680f-4886-9f5c-da7685cf4f76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_901a446b-de8b-4a1c-bc15-81d8378f6f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_199039e6-90a7-433d-85cc-7acfebc6ee0a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_901a446b-de8b-4a1c-bc15-81d8378f6f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ef63afbe-bb89-4024-8ce6-d39e9ecf81db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_199039e6-90a7-433d-85cc-7acfebc6ee0a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ef63afbe-bb89-4024-8ce6-d39e9ecf81db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3a63d804-f279-43dd-8d7d-0cc9bb582639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5c01ce5b-8a34-40fb-89ab-f92fb63727fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a63d804-f279-43dd-8d7d-0cc9bb582639" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5c01ce5b-8a34-40fb-89ab-f92fb63727fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_75f45101-5d57-4ba6-8e07-82136c0492c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a63d804-f279-43dd-8d7d-0cc9bb582639" xlink:to="loc_us-gaap_LiabilitiesCurrent_75f45101-5d57-4ba6-8e07-82136c0492c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_279c84cf-44ec-4740-84fb-221766b5250e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a63d804-f279-43dd-8d7d-0cc9bb582639" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_279c84cf-44ec-4740-84fb-221766b5250e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7c9fcc24-e9df-43c3-b39c-27df3756aec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a63d804-f279-43dd-8d7d-0cc9bb582639" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7c9fcc24-e9df-43c3-b39c-27df3756aec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26dcbf3a-441b-4231-b5c1-a9c619639880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a63d804-f279-43dd-8d7d-0cc9bb582639" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26dcbf3a-441b-4231-b5c1-a9c619639880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5b6acdc3-da9c-43cb-b6c3-8ded7043ddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e10577b-d585-4774-99cf-1622306ff46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b6acdc3-da9c-43cb-b6c3-8ded7043ddd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e10577b-d585-4774-99cf-1622306ff46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9e82caad-3ae4-4b0e-a64f-82971e427439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b6acdc3-da9c-43cb-b6c3-8ded7043ddd7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9e82caad-3ae4-4b0e-a64f-82971e427439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7b5f2ecc-e99e-4260-aa59-088a9d7a0b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b6acdc3-da9c-43cb-b6c3-8ded7043ddd7" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7b5f2ecc-e99e-4260-aa59-088a9d7a0b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7935b317-2235-4647-a709-0449ef6e0c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b6acdc3-da9c-43cb-b6c3-8ded7043ddd7" xlink:to="loc_us-gaap_InventoryNet_7935b317-2235-4647-a709-0449ef6e0c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_14f35bdb-2dde-424f-967b-c478b0d2d734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b6acdc3-da9c-43cb-b6c3-8ded7043ddd7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_14f35bdb-2dde-424f-967b-c478b0d2d734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_498d8fde-e7ae-4b13-a7dd-cc615ddb1850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b6acdc3-da9c-43cb-b6c3-8ded7043ddd7" xlink:to="loc_us-gaap_IncomeTaxesReceivable_498d8fde-e7ae-4b13-a7dd-cc615ddb1850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea1c1707-a04b-4386-a852-b34f8bfd36ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_caf42cbf-a73e-4a18-bce5-a7d745479ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea1c1707-a04b-4386-a852-b34f8bfd36ba" xlink:to="loc_us-gaap_MinorityInterest_caf42cbf-a73e-4a18-bce5-a7d745479ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_023b3666-e09f-4476-86cc-07396fab2edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea1c1707-a04b-4386-a852-b34f8bfd36ba" xlink:to="loc_us-gaap_StockholdersEquity_023b3666-e09f-4476-86cc-07396fab2edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bbd475e2-4899-4649-95a7-8e2105692c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b31433fd-55d2-40c5-a0f0-43037dafbd45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bbd475e2-4899-4649-95a7-8e2105692c5c" xlink:to="loc_us-gaap_CommonStockValue_b31433fd-55d2-40c5-a0f0-43037dafbd45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f30feff7-2cb3-4f5a-a09c-0b7064b9ee18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bbd475e2-4899-4649-95a7-8e2105692c5c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f30feff7-2cb3-4f5a-a09c-0b7064b9ee18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d26a501b-85bd-4595-8a99-80f696a60e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bbd475e2-4899-4649-95a7-8e2105692c5c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d26a501b-85bd-4595-8a99-80f696a60e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_908d341d-0b91-446b-9f75-0bde143ad732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bbd475e2-4899-4649-95a7-8e2105692c5c" xlink:to="loc_us-gaap_PreferredStockValue_908d341d-0b91-446b-9f75-0bde143ad732" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bb292b4d-c777-4715-802c-5da1ed7a564e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7ce9eb3b-33b9-4645-885b-f171fd3e26d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bb292b4d-c777-4715-802c-5da1ed7a564e" xlink:to="loc_us-gaap_OperatingExpenses_7ce9eb3b-33b9-4645-885b-f171fd3e26d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_04143426-9308-4551-846d-9b452caf3209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bb292b4d-c777-4715-802c-5da1ed7a564e" xlink:to="loc_us-gaap_GrossProfit_04143426-9308-4551-846d-9b452caf3209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6bc29e89-4354-49b1-913b-711516ca48d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b5132efb-5645-4ae7-9c25-87869f9705f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6bc29e89-4354-49b1-913b-711516ca48d9" xlink:to="loc_us-gaap_ProfitLoss_b5132efb-5645-4ae7-9c25-87869f9705f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_062f0b6a-9252-446a-8012-2a9850de6212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6bc29e89-4354-49b1-913b-711516ca48d9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_062f0b6a-9252-446a-8012-2a9850de6212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf34a2a2-b924-44f9-9dbd-b2e992e85d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3ade8aa2-98f2-4e89-a57b-71dc55695f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf34a2a2-b924-44f9-9dbd-b2e992e85d52" xlink:to="loc_us-gaap_OperatingIncomeLoss_3ade8aa2-98f2-4e89-a57b-71dc55695f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5b9049e3-f028-443d-a4fb-0fa1fd726711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf34a2a2-b924-44f9-9dbd-b2e992e85d52" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5b9049e3-f028-443d-a4fb-0fa1fd726711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_887292ca-566c-4b0a-8c74-3aa385eaffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_9f87c701-e8c1-49cd-b34d-a47bc5b43c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_887292ca-566c-4b0a-8c74-3aa385eaffbc" xlink:to="loc_us-gaap_InterestIncomeOperating_9f87c701-e8c1-49cd-b34d-a47bc5b43c2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4c89fc00-af1e-4564-9d64-cb381d6650ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_887292ca-566c-4b0a-8c74-3aa385eaffbc" xlink:to="loc_us-gaap_InterestExpense_4c89fc00-af1e-4564-9d64-cb381d6650ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f14b6fa8-b8af-4f43-befd-b8c319af76c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_887292ca-566c-4b0a-8c74-3aa385eaffbc" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f14b6fa8-b8af-4f43-befd-b8c319af76c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b859f9a6-fda3-461b-a75c-4c8f742b1455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f87e56b-4d4c-46ce-ac09-bd64f09af8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b859f9a6-fda3-461b-a75c-4c8f742b1455" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f87e56b-4d4c-46ce-ac09-bd64f09af8bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5c790252-8ce4-47ac-8ee9-ddda4090592b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b859f9a6-fda3-461b-a75c-4c8f742b1455" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5c790252-8ce4-47ac-8ee9-ddda4090592b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fdc0794a-0353-4fa8-8dbe-eb47f6ca1016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d71e8d2b-da53-40b9-a16d-ff2b9c7ab303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fdc0794a-0353-4fa8-8dbe-eb47f6ca1016" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d71e8d2b-da53-40b9-a16d-ff2b9c7ab303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_1c2926ab-3745-4dca-94bd-f0cf71fc2f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fdc0794a-0353-4fa8-8dbe-eb47f6ca1016" xlink:to="loc_us-gaap_ProfessionalFees_1c2926ab-3745-4dca-94bd-f0cf71fc2f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_f36c4905-86af-4f6a-b166-ba678f6fadce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fdc0794a-0353-4fa8-8dbe-eb47f6ca1016" xlink:to="loc_us-gaap_SalariesAndWages_f36c4905-86af-4f6a-b166-ba678f6fadce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_07ffb604-57f6-45ae-99fa-f8fdeaf8f08d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_fdc0794a-0353-4fa8-8dbe-eb47f6ca1016" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_07ffb604-57f6-45ae-99fa-f8fdeaf8f08d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f633d1f2-a5c0-43a7-b835-0ee2d0575929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78c6d60c-0896-494b-b5b7-c0fa3ac66af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_f633d1f2-a5c0-43a7-b835-0ee2d0575929" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78c6d60c-0896-494b-b5b7-c0fa3ac66af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7da7fd37-7f96-424e-a18e-4eed94d4a6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_f633d1f2-a5c0-43a7-b835-0ee2d0575929" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7da7fd37-7f96-424e-a18e-4eed94d4a6bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ef28de8-7e6e-48aa-9228-085bb4f07003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab625cad-435f-4239-be8a-ae731d66c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ef28de8-7e6e-48aa-9228-085bb4f07003" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab625cad-435f-4239-be8a-ae731d66c9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a18b0307-d59d-4323-bbe7-643843f59cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ef28de8-7e6e-48aa-9228-085bb4f07003" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a18b0307-d59d-4323-bbe7-643843f59cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9979d4c6-4c76-4de9-8999-b67c05af7473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ef28de8-7e6e-48aa-9228-085bb4f07003" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9979d4c6-4c76-4de9-8999-b67c05af7473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fefaea8f-229f-4154-91bb-829bff6ef789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ef28de8-7e6e-48aa-9228-085bb4f07003" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fefaea8f-229f-4154-91bb-829bff6ef789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d440b45-9831-41f5-b6e6-04ef166d2724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e566eb64-ecee-4e7c-9152-59e319a61393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d440b45-9831-41f5-b6e6-04ef166d2724" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e566eb64-ecee-4e7c-9152-59e319a61393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarrantyExpenseNet_71fcc4e1-44d8-4aaf-9512-209709aefe21" xlink:href="apyx-20221231.xsd#apyx_ProductWarrantyExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_apyx_ProductWarrantyExpenseNet_71fcc4e1-44d8-4aaf-9512-209709aefe21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c5d5d661-ee2e-45fb-b1d1-fd62ec17c688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c5d5d661-ee2e-45fb-b1d1-fd62ec17c688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_76551b76-1dc3-4dad-8fe0-2acb68904866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_76551b76-1dc3-4dad-8fe0-2acb68904866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_dd41e753-d253-4743-815a-8a0dbf7f7b3d" xlink:href="apyx-20221231.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_dd41e753-d253-4743-815a-8a0dbf7f7b3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2284035-7503-4281-ab9d-34ceeb21bbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_ProfitLoss_f2284035-7503-4281-ab9d-34ceeb21bbd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_58120907-f527-48cf-b36a-15ac4a78fbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_58120907-f527-48cf-b36a-15ac4a78fbd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_cd7aa7fd-2fd2-4850-aa8b-f945fae0b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_cd7aa7fd-2fd2-4850-aa8b-f945fae0b79e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_68af730c-ee14-4dff-b571-c4b08bc7cacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_ShareBasedCompensation_68af730c-ee14-4dff-b571-c4b08bc7cacf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_09c6452f-d44a-4eb2-8bbb-996c48980c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_09c6452f-d44a-4eb2-8bbb-996c48980c83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_65c02741-3055-487c-ae57-80fcd8ae4d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_65c02741-3055-487c-ae57-80fcd8ae4d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_e50b987e-854a-431c-8e1f-48b17f7c30f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_e50b987e-854a-431c-8e1f-48b17f7c30f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_513a5237-bf03-45b6-a7d5-cf78471d99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_513a5237-bf03-45b6-a7d5-cf78471d99d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d155ecbc-0a45-49ab-b7fe-41a7cb16a242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f5208f79-d022-49ce-b53c-33b9b514ca68" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d155ecbc-0a45-49ab-b7fe-41a7cb16a242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78fc9c36-582c-4a83-b082-507bb42f35da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_8567bcd0-9a27-485b-be6c-85b928e48133" xlink:href="apyx-20221231.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78fc9c36-582c-4a83-b082-507bb42f35da" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_8567bcd0-9a27-485b-be6c-85b928e48133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentOfFinanceLeaseLiabilities_4dc2f4dd-4848-4e43-b882-148bf8542cd3" xlink:href="apyx-20221231.xsd#apyx_RepaymentOfFinanceLeaseLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78fc9c36-582c-4a83-b082-507bb42f35da" xlink:to="loc_apyx_RepaymentOfFinanceLeaseLiabilities_4dc2f4dd-4848-4e43-b882-148bf8542cd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_749103a4-96ae-4118-97e7-dfe4726ff3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78fc9c36-582c-4a83-b082-507bb42f35da" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_749103a4-96ae-4118-97e7-dfe4726ff3ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INVENTORIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_45e0ee84-2367-4374-b43f-ecc473183a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_4622686a-ef61-486d-925b-40537db08a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_45e0ee84-2367-4374-b43f-ecc473183a1b" xlink:to="loc_us-gaap_InventoryRawMaterials_4622686a-ef61-486d-925b-40537db08a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_d40925c6-4759-4d4a-ba3b-49c6ba6f38ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_45e0ee84-2367-4374-b43f-ecc473183a1b" xlink:to="loc_us-gaap_InventoryWorkInProcess_d40925c6-4759-4d4a-ba3b-49c6ba6f38ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e6a82043-0554-49e8-871b-2d4b391a89f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_45e0ee84-2367-4374-b43f-ecc473183a1b" xlink:to="loc_us-gaap_InventoryFinishedGoods_e6a82043-0554-49e8-871b-2d4b391a89f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_eef7a137-e25e-4b0e-b092-f94bfe41b447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_77bdc9ef-51c5-4a2b-bab9-fbe45e0c8f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_eef7a137-e25e-4b0e-b092-f94bfe41b447" xlink:to="loc_us-gaap_InventoryGross_77bdc9ef-51c5-4a2b-bab9-fbe45e0c8f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_b28a8136-a4d3-4def-b085-d941243919a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_eef7a137-e25e-4b0e-b092-f94bfe41b447" xlink:to="loc_us-gaap_InventoryValuationReserves_b28a8136-a4d3-4def-b085-d941243919a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_71b018d1-8edb-45b5-be74-2f0ef81dda20" xlink:href="apyx-20221231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bb80dc18-73f1-40f4-9f76-4b866189dcda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_71b018d1-8edb-45b5-be74-2f0ef81dda20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bb80dc18-73f1-40f4-9f76-4b866189dcda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_48fae5e3-e0b7-48e5-82f3-7ee809c66ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_71b018d1-8edb-45b5-be74-2f0ef81dda20" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_48fae5e3-e0b7-48e5-82f3-7ee809c66ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_50c4ff1a-a5d2-488b-a8fa-9de9dc7f2586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_1edd9b76-d258-4eba-8a82-3f07dde5e300" xlink:href="apyx-20221231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_50c4ff1a-a5d2-488b-a8fa-9de9dc7f2586" xlink:to="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_1edd9b76-d258-4eba-8a82-3f07dde5e300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0c601eab-2ff7-4729-9516-ca757cccc22b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_50c4ff1a-a5d2-488b-a8fa-9de9dc7f2586" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0c601eab-2ff7-4729-9516-ca757cccc22b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_893a8409-ada8-411e-a2c6-896c3caad3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ec265971-dd02-4751-b400-93460f24eef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_893a8409-ada8-411e-a2c6-896c3caad3b2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ec265971-dd02-4751-b400-93460f24eef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_9e82b925-d453-4bff-a79e-697d2e029f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_893a8409-ada8-411e-a2c6-896c3caad3b2" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_9e82b925-d453-4bff-a79e-697d2e029f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_db80f58b-70d3-4ed7-8d35-fae0e6da9989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_893a8409-ada8-411e-a2c6-896c3caad3b2" xlink:to="loc_us-gaap_VariableLeaseCost_db80f58b-70d3-4ed7-8d35-fae0e6da9989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_78840c14-a088-4b52-bca5-4735d7932638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_893a8409-ada8-411e-a2c6-896c3caad3b2" xlink:to="loc_us-gaap_OperatingLeaseCost_78840c14-a088-4b52-bca5-4735d7932638" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_302c08be-fcd8-4c2c-a0b2-8979df1abce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_259884f4-12e4-4a59-873d-4611937c4d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_302c08be-fcd8-4c2c-a0b2-8979df1abce7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_259884f4-12e4-4a59-873d-4611937c4d4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_55deca76-ff79-4af1-adde-ae26dd0febab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_302c08be-fcd8-4c2c-a0b2-8979df1abce7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_55deca76-ff79-4af1-adde-ae26dd0febab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_39ec7265-675b-4759-a73c-fb15be70fd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_302c08be-fcd8-4c2c-a0b2-8979df1abce7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_39ec7265-675b-4759-a73c-fb15be70fd83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f5bb5e2d-81df-4fe9-bc0f-5904a43c3c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_302c08be-fcd8-4c2c-a0b2-8979df1abce7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f5bb5e2d-81df-4fe9-bc0f-5904a43c3c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2cf4cad8-9971-4c37-8f81-13d50d943cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_302c08be-fcd8-4c2c-a0b2-8979df1abce7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2cf4cad8-9971-4c37-8f81-13d50d943cf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c06d2291-6ca4-4c48-a254-0a95b8e9017c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73a307e1-bbfb-48ae-a139-101b9c86e170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_c06d2291-6ca4-4c48-a254-0a95b8e9017c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73a307e1-bbfb-48ae-a139-101b9c86e170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8233fe90-6ca7-4fa9-a9cc-81a8d7c0a27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_c06d2291-6ca4-4c48-a254-0a95b8e9017c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8233fe90-6ca7-4fa9-a9cc-81a8d7c0a27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_90438049-1368-4a0a-ad97-453580fff740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_8989b3fa-92fc-4441-95ee-2bc803f4e8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_90438049-1368-4a0a-ad97-453580fff740" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_8989b3fa-92fc-4441-95ee-2bc803f4e8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b843d2c2-f96e-40b7-9a62-74e34e5bd91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_90438049-1368-4a0a-ad97-453580fff740" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b843d2c2-f96e-40b7-9a62-74e34e5bd91f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_72b28c9b-9668-45e6-a11b-cbbf16becf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_da98e5ff-08fa-41c6-87db-de6ce150769d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_72b28c9b-9668-45e6-a11b-cbbf16becf5b" xlink:to="loc_us-gaap_OperatingLeaseLiability_da98e5ff-08fa-41c6-87db-de6ce150769d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e2532ce8-6cd7-4edf-af40-b9041134d0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_72b28c9b-9668-45e6-a11b-cbbf16becf5b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e2532ce8-6cd7-4edf-af40-b9041134d0ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a95038fd-0608-498f-a285-89d4f9f33421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_4cb07d17-0871-45b0-b605-26bfcf28fe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a95038fd-0608-498f-a285-89d4f9f33421" xlink:to="loc_us-gaap_FinanceLeaseLiability_4cb07d17-0871-45b0-b605-26bfcf28fe0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3c60c740-ed03-42af-af8e-9346d46865e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a95038fd-0608-498f-a285-89d4f9f33421" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3c60c740-ed03-42af-af8e-9346d46865e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1217c878-4a5f-4657-85aa-aabf73d81759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58f8c05c-e63e-48e9-9e14-5ef4cc09002f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1217c878-4a5f-4657-85aa-aabf73d81759" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58f8c05c-e63e-48e9-9e14-5ef4cc09002f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f2070d24-d091-45c3-8ee5-6eb9c34b4828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1217c878-4a5f-4657-85aa-aabf73d81759" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f2070d24-d091-45c3-8ee5-6eb9c34b4828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a398e839-aa50-4f84-babb-907d29dd436c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1217c878-4a5f-4657-85aa-aabf73d81759" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a398e839-aa50-4f84-babb-907d29dd436c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5bb347c7-5f23-41b1-b6a5-4f20f42fafdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1217c878-4a5f-4657-85aa-aabf73d81759" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5bb347c7-5f23-41b1-b6a5-4f20f42fafdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ba42af49-78ab-466a-bcdf-e448a352a6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1217c878-4a5f-4657-85aa-aabf73d81759" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ba42af49-78ab-466a-bcdf-e448a352a6fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShortTermContractLiabilities_e9e49048-f53b-48fb-aa90-16a652276dd1" xlink:href="apyx-20221231.xsd#apyx_ShortTermContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_apyx_ShortTermContractLiabilities_e9e49048-f53b-48fb-aa90-16a652276dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_5b2f7509-6b6d-41a3-a6f0-8348bc175535" xlink:href="apyx-20221231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_5b2f7509-6b6d-41a3-a6f0-8348bc175535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_5b8f5f53-8d86-4fad-a1f0-9bc9dc2ecda5" xlink:href="apyx-20221231.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_5b8f5f53-8d86-4fad-a1f0-9bc9dc2ecda5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_7aa1a0b4-c1d4-4bea-b2d6-24062e8f449f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_us-gaap_AccruedBonusesCurrent_7aa1a0b4-c1d4-4bea-b2d6-24062e8f449f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_ef886d91-99a4-40ff-8299-49a1bd3389d8" xlink:href="apyx-20221231.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_apyx_UncertainTaxPositionsLiability_ef886d91-99a4-40ff-8299-49a1bd3389d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_228b82bc-723e-4ccd-886f-bf1fa829e330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_228b82bc-723e-4ccd-886f-bf1fa829e330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_b778bceb-b77a-40e1-8d74-bf48e6ebae47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_b778bceb-b77a-40e1-8d74-bf48e6ebae47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_c58aa545-e837-44f2-9994-e7542c71e05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_c58aa545-e837-44f2-9994-e7542c71e05a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_73794f8c-de1d-416d-8ec4-c234e128f31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_73794f8c-de1d-416d-8ec4-c234e128f31b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_28a04d89-6411-46e5-a0de-cc556b85bda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_28a04d89-6411-46e5-a0de-cc556b85bda0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_8bc9efed-628f-4c54-bc8e-adf3b1c559d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2f5082cd-b615-4b2d-95c8-ae4630868604" xlink:to="loc_us-gaap_AccruedSalariesCurrent_8bc9efed-628f-4c54-bc8e-adf3b1c559d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a97ce40e-362e-44d1-beb3-b2fe6bd2103a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e48ac119-55fc-40f0-9309-f63ca557cd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97ce40e-362e-44d1-beb3-b2fe6bd2103a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e48ac119-55fc-40f0-9309-f63ca557cd48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance_816aa62a-5d37-4c69-81da-59ff89cd54cf" xlink:href="apyx-20221231.xsd#apyx_IncomeTaxExpenseBenefitValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97ce40e-362e-44d1-beb3-b2fe6bd2103a" xlink:to="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance_816aa62a-5d37-4c69-81da-59ff89cd54cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_846ba3b6-c5c6-48b9-a745-e9cd889f6caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97ce40e-362e-44d1-beb3-b2fe6bd2103a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_846ba3b6-c5c6-48b9-a745-e9cd889f6caf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7bcec08f-b930-4469-86f9-44787d11fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6da6ad3e-db6d-4f0d-b8d8-87bcc19510e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7bcec08f-b930-4469-86f9-44787d11fff5" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6da6ad3e-db6d-4f0d-b8d8-87bcc19510e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d605917d-153e-437d-82f2-ee49e5d83fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7bcec08f-b930-4469-86f9-44787d11fff5" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d605917d-153e-437d-82f2-ee49e5d83fcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9eab23c6-fc7b-4d85-bee4-a60a2be8c813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_26155ce9-bce3-4af8-8e65-a06f3b534924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9eab23c6-fc7b-4d85-bee4-a60a2be8c813" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_26155ce9-bce3-4af8-8e65-a06f3b534924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_37f55dd4-6e6d-4e9f-9888-1b1a01a63e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9eab23c6-fc7b-4d85-bee4-a60a2be8c813" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_37f55dd4-6e6d-4e9f-9888-1b1a01a63e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_544e309c-5e50-4f19-af7d-7c4eab8f6e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9eab23c6-fc7b-4d85-bee4-a60a2be8c813" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_544e309c-5e50-4f19-af7d-7c4eab8f6e97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_cc07d12c-9d3f-4e49-8a1b-c642f3fae0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a17fe358-da0b-4404-a767-b9bc4b3a7b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_cc07d12c-9d3f-4e49-8a1b-c642f3fae0dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a17fe358-da0b-4404-a767-b9bc4b3a7b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_47746162-02d1-4179-9579-a464caaabc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_cc07d12c-9d3f-4e49-8a1b-c642f3fae0dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_47746162-02d1-4179-9579-a464caaabc9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_eeca9071-8756-4806-b596-307edf15adbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_cc07d12c-9d3f-4e49-8a1b-c642f3fae0dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_eeca9071-8756-4806-b596-307edf15adbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent_85c20da8-0d57-44f1-b5c8-e9bcbabcbb77" xlink:href="apyx-20221231.xsd#apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_cc07d12c-9d3f-4e49-8a1b-c642f3fae0dc" xlink:to="loc_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent_85c20da8-0d57-44f1-b5c8-e9bcbabcbb77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_67ba5af8-4228-4f46-9d7f-7f0d217600c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_cc07d12c-9d3f-4e49-8a1b-c642f3fae0dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_67ba5af8-4228-4f46-9d7f-7f0d217600c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_bc4b9fc1-09c1-484a-b847-f4f9e2a5adf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_cc07d12c-9d3f-4e49-8a1b-c642f3fae0dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_bc4b9fc1-09c1-484a-b847-f4f9e2a5adf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_cb070537-f3e1-43dc-988a-2c7161e6d686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_cc07d12c-9d3f-4e49-8a1b-c642f3fae0dc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_cb070537-f3e1-43dc-988a-2c7161e6d686" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9b961004-81c5-4005-812a-5631f5f689bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6caeea50-d496-4755-93f5-0f78de1757ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9b961004-81c5-4005-812a-5631f5f689bd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6caeea50-d496-4755-93f5-0f78de1757ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_eadc265e-b412-4a7a-bd15-7b1f55bb771b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9b961004-81c5-4005-812a-5631f5f689bd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_eadc265e-b412-4a7a-bd15-7b1f55bb771b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8ac1a95d-0726-494c-8c7a-5317685dc16d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4fe90f39-ca03-4dae-bca3-722eaf0007e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_8ac1a95d-0726-494c-8c7a-5317685dc16d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4fe90f39-ca03-4dae-bca3-722eaf0007e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_85768c4f-e664-4f05-80dc-9cac609880aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_8ac1a95d-0726-494c-8c7a-5317685dc16d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_85768c4f-e664-4f05-80dc-9cac609880aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3279c147-576b-459c-bbad-77aab25bb31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_92ffe7a4-f004-4793-9b80-e2a795d2ef46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3279c147-576b-459c-bbad-77aab25bb31c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_92ffe7a4-f004-4793-9b80-e2a795d2ef46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0dc34e25-f8d4-42da-ae98-93370ec4abce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3279c147-576b-459c-bbad-77aab25bb31c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_0dc34e25-f8d4-42da-ae98-93370ec4abce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c3f1539b-6f77-432c-a5cc-1ec562f2059b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c3f1539b-6f77-432c-a5cc-1ec562f2059b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_35c3b6e1-c817-44a0-889f-a6a87aac8c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_35c3b6e1-c817-44a0-889f-a6a87aac8c21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bf951345-9c50-4fe3-99c2-09725251b893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bf951345-9c50-4fe3-99c2-09725251b893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_4558fed4-a7a2-44ca-b626-c2329aab920c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_4558fed4-a7a2-44ca-b626-c2329aab920c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles_c4041a95-6457-47ee-a5d4-71c85e7a7f66" xlink:href="apyx-20221231.xsd#apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:to="loc_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles_c4041a95-6457-47ee-a5d4-71c85e7a7f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6d277018-2cdb-45bd-954a-bd1ce903fa88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6d277018-2cdb-45bd-954a-bd1ce903fa88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_f4e2ad0a-0ddf-4cb9-9013-fcafbe54325a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_f4e2ad0a-0ddf-4cb9-9013-fcafbe54325a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_4cb124d9-66d4-4f3f-81ce-2f42c2d2ef58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_401e8ff4-0327-4bbb-8244-6bd0bd62544b" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_4cb124d9-66d4-4f3f-81ce-2f42c2d2ef58" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>apyx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:45c174b4-24e6-4af0-9ca8-997a51f8c128,g:9f6ae534-5ac4-415d-9362-3e1615bb09a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended" id="i7afad7f0c001400f9b30c8d95f16a3ab_CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f5f0838c-8113-42e4-b568-3d72a8849cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f5f0838c-8113-42e4-b568-3d72a8849cb1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e4e97ef6-0ad0-406b-8051-728067ac67b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_SharesIssued_e4e97ef6-0ad0-406b-8051-728067ac67b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64b6b829-a3dd-4568-9cb8-5c1a04aa27f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64b6b829-a3dd-4568-9cb8-5c1a04aa27f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a9c22085-1421-4e7c-b174-d267d1df04a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a9c22085-1421-4e7c-b174-d267d1df04a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1208b051-cc26-47e1-9450-94f945429aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1208b051-cc26-47e1-9450-94f945429aff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b0f5d5d-af5b-4690-bcc6-5177ecfb3a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b0f5d5d-af5b-4690-bcc6-5177ecfb3a6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e22201-a552-4ca4-bddd-9a076628ae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e22201-a552-4ca4-bddd-9a076628ae3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_ca7a0da2-aab8-4e8c-ad6c-61cdf906293f" xlink:href="apyx-20221231.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_ca7a0da2-aab8-4e8c-ad6c-61cdf906293f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c2780a57-ff9b-4d9c-9a2d-c41ccbf76239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_ProfitLoss_c2780a57-ff9b-4d9c-9a2d-c41ccbf76239" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e8b1ae16-5f00-4de9-9da7-d4ede29ab3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3afe5d35-0bd4-4410-9d85-ae5db58bb42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_506f00a8-e157-443d-b45d-fd9b89c8b753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f5f0838c-8113-42e4-b568-3d72a8849cb1" xlink:to="loc_us-gaap_StatementTable_506f00a8-e157-443d-b45d-fd9b89c8b753" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_de6a5879-100e-476f-abaa-fcdbed654050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_506f00a8-e157-443d-b45d-fd9b89c8b753" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_de6a5879-100e-476f-abaa-fcdbed654050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_de6a5879-100e-476f-abaa-fcdbed654050_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de6a5879-100e-476f-abaa-fcdbed654050" xlink:to="loc_us-gaap_EquityComponentDomain_de6a5879-100e-476f-abaa-fcdbed654050_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de6a5879-100e-476f-abaa-fcdbed654050" xlink:to="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ad75746-fd95-45ba-9166-d1a387a50fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:to="loc_us-gaap_CommonStockMember_9ad75746-fd95-45ba-9166-d1a387a50fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_89f13844-063e-4c7f-a9db-a49a1f995fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_89f13844-063e-4c7f-a9db-a49a1f995fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_08f94a81-db00-4217-89e3-0b4155d7ded6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:to="loc_us-gaap_RetainedEarningsMember_08f94a81-db00-4217-89e3-0b4155d7ded6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_17ad8ba7-2782-46d2-a68b-f7821cb1a9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_17ad8ba7-2782-46d2-a68b-f7821cb1a9e0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="ic458fe8ceeeb4c86a53b24d54e52241d_DESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7521a2c7-dc1d-4a3c-8b0a-bc60bd069a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7521a2c7-dc1d-4a3c-8b0a-bc60bd069a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_50a35274-7810-4d6d-a3fa-0251942fa779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_OperatingIncomeLoss_50a35274-7810-4d6d-a3fa-0251942fa779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_009afcb4-66c3-409a-b176-bae74b82db0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_009afcb4-66c3-409a-b176-bae74b82db0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614a6c37-df67-484e-a1ec-3b8f1521ae49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614a6c37-df67-484e-a1ec-3b8f1521ae49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SecuritiesRegisteredNewIssues_f02ed81a-e79b-4c6f-b302-eee5325ac875" xlink:href="apyx-20221231.xsd#apyx_SecuritiesRegisteredNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_apyx_SecuritiesRegisteredNewIssues_f02ed81a-e79b-4c6f-b302-eee5325ac875" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2da86f46-cfef-4ee5-a933-01165bee18f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2da86f46-cfef-4ee5-a933-01165bee18f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e90d8e02-37b8-4166-8802-d0b08ba59afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e90d8e02-37b8-4166-8802-d0b08ba59afc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_df5a21fa-e4c7-4f47-833b-646867aa5a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_df5a21fa-e4c7-4f47-833b-646867aa5a87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement_a8c81857-6bd6-4f59-a8b0-771bf6df2554" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_apyx_SaleLeasebackPurchaseAgreement_a8c81857-6bd6-4f59-a8b0-771bf6df2554" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77d9f9bb-d272-49d9-9289-49beb1e76f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77d9f9bb-d272-49d9-9289-49beb1e76f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77d9f9bb-d272-49d9-9289-49beb1e76f0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77d9f9bb-d272-49d9-9289-49beb1e76f0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77d9f9bb-d272-49d9-9289-49beb1e76f0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf48edc-9cc4-4510-8bd3-4941a1b622da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77d9f9bb-d272-49d9-9289-49beb1e76f0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf48edc-9cc4-4510-8bd3-4941a1b622da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShelfRegistrationMember_b67854f6-4425-4520-a252-cac863c31632" xlink:href="apyx-20221231.xsd#apyx_ShelfRegistrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf48edc-9cc4-4510-8bd3-4941a1b622da" xlink:to="loc_apyx_ShelfRegistrationMember_b67854f6-4425-4520-a252-cac863c31632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AtTheMarketFacilityMember_8c10285e-b26e-4790-9cf8-4f768bdbad16" xlink:href="apyx-20221231.xsd#apyx_AtTheMarketFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf48edc-9cc4-4510-8bd3-4941a1b622da" xlink:to="loc_apyx_AtTheMarketFacilityMember_8c10285e-b26e-4790-9cf8-4f768bdbad16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b1a134c7-79bd-4afc-ac6f-fb321784f410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_CreditFacilityAxis_b1a134c7-79bd-4afc-ac6f-fb321784f410" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b1a134c7-79bd-4afc-ac6f-fb321784f410_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b1a134c7-79bd-4afc-ac6f-fb321784f410" xlink:to="loc_us-gaap_CreditFacilityDomain_b1a134c7-79bd-4afc-ac6f-fb321784f410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_50ef89ea-adc9-4342-8151-f0fecbe90418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b1a134c7-79bd-4afc-ac6f-fb321784f410" xlink:to="loc_us-gaap_CreditFacilityDomain_50ef89ea-adc9-4342-8151-f0fecbe90418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_9f5232b3-16bb-4d89-b0db-885a4b36f428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_50ef89ea-adc9-4342-8151-f0fecbe90418" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_9f5232b3-16bb-4d89-b0db-885a4b36f428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_cdb36e49-8860-4643-b87f-f662b7229d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_50ef89ea-adc9-4342-8151-f0fecbe90418" xlink:to="loc_us-gaap_SecuredDebtMember_cdb36e49-8860-4643-b87f-f662b7229d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6be53a75-4eeb-443f-b67c-d7204c038743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6be53a75-4eeb-443f-b67c-d7204c038743" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6be53a75-4eeb-443f-b67c-d7204c038743_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6be53a75-4eeb-443f-b67c-d7204c038743" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6be53a75-4eeb-443f-b67c-d7204c038743_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_094bfe98-ef6d-4ff8-bac8-7055e947eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6be53a75-4eeb-443f-b67c-d7204c038743" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_094bfe98-ef6d-4ff8-bac8-7055e947eedc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c9e051da-f64c-4a3d-a6d9-4bd9abbe3224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_094bfe98-ef6d-4ff8-bac8-7055e947eedc" xlink:to="loc_us-gaap_LineOfCreditMember_c9e051da-f64c-4a3d-a6d9-4bd9abbe3224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_330d6343-3be9-45dd-8c10-3181afc91ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_330d6343-3be9-45dd-8c10-3181afc91ede" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_330d6343-3be9-45dd-8c10-3181afc91ede_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_330d6343-3be9-45dd-8c10-3181afc91ede" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_330d6343-3be9-45dd-8c10-3181afc91ede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_75def93b-b0ec-4a28-adc6-58f6f65051b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_330d6343-3be9-45dd-8c10-3181afc91ede" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_75def93b-b0ec-4a28-adc6-58f6f65051b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6e3bae99-e08d-4b1a-ad94-a0bb1cd68dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_75def93b-b0ec-4a28-adc6-58f6f65051b5" xlink:to="loc_us-gaap_SubsequentEventMember_6e3bae99-e08d-4b1a-ad94-a0bb1cd68dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9281f965-83a8-45e8-a9c4-0987cf895be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_DebtInstrumentAxis_9281f965-83a8-45e8-a9c4-0987cf895be3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9281f965-83a8-45e8-a9c4-0987cf895be3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9281f965-83a8-45e8-a9c4-0987cf895be3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9281f965-83a8-45e8-a9c4-0987cf895be3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a1becef4-8ab6-4c5e-9c0a-da4b1e3ec8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9281f965-83a8-45e8-a9c4-0987cf895be3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a1becef4-8ab6-4c5e-9c0a-da4b1e3ec8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember_259dcdb2-6fbc-4705-ae17-dde9f9eecd40" xlink:href="apyx-20221231.xsd#apyx_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1becef4-8ab6-4c5e-9c0a-da4b1e3ec8a6" xlink:to="loc_apyx_CreditAgreementMember_259dcdb2-6fbc-4705-ae17-dde9f9eecd40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis_79274090-ac9d-4ad8-88f7-8810ff9bc049" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_apyx_DebtInstrumentCovenantsAxis_79274090-ac9d-4ad8-88f7-8810ff9bc049" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_79274090-ac9d-4ad8-88f7-8810ff9bc049_default" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_79274090-ac9d-4ad8-88f7-8810ff9bc049" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_79274090-ac9d-4ad8-88f7-8810ff9bc049_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_79274090-ac9d-4ad8-88f7-8810ff9bc049" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember_18f7b116-5c64-4ad5-9f30-dc3de8087e6e" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheOneMember_18f7b116-5c64-4ad5-9f30-dc3de8087e6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_abadd131-f57d-4ffb-b993-97e77bd6f355" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_abadd131-f57d-4ffb-b993-97e77bd6f355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_65445aca-81ce-4dcf-a30d-b5150ecf0544" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_65445aca-81ce-4dcf-a30d-b5150ecf0544" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="if4376404f11b41d0bc4764b324e5c7cb_SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f9066a4b-9797-4789-b6b7-a259d69502ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f9066a4b-9797-4789-b6b7-a259d69502ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e7b5fe36-721b-45dc-a307-848a7ad2c1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e7b5fe36-721b-45dc-a307-848a7ad2c1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0799046c-81bc-4668-977a-922769973968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0799046c-81bc-4668-977a-922769973968" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarranty_ba9ed7b1-9674-402d-bf89-48483fd28f09" xlink:href="apyx-20221231.xsd#apyx_ProductWarranty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_apyx_ProductWarranty_ba9ed7b1-9674-402d-bf89-48483fd28f09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_13c6185d-525f-4b96-b230-3e3e3d064c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_AdvertisingExpense_13c6185d-525f-4b96-b230-3e3e3d064c64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60667595-71b3-4d15-9579-ebbdd2593a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60667595-71b3-4d15-9579-ebbdd2593a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60667595-71b3-4d15-9579-ebbdd2593a98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60667595-71b3-4d15-9579-ebbdd2593a98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60667595-71b3-4d15-9579-ebbdd2593a98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60667595-71b3-4d15-9579-ebbdd2593a98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_d50a73cd-70d8-49b6-9ecf-407347f83326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_d50a73cd-70d8-49b6-9ecf-407347f83326" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_48021a18-ee9f-45f6-b7f6-9334be055c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_48021a18-ee9f-45f6-b7f6-9334be055c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9b561f65-48e2-4711-bdfc-e3236ef5f266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9b561f65-48e2-4711-bdfc-e3236ef5f266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember_259bb83d-e75d-4c4f-8774-3632b4d35727" xlink:href="apyx-20221231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_apyx_ComputerEquipmentandSoftwareMember_259bb83d-e75d-4c4f-8774-3632b4d35727" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_fa8d0269-3a1d-4e3d-81ff-253e2f45a8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_fa8d0269-3a1d-4e3d-81ff-253e2f45a8ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RenuvionJPlasmaGeneratorsMember_3eb58348-8601-4f41-a37b-6113c03906c1" xlink:href="apyx-20221231.xsd#apyx_RenuvionJPlasmaGeneratorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_apyx_RenuvionJPlasmaGeneratorsMember_3eb58348-8601-4f41-a37b-6113c03906c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MountingFixturesMember_15eb8f05-8821-40e7-acce-6dfc0cb486e8" xlink:href="apyx-20221231.xsd#apyx_MountingFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_apyx_MountingFixturesMember_15eb8f05-8821-40e7-acce-6dfc0cb486e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccessoriesMember_435c3d16-8e8c-4f6b-81d8-2bcc4a725674" xlink:href="apyx-20221231.xsd#apyx_AccessoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_apyx_AccessoriesMember_435c3d16-8e8c-4f6b-81d8-2bcc4a725674" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_47853f99-64af-43e0-b90a-2bbfd65d7db3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:to="loc_srt_RangeAxis_47853f99-64af-43e0-b90a-2bbfd65d7db3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47853f99-64af-43e0-b90a-2bbfd65d7db3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_47853f99-64af-43e0-b90a-2bbfd65d7db3" xlink:to="loc_srt_RangeMember_47853f99-64af-43e0-b90a-2bbfd65d7db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_84b15d86-c1a9-4728-b102-b052e33aa66f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_47853f99-64af-43e0-b90a-2bbfd65d7db3" xlink:to="loc_srt_RangeMember_84b15d86-c1a9-4728-b102-b052e33aa66f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d23d2868-d65b-4660-90f6-0d1a559537f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_84b15d86-c1a9-4728-b102-b052e33aa66f" xlink:to="loc_srt_MinimumMember_d23d2868-d65b-4660-90f6-0d1a559537f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e0c35525-a934-461b-8059-f770e407e8ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_84b15d86-c1a9-4728-b102-b052e33aa66f" xlink:to="loc_srt_MaximumMember_e0c35525-a934-461b-8059-f770e407e8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:to="loc_srt_OwnershipAxis_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d" xlink:to="loc_srt_OwnershipDomain_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b917e51c-cd5c-4bc1-939c-c54f77d76ce8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d" xlink:to="loc_srt_OwnershipDomain_b917e51c-cd5c-4bc1-939c-c54f77d76ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_58e543fe-e9fe-478e-b16d-6b6bd6239041" xlink:href="apyx-20221231.xsd#apyx_ApyxSYMedicalDevicesNingboCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b917e51c-cd5c-4bc1-939c-c54f77d76ce8" xlink:to="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_58e543fe-e9fe-478e-b16d-6b6bd6239041" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#DISPOSITIONOFTHECOREBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="extended" id="ie51907fc71dd40158d73e41801af36fb_DISPOSITIONOFTHECOREBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_d6cbf957-b54f-4342-a681-e6b6a7a15a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_d6cbf957-b54f-4342-a681-e6b6a7a15a22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_543f7c53-42b0-44b3-bdd7-96cbd64fd45a" xlink:href="apyx-20221231.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_543f7c53-42b0-44b3-bdd7-96cbd64fd45a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9bd2f725-150e-46be-8d0a-bce071a29b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9bd2f725-150e-46be-8d0a-bce071a29b3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_e9fea209-2774-4ae4-9a3a-182d9b6a1c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_e9fea209-2774-4ae4-9a3a-182d9b6a1c5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_1a525bed-5707-4fee-9038-97c1da920980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_1a525bed-5707-4fee-9038-97c1da920980" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_402bdf4e-d5d8-4205-b760-46b3d1fd879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_402bdf4e-d5d8-4205-b760-46b3d1fd879e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_87eb9d8f-bdae-4639-9692-09ebcb8809f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_87eb9d8f-bdae-4639-9692-09ebcb8809f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_87eb9d8f-bdae-4639-9692-09ebcb8809f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_87eb9d8f-bdae-4639-9692-09ebcb8809f2" xlink:to="loc_us-gaap_RelatedPartyDomain_87eb9d8f-bdae-4639-9692-09ebcb8809f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_37ecf9a0-24f3-4cc0-880f-ae312e64af65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_87eb9d8f-bdae-4639-9692-09ebcb8809f2" xlink:to="loc_us-gaap_RelatedPartyDomain_37ecf9a0-24f3-4cc0-880f-ae312e64af65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_92816efb-bcea-4ed6-8734-08e351e7d2f2" xlink:href="apyx-20221231.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_37ecf9a0-24f3-4cc0-880f-ae312e64af65" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_92816efb-bcea-4ed6-8734-08e351e7d2f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_00a431b3-24c2-416b-b204-da83f88bfc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_00a431b3-24c2-416b-b204-da83f88bfc31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_00a431b3-24c2-416b-b204-da83f88bfc31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_00a431b3-24c2-416b-b204-da83f88bfc31" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_00a431b3-24c2-416b-b204-da83f88bfc31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0cd3025f-ccd7-451d-8706-bfb9c168a7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_00a431b3-24c2-416b-b204-da83f88bfc31" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0cd3025f-ccd7-451d-8706-bfb9c168a7ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_75b4cb90-6636-4ccc-9fc3-c76fbad0a6f6" xlink:href="apyx-20221231.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0cd3025f-ccd7-451d-8706-bfb9c168a7ee" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_75b4cb90-6636-4ccc-9fc3-c76fbad0a6f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="extended" id="i3315e351dcf34a05ad17c84fac6a7ca4_INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c3d48950-5897-4870-8dc2-8404d335de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c3d48950-5897-4870-8dc2-8404d335de1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_d4e5b72a-991a-4404-9e1e-f9e4e5966ef8" xlink:href="apyx-20221231.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_d4e5b72a-991a-4404-9e1e-f9e4e5966ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_c787e0fb-15da-45e9-ad85-0acfa4d40e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_c787e0fb-15da-45e9-ad85-0acfa4d40e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:to="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:to="loc_srt_OwnershipAxis_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525" xlink:to="loc_srt_OwnershipDomain_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b0b99f5b-b0d2-4ecf-9fe9-6b3d64185606" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525" xlink:to="loc_srt_OwnershipDomain_b0b99f5b-b0d2-4ecf-9fe9-6b3d64185606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_bccbe18a-3370-4434-9d52-a2206c432a58" xlink:href="apyx-20221231.xsd#apyx_ChineseSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b0b99f5b-b0d2-4ecf-9fe9-6b3d64185606" xlink:to="loc_apyx_ChineseSupplierMember_bccbe18a-3370-4434-9d52-a2206c432a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ea756753-306f-4b72-98db-b53aab5192a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ea756753-306f-4b72-98db-b53aab5192a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ea756753-306f-4b72-98db-b53aab5192a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ea756753-306f-4b72-98db-b53aab5192a1" xlink:to="loc_us-gaap_RelatedPartyDomain_ea756753-306f-4b72-98db-b53aab5192a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_72edd418-9cc3-4366-aac4-1dc40eb167fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ea756753-306f-4b72-98db-b53aab5192a1" xlink:to="loc_us-gaap_RelatedPartyDomain_72edd418-9cc3-4366-aac4-1dc40eb167fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_8f366e8d-40bb-447c-bc7d-f18d82b8e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_72edd418-9cc3-4366-aac4-1dc40eb167fe" xlink:to="loc_us-gaap_CorporateJointVentureMember_8f366e8d-40bb-447c-bc7d-f18d82b8e89f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="extended" id="i852b453840084de2a606eac79691eff7_INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_b9059680-f0c4-4d2d-87b0-85abe322c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9059680-f0c4-4d2d-87b0-85abe322c7d0" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_aa625330-480e-4235-b528-975e48c780b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:to="loc_us-gaap_MinorityInterest_aa625330-480e-4235-b528-975e48c780b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_825c771e-d2e9-41e8-9ea0-f7778021553f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_825c771e-d2e9-41e8-9ea0-f7778021553f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e5445206-c728-4253-9d49-373457b1bd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e5445206-c728-4253-9d49-373457b1bd21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d1d2da56-d03e-4780-99f2-274d167631f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_ffdd18d3-ff07-449a-a123-73750b1c171b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9059680-f0c4-4d2d-87b0-85abe322c7d0" xlink:to="loc_us-gaap_MinorityInterestTable_ffdd18d3-ff07-449a-a123-73750b1c171b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3042482a-9ab4-434e-ba2f-40d16235cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_ffdd18d3-ff07-449a-a123-73750b1c171b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3042482a-9ab4-434e-ba2f-40d16235cdf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3042482a-9ab4-434e-ba2f-40d16235cdf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3042482a-9ab4-434e-ba2f-40d16235cdf7" xlink:to="loc_us-gaap_RelatedPartyDomain_3042482a-9ab4-434e-ba2f-40d16235cdf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_04bc8af8-b9bb-4fdc-be3e-5d70734dcf59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3042482a-9ab4-434e-ba2f-40d16235cdf7" xlink:to="loc_us-gaap_RelatedPartyDomain_04bc8af8-b9bb-4fdc-be3e-5d70734dcf59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_3aa0074f-9994-4b6e-bd89-668254534085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_04bc8af8-b9bb-4fdc-be3e-5d70734dcf59" xlink:to="loc_us-gaap_CorporateJointVentureMember_3aa0074f-9994-4b6e-bd89-668254534085" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="ie17307ba637e4a5f8be7618f4dcdecfb_PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b4ef2f97-a0c0-4879-9594-b3f51bbb1ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b4ef2f97-a0c0-4879-9594-b3f51bbb1ef5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05ac6ba1-af02-424f-87f0-f335f22d43ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05ac6ba1-af02-424f-87f0-f335f22d43ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_409623b8-3080-4497-829b-8109ea21f400" xlink:href="apyx-20221231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_409623b8-3080-4497-829b-8109ea21f400" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4864f7f9-301a-43c2-9585-1951d1936e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4864f7f9-301a-43c2-9585-1951d1936e19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9a5fbe5f-e951-4898-8ac5-05747f6271c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9a5fbe5f-e951-4898-8ac5-05747f6271c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4f33aea6-a187-4639-82bc-2aedfcdcd930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_Depreciation_4f33aea6-a187-4639-82bc-2aedfcdcd930" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bc5db9c3-1e0b-47cf-b57a-284ff87389a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bc5db9c3-1e0b-47cf-b57a-284ff87389a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c632fc3c-78ec-4293-bd82-3f73e0f00a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bc5db9c3-1e0b-47cf-b57a-284ff87389a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c632fc3c-78ec-4293-bd82-3f73e0f00a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c632fc3c-78ec-4293-bd82-3f73e0f00a0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c632fc3c-78ec-4293-bd82-3f73e0f00a0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c632fc3c-78ec-4293-bd82-3f73e0f00a0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c632fc3c-78ec-4293-bd82-3f73e0f00a0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0aa7fb3c-1ef5-40f3-b8b7-53533f3ddb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_LandMember_0aa7fb3c-1ef5-40f3-b8b7-53533f3ddb06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_bdacff3b-0d2e-4b48-8352-4a3d86a3dc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_bdacff3b-0d2e-4b48-8352-4a3d86a3dc7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_87f1bb77-0e56-4839-b258-59a577deba53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_87f1bb77-0e56-4839-b258-59a577deba53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_aaf50953-c129-4102-a3ed-986ad0ff8719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_aaf50953-c129-4102-a3ed-986ad0ff8719" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember_58280ae5-6148-47fa-a20b-cfe80b09c2b9" xlink:href="apyx-20221231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_apyx_ComputerEquipmentandSoftwareMember_58280ae5-6148-47fa-a20b-cfe80b09c2b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_f1b2c76e-01a9-4ca3-be61-674ddad31fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_f1b2c76e-01a9-4ca3-be61-674ddad31fd8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_4a44a2f1-6a66-4306-a16d-a8bfb7283f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_4a44a2f1-6a66-4306-a16d-a8bfb7283f2c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="extended" id="if17b69c4a3da4839b196299351cbcc95_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_c27d6e5e-1feb-44bf-90a9-463d0b50b663" xlink:href="apyx-20221231.xsd#apyx_LesseeDiscountRateIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_c27d6e5e-1feb-44bf-90a9-463d0b50b663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c9786cae-8a30-4558-ab89-0fc372ef0418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c9786cae-8a30-4558-ab89-0fc372ef0418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeOperatingLeaseNumberOfLeasesExtended_925a1b70-a820-4602-add2-bd8e976cccb3" xlink:href="apyx-20221231.xsd#apyx_LesseeOperatingLeaseNumberOfLeasesExtended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_apyx_LesseeOperatingLeaseNumberOfLeasesExtended_925a1b70-a820-4602-add2-bd8e976cccb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_75acde10-ea33-43d9-bca4-879a9b243876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_75acde10-ea33-43d9-bca4-879a9b243876" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6856b508-8e10-4b1f-801f-94b22607382e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:to="loc_srt_RangeAxis_6856b508-8e10-4b1f-801f-94b22607382e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6856b508-8e10-4b1f-801f-94b22607382e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6856b508-8e10-4b1f-801f-94b22607382e" xlink:to="loc_srt_RangeMember_6856b508-8e10-4b1f-801f-94b22607382e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45a84418-07d7-4fbb-bd9b-5819040c62ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6856b508-8e10-4b1f-801f-94b22607382e" xlink:to="loc_srt_RangeMember_45a84418-07d7-4fbb-bd9b-5819040c62ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cff17e9-3471-45a7-ab89-d6c161541a9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45a84418-07d7-4fbb-bd9b-5819040c62ab" xlink:to="loc_srt_MinimumMember_7cff17e9-3471-45a7-ab89-d6c161541a9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c8928940-1e73-41e4-8850-ee6ea31a998f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45a84418-07d7-4fbb-bd9b-5819040c62ab" xlink:to="loc_srt_MaximumMember_c8928940-1e73-41e4-8850-ee6ea31a998f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b478a8b-e8d3-4cd0-baa9-163908e5fa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b478a8b-e8d3-4cd0-baa9-163908e5fa03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b478a8b-e8d3-4cd0-baa9-163908e5fa03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b478a8b-e8d3-4cd0-baa9-163908e5fa03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b478a8b-e8d3-4cd0-baa9-163908e5fa03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_add1ebc1-049a-4ef0-ab23-ba83c3909ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b478a8b-e8d3-4cd0-baa9-163908e5fa03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_add1ebc1-049a-4ef0-ab23-ba83c3909ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0b8e24b4-6ce3-454e-b0e7-5631f7c2f828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_add1ebc1-049a-4ef0-ab23-ba83c3909ff7" xlink:to="loc_us-gaap_ComputerEquipmentMember_0b8e24b4-6ce3-454e-b0e7-5631f7c2f828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9d58b100-bd28-4d68-aaea-469b5a0a49d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_add1ebc1-049a-4ef0-ab23-ba83c3909ff7" xlink:to="loc_us-gaap_BuildingMember_9d58b100-bd28-4d68-aaea-469b5a0a49d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="i7234f1dbf5fb430391b1716ca6ef56bc_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_af80d401-ab12-49c2-ad4b-0249bfe80b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_af80d401-ab12-49c2-ad4b-0249bfe80b80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14c684f6-aa6d-4c1f-9a74-d1a9043abdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_af80d401-ab12-49c2-ad4b-0249bfe80b80" xlink:to="loc_us-gaap_NetIncomeLoss_14c684f6-aa6d-4c1f-9a74-d1a9043abdfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d511ce95-0042-47e1-9aa5-3aad6239a83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d511ce95-0042-47e1-9aa5-3aad6239a83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91f5611c-81e7-4dfb-9723-bb576390bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91f5611c-81e7-4dfb-9723-bb576390bcfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4c334f0b-810f-40c3-b761-f15163313f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_EarningsPerShareBasic_4c334f0b-810f-40c3-b761-f15163313f6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_84eece68-1af2-4607-89b6-52dc14c6744c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_EarningsPerShareDiluted_84eece68-1af2-4607-89b6-52dc14c6744c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_0eeab5b3-7a7f-414a-85c4-2ae87393864b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_0eeab5b3-7a7f-414a-85c4-2ae87393864b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d61945cd-da78-4968-b233-0f9c028b8b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_0eeab5b3-7a7f-414a-85c4-2ae87393864b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d61945cd-da78-4968-b233-0f9c028b8b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75573efa-68fb-4417-9c52-221f20f8948c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75573efa-68fb-4417-9c52-221f20f8948c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d6719216-f593-4a50-959f-16acc4c8fdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75573efa-68fb-4417-9c52-221f20f8948c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d6719216-f593-4a50-959f-16acc4c8fdd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d6719216-f593-4a50-959f-16acc4c8fdd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d6719216-f593-4a50-959f-16acc4c8fdd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d6719216-f593-4a50-959f-16acc4c8fdd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89d20c44-6665-42b9-aabb-d47bca015de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d6719216-f593-4a50-959f-16acc4c8fdd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89d20c44-6665-42b9-aabb-d47bca015de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_3514bdd3-9296-4628-b262-e78d30767903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89d20c44-6665-42b9-aabb-d47bca015de4" xlink:to="loc_us-gaap_OptionOnSecuritiesMember_3514bdd3-9296-4628-b262-e78d30767903" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="i3e63586d7a8c409d966ae3292e2cbff3_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9abc4d46-8ae4-44a6-9b54-ba478aa2d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_5ec9a52b-ff4d-49b4-91c3-16225b4a60dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9abc4d46-8ae4-44a6-9b54-ba478aa2d79c" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_5ec9a52b-ff4d-49b4-91c3-16225b4a60dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_625c0555-f52c-4456-a754-bcf43f0b4d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9abc4d46-8ae4-44a6-9b54-ba478aa2d79c" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_625c0555-f52c-4456-a754-bcf43f0b4d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_91ff978c-44d2-47d6-85bb-c03b52efd98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9abc4d46-8ae4-44a6-9b54-ba478aa2d79c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_91ff978c-44d2-47d6-85bb-c03b52efd98c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_70fc3e0d-af03-486d-88be-155bcb1a14d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_91ff978c-44d2-47d6-85bb-c03b52efd98c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_70fc3e0d-af03-486d-88be-155bcb1a14d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_70fc3e0d-af03-486d-88be-155bcb1a14d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_70fc3e0d-af03-486d-88be-155bcb1a14d7" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_70fc3e0d-af03-486d-88be-155bcb1a14d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_927c6ef0-164d-4d34-823a-46d5ad97eec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_70fc3e0d-af03-486d-88be-155bcb1a14d7" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_927c6ef0-164d-4d34-823a-46d5ad97eec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_6fd5dfa5-6d60-429f-94cf-e4d5c381be97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_927c6ef0-164d-4d34-823a-46d5ad97eec3" xlink:to="loc_us-gaap_CoVenturerMember_6fd5dfa5-6d60-429f-94cf-e4d5c381be97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="ice41d1a0736542db860722c8a435d0a2_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1810fadf-9447-48f0-bf88-c1a34d205009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1810fadf-9447-48f0-bf88-c1a34d205009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e96cdaa0-f7eb-4842-bff1-8af10410a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e96cdaa0-f7eb-4842-bff1-8af10410a0f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_86675939-7226-41da-bc6c-1a0d1427577a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_86675939-7226-41da-bc6c-1a0d1427577a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_05b4ab32-4214-4cde-9100-6057ba86c6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_05b4ab32-4214-4cde-9100-6057ba86c6e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_d9ceab54-5db0-49cc-aaac-cec2f556aa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_PurchaseObligation_d9ceab54-5db0-49cc-aaac-cec2f556aa5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bdf8dc09-71d4-4f26-9a93-7b1c7a631063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bdf8dc09-71d4-4f26-9a93-7b1c7a631063" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d965827f-4b41-45a2-938f-d6e04cae9f4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_srt_MajorCustomersAxis_d965827f-4b41-45a2-938f-d6e04cae9f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d965827f-4b41-45a2-938f-d6e04cae9f4a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d965827f-4b41-45a2-938f-d6e04cae9f4a" xlink:to="loc_srt_NameOfMajorCustomerDomain_d965827f-4b41-45a2-938f-d6e04cae9f4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_afac9fcb-cffb-48cd-b211-b77d7b7610af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d965827f-4b41-45a2-938f-d6e04cae9f4a" xlink:to="loc_srt_NameOfMajorCustomerDomain_afac9fcb-cffb-48cd-b211-b77d7b7610af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LargestCustomerMember_fbdae395-7e74-4743-b915-27a28ad31a33" xlink:href="apyx-20221231.xsd#apyx_LargestCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_afac9fcb-cffb-48cd-b211-b77d7b7610af" xlink:to="loc_apyx_LargestCustomerMember_fbdae395-7e74-4743-b915-27a28ad31a33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoLargestCustomersMember_4835c3d3-dd65-4d8a-8786-1c3ac56a219f" xlink:href="apyx-20221231.xsd#apyx_TwoLargestCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_afac9fcb-cffb-48cd-b211-b77d7b7610af" xlink:to="loc_apyx_TwoLargestCustomersMember_4835c3d3-dd65-4d8a-8786-1c3ac56a219f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_476b12df-2441-44be-a1ec-dbb4434c3070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_476b12df-2441-44be-a1ec-dbb4434c3070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cd123cb6-7960-4003-bdb0-1103f239fc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_476b12df-2441-44be-a1ec-dbb4434c3070" xlink:to="loc_us-gaap_SalesRevenueNetMember_cd123cb6-7960-4003-bdb0-1103f239fc5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccountsReceivableBenchmarkMember_df47bd01-6bc9-4727-ab7e-0216ecb42855" xlink:href="apyx-20221231.xsd#apyx_AccountsReceivableBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_476b12df-2441-44be-a1ec-dbb4434c3070" xlink:to="loc_apyx_AccountsReceivableBenchmarkMember_df47bd01-6bc9-4727-ab7e-0216ecb42855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_79c929b9-cc1e-4f06-bb62-91295e189767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_79c929b9-cc1e-4f06-bb62-91295e189767" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_79c929b9-cc1e-4f06-bb62-91295e189767_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_79c929b9-cc1e-4f06-bb62-91295e189767" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_79c929b9-cc1e-4f06-bb62-91295e189767_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_03e89857-a551-4c11-a3a8-4843b99f6146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_79c929b9-cc1e-4f06-bb62-91295e189767" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_03e89857-a551-4c11-a3a8-4843b99f6146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a45ec43a-8748-4344-82f4-c0e27177282a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_03e89857-a551-4c11-a3a8-4843b99f6146" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a45ec43a-8748-4344-82f4-c0e27177282a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3bd7e524-a055-4792-9382-bfdda1259e6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_srt_LitigationCaseAxis_3bd7e524-a055-4792-9382-bfdda1259e6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3bd7e524-a055-4792-9382-bfdda1259e6a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3bd7e524-a055-4792-9382-bfdda1259e6a" xlink:to="loc_srt_LitigationCaseTypeDomain_3bd7e524-a055-4792-9382-bfdda1259e6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3bd7e524-a055-4792-9382-bfdda1259e6a" xlink:to="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ContractWithInternationalDistributorMember_524a9804-318c-459b-b2ee-8077bb4311fc" xlink:href="apyx-20221231.xsd#apyx_ContractWithInternationalDistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:to="loc_apyx_ContractWithInternationalDistributorMember_524a9804-318c-459b-b2ee-8077bb4311fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember_0b69feba-ec27-412e-ad69-66a64aaaf723" xlink:href="apyx-20221231.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:to="loc_apyx_SuitAgainstGoodwinAndSimbMember_0b69feba-ec27-412e-ad69-66a64aaaf723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitsFiledIn2022Member_d3426a51-761b-4ecf-9eff-e273cf2f817a" xlink:href="apyx-20221231.xsd#apyx_SuitsFiledIn2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:to="loc_apyx_SuitsFiledIn2022Member_d3426a51-761b-4ecf-9eff-e273cf2f817a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_srt_RangeAxis_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d" xlink:to="loc_srt_RangeMember_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6edca26-703b-4885-bd37-ae04a23ac20e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d" xlink:to="loc_srt_RangeMember_e6edca26-703b-4885-bd37-ae04a23ac20e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dae764ad-995b-4cbe-aae4-fa258f1a9dbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6edca26-703b-4885-bd37-ae04a23ac20e" xlink:to="loc_srt_MinimumMember_dae764ad-995b-4cbe-aae4-fa258f1a9dbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_44c063e4-0c37-42ca-aebf-f9dc29160d06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6edca26-703b-4885-bd37-ae04a23ac20e" xlink:to="loc_srt_MaximumMember_44c063e4-0c37-42ca-aebf-f9dc29160d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e616ade7-5b76-4567-8bea-a490b55713bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e616ade7-5b76-4567-8bea-a490b55713bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e616ade7-5b76-4567-8bea-a490b55713bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e616ade7-5b76-4567-8bea-a490b55713bf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e616ade7-5b76-4567-8bea-a490b55713bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f66d3b5d-5eee-42c0-9c1d-e62464181982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e616ade7-5b76-4567-8bea-a490b55713bf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f66d3b5d-5eee-42c0-9c1d-e62464181982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e282fb64-3119-4961-ac97-11d63adf76e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f66d3b5d-5eee-42c0-9c1d-e62464181982" xlink:to="loc_us-gaap_SubsequentEventMember_e282fb64-3119-4961-ac97-11d63adf76e3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#STOCKOPTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="extended" id="i70afa56ad71d4b4f9296809f4b88ad96_STOCKOPTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_830bda70-a0b8-4978-a9cb-ff0256237534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_830bda70-a0b8-4978-a9cb-ff0256237534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b346ef8-626b-4751-988f-c10905254254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b346ef8-626b-4751-988f-c10905254254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_792c95c9-f102-481f-aee5-80296df63d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_792c95c9-f102-481f-aee5-80296df63d38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d310391-9d0a-4097-a138-67432b15d3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d310391-9d0a-4097-a138-67432b15d3d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1343f1e4-0ee3-4c1d-b424-48828da15035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1343f1e4-0ee3-4c1d-b424-48828da15035" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_2032a4ab-dd99-4306-aa9b-0c6a3fb73720" xlink:href="apyx-20221231.xsd#apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_2032a4ab-dd99-4306-aa9b-0c6a3fb73720" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0428cbe0-3d85-4f18-90bc-49b7f756515a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0428cbe0-3d85-4f18-90bc-49b7f756515a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a2bde3a8-5c21-4ad9-a72e-43f1a02027e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a2bde3a8-5c21-4ad9-a72e-43f1a02027e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e87e9fcf-79b5-4ce8-8fad-bb2b6c3d0e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e87e9fcf-79b5-4ce8-8fad-bb2b6c3d0e82" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1bd388a2-219d-46cf-a101-92bb1a190e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1bd388a2-219d-46cf-a101-92bb1a190e5d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_337e4c27-ea78-483e-92e6-5451a6706372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_337e4c27-ea78-483e-92e6-5451a6706372" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24c053e1-c8e2-409a-b65d-9196ae8543a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24c053e1-c8e2-409a-b65d-9196ae8543a8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2243886d-0e83-4fdb-a35a-0d7f6359526b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2243886d-0e83-4fdb-a35a-0d7f6359526b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_87b9f686-8b63-4b43-95a3-1d404e3c7178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_87b9f686-8b63-4b43-95a3-1d404e3c7178" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b34df018-a287-4626-84db-5016d3c341d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b34df018-a287-4626-84db-5016d3c341d3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_b0cb41bf-f675-48d1-8552-63de0fc07226" xlink:href="apyx-20221231.xsd#apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_b0cb41bf-f675-48d1-8552-63de0fc07226" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e12d99c-6704-4f3a-a87e-b866b5161936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e12d99c-6704-4f3a-a87e-b866b5161936" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_36aa58bd-b07d-4591-9d95-b90406603137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_36aa58bd-b07d-4591-9d95-b90406603137" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_8d68ef25-4272-4a56-98f3-e353e5eeeb68" xlink:href="apyx-20221231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_8d68ef25-4272-4a56-98f3-e353e5eeeb68" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_a67838a3-09ca-4a98-b13e-ae2d8ab4a04a" xlink:href="apyx-20221231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_a67838a3-09ca-4a98-b13e-ae2d8ab4a04a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_597e2b08-7f2a-4ee5-8538-fcf9fc9d0574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_597e2b08-7f2a-4ee5-8538-fcf9fc9d0574" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_79d61ab3-a0d1-42a0-9b83-094badedff56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_79d61ab3-a0d1-42a0-9b83-094badedff56" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_04cede3f-4076-48b2-85b9-d4088771c052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:to="loc_us-gaap_PlanNameAxis_04cede3f-4076-48b2-85b9-d4088771c052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_04cede3f-4076-48b2-85b9-d4088771c052_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_04cede3f-4076-48b2-85b9-d4088771c052" xlink:to="loc_us-gaap_PlanNameDomain_04cede3f-4076-48b2-85b9-d4088771c052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_04cede3f-4076-48b2-85b9-d4088771c052" xlink:to="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_862a4bbf-7eb2-4caf-ad11-cbd17e4c021d" xlink:href="apyx-20221231.xsd#apyx_A2001ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_862a4bbf-7eb2-4caf-ad11-cbd17e4c021d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_092efeff-a8e8-4dee-ab22-006869e85074" xlink:href="apyx-20221231.xsd#apyx_A2003ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_092efeff-a8e8-4dee-ab22-006869e85074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandTwelveShareIncentivePlanMember_39aa5f7f-1e14-4394-9cd7-d24aa1d4f8ca" xlink:href="apyx-20221231.xsd#apyx_TwoThousandTwelveShareIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_TwoThousandTwelveShareIncentivePlanMember_39aa5f7f-1e14-4394-9cd7-d24aa1d4f8ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_70b54e0d-e1f3-45de-96bf-49efc83615d0" xlink:href="apyx-20221231.xsd#apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_70b54e0d-e1f3-45de-96bf-49efc83615d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_7feefb78-0b08-4c5b-a630-e15a172cc358" xlink:href="apyx-20221231.xsd#apyx_A2017ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_7feefb78-0b08-4c5b-a630-e15a172cc358" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2019ShareIncentivePlanMember_f3aec5aa-e05e-43b0-8c09-67d0dd832301" xlink:href="apyx-20221231.xsd#apyx_A2019ShareIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2019ShareIncentivePlanMember_f3aec5aa-e05e-43b0-8c09-67d0dd832301" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2021ShareIncentivePlanMember_df65c703-df90-492b-9344-3b4e57a0d054" xlink:href="apyx-20221231.xsd#apyx_A2021ShareIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2021ShareIncentivePlanMember_df65c703-df90-492b-9344-3b4e57a0d054" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6df1359-450f-4d77-aaef-7c1151418944" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:to="loc_srt_RangeAxis_c6df1359-450f-4d77-aaef-7c1151418944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6df1359-450f-4d77-aaef-7c1151418944_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c6df1359-450f-4d77-aaef-7c1151418944" xlink:to="loc_srt_RangeMember_c6df1359-450f-4d77-aaef-7c1151418944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61bf626d-945d-4ba8-8f6e-770665e4ceb6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c6df1359-450f-4d77-aaef-7c1151418944" xlink:to="loc_srt_RangeMember_61bf626d-945d-4ba8-8f6e-770665e4ceb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d6ec1a37-aa50-47e0-a23b-5dc91d348174" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_61bf626d-945d-4ba8-8f6e-770665e4ceb6" xlink:to="loc_srt_MinimumMember_d6ec1a37-aa50-47e0-a23b-5dc91d348174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9d0f428-7100-4057-aee8-b9cf00b90ae7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_61bf626d-945d-4ba8-8f6e-770665e4ceb6" xlink:to="loc_srt_MaximumMember_a9d0f428-7100-4057-aee8-b9cf00b90ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b990bfaa-ff4a-4ff3-aef3-92926fcc8598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b990bfaa-ff4a-4ff3-aef3-92926fcc8598" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b990bfaa-ff4a-4ff3-aef3-92926fcc8598_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b990bfaa-ff4a-4ff3-aef3-92926fcc8598" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b990bfaa-ff4a-4ff3-aef3-92926fcc8598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_feae2135-62fc-4a34-80bd-e09895222530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b990bfaa-ff4a-4ff3-aef3-92926fcc8598" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_feae2135-62fc-4a34-80bd-e09895222530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7cb1b6c5-80bf-4b5e-a902-f9d80edebb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_feae2135-62fc-4a34-80bd-e09895222530" xlink:to="loc_us-gaap_SubsequentEventMember_7cb1b6c5-80bf-4b5e-a902-f9d80edebb74" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="extended" id="ie3d44a1db67045a2a73c1673579a6ac1_STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fea2c227-32cf-4497-84b2-2471e8a418fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fea2c227-32cf-4497-84b2-2471e8a418fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6141dd82-132a-4ba5-b140-574bda5a4908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6141dd82-132a-4ba5-b140-574bda5a4908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_00408403-5fbc-43b3-b5ae-5a089b0631c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_00408403-5fbc-43b3-b5ae-5a089b0631c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_368e3478-3397-4c88-bbd1-1ef89898d631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_368e3478-3397-4c88-bbd1-1ef89898d631" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a24ceb45-78ce-4d39-9ecf-29b9dfd31393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a24ceb45-78ce-4d39-9ecf-29b9dfd31393" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_52406283-e4d7-45a7-9b8e-97b664ebb2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_52406283-e4d7-45a7-9b8e-97b664ebb2c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf824bf-4e62-4a89-af5f-cf25025eb0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf824bf-4e62-4a89-af5f-cf25025eb0d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf824bf-4e62-4a89-af5f-cf25025eb0d3" xlink:to="loc_srt_RangeAxis_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e" xlink:to="loc_srt_RangeMember_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82c74c43-885e-406f-92ef-c002300ecad3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e" xlink:to="loc_srt_RangeMember_82c74c43-885e-406f-92ef-c002300ecad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_17ab326e-f669-46dd-8886-da723164a915" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82c74c43-885e-406f-92ef-c002300ecad3" xlink:to="loc_srt_MinimumMember_17ab326e-f669-46dd-8886-da723164a915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4f5566e3-3d53-4c10-b73d-e5406df17fc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82c74c43-885e-406f-92ef-c002300ecad3" xlink:to="loc_srt_MaximumMember_4f5566e3-3d53-4c10-b73d-e5406df17fc9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended" id="i3434cbae15dd4ddd97ea94501427966e_GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8b48d21-f64d-4226-98de-23ddd3f9de57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8b48d21-f64d-4226-98de-23ddd3f9de57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d5b38c22-5d5e-4510-a10a-992f432a5c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_OperatingIncomeLoss_d5b38c22-5d5e-4510-a10a-992f432a5c45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_63f9b8f8-c42e-49c6-88b0-7090ff517cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_InterestIncomeOperating_63f9b8f8-c42e-49c6-88b0-7090ff517cd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4dc6c974-2da9-4660-87ed-cccc9a9da170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_InterestExpense_4dc6c974-2da9-4660-87ed-cccc9a9da170" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0d592faa-5dcf-40f9-8169-e7c31a293689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0d592faa-5dcf-40f9-8169-e7c31a293689" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c0d56f9a-1323-497e-9546-23d8dd3d5c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c0d56f9a-1323-497e-9546-23d8dd3d5c93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_72a13aee-925b-4f85-83ec-30ecb689eb83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:to="loc_srt_ConsolidationItemsAxis_72a13aee-925b-4f85-83ec-30ecb689eb83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_72a13aee-925b-4f85-83ec-30ecb689eb83_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_72a13aee-925b-4f85-83ec-30ecb689eb83" xlink:to="loc_srt_ConsolidationItemsDomain_72a13aee-925b-4f85-83ec-30ecb689eb83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5b313b1c-9505-4275-980c-29939bd79eaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_72a13aee-925b-4f85-83ec-30ecb689eb83" xlink:to="loc_srt_ConsolidationItemsDomain_5b313b1c-9505-4275-980c-29939bd79eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_dc7cdff2-9a34-4ddf-a7cf-7124da3505ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_5b313b1c-9505-4275-980c-29939bd79eaa" xlink:to="loc_us-gaap_OperatingSegmentsMember_dc7cdff2-9a34-4ddf-a7cf-7124da3505ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8019949f-4382-4e91-9724-a725479ed286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_5b313b1c-9505-4275-980c-29939bd79eaa" xlink:to="loc_us-gaap_CorporateNonSegmentMember_8019949f-4382-4e91-9724-a725479ed286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7cf88c01-852a-47d9-8384-2599da172a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7cf88c01-852a-47d9-8384-2599da172a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7cf88c01-852a-47d9-8384-2599da172a34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7cf88c01-852a-47d9-8384-2599da172a34" xlink:to="loc_us-gaap_SegmentDomain_7cf88c01-852a-47d9-8384-2599da172a34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cbbf3af4-b6cc-4230-847f-b2b38751f3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7cf88c01-852a-47d9-8384-2599da172a34" xlink:to="loc_us-gaap_SegmentDomain_cbbf3af4-b6cc-4230-847f-b2b38751f3c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_36014e7e-f761-4e22-9d79-05f742b05da2" xlink:href="apyx-20221231.xsd#apyx_AdvancedEnergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cbbf3af4-b6cc-4230-847f-b2b38751f3c6" xlink:to="loc_apyx_AdvancedEnergyMember_36014e7e-f761-4e22-9d79-05f742b05da2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_cbc8a63b-e60e-4680-8b81-fead91348d6c" xlink:href="apyx-20221231.xsd#apyx_OEMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cbbf3af4-b6cc-4230-847f-b2b38751f3c6" xlink:to="loc_apyx_OEMMember_cbc8a63b-e60e-4680-8b81-fead91348d6c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended" id="icd6eb651efa14619a1127b632dd52527_GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9c738a95-dc2f-4a41-b044-24815933ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_46b72a2a-e5e9-4159-a6d7-f539147c7ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9c738a95-dc2f-4a41-b044-24815933ac1f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_46b72a2a-e5e9-4159-a6d7-f539147c7ba4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db42486a-304d-4a94-9cd0-5663f0be9e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9c738a95-dc2f-4a41-b044-24815933ac1f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db42486a-304d-4a94-9cd0-5663f0be9e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9c738a95-dc2f-4a41-b044-24815933ac1f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_990645ed-8332-4b53-8c2b-9749c1b2b6ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:to="loc_srt_StatementGeographicalAxis_990645ed-8332-4b53-8c2b-9749c1b2b6ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_990645ed-8332-4b53-8c2b-9749c1b2b6ac_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_990645ed-8332-4b53-8c2b-9749c1b2b6ac" xlink:to="loc_srt_SegmentGeographicalDomain_990645ed-8332-4b53-8c2b-9749c1b2b6ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4f4164ab-30c4-42bb-ab5a-31ea9203d496" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_990645ed-8332-4b53-8c2b-9749c1b2b6ac" xlink:to="loc_srt_SegmentGeographicalDomain_4f4164ab-30c4-42bb-ab5a-31ea9203d496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a1ab8fcf-c5f3-41d2-b99e-b514c34ec836" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4f4164ab-30c4-42bb-ab5a-31ea9203d496" xlink:to="loc_country_US_a1ab8fcf-c5f3-41d2-b99e-b514c34ec836" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_f407beea-af42-4970-a340-2a51f11bf0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4f4164ab-30c4-42bb-ab5a-31ea9203d496" xlink:to="loc_us-gaap_NonUsMember_f407beea-af42-4970-a340-2a51f11bf0dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d9727e7d-b4af-4adc-8a1d-8e432aea8d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d9727e7d-b4af-4adc-8a1d-8e432aea8d57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d9727e7d-b4af-4adc-8a1d-8e432aea8d57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d9727e7d-b4af-4adc-8a1d-8e432aea8d57" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d9727e7d-b4af-4adc-8a1d-8e432aea8d57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fca3e673-4ca8-43ed-91a7-a083dbfcce81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d9727e7d-b4af-4adc-8a1d-8e432aea8d57" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fca3e673-4ca8-43ed-91a7-a083dbfcce81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_8e46d6e6-d549-43b0-b78b-1d2725487b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fca3e673-4ca8-43ed-91a7-a083dbfcce81" xlink:to="loc_us-gaap_SalesRevenueNetMember_8e46d6e6-d549-43b0-b78b-1d2725487b91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b200796d-d85f-4d3d-a913-6bfddf336e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b200796d-d85f-4d3d-a913-6bfddf336e2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b200796d-d85f-4d3d-a913-6bfddf336e2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b200796d-d85f-4d3d-a913-6bfddf336e2c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b200796d-d85f-4d3d-a913-6bfddf336e2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ab6d65c6-2781-441c-b5d9-06aa0caa219b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b200796d-d85f-4d3d-a913-6bfddf336e2c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ab6d65c6-2781-441c-b5d9-06aa0caa219b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_517993f6-80f0-43e9-89db-f6dbd3b09b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ab6d65c6-2781-441c-b5d9-06aa0caa219b" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_517993f6-80f0-43e9-89db-f6dbd3b09b58" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="i987dfb00d0174927b9a098c110ee0ab2_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_df34a9e0-cb7d-4788-92c9-490b10ab543e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_df34a9e0-cb7d-4788-92c9-490b10ab543e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d26c173c-a092-4c17-b6fe-cf2c2c4297c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d26c173c-a092-4c17-b6fe-cf2c2c4297c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ccf75bc7-d8db-4f7b-8900-05da9c447e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ccf75bc7-d8db-4f7b-8900-05da9c447e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorPercent_d17b93c9-f697-4992-a7d3-1c85f85fb822" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentInterestRateFloorPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentInterestRateFloorPercent_d17b93c9-f697-4992-a7d3-1c85f85fb822" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7c2c1930-6bfb-44fa-997a-50c0f1bbb02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7c2c1930-6bfb-44fa-997a-50c0f1bbb02d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPeriodOfInterestOnly_ca1a5347-481c-4ea7-91c0-12b3c7535da6" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPeriodOfInterestOnly"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentPeriodOfInterestOnly_ca1a5347-481c-4ea7-91c0-12b3c7535da6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExtensionPeriod_11c77e0e-8da8-4fe4-99c7-7ec3e474d110" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentExtensionPeriod_11c77e0e-8da8-4fe4-99c7-7ec3e474d110" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPayments_3464161b-cf89-4131-9091-f3db6b8cba5b" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentNumberOfMonthlyPayments_3464161b-cf89-4131-9091-f3db6b8cba5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_18754a8c-402d-4de5-aaa4-460015dc45bc" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_18754a8c-402d-4de5-aaa4-460015dc45bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentFeePercent_9c4d25b0-b16a-441f-b775-5002891c424c" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentPrepaymentFeePercent_9c4d25b0-b16a-441f-b775-5002891c424c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExitFee_24d4e7c5-7bbc-40f7-9dac-bfe7c9cdcd03" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentExitFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentExitFee_24d4e7c5-7bbc-40f7-9dac-bfe7c9cdcd03" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentAnnualFeePercent_96a9f8aa-7dc5-4cf3-be72-b8db4943994b" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentAnnualFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentAnnualFeePercent_96a9f8aa-7dc5-4cf3-be72-b8db4943994b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationFees_f20e514d-8b3e-4a2d-a27a-8eb414845852" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentTerminationFees_f20e514d-8b3e-4a2d-a27a-8eb414845852" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_d153907c-f275-46d9-b8ac-86bb10718e18" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_d153907c-f275-46d9-b8ac-86bb10718e18" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_8f9224c1-ce09-40ef-abc7-7e0fe7fc5b57" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_8f9224c1-ce09-40ef-abc7-7e0fe7fc5b57" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_ba2b4d7b-480f-4267-a7f3-2fa28714ce15" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_ba2b4d7b-480f-4267-a7f3-2fa28714ce15" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_34e236a4-2c38-453f-bfc1-623d9a90e127" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_34e236a4-2c38-453f-bfc1-623d9a90e127" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_64ef78a7-1b6e-432e-981f-3a5c3804bad3" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_64ef78a7-1b6e-432e-981f-3a5c3804bad3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_d7c595ea-de85-4c19-9df9-55389beba770" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_d7c595ea-de85-4c19-9df9-55389beba770" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentDefaultApplicableInterestRate_90c4ab20-6bad-4af4-8810-b360f11cf145" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentDefaultApplicableInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentDefaultApplicableInterestRate_90c4ab20-6bad-4af4-8810-b360f11cf145" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_708e0817-d4cc-45e9-a25a-ed43587793dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_708e0817-d4cc-45e9-a25a-ed43587793dd" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_073405fb-a073-4d92-897f-c82f64d5e5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_073405fb-a073-4d92-897f-c82f64d5e5eb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f05343de-a5d1-481e-80c9-551f8a0d851b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f05343de-a5d1-481e-80c9-551f8a0d851b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement_f9ec013c-1237-4f8c-893b-59e1cdc4c4a4" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackPurchaseAgreement_f9ec013c-1237-4f8c-893b-59e1cdc4c4a4" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackDueDiligencePeriod_8861bfe2-73ff-4e0f-b59d-cbd2a63522ea" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackDueDiligencePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackDueDiligencePeriod_8861bfe2-73ff-4e0f-b59d-cbd2a63522ea" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence_837ef57e-559c-4657-8c65-84cb8895e3bf" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackCompletionPeriodAfterDueDiligence"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence_837ef57e-559c-4657-8c65-84cb8895e3bf" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackEscrow_4a0e9612-6ae9-42f3-be5b-47a8a7e6c175" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackEscrow_4a0e9612-6ae9-42f3-be5b-47a8a7e6c175" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackTermOfLease_e38861a1-360f-49fe-8a4b-919071dbcdd7" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackTermOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackTermOfLease_e38861a1-360f-49fe-8a4b-919071dbcdd7" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackRenewalTerm_3919d666-552d-4553-8c14-89f321b3a8fb" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackRenewalTerm_3919d666-552d-4553-8c14-89f321b3a8fb" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentPayment_6af45213-8774-4bd1-a8a4-bb7465bd1f5d" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackAnnualRentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackAnnualRentPayment_6af45213-8774-4bd1-a8a4-bb7465bd1f5d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentIncrease_1d0dddcd-f512-411a-86e2-603b73023ae3" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackAnnualRentIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackAnnualRentIncrease_1d0dddcd-f512-411a-86e2-603b73023ae3" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackManagementFeeOnRentPayment_e25cf0f4-8c63-4978-b642-b75da3b1e73b" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackManagementFeeOnRentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackManagementFeeOnRentPayment_e25cf0f4-8c63-4978-b642-b75da3b1e73b" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackNetCashProceeds_7ce3ea11-84c9-4743-a03f-8985aedc6572" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackNetCashProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackNetCashProceeds_7ce3ea11-84c9-4743-a03f-8985aedc6572" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_DebtInstrumentAxis_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5ecd9590-d09e-4cb5-b74b-b2566ab194de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5ecd9590-d09e-4cb5-b74b-b2566ab194de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember_f223c562-7218-4dfd-b291-528fe1fa644a" xlink:href="apyx-20221231.xsd#apyx_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ecd9590-d09e-4cb5-b74b-b2566ab194de" xlink:to="loc_apyx_CreditAgreementMember_f223c562-7218-4dfd-b291-528fe1fa644a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_20c41020-db8d-4409-94d9-a8e111fbd914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_20c41020-db8d-4409-94d9-a8e111fbd914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_20c41020-db8d-4409-94d9-a8e111fbd914_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_20c41020-db8d-4409-94d9-a8e111fbd914" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_20c41020-db8d-4409-94d9-a8e111fbd914_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2da6a80f-e19c-4528-bad8-3d7ebb4c8b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_20c41020-db8d-4409-94d9-a8e111fbd914" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2da6a80f-e19c-4528-bad8-3d7ebb4c8b76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1c2073aa-3263-4941-985b-498d3ffea951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2da6a80f-e19c-4528-bad8-3d7ebb4c8b76" xlink:to="loc_us-gaap_LineOfCreditMember_1c2073aa-3263-4941-985b-498d3ffea951" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ecb98a8c-3f48-4687-ae92-d8181c6414f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ecb98a8c-3f48-4687-ae92-d8181c6414f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ecb98a8c-3f48-4687-ae92-d8181c6414f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ecb98a8c-3f48-4687-ae92-d8181c6414f6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ecb98a8c-3f48-4687-ae92-d8181c6414f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cbf94d07-da42-4b53-8f42-0d61c70e694c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ecb98a8c-3f48-4687-ae92-d8181c6414f6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cbf94d07-da42-4b53-8f42-0d61c70e694c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1de8b2d7-0938-40ad-afa5-b5556acfac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cbf94d07-da42-4b53-8f42-0d61c70e694c" xlink:to="loc_us-gaap_SubsequentEventMember_1de8b2d7-0938-40ad-afa5-b5556acfac8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_CreditFacilityAxis_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac" xlink:to="loc_us-gaap_CreditFacilityDomain_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_08ddfde5-a9ce-42cf-a9c9-38be2842925f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac" xlink:to="loc_us-gaap_CreditFacilityDomain_08ddfde5-a9ce-42cf-a9c9-38be2842925f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d575621c-ae18-4556-a461-dfbab6313d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_08ddfde5-a9ce-42cf-a9c9-38be2842925f" xlink:to="loc_us-gaap_SecuredDebtMember_d575621c-ae18-4556-a461-dfbab6313d3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_7c1a48e0-fe50-4aa8-be5a-4591769bc89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_08ddfde5-a9ce-42cf-a9c9-38be2842925f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_7c1a48e0-fe50-4aa8-be5a-4591769bc89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis_94e029d1-8f12-45d7-8203-68a7c9a0a330" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_apyx_DebtInstrumentCovenantsAxis_94e029d1-8f12-45d7-8203-68a7c9a0a330" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_94e029d1-8f12-45d7-8203-68a7c9a0a330_default" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_94e029d1-8f12-45d7-8203-68a7c9a0a330" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_94e029d1-8f12-45d7-8203-68a7c9a0a330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_94e029d1-8f12-45d7-8203-68a7c9a0a330" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember_6920ed41-64c5-46ab-ad17-512c132b9630" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheOneMember_6920ed41-64c5-46ab-ad17-512c132b9630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_6b2b0f1b-e81a-4bb0-9a64-0d3b17ae6c6a" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_6b2b0f1b-e81a-4bb0-9a64-0d3b17ae6c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_2eac1202-02a5-4172-bc1e-2ae17e0b31e7" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_2eac1202-02a5-4172-bc1e-2ae17e0b31e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_722593fd-99da-47dd-bd0f-7ea7ec1e4d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_VariableRateAxis_722593fd-99da-47dd-bd0f-7ea7ec1e4d30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_722593fd-99da-47dd-bd0f-7ea7ec1e4d30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_722593fd-99da-47dd-bd0f-7ea7ec1e4d30" xlink:to="loc_us-gaap_VariableRateDomain_722593fd-99da-47dd-bd0f-7ea7ec1e4d30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7def881f-e4d0-498f-80a3-5eab00e3cb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_722593fd-99da-47dd-bd0f-7ea7ec1e4d30" xlink:to="loc_us-gaap_VariableRateDomain_7def881f-e4d0-498f-80a3-5eab00e3cb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_fa7ab2d9-506e-4aad-8c7b-d01f36dcd927" xlink:href="apyx-20221231.xsd#apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7def881f-e4d0-498f-80a3-5eab00e3cb59" xlink:to="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_fa7ab2d9-506e-4aad-8c7b-d01f36dcd927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_70798af5-3250-4280-adbb-5f1e1422e8ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_srt_RangeAxis_70798af5-3250-4280-adbb-5f1e1422e8ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_70798af5-3250-4280-adbb-5f1e1422e8ce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_70798af5-3250-4280-adbb-5f1e1422e8ce" xlink:to="loc_srt_RangeMember_70798af5-3250-4280-adbb-5f1e1422e8ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dcc18b62-0345-4841-980d-d38a87cef878" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_70798af5-3250-4280-adbb-5f1e1422e8ce" xlink:to="loc_srt_RangeMember_dcc18b62-0345-4841-980d-d38a87cef878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e52b72a6-48c6-4670-bf57-f7f268c74a0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dcc18b62-0345-4841-980d-d38a87cef878" xlink:to="loc_srt_MinimumMember_e52b72a6-48c6-4670-bf57-f7f268c74a0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_c1347723-b95d-41f5-896d-e08dced77f54" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_c1347723-b95d-41f5-896d-e08dced77f54" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_c1347723-b95d-41f5-896d-e08dced77f54_default" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_c1347723-b95d-41f5-896d-e08dced77f54" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_c1347723-b95d-41f5-896d-e08dced77f54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_c1347723-b95d-41f5-896d-e08dced77f54" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember_7e9c616a-eaaa-4328-8a5c-89e805678a91" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember_7e9c616a-eaaa-4328-8a5c-89e805678a91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember_5f3afc53-0f62-4975-8cbe-39f27f3f627c" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember_5f3afc53-0f62-4975-8cbe-39f27f3f627c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember_4bae422c-d1b4-4c8d-a188-3d271114fd1a" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember_4bae422c-d1b4-4c8d-a188-3d271114fd1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodAxis_0776d667-5f98-4c12-abd8-5253fbbd28c7" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodAxis_0776d667-5f98-4c12-abd8-5253fbbd28c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodDomain_0776d667-5f98-4c12-abd8-5253fbbd28c7_default" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodAxis_0776d667-5f98-4c12-abd8-5253fbbd28c7" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodDomain_0776d667-5f98-4c12-abd8-5253fbbd28c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodAxis_0776d667-5f98-4c12-abd8-5253fbbd28c7" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodOneMember_efadc6bf-c272-4333-84f3-3a64332e4ade" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodOneMember_efadc6bf-c272-4333-84f3-3a64332e4ade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodTwoMember_6003cb38-d063-4eb5-9827-6d59d06e4dfb" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodTwoMember_6003cb38-d063-4eb5-9827-6d59d06e4dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodThreeMember_227a71ef-0ded-4085-82e3-f0d57a6665f2" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodThreeMember_227a71ef-0ded-4085-82e3-f0d57a6665f2" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>apyx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:45c174b4-24e6-4af0-9ca8-997a51f8c128,g:9f6ae534-5ac4-415d-9362-3e1615bb09a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_28732549-329d-43f2-acd5-3bf81eb7c404_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5750450e-c064-4c6b-bd19-de554d408a01_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_2db318d2-21d5-443b-847e-4b794d6d81d5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae020f07-3d5f-4c19-b735-f006672340d1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d23d5ffc-1ebd-4b75-add0-083bb6c6242e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_0164a25c-d958-47c7-8ef6-48d3658a2115_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4d2d8c4e-2126-48a5-9dd9-8457c2ac2346_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_613494de-e614-4e20-bb66-2afeac00a8ce_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_330c5d70-5065-4cad-99e5-570110573bb5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_6d353776-2720-48e0-b786-ec1e993ff82a_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_ebc4cf36-ad47-4097-86c7-05d8735f872d_totalLabel_en-US" xlink:label="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment in service</link:label>
    <link:label id="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_label_en-US" xlink:label="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property, plant and equipment of continuing and discontinued operations</link:label>
    <link:label id="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_documentation_en-US" xlink:label="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property, plant and equipment of continuing and discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:href="apyx-20221231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:to="lab_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_499ed2a3-bb9d-4ae6-9b24-54d4bea01d12_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_65d6271a-a2d3-4301-90e2-a2c2aa8bd936_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_e7e2c686-6bf1-4866-b69b-418c26c781f3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_b9d285b9-df78-4c9f-b16e-68555a6797e6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember_da4bff11-9c81-4209-ae9c-baa2908146c9_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period, One</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period One [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2f9f288a-b521-4f77-9071-99fefe34f1d6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3173451b-a283-420d-9a33-c26ef2e67f29_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_bbbd18dd-a811-4edd-9e71-d76c0af5237d_terseLabel_en-US" xlink:label="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing stock price for computation of intrinsic value (in dollars per share)</link:label>
    <link:label id="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_label_en-US" xlink:label="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price</link:label>
    <link:label id="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_documentation_en-US" xlink:label="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:href="apyx-20221231.xsd#apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:to="lab_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_588190f3-d2b0-4807-927f-343f2b23daf6_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_18ba9a83-f765-4b50-add8-6841e26d652d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_6890e421-4407-4277-9467-c6bc3374c84d_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_808ee1db-7384-4631-887b-480f8c2ac75b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheOneMember_eac5ea54-ea36-41a4-822c-969d33017ef3_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheOneMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche One [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheOneMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:to="lab_apyx_DebtInstrumentCovenantTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b5b0c924-eb3d-4cf4-8ae2-bf90b827b167_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2d3f060d-9d8d-4989-ab15-6e8a413c42c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_067f8d64-539e-409a-a211-efa0a9a7f8b4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_e6f66b21-8196-49f4-84d6-8e62f9221674_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:href="apyx-20221231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate_4d16878b-c2fa-49e7-9581-cdb7cbb2eeb7_terseLabel_en-US" xlink:label="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate_label_en-US" xlink:label="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Discount Rate, Incremental Borrowing Rate</link:label>
    <link:label id="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Discount Rate, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:href="apyx-20221231.xsd#apyx_LesseeDiscountRateIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:to="lab_apyx_LesseeDiscountRateIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_93473498-5bd7-42fb-b102-9f4605ac8923_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9fffd5dd-7791-4d20-a3b6-b98cdf616cfc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1f6630da-1ea0-460e-92c8-1a79193e11c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_c65c5a48-1078-487d-8dc1-460eb952c7ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_b083beba-a755-4786-9c83-d1969601d0ce_terseLabel_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, vesting period</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_label_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Vesting Period</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_documentation_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:href="apyx-20221231.xsd#apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:to="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_546898bb-7750-449e-89fd-e9bfc1900654_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9d11d20a-2daf-4afb-8288-669151bedbdc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_3d89fa14-6115-47c9-9d6f-e23018dbbaca_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4d8621a4-4268-4ebf-86b7-97c5e7aa23de_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7e7fab8a-6374-4623-9184-f69fd083eb53_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6680ad0c-b535-4eb9-a070-07642c1d29ab_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_d18c10ae-b139-4c99-a4c3-3b7fcb4da54c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackManagementFeeOnRentPayment_597136b1-217e-42c2-b095-989cf6edf217_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, management fee on rent payment</link:label>
    <link:label id="lab_apyx_SaleLeasebackManagementFeeOnRentPayment_label_en-US" xlink:label="lab_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Management Fee On Rent Payment</link:label>
    <link:label id="lab_apyx_SaleLeasebackManagementFeeOnRentPayment_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Management Fee On Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackManagementFeeOnRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:to="lab_apyx_SaleLeasebackManagementFeeOnRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointandSeveralPayrollLiabilityTextBlock_f1df16cb-a2c0-48d7-81e5-21c20d5ac5b6_terseLabel_en-US" xlink:label="lab_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JOINT AND SEVERAL PAYROLL LIABILITY</link:label>
    <link:label id="lab_apyx_JointandSeveralPayrollLiabilityTextBlock_label_en-US" xlink:label="lab_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and Several Payroll Liability [Text Block]</link:label>
    <link:label id="lab_apyx_JointandSeveralPayrollLiabilityTextBlock_documentation_en-US" xlink:label="lab_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and Several Payroll Liability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:href="apyx-20221231.xsd#apyx_JointandSeveralPayrollLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:to="lab_apyx_JointandSeveralPayrollLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b9438c67-58cc-4e29-8fe5-082629cbfbcc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a3ec0a9-ab18-4b92-b13e-400fb1937cff_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OEMMember_b734d31c-6a29-4d94-a551-588101426585_terseLabel_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM</link:label>
    <link:label id="lab_apyx_OEMMember_label_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember" xlink:href="apyx-20221231.xsd#apyx_OEMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OEMMember" xlink:to="lab_apyx_OEMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1aa6259a-c4a3-4e8f-8080-1a11b399d9b2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_008642f9-c55b-4d53-a9eb-ac9cc0526159_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_63b4a132-e8d1-4f7b-86fe-ae1207f6468a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4fb7944b-ec93-484f-90d7-0df6f50211dc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b5ac5d79-641e-4cc8-9d1f-04aaba6e327a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_5f74714b-439d-4a31-a36a-44c866c378e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_291708e4-c2bb-4fd7-b042-dc3ac1cc8306_terseLabel_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_label_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_documentation_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:href="apyx-20221231.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:to="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e52377bb-f1a0-4275-959c-31fafdcc27be_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent_f6392c24-93ec-40c9-97b1-34c059bfd773_terseLabel_en-US" xlink:label="lab_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 162(m) compensation</link:label>
    <link:label id="lab_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent_label_en-US" xlink:label="lab_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Section 162(m) Compensation, Percent</link:label>
    <link:label id="lab_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent_documentation_en-US" xlink:label="lab_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Section 162(m) Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" xlink:href="apyx-20221231.xsd#apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" xlink:to="lab_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ab9cf98d-17a2-43e5-8f7c-a0b406bc936c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_005079fa-75f1-484b-a909-7c9f8c71fe60_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_25a68c5e-6270-402a-86d7-914786c45730_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_430ab7d3-41c5-4d10-b3fb-9cd91f47bea0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1c1d432b-a512-4bb3-8d02-843f19fcf2ba_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b105d07a-270f-4881-aeba-32f00e02eca0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_527fd619-0d25-4b16-902a-b49164444d59_terseLabel_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_label_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_documentation_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm" xlink:href="apyx-20221231.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AssetPurchaseAgreementTerm" xlink:to="lab_apyx_AssetPurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_904c9981-7100-41a1-8c4e-650acbcfd395_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_1b527332-af77-47ad-b0b4-fd54a7bee77d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerators:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_f0d17d9f-8196-40c5-8a64-0b966d69fc19_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_df173c32-2de2-4581-896b-f0bf4b50adbe_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_RepaymentOfFinanceLeaseLiabilities_20f85d35-0622-473c-967a-65d3592f57ba_negatedTerseLabel_en-US" xlink:label="lab_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of finance lease liabilities</link:label>
    <link:label id="lab_apyx_RepaymentOfFinanceLeaseLiabilities_label_en-US" xlink:label="lab_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Finance Lease Liabilities</link:label>
    <link:label id="lab_apyx_RepaymentOfFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Finance Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:href="apyx-20221231.xsd#apyx_RepaymentOfFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:to="lab_apyx_RepaymentOfFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c894fa18-9502-4130-ab1f-e8cfb56f907b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized under common stock option plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_701d8445-4612-41bb-9f44-1d33c784f854_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_09b04fba-b237-43cc-ab2c-238fa7674f81_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_3b40d701-357a-481f-b947-c94071089378_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d4cd7445-4c0e-449d-ae4c-0cf93de9118c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e96fb79a-e0b9-4835-b0b1-9c7434331077_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the statutory federal income tax rate to our effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_5815d44c-148d-4c4c-a35f-4aefde533e6b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c62869e6-95fb-4e24-ae36-da200a0fb21a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8603486a-aec3-4f22-91a2-dbaaa3ea6c10_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_e77d8559-fbd4-468e-a4b1-91f26a27f5f3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantsAxis_eb0f3f1d-997a-45a7-90d3-fbe311e702be_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantsAxis_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantsAxis_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis" xlink:to="lab_apyx_DebtInstrumentCovenantsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_20eb57f4-40b5-45de-aa48-0ddad40e722b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ba775ba5-1e56-427a-b60b-d542b9420bb6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_bd5650cd-8d83-44e6-b882-5e34339ba4ce_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e71fe3cb-5ea6-4be0-b821-7c131548798f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4ec65ed4-a69f-4429-a644-85999b7c470a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_06f97b45-8b1f-4c26-9dfb-339c7ce3594e_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing base, minimum balance</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:to="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c553576-49ba-4765-b114-167c8b53854f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_49257ccc-1897-45a3-922e-873df259f358_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5a49c761-cff5-4cbd-882a-076e4c2c1bd0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_82e5685c-e9f3-4dc3-bd98-405eed603235_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AuditInformationAbstract_label_en-US" xlink:label="lab_apyx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_apyx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_apyx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AuditInformationAbstract" xlink:href="apyx-20221231.xsd#apyx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AuditInformationAbstract" xlink:to="lab_apyx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_5b2cf51f-d0dc-42f6-86e6-3d9dcf7c2bf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_81f5a985-b662-4478-a80c-6a1dd116527a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_59016622-d3b0-41a3-92ac-822174142379_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3e3b563a-aabd-412d-b1cc-76974b560660_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_4cabd758-e2ef-496f-ac01-add715bb0fc2_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_71b28842-1b0b-4d21-901f-59f09258199c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_26d50899-af53-422e-b8db-a483d2df4840_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a57848ce-7b0a-44c4-931a-59d537b59952_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2e87d7d3-5c27-41ef-842f-443dab1e03e3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d4af0b8-7bf6-48b5-a1d1-22b841327e38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a88037f-8cdd-49ed-b1ea-7ed9b079b17b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackTermOfLease_787194fc-73d4-402e-90c1-390de48117e1_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackTermOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, term of lease</link:label>
    <link:label id="lab_apyx_SaleLeasebackTermOfLease_label_en-US" xlink:label="lab_apyx_SaleLeasebackTermOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Term Of Lease</link:label>
    <link:label id="lab_apyx_SaleLeasebackTermOfLease_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackTermOfLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Term Of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackTermOfLease" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackTermOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackTermOfLease" xlink:to="lab_apyx_SaleLeasebackTermOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_842c3a4b-2d0c-460e-a9c2-1fe8fab31de4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_a7dcd931-f27d-449e-af36-cd14044d15a5_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_201971a9-8e90-4f8e-9815-0b21db5bb598_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3326df2f-0749-4977-9f40-dd42b6c66bbf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5240424d-159c-4e67-86b3-62bdc87ccc2a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_7c291c6a-9d7d-47e2-8b14-63fb55f11964_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b056eb85-51ee-47e3-8d2e-f58c15d3ef07_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_931ad761-8b56-4274-bac4-ddbe03cdda39_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_67174547-9639-40fd-b3f8-1d4df58dcd78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ef4b90e0-60a4-4486-9a7a-dff70068cb7a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e66797da-94b2-4b03-9360-d2b1bfba614e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e04cc32e-314a-43e4-88cf-4e8b87fa4068_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualPayments_bc54ca47-f675-4516-9e92-e145c800f2a0_negatedLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product warranty costs incurred</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_StandardProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_b3886aa3-42f0-4aa7-9b7c-dd038a2a699b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_98b060d3-9b34-4059-9459-5b63dc75985c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_MountingFixturesMember_a7f0b535-b65f-4f77-af3b-c23d610efc3f_terseLabel_en-US" xlink:label="lab_apyx_MountingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounting Fixtures</link:label>
    <link:label id="lab_apyx_MountingFixturesMember_label_en-US" xlink:label="lab_apyx_MountingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounting Fixtures [Member]</link:label>
    <link:label id="lab_apyx_MountingFixturesMember_documentation_en-US" xlink:label="lab_apyx_MountingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mounting Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MountingFixturesMember" xlink:href="apyx-20221231.xsd#apyx_MountingFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_MountingFixturesMember" xlink:to="lab_apyx_MountingFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_39aedbf0-8681-438b-a726-7ea262e1d9c8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentAnnualFeePercent_4d6210d9-b8d8-4b04-b6ec-258e91b1df6c_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentAnnualFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fee</link:label>
    <link:label id="lab_apyx_DebtInstrumentAnnualFeePercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentAnnualFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Fee, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentAnnualFeePercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentAnnualFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Fee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentAnnualFeePercent" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentAnnualFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentAnnualFeePercent" xlink:to="lab_apyx_DebtInstrumentAnnualFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_f099f3e6-c35c-4056-9056-a52b4bae8e56_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7243497d-2527-40e6-86a5-9b2ece010783_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_8492fcec-b8e9-46e8-9765-8aa849a5e77c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases for tax positions related to prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember_cab842be-5db8-464a-adf6-6821d49a8f4e_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Three</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Three [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_62f90cf1-c851-432e-bef8-0e0e025ec2df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AtTheMarketFacilityMember_6731f79f-7dbd-45cc-b257-5e0030fd26f9_terseLabel_en-US" xlink:label="lab_apyx_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Facility</link:label>
    <link:label id="lab_apyx_AtTheMarketFacilityMember_label_en-US" xlink:label="lab_apyx_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Facility [Member]</link:label>
    <link:label id="lab_apyx_AtTheMarketFacilityMember_documentation_en-US" xlink:label="lab_apyx_AtTheMarketFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AtTheMarketFacilityMember" xlink:href="apyx-20221231.xsd#apyx_AtTheMarketFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AtTheMarketFacilityMember" xlink:to="lab_apyx_AtTheMarketFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_0b096731-3f21-4a62-b344-863e2201e5bb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_f071b7b1-a0ec-4412-9ef1-1d04562563bc_terseLabel_en-US" xlink:label="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2001 Executive and Employee Stock Option Plan</link:label>
    <link:label id="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2001 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:label id="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_documentation_en-US" xlink:label="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2001 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:href="apyx-20221231.xsd#apyx_A2001ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:to="lab_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_9266acd6-62fb-4bf5-8f22-37a4b99e0f59_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d67cefcc-85a1-44a5-be7c-099332d0bfcf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_752fa544-f27c-43b4-acee-da2dc664e5e1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_475e2787-6a5a-4917-ab72-a2a7cabccdf8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AccessoriesMember_0ae9f988-7de8-4d5c-a4a6-484e1a608d79_terseLabel_en-US" xlink:label="lab_apyx_AccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accessories</link:label>
    <link:label id="lab_apyx_AccessoriesMember_label_en-US" xlink:label="lab_apyx_AccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accessories [Member]</link:label>
    <link:label id="lab_apyx_AccessoriesMember_documentation_en-US" xlink:label="lab_apyx_AccessoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accessories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccessoriesMember" xlink:href="apyx-20221231.xsd#apyx_AccessoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AccessoriesMember" xlink:to="lab_apyx_AccessoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_9f60a3b3-b658-4980-a7f7-1eebb543fd64_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0ea34358-e94a-4e46-9fba-7f17fb89129d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentDefaultApplicableInterestRate_e95e9f4e-f231-4460-a604-58be804329de_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default, applicable interest rate</link:label>
    <link:label id="lab_apyx_DebtInstrumentDefaultApplicableInterestRate_label_en-US" xlink:label="lab_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default, Applicable Interest Rate</link:label>
    <link:label id="lab_apyx_DebtInstrumentDefaultApplicableInterestRate_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default, Applicable Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentDefaultApplicableInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:to="lab_apyx_DebtInstrumentDefaultApplicableInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_21328560-4a72-4220-b4df-48050e09055a_terseLabel_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_label_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_documentation_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:href="apyx-20221231.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:to="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8b2c95e6-fae6-4f10-80d1-3e5d718c8b52_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_22aab858-c447-420d-a95f-9f88ef60a228_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales tax payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodDomain_32dac865-600c-4071-a639-5ee97db03bd8_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodDomain_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodDomain_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aacd6781-9b23-4cc1-8858-5de9b5518a67_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_1a346821-352c-45eb-8eaa-e21639af7ca0_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_5b40999e-9521-405e-a2cc-6edc57b5cbed_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_58e97767-ca93-4a2e-9e79-ffcdeff14b51_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4d0f2f36-f768-4704-9898-4c25732c2bba_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ac4b1e40-b8d8-4303-97cf-0fda9017a4bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ebfcf692-58c4-4325-9915-d81696d0e809_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_86c0a370-e426-42fb-92c7-70a56f15ab7b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackEscrow_c024a1e5-de9d-4096-ac19-1e8f0818f1a3_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, escrow</link:label>
    <link:label id="lab_apyx_SaleLeasebackEscrow_label_en-US" xlink:label="lab_apyx_SaleLeasebackEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Escrow</link:label>
    <link:label id="lab_apyx_SaleLeasebackEscrow_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackEscrow" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackEscrow" xlink:to="lab_apyx_SaleLeasebackEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_408ee218-15c4-4107-86d7-24d3a2f46c1f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_63366bdc-36dd-46fc-ad00-aa9fd81afa79_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheThreeMember_7f06416f-dd0f-499d-bf2d-b54ebc7691f6_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheThreeMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Three [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheThreeMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:to="lab_apyx_DebtInstrumentCovenantTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40aa0394-8d15-47b2-8059-3b66f363cac4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d6217710-0fe3-411a-b259-3cc0c7dbae9d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07a05923-9633-465a-82b2-75777c4befbb_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_28cf05f7-912d-475e-9ff4-39e99d914996_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d51b14cb-24dd-48f9-85f5-aadb53fa08d8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_1dc73080-181f-44c1-a9cd-3fbb081e8cd6_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTEREST IN JOINT VENTURE INVESTMENT</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_e1422330-3059-4759-94cd-53eeb2c68a24_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_f7161d49-5157-4cb0-aca3-af73962e962e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e88ce197-6475-481d-b112-4faf4cc29bda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_b99fb6c9-dd00-4f7b-8cfe-117f88814041_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_c9c71679-2696-40c1-8bbc-419f6589c7f0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CreditAgreementMember_b6d57212-5579-4701-9538-7162e6f7ecd5_terseLabel_en-US" xlink:label="lab_apyx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_apyx_CreditAgreementMember_label_en-US" xlink:label="lab_apyx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_apyx_CreditAgreementMember_documentation_en-US" xlink:label="lab_apyx_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember" xlink:href="apyx-20221231.xsd#apyx_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CreditAgreementMember" xlink:to="lab_apyx_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SecuritiesRegisteredNewIssues_406bdf0f-61d4-4dc4-b84b-2af2b6287d11_terseLabel_en-US" xlink:label="lab_apyx_SecuritiesRegisteredNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Registered, New Issues</link:label>
    <link:label id="lab_apyx_SecuritiesRegisteredNewIssues_label_en-US" xlink:label="lab_apyx_SecuritiesRegisteredNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Registered, New Issues</link:label>
    <link:label id="lab_apyx_SecuritiesRegisteredNewIssues_documentation_en-US" xlink:label="lab_apyx_SecuritiesRegisteredNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Registered, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SecuritiesRegisteredNewIssues" xlink:href="apyx-20221231.xsd#apyx_SecuritiesRegisteredNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SecuritiesRegisteredNewIssues" xlink:to="lab_apyx_SecuritiesRegisteredNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9b23e80e-a24f-4bc5-bff8-485d2b28b001_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_7dbbb244-e27d-4610-8d8e-a5f9c34a4e0b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f31d6df1-926a-46a5-b813-06f85de82b9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Provision For Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0cc50c16-2c6e-449e-bf99-0ce1fbfa57f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_54a66697-cd93-4a56-bf1e-1a11a8f325ba_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_04f27d8c-498f-4c9f-9e59-e3b6d404e25e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5bcba1ba-2d58-41a4-822e-40187a75ebc1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_e85333cd-2a6e-47a3-967e-464677256fae_terseLabel_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_label_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_documentation_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability" xlink:href="apyx-20221231.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_UncertainTaxPositionsLiability" xlink:to="lab_apyx_UncertainTaxPositionsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_84fb5106-b0ee-4052-ae6e-3ab1f14adf59_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_61d99f6a-6c7a-4afe-a79c-43a7899fbff0_terseLabel_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of right-of-use assets to property and equipment on exercise of purchase option</link:label>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_label_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfer Of Other Assets To Fixed Assets</link:label>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_documentation_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfer Of Other Assets To Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:href="apyx-20221231.xsd#apyx_NonCashTransferOfOtherAssetsToFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:to="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_a9ebb952-3369-4695-be89-995c7e9fd400_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_ca1be274-042d-4046-ba98-6c40373ce4bd_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_61b6dd8b-d776-4447-b9bd-6601af87e318_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_31e62f3f-55bb-4d6a-9878-c874ffda618c_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing base, minimum balance</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:to="lab_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_bfd74e1e-0b57-4676-ab2a-2fd022ef5cd4_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentPayment_a1fd57a2-ac83-4a04-b909-5d9b17b5e5f2_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback. annual rent payment</link:label>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentPayment_label_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback. Annual Rent Payment</link:label>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentPayment_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback. Annual Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentPayment" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackAnnualRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackAnnualRentPayment" xlink:to="lab_apyx_SaleLeasebackAnnualRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_FinanceLeasePayments_3599da4e-a9b3-43f0-a20d-34288a09faa0_terseLabel_en-US" xlink:label="lab_apyx_FinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for lease liabilities</link:label>
    <link:label id="lab_apyx_FinanceLeasePayments_label_en-US" xlink:label="lab_apyx_FinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Payments</link:label>
    <link:label id="lab_apyx_FinanceLeasePayments_documentation_en-US" xlink:label="lab_apyx_FinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeasePayments" xlink:href="apyx-20221231.xsd#apyx_FinanceLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_FinanceLeasePayments" xlink:to="lab_apyx_FinanceLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a45abe25-9359-43a5-9fdd-868ab76fb978_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_5443e6ed-d4a6-452c-814a-961ee79d4455_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on net settlement of stock options (in shares)</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options, Shares</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares" xlink:href="apyx-20221231.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsShares" xlink:to="lab_apyx_StockSwapToAcquireOptionsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_38cd3c20-4933-46b0-b450-4ae2178fd3fb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TwoThousandTwelveShareIncentivePlanMember_43192481-ebd6-4c69-8f27-122df9a256a9_terseLabel_en-US" xlink:label="lab_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Share Incentive Plan</link:label>
    <link:label id="lab_apyx_TwoThousandTwelveShareIncentivePlanMember_label_en-US" xlink:label="lab_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 Share Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:href="apyx-20221231.xsd#apyx_TwoThousandTwelveShareIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:to="lab_apyx_TwoThousandTwelveShareIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ae925681-723c-4a5b-abdf-ad46fc1889c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackNetCashProceeds_654ed629-6ff5-4f57-bcf8-dff5e0aa18bf_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackNetCashProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, net cash proceeds</link:label>
    <link:label id="lab_apyx_SaleLeasebackNetCashProceeds_label_en-US" xlink:label="lab_apyx_SaleLeasebackNetCashProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Net Cash Proceeds</link:label>
    <link:label id="lab_apyx_SaleLeasebackNetCashProceeds_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackNetCashProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Net Cash Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackNetCashProceeds" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackNetCashProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackNetCashProceeds" xlink:to="lab_apyx_SaleLeasebackNetCashProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_652aa542-f4c0-4ffa-ab26-e1135038813d_terseLabel_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses and current liabilities</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:href="apyx-20221231.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:to="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_eeb8dd64-d1f0-4ba1-8bab-41c7651d3a8d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_14f77c42-500c-46e1-8a94-c6cf2c964db8_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RETIREMENT PLAN</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_2fc30093-6122-4142-8585-8fa8cd151376_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_RenuvionJPlasmaGeneratorsMember_415f875e-c7f2-4a42-ad62-6a826806e480_terseLabel_en-US" xlink:label="lab_apyx_RenuvionJPlasmaGeneratorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renuvion/J-Plasma generators</link:label>
    <link:label id="lab_apyx_RenuvionJPlasmaGeneratorsMember_label_en-US" xlink:label="lab_apyx_RenuvionJPlasmaGeneratorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renuvion/J-Plasma Generators [Member]</link:label>
    <link:label id="lab_apyx_RenuvionJPlasmaGeneratorsMember_documentation_en-US" xlink:label="lab_apyx_RenuvionJPlasmaGeneratorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renuvion/J-Plasma Generators [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RenuvionJPlasmaGeneratorsMember" xlink:href="apyx-20221231.xsd#apyx_RenuvionJPlasmaGeneratorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RenuvionJPlasmaGeneratorsMember" xlink:to="lab_apyx_RenuvionJPlasmaGeneratorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e929592-fbef-43f0-8de0-77a40e089604_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c03030ef-b831-41c1-8e6d-14fb45adf853_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2699de8f-b2be-4275-ba7c-50cf8b2096bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_16ed5e00-db2e-4ab0-86e3-720616cd6ef1_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Financial Statements</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_03e7b962-7004-4ca3-8dce-efb15df4dfd9_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_15b62f81-8b2d-4b1a-8253-405d66c9798e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_084dfb9e-9d20-47d4-99dd-88512df5e5d7_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_3b129ee2-d829-4e12-b8b1-4e8565d8008b_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_d5418506-2ac8-47aa-9113-d0036f142db7_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_993ceba6-2dfa-4e6f-a354-133ed94ec075_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e4afae0e-edd9-42bd-8df3-f722c4dac9ce_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dd5c546a-e063-4d1b-9a6e-ca89b4b4893f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ContractWithInternationalDistributorMember_f4fa0f0b-83dd-4425-859e-aa235c3f25dc_terseLabel_en-US" xlink:label="lab_apyx_ContractWithInternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With International Distributor</link:label>
    <link:label id="lab_apyx_ContractWithInternationalDistributorMember_label_en-US" xlink:label="lab_apyx_ContractWithInternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With International Distributor [Member]</link:label>
    <link:label id="lab_apyx_ContractWithInternationalDistributorMember_documentation_en-US" xlink:label="lab_apyx_ContractWithInternationalDistributorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With International Distributor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ContractWithInternationalDistributorMember" xlink:href="apyx-20221231.xsd#apyx_ContractWithInternationalDistributorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ContractWithInternationalDistributorMember" xlink:to="lab_apyx_ContractWithInternationalDistributorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e2bf4481-8b92-4598-9c8f-c56335b518ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_077b5fe4-192c-4b5a-a45b-4ce173bd035f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_c7ccf979-48ef-4db7-a0d3-9ffc528dffa9_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_de9332e1-477b-4b03-b80c-f2ce357ca19f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f4e75ce9-30f7-4e0c-9f84-dd73c4513070_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CapitalizationOfLeaseDerecognizedExecution_1f355eb3-f588-4de5-97e0-3532e89df815_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseDerecognizedExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseDerecognizedExecution_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseDerecognizedExecution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Derecognized, Execution</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseDerecognizedExecution_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseDerecognizedExecution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Derecognized, Execution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseDerecognizedExecution" xlink:href="apyx-20221231.xsd#apyx_CapitalizationOfLeaseDerecognizedExecution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseDerecognizedExecution" xlink:to="lab_apyx_CapitalizationOfLeaseDerecognizedExecution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_cfe1a5da-778a-490a-a54b-1c478b65c4fa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3923bce1-8fd0-4f61-a59c-67c059c763a0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2019ShareIncentivePlanMember_a31ed893-53eb-4b40-9e95-f696c669d1e8_terseLabel_en-US" xlink:label="lab_apyx_A2019ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Incentive Plan</link:label>
    <link:label id="lab_apyx_A2019ShareIncentivePlanMember_label_en-US" xlink:label="lab_apyx_A2019ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Incentive Plan [Member]</link:label>
    <link:label id="lab_apyx_A2019ShareIncentivePlanMember_documentation_en-US" xlink:label="lab_apyx_A2019ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2019ShareIncentivePlanMember" xlink:href="apyx-20221231.xsd#apyx_A2019ShareIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2019ShareIncentivePlanMember" xlink:to="lab_apyx_A2019ShareIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_626a6b5d-413d-4743-9fca-2a357323c915_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of tax positions related to the prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e60aa206-365d-4bb5-8713-3909ddaecdaf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and exercisable, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_1cbb35a8-9488-4bbf-9221-379dfff71668_terseLabel_en-US" xlink:label="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Executive and Employee Stock Option Plan</link:label>
    <link:label id="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:href="apyx-20221231.xsd#apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:to="lab_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_09151dcd-b3f3-44dd-8365-831e0bf800c9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3d1cb49f-971d-4701-bb17-3de27b302e6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_250eb57c-b306-4275-b8e1-0c9a0e1b3756_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates in the Preparation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_31dac6b0-7c08-48d3-952a-b69bcfdc1300_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product liability claim insurance deductibles</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodAxis_8a390c61-23c2-491c-8914-0bb8dd0394eb_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodAxis_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodAxis_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodAxis" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodAxis" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_bc3c5185-5c7f-48e0-92f5-a0fe36ad09cf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_16e9b6a9-847f-423f-b3c3-d0b1730a71fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d6fe156c-b1db-4d8e-8012-3af0d9f8d16c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_e2845ed7-9c43-4ab2-ab52-8ec29715ba67_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_58475edc-6e39-4859-90ac-85f3f3aeea08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility - maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c1934a6a-ebe3-46c1-b19d-ec7318a47232_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_85a13975-86f1-4cb9-a108-ef77b47dcf0a_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to supplier</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9f439528-daaa-4650-bee0-a2f16ef6b820_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AdvancedEnergyMember_48c70665-eb56-49a7-a1f4-8fb0f931ad74_terseLabel_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_label_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_documentation_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember" xlink:href="apyx-20221231.xsd#apyx_AdvancedEnergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdvancedEnergyMember" xlink:to="lab_apyx_AdvancedEnergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1eafd8f1-a0d7-4301-984a-3e6fc6bb87cc_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a56bbb20-e1de-4edb-989c-f9108f128f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_57a51e25-ce8d-4463-bd83-3fd4d6d6c5d4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_6607ebd3-24bd-4692-a0eb-0739ee14c8ee_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_451ef93e-57e8-49f0-a0a1-05bbaaeeff79_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackPurchaseAgreement_0e6d7425-2b7f-4117-a7e0-622efbadd09b_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, purchase agreement</link:label>
    <link:label id="lab_apyx_SaleLeasebackPurchaseAgreement_label_en-US" xlink:label="lab_apyx_SaleLeasebackPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Purchase Agreement</link:label>
    <link:label id="lab_apyx_SaleLeasebackPurchaseAgreement_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackPurchaseAgreement" xlink:to="lab_apyx_SaleLeasebackPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_d02e4058-a347-4661-8b84-dbcf0de4b7a0_terseLabel_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, vesting percentage after 3 years</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_label_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_documentation_en-US" xlink:label="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:href="apyx-20221231.xsd#apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:to="lab_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_fc7389b4-7b20-4bb6-9528-be10d17b0604_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate (Other)</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_753a8d18-92b5-4a47-b0b1-95a25200db21_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, 12 month net revenue target, year one</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:to="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_6a9d8506-055d-4188-a889-303ebb45543a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_fb9188ea-cb9c-4efb-b9be-062c91d39994_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_17b15872-9406-4fdc-be31-b9ff0bc41cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5294dace-006c-4647-81b6-a6db7a4e0c08_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_5c8df1d8-f2fb-40c0-a4b5-ac7093de1659_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss and credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_d7a84c07-227b-42e4-a8cd-a16b3ffe455f_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b6e6dea5-0310-483a-8747-98f03fb28761_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_973120db-e626-4428-a238-510747a48d46_verboseLabel_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease costs:</link:label>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_8c882ae9-a6f0-4073-8252-f5a152ae2f3c_terseLabel_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_label_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Costs [Abstract]</link:label>
    <link:label id="lab_apyx_FinanceLeaseCostsAbstract_documentation_en-US" xlink:label="lab_apyx_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract" xlink:href="apyx-20221231.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_FinanceLeaseCostsAbstract" xlink:to="lab_apyx_FinanceLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_75477d61-f1c7-451e-bcd2-cf45a58cd007_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_26e5ee89-7144-4eea-a168-97fde5396d93_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d4c22c0-a94e-4180-b491-08ec1fd53dba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b9d27d7e-4948-4db7-8d48-f7d524abcd32_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in current assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_187016a6-ce02-468f-a869-db0398896af6_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, 12 month net revenue target, year two</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:to="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_023cd38c-a5ab-4cd3-b83a-e77f6cebae40_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_763c0592-7318-4f05-b6b5-1dd886a9d8fe_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c738d15a-856d-4cfa-96f3-ddb635066c23_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_6f0f0c39-3ac4-4281-b0e8-b377c656d639_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_e3f14118-f1b3-425a-9538-f95770ce1a8e_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2d537f4a-c0d9-4705-9b38-24478a467bfc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_3ccf3453-41b8-4553-92a6-ab19034e6117_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_274a6699-a923-4d81-b34c-d3735a0b0f92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining shares for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_4c8053ef-ec48-4821-8016-0fd93c99f68a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_21a943c9-7fd0-406e-8a85-11ebe7bbf47f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cdb95319-0619-45a2-b608-c744020cbd0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_415a4bf0-360c-4cac-beb6-e2fbe6708e74_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_92f48744-cd40-4eca-be46-fa528159b35b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_abc9b438-9242-479c-a1ed-631281520244_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c8b254a0-79f5-4c61-9274-bbba09057a1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ChineseSupplierMember_bebbe54d-0412-4185-bfb2-8f15605c39ae_terseLabel_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_label_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier [Member]</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_documentation_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember" xlink:href="apyx-20221231.xsd#apyx_ChineseSupplierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ChineseSupplierMember" xlink:to="lab_apyx_ChineseSupplierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f10dda4e-273c-45b6-976c-81b262c41498_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_365e2556-9bd7-4ecb-b64c-b459c5c7f1c7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d1267d52-2bdc-416e-8dd0-76bfe888b833_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProductWarrantyExpenseNet_e01f5a4b-25aa-4941-999d-bd0d08c6e71d_terseLabel_en-US" xlink:label="lab_apyx_ProductWarrantyExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for product warranties</link:label>
    <link:label id="lab_apyx_ProductWarrantyExpenseNet_label_en-US" xlink:label="lab_apyx_ProductWarrantyExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Expense, Net</link:label>
    <link:label id="lab_apyx_ProductWarrantyExpenseNet_documentation_en-US" xlink:label="lab_apyx_ProductWarrantyExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarrantyExpenseNet" xlink:href="apyx-20221231.xsd#apyx_ProductWarrantyExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProductWarrantyExpenseNet" xlink:to="lab_apyx_ProductWarrantyExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_679a7c6e-4cb1-4463-bda5-7d5dd2cd26ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net of allowance of $668 and $430</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ComputerEquipmentandSoftwareMember_c9457887-54f3-480e-b793-32ffa8dce53a_terseLabel_en-US" xlink:label="lab_apyx_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_apyx_ComputerEquipmentandSoftwareMember_label_en-US" xlink:label="lab_apyx_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_apyx_ComputerEquipmentandSoftwareMember_documentation_en-US" xlink:label="lab_apyx_ComputerEquipmentandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember" xlink:href="apyx-20221231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ComputerEquipmentandSoftwareMember" xlink:to="lab_apyx_ComputerEquipmentandSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_379c37e1-12bc-445a-bfe9-f310416341be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_ba4a545f-9e2e-4e81-acee-0636035bc7cc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_4fed876e-c277-411d-8e4e-fec9c648a1a7_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a4a5b226-e71c-4ea0-ae11-557ebfd9ca86_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e80f7bfb-b6fd-488e-a013-e3473cc7e818_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a705eb5c-d5fb-489e-b357-d3fa0fdf9832_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_4ba9d091-509e-4d7a-9b15-0db8a485ffda_terseLabel_en-US" xlink:label="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Executive and Employee Stock Option Plan</link:label>
    <link:label id="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:label id="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_documentation_en-US" xlink:label="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:href="apyx-20221231.xsd#apyx_A2003ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:to="lab_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_69b9ed3f-5f70-4872-a863-4d48ff0c9b55_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_b114ff6e-1df5-4787-a243-0ec4d6a5f6ff_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fa6eb0ac-b11d-40c5-b9f1-d01ff9af21d9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CapitalizationOfLeaseRecongizedNonCash_f97fe4b1-ad01-4991-8d75-e9be1e623e65_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseRecongizedNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseRecongizedNonCash_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseRecongizedNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Recongized, Non Cash</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseRecongizedNonCash_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseRecongizedNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Recongized, Non Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseRecongizedNonCash" xlink:href="apyx-20221231.xsd#apyx_CapitalizationOfLeaseRecongizedNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseRecongizedNonCash" xlink:to="lab_apyx_CapitalizationOfLeaseRecongizedNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProductWarranty_bf943dcc-b56f-4de7-863c-279c05c03d79_terseLabel_en-US" xlink:label="lab_apyx_ProductWarranty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product warranty</link:label>
    <link:label id="lab_apyx_ProductWarranty_label_en-US" xlink:label="lab_apyx_ProductWarranty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty</link:label>
    <link:label id="lab_apyx_ProductWarranty_documentation_en-US" xlink:label="lab_apyx_ProductWarranty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarranty" xlink:href="apyx-20221231.xsd#apyx_ProductWarranty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProductWarranty" xlink:to="lab_apyx_ProductWarranty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_070f3efe-7858-4f2b-b96c-c720cd8bf157_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_95635b98-52c0-4bfa-affd-02d93af4a308_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_81013880-c2df-401a-bba6-7a3bd27530df_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_27447f68-ff9c-43fd-ae3f-7855d2fbcac5_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e1ef30f5-aaeb-4e1b-8d37-f46a2a7a9944_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d7e020d9-7557-4163-b049-c992ec2286fc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_ac0179b4-e93f-455c-b9a4-5dc3bca9a93a_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesAndWages_ae0e3f9b-a7de-4a39-bcf1-706267b35293_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and related costs</link:label>
    <link:label id="lab_us-gaap_SalariesAndWages_label_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages" xlink:to="lab_us-gaap_SalariesAndWages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d3f2e237-74c5-4fbf-aa0d-d44c689cb3b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and expected to vest, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_71260dc9-64aa-401d-9017-7dade7acf97f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9425bd0e-26d2-462d-8744-a96c96452f7e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_de05931d-db49-4d62-b1ce-84342795a4ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Options And Stock Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c34f907a-ade8-47a7-bd13-9fed964e7316_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7db33a04-f2ce-492a-a847-ee6089752e99_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_58878980-7e09-4260-a5f2-32ef886bd996_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_be7d586f-f262-46a4-89b9-2b4d05893fd4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory 263A adjustment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_283548f0-7901-4304-b513-de4cb4a987da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_83ce9842-3883-4f77-8e0e-938062f19f99_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodOneMember_f3387456-25fe-47e4-8684-637cf7322908_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period One</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodOneMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period One [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodOneMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0b5176fe-da05-452a-8e6f-f38d89d06760_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_48f3da25-3f49-475d-bde4-602f3e072601_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheTwoMember_62905f63-899a-4c72-a8e7-affcfd94bc4d_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheTwoMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Two [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTrancheTwoMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:to="lab_apyx_DebtInstrumentCovenantTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1f4f726b-aa43-45d2-a2ef-4e9de6d7ecc5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_32e70ca7-be99-40f8-aae9-e394e88d69a4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_78ba0076-ab15-40cf-869a-4928a2f6b22b_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard Product Warranty Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard Product Warranty Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInStandardProductWarrantyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:to="lab_us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_837133c8-d4fd-4e26-ba88-8d2e5237c192_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_de66fe2e-f703-4334-be8d-debcdbd84541_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_8e4d27c5-aba8-4d06-afa9-c726075bb559_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPayments_ee33c537-55cf-44a6-bc15-89fd8c0afb84_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly payments</link:label>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPayments_label_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments</link:label>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPayments_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:to="lab_apyx_DebtInstrumentNumberOfMonthlyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f576933-77de-43d0-871a-30c05fda2fff_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_dba747e4-0761-4f81-8468-eeaa0e29a1df_periodStartLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_c62187d0-e241-41d2-b6a3-1550c7001290_periodEndLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrual" xlink:to="lab_us-gaap_StandardProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a88a61a0-8aa0-40dc-9ee9-e957738ae765_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a9ba6fa2-19c2-4ee7-bb13-43892e5face3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_2368c169-7256-49bf-88b7-34c49d57b569_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantsDomain_14687133-346a-4aed-9955-d3a8f4aa8634_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantsDomain_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantsDomain_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenants [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain" xlink:to="lab_apyx_DebtInstrumentCovenantsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f21d1188-4d46-4aa4-94f5-6713b9f25b92_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b424f5ca-bc69-4deb-acbf-8bc23276a382_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8ad23f42-62cd-47d5-8a29-db6232c351d1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_70be688c-3a46-4f0f-8c60-d87ec93da05b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Warranty Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f3f97291-1fa2-40ee-a9d7-86929ef5148f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_929e1942-f24d-4282-879f-d300af7d429b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8786f48d-469f-47f3-87b5-8d967463d869_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3d091354-d2bc-4c1a-a8dc-a949c838e4dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9961b907-12f0-4226-b0f8-15e5b807daf7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2021ShareIncentivePlanMember_5ea10eea-1783-4c5e-b58f-6aae926b27a9_terseLabel_en-US" xlink:label="lab_apyx_A2021ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Incentive Plan</link:label>
    <link:label id="lab_apyx_A2021ShareIncentivePlanMember_label_en-US" xlink:label="lab_apyx_A2021ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Incentive Plan [Member]</link:label>
    <link:label id="lab_apyx_A2021ShareIncentivePlanMember_documentation_en-US" xlink:label="lab_apyx_A2021ShareIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2021ShareIncentivePlanMember" xlink:href="apyx-20221231.xsd#apyx_A2021ShareIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2021ShareIncentivePlanMember" xlink:to="lab_apyx_A2021ShareIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_21c20657-b010-4354-91ec-b456a0f63c37_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_000c7f8e-350d-4571-ab77-9bd0ad7aa9ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b764659a-ba83-4cfa-ba61-4e320d7c5b4c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_60f54dd9-fd92-4def-bba7-3902b1afb271_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_e40cd354-1e41-4ced-b228-0d3af99c9e4e_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, 12 month net revenue target, year three</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:to="lab_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4780c711-d087-4c48-a9b9-a352f751a746_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2dbb7641-333a-436f-b6e0-9f4edfb9268c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36503c12-24b9-4097-9714-7acf93643165_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ff437f46-8590-4482-8cfc-73c0ab40f56d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d3db8734-6b95-4d18-9bd1-0b4984e8e437_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility - minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1da92cf3-b3ca-45e7-bc7a-d44c284295ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c945dbbf-f1f6-4989-8db2-18175c38f843_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodTwoMember_07fd5eb1-e45c-48e5-9e4e-8ecc369aa961_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Two</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodTwoMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Two [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodTwoMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c87c7df4-76f0-4a63-ac70-2bb69cb23ecf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_bfe8b674-8e9c-4461-bbd5-71ea9ad3615a_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_2ef5b51e-d195-462c-a29d-60a0553e14cf_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease_6adacf3a-a3f3-4715-9e50-dcda4b49ecb4_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate to fulfill prior-year warranty obligations</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease" xlink:to="lab_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9e6cc9a5-e101-40bf-bf2c-c2b8c7fa8f12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of December&#160;31, 2022, and 34,409,912 issued and outstanding as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_0219038b-f0cf-4f22-8e9e-e216c58cf872_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, cash and cash equivalents balance</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_label_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash And Cash Equivalents Balance</link:label>
    <link:label id="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash And Cash Equivalents Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:to="lab_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_15b7a15d-387b-4b1a-aff1-174cd11105f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_dc03098d-51e3-493b-bd82-0cee09b3b735_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (losses), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_1eeb044f-1606-42cb-8da7-3a158c441aec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_41165b52-4be1-4720-b4f9-adb9c4baaac2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of currently exercisable stock options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_bc6722d3-77ab-4bf5-a785-7514f65e181e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyDisclosureTextBlock_96b96d00-c98c-475e-b849-e2ec56882670_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRODUCT WARRANTIES</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:to="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6d46e2a2-9df6-4463-bc03-0eb69a265f3b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_5f381328-cf04-4931-b99e-6c86972d2e0e_terseLabel_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options granted</link:label>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_label_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value</link:label>
    <link:label id="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_documentation_en-US" xlink:label="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:href="apyx-20221231.xsd#apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="lab_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_813ae247-90d2-4ab5-9f03-825a8a75a5f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af9ba371-e83d-489a-9b16-55e6ef80ed12_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_b260097b-27c5-4970-ad39-d3c7bd418daf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_33d863d1-1eb1-4c42-b7a8-d661b55eb52b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e52ab865-fa8f-49ec-8faf-7754eba21af6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Apyx</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_43e515ec-34d8-4476-ba8d-51d699638bf6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_00f952b1-b69e-45d2-832a-dd225ef14d47_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a26401fb-7bd3-4368-9615-8d6cc9554764_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_a4dcad1f-4908-48eb-a5ce-f0efba2bb2cb_terseLabel_en-US" xlink:label="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Term Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Term Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Term Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:href="apyx-20221231.xsd#apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:to="lab_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c0ad5c19-989d-4282-b5bc-dad4a8e4adcf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_304f109b-8989-4abd-b78c-1536ecc087c7_terseLabel_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_label_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Costs [Abstract]</link:label>
    <link:label id="lab_apyx_OperatingLeaseCostsAbstract_documentation_en-US" xlink:label="lab_apyx_OperatingLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract" xlink:href="apyx-20221231.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OperatingLeaseCostsAbstract" xlink:to="lab_apyx_OperatingLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_550613c6-757a-4bb9-8fa9-58cd49913e11_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_2b9b95dd-e2d0-47cc-a833-549f566c7f88_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AccountsReceivableBenchmarkMember_4269e828-d84d-4845-bf1f-c86186e287f4_terseLabel_en-US" xlink:label="lab_apyx_AccountsReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Benchmark</link:label>
    <link:label id="lab_apyx_AccountsReceivableBenchmarkMember_label_en-US" xlink:label="lab_apyx_AccountsReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Benchmark [Member]</link:label>
    <link:label id="lab_apyx_AccountsReceivableBenchmarkMember_documentation_en-US" xlink:label="lab_apyx_AccountsReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccountsReceivableBenchmarkMember" xlink:href="apyx-20221231.xsd#apyx_AccountsReceivableBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AccountsReceivableBenchmarkMember" xlink:to="lab_apyx_AccountsReceivableBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodAxis_ed454a1a-cd48-46d0-8be7-9c452b29242f_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodAxis_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period [Axis]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodAxis_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles_f42a50ac-898f-469d-a910-9309f4068668_terseLabel_en-US" xlink:label="lab_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued insurance deductibles</link:label>
    <link:label id="lab_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles_label_en-US" xlink:label="lab_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Accrued Insurance Deductibles</link:label>
    <link:label id="lab_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles_documentation_en-US" xlink:label="lab_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Accrued Insurance Deductibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" xlink:href="apyx-20221231.xsd#apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" xlink:to="lab_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_ae967994-665f-440b-baad-2200af403adf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_83bca480-164c-4cc3-875c-9aa6f8f49b55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorPercent_7f22aa74-f4db-4a6c-b211-fdacdfa4e2e3_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate floor</link:label>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorPercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate Floor, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentInterestRateFloorPercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentInterestRateFloorPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate Floor, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorPercent" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentInterestRateFloorPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentInterestRateFloorPercent" xlink:to="lab_apyx_DebtInstrumentInterestRateFloorPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_51a25613-e112-49e4-958d-ca1f548589f6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_35218309-4cd3-4d03-8622-84ebec45f02a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_dbaf6002-d23d-4338-8faa-a2957ad295a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_c757f217-60e7-4aa3-aec6-917dfa31b6c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9a10d76f-4afe-4609-a744-81100d28da46_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_39d1130d-40e4-43a3-b41b-d0f9d8be8259_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loan, principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_c5ed6e1f-9610-449c-84ae-6be66e018302_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionOnSecuritiesMember_2ec0afa3-5dbd-4dfb-86e7-c68b267dfbfd_terseLabel_en-US" xlink:label="lab_us-gaap_OptionOnSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_OptionOnSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OptionOnSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option on Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionOnSecuritiesMember" xlink:to="lab_us-gaap_OptionOnSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_de403fce-daca-4b13-9496-78cbc2bfa0bb_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_947106c1-a200-4b9d-876b-8ee196db753a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reporting Information by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_512d1b62-545e-4105-a7a9-01cad3c6bd5e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DefinedContributionPlanRequisiteServicePeriod_259b85d4-cbf0-4c35-96dd-120db43908c6_terseLabel_en-US" xlink:label="lab_apyx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service period</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanRequisiteServicePeriod_label_en-US" xlink:label="lab_apyx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Requisite Service Period</link:label>
    <link:label id="lab_apyx_DefinedContributionPlanRequisiteServicePeriod_documentation_en-US" xlink:label="lab_apyx_DefinedContributionPlanRequisiteServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanRequisiteServicePeriod" xlink:href="apyx-20221231.xsd#apyx_DefinedContributionPlanRequisiteServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DefinedContributionPlanRequisiteServicePeriod" xlink:to="lab_apyx_DefinedContributionPlanRequisiteServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ffb273e1-477d-4df5-9a08-769a3311a26d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_9aeaeaf1-ddc5-43b4-a445-646491616b38_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases from supplier</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_ae6b5ed6-9ef6-4ffa-aba4-e48ae48a5f58_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_048433bc-bdd4-45f7-971a-f270d9caaf73_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11549d69-fb50-4d22-aff3-523cba92489f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax provision</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_0a64db12-d885-446e-a9d4-c8fa8594efaf_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for product warranties</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2370e5de-7245-463f-97b9-2b00f68a7550_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_018c772a-caec-43ce-b266-2c5745c9c6b4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_e02d8c57-c02a-472b-80fd-70b03ce411c2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock compensation expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7e04b0e8-f5f5-4b47-9fa6-609dc63911db_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_19fc929c-3ff4-4da2-9427-e274c51aad28_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cfb1763b-ae24-45c4-bb6b-be64e05fd5cf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8487994f-e33b-4995-8818-81aea5cd1e31_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9edd0c8a-110c-45ed-acc4-274d4a10097b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a2f4a053-83e9-4cfb-98e4-9241fb6e86f5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_dfc55f49-7f5a-4eeb-8ef9-259644160464_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_0efee491-9cea-403d-b594-2d0a336a5c23_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_label_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_documentation_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory" xlink:href="apyx-20221231.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForObsolescenceInventory" xlink:to="lab_apyx_ProvisionForObsolescenceInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_cbbd0da2-ca60-4533-b325-7971648220a9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b5a15166-40d1-445b-a3a7-45e117493528_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercises for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c1f67bc4-f3a0-4aba-b948-748d0d833c1d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7dd5fb65-0e7a-496b-9b6b-db48b8423afd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e594590b-2cea-4874-af4a-980efc919e70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_be4e3c30-e64d-4c8e-a3f7-f59de8bc0461_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China joint venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentExitFee_5648af3d-8b63-46fa-a767-80b6235ce9f7_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee</link:label>
    <link:label id="lab_apyx_DebtInstrumentExitFee_label_en-US" xlink:label="lab_apyx_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:label id="lab_apyx_DebtInstrumentExitFee_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExitFee" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentExitFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentExitFee" xlink:to="lab_apyx_DebtInstrumentExitFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7c70cb76-720e-4823-9e8a-0dd669909101_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_65f0a840-a424-4061-a981-652219a02d76_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodDomain_04cb931c-504c-4735-a4c2-fa59468cc101_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodDomain_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Domain]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodDomain_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodDomain" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_6f3e8770-5036-4690-98b3-357deb7383fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_10a7e4b2-bc98-46cf-9e6e-dc00d213a76c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_7edebc83-ff53-4db7-a722-ac79c7c7f786_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_db080c3e-0ecb-4764-8896-2193532da148_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentFeePercent_904f9485-9224-42bf-9303-cec9f97cc482_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentFeePercent_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percent</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentFeePercent_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentFeePercent" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentFeePercent" xlink:to="lab_apyx_DebtInstrumentPrepaymentFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b69fb804-2ee2-49a4-b61a-c482580ba85a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b319a087-eed9-448b-9a07-843bbd0b38af_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9080f09d-0f5c-4dc5-959b-389136242de0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_a667f41f-a96c-47b6-8e45-fbd3dbfe7649_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_ca017286-5bc0-4528-9610-0e48ddc9a01e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_acb1f3fc-8fbb-43e2-b345-ddf2e7056503_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_15fa323c-fb9e-4170-91f2-c54ab327e949_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d20f9ab1-291e-4feb-8403-b313c06cacbd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_dad81524-a3cd-4f09-9b7c-719d53a7b63b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_43e37cd7-4df5-4308-89a3-825b82861d9a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_c7e898d1-d79e-4595-9d1f-c79dd04052f9_terseLabel_en-US" xlink:label="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="apyx-20221231.xsd#apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6fab6eff-4acf-4327-842d-7aa68a3b0926_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dfec126a-842b-448c-9638-66e43553bb80_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f3f6c2ad-dda1-4cef-b3a8-fb8c68b92a6e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7fc63bb1-d91f-4d0b-a963-c9fa49734bd4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Roll-Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime_f2f2422e-e07c-4fa0-80be-1e8b8ae529f0_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll liability, eecrease due to lapse of time</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability, Decrease Due To Lapse Of Time</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability, Decrease Due To Lapse Of Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" xlink:href="apyx-20221231.xsd#apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" xlink:to="lab_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_a049dcc6-df33-4e50-b0db-ca81b80a302f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationFees_66fe3b35-4eef-42d1-ad77-bab3bd637ee6_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination fees</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationFees_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Fees</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationFees_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationFees" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationFees" xlink:to="lab_apyx_DebtInstrumentTerminationFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_086ae608-6951-4526-bfdf-4a7e6dc3c1ef_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8aa7ed24-0009-476b-b1a7-959dd9dc6665_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b457968e-c2e9-425a-b358-14581e0a805b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercises for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_889d130f-b534-4748-a6a7-707d36309517_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of transaction fees and other costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b7dc42f9-7b0f-47f4-9d70-3f0798861f37_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_3cd76cc7-b029-46d0-ac91-82b30e0b143e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEOGRAPHIC AND SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f67ee818-ec94-49a9-a83f-f62b863978be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_046d1b69-e3c2-4be3-92d9-5bfd158bbc10_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_43b26ca5-6b53-4c96-82d5-0aecad99c7d6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_65500621-e1e3-4d75-a4e4-e1b52d7f161c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ToolsDiesAndMoldsMember_2d205036-1e31-4211-9d90-e7a0e4e60b7f_terseLabel_en-US" xlink:label="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molds</link:label>
    <link:label id="lab_us-gaap_ToolsDiesAndMoldsMember_label_en-US" xlink:label="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tools, Dies and Molds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ToolsDiesAndMoldsMember" xlink:to="lab_us-gaap_ToolsDiesAndMoldsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_43a0c881-d5c4-4596-8f41-cca504cc26c9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_8caabacc-3fa4-41d2-9171-f99264c9f694_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74396ee9-4062-46d8-814d-19eb1ba4a9c9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_490e63fc-f187-4e86-9305-d49048797041_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_36d8bd62-46d6-4ef3-9597-2bc6fbdf3d18_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_4d564231-9426-49c5-abff-e75aafb6d507_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled and forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_34de9490-e589-49b9-a3c7-535e9fe90114_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_bea40fbf-2fff-4b65-b648-52f4b42a76e2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net of provision for obsolescence of $457 and $263</link:label>
    <link:label id="lab_us-gaap_InventoryNet_b7efb6f6-49b9-45fb-b5ed-02d5df615e50_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_e25b3401-8ba7-4da7-8918-d784ae14bb17_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_49d71d6a-524a-4e84-bcb8-372f0bfc9828_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_728ae5d0-e657-4fa7-a248-6738c3b9efc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of all stock options outstanding and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_a2d2d0ff-4e7d-4c21-ba7d-e764c728b9dc_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e0226770-1bec-4ee1-b256-d12bbc6f928b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7fa3b223-6272-462b-97a6-12304572ac89_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed18423f-e53d-48cf-9faf-19668c064fce_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_a3c466a3-1f06-44f8-a6e1-bae617bf4694_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_33d5488e-d4b6-4eb1-984a-a8dbe715dd42_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7485807e-28ef-47eb-9e7c-dc7c27e8b38a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_23a0320a-f13f-4df7-9ae7-7748ebb17070_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_dddcdf63-2b97-4f3f-b52f-c7970f77b694_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost accrued</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPeriodOfInterestOnly_515d4590-d089-4fb6-9424-37740420da0d_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of interest only</link:label>
    <link:label id="lab_apyx_DebtInstrumentPeriodOfInterestOnly_label_en-US" xlink:label="lab_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest Only</link:label>
    <link:label id="lab_apyx_DebtInstrumentPeriodOfInterestOnly_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period Of Interest Only</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPeriodOfInterestOnly"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:to="lab_apyx_DebtInstrumentPeriodOfInterestOnly" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3c719157-14cd-44a3-9be6-9af56d500ea0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_902199f3-afda-4888-b0fc-42be1d8ededd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 17)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6e025c53-c577-4175-a463-954dcd741e0a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65d2f2d7-a3bb-450a-af6a-73865ffdb7b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_67a797a3-9c39-4079-aaa7-c17f420d071e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7b67aa56-5e09-47e3-8259-3579ddfd244c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LesseeOperatingLeaseNumberOfLeasesExtended_f4864aab-de14-4810-9876-08fe1f919905_terseLabel_en-US" xlink:label="lab_apyx_LesseeOperatingLeaseNumberOfLeasesExtended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases extended</link:label>
    <link:label id="lab_apyx_LesseeOperatingLeaseNumberOfLeasesExtended_label_en-US" xlink:label="lab_apyx_LesseeOperatingLeaseNumberOfLeasesExtended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Leases Extended</link:label>
    <link:label id="lab_apyx_LesseeOperatingLeaseNumberOfLeasesExtended_documentation_en-US" xlink:label="lab_apyx_LesseeOperatingLeaseNumberOfLeasesExtended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Leases Extended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeOperatingLeaseNumberOfLeasesExtended" xlink:href="apyx-20221231.xsd#apyx_LesseeOperatingLeaseNumberOfLeasesExtended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LesseeOperatingLeaseNumberOfLeasesExtended" xlink:to="lab_apyx_LesseeOperatingLeaseNumberOfLeasesExtended" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d20ee6b2-eef3-4b72-9abf-41efc18ccd7c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db307c92-234d-419a-bd04-4051592c5bc6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e8f5a9c6-4e5b-4992-8dd9-1202e892e171_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_f8a6b6ba-75c8-4b4e-878c-85bd042be428_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_361738dd-6f74-4c6b-82dd-796651fe3c01_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer matching contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_966990dd-b8af-4b58-a221-2df79eb32628_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_144fa454-78c0-407f-9095-95c18c9dec1f_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aafab595-3f02-4953-83e3-44a072817018_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK OPTIONS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c964ce38-1ecc-442e-8c1f-2f29f257c58d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_86a766e8-d344-49ff-be11-1cae05a9a21d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_babc37a6-dc62-4362-a1b5-a549450cd4c1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0c3621a2-4185-4f46-adfb-f10b34ffa547_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTRACT ASSETS AND LIABILITIES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_0d5200ed-0b74-45c0-b826-f7780463c1df_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_e1621368-2803-4055-9316-3844fe7b4e28_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_7592a73a-1726-485d-9a07-c04641cf7db0_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_20ea9721-e656-4295-9862-a7bd224d4c37_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_66d5bc4d-0265-4e9e-b26a-d7dc0c4046d9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c2c84c9f-fa27-489b-ba8f-20427552a18d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_7befdd52-9b77-4238-a060-d6f50f9f7941_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability" xlink:href="apyx-20221231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollLiability" xlink:to="lab_apyx_JointAndSeveralPayrollLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_73da37d9-dbb1-4239-afd2-fea0979009cc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SuitsFiledIn2022Member_5a9a0fb5-b90c-43b7-ac46-15ed94b0c662_terseLabel_en-US" xlink:label="lab_apyx_SuitsFiledIn2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suits Filed in 2022</link:label>
    <link:label id="lab_apyx_SuitsFiledIn2022Member_label_en-US" xlink:label="lab_apyx_SuitsFiledIn2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suits Filed in 2022 [Member]</link:label>
    <link:label id="lab_apyx_SuitsFiledIn2022Member_documentation_en-US" xlink:label="lab_apyx_SuitsFiledIn2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suits Filed in 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitsFiledIn2022Member" xlink:href="apyx-20221231.xsd#apyx_SuitsFiledIn2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SuitsFiledIn2022Member" xlink:to="lab_apyx_SuitsFiledIn2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_680734e7-c414-44ff-a4c1-1e37676ab33e_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e755ed92-80dd-4302-9139-47daea4d3305_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dcb23bb2-be69-4ce4-bcae-48780183303e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3762ef65-c4a4-4d0b-8640-c83aff5b247f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_de3a4ef5-7162-450a-8471-b5332e4fb6b7_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_28296abd-7796-4cd2-b54b-01b1e1543e56_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_d86ba1a8-2ba3-4ea5-ac30-523ce0066ecd_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_9ba2f229-5f8a-43a0-b9f7-020861332cf0_terseLabel_en-US" xlink:label="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apyx SY Medical Devices (Ningbo) Co., Ltd</link:label>
    <link:label id="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_label_en-US" xlink:label="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apyx SY Medical Devices (Ningbo) Co., Ltd [Member]</link:label>
    <link:label id="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_documentation_en-US" xlink:label="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apyx SY Medical Devices (Ningbo) Co., Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:href="apyx-20221231.xsd#apyx_ApyxSYMedicalDevicesNingboCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:to="lab_apyx_ApyxSYMedicalDevicesNingboCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad2738db-83a0-4a1c-9d6e-c028d166c210_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_b9296107-4c97-40bc-9b6f-472de4081f0f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_64223d9e-fc4a-4f7f-aace-e0334ef9f978_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_98ef9ee1-5770-4630-ba92-17eef5a7584d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_51da5a13-62f9-4792-8ba7-f266361abf48_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f7c4e89e-159b-4728-9b82-6fd8c42c1796_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7aa2c43c-6ffb-448a-b4d2-a8cb09c3abc5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e10b8e22-ecdb-458c-8288-009efd75ec90_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a826801e-4fbb-4c25-b97d-3bd6c2774510_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CoVenturerMember_819f4458-979c-4709-9975-71fb9f07ea0a_terseLabel_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer</link:label>
    <link:label id="lab_us-gaap_CoVenturerMember_label_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CoVenturerMember" xlink:to="lab_us-gaap_CoVenturerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_39ff5a2c-468a-4d4e-b2bc-7793e778f055_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5b80660e-121f-4ee0-84dc-54cb27d6eba5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_c668e702-47a9-44df-ba71-7f8115feca88_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_8187e261-0ec3-45b0-ab67-e3ef4c3cbc43_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_41516a0c-6291-4c0e-af9b-813d2dfa66b9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_51476f20-0553-436e-940e-45f361f6dae9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_66660ebd-f083-448a-89f1-d8d6aecdecd0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_19d2b404-7517-4f46-ab9c-637d52c25990_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncontrolling Interest</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:href="apyx-20221231.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:to="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_9612bd70-6b96-4417-b277-dd4ea2542573_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments excluded from diluted loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_0cbb8f68-a6b4-447f-9137-21de9fe508e8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7fd5f165-0974-4e88-8976-7958501be346_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a465bc80-32fb-4206-9e96-f5eb10d5fa38_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c0de6fc2-34e9-49a7-8798-2046a4c30e98_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_f9d76865-f419-4e3e-8baf-29a82ee1ba14_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_b81dd73e-4979-4e5d-8cea-63bba2c945f2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISPOSITION OF THE CORE BUSINESS</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f52eb9cc-92cf-4ea4-86c4-9531b7df1be7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4dca84aa-2a18-4216-be1d-2107d933a27c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_af26f741-f0ac-4645-97dd-474ba66de9a7_terseLabel_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit Against Goodwin And Simb</link:label>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_label_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit Against Goodwin And Simb [Member]</link:label>
    <link:label id="lab_apyx_SuitAgainstGoodwinAndSimbMember_documentation_en-US" xlink:label="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Suit Against Goodwin And Simb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember" xlink:href="apyx-20221231.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SuitAgainstGoodwinAndSimbMember" xlink:to="lab_apyx_SuitAgainstGoodwinAndSimbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b72c69f2-8797-4584-9ddf-5a17e88ad5bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_e290a4c6-3455-4d2e-8b35-2d97e5ef05ce_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required capital contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:href="apyx-20221231.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:to="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7ede889c-65e4-4029-8047-ff055f0dbda7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentIncrease_132148ac-dc37-41cc-8fdb-d33f87b194b7_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, annual rent increase</link:label>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentIncrease_label_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Annual Rent Increase</link:label>
    <link:label id="lab_apyx_SaleLeasebackAnnualRentIncrease_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackAnnualRentIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Annual Rent Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentIncrease" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackAnnualRentIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackAnnualRentIncrease" xlink:to="lab_apyx_SaleLeasebackAnnualRentIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_209fc550-f373-4f2d-80ea-0143662d6cb2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_89e638fe-4131-413e-88d0-c4d2a10dddbb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance_2030b284-aca8-460d-8e2c-f383f00d6928_negatedTerseLabel_en-US" xlink:label="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance_label_en-US" xlink:label="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Valuation Allowance</link:label>
    <link:label id="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance_documentation_en-US" xlink:label="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:href="apyx-20221231.xsd#apyx_IncomeTaxExpenseBenefitValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:to="lab_apyx_IncomeTaxExpenseBenefitValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_3586310e-2222-457d-a0b8-7bc6998b158e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodThreeMember_d9521345-80eb-423c-8437-bb0c888a4f39_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Three</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodThreeMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Three [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentTerminationPeriodThreeMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Termination Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:to="lab_apyx_DebtInstrumentTerminationPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_141ef330-5bfc-48a7-a8b6-1cb8c4eaaec4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5750c16f-aeff-4663-9ebb-73b182858cea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackRenewalTerm_7bbaa72a-6b93-48d5-b95f-88a49e41c510_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, renewal term</link:label>
    <link:label id="lab_apyx_SaleLeasebackRenewalTerm_label_en-US" xlink:label="lab_apyx_SaleLeasebackRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Renewal Term</link:label>
    <link:label id="lab_apyx_SaleLeasebackRenewalTerm_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackRenewalTerm" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackRenewalTerm" xlink:to="lab_apyx_SaleLeasebackRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_feb11b1f-e6f0-445b-b396-4697e3b38dca_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_68005f08-481f-4688-b96c-5f401709f975_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TwoLargestCustomersMember_66d89fe9-29a6-4f7a-baa6-0146637b57a4_terseLabel_en-US" xlink:label="lab_apyx_TwoLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Largest Customers</link:label>
    <link:label id="lab_apyx_TwoLargestCustomersMember_label_en-US" xlink:label="lab_apyx_TwoLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Largest Customers [Member]</link:label>
    <link:label id="lab_apyx_TwoLargestCustomersMember_documentation_en-US" xlink:label="lab_apyx_TwoLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Largest Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoLargestCustomersMember" xlink:href="apyx-20221231.xsd#apyx_TwoLargestCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TwoLargestCustomersMember" xlink:to="lab_apyx_TwoLargestCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_fa2bc2c0-13c3-469e-b258-74e930801130_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: provision for obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6a081e83-77cb-42da-b413-8783bf6b74bf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_d5442878-2533-4e9c-b59a-a8ab248010a8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_c6e73e83-6e59-4086-ae82-b78d8fafd385_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_7ed93227-d171-42a6-a171-b8abf7306f58_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_e4d4dc2c-c195-4924-a74a-18829a53700d_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_9da8d896-d6d7-4acf-baa1-b2daee5ebb3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_c899fe28-3b80-4a19-981c-d2e0419849e6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence_564c7df9-8866-4b9f-88d0-4c9cb85e4b26_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, completion period after due diligence</link:label>
    <link:label id="lab_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence_label_en-US" xlink:label="lab_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Completion Period After Due Diligence</link:label>
    <link:label id="lab_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Completion Period After Due Diligence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackCompletionPeriodAfterDueDiligence"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence" xlink:to="lab_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a5d6fb72-e21e-4b00-b009-6eca949d2063_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4f9f401c-dcf3-4395-a167-f27d5a8cb9e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Weighted Average Grant-Date Fair Values of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_63b194a5-86a8-48de-882e-6b1702515425_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received in stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:href="apyx-20221231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ShelfRegistrationMember_d640847c-6856-4db3-80b0-e43a2406d28b_terseLabel_en-US" xlink:label="lab_apyx_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration</link:label>
    <link:label id="lab_apyx_ShelfRegistrationMember_label_en-US" xlink:label="lab_apyx_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration [Member]</link:label>
    <link:label id="lab_apyx_ShelfRegistrationMember_documentation_en-US" xlink:label="lab_apyx_ShelfRegistrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShelfRegistrationMember" xlink:href="apyx-20221231.xsd#apyx_ShelfRegistrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ShelfRegistrationMember" xlink:to="lab_apyx_ShelfRegistrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8d419e92-d4aa-4c5c-87d1-91400d5de660_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_90c56f92-48fa-4e1d-b8b0-1dfb78f48f30_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_3b6da131-ad39-4df7-8e3c-0ee4005fb77f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_6fa55a4d-f400-4c00-af4b-c17322618709_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ShortTermContractLiabilities_7eae6c34-a357-4f35-a8de-25acf5b89acd_terseLabel_en-US" xlink:label="lab_apyx_ShortTermContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contract liabilities</link:label>
    <link:label id="lab_apyx_ShortTermContractLiabilities_label_en-US" xlink:label="lab_apyx_ShortTermContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Contract Liabilities</link:label>
    <link:label id="lab_apyx_ShortTermContractLiabilities_documentation_en-US" xlink:label="lab_apyx_ShortTermContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShortTermContractLiabilities" xlink:href="apyx-20221231.xsd#apyx_ShortTermContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ShortTermContractLiabilities" xlink:to="lab_apyx_ShortTermContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SaleLeasebackDueDiligencePeriod_2951d9b1-fedf-4c81-a390-f37083fd345a_terseLabel_en-US" xlink:label="lab_apyx_SaleLeasebackDueDiligencePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale leaseback, due diligence period</link:label>
    <link:label id="lab_apyx_SaleLeasebackDueDiligencePeriod_label_en-US" xlink:label="lab_apyx_SaleLeasebackDueDiligencePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Due Diligence Period</link:label>
    <link:label id="lab_apyx_SaleLeasebackDueDiligencePeriod_documentation_en-US" xlink:label="lab_apyx_SaleLeasebackDueDiligencePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Leaseback, Due Diligence Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackDueDiligencePeriod" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackDueDiligencePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SaleLeasebackDueDiligencePeriod" xlink:to="lab_apyx_SaleLeasebackDueDiligencePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantiesDisclosuresAbstract_bfd3077f-8547-474e-ad5a-6be0ef3d3964_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ProductWarrantiesDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:to="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_bc6460ad-d1f9-4f2b-bb80-98c877221be5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1b82067-09ee-4d28-b9ad-778fde66ebd1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_b44cbec7-334b-4297-bae7-1dadc0de3e0d_terseLabel_en-US" xlink:label="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Executive and Employee Stock Option Plan</link:label>
    <link:label id="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:label id="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_documentation_en-US" xlink:label="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Executive and Employee Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:href="apyx-20221231.xsd#apyx_A2017ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:to="lab_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1acd0172-20b3-4aee-be74-da5b9c963796_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a57e87a0-5d5a-416b-b4cb-71c9d019a7b1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_bd67904f-fbbb-4404-ad8e-164f73c5cccd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd7490cb-adde-4cd7-88c2-aba078532eee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_64e74874-6031-421b-94f8-bff01a641dc4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_454210c4-be6e-4036-9a62-1195613f645d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees and legal related contingent liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e0f35562-ff92-4693-a5af-72eb59044a3e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b7b1056c-ad75-49f0-8dfc-52e81c500276_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_829d55b0-1f63-48d1-9abc-e92954f16218_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_07f31c71-8798-49b3-9f24-d65dba900ab6_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_bbcf12e8-5c8e-485f-be08-304fb4b6bb54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0972ea8f-3cce-4cca-bdb4-41b047721c95_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3edb9fad-46f0-483b-b8a2-2b3a98b79d93_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Non-vested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d3bd6066-9450-4f32-ac0c-0b37a9407edd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_32edf619-8398-4234-9b3e-f1e45fc4bb25_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_7a418cd8-28b9-439a-9f70-75087678f837_terseLabel_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc.</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_label_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_documentation_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member" xlink:href="apyx-20221231.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SymmetrySurgicalInc.Member" xlink:to="lab_apyx_SymmetrySurgicalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_203896e2-5c8a-4d9a-b4be-ac607dd1a075_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CapitalizationOfLeaseRecognizedExecution_fa76eaed-5879-4916-ac53-90b2f02a7e11_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseRecognizedExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseRecognizedExecution_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseRecognizedExecution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Recognized, Execution</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseRecognizedExecution_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseRecognizedExecution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Recognized, Execution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseRecognizedExecution" xlink:href="apyx-20221231.xsd#apyx_CapitalizationOfLeaseRecognizedExecution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseRecognizedExecution" xlink:to="lab_apyx_CapitalizationOfLeaseRecognizedExecution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21305162-7c95-4f3d-ae68-66162ddfbfde_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LargestCustomerMember_c370c21e-f45d-447d-9007-2b5c1d218c08_terseLabel_en-US" xlink:label="lab_apyx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customer</link:label>
    <link:label id="lab_apyx_LargestCustomerMember_label_en-US" xlink:label="lab_apyx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:label id="lab_apyx_LargestCustomerMember_documentation_en-US" xlink:label="lab_apyx_LargestCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Largest Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LargestCustomerMember" xlink:href="apyx-20221231.xsd#apyx_LargestCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LargestCustomerMember" xlink:to="lab_apyx_LargestCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_b9311962-6738-4170-857f-fe1398a1fb61_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earning (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_968fd7dd-4727-4391-8242-2ee95071305d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a057da3a-64f4-467a-9d33-acefe0136446_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2bcf7789-ffff-4033-a4ec-2810284d7294_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6da54897-2703-4cf9-9d82-0675facdaa57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_01e15378-87ae-4621-a214-2d9ffc6730ca_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ContractWithCustomerAssetRevenueRecognized_733addfc-b3b0-48c2-bd82-ead73beafded_terseLabel_en-US" xlink:label="lab_apyx_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, revenue recognized</link:label>
    <link:label id="lab_apyx_ContractWithCustomerAssetRevenueRecognized_label_en-US" xlink:label="lab_apyx_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Revenue Recognized</link:label>
    <link:label id="lab_apyx_ContractWithCustomerAssetRevenueRecognized_documentation_en-US" xlink:label="lab_apyx_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ContractWithCustomerAssetRevenueRecognized" xlink:href="apyx-20221231.xsd#apyx_ContractWithCustomerAssetRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ContractWithCustomerAssetRevenueRecognized" xlink:to="lab_apyx_ContractWithCustomerAssetRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c7baa8f8-a811-4888-a8ef-a304b35b0834_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1a36fa38-1fdf-4111-b93e-79c3079c0eae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_f8e60110-87a2-4f5c-8615-811e7911734a_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly payments, extension</link:label>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_label_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments, Extension</link:label>
    <link:label id="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Monthly Payments, Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:to="lab_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_b06dcca0-832d-4e76-8d2e-7459ff3e705a_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_label_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_documentation_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence" xlink:href="apyx-20221231.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForInventoryObsolescence" xlink:to="lab_apyx_ProvisionForInventoryObsolescence" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c9cb2d7-e020-45cd-a507-116d991f0d00_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_71ccca0e-01da-4c7f-94d3-0971a40fb7f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentExtensionPeriod_6f7078e1-73cf-4861-9e02-3d8e533ee969_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_apyx_DebtInstrumentExtensionPeriod_label_en-US" xlink:label="lab_apyx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Extension Period</link:label>
    <link:label id="lab_apyx_DebtInstrumentExtensionPeriod_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExtensionPeriod" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentExtensionPeriod" xlink:to="lab_apyx_DebtInstrumentExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_b65bee6c-be3f-40cf-b483-e566f49fd8f0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, Non-vested Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember_db0858f9-afe0-42d3-b66b-9ae7e56cb82e_terseLabel_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Two</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember_label_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Two [Member]</link:label>
    <link:label id="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember_documentation_en-US" xlink:label="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:to="lab_apyx_DebtInstrumentPrepaymentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c92daf59-1113-44f8-b7ce-43c8d56b483e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_9db58d99-8524-4238-8211-1e0f5e878e24_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in headcount</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_fc5041ce-3cf3-4e4b-af0c-4472528a7a72_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>apyx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:45c174b4-24e6-4af0-9ca8-997a51f8c128,g:9f6ae534-5ac4-415d-9362-3e1615bb09a1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8da2f06a-bcf1-463c-ab50-0f9e65909089" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_DocumentType_8da2f06a-bcf1-463c-ab50-0f9e65909089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_79149bb7-f2d2-4432-8061-224bae96f567" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_DocumentAnnualReport_79149bb7-f2d2-4432-8061-224bae96f567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_11a5c1d5-e8ad-4cf1-87db-f529a5f1dfe6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_CurrentFiscalYearEndDate_11a5c1d5-e8ad-4cf1-87db-f529a5f1dfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_116a2bb9-46d2-4a21-a4db-ecb9faa3e937" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_DocumentPeriodEndDate_116a2bb9-46d2-4a21-a4db-ecb9faa3e937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2937eed8-6c80-400b-a19d-626d42b4e971" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_DocumentTransitionReport_2937eed8-6c80-400b-a19d-626d42b4e971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ce6f353f-cce9-40a6-8c76-2bf6a6e57e0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityFileNumber_ce6f353f-cce9-40a6-8c76-2bf6a6e57e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cbc685a3-342d-4c2a-9799-c58786655920" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityRegistrantName_cbc685a3-342d-4c2a-9799-c58786655920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_40bfeaae-0801-4f4b-9f01-ef734f2772a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_40bfeaae-0801-4f4b-9f01-ef734f2772a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ffb712c1-6e0f-477e-8ccd-5faf07e1c145" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityTaxIdentificationNumber_ffb712c1-6e0f-477e-8ccd-5faf07e1c145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_26f49f90-1839-44ef-962c-060c8ae1cd60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityAddressAddressLine1_26f49f90-1839-44ef-962c-060c8ae1cd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a71eef19-5885-4726-897e-d4bef493861e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityAddressCityOrTown_a71eef19-5885-4726-897e-d4bef493861e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_50809d0b-39fb-4060-bafa-8bcaf840fa60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityAddressStateOrProvince_50809d0b-39fb-4060-bafa-8bcaf840fa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9768e877-a3f4-40ae-baaa-5e0ea3744414" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityAddressPostalZipCode_9768e877-a3f4-40ae-baaa-5e0ea3744414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_356b9c64-d00f-4179-a4d1-a8eeb610dcac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_CityAreaCode_356b9c64-d00f-4179-a4d1-a8eeb610dcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_45fe09e2-6013-4530-a5b0-7d69f7f19705" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_LocalPhoneNumber_45fe09e2-6013-4530-a5b0-7d69f7f19705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d737cf78-7992-44a8-b271-d5ea20a960b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_Security12bTitle_d737cf78-7992-44a8-b271-d5ea20a960b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b9b81e30-18d1-49b0-8226-3cf77fc6ac7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_TradingSymbol_b9b81e30-18d1-49b0-8226-3cf77fc6ac7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_90403baa-2265-4807-b493-ddd002c63fa3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_SecurityExchangeName_90403baa-2265-4807-b493-ddd002c63fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_188e9a99-43cb-4b1e-99b0-56386b522705" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_188e9a99-43cb-4b1e-99b0-56386b522705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_2889a77d-596c-412d-9980-1e1299015ff9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityVoluntaryFilers_2889a77d-596c-412d-9980-1e1299015ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6ff031e3-0b93-4896-8734-bd42a53b3623" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityCurrentReportingStatus_6ff031e3-0b93-4896-8734-bd42a53b3623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_02c7f409-3e9e-49d5-9633-ddaa737a951f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityInteractiveDataCurrent_02c7f409-3e9e-49d5-9633-ddaa737a951f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_289dc3d7-8ee5-4466-a6b3-a43593385d00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityFilerCategory_289dc3d7-8ee5-4466-a6b3-a43593385d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f133757a-65d4-451d-be31-c48962eba4a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntitySmallBusiness_f133757a-65d4-451d-be31-c48962eba4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5ac0cc3e-c7cf-4a7f-92c6-76ef9dbbc22c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityEmergingGrowthCompany_5ac0cc3e-c7cf-4a7f-92c6-76ef9dbbc22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_12a4f0fa-fec0-4033-a623-63f65630b30a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_IcfrAuditorAttestationFlag_12a4f0fa-fec0-4033-a623-63f65630b30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b7fd0c39-ff6a-4179-95d5-bb8590ebe62d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityShellCompany_b7fd0c39-ff6a-4179-95d5-bb8590ebe62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_8dd1a98a-31ce-4312-bf10-f8c82cc5ec0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityPublicFloat_8dd1a98a-31ce-4312-bf10-f8c82cc5ec0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d5481ebd-be69-43fb-a1ac-a99c773e455b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d5481ebd-be69-43fb-a1ac-a99c773e455b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b122763e-58df-4e3d-8cbd-04ea32ba7496" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_EntityCentralIndexKey_b122763e-58df-4e3d-8cbd-04ea32ba7496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7936bcbe-333a-4608-a23b-1e99611c9430" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_AmendmentFlag_7936bcbe-333a-4608-a23b-1e99611c9430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fe880d0f-e820-4a55-9504-6f0be17c90ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fe880d0f-e820-4a55-9504-6f0be17c90ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_840877e5-1471-4323-b54f-1b4e98a9fc19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d657e6c7-d384-46bc-8197-015457d563c9" xlink:to="loc_dei_DocumentFiscalYearFocus_840877e5-1471-4323-b54f-1b4e98a9fc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/AuditInformation" xlink:type="simple" xlink:href="apyx-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AuditInformationAbstract_c05b4f2d-cc99-4671-853b-5614bd6d9b3c" xlink:href="apyx-20221231.xsd#apyx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d6950613-05f1-4a8a-9e22-e16384e7b4b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_AuditInformationAbstract_c05b4f2d-cc99-4671-853b-5614bd6d9b3c" xlink:to="loc_dei_AuditorFirmId_d6950613-05f1-4a8a-9e22-e16384e7b4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_5a51ed83-f0ca-4a34-bc41-2e2a7959ef6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_AuditInformationAbstract_c05b4f2d-cc99-4671-853b-5614bd6d9b3c" xlink:to="loc_dei_AuditorName_5a51ed83-f0ca-4a34-bc41-2e2a7959ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_7e4636c6-ad13-465b-b12a-69a081add6a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_AuditInformationAbstract_c05b4f2d-cc99-4671-853b-5614bd6d9b3c" xlink:to="loc_dei_AuditorLocation_7e4636c6-ad13-465b-b12a-69a081add6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9272f3e1-5104-4a23-a431-fa14bffbf0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_381a53e3-8cdb-414f-b064-c307337f0c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9272f3e1-5104-4a23-a431-fa14bffbf0a3" xlink:to="loc_us-gaap_AssetsAbstract_381a53e3-8cdb-414f-b064-c307337f0c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_381a53e3-8cdb-414f-b064-c307337f0c3f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68f78229-e1f4-4b66-be7b-ad8e76015e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68f78229-e1f4-4b66-be7b-ad8e76015e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eba41f47-d4c8-4bff-824d-2c02bff269fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eba41f47-d4c8-4bff-824d-2c02bff269fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_2b94a5c1-f555-4459-8fcb-4b6c03f284e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:to="loc_us-gaap_IncomeTaxesReceivable_2b94a5c1-f555-4459-8fcb-4b6c03f284e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_639724e8-1391-4518-9bed-f586c161b62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_639724e8-1391-4518-9bed-f586c161b62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_21225c80-3572-4d1e-bfad-4aa9d3df6337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:to="loc_us-gaap_InventoryNet_21225c80-3572-4d1e-bfad-4aa9d3df6337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_059ef7dd-25c7-4401-bbad-f4367d53b9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_059ef7dd-25c7-4401-bbad-f4367d53b9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fb3a21c2-ca1d-4e96-bb39-f150b56fcdef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ee9ad834-e7f3-4788-9a82-0a4bbcc3e145" xlink:to="loc_us-gaap_AssetsCurrent_fb3a21c2-ca1d-4e96-bb39-f150b56fcdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c85b0697-692e-46ce-b200-46b67a4e1f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_381a53e3-8cdb-414f-b064-c307337f0c3f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c85b0697-692e-46ce-b200-46b67a4e1f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e0fe1d43-32ac-407a-ab4f-b36c58a97a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_381a53e3-8cdb-414f-b064-c307337f0c3f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e0fe1d43-32ac-407a-ab4f-b36c58a97a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_ffb2f205-7c3b-40c2-89ee-dfd1e5465d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_381a53e3-8cdb-414f-b064-c307337f0c3f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_ffb2f205-7c3b-40c2-89ee-dfd1e5465d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cdef092c-d6cf-40ca-bba8-f31b52fbe5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_381a53e3-8cdb-414f-b064-c307337f0c3f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cdef092c-d6cf-40ca-bba8-f31b52fbe5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_927fce8c-11de-4a2c-9a87-f14783163867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_381a53e3-8cdb-414f-b064-c307337f0c3f" xlink:to="loc_us-gaap_Assets_927fce8c-11de-4a2c-9a87-f14783163867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9272f3e1-5104-4a23-a431-fa14bffbf0a3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b67addc6-50ac-414a-8a8e-b660dac6ff9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b67addc6-50ac-414a-8a8e-b660dac6ff9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d1e779e1-9d71-49a2-bd77-997ccf6a634d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b67addc6-50ac-414a-8a8e-b660dac6ff9c" xlink:to="loc_us-gaap_AccountsPayableCurrent_d1e779e1-9d71-49a2-bd77-997ccf6a634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_01f03ec8-2dce-43d6-a48e-a7ba2e5fa8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b67addc6-50ac-414a-8a8e-b660dac6ff9c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_01f03ec8-2dce-43d6-a48e-a7ba2e5fa8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_07822cdc-da4e-43ba-82a6-00ff1fb1ae85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b67addc6-50ac-414a-8a8e-b660dac6ff9c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_07822cdc-da4e-43ba-82a6-00ff1fb1ae85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ef5d48a3-4a94-428f-a2ed-0c8fca54d094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b67addc6-50ac-414a-8a8e-b660dac6ff9c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ef5d48a3-4a94-428f-a2ed-0c8fca54d094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4f385979-9c4b-41f0-94f3-e8553a66eb09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b67addc6-50ac-414a-8a8e-b660dac6ff9c" xlink:to="loc_us-gaap_LiabilitiesCurrent_4f385979-9c4b-41f0-94f3-e8553a66eb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a72037bf-0c84-4915-852e-09426bc93ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a72037bf-0c84-4915-852e-09426bc93ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_939547e4-bb9a-4d22-a53a-e6ea360376c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_939547e4-bb9a-4d22-a53a-e6ea360376c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_af8b883e-123c-4bf9-be34-855a1d9218ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_af8b883e-123c-4bf9-be34-855a1d9218ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3a9b1cb7-9a5c-4a6e-9df1-a357b2e790f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3a9b1cb7-9a5c-4a6e-9df1-a357b2e790f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_de93e7f0-0892-49e4-b502-24decdb4caf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_Liabilities_de93e7f0-0892-49e4-b502-24decdb4caf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_52ebc886-188d-4bb4-9e13-e7f784f80e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_CommitmentsAndContingencies_52ebc886-188d-4bb4-9e13-e7f784f80e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_db5cd361-f660-4b03-9b52-af1e134fa783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:to="loc_us-gaap_PreferredStockValue_db5cd361-f660-4b03-9b52-af1e134fa783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f523d7f5-4c31-4928-9d60-80544b3d98e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:to="loc_us-gaap_CommonStockValue_f523d7f5-4c31-4928-9d60-80544b3d98e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a4dc7ada-2063-4004-99d4-9bf581833599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a4dc7ada-2063-4004-99d4-9bf581833599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64370849-1f5e-43cb-bf4c-c8c451fd2ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64370849-1f5e-43cb-bf4c-c8c451fd2ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0809400-1c9c-4e77-b5dd-2caf6d18e332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:to="loc_us-gaap_StockholdersEquity_f0809400-1c9c-4e77-b5dd-2caf6d18e332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_86f2ac74-5239-4a12-bab5-076a11941b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:to="loc_us-gaap_MinorityInterest_86f2ac74-5239-4a12-bab5-076a11941b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_274f135d-ba7d-45e1-8377-59cfbb6a8704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a320aacc-9583-42ad-85fc-b73277a9489b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_274f135d-ba7d-45e1-8377-59cfbb6a8704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54858758-a7c0-46aa-8311-a4165274ab6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bfa7fcdd-5951-4087-8465-7abf14112104" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54858758-a7c0-46aa-8311-a4165274ab6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_abb5f0a5-1bd9-4a4a-8500-7ecad58a560c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9272f3e1-5104-4a23-a431-fa14bffbf0a3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_abb5f0a5-1bd9-4a4a-8500-7ecad58a560c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f10e2550-4786-418d-98a4-67680094669c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f10e2550-4786-418d-98a4-67680094669c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory_5c06b76b-c3e8-4c01-86ae-c5459bef5320" xlink:href="apyx-20221231.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_apyx_ProvisionForObsolescenceInventory_5c06b76b-c3e8-4c01-86ae-c5459bef5320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9ce69a4e-a08f-4424-b7fd-e7b1974dd3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9ce69a4e-a08f-4424-b7fd-e7b1974dd3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c244ea78-e8ba-4c61-9e9d-cb1643fedf82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c244ea78-e8ba-4c61-9e9d-cb1643fedf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_902f35c1-a4cc-4b5c-98bd-f3dbd6c57cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_PreferredStockSharesIssued_902f35c1-a4cc-4b5c-98bd-f3dbd6c57cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_529d7899-77d4-4258-908c-e07688833a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_529d7899-77d4-4258-908c-e07688833a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_65d16019-bf2a-4f14-804a-b7e491295173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_65d16019-bf2a-4f14-804a-b7e491295173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d2beb204-9c3f-4ec6-a174-6f5c065c08ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d2beb204-9c3f-4ec6-a174-6f5c065c08ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7dde9318-f1c4-4a64-b704-000bab1bc152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7dde9318-f1c4-4a64-b704-000bab1bc152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4826eff0-38f7-48a9-8e6b-3e722cb70c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0cb7db3-6b80-4911-89ca-bcf354c77565" xlink:to="loc_us-gaap_CommonStockSharesIssued_4826eff0-38f7-48a9-8e6b-3e722cb70c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d198b97-019a-4663-9d4f-0edae35c8e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d198b97-019a-4663-9d4f-0edae35c8e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5b8c00bf-14ab-48ae-a852-88b0e9a43050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5b8c00bf-14ab-48ae-a852-88b0e9a43050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_03262cad-7f12-43ce-a599-4a1c17dbc89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_GrossProfit_03262cad-7f12-43ce-a599-4a1c17dbc89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ca2b5016-83cf-4245-ad8b-68b502ef8894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ca2b5016-83cf-4245-ad8b-68b502ef8894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9c375f70-ee44-427b-be46-b1e888f60b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ca2b5016-83cf-4245-ad8b-68b502ef8894" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9c375f70-ee44-427b-be46-b1e888f60b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_a8ffe1df-5e71-40a2-a77d-12f51a5700eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ca2b5016-83cf-4245-ad8b-68b502ef8894" xlink:to="loc_us-gaap_ProfessionalFees_a8ffe1df-5e71-40a2-a77d-12f51a5700eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_0b9919ff-5c92-4107-ac22-9055043fae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ca2b5016-83cf-4245-ad8b-68b502ef8894" xlink:to="loc_us-gaap_SalariesAndWages_0b9919ff-5c92-4107-ac22-9055043fae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_eab5b57f-509a-4c9a-aa6c-d99a0e70f10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ca2b5016-83cf-4245-ad8b-68b502ef8894" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_eab5b57f-509a-4c9a-aa6c-d99a0e70f10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_51baf6fa-cd91-4957-8481-6093a15d4326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ca2b5016-83cf-4245-ad8b-68b502ef8894" xlink:to="loc_us-gaap_OperatingExpenses_51baf6fa-cd91-4957-8481-6093a15d4326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0cacb2d9-4763-446d-8723-15735738dc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_OperatingIncomeLoss_0cacb2d9-4763-446d-8723-15735738dc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_b9160b2c-acf2-467f-830b-e51aeb7d68d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_InterestIncomeOperating_b9160b2c-acf2-467f-830b-e51aeb7d68d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f619d45b-a543-4e07-a7a0-5421de87aab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_InterestExpense_f619d45b-a543-4e07-a7a0-5421de87aab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_832aec59-1d9d-40fc-b1ce-1ebfaccc5dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_832aec59-1d9d-40fc-b1ce-1ebfaccc5dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e94b31c3-75f3-44b0-b9f4-f9db74a0c022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e94b31c3-75f3-44b0-b9f4-f9db74a0c022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e66299fd-3f8c-410c-8786-fa063d4b1c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e66299fd-3f8c-410c-8786-fa063d4b1c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_35490ffa-0f8d-46b7-bb8c-f91cbcf85ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_35490ffa-0f8d-46b7-bb8c-f91cbcf85ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9867dc08-490c-476e-b90e-e4fd9a64e697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_ProfitLoss_9867dc08-490c-476e-b90e-e4fd9a64e697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_780aa701-d76a-44f5-8e74-8b30bb022c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_780aa701-d76a-44f5-8e74-8b30bb022c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0ba3d51-5291-40e4-a4dc-c15f2ea71356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_NetIncomeLoss_e0ba3d51-5291-40e4-a4dc-c15f2ea71356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b74a2250-d4ba-4a1c-a588-274211d7e983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_EarningsPerShareBasic_b74a2250-d4ba-4a1c-a588-274211d7e983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_00d17b31-4878-433d-ac83-32c8cd38243a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_EarningsPerShareDiluted_00d17b31-4878-433d-ac83-32c8cd38243a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c97fc220-4984-4b14-afd8-cb62c18fdfff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c97fc220-4984-4b14-afd8-cb62c18fdfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_889e9b57-c9d6-4e78-afd5-2ebe4278f2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d8b22c16-ec7b-4ba7-baca-b4a78de2c968" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_889e9b57-c9d6-4e78-afd5-2ebe4278f2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_970782d3-32fb-41a9-8f0c-bd5d734c702d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_506f00a8-e157-443d-b45d-fd9b89c8b753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_970782d3-32fb-41a9-8f0c-bd5d734c702d" xlink:to="loc_us-gaap_StatementTable_506f00a8-e157-443d-b45d-fd9b89c8b753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_de6a5879-100e-476f-abaa-fcdbed654050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_506f00a8-e157-443d-b45d-fd9b89c8b753" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_de6a5879-100e-476f-abaa-fcdbed654050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_de6a5879-100e-476f-abaa-fcdbed654050" xlink:to="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ad75746-fd95-45ba-9166-d1a387a50fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:to="loc_us-gaap_CommonStockMember_9ad75746-fd95-45ba-9166-d1a387a50fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_89f13844-063e-4c7f-a9db-a49a1f995fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_89f13844-063e-4c7f-a9db-a49a1f995fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_08f94a81-db00-4217-89e3-0b4155d7ded6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:to="loc_us-gaap_RetainedEarningsMember_08f94a81-db00-4217-89e3-0b4155d7ded6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_17ad8ba7-2782-46d2-a68b-f7821cb1a9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_88a098c7-88e6-4a1c-85c7-fcf7c4bdcea0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_17ad8ba7-2782-46d2-a68b-f7821cb1a9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f5f0838c-8113-42e4-b568-3d72a8849cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_506f00a8-e157-443d-b45d-fd9b89c8b753" xlink:to="loc_us-gaap_StatementLineItems_f5f0838c-8113-42e4-b568-3d72a8849cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f5f0838c-8113-42e4-b568-3d72a8849cb1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e4e97ef6-0ad0-406b-8051-728067ac67b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_SharesIssued_e4e97ef6-0ad0-406b-8051-728067ac67b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64b6b829-a3dd-4568-9cb8-5c1a04aa27f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64b6b829-a3dd-4568-9cb8-5c1a04aa27f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a9c22085-1421-4e7c-b174-d267d1df04a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a9c22085-1421-4e7c-b174-d267d1df04a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1208b051-cc26-47e1-9450-94f945429aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1208b051-cc26-47e1-9450-94f945429aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b0f5d5d-af5b-4690-bcc6-5177ecfb3a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b0f5d5d-af5b-4690-bcc6-5177ecfb3a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e22201-a552-4ca4-bddd-9a076628ae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_48e22201-a552-4ca4-bddd-9a076628ae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_ca7a0da2-aab8-4e8c-ad6c-61cdf906293f" xlink:href="apyx-20221231.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_ca7a0da2-aab8-4e8c-ad6c-61cdf906293f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c2780a57-ff9b-4d9c-9a2d-c41ccbf76239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_ProfitLoss_c2780a57-ff9b-4d9c-9a2d-c41ccbf76239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e8b1ae16-5f00-4de9-9da7-d4ede29ab3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_SharesIssued_e8b1ae16-5f00-4de9-9da7-d4ede29ab3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3afe5d35-0bd4-4410-9d85-ae5db58bb42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_119c50ae-117f-4072-8507-29f829a024f6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3afe5d35-0bd4-4410-9d85-ae5db58bb42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_50aaab58-b12a-4d0a-a245-2f08ca1853d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_50aaab58-b12a-4d0a-a245-2f08ca1853d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c703bb1e-0878-4e5c-a84e-b85182a9d00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_50aaab58-b12a-4d0a-a245-2f08ca1853d4" xlink:to="loc_us-gaap_ProfitLoss_c703bb1e-0878-4e5c-a84e-b85182a9d00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_50aaab58-b12a-4d0a-a245-2f08ca1853d4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d5384c75-fd42-4031-9198-5d1079621397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d5384c75-fd42-4031-9198-5d1079621397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_ca85c85a-2442-4072-ba1d-d087d94d1e6a" xlink:href="apyx-20221231.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_ca85c85a-2442-4072-ba1d-d087d94d1e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarrantyExpenseNet_81cd090e-f9d1-4e43-a418-837fb47c3820" xlink:href="apyx-20221231.xsd#apyx_ProductWarrantyExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:to="loc_apyx_ProductWarrantyExpenseNet_81cd090e-f9d1-4e43-a418-837fb47c3820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_a0cc8a6c-996f-4186-a32c-25dc4fa57580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_a0cc8a6c-996f-4186-a32c-25dc4fa57580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b01f54d5-4873-4ef1-8506-3d3e437446f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:to="loc_us-gaap_ShareBasedCompensation_b01f54d5-4873-4ef1-8506-3d3e437446f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_75467104-6236-4318-bfb0-12b4189c5533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_75467104-6236-4318-bfb0-12b4189c5533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b92b41cf-c39d-4693-97ce-b043e1f7b0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c1216cc-c808-440c-919a-83ceb7426752" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b92b41cf-c39d-4693-97ce-b043e1f7b0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f58d7e7-5503-49d3-8836-d8aa9a3335bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b92b41cf-c39d-4693-97ce-b043e1f7b0a3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f58d7e7-5503-49d3-8836-d8aa9a3335bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_eb65eb30-2910-4304-98e9-2b6cc78d1ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b92b41cf-c39d-4693-97ce-b043e1f7b0a3" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_eb65eb30-2910-4304-98e9-2b6cc78d1ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8ac2d6f-88b1-4a85-bb81-a4cde612a35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b92b41cf-c39d-4693-97ce-b043e1f7b0a3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b8ac2d6f-88b1-4a85-bb81-a4cde612a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_171c70e5-caee-4c4c-a805-c3e655e9644c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b92b41cf-c39d-4693-97ce-b043e1f7b0a3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_171c70e5-caee-4c4c-a805-c3e655e9644c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_54f02e7e-3e16-47b3-8e20-7b89d48ca981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b92b41cf-c39d-4693-97ce-b043e1f7b0a3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_54f02e7e-3e16-47b3-8e20-7b89d48ca981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4d060dcf-0771-48b5-9665-202e19c93feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b92b41cf-c39d-4693-97ce-b043e1f7b0a3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4d060dcf-0771-48b5-9665-202e19c93feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80faa95c-6f12-4b24-8e58-a25c5e72a6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_50aaab58-b12a-4d0a-a245-2f08ca1853d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80faa95c-6f12-4b24-8e58-a25c5e72a6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f44a732-9e21-49a1-8b7c-0a1a78fce127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f44a732-9e21-49a1-8b7c-0a1a78fce127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_89b08f50-a7e0-4823-ab2e-3b986d473eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f44a732-9e21-49a1-8b7c-0a1a78fce127" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_89b08f50-a7e0-4823-ab2e-3b986d473eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0d145245-b9da-43d2-aaf4-6826fe197bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f44a732-9e21-49a1-8b7c-0a1a78fce127" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0d145245-b9da-43d2-aaf4-6826fe197bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7515f560-4234-4f2f-b652-5d131e998723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7515f560-4234-4f2f-b652-5d131e998723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_b33ee98b-6e8a-47ab-88c1-c3c4e96cf366" xlink:href="apyx-20221231.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7515f560-4234-4f2f-b652-5d131e998723" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_b33ee98b-6e8a-47ab-88c1-c3c4e96cf366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentOfFinanceLeaseLiabilities_dd73d319-472e-496b-be48-5ee34a05b111" xlink:href="apyx-20221231.xsd#apyx_RepaymentOfFinanceLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7515f560-4234-4f2f-b652-5d131e998723" xlink:to="loc_apyx_RepaymentOfFinanceLeaseLiabilities_dd73d319-472e-496b-be48-5ee34a05b111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_77e7393b-6770-491a-b36b-211f1785a896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7515f560-4234-4f2f-b652-5d131e998723" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_77e7393b-6770-491a-b36b-211f1785a896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42db1ecd-5765-4f18-b4e9-c7a65082e6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7515f560-4234-4f2f-b652-5d131e998723" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42db1ecd-5765-4f18-b4e9-c7a65082e6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e6289e5-0b5f-4880-a5b3-8318f5179379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e6289e5-0b5f-4880-a5b3-8318f5179379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4a5d574-83ec-40a6-8b29-482a263e1114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4a5d574-83ec-40a6-8b29-482a263e1114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96e6d7f8-d949-4905-a87e-3921fa3e4a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96e6d7f8-d949-4905-a87e-3921fa3e4a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224161f2-faa3-4b1c-96b6-34e9df73d301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224161f2-faa3-4b1c-96b6-34e9df73d301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1e533941-4b4a-400e-aac4-d0869b597a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1e533941-4b4a-400e-aac4-d0869b597a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_739f7c0e-a7c4-481d-9b28-df1cb39f8158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1e533941-4b4a-400e-aac4-d0869b597a8c" xlink:to="loc_us-gaap_InterestPaidNet_739f7c0e-a7c4-481d-9b28-df1cb39f8158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_55d65217-0302-4d31-942c-03ad4fcb3691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1e533941-4b4a-400e-aac4-d0869b597a8c" xlink:to="loc_us-gaap_IncomeTaxesPaid_55d65217-0302-4d31-942c-03ad4fcb3691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7449f7c9-8e36-49f2-93ef-a1b72d785a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a139f1f-b249-4794-98b2-053611c08db3" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7449f7c9-8e36-49f2-93ef-a1b72d785a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseRecongizedNonCash_bf617045-8b0b-4735-8039-357d1b727433" xlink:href="apyx-20221231.xsd#apyx_CapitalizationOfLeaseRecongizedNonCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7449f7c9-8e36-49f2-93ef-a1b72d785a0e" xlink:to="loc_apyx_CapitalizationOfLeaseRecongizedNonCash_bf617045-8b0b-4735-8039-357d1b727433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseRecognizedExecution_858b3fd5-cd4e-42a1-b60e-5ab94c49c878" xlink:href="apyx-20221231.xsd#apyx_CapitalizationOfLeaseRecognizedExecution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7449f7c9-8e36-49f2-93ef-a1b72d785a0e" xlink:to="loc_apyx_CapitalizationOfLeaseRecognizedExecution_858b3fd5-cd4e-42a1-b60e-5ab94c49c878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseDerecognizedExecution_518e3a17-c253-47d8-9268-2101803d13ae" xlink:href="apyx-20221231.xsd#apyx_CapitalizationOfLeaseDerecognizedExecution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7449f7c9-8e36-49f2-93ef-a1b72d785a0e" xlink:to="loc_apyx_CapitalizationOfLeaseDerecognizedExecution_518e3a17-c253-47d8-9268-2101803d13ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_26fcc572-507a-4144-98cc-7234df2b606c" xlink:href="apyx-20221231.xsd#apyx_NonCashTransferOfOtherAssetsToFixedAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7449f7c9-8e36-49f2-93ef-a1b72d785a0e" xlink:to="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_26fcc572-507a-4144-98cc-7234df2b606c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="apyx-20221231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff3f03ff-d948-463e-802e-0cc96407a740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6581e31b-ded2-4127-9342-ae70f5b678a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff3f03ff-d948-463e-802e-0cc96407a740" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6581e31b-ded2-4127-9342-ae70f5b678a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="apyx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6a20b98-1acc-47c8-813b-3ff2d8a71ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_33032fa6-5a94-4d0b-ba26-660bc62705c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6a20b98-1acc-47c8-813b-3ff2d8a71ab6" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_33032fa6-5a94-4d0b-ba26-660bc62705c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20221231.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_99138f10-fcce-4b3f-bdf3-c606f9e34b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d1a195aa-0424-4508-9112-f861c68130f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_99138f10-fcce-4b3f-bdf3-c606f9e34b6c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d1a195aa-0424-4508-9112-f861c68130f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS" xlink:type="simple" xlink:href="apyx-20221231.xsd#DISPOSITIONOFTHECOREBUSINESS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b2ceba96-8879-41fa-943d-7e6bbe5ee8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e5041adb-f721-4b90-af81-4a089e4cc5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b2ceba96-8879-41fa-943d-7e6bbe5ee8c9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e5041adb-f721-4b90-af81-4a089e4cc5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="simple" xlink:href="apyx-20221231.xsd#INTERESTINJOINTVENTUREINVESTMENT"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_3d53652a-a54a-4f07-bd67-b96ab638ccf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_7aa6a652-b00e-4752-a686-025bf5717327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3d53652a-a54a-4f07-bd67-b96ab638ccf1" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_7aa6a652-b00e-4752-a686-025bf5717327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20221231.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0a61a6af-2f01-4334-a598-1c5dde493059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_32a93abc-be93-4d54-a244-6d29abed67bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0a61a6af-2f01-4334-a598-1c5dde493059" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_32a93abc-be93-4d54-a244-6d29abed67bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="apyx-20221231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a801b032-49a3-448f-998c-79de0885381c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_30738778-3caf-4f62-ab37-69d23f08087e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a801b032-49a3-448f-998c-79de0885381c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_30738778-3caf-4f62-ab37-69d23f08087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASES" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_53a4b2bd-86ac-487c-ba8e-f8fff91aa042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_42e6224a-78b6-4578-bded-8ca50c6cff07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53a4b2bd-86ac-487c-ba8e-f8fff91aa042" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_42e6224a-78b6-4578-bded-8ca50c6cff07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d3aba63c-67e7-4035-9d0a-8e9c9118d3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_53a4b2bd-86ac-487c-ba8e-f8fff91aa042" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d3aba63c-67e7-4035-9d0a-8e9c9118d3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20221231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9c206cb6-adcb-4d36-b11e-ac4f61bd059d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3e9c5a85-d321-4ce3-b5fd-20147916eee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9c206cb6-adcb-4d36-b11e-ac4f61bd059d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3e9c5a85-d321-4ce3-b5fd-20147916eee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIES" xlink:type="simple" xlink:href="apyx-20221231.xsd#PRODUCTWARRANTIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_93e3a38f-f7fb-4f7b-aa59-b0e0a12f3413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyDisclosureTextBlock_02d670c7-d8cb-410e-a24f-8b093438c9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_93e3a38f-f7fb-4f7b-aa59-b0e0a12f3413" xlink:to="loc_us-gaap_ProductWarrantyDisclosureTextBlock_02d670c7-d8cb-410e-a24f-8b093438c9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY" xlink:type="simple" xlink:href="apyx-20221231.xsd#JOINTANDSEVERALPAYROLLLIABILITY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d4051dd7-3f29-44ad-ad07-fbf171b72ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointandSeveralPayrollLiabilityTextBlock_672c9082-46e2-4255-8231-61dc79f55db9" xlink:href="apyx-20221231.xsd#apyx_JointandSeveralPayrollLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d4051dd7-3f29-44ad-ad07-fbf171b72ae2" xlink:to="loc_apyx_JointandSeveralPayrollLiabilityTextBlock_672c9082-46e2-4255-8231-61dc79f55db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIES" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONTRACTASSETSANDLIABILITIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_de48b459-4a57-467e-960a-2417ed8926c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_41db3536-7d3c-4ec6-bfae-57a44b99c382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_de48b459-4a57-467e-960a-2417ed8926c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_41db3536-7d3c-4ec6-bfae-57a44b99c382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20221231.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84c60ec3-1cec-4c42-8ebc-39fed9b8302f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_73ae01fd-292e-4282-a630-cae1f344dcac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84c60ec3-1cec-4c42-8ebc-39fed9b8302f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_73ae01fd-292e-4282-a630-cae1f344dcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6a271241-9574-41a0-8edc-8041e388c6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_803f719b-f8bd-4f61-a711-efc832fd6302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a271241-9574-41a0-8edc-8041e388c6a3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_803f719b-f8bd-4f61-a711-efc832fd6302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RETIREMENTPLAN" xlink:type="simple" xlink:href="apyx-20221231.xsd#RETIREMENTPLAN"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RETIREMENTPLAN" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8d0cece9-72f8-4fc4-a224-b70e9dbc3210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b7ffb3a2-1f9d-4fb7-845b-b6bd9fedbeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8d0cece9-72f8-4fc4-a224-b70e9dbc3210" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b7ffb3a2-1f9d-4fb7-845b-b6bd9fedbeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20221231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b00a3095-56bf-4b02-9546-1ccb1da05eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6b5c3f51-a2e8-4602-b633-dda96837d3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b00a3095-56bf-4b02-9546-1ccb1da05eb1" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6b5c3f51-a2e8-4602-b633-dda96837d3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20221231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92df0d42-e834-4f79-ba9d-f3b4bd27b5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4040b23b-d052-49d6-97d6-f0116c9b1b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92df0d42-e834-4f79-ba9d-f3b4bd27b5bf" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4040b23b-d052-49d6-97d6-f0116c9b1b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONS" xlink:type="simple" xlink:href="apyx-20221231.xsd#STOCKOPTIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81825ff8-8157-4b76-ad77-ffd3eb46a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_310a255d-945c-4921-ae54-92272f5ed0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81825ff8-8157-4b76-ad77-ffd3eb46a6f3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_310a255d-945c-4921-ae54-92272f5ed0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20221231.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a3fd1b82-0d01-4ac6-b0bc-337d6ba6484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_9815a5ba-5038-493b-9d78-48fa582b447d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a3fd1b82-0d01-4ac6-b0bc-337d6ba6484a" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_9815a5ba-5038-493b-9d78-48fa582b447d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="apyx-20221231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b4687c96-ccbc-4814-8ff6-d010829180d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_77c81d2d-77c2-4a9d-8083-913de5771d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b4687c96-ccbc-4814-8ff6-d010829180d9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_77c81d2d-77c2-4a9d-8083-913de5771d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="apyx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_11b8a0be-91d6-424f-b850-b02f289e86a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_11b8a0be-91d6-424f-b850-b02f289e86a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_acdc8001-001b-46cd-8473-460329a980e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_UseOfEstimates_acdc8001-001b-46cd-8473-460329a980e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fbdc4787-f2bc-4461-9cb4-89d61ab538b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_fbdc4787-f2bc-4461-9cb4-89d61ab538b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_36f3b1bb-7c63-4197-bc8b-d1b2719b02eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_36f3b1bb-7c63-4197-bc8b-d1b2719b02eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_aa5dfec3-80ef-41f7-8848-bebcef5b5800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_aa5dfec3-80ef-41f7-8848-bebcef5b5800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_793ce637-4242-4adb-9d63-b44327b125d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_793ce637-4242-4adb-9d63-b44327b125d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2d62429d-7ad3-4d75-9b3b-6f8ab505e4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2d62429d-7ad3-4d75-9b3b-6f8ab505e4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a2bdd347-a76f-48e2-8cb6-c58147a5618b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a2bdd347-a76f-48e2-8cb6-c58147a5618b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_1e60a4f9-0e1a-4a8b-9055-b5c62bd81f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_1e60a4f9-0e1a-4a8b-9055-b5c62bd81f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5687e062-8a2d-4c74-8464-71fba2135686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5687e062-8a2d-4c74-8464-71fba2135686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_50f0d159-3964-41dc-94c7-63eabe126c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_50f0d159-3964-41dc-94c7-63eabe126c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e625d86d-00d0-40d4-a982-259407c4b263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e625d86d-00d0-40d4-a982-259407c4b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_3d928cf8-ccb5-4f02-ad40-ab214b6023a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_3d928cf8-ccb5-4f02-ad40-ab214b6023a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_bb6f6e0c-922e-4390-89ce-7b8a3d71901d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_bb6f6e0c-922e-4390-89ce-7b8a3d71901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6ccf50d1-e42f-4e07-afa9-8a10ea64ffd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_6ccf50d1-e42f-4e07-afa9-8a10ea64ffd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_337c790f-d897-4c61-9522-0cd6eef8f467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_337c790f-d897-4c61-9522-0cd6eef8f467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_520aa773-476a-401a-9a76-40e9bcd00227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_520aa773-476a-401a-9a76-40e9bcd00227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_49458967-bb74-486e-93bf-0935e8f8b945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_49458967-bb74-486e-93bf-0935e8f8b945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a77ef285-5a2c-40e4-912e-e2df791c14cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9b9ffab-8075-4f5b-84ff-55f4bd70aa4a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a77ef285-5a2c-40e4-912e-e2df791c14cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#INTERESTINJOINTVENTUREINVESTMENTTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_10be728a-47d8-4d74-bb7e-71d06090875e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock_22cd0648-619c-4b00-a027-2b549c5b7cc6" xlink:href="apyx-20221231.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_10be728a-47d8-4d74-bb7e-71d06090875e" xlink:to="loc_apyx_NoncontrollingInterestTableTextBlock_22cd0648-619c-4b00-a027-2b549c5b7cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f2b91d2e-25d2-4a62-806f-171712d15074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0d0d4c2d-d043-4492-a739-ab94d5d7a658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f2b91d2e-25d2-4a62-806f-171712d15074" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0d0d4c2d-d043-4492-a739-ab94d5d7a658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_afad5aef-0c75-4ff8-9824-7c0e1c98c455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_531ed585-fb9c-46da-ad6f-acdef76977d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_afad5aef-0c75-4ff8-9824-7c0e1c98c455" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_531ed585-fb9c-46da-ad6f-acdef76977d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ad73036e-8f31-4418-bc71-6a028bb824cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6f5b680f-fa40-4c44-ab99-056df7b8c289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ad73036e-8f31-4418-bc71-6a028bb824cc" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6f5b680f-fa40-4c44-ab99-056df7b8c289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_cd66ff4f-b1e4-44a6-8764-248dce8e5dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ad73036e-8f31-4418-bc71-6a028bb824cc" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_cd66ff4f-b1e4-44a6-8764-248dce8e5dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_259dbd6d-ab5d-41c6-b11a-1268d1e84233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ad73036e-8f31-4418-bc71-6a028bb824cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_259dbd6d-ab5d-41c6-b11a-1268d1e84233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_543f93a8-529b-432d-aea4-921da6164da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_878859ca-1dc8-4e28-96ac-61d220aa5741" xlink:href="apyx-20221231.xsd#apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_543f93a8-529b-432d-aea4-921da6164da7" xlink:to="loc_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_878859ca-1dc8-4e28-96ac-61d220aa5741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#PRODUCTWARRANTIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_5f01109e-8c63-4e78-bd9f-ffe0f9da4bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_3d2eb53a-d52e-46f8-9d5a-878fc8b9933d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_5f01109e-8c63-4e78-bd9f-ffe0f9da4bc7" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_3d2eb53a-d52e-46f8-9d5a-878fc8b9933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20221231.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_024860ab-edc6-4289-8726-0919f96ab2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c2e82c12-39c7-4bcd-8472-1661bc83f189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_024860ab-edc6-4289-8726-0919f96ab2ce" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c2e82c12-39c7-4bcd-8472-1661bc83f189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_30361e5b-5ab3-473f-bbac-fd41f24f2fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_57a21457-01a0-4a56-9d97-2ca37ce36512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30361e5b-5ab3-473f-bbac-fd41f24f2fc9" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_57a21457-01a0-4a56-9d97-2ca37ce36512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7b65e02e-eabd-4a33-a12d-c942a7a53338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30361e5b-5ab3-473f-bbac-fd41f24f2fc9" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7b65e02e-eabd-4a33-a12d-c942a7a53338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4aa24de9-073b-401b-ad29-6ed37aa5a331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30361e5b-5ab3-473f-bbac-fd41f24f2fc9" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4aa24de9-073b-401b-ad29-6ed37aa5a331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_664be170-6ad9-4322-ad03-4882c80cc8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30361e5b-5ab3-473f-bbac-fd41f24f2fc9" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_664be170-6ad9-4322-ad03-4882c80cc8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#STOCKOPTIONSTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c0b7342-c229-48fa-ae87-4bebb884307d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0a182848-e2cf-48d0-b6a0-941d42f9cebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c0b7342-c229-48fa-ae87-4bebb884307d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0a182848-e2cf-48d0-b6a0-941d42f9cebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4e7af8cc-eeaa-4917-b93e-0a24a1dbb912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c0b7342-c229-48fa-ae87-4bebb884307d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4e7af8cc-eeaa-4917-b93e-0a24a1dbb912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ad2be358-3439-4ed0-98f0-2ee00e6df650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c0b7342-c229-48fa-ae87-4bebb884307d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ad2be358-3439-4ed0-98f0-2ee00e6df650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20221231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4cf92ba2-982c-434d-88f6-a6ef5947e47f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_57bc2775-e549-4c39-a472-e848dfb48fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4cf92ba2-982c-434d-88f6-a6ef5947e47f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_57bc2775-e549-4c39-a472-e848dfb48fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_f2e25428-4ddb-4ff4-b9d9-6a03b756c1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4cf92ba2-982c-434d-88f6-a6ef5947e47f" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_f2e25428-4ddb-4ff4-b9d9-6a03b756c1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54849c4f-fbcc-431d-9ad6-77702b59f1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54849c4f-fbcc-431d-9ad6-77702b59f1be" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77d9f9bb-d272-49d9-9289-49beb1e76f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77d9f9bb-d272-49d9-9289-49beb1e76f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf48edc-9cc4-4510-8bd3-4941a1b622da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77d9f9bb-d272-49d9-9289-49beb1e76f0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf48edc-9cc4-4510-8bd3-4941a1b622da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShelfRegistrationMember_b67854f6-4425-4520-a252-cac863c31632" xlink:href="apyx-20221231.xsd#apyx_ShelfRegistrationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf48edc-9cc4-4510-8bd3-4941a1b622da" xlink:to="loc_apyx_ShelfRegistrationMember_b67854f6-4425-4520-a252-cac863c31632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AtTheMarketFacilityMember_8c10285e-b26e-4790-9cf8-4f768bdbad16" xlink:href="apyx-20221231.xsd#apyx_AtTheMarketFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7bf48edc-9cc4-4510-8bd3-4941a1b622da" xlink:to="loc_apyx_AtTheMarketFacilityMember_8c10285e-b26e-4790-9cf8-4f768bdbad16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b1a134c7-79bd-4afc-ac6f-fb321784f410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_CreditFacilityAxis_b1a134c7-79bd-4afc-ac6f-fb321784f410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_50ef89ea-adc9-4342-8151-f0fecbe90418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b1a134c7-79bd-4afc-ac6f-fb321784f410" xlink:to="loc_us-gaap_CreditFacilityDomain_50ef89ea-adc9-4342-8151-f0fecbe90418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_9f5232b3-16bb-4d89-b0db-885a4b36f428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_50ef89ea-adc9-4342-8151-f0fecbe90418" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_9f5232b3-16bb-4d89-b0db-885a4b36f428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_cdb36e49-8860-4643-b87f-f662b7229d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_50ef89ea-adc9-4342-8151-f0fecbe90418" xlink:to="loc_us-gaap_SecuredDebtMember_cdb36e49-8860-4643-b87f-f662b7229d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6be53a75-4eeb-443f-b67c-d7204c038743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6be53a75-4eeb-443f-b67c-d7204c038743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_094bfe98-ef6d-4ff8-bac8-7055e947eedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6be53a75-4eeb-443f-b67c-d7204c038743" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_094bfe98-ef6d-4ff8-bac8-7055e947eedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c9e051da-f64c-4a3d-a6d9-4bd9abbe3224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_094bfe98-ef6d-4ff8-bac8-7055e947eedc" xlink:to="loc_us-gaap_LineOfCreditMember_c9e051da-f64c-4a3d-a6d9-4bd9abbe3224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_330d6343-3be9-45dd-8c10-3181afc91ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_330d6343-3be9-45dd-8c10-3181afc91ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_75def93b-b0ec-4a28-adc6-58f6f65051b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_330d6343-3be9-45dd-8c10-3181afc91ede" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_75def93b-b0ec-4a28-adc6-58f6f65051b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6e3bae99-e08d-4b1a-ad94-a0bb1cd68dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_75def93b-b0ec-4a28-adc6-58f6f65051b5" xlink:to="loc_us-gaap_SubsequentEventMember_6e3bae99-e08d-4b1a-ad94-a0bb1cd68dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9281f965-83a8-45e8-a9c4-0987cf895be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_DebtInstrumentAxis_9281f965-83a8-45e8-a9c4-0987cf895be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a1becef4-8ab6-4c5e-9c0a-da4b1e3ec8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9281f965-83a8-45e8-a9c4-0987cf895be3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a1becef4-8ab6-4c5e-9c0a-da4b1e3ec8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember_259dcdb2-6fbc-4705-ae17-dde9f9eecd40" xlink:href="apyx-20221231.xsd#apyx_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a1becef4-8ab6-4c5e-9c0a-da4b1e3ec8a6" xlink:to="loc_apyx_CreditAgreementMember_259dcdb2-6fbc-4705-ae17-dde9f9eecd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis_79274090-ac9d-4ad8-88f7-8810ff9bc049" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_apyx_DebtInstrumentCovenantsAxis_79274090-ac9d-4ad8-88f7-8810ff9bc049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_79274090-ac9d-4ad8-88f7-8810ff9bc049" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember_18f7b116-5c64-4ad5-9f30-dc3de8087e6e" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheOneMember_18f7b116-5c64-4ad5-9f30-dc3de8087e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_abadd131-f57d-4ffb-b993-97e77bd6f355" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_abadd131-f57d-4ffb-b993-97e77bd6f355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_65445aca-81ce-4dcf-a30d-b5150ecf0544" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_cc70ad74-6ac7-4929-8933-ff7ea3c85f51" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_65445aca-81ce-4dcf-a30d-b5150ecf0544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4e0ee5af-5cf8-41dc-9b31-5fef94e62d9e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7521a2c7-dc1d-4a3c-8b0a-bc60bd069a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7521a2c7-dc1d-4a3c-8b0a-bc60bd069a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_50a35274-7810-4d6d-a3fa-0251942fa779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_OperatingIncomeLoss_50a35274-7810-4d6d-a3fa-0251942fa779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_009afcb4-66c3-409a-b176-bae74b82db0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_009afcb4-66c3-409a-b176-bae74b82db0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614a6c37-df67-484e-a1ec-3b8f1521ae49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614a6c37-df67-484e-a1ec-3b8f1521ae49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SecuritiesRegisteredNewIssues_f02ed81a-e79b-4c6f-b302-eee5325ac875" xlink:href="apyx-20221231.xsd#apyx_SecuritiesRegisteredNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_apyx_SecuritiesRegisteredNewIssues_f02ed81a-e79b-4c6f-b302-eee5325ac875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2da86f46-cfef-4ee5-a933-01165bee18f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2da86f46-cfef-4ee5-a933-01165bee18f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e90d8e02-37b8-4166-8802-d0b08ba59afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e90d8e02-37b8-4166-8802-d0b08ba59afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_df5a21fa-e4c7-4f47-833b-646867aa5a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_df5a21fa-e4c7-4f47-833b-646867aa5a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement_a8c81857-6bd6-4f59-a8b0-771bf6df2554" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e209cf9f-f679-4fe8-b739-4538367b8b12" xlink:to="loc_apyx_SaleLeasebackPurchaseAgreement_a8c81857-6bd6-4f59-a8b0-771bf6df2554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_007c53d6-ed01-4e84-ad6f-c4d85fd510de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_007c53d6-ed01-4e84-ad6f-c4d85fd510de" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60667595-71b3-4d15-9579-ebbdd2593a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60667595-71b3-4d15-9579-ebbdd2593a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_60667595-71b3-4d15-9579-ebbdd2593a98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_d50a73cd-70d8-49b6-9ecf-407347f83326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_d50a73cd-70d8-49b6-9ecf-407347f83326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_48021a18-ee9f-45f6-b7f6-9334be055c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_48021a18-ee9f-45f6-b7f6-9334be055c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9b561f65-48e2-4711-bdfc-e3236ef5f266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9b561f65-48e2-4711-bdfc-e3236ef5f266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember_259bb83d-e75d-4c4f-8774-3632b4d35727" xlink:href="apyx-20221231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_apyx_ComputerEquipmentandSoftwareMember_259bb83d-e75d-4c4f-8774-3632b4d35727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_fa8d0269-3a1d-4e3d-81ff-253e2f45a8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_fa8d0269-3a1d-4e3d-81ff-253e2f45a8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RenuvionJPlasmaGeneratorsMember_3eb58348-8601-4f41-a37b-6113c03906c1" xlink:href="apyx-20221231.xsd#apyx_RenuvionJPlasmaGeneratorsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_apyx_RenuvionJPlasmaGeneratorsMember_3eb58348-8601-4f41-a37b-6113c03906c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_MountingFixturesMember_15eb8f05-8821-40e7-acce-6dfc0cb486e8" xlink:href="apyx-20221231.xsd#apyx_MountingFixturesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_apyx_MountingFixturesMember_15eb8f05-8821-40e7-acce-6dfc0cb486e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccessoriesMember_435c3d16-8e8c-4f6b-81d8-2bcc4a725674" xlink:href="apyx-20221231.xsd#apyx_AccessoriesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8004d52b-72fe-4f6e-89ea-364326746603" xlink:to="loc_apyx_AccessoriesMember_435c3d16-8e8c-4f6b-81d8-2bcc4a725674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_47853f99-64af-43e0-b90a-2bbfd65d7db3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:to="loc_srt_RangeAxis_47853f99-64af-43e0-b90a-2bbfd65d7db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_84b15d86-c1a9-4728-b102-b052e33aa66f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_47853f99-64af-43e0-b90a-2bbfd65d7db3" xlink:to="loc_srt_RangeMember_84b15d86-c1a9-4728-b102-b052e33aa66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d23d2868-d65b-4660-90f6-0d1a559537f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_84b15d86-c1a9-4728-b102-b052e33aa66f" xlink:to="loc_srt_MinimumMember_d23d2868-d65b-4660-90f6-0d1a559537f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e0c35525-a934-461b-8059-f770e407e8ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_84b15d86-c1a9-4728-b102-b052e33aa66f" xlink:to="loc_srt_MaximumMember_e0c35525-a934-461b-8059-f770e407e8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:to="loc_srt_OwnershipAxis_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b917e51c-cd5c-4bc1-939c-c54f77d76ce8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_9e021ef7-8dbf-4309-84f9-6758f1ba6e5d" xlink:to="loc_srt_OwnershipDomain_b917e51c-cd5c-4bc1-939c-c54f77d76ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_58e543fe-e9fe-478e-b16d-6b6bd6239041" xlink:href="apyx-20221231.xsd#apyx_ApyxSYMedicalDevicesNingboCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b917e51c-cd5c-4bc1-939c-c54f77d76ce8" xlink:to="loc_apyx_ApyxSYMedicalDevicesNingboCoLtdMember_58e543fe-e9fe-478e-b16d-6b6bd6239041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_84fa235e-4231-4e49-92e5-1b1c9158fac3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f9066a4b-9797-4789-b6b7-a259d69502ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f9066a4b-9797-4789-b6b7-a259d69502ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e7b5fe36-721b-45dc-a307-848a7ad2c1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_e7b5fe36-721b-45dc-a307-848a7ad2c1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0799046c-81bc-4668-977a-922769973968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0799046c-81bc-4668-977a-922769973968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProductWarranty_ba9ed7b1-9674-402d-bf89-48483fd28f09" xlink:href="apyx-20221231.xsd#apyx_ProductWarranty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_apyx_ProductWarranty_ba9ed7b1-9674-402d-bf89-48483fd28f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_13c6185d-525f-4b96-b230-3e3e3d064c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fbfcecba-9ba0-4a37-ab29-c8e951e72bb9" xlink:to="loc_us-gaap_AdvertisingExpense_13c6185d-525f-4b96-b230-3e3e3d064c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#DISPOSITIONOFTHECOREBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_dd64768c-b976-44f1-b44d-b22122532fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_dd64768c-b976-44f1-b44d-b22122532fed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_87eb9d8f-bdae-4639-9692-09ebcb8809f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_87eb9d8f-bdae-4639-9692-09ebcb8809f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_37ecf9a0-24f3-4cc0-880f-ae312e64af65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_87eb9d8f-bdae-4639-9692-09ebcb8809f2" xlink:to="loc_us-gaap_RelatedPartyDomain_37ecf9a0-24f3-4cc0-880f-ae312e64af65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_92816efb-bcea-4ed6-8734-08e351e7d2f2" xlink:href="apyx-20221231.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_37ecf9a0-24f3-4cc0-880f-ae312e64af65" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_92816efb-bcea-4ed6-8734-08e351e7d2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_00a431b3-24c2-416b-b204-da83f88bfc31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_00a431b3-24c2-416b-b204-da83f88bfc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0cd3025f-ccd7-451d-8706-bfb9c168a7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_00a431b3-24c2-416b-b204-da83f88bfc31" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0cd3025f-ccd7-451d-8706-bfb9c168a7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_75b4cb90-6636-4ccc-9fc3-c76fbad0a6f6" xlink:href="apyx-20221231.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0cd3025f-ccd7-451d-8706-bfb9c168a7ee" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_75b4cb90-6636-4ccc-9fc3-c76fbad0a6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27cc01d2-b5b5-4adf-965a-6179a2ba8aca" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_d6cbf957-b54f-4342-a681-e6b6a7a15a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_d6cbf957-b54f-4342-a681-e6b6a7a15a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_543f7c53-42b0-44b3-bdd7-96cbd64fd45a" xlink:href="apyx-20221231.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_543f7c53-42b0-44b3-bdd7-96cbd64fd45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9bd2f725-150e-46be-8d0a-bce071a29b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9bd2f725-150e-46be-8d0a-bce071a29b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_e9fea209-2774-4ae4-9a3a-182d9b6a1c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_e9fea209-2774-4ae4-9a3a-182d9b6a1c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_1a525bed-5707-4fee-9038-97c1da920980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_1a525bed-5707-4fee-9038-97c1da920980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_402bdf4e-d5d8-4205-b760-46b3d1fd879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f7467409-109d-40c6-b630-94a65bfc8e4f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_402bdf4e-d5d8-4205-b760-46b3d1fd879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_bbc79cc8-1628-4aac-86c7-f991d636a195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_bbc79cc8-1628-4aac-86c7-f991d636a195" xlink:to="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:to="loc_srt_OwnershipAxis_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b0b99f5b-b0d2-4ecf-9fe9-6b3d64185606" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_bf3eaa8d-47b6-430e-8d14-ab3b9e55c525" xlink:to="loc_srt_OwnershipDomain_b0b99f5b-b0d2-4ecf-9fe9-6b3d64185606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_bccbe18a-3370-4434-9d52-a2206c432a58" xlink:href="apyx-20221231.xsd#apyx_ChineseSupplierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b0b99f5b-b0d2-4ecf-9fe9-6b3d64185606" xlink:to="loc_apyx_ChineseSupplierMember_bccbe18a-3370-4434-9d52-a2206c432a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ea756753-306f-4b72-98db-b53aab5192a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ea756753-306f-4b72-98db-b53aab5192a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_72edd418-9cc3-4366-aac4-1dc40eb167fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ea756753-306f-4b72-98db-b53aab5192a1" xlink:to="loc_us-gaap_RelatedPartyDomain_72edd418-9cc3-4366-aac4-1dc40eb167fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_8f366e8d-40bb-447c-bc7d-f18d82b8e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_72edd418-9cc3-4366-aac4-1dc40eb167fe" xlink:to="loc_us-gaap_CorporateJointVentureMember_8f366e8d-40bb-447c-bc7d-f18d82b8e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_61d4a831-d8a4-4b5f-99d3-745c94a01bbb" xlink:to="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c3d48950-5897-4870-8dc2-8404d335de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c3d48950-5897-4870-8dc2-8404d335de1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_d4e5b72a-991a-4404-9e1e-f9e4e5966ef8" xlink:href="apyx-20221231.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_d4e5b72a-991a-4404-9e1e-f9e4e5966ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_c787e0fb-15da-45e9-ad85-0acfa4d40e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_54351f0f-a535-4e72-8850-60206610c1f4" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_c787e0fb-15da-45e9-ad85-0acfa4d40e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_8781f686-c687-459f-ab12-4e09c74386c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_ffdd18d3-ff07-449a-a123-73750b1c171b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_8781f686-c687-459f-ab12-4e09c74386c5" xlink:to="loc_us-gaap_MinorityInterestTable_ffdd18d3-ff07-449a-a123-73750b1c171b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3042482a-9ab4-434e-ba2f-40d16235cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ffdd18d3-ff07-449a-a123-73750b1c171b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3042482a-9ab4-434e-ba2f-40d16235cdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_04bc8af8-b9bb-4fdc-be3e-5d70734dcf59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3042482a-9ab4-434e-ba2f-40d16235cdf7" xlink:to="loc_us-gaap_RelatedPartyDomain_04bc8af8-b9bb-4fdc-be3e-5d70734dcf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_3aa0074f-9994-4b6e-bd89-668254534085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_04bc8af8-b9bb-4fdc-be3e-5d70734dcf59" xlink:to="loc_us-gaap_CorporateJointVentureMember_3aa0074f-9994-4b6e-bd89-668254534085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_b9059680-f0c4-4d2d-87b0-85abe322c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_ffdd18d3-ff07-449a-a123-73750b1c171b" xlink:to="loc_us-gaap_MinorityInterestLineItems_b9059680-f0c4-4d2d-87b0-85abe322c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_b9059680-f0c4-4d2d-87b0-85abe322c7d0" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_aa625330-480e-4235-b528-975e48c780b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:to="loc_us-gaap_MinorityInterest_aa625330-480e-4235-b528-975e48c780b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_825c771e-d2e9-41e8-9ea0-f7778021553f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_825c771e-d2e9-41e8-9ea0-f7778021553f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e5445206-c728-4253-9d49-373457b1bd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e5445206-c728-4253-9d49-373457b1bd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d1d2da56-d03e-4780-99f2-274d167631f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_73deae69-8e22-4b24-b1f9-4399e30762fd" xlink:to="loc_us-gaap_MinorityInterest_d1d2da56-d03e-4780-99f2-274d167631f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INVENTORIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_faba0a96-8846-4803-a974-20282b1a38c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_f4636797-9eb9-4232-b239-3cc6e6fbcdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_faba0a96-8846-4803-a974-20282b1a38c8" xlink:to="loc_us-gaap_InventoryRawMaterials_f4636797-9eb9-4232-b239-3cc6e6fbcdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_480ee25d-327b-452c-a938-01eac34319a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_faba0a96-8846-4803-a974-20282b1a38c8" xlink:to="loc_us-gaap_InventoryWorkInProcess_480ee25d-327b-452c-a938-01eac34319a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_fbdf3303-4439-439b-9b2e-1d8336088c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_faba0a96-8846-4803-a974-20282b1a38c8" xlink:to="loc_us-gaap_InventoryFinishedGoods_fbdf3303-4439-439b-9b2e-1d8336088c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_ba92439e-3d10-44c8-921c-b6213d39bbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_faba0a96-8846-4803-a974-20282b1a38c8" xlink:to="loc_us-gaap_InventoryGross_ba92439e-3d10-44c8-921c-b6213d39bbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_2772e791-a520-4098-9bd5-4e3a7fdc8133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_faba0a96-8846-4803-a974-20282b1a38c8" xlink:to="loc_us-gaap_InventoryValuationReserves_2772e791-a520-4098-9bd5-4e3a7fdc8133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f28f8dd5-07ad-4678-afc4-0e2b221f91a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_faba0a96-8846-4803-a974-20282b1a38c8" xlink:to="loc_us-gaap_InventoryNet_f28f8dd5-07ad-4678-afc4-0e2b221f91a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4a48bb38-0c0f-435b-948c-d4bfdf4cad98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bc5db9c3-1e0b-47cf-b57a-284ff87389a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4a48bb38-0c0f-435b-948c-d4bfdf4cad98" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bc5db9c3-1e0b-47cf-b57a-284ff87389a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c632fc3c-78ec-4293-bd82-3f73e0f00a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bc5db9c3-1e0b-47cf-b57a-284ff87389a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c632fc3c-78ec-4293-bd82-3f73e0f00a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c632fc3c-78ec-4293-bd82-3f73e0f00a0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0aa7fb3c-1ef5-40f3-b8b7-53533f3ddb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_LandMember_0aa7fb3c-1ef5-40f3-b8b7-53533f3ddb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_bdacff3b-0d2e-4b48-8352-4a3d86a3dc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_bdacff3b-0d2e-4b48-8352-4a3d86a3dc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_87f1bb77-0e56-4839-b258-59a577deba53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_87f1bb77-0e56-4839-b258-59a577deba53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_aaf50953-c129-4102-a3ed-986ad0ff8719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_aaf50953-c129-4102-a3ed-986ad0ff8719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ComputerEquipmentandSoftwareMember_58280ae5-6148-47fa-a20b-cfe80b09c2b9" xlink:href="apyx-20221231.xsd#apyx_ComputerEquipmentandSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_apyx_ComputerEquipmentandSoftwareMember_58280ae5-6148-47fa-a20b-cfe80b09c2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_f1b2c76e-01a9-4ca3-be61-674ddad31fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_f1b2c76e-01a9-4ca3-be61-674ddad31fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ToolsDiesAndMoldsMember_4a44a2f1-6a66-4306-a16d-a8bfb7283f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be0c099-8c92-45d5-b57d-e218c8a8f1c3" xlink:to="loc_us-gaap_ToolsDiesAndMoldsMember_4a44a2f1-6a66-4306-a16d-a8bfb7283f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bc5db9c3-1e0b-47cf-b57a-284ff87389a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b4ef2f97-a0c0-4879-9594-b3f51bbb1ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b4ef2f97-a0c0-4879-9594-b3f51bbb1ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05ac6ba1-af02-424f-87f0-f335f22d43ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05ac6ba1-af02-424f-87f0-f335f22d43ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_409623b8-3080-4497-829b-8109ea21f400" xlink:href="apyx-20221231.xsd#apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations_409623b8-3080-4497-829b-8109ea21f400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4864f7f9-301a-43c2-9585-1951d1936e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_4864f7f9-301a-43c2-9585-1951d1936e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9a5fbe5f-e951-4898-8ac5-05747f6271c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9a5fbe5f-e951-4898-8ac5-05747f6271c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4f33aea6-a187-4639-82bc-2aedfcdcd930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f495a9d1-1a60-41fe-b851-dbdc3fbd1c62" xlink:to="loc_us-gaap_Depreciation_4f33aea6-a187-4639-82bc-2aedfcdcd930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b0cb3af3-7521-45a4-9c07-9fb30a04e8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_4e6d9093-7d75-4c73-a2d6-118c8a1ea04c" xlink:href="apyx-20221231.xsd#apyx_LesseeDiscountRateIncrementalBorrowingRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b0cb3af3-7521-45a4-9c07-9fb30a04e8b1" xlink:to="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_4e6d9093-7d75-4c73-a2d6-118c8a1ea04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b0cb3af3-7521-45a4-9c07-9fb30a04e8b1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6856b508-8e10-4b1f-801f-94b22607382e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:to="loc_srt_RangeAxis_6856b508-8e10-4b1f-801f-94b22607382e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45a84418-07d7-4fbb-bd9b-5819040c62ab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6856b508-8e10-4b1f-801f-94b22607382e" xlink:to="loc_srt_RangeMember_45a84418-07d7-4fbb-bd9b-5819040c62ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cff17e9-3471-45a7-ab89-d6c161541a9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45a84418-07d7-4fbb-bd9b-5819040c62ab" xlink:to="loc_srt_MinimumMember_7cff17e9-3471-45a7-ab89-d6c161541a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c8928940-1e73-41e4-8850-ee6ea31a998f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45a84418-07d7-4fbb-bd9b-5819040c62ab" xlink:to="loc_srt_MaximumMember_c8928940-1e73-41e4-8850-ee6ea31a998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b478a8b-e8d3-4cd0-baa9-163908e5fa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b478a8b-e8d3-4cd0-baa9-163908e5fa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_add1ebc1-049a-4ef0-ab23-ba83c3909ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0b478a8b-e8d3-4cd0-baa9-163908e5fa03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_add1ebc1-049a-4ef0-ab23-ba83c3909ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_0b8e24b4-6ce3-454e-b0e7-5631f7c2f828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_add1ebc1-049a-4ef0-ab23-ba83c3909ff7" xlink:to="loc_us-gaap_ComputerEquipmentMember_0b8e24b4-6ce3-454e-b0e7-5631f7c2f828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9d58b100-bd28-4d68-aaea-469b5a0a49d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_add1ebc1-049a-4ef0-ab23-ba83c3909ff7" xlink:to="loc_us-gaap_BuildingMember_9d58b100-bd28-4d68-aaea-469b5a0a49d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2e9d04e6-ff8d-484c-a122-2c3379b4adb2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_c27d6e5e-1feb-44bf-90a9-463d0b50b663" xlink:href="apyx-20221231.xsd#apyx_LesseeDiscountRateIncrementalBorrowingRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_apyx_LesseeDiscountRateIncrementalBorrowingRate_c27d6e5e-1feb-44bf-90a9-463d0b50b663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c9786cae-8a30-4558-ab89-0fc372ef0418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c9786cae-8a30-4558-ab89-0fc372ef0418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LesseeOperatingLeaseNumberOfLeasesExtended_925a1b70-a820-4602-add2-bd8e976cccb3" xlink:href="apyx-20221231.xsd#apyx_LesseeOperatingLeaseNumberOfLeasesExtended"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_apyx_LesseeOperatingLeaseNumberOfLeasesExtended_925a1b70-a820-4602-add2-bd8e976cccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_75acde10-ea33-43d9-bca4-879a9b243876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66a46ad0-d2f1-47a0-a395-f28a147940b3" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_75acde10-ea33-43d9-bca4-879a9b243876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f44b203c-fde2-4e28-b200-b608690d1dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d5df2fdb-3ff4-42d3-8ae6-ded669a4fb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f44b203c-fde2-4e28-b200-b608690d1dec" xlink:to="loc_us-gaap_OperatingLeaseCost_d5df2fdb-3ff4-42d3-8ae6-ded669a4fb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract_798b72d2-e296-4386-bc57-aae2b5ed96e7" xlink:href="apyx-20221231.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f44b203c-fde2-4e28-b200-b608690d1dec" xlink:to="loc_apyx_FinanceLeaseCostsAbstract_798b72d2-e296-4386-bc57-aae2b5ed96e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1ced7f56-1e78-4f69-affc-b60ba250e57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_798b72d2-e296-4386-bc57-aae2b5ed96e7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1ced7f56-1e78-4f69-affc-b60ba250e57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_5cfb315d-acd5-4bb1-bf0b-33bd883cab06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_798b72d2-e296-4386-bc57-aae2b5ed96e7" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_5cfb315d-acd5-4bb1-bf0b-33bd883cab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_57417cfd-8118-4ffc-b0b2-5b79ef96269d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f44b203c-fde2-4e28-b200-b608690d1dec" xlink:to="loc_us-gaap_VariableLeaseCost_57417cfd-8118-4ffc-b0b2-5b79ef96269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f45c10e5-a49b-429f-81a7-30b8541426ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f44b203c-fde2-4e28-b200-b608690d1dec" xlink:to="loc_us-gaap_LeaseCost_f45c10e5-a49b-429f-81a7-30b8541426ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESCashandNonCashInformationDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d38a3f96-606c-4f8d-bbf1-acd1346b6a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract_3bdf164b-a99f-4c8e-99ac-aceac7f86e45" xlink:href="apyx-20221231.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d38a3f96-606c-4f8d-bbf1-acd1346b6a34" xlink:to="loc_apyx_OperatingLeaseCostsAbstract_3bdf164b-a99f-4c8e-99ac-aceac7f86e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_82b5e529-fcff-4fba-9a0f-6900a6dfff76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_3bdf164b-a99f-4c8e-99ac-aceac7f86e45" xlink:to="loc_us-gaap_OperatingLeasePayments_82b5e529-fcff-4fba-9a0f-6900a6dfff76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract_ad778d3a-2b19-4f01-a47a-4526593f9b80" xlink:href="apyx-20221231.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d38a3f96-606c-4f8d-bbf1-acd1346b6a34" xlink:to="loc_apyx_FinanceLeaseCostsAbstract_ad778d3a-2b19-4f01-a47a-4526593f9b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeasePayments_0b0b269b-136d-4ae8-aabe-c7174a1afc79" xlink:href="apyx-20221231.xsd#apyx_FinanceLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_ad778d3a-2b19-4f01-a47a-4526593f9b80" xlink:to="loc_apyx_FinanceLeasePayments_0b0b269b-136d-4ae8-aabe-c7174a1afc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESLeaseTermsandDiscountRatesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_05091728-d23f-4a95-9a19-d90b0a2c3255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OperatingLeaseCostsAbstract_6ecf0799-da8a-4899-a61e-e1a93cad2d80" xlink:href="apyx-20221231.xsd#apyx_OperatingLeaseCostsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_05091728-d23f-4a95-9a19-d90b0a2c3255" xlink:to="loc_apyx_OperatingLeaseCostsAbstract_6ecf0799-da8a-4899-a61e-e1a93cad2d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab77ec67-060d-49fb-ad42-487385617c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_6ecf0799-da8a-4899-a61e-e1a93cad2d80" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab77ec67-060d-49fb-ad42-487385617c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0d650f6a-7742-410c-8210-521762a4e182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_OperatingLeaseCostsAbstract_6ecf0799-da8a-4899-a61e-e1a93cad2d80" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0d650f6a-7742-410c-8210-521762a4e182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_FinanceLeaseCostsAbstract_4c695967-43cb-43b2-8f65-f773a80850b5" xlink:href="apyx-20221231.xsd#apyx_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_05091728-d23f-4a95-9a19-d90b0a2c3255" xlink:to="loc_apyx_FinanceLeaseCostsAbstract_4c695967-43cb-43b2-8f65-f773a80850b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_d85e91cf-4aa1-4416-b851-3c2bff6c5af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_4c695967-43cb-43b2-8f65-f773a80850b5" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_d85e91cf-4aa1-4416-b851-3c2bff6c5af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_e5bb6e9b-8259-415c-b762-7c127b5530de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_FinanceLeaseCostsAbstract_4c695967-43cb-43b2-8f65-f773a80850b5" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_e5bb6e9b-8259-415c-b762-7c127b5530de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5dc2cf9c-2590-4418-837c-4caa04478b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5dc2cf9c-2590-4418-837c-4caa04478b4a" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1e106bc2-def5-4185-a555-4390a3d5598d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1e106bc2-def5-4185-a555-4390a3d5598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bf0a7ac0-d8da-42a4-b1b8-c5f3e2f20847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bf0a7ac0-d8da-42a4-b1b8-c5f3e2f20847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9ae4b4fc-7f82-45a0-885d-e70777f0c9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9ae4b4fc-7f82-45a0-885d-e70777f0c9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_66276555-6981-4677-9ebf-7b4a6d342f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_66276555-6981-4677-9ebf-7b4a6d342f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4c01362a-6bd8-4552-868e-2159fa35afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4c01362a-6bd8-4552-868e-2159fa35afaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_59d2f6ce-5a2f-4c91-aad5-24cedfd3cb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_59d2f6ce-5a2f-4c91-aad5-24cedfd3cb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f8d90528-f132-42d1-9746-3e48acd1be05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f8d90528-f132-42d1-9746-3e48acd1be05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2da58a17-3373-4044-8200-af34dea0c535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_OperatingLeaseLiability_2da58a17-3373-4044-8200-af34dea0c535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_66de9571-be93-4f4b-9faf-7f7da868fbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_66de9571-be93-4f4b-9faf-7f7da868fbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_64b87c93-ddd0-4056-a267-3eb0bb4b8719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12ed2c35-a7f2-440b-9548-82efc429177d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_64b87c93-ddd0-4056-a267-3eb0bb4b8719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5dc2cf9c-2590-4418-837c-4caa04478b4a" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_70cc6a57-3735-4254-9013-134b65227655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_70cc6a57-3735-4254-9013-134b65227655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b3dffe40-b31b-4d01-9e88-5f1e6894571d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b3dffe40-b31b-4d01-9e88-5f1e6894571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4868ed85-ad63-492c-bc31-478624f65e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4868ed85-ad63-492c-bc31-478624f65e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e5b28670-f448-484c-a26d-f8fb4c98b713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e5b28670-f448-484c-a26d-f8fb4c98b713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_e12e42c7-e191-40e3-b96d-ca3ed58745e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_e12e42c7-e191-40e3-b96d-ca3ed58745e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d942c9e9-6a5c-4eea-9d6d-38842c1fe4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d942c9e9-6a5c-4eea-9d6d-38842c1fe4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_585cf7d5-fde0-46fb-8825-cc803b3366e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_585cf7d5-fde0-46fb-8825-cc803b3366e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_1d1d8d66-8ab6-439f-8abe-d0c6d7fa3b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiability_1d1d8d66-8ab6-439f-8abe-d0c6d7fa3b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2d122ed7-af21-4abd-bd2a-7492e2e2eb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2d122ed7-af21-4abd-bd2a-7492e2e2eb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_41905fa3-2fe3-4fde-a2f1-aa384a6f74d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_87293019-07b6-4674-903d-98312c38d119" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_41905fa3-2fe3-4fde-a2f1-aa384a6f74d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="apyx-20221231.xsd#LEASESMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_858f92ed-686c-4023-a7b4-614a38fb476b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_us-gaap_AccruedSalariesCurrent_858f92ed-686c-4023-a7b4-614a38fb476b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_37e9306f-a180-4209-9817-fa7f091f0401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_us-gaap_AccruedBonusesCurrent_37e9306f-a180-4209-9817-fa7f091f0401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_4ce1cb7f-ab8d-4ec8-9c38-4bc96493630a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_4ce1cb7f-ab8d-4ec8-9c38-4bc96493630a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_51699906-ee37-4849-be85-982bd93319f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_51699906-ee37-4849-be85-982bd93319f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_1513aa6e-b8c8-44d1-ab36-6ffa5f51b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_1513aa6e-b8c8-44d1-ab36-6ffa5f51b53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a83b8200-2d55-48dd-a9f7-78a246981a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a83b8200-2d55-48dd-a9f7-78a246981a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_82b6a2c7-cc4a-4224-a875-c5cb42d46e5f" xlink:href="apyx-20221231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_82b6a2c7-cc4a-4224-a875-c5cb42d46e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShortTermContractLiabilities_24b11dca-de36-4653-896f-7c9bbf8af0ab" xlink:href="apyx-20221231.xsd#apyx_ShortTermContractLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_apyx_ShortTermContractLiabilities_24b11dca-de36-4653-896f-7c9bbf8af0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_143eeb1b-12ff-453e-a5b4-bddbed8ba014" xlink:href="apyx-20221231.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_apyx_UncertainTaxPositionsLiability_143eeb1b-12ff-453e-a5b4-bddbed8ba014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_acedb07a-8282-4c12-a9c0-2c107d831b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_acedb07a-8282-4c12-a9c0-2c107d831b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_919c3ff3-5286-4bdd-bb79-008bb3f41212" xlink:href="apyx-20221231.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_919c3ff3-5286-4bdd-bb79-008bb3f41212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4e0f1546-2c87-4bb3-8dc6-88161a5579ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_301fd5bf-d2f3-4c96-b4de-338ebe18d0a7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4e0f1546-2c87-4bb3-8dc6-88161a5579ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#PRODUCTWARRANTIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/PRODUCTWARRANTIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_4a719fa0-a1b4-43bb-9924-5cb487b51655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_b1718245-36d4-474b-b46d-250a8c713bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInStandardProductWarrantyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_4a719fa0-a1b4-43bb-9924-5cb487b51655" xlink:to="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_b1718245-36d4-474b-b46d-250a8c713bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_0fdd154d-aeed-451a-b52e-5bcc93a47d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_b1718245-36d4-474b-b46d-250a8c713bac" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_0fdd154d-aeed-451a-b52e-5bcc93a47d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_5c026459-4d98-4b0b-903c-bd0578f4303e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_b1718245-36d4-474b-b46d-250a8c713bac" xlink:to="loc_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_5c026459-4d98-4b0b-903c-bd0578f4303e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease_d5572583-ea0b-4195-b703-1930a9d52522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_b1718245-36d4-474b-b46d-250a8c713bac" xlink:to="loc_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease_d5572583-ea0b-4195-b703-1930a9d52522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualPayments_e31e8158-db59-4dac-94e7-08cc604b2ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_b1718245-36d4-474b-b46d-250a8c713bac" xlink:to="loc_us-gaap_StandardProductWarrantyAccrualPayments_e31e8158-db59-4dac-94e7-08cc604b2ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyAccrual_01e6dc24-0bb5-4cef-9593-60f332893e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardProductWarrantyAccrualRollForward_b1718245-36d4-474b-b46d-250a8c713bac" xlink:to="loc_us-gaap_StandardProductWarrantyAccrual_01e6dc24-0bb5-4cef-9593-60f332893e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#JOINTANDSEVERALPAYROLLLIABILITYDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7fbe9274-90f8-4bdd-9aaa-9220a613f660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_cfa845d6-f142-4187-8561-7be0d4e22078" xlink:href="apyx-20221231.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7fbe9274-90f8-4bdd-9aaa-9220a613f660" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_cfa845d6-f142-4187-8561-7be0d4e22078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime_24890243-b0ee-4784-aeeb-c5a21c1602ad" xlink:href="apyx-20221231.xsd#apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7fbe9274-90f8-4bdd-9aaa-9220a613f660" xlink:to="loc_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime_24890243-b0ee-4784-aeeb-c5a21c1602ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#CONTRACTASSETSANDLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c39d26d2-bda5-4549-b13d-2bc02f90d8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_03818caa-9e6c-4cc7-8085-1e700611e6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c39d26d2-bda5-4549-b13d-2bc02f90d8d9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_03818caa-9e6c-4cc7-8085-1e700611e6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b3bfc237-1c8d-428b-8f93-0e7d4fc1de15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c39d26d2-bda5-4549-b13d-2bc02f90d8d9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b3bfc237-1c8d-428b-8f93-0e7d4fc1de15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b8e8d0d7-3b65-497a-aa07-0686f4ff98c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c39d26d2-bda5-4549-b13d-2bc02f90d8d9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b8e8d0d7-3b65-497a-aa07-0686f4ff98c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_846c516e-3314-41df-bac3-d3f4c8bb247f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c39d26d2-bda5-4549-b13d-2bc02f90d8d9" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_846c516e-3314-41df-bac3-d3f4c8bb247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_98e4e82b-68c2-4ab5-90b8-08046476ac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c39d26d2-bda5-4549-b13d-2bc02f90d8d9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_98e4e82b-68c2-4ab5-90b8-08046476ac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ContractWithCustomerAssetRevenueRecognized_8a061b8f-bc8b-4106-987d-2c539be3b30c" xlink:href="apyx-20221231.xsd#apyx_ContractWithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c39d26d2-bda5-4549-b13d-2bc02f90d8d9" xlink:to="loc_apyx_ContractWithCustomerAssetRevenueRecognized_8a061b8f-bc8b-4106-987d-2c539be3b30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9c4aa823-5733-40d7-bcce-8c5f9c165cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75573efa-68fb-4417-9c52-221f20f8948c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9c4aa823-5733-40d7-bcce-8c5f9c165cc5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75573efa-68fb-4417-9c52-221f20f8948c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d6719216-f593-4a50-959f-16acc4c8fdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75573efa-68fb-4417-9c52-221f20f8948c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d6719216-f593-4a50-959f-16acc4c8fdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89d20c44-6665-42b9-aabb-d47bca015de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d6719216-f593-4a50-959f-16acc4c8fdd5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89d20c44-6665-42b9-aabb-d47bca015de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_3514bdd3-9296-4628-b262-e78d30767903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_89d20c44-6665-42b9-aabb-d47bca015de4" xlink:to="loc_us-gaap_OptionOnSecuritiesMember_3514bdd3-9296-4628-b262-e78d30767903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75573efa-68fb-4417-9c52-221f20f8948c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_af80d401-ab12-49c2-ad4b-0249bfe80b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_af80d401-ab12-49c2-ad4b-0249bfe80b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14c684f6-aa6d-4c1f-9a74-d1a9043abdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_af80d401-ab12-49c2-ad4b-0249bfe80b80" xlink:to="loc_us-gaap_NetIncomeLoss_14c684f6-aa6d-4c1f-9a74-d1a9043abdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d511ce95-0042-47e1-9aa5-3aad6239a83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d511ce95-0042-47e1-9aa5-3aad6239a83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91f5611c-81e7-4dfb-9723-bb576390bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_91f5611c-81e7-4dfb-9723-bb576390bcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4c334f0b-810f-40c3-b761-f15163313f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_EarningsPerShareBasic_4c334f0b-810f-40c3-b761-f15163313f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_84eece68-1af2-4607-89b6-52dc14c6744c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_EarningsPerShareDiluted_84eece68-1af2-4607-89b6-52dc14c6744c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_0eeab5b3-7a7f-414a-85c4-2ae87393864b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3948ca3b-5532-4d9b-9b03-f95aaecdeb06" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_0eeab5b3-7a7f-414a-85c4-2ae87393864b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d61945cd-da78-4968-b233-0f9c028b8b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_0eeab5b3-7a7f-414a-85c4-2ae87393864b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d61945cd-da78-4968-b233-0f9c028b8b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91b0ff09-8ac8-4cfc-8c07-3d3c2a902e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_49430158-9a4e-439e-a3b7-5088a2f7a84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91b0ff09-8ac8-4cfc-8c07-3d3c2a902e59" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_49430158-9a4e-439e-a3b7-5088a2f7a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_edfa4ac3-c848-4fc0-8611-dfbf34ae483b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_49430158-9a4e-439e-a3b7-5088a2f7a84d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_edfa4ac3-c848-4fc0-8611-dfbf34ae483b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2d0d0114-ada9-4816-acf5-6f4eeb4a4f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_49430158-9a4e-439e-a3b7-5088a2f7a84d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2d0d0114-ada9-4816-acf5-6f4eeb4a4f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4b7e4c8e-f981-4c91-ab5b-dad819b48c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_49430158-9a4e-439e-a3b7-5088a2f7a84d" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4b7e4c8e-f981-4c91-ab5b-dad819b48c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e6800b23-c182-427f-b67a-c5c749dc63d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_49430158-9a4e-439e-a3b7-5088a2f7a84d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e6800b23-c182-427f-b67a-c5c749dc63d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_91a2f538-cb14-41d8-9c55-a8ae8a26ed30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91b0ff09-8ac8-4cfc-8c07-3d3c2a902e59" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_91a2f538-cb14-41d8-9c55-a8ae8a26ed30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a4837cae-911b-41f1-969d-3e20cd80531a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_91a2f538-cb14-41d8-9c55-a8ae8a26ed30" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a4837cae-911b-41f1-969d-3e20cd80531a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e83ceb13-7e97-4015-a108-fee9590cbf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_91a2f538-cb14-41d8-9c55-a8ae8a26ed30" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e83ceb13-7e97-4015-a108-fee9590cbf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_42c2952f-2025-4ab3-9a7f-9f9cedf871ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_91a2f538-cb14-41d8-9c55-a8ae8a26ed30" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_42c2952f-2025-4ab3-9a7f-9f9cedf871ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance_b6870b70-ed5b-4057-914d-53cdfd9cef3a" xlink:href="apyx-20221231.xsd#apyx_IncomeTaxExpenseBenefitValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_91a2f538-cb14-41d8-9c55-a8ae8a26ed30" xlink:to="loc_apyx_IncomeTaxExpenseBenefitValuationAllowance_b6870b70-ed5b-4057-914d-53cdfd9cef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_77b2a0e4-2df7-4bbf-a643-6ca01f5f3fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91b0ff09-8ac8-4cfc-8c07-3d3c2a902e59" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_77b2a0e4-2df7-4bbf-a643-6ca01f5f3fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_993ec901-6189-46e7-9bd5-42294c95296f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_993ec901-6189-46e7-9bd5-42294c95296f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_969feb97-9738-444a-a598-61cc6eb49192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_969feb97-9738-444a-a598-61cc6eb49192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e4500968-78f9-4507-8d06-839bf91c3357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e4500968-78f9-4507-8d06-839bf91c3357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e17b74ac-a20b-413f-9c93-48e23a6873f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e17b74ac-a20b-413f-9c93-48e23a6873f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9fdcf382-208d-403d-b133-7658e57b6c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_9fdcf382-208d-403d-b133-7658e57b6c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent_bcb41d24-ff9a-4db7-864f-dd78fb85ff80" xlink:href="apyx-20221231.xsd#apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:to="loc_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent_bcb41d24-ff9a-4db7-864f-dd78fb85ff80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_b0e30ba8-189a-4e99-97c7-d5a712d46b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_b0e30ba8-189a-4e99-97c7-d5a712d46b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_fda065a1-401c-4dc4-b493-38624e26943d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_fda065a1-401c-4dc4-b493-38624e26943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_4c87bce7-e23c-40ee-89fd-68e8f95a5fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1dbfdd44-2b3b-478d-b7c0-00924dd0f3af" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_4c87bce7-e23c-40ee-89fd-68e8f95a5fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee6a083-b1a6-40e0-8e4e-426df5d40b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee6a083-b1a6-40e0-8e4e-426df5d40b58" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_493ddef0-8c80-42ab-aabd-e04ffef25b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_493ddef0-8c80-42ab-aabd-e04ffef25b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5d4a7819-dace-4c16-a896-e657d524f4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5d4a7819-dace-4c16-a896-e657d524f4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_39bd6bf0-97eb-4dfe-8c58-0920f7cb7c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_39bd6bf0-97eb-4dfe-8c58-0920f7cb7c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles_9a91b4da-b57b-47cd-be28-afdad4b0b7af" xlink:href="apyx-20221231.xsd#apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles_9a91b4da-b57b-47cd-be28-afdad4b0b7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_68dbc3a1-b6ff-46fb-a033-1ded9c089940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_68dbc3a1-b6ff-46fb-a033-1ded9c089940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_971455e7-21ca-4d79-b13f-c617821e9280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_971455e7-21ca-4d79-b13f-c617821e9280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_e20a9cbb-be4c-43d3-a63f-c5fbdded4f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_e20a9cbb-be4c-43d3-a63f-c5fbdded4f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_05312f17-b608-4b34-a0d9-7b35b7a645ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_05312f17-b608-4b34-a0d9-7b35b7a645ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9c97ceb6-ed03-403f-a2f5-0ee36f36a2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_9c97ceb6-ed03-403f-a2f5-0ee36f36a2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8d96e9d6-8472-4bee-acf8-33b71a99aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8d96e9d6-8472-4bee-acf8-33b71a99aa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a3714a07-92c0-4be0-9821-ba201f4c2b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8209fe50-35f2-4154-ac13-f2de99a13fa2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a3714a07-92c0-4be0-9821-ba201f4c2b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7a3f4d74-c89b-4feb-b579-04259519d7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee6a083-b1a6-40e0-8e4e-426df5d40b58" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7a3f4d74-c89b-4feb-b579-04259519d7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3838c4ce-821d-45d4-a38b-d624b1853248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7a3f4d74-c89b-4feb-b579-04259519d7b0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3838c4ce-821d-45d4-a38b-d624b1853248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_fb7c3d36-09e0-4f18-9b66-3cdfabb19315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7a3f4d74-c89b-4feb-b579-04259519d7b0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_fb7c3d36-09e0-4f18-9b66-3cdfabb19315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e910038b-95e0-4e18-9bb7-535c4c053765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7a3f4d74-c89b-4feb-b579-04259519d7b0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e910038b-95e0-4e18-9bb7-535c4c053765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4a4a2845-e9b0-420e-a79a-411a2e031026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee6a083-b1a6-40e0-8e4e-426df5d40b58" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4a4a2845-e9b0-420e-a79a-411a2e031026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a1ed729d-87c9-4bcf-877e-b649bbb64a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f707d242-7b37-43b3-a4fa-cd34d57cb7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a1ed729d-87c9-4bcf-877e-b649bbb64a8e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f707d242-7b37-43b3-a4fa-cd34d57cb7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3fe41ae2-4771-4b6c-a4ae-024604781e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a1ed729d-87c9-4bcf-877e-b649bbb64a8e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3fe41ae2-4771-4b6c-a4ae-024604781e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_75aa9a1c-5fde-4dd9-b744-8983c8733579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cb5f0eb4-3a99-4724-ab89-f87f97a663e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75aa9a1c-5fde-4dd9-b744-8983c8733579" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cb5f0eb4-3a99-4724-ab89-f87f97a663e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7c1f84f7-875f-4acb-af9e-357980d29839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cb5f0eb4-3a99-4724-ab89-f87f97a663e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7c1f84f7-875f-4acb-af9e-357980d29839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_745935d4-fbf2-4790-9bbb-92154aa495b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cb5f0eb4-3a99-4724-ab89-f87f97a663e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_745935d4-fbf2-4790-9bbb-92154aa495b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_82ab45d1-790f-43aa-b1f9-462dd6c9321a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cb5f0eb4-3a99-4724-ab89-f87f97a663e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_82ab45d1-790f-43aa-b1f9-462dd6c9321a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_97bf843c-fca2-497e-b53f-5db34af78ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cb5f0eb4-3a99-4724-ab89-f87f97a663e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_97bf843c-fca2-497e-b53f-5db34af78ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1afb2cec-d826-4b64-b0dd-a027b7d84a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cb5f0eb4-3a99-4724-ab89-f87f97a663e5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1afb2cec-d826-4b64-b0dd-a027b7d84a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#RETIREMENTPLANNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e900947c-39ed-424f-9955-041a91e8fc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanRequisiteServicePeriod_2cbf9152-5b96-4386-980e-bd349fcd808a" xlink:href="apyx-20221231.xsd#apyx_DefinedContributionPlanRequisiteServicePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e900947c-39ed-424f-9955-041a91e8fc92" xlink:to="loc_apyx_DefinedContributionPlanRequisiteServicePeriod_2cbf9152-5b96-4386-980e-bd349fcd808a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_0f9c6292-12b8-4c51-94a8-90ab63f3f682" xlink:href="apyx-20221231.xsd#apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e900947c-39ed-424f-9955-041a91e8fc92" xlink:to="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_0f9c6292-12b8-4c51-94a8-90ab63f3f682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_2a3261db-46e7-48a7-bb7d-6b19a93cff90" xlink:href="apyx-20221231.xsd#apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e900947c-39ed-424f-9955-041a91e8fc92" xlink:to="loc_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears_2a3261db-46e7-48a7-bb7d-6b19a93cff90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_c20c4004-4c93-4cf9-a822-815d5e5d9711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e900947c-39ed-424f-9955-041a91e8fc92" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_c20c4004-4c93-4cf9-a822-815d5e5d9711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e5dc30e4-b48b-4521-b2d1-07c81dbfc91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e900947c-39ed-424f-9955-041a91e8fc92" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e5dc30e4-b48b-4521-b2d1-07c81dbfc91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_fb0b3bef-df9a-4e8c-aceb-f18d3a7313c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e900947c-39ed-424f-9955-041a91e8fc92" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_fb0b3bef-df9a-4e8c-aceb-f18d3a7313c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a8e49c31-bddd-45a8-8b32-004fb6100266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_91ff978c-44d2-47d6-85bb-c03b52efd98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a8e49c31-bddd-45a8-8b32-004fb6100266" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_91ff978c-44d2-47d6-85bb-c03b52efd98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_70fc3e0d-af03-486d-88be-155bcb1a14d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_91ff978c-44d2-47d6-85bb-c03b52efd98c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_70fc3e0d-af03-486d-88be-155bcb1a14d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_927c6ef0-164d-4d34-823a-46d5ad97eec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_70fc3e0d-af03-486d-88be-155bcb1a14d7" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_927c6ef0-164d-4d34-823a-46d5ad97eec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_6fd5dfa5-6d60-429f-94cf-e4d5c381be97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CoVenturerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_927c6ef0-164d-4d34-823a-46d5ad97eec3" xlink:to="loc_us-gaap_CoVenturerMember_6fd5dfa5-6d60-429f-94cf-e4d5c381be97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9abc4d46-8ae4-44a6-9b54-ba478aa2d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_91ff978c-44d2-47d6-85bb-c03b52efd98c" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9abc4d46-8ae4-44a6-9b54-ba478aa2d79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_5ec9a52b-ff4d-49b4-91c3-16225b4a60dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9abc4d46-8ae4-44a6-9b54-ba478aa2d79c" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_5ec9a52b-ff4d-49b4-91c3-16225b4a60dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_625c0555-f52c-4456-a754-bcf43f0b4d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9abc4d46-8ae4-44a6-9b54-ba478aa2d79c" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_625c0555-f52c-4456-a754-bcf43f0b4d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76074c2f-c9d1-4bad-93d6-b97aaad4c189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76074c2f-c9d1-4bad-93d6-b97aaad4c189" xlink:to="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d965827f-4b41-45a2-938f-d6e04cae9f4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_srt_MajorCustomersAxis_d965827f-4b41-45a2-938f-d6e04cae9f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_afac9fcb-cffb-48cd-b211-b77d7b7610af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d965827f-4b41-45a2-938f-d6e04cae9f4a" xlink:to="loc_srt_NameOfMajorCustomerDomain_afac9fcb-cffb-48cd-b211-b77d7b7610af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LargestCustomerMember_fbdae395-7e74-4743-b915-27a28ad31a33" xlink:href="apyx-20221231.xsd#apyx_LargestCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_afac9fcb-cffb-48cd-b211-b77d7b7610af" xlink:to="loc_apyx_LargestCustomerMember_fbdae395-7e74-4743-b915-27a28ad31a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoLargestCustomersMember_4835c3d3-dd65-4d8a-8786-1c3ac56a219f" xlink:href="apyx-20221231.xsd#apyx_TwoLargestCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_afac9fcb-cffb-48cd-b211-b77d7b7610af" xlink:to="loc_apyx_TwoLargestCustomersMember_4835c3d3-dd65-4d8a-8786-1c3ac56a219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_476b12df-2441-44be-a1ec-dbb4434c3070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9c4ae9db-8c9d-42aa-b61c-c0bd144d1f89" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_476b12df-2441-44be-a1ec-dbb4434c3070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cd123cb6-7960-4003-bdb0-1103f239fc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_476b12df-2441-44be-a1ec-dbb4434c3070" xlink:to="loc_us-gaap_SalesRevenueNetMember_cd123cb6-7960-4003-bdb0-1103f239fc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccountsReceivableBenchmarkMember_df47bd01-6bc9-4727-ab7e-0216ecb42855" xlink:href="apyx-20221231.xsd#apyx_AccountsReceivableBenchmarkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_476b12df-2441-44be-a1ec-dbb4434c3070" xlink:to="loc_apyx_AccountsReceivableBenchmarkMember_df47bd01-6bc9-4727-ab7e-0216ecb42855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_79c929b9-cc1e-4f06-bb62-91295e189767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_79c929b9-cc1e-4f06-bb62-91295e189767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_03e89857-a551-4c11-a3a8-4843b99f6146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_79c929b9-cc1e-4f06-bb62-91295e189767" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_03e89857-a551-4c11-a3a8-4843b99f6146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a45ec43a-8748-4344-82f4-c0e27177282a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_03e89857-a551-4c11-a3a8-4843b99f6146" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a45ec43a-8748-4344-82f4-c0e27177282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3bd7e524-a055-4792-9382-bfdda1259e6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_srt_LitigationCaseAxis_3bd7e524-a055-4792-9382-bfdda1259e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3bd7e524-a055-4792-9382-bfdda1259e6a" xlink:to="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ContractWithInternationalDistributorMember_524a9804-318c-459b-b2ee-8077bb4311fc" xlink:href="apyx-20221231.xsd#apyx_ContractWithInternationalDistributorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:to="loc_apyx_ContractWithInternationalDistributorMember_524a9804-318c-459b-b2ee-8077bb4311fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitAgainstGoodwinAndSimbMember_0b69feba-ec27-412e-ad69-66a64aaaf723" xlink:href="apyx-20221231.xsd#apyx_SuitAgainstGoodwinAndSimbMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:to="loc_apyx_SuitAgainstGoodwinAndSimbMember_0b69feba-ec27-412e-ad69-66a64aaaf723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SuitsFiledIn2022Member_d3426a51-761b-4ecf-9eff-e273cf2f817a" xlink:href="apyx-20221231.xsd#apyx_SuitsFiledIn2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0782c695-ebd0-413d-8232-aac739fd76c8" xlink:to="loc_apyx_SuitsFiledIn2022Member_d3426a51-761b-4ecf-9eff-e273cf2f817a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_srt_RangeAxis_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6edca26-703b-4885-bd37-ae04a23ac20e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b6ff7707-41b2-4eb1-8e5f-62a2f1c2520d" xlink:to="loc_srt_RangeMember_e6edca26-703b-4885-bd37-ae04a23ac20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dae764ad-995b-4cbe-aae4-fa258f1a9dbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6edca26-703b-4885-bd37-ae04a23ac20e" xlink:to="loc_srt_MinimumMember_dae764ad-995b-4cbe-aae4-fa258f1a9dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_44c063e4-0c37-42ca-aebf-f9dc29160d06" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6edca26-703b-4885-bd37-ae04a23ac20e" xlink:to="loc_srt_MaximumMember_44c063e4-0c37-42ca-aebf-f9dc29160d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e616ade7-5b76-4567-8bea-a490b55713bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e616ade7-5b76-4567-8bea-a490b55713bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f66d3b5d-5eee-42c0-9c1d-e62464181982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e616ade7-5b76-4567-8bea-a490b55713bf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f66d3b5d-5eee-42c0-9c1d-e62464181982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e282fb64-3119-4961-ac97-11d63adf76e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f66d3b5d-5eee-42c0-9c1d-e62464181982" xlink:to="loc_us-gaap_SubsequentEventMember_e282fb64-3119-4961-ac97-11d63adf76e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_27f72660-62cb-4333-ae08-ffa142dbf8fe" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1810fadf-9447-48f0-bf88-c1a34d205009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1810fadf-9447-48f0-bf88-c1a34d205009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e96cdaa0-f7eb-4842-bff1-8af10410a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e96cdaa0-f7eb-4842-bff1-8af10410a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_86675939-7226-41da-bc6c-1a0d1427577a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_86675939-7226-41da-bc6c-1a0d1427577a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_05b4ab32-4214-4cde-9100-6057ba86c6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_05b4ab32-4214-4cde-9100-6057ba86c6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_d9ceab54-5db0-49cc-aaac-cec2f556aa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_PurchaseObligation_d9ceab54-5db0-49cc-aaac-cec2f556aa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bdf8dc09-71d4-4f26-9a93-7b1c7a631063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_74010752-d461-4ac9-8524-30337628a9df" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bdf8dc09-71d4-4f26-9a93-7b1c7a631063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#STOCKOPTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f7d48b2f-2a35-49f4-83d1-b52db516aac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f7d48b2f-2a35-49f4-83d1-b52db516aac8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_04cede3f-4076-48b2-85b9-d4088771c052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:to="loc_us-gaap_PlanNameAxis_04cede3f-4076-48b2-85b9-d4088771c052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_04cede3f-4076-48b2-85b9-d4088771c052" xlink:to="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_862a4bbf-7eb2-4caf-ad11-cbd17e4c021d" xlink:href="apyx-20221231.xsd#apyx_A2001ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2001ExecutiveandEmployeeStockOptionPlanMember_862a4bbf-7eb2-4caf-ad11-cbd17e4c021d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_092efeff-a8e8-4dee-ab22-006869e85074" xlink:href="apyx-20221231.xsd#apyx_A2003ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2003ExecutiveandEmployeeStockOptionPlanMember_092efeff-a8e8-4dee-ab22-006869e85074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandTwelveShareIncentivePlanMember_39aa5f7f-1e14-4394-9cd7-d24aa1d4f8ca" xlink:href="apyx-20221231.xsd#apyx_TwoThousandTwelveShareIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_TwoThousandTwelveShareIncentivePlanMember_39aa5f7f-1e14-4394-9cd7-d24aa1d4f8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_70b54e0d-e1f3-45de-96bf-49efc83615d0" xlink:href="apyx-20221231.xsd#apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember_70b54e0d-e1f3-45de-96bf-49efc83615d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_7feefb78-0b08-4c5b-a630-e15a172cc358" xlink:href="apyx-20221231.xsd#apyx_A2017ExecutiveandEmployeeStockOptionPlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2017ExecutiveandEmployeeStockOptionPlanMember_7feefb78-0b08-4c5b-a630-e15a172cc358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2019ShareIncentivePlanMember_f3aec5aa-e05e-43b0-8c09-67d0dd832301" xlink:href="apyx-20221231.xsd#apyx_A2019ShareIncentivePlanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2019ShareIncentivePlanMember_f3aec5aa-e05e-43b0-8c09-67d0dd832301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_A2021ShareIncentivePlanMember_df65c703-df90-492b-9344-3b4e57a0d054" xlink:href="apyx-20221231.xsd#apyx_A2021ShareIncentivePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d2e384f-189e-4389-8b03-33835f485265" xlink:to="loc_apyx_A2021ShareIncentivePlanMember_df65c703-df90-492b-9344-3b4e57a0d054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6df1359-450f-4d77-aaef-7c1151418944" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:to="loc_srt_RangeAxis_c6df1359-450f-4d77-aaef-7c1151418944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61bf626d-945d-4ba8-8f6e-770665e4ceb6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c6df1359-450f-4d77-aaef-7c1151418944" xlink:to="loc_srt_RangeMember_61bf626d-945d-4ba8-8f6e-770665e4ceb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d6ec1a37-aa50-47e0-a23b-5dc91d348174" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_61bf626d-945d-4ba8-8f6e-770665e4ceb6" xlink:to="loc_srt_MinimumMember_d6ec1a37-aa50-47e0-a23b-5dc91d348174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9d0f428-7100-4057-aee8-b9cf00b90ae7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_61bf626d-945d-4ba8-8f6e-770665e4ceb6" xlink:to="loc_srt_MaximumMember_a9d0f428-7100-4057-aee8-b9cf00b90ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b990bfaa-ff4a-4ff3-aef3-92926fcc8598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b990bfaa-ff4a-4ff3-aef3-92926fcc8598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_feae2135-62fc-4a34-80bd-e09895222530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b990bfaa-ff4a-4ff3-aef3-92926fcc8598" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_feae2135-62fc-4a34-80bd-e09895222530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7cb1b6c5-80bf-4b5e-a902-f9d80edebb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_feae2135-62fc-4a34-80bd-e09895222530" xlink:to="loc_us-gaap_SubsequentEventMember_7cb1b6c5-80bf-4b5e-a902-f9d80edebb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07a4fc1c-d7ab-44e1-9a48-14f7d7049bc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_830bda70-a0b8-4978-a9cb-ff0256237534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_830bda70-a0b8-4978-a9cb-ff0256237534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b346ef8-626b-4751-988f-c10905254254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b346ef8-626b-4751-988f-c10905254254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_792c95c9-f102-481f-aee5-80296df63d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_792c95c9-f102-481f-aee5-80296df63d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d310391-9d0a-4097-a138-67432b15d3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1d310391-9d0a-4097-a138-67432b15d3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1343f1e4-0ee3-4c1d-b424-48828da15035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1343f1e4-0ee3-4c1d-b424-48828da15035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_2032a4ab-dd99-4306-aa9b-0c6a3fb73720" xlink:href="apyx-20221231.xsd#apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice_2032a4ab-dd99-4306-aa9b-0c6a3fb73720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0428cbe0-3d85-4f18-90bc-49b7f756515a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0428cbe0-3d85-4f18-90bc-49b7f756515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a2bde3a8-5c21-4ad9-a72e-43f1a02027e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a2bde3a8-5c21-4ad9-a72e-43f1a02027e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e87e9fcf-79b5-4ce8-8fad-bb2b6c3d0e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e87e9fcf-79b5-4ce8-8fad-bb2b6c3d0e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1bd388a2-219d-46cf-a101-92bb1a190e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1bd388a2-219d-46cf-a101-92bb1a190e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_337e4c27-ea78-483e-92e6-5451a6706372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_337e4c27-ea78-483e-92e6-5451a6706372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24c053e1-c8e2-409a-b65d-9196ae8543a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_24c053e1-c8e2-409a-b65d-9196ae8543a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2243886d-0e83-4fdb-a35a-0d7f6359526b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2243886d-0e83-4fdb-a35a-0d7f6359526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_87b9f686-8b63-4b43-95a3-1d404e3c7178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_87b9f686-8b63-4b43-95a3-1d404e3c7178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b34df018-a287-4626-84db-5016d3c341d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b34df018-a287-4626-84db-5016d3c341d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_b0cb41bf-f675-48d1-8552-63de0fc07226" xlink:href="apyx-20221231.xsd#apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_b0cb41bf-f675-48d1-8552-63de0fc07226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e12d99c-6704-4f3a-a87e-b866b5161936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e12d99c-6704-4f3a-a87e-b866b5161936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_36aa58bd-b07d-4591-9d95-b90406603137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_36aa58bd-b07d-4591-9d95-b90406603137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_8d68ef25-4272-4a56-98f3-e353e5eeeb68" xlink:href="apyx-20221231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_8d68ef25-4272-4a56-98f3-e353e5eeeb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_a67838a3-09ca-4a98-b13e-ae2d8ab4a04a" xlink:href="apyx-20221231.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_a67838a3-09ca-4a98-b13e-ae2d8ab4a04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_597e2b08-7f2a-4ee5-8538-fcf9fc9d0574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_597e2b08-7f2a-4ee5-8538-fcf9fc9d0574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_79d61ab3-a0d1-42a0-9b83-094badedff56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9be8d05e-ed09-4278-8d57-6746639592b5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_79d61ab3-a0d1-42a0-9b83-094badedff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#STOCKOPTIONSSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b467aa6c-9e26-40b0-a89d-17d127b9dda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_125397cb-9b60-45ef-b6f1-f678e83cae5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b467aa6c-9e26-40b0-a89d-17d127b9dda8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_125397cb-9b60-45ef-b6f1-f678e83cae5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9f61960a-7fc7-43c4-91bf-b4e759a67d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_125397cb-9b60-45ef-b6f1-f678e83cae5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9f61960a-7fc7-43c4-91bf-b4e759a67d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a8f5b80-f634-4366-b182-d864119d0ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_125397cb-9b60-45ef-b6f1-f678e83cae5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a8f5b80-f634-4366-b182-d864119d0ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4e4f3552-8e35-41d0-b908-3639d116266b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_125397cb-9b60-45ef-b6f1-f678e83cae5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4e4f3552-8e35-41d0-b908-3639d116266b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_942ef000-f92a-4926-bc1a-9c3a1d42fe19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_125397cb-9b60-45ef-b6f1-f678e83cae5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_942ef000-f92a-4926-bc1a-9c3a1d42fe19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_307eb84c-8d7d-4f31-bbe0-40df89b99a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_125397cb-9b60-45ef-b6f1-f678e83cae5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_307eb84c-8d7d-4f31-bbe0-40df89b99a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6965bb73-99f5-4461-9ad0-2caef9c523a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b467aa6c-9e26-40b0-a89d-17d127b9dda8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6965bb73-99f5-4461-9ad0-2caef9c523a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f8e69a7c-9944-4f95-9473-bc7d3ae1db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6965bb73-99f5-4461-9ad0-2caef9c523a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f8e69a7c-9944-4f95-9473-bc7d3ae1db2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4d6289eb-79b1-4116-9a02-10b7ec9fc86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6965bb73-99f5-4461-9ad0-2caef9c523a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4d6289eb-79b1-4116-9a02-10b7ec9fc86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_195fdfe9-48db-4447-8d63-94b8f8bda801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6965bb73-99f5-4461-9ad0-2caef9c523a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_195fdfe9-48db-4447-8d63-94b8f8bda801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d1186f67-9695-434f-8d32-8c1188dd14a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6965bb73-99f5-4461-9ad0-2caef9c523a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d1186f67-9695-434f-8d32-8c1188dd14a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a96fabe0-089f-46ba-a873-9901e434c8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6965bb73-99f5-4461-9ad0-2caef9c523a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a96fabe0-089f-46ba-a873-9901e434c8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a74fbb1-0c27-4dc0-9b5f-de92729169c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_7a5cf86d-8a8a-41fb-889a-f8f82d63e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a74fbb1-0c27-4dc0-9b5f-de92729169c8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_7a5cf86d-8a8a-41fb-889a-f8f82d63e4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_da91ff3f-28b5-41a9-a769-1b996bdbaf52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_7a5cf86d-8a8a-41fb-889a-f8f82d63e4e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_da91ff3f-28b5-41a9-a769-1b996bdbaf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9764f12c-365a-478b-a053-ab0705a09259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_7a5cf86d-8a8a-41fb-889a-f8f82d63e4e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9764f12c-365a-478b-a053-ab0705a09259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c90e4a78-e31d-469c-969b-d57bb8460e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_7a5cf86d-8a8a-41fb-889a-f8f82d63e4e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c90e4a78-e31d-469c-969b-d57bb8460e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_14955bea-3476-4fdb-a9a7-292e45b0dff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_7a5cf86d-8a8a-41fb-889a-f8f82d63e4e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_14955bea-3476-4fdb-a9a7-292e45b0dff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_b31d0054-46a0-418e-9492-b883c3f47f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_7a5cf86d-8a8a-41fb-889a-f8f82d63e4e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_b31d0054-46a0-418e-9492-b883c3f47f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_923e5719-9501-47fa-a457-af8e31601192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a74fbb1-0c27-4dc0-9b5f-de92729169c8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_923e5719-9501-47fa-a457-af8e31601192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_a923b4ff-2b5c-433c-81f9-6178ab08e89a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_923e5719-9501-47fa-a457-af8e31601192" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_a923b4ff-2b5c-433c-81f9-6178ab08e89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_126ac78a-f523-4310-a995-0c11a09d3abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_923e5719-9501-47fa-a457-af8e31601192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_126ac78a-f523-4310-a995-0c11a09d3abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_ce7d4919-8bab-40cc-9c5e-5c174fe2d958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_923e5719-9501-47fa-a457-af8e31601192" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_ce7d4919-8bab-40cc-9c5e-5c174fe2d958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_22d1b5df-d678-443c-ba37-2d11b9977707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_923e5719-9501-47fa-a457-af8e31601192" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_22d1b5df-d678-443c-ba37-2d11b9977707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_444ab210-3d86-4e0c-91b5-1b99a1c3fc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_923e5719-9501-47fa-a457-af8e31601192" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_444ab210-3d86-4e0c-91b5-1b99a1c3fc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7221353e-d70f-41ac-8de7-3d75ecdc791b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf824bf-4e62-4a89-af5f-cf25025eb0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7221353e-d70f-41ac-8de7-3d75ecdc791b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf824bf-4e62-4a89-af5f-cf25025eb0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf824bf-4e62-4a89-af5f-cf25025eb0d3" xlink:to="loc_srt_RangeAxis_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82c74c43-885e-406f-92ef-c002300ecad3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2b0a9e52-6e6d-4627-b34c-ba0a8ca5c00e" xlink:to="loc_srt_RangeMember_82c74c43-885e-406f-92ef-c002300ecad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_17ab326e-f669-46dd-8886-da723164a915" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82c74c43-885e-406f-92ef-c002300ecad3" xlink:to="loc_srt_MinimumMember_17ab326e-f669-46dd-8886-da723164a915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4f5566e3-3d53-4c10-b73d-e5406df17fc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82c74c43-885e-406f-92ef-c002300ecad3" xlink:to="loc_srt_MaximumMember_4f5566e3-3d53-4c10-b73d-e5406df17fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ebf824bf-4e62-4a89-af5f-cf25025eb0d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fea2c227-32cf-4497-84b2-2471e8a418fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fea2c227-32cf-4497-84b2-2471e8a418fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6141dd82-132a-4ba5-b140-574bda5a4908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6141dd82-132a-4ba5-b140-574bda5a4908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_00408403-5fbc-43b3-b5ae-5a089b0631c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_00408403-5fbc-43b3-b5ae-5a089b0631c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_368e3478-3397-4c88-bbd1-1ef89898d631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_368e3478-3397-4c88-bbd1-1ef89898d631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a24ceb45-78ce-4d39-9ecf-29b9dfd31393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a24ceb45-78ce-4d39-9ecf-29b9dfd31393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_52406283-e4d7-45a7-9b8e-97b664ebb2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a865b56-c918-4520-9306-68d70f4827e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_52406283-e4d7-45a7-9b8e-97b664ebb2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_25e0dbb3-acc2-4778-83fc-f37dd4c40fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3b0b8f55-df06-4bfb-a788-b2f90b56551b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_25e0dbb3-acc2-4778-83fc-f37dd4c40fff" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3b0b8f55-df06-4bfb-a788-b2f90b56551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ff8d4ce9-8cf2-4dd0-a363-35d16f68017b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ff8d4ce9-8cf2-4dd0-a363-35d16f68017b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_72a13aee-925b-4f85-83ec-30ecb689eb83" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:to="loc_srt_ConsolidationItemsAxis_72a13aee-925b-4f85-83ec-30ecb689eb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5b313b1c-9505-4275-980c-29939bd79eaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_72a13aee-925b-4f85-83ec-30ecb689eb83" xlink:to="loc_srt_ConsolidationItemsDomain_5b313b1c-9505-4275-980c-29939bd79eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_dc7cdff2-9a34-4ddf-a7cf-7124da3505ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_5b313b1c-9505-4275-980c-29939bd79eaa" xlink:to="loc_us-gaap_OperatingSegmentsMember_dc7cdff2-9a34-4ddf-a7cf-7124da3505ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8019949f-4382-4e91-9724-a725479ed286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_5b313b1c-9505-4275-980c-29939bd79eaa" xlink:to="loc_us-gaap_CorporateNonSegmentMember_8019949f-4382-4e91-9724-a725479ed286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7cf88c01-852a-47d9-8384-2599da172a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7cf88c01-852a-47d9-8384-2599da172a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cbbf3af4-b6cc-4230-847f-b2b38751f3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7cf88c01-852a-47d9-8384-2599da172a34" xlink:to="loc_us-gaap_SegmentDomain_cbbf3af4-b6cc-4230-847f-b2b38751f3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_36014e7e-f761-4e22-9d79-05f742b05da2" xlink:href="apyx-20221231.xsd#apyx_AdvancedEnergyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cbbf3af4-b6cc-4230-847f-b2b38751f3c6" xlink:to="loc_apyx_AdvancedEnergyMember_36014e7e-f761-4e22-9d79-05f742b05da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_cbc8a63b-e60e-4680-8b81-fead91348d6c" xlink:href="apyx-20221231.xsd#apyx_OEMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cbbf3af4-b6cc-4230-847f-b2b38751f3c6" xlink:to="loc_apyx_OEMMember_cbc8a63b-e60e-4680-8b81-fead91348d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c51c5cf7-ddb9-44a9-a78c-e5bfafa852c5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8b48d21-f64d-4226-98de-23ddd3f9de57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8b48d21-f64d-4226-98de-23ddd3f9de57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d5b38c22-5d5e-4510-a10a-992f432a5c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_OperatingIncomeLoss_d5b38c22-5d5e-4510-a10a-992f432a5c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_63f9b8f8-c42e-49c6-88b0-7090ff517cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_InterestIncomeOperating_63f9b8f8-c42e-49c6-88b0-7090ff517cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4dc6c974-2da9-4660-87ed-cccc9a9da170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_InterestExpense_4dc6c974-2da9-4660-87ed-cccc9a9da170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0d592faa-5dcf-40f9-8169-e7c31a293689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0d592faa-5dcf-40f9-8169-e7c31a293689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c0d56f9a-1323-497e-9546-23d8dd3d5c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6571f23a-6948-4fbd-96de-ad03394c5857" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c0d56f9a-1323-497e-9546-23d8dd3d5c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_60e86ef0-df76-4cad-a392-40739074b0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_60e86ef0-df76-4cad-a392-40739074b0cd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_990645ed-8332-4b53-8c2b-9749c1b2b6ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:to="loc_srt_StatementGeographicalAxis_990645ed-8332-4b53-8c2b-9749c1b2b6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4f4164ab-30c4-42bb-ab5a-31ea9203d496" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_990645ed-8332-4b53-8c2b-9749c1b2b6ac" xlink:to="loc_srt_SegmentGeographicalDomain_4f4164ab-30c4-42bb-ab5a-31ea9203d496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a1ab8fcf-c5f3-41d2-b99e-b514c34ec836" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4f4164ab-30c4-42bb-ab5a-31ea9203d496" xlink:to="loc_country_US_a1ab8fcf-c5f3-41d2-b99e-b514c34ec836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_f407beea-af42-4970-a340-2a51f11bf0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4f4164ab-30c4-42bb-ab5a-31ea9203d496" xlink:to="loc_us-gaap_NonUsMember_f407beea-af42-4970-a340-2a51f11bf0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d9727e7d-b4af-4adc-8a1d-8e432aea8d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d9727e7d-b4af-4adc-8a1d-8e432aea8d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fca3e673-4ca8-43ed-91a7-a083dbfcce81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d9727e7d-b4af-4adc-8a1d-8e432aea8d57" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fca3e673-4ca8-43ed-91a7-a083dbfcce81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_8e46d6e6-d549-43b0-b78b-1d2725487b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fca3e673-4ca8-43ed-91a7-a083dbfcce81" xlink:to="loc_us-gaap_SalesRevenueNetMember_8e46d6e6-d549-43b0-b78b-1d2725487b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b200796d-d85f-4d3d-a913-6bfddf336e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b200796d-d85f-4d3d-a913-6bfddf336e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ab6d65c6-2781-441c-b5d9-06aa0caa219b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b200796d-d85f-4d3d-a913-6bfddf336e2c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ab6d65c6-2781-441c-b5d9-06aa0caa219b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_517993f6-80f0-43e9-89db-f6dbd3b09b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ab6d65c6-2781-441c-b5d9-06aa0caa219b" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_517993f6-80f0-43e9-89db-f6dbd3b09b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9c738a95-dc2f-4a41-b044-24815933ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_53e65dea-8db6-45a7-b547-46611fa727cd" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_9c738a95-dc2f-4a41-b044-24815933ac1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_46b72a2a-e5e9-4159-a6d7-f539147c7ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9c738a95-dc2f-4a41-b044-24815933ac1f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_46b72a2a-e5e9-4159-a6d7-f539147c7ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db42486a-304d-4a94-9cd0-5663f0be9e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9c738a95-dc2f-4a41-b044-24815933ac1f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db42486a-304d-4a94-9cd0-5663f0be9e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="apyx-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0b6ee6cf-2732-4b5c-8358-32985729aa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0b6ee6cf-2732-4b5c-8358-32985729aa9c" xlink:to="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_DebtInstrumentAxis_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5ecd9590-d09e-4cb5-b74b-b2566ab194de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a56b0480-6fc3-43ac-9e0f-47d6c1779a8a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5ecd9590-d09e-4cb5-b74b-b2566ab194de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CreditAgreementMember_f223c562-7218-4dfd-b291-528fe1fa644a" xlink:href="apyx-20221231.xsd#apyx_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5ecd9590-d09e-4cb5-b74b-b2566ab194de" xlink:to="loc_apyx_CreditAgreementMember_f223c562-7218-4dfd-b291-528fe1fa644a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_20c41020-db8d-4409-94d9-a8e111fbd914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_20c41020-db8d-4409-94d9-a8e111fbd914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2da6a80f-e19c-4528-bad8-3d7ebb4c8b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_20c41020-db8d-4409-94d9-a8e111fbd914" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2da6a80f-e19c-4528-bad8-3d7ebb4c8b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_1c2073aa-3263-4941-985b-498d3ffea951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2da6a80f-e19c-4528-bad8-3d7ebb4c8b76" xlink:to="loc_us-gaap_LineOfCreditMember_1c2073aa-3263-4941-985b-498d3ffea951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ecb98a8c-3f48-4687-ae92-d8181c6414f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ecb98a8c-3f48-4687-ae92-d8181c6414f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cbf94d07-da42-4b53-8f42-0d61c70e694c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ecb98a8c-3f48-4687-ae92-d8181c6414f6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cbf94d07-da42-4b53-8f42-0d61c70e694c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1de8b2d7-0938-40ad-afa5-b5556acfac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cbf94d07-da42-4b53-8f42-0d61c70e694c" xlink:to="loc_us-gaap_SubsequentEventMember_1de8b2d7-0938-40ad-afa5-b5556acfac8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_CreditFacilityAxis_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_08ddfde5-a9ce-42cf-a9c9-38be2842925f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2cc00de7-4c64-4fab-a61d-b3e2d16f6dac" xlink:to="loc_us-gaap_CreditFacilityDomain_08ddfde5-a9ce-42cf-a9c9-38be2842925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d575621c-ae18-4556-a461-dfbab6313d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_08ddfde5-a9ce-42cf-a9c9-38be2842925f" xlink:to="loc_us-gaap_SecuredDebtMember_d575621c-ae18-4556-a461-dfbab6313d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_7c1a48e0-fe50-4aa8-be5a-4591769bc89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_08ddfde5-a9ce-42cf-a9c9-38be2842925f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_7c1a48e0-fe50-4aa8-be5a-4591769bc89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsAxis_94e029d1-8f12-45d7-8203-68a7c9a0a330" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_apyx_DebtInstrumentCovenantsAxis_94e029d1-8f12-45d7-8203-68a7c9a0a330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsAxis_94e029d1-8f12-45d7-8203-68a7c9a0a330" xlink:to="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheOneMember_6920ed41-64c5-46ab-ad17-512c132b9630" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheOneMember_6920ed41-64c5-46ab-ad17-512c132b9630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_6b2b0f1b-e81a-4bb0-9a64-0d3b17ae6c6a" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheTwoMember_6b2b0f1b-e81a-4bb0-9a64-0d3b17ae6c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_2eac1202-02a5-4172-bc1e-2ae17e0b31e7" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentCovenantsDomain_44fb99d0-f4e5-43f6-80b2-f621456d0be5" xlink:to="loc_apyx_DebtInstrumentCovenantTrancheThreeMember_2eac1202-02a5-4172-bc1e-2ae17e0b31e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_722593fd-99da-47dd-bd0f-7ea7ec1e4d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_VariableRateAxis_722593fd-99da-47dd-bd0f-7ea7ec1e4d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7def881f-e4d0-498f-80a3-5eab00e3cb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_722593fd-99da-47dd-bd0f-7ea7ec1e4d30" xlink:to="loc_us-gaap_VariableRateDomain_7def881f-e4d0-498f-80a3-5eab00e3cb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_fa7ab2d9-506e-4aad-8c7b-d01f36dcd927" xlink:href="apyx-20221231.xsd#apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7def881f-e4d0-498f-80a3-5eab00e3cb59" xlink:to="loc_apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember_fa7ab2d9-506e-4aad-8c7b-d01f36dcd927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_70798af5-3250-4280-adbb-5f1e1422e8ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_srt_RangeAxis_70798af5-3250-4280-adbb-5f1e1422e8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dcc18b62-0345-4841-980d-d38a87cef878" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_70798af5-3250-4280-adbb-5f1e1422e8ce" xlink:to="loc_srt_RangeMember_dcc18b62-0345-4841-980d-d38a87cef878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e52b72a6-48c6-4670-bf57-f7f268c74a0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dcc18b62-0345-4841-980d-d38a87cef878" xlink:to="loc_srt_MinimumMember_e52b72a6-48c6-4670-bf57-f7f268c74a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_c1347723-b95d-41f5-896d-e08dced77f54" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_c1347723-b95d-41f5-896d-e08dced77f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodAxis_c1347723-b95d-41f5-896d-e08dced77f54" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember_7e9c616a-eaaa-4328-8a5c-89e805678a91" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodOneMember_7e9c616a-eaaa-4328-8a5c-89e805678a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember_5f3afc53-0f62-4975-8cbe-39f27f3f627c" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodTwoMember_5f3afc53-0f62-4975-8cbe-39f27f3f627c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember_4bae422c-d1b4-4c8d-a188-3d271114fd1a" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentPrepaymentPeriodDomain_d916ebb3-653c-4165-90cb-d59bccb4162a" xlink:to="loc_apyx_DebtInstrumentPrepaymentPeriodThreeMember_4bae422c-d1b4-4c8d-a188-3d271114fd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodAxis_0776d667-5f98-4c12-abd8-5253fbbd28c7" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodAxis_0776d667-5f98-4c12-abd8-5253fbbd28c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodAxis_0776d667-5f98-4c12-abd8-5253fbbd28c7" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodOneMember_efadc6bf-c272-4333-84f3-3a64332e4ade" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodOneMember_efadc6bf-c272-4333-84f3-3a64332e4ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodTwoMember_6003cb38-d063-4eb5-9827-6d59d06e4dfb" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodTwoMember_6003cb38-d063-4eb5-9827-6d59d06e4dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationPeriodThreeMember_227a71ef-0ded-4085-82e3-f0d57a6665f2" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_apyx_DebtInstrumentTerminationPeriodDomain_e120a8da-f5b0-4458-864f-1e5366987874" xlink:to="loc_apyx_DebtInstrumentTerminationPeriodThreeMember_227a71ef-0ded-4085-82e3-f0d57a6665f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_df52b278-983a-488c-8ca2-6779da345c7c" xlink:to="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_df34a9e0-cb7d-4788-92c9-490b10ab543e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_df34a9e0-cb7d-4788-92c9-490b10ab543e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d26c173c-a092-4c17-b6fe-cf2c2c4297c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d26c173c-a092-4c17-b6fe-cf2c2c4297c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ccf75bc7-d8db-4f7b-8900-05da9c447e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ccf75bc7-d8db-4f7b-8900-05da9c447e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentInterestRateFloorPercent_d17b93c9-f697-4992-a7d3-1c85f85fb822" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentInterestRateFloorPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentInterestRateFloorPercent_d17b93c9-f697-4992-a7d3-1c85f85fb822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7c2c1930-6bfb-44fa-997a-50c0f1bbb02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7c2c1930-6bfb-44fa-997a-50c0f1bbb02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPeriodOfInterestOnly_ca1a5347-481c-4ea7-91c0-12b3c7535da6" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPeriodOfInterestOnly"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentPeriodOfInterestOnly_ca1a5347-481c-4ea7-91c0-12b3c7535da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExtensionPeriod_11c77e0e-8da8-4fe4-99c7-7ec3e474d110" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentExtensionPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentExtensionPeriod_11c77e0e-8da8-4fe4-99c7-7ec3e474d110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPayments_3464161b-cf89-4131-9091-f3db6b8cba5b" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentNumberOfMonthlyPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentNumberOfMonthlyPayments_3464161b-cf89-4131-9091-f3db6b8cba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_18754a8c-402d-4de5-aaa4-460015dc45bc" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension_18754a8c-402d-4de5-aaa4-460015dc45bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentPrepaymentFeePercent_9c4d25b0-b16a-441f-b775-5002891c424c" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentPrepaymentFeePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentPrepaymentFeePercent_9c4d25b0-b16a-441f-b775-5002891c424c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentExitFee_24d4e7c5-7bbc-40f7-9dac-bfe7c9cdcd03" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentExitFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentExitFee_24d4e7c5-7bbc-40f7-9dac-bfe7c9cdcd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentAnnualFeePercent_96a9f8aa-7dc5-4cf3-be72-b8db4943994b" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentAnnualFeePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentAnnualFeePercent_96a9f8aa-7dc5-4cf3-be72-b8db4943994b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentTerminationFees_f20e514d-8b3e-4a2d-a27a-8eb414845852" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentTerminationFees"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentTerminationFees_f20e514d-8b3e-4a2d-a27a-8eb414845852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_d153907c-f275-46d9-b8ac-86bb10718e18" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent_d153907c-f275-46d9-b8ac-86bb10718e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_8f9224c1-ce09-40ef-abc7-7e0fe7fc5b57" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount_8f9224c1-ce09-40ef-abc7-7e0fe7fc5b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_ba2b4d7b-480f-4267-a7f3-2fa28714ce15" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne_ba2b4d7b-480f-4267-a7f3-2fa28714ce15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_34e236a4-2c38-453f-bfc1-623d9a90e127" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo_34e236a4-2c38-453f-bfc1-623d9a90e127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_64ef78a7-1b6e-432e-981f-3a5c3804bad3" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree_64ef78a7-1b6e-432e-981f-3a5c3804bad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_d7c595ea-de85-4c19-9df9-55389beba770" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance_d7c595ea-de85-4c19-9df9-55389beba770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_DebtInstrumentDefaultApplicableInterestRate_90c4ab20-6bad-4af4-8810-b360f11cf145" xlink:href="apyx-20221231.xsd#apyx_DebtInstrumentDefaultApplicableInterestRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_DebtInstrumentDefaultApplicableInterestRate_90c4ab20-6bad-4af4-8810-b360f11cf145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_708e0817-d4cc-45e9-a25a-ed43587793dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_708e0817-d4cc-45e9-a25a-ed43587793dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_073405fb-a073-4d92-897f-c82f64d5e5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_073405fb-a073-4d92-897f-c82f64d5e5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f05343de-a5d1-481e-80c9-551f8a0d851b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f05343de-a5d1-481e-80c9-551f8a0d851b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackPurchaseAgreement_f9ec013c-1237-4f8c-893b-59e1cdc4c4a4" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackPurchaseAgreement"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackPurchaseAgreement_f9ec013c-1237-4f8c-893b-59e1cdc4c4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackDueDiligencePeriod_8861bfe2-73ff-4e0f-b59d-cbd2a63522ea" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackDueDiligencePeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackDueDiligencePeriod_8861bfe2-73ff-4e0f-b59d-cbd2a63522ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence_837ef57e-559c-4657-8c65-84cb8895e3bf" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackCompletionPeriodAfterDueDiligence"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence_837ef57e-559c-4657-8c65-84cb8895e3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackEscrow_4a0e9612-6ae9-42f3-be5b-47a8a7e6c175" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackEscrow"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackEscrow_4a0e9612-6ae9-42f3-be5b-47a8a7e6c175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackTermOfLease_e38861a1-360f-49fe-8a4b-919071dbcdd7" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackTermOfLease"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackTermOfLease_e38861a1-360f-49fe-8a4b-919071dbcdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackRenewalTerm_3919d666-552d-4553-8c14-89f321b3a8fb" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackRenewalTerm"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackRenewalTerm_3919d666-552d-4553-8c14-89f321b3a8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentPayment_6af45213-8774-4bd1-a8a4-bb7465bd1f5d" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackAnnualRentPayment"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackAnnualRentPayment_6af45213-8774-4bd1-a8a4-bb7465bd1f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackAnnualRentIncrease_1d0dddcd-f512-411a-86e2-603b73023ae3" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackAnnualRentIncrease"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackAnnualRentIncrease_1d0dddcd-f512-411a-86e2-603b73023ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackManagementFeeOnRentPayment_e25cf0f4-8c63-4978-b642-b75da3b1e73b" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackManagementFeeOnRentPayment"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackManagementFeeOnRentPayment_e25cf0f4-8c63-4978-b642-b75da3b1e73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SaleLeasebackNetCashProceeds_7ce3ea11-84c9-4743-a03f-8985aedc6572" xlink:href="apyx-20221231.xsd#apyx_SaleLeasebackNetCashProceeds"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c48b24f-4ddc-4b40-bdc4-780c2054d41b" xlink:to="loc_apyx_SaleLeasebackNetCashProceeds_7ce3ea11-84c9-4743-a03f-8985aedc6572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>apyx-20221231_g1.jpg
<TEXT>
begin 644 apyx-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *0 _(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "L;Q5XNTGP5I$NI:S>)9VB< MRSMV5
M5'+'V%/\4^)K#P=X?O=8U*3RK.U3>Y')8YP% [DD@#W-?"'Q(^(^J_$OQ!)J
M.H2,D"DBVLU8F.W3T'N<#+=_R ^7SO.X93348J]26R_5^7YGU>0Y%/.*CE)\
MM..[[^2\_P CU#QW^UEK>JS20>&+=-'L^@N9T66X;WP<JOTPWUKR#5_'7B+7
MG9M1UW4;S/\ #-<N5'?@9P/PK#HK\>Q69XS&R<J]1ORV7W;'[1A,KP6!BHT*
M27GN_O>I=@US4;6020ZA=0R#H\<S C\0:[KPK^T%XX\*R)MUB35+<'FWU+,X
M/_ B=X_!J\XHKFHXO$8>7-1J.+\F=5?!X;$QY*U-27FD?;/PL_:%T+XB216%
MPO\ 8^MMPMK,^4F/_3-^,G_9.#Z9ZUZO7YHQR-%(KHQ1U.593@@CN*^O/V<O
MC2_C2R_X1[6I]^MVL>Z&>0_-=1#U]77C/J.>Q-?J.0\2/&36%Q?QO9]_)^?Y
M_G^4<0<,K!0>+P?P+==O->7XKTV]RHHHK]!/SD**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLWQ%KEMX9T
M&_U:\?;;6<+3/[@#.![GH/<U,I*$7*3LD5&,IR48J[9\S_M;>/#?:U9>%;67
M]Q9J+F[53UE8?(I_W4.?^VGM7SS6AXAURY\3:Y?ZK>-NNKR9II/0%CG ]AT'
MTK/K^=\SQLLPQ<\0]F]/3I^!_265X&.78.GAENEKYOK^(4445YAZ@4444 %:
M7AO7[OPKKUAJ]BYCNK.994.>N#R#[$9!]B:S:*J,I0DI1=FB91C.+A)73/T>
M\.ZY;>)M!L-6LWW6UY"LR>P(S@^XZ'W%:5?/'[(_CK[=HM_X6N),S6)-U:@]
M3$Q^=1_NN0?^VE?0]?T/EF,6882GB%NUKZ]?Q/YNS3 RR[&5,,]D]/1[?@%%
M%%>H>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?/'[7'CK[#HMAX6MY,37Q%U= =1$I^13_ +S@G_MG7T'/,EM#
M)-*ZQQ1J7=V. H R2:_/OXF>,I/'WCC5=:8MY,TNV!6_AA7Y4&.W !/N37Q?
M%6/^JX+V$7[U33Y=?\OF?<<)9?\ 6\=[>:]VGK\^G^?R.7HHHK\6/W ***.M
M !174^/_ (>ZE\.[W3[;45PUY917:\$;2P^9#_M*P(/X>M<M6M6E.A-TZBLU
MT,J5:G7@JE)WB^H4445D:G4?#/QE)X!\<:5K2EO)AEVSJO\ %"WRN,=^"2/<
M"OT$@F2YACFB=9(I%#HZG(8$9!%?FG7V=^S#XZ_X2KX?IIL\N^^T9A;,">3"
M<F(_D"O_  "OT?@_'\E6>"F]):KU6_WK\C\TXTR_VE*&.@M8Z/T>WW/\SV*B
MBBOU8_(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ&X
MNH;*!YKB6."%!EI)&"JH]23TKS/Q/^TEX&\-EXTU)]8N%_Y9Z;'Y@_[[.$/X
M$UR8C%X?"1YJ\U'U9V8;!XG&2Y</3<GY(]2HKY:\0?MBZA(S+HGA^WMUZ"2^
ME:4GWVKMQ^9KS_6/VC?'^K[A_;?V*,_\L[.!(\?\"QN_6OF*_%F74M(-S]%_
MG8^KP_"&9UM9J,/5_P"5S[EJ*:XBMU#2RI$I. 78#^=?GCJ'CSQ+JV?MOB#5
M+H'M->2,._8GW/YUB22/,Y=V9W/5F.2:\:IQI#_EW0OZRM^C/:I\#S?\3$)>
MD;_JC]&V\3:0K%6U6Q# X(-RF1^M'_"4:-_T%K'_ ,"4_P :_.*BN;_72I_S
MX7_@7_ .C_4>G_T$/_P'_@GZ0PZYIMUGR=0M9L<'RYE;'Y&K]?F?5JSU6]TT
MYM+RXM3ZPRLG\C6L.-/YZ'_DW_ ,Y<#_ ,F(^^/_ -L?I-17Y_Z7\8/&VC$?
M9O$^I8'19YS,H_!\BNWT/]J_QKIK*+X6&KI_$9X/+?\  QE0/R->I1XPP,]*
MD)1^YK\[_@>36X+Q]/6E.,OO3_*WXGV317@'AO\ :_T*^98]:TB[TMSP9+=A
M<1CW/W6'X UZYX6^(?AOQJ@;1=8M;Y\9,*OME ]T;##\J^FPN:8+&Z4*J;[;
M/[GJ?+8O*<=@=<12:7?=?>KHZ.BBBO5/)"BBB@ HHJ.:(3PR1DLH=2I9&*L,
MCL1R#[T@)**^#_&GBCQQX-\5ZIHMQXLU[S+.=HPQU&;YUZJWWNZE3^-8O_"S
M_&7_ $-NN?\ @RF_^*K\_J<84:<W"=&2:=GJNA^C4^"ZU6"J0KQ::NM'U/T*
MHK\]?^%G^,O^AMUS_P &4W_Q5*GQ1\91L&'BS7"0<_-J,Q'Y%JC_ %SP_P#S
MY?WHT_U(Q/\ S^C]S/T)HKXX\ ?M1>)?#MY%%KTG]O:82 ^]56XC'JK@#<?9
MNO3(KZVT'7K'Q-H]KJFF7"W5C<IOCE7N/0CL0<@@]",5]1EF<87-(OV+M);I
M[_\ #'R>:9+BLIDO;J\7LUM_P&:-%%%>X>"%%%% !1110 4444 %%%% !111
M0 4444 %%%% !17(?$KXE:7\,= .HZAF::0E+:TC(#SOCH/0#C+=L]S@'Y+\
M5?M%>-_$UU(T6J-H]J3\EOI_[O:/=_O$_C^ KYS,\^PF5R]G4O*?9?KV/ILJ
MX?QF;1]I3M&'=_IW/N.BOSU_X6?XR_Z&W7/_  93?_%4?\+/\9?]#;KG_@RF
M_P#BJ^=_USP__/E_>CZ3_4C$?\_H_<S]"J*_/7_A9_C+_H;=<_\ !E-_\57O
M7[*\_B3Q1J&K:UJ^NZIJ&GVJ"UBANKR22-I6PS'#,1E5 _[[KT,!Q-3S#$1P
MU.D[OS6AYV8<*U,NPTL34K)J/2SU/I"BBO%/VD/#_B6+1E\2>&M;U6R-FF+V
MSL[R6-&B_P">H56QE>_'3G^&OI\;B982A*O&#ERZV6]O^ ?*X'#1QF(C0E-0
MYM+O:_3[SVNBOSU_X6?XR_Z&W7/_  93?_%4?\+/\9?]#;KG_@RF_P#BJ^(_
MUSP__/E_>C[O_4C$?\_H_<S]"J*_/7_A9_C+_H;=<_\ !E-_\51_PM#QE_T-
MNN?^#&;_ .*H_P!<\/\ \^7]Z#_4C$?\_H_<S]"J*^)_!O[2OC'PQ=Q_;KS^
MWK'(WV][C?C_ &9 -P/UR/:OK?P+XXTOXA>'8-8TJ0M!(2KQR8$D+CJC#L1Q
M]001P:^ERS/,+FEXTKJ2Z/?Y=SY?-<AQ>4VE62<7U6WH^QT-%%%?0'SH4444
M %%%% !1110 4444 %%%% !117C?QL_: M_AO*VCZ5#'?Z^R!G\P_NK8$9&X
M#DL1R%XX()/0'BQF,HX&DZ]>5HK^K([L'@J^85E0P\;R?]7?D>R45\"ZQ\;/
M'.M3M+/XFU" DY"V<QMU'L!'BL__ (6?XR_Z&W7/_!E-_P#%5\5+C/#7]VE)
MKY'W4>",4U[U:*?S/T*HK\]?^%G^,O\ H;=<_P#!E-_\51_PL_QE_P!#;KG_
M (,IO_BJC_7/#_\ /E_>BO\ 4C$?\_H_<S]"J*_/W3_'WCK5KZWLK3Q-K]Q=
M7$BQ11)J,Q9V)P /F]:^V_AWX9O_  IX5M+'5-4N]8U(CS;FZN[AYCYA RJE
MCD*,8 ]L]2:]_*<[6;3DJ=)I1W;?X'SV<9$\GA%U*JE*6R2U]3IZ**^:/&WP
MI\>>#?"NI:V_Q.U>Z6RB,IA6XG4OR!C/FG'6O3QV+JX.'/"DYK5NS2M;U_3L
M>7E^#I8V?LZE90=TE=-W;]/U[GTO17R_\._AOX[^('@[3]?C^)>KV27GF8@:
MXG<KLD9.OFCKMST[UT?[3FMZUX2\'^&4T_6;ZSN?-,4UQ:W#Q--B,<L5.3SS
MS7G+.)K!RQM2@XP236JU3]/U/2>2PEC88&E74IMM/1KE:[WW^1[[17$?!WQX
MOQ$\!V&ILP-]&/L]XH[3*!D_\"&&_P"!5YS^U'\4KOPQ9V'A_1K^:QU*Y/VF
MXGM93')'$"0JAE.1N;/X+[UVXC-*&'P7UYN\6DUYWV1PX;*L1B,=]02M--I^
M5MW_ %N>^T5\T>'?%FN3>']+DDUK4))'M8F9FNG))*#))SUHKBCG=.45+D>I
MWRR&I&3CSK0^EZ***^D/EPHHHH **** "BBB@ HHHH **** /'?VGO'7_"*_
M#]]-@EV7VLL;90#R(1@RG\B%_P"!U\8UZ5^T%XX_X3?XCWS0R^9I^G_Z%;;3
MP0I.]O?+;N?0+7FM?@W$&/\ K^/G*+]V/NKY=?FS^@N'<O\ [/R^$9+WI>\_
MGLODK?,****^;/I@KTG]GWP-_P )Q\1K%9H_,T_3_P#3;G(X(4C8OOEMO'H&
MKS:OL_\ 9A\#?\(K\/TU*>+9?:RPN&)'(A'$0_(EO^!U])P_@?K^/A&2]V/O
M/Y=/F_P/F>(LP_L_+YRB_>E[J^>[^2_$/VGO W_"5?#]]2@BWWVC,;A2!R83
MQ*/R ;_@%?&%?I7/!'=020RHLL4BE'1AD,I&""/3%?GY\3/!LG@'QQJNBN#Y
M4,NZW8\[H6^9#GN=I /N#7T?&& Y*L,;!:2T?JMOO7Y'S7!>8>TI3P,WK'5>
MCW^Y_F<O1117YP?I85Z5^S[XX_X0CXCV+32^7I^H?Z%<[CP Q&QO;#;>?0M7
MFM'2NK"XB>$KPKT]XNYRXK#0QE">'J;25C],**X/X)^./^$^^'NFW\L@DOH1
M]EN_7S4 &X_[PVM_P*N\K^B\/7AB:4:U/:23^\_FG$4)X6M.A46L6T_D%%%%
M=!SA1110 4444 %%%% !1110 4444 %%%% !117FWQ9^-VC_  OMS;G&H:Y(
MN8K"-L;<]&D/\*^W4]O4<V(Q-'"4W6KRY8HZL-A:V,JJC0CS29W>L:U8>']/
MEOM2O(;&TB&7FG<*H]LGO[=Z^?/B!^UM!;M+9^$K(73#C^T;P$)]4CX)^K$?
M0UX-XY^(VN_$34C=ZS>-*%),5LGRPPCT5>WUZGN37,U^59GQ97K-T\$N2/?[
M3_R_/S/UO*^$,/ATJF.?/+M]E?Y_EY&]XJ\>>(/&USYVMZK<7_.Y8W;$:'_9
M085?P%8-%%?"5*DZLG.HVV^KU/OZ=.%&*A3BDET6B"BBBLS0**** "BBB@ H
MHHH **** "GPS/;R+)$[1R*<JZ'!!]0:910!ZUX%_:6\6^$6C@OIQX@L%/,=
MZQ,H'^S+U_[ZW?2OI;X=?&[PS\2%6&RN39ZGC)T^[PLGOMYPX^G/J!7P?3HY
M'AD61&9)%(974X((Y!!KZO+N),;@6HS?/#L_T>_YKR/DLRX9P.8)RA'V<^ZV
M^:V?X/S/TNHKY0^$?[4%YH[P:7XN>2_L.%34L%IH>WS_ -]??[W7[W2OJ?3[
M^VU2SAN[.>.ZM9E#QS0L&1U/0@CK7ZWEN:8;-*?/0>JW3W7]=S\=S/*<5E53
MDKK1[-;/^NQ8HHHKUSQCY?\ VO/!/DWFE^*;>/Y)A]BNB.FX9:-OQ&X?\!6O
MF^OT*^)'@^/QWX)U;17"^9<0DPNW195^9#_WT!GVS7Y\30R6TTD,J-'+&Q1T
M88*D'!!K\8XKP/U;&^WBO=J:_-;_ */YG[?PCC_K6!^KR?O4]/D]OU7R&444
M5\2?<A7TA^R'XX:.\U/PK<RDQR+]LM%8]&&!(H^HVG'^RWK7S?6UX+\33^#?
M%6EZU;@F2RG60J.-Z]&7\5)'XUZV58UY?C*=?HGKZ/<\C-L"LQP53#]6M/5;
M'Z+456T^^@U2QMKVVD$MM<Q+-%(.C(P!4_B"*LU_0R:DKH_F]IQ=F%%%%,04
M444 %%%% !1110 4444 %%%% !117&?%[QH/ 7P_U;54<)=^7Y-KZF9^%(]<
M<M]%-85ZT,/2E6J;13;^1O0HSQ%6-&FM9-)?,^3_ -H;QP?&GQ(OEBEWZ?II
M-E;@?=^4_.WXOGGN M>94I)8DDY)Y.:2OYSQ6(GBZ\Z]3>3N?TOA<-#!T(8>
MGM%6_P"#\PHHHKE.H4 L0 ,D\#%??OPD\&#P'\/])TID"W2Q^==>IF?YF'OC
M.WZ**^3?V>/!?_"9?$RP,J;K+3O].GXX.PC8OXN5X] :^Y*_4N#L#:-3&R6_
MNK]?T^YGY1QKC^:5/ P>WO/\E^OWH*9)&DT;QR(KQL"K*PR"#U!%/HK]+/RX
M^'OCU\*7^&OBDRV<;?V%?DR6C=1$>K1$^W;U!'4@UYA7Z&^/_!%C\0O"UYHM
M^-J2C=%,!EH9!G:X^A_,$CO7P-XF\.7WA'7KW2-2B\F\M9#&X['T8>H(P0>X
M-?B/$>4?V?7]K27[N>WD^W^7_ /W;AG.?[2P_L:K_>PW\UW_ ,_/U,NBBBOD
M#[(*](^!OQ4D^&?BI#<NQT2](BO(QSM_NR@>JY_$$CTKS>BNG#8FIA*T:])V
ME$Y<5AJ6,HRH5E>,E8_2R">.ZACFA=98I%#I(IR&4C((/IBI*^;OV6_BX;F)
M?!NJS9EC!;3I7/WE')A_#DK[9'85](U_0.6X^GF6&CB*?7==GU1_.V9Y?5RS
M$RP]7IL^ZZ/^NH4445Z9Y04444 %%%% !1110 4456U#4+;2K&XO+N9+>UMX
MVEEFD.%10,DG\*3:BKL:3D[(Y+XM?$BV^&/A&?4I-LM_+F*RMV_Y:2D<$_[*
M]3],=2*^#M2U*YU?4+F^O)FN+NXD:665SDLQ.2:Z_P",'Q+N/B=XNFOR7CTV
M',-E;L?N1Y^\1_>8\G\!V%</7X9Q!FSS/$VIO]W'1>?=_/IY'[YP[DZRO#<U
M1?O)ZOR[+Y=?/Y!1117RQ]6%%%>E_ GX5O\ $OQ4IND8:'8E9+Q^F_\ NQ#W
M;'/H ?:NG"X:IC*T:%)7E(Y<5B:6#HRQ%9VC%7/6/V6_A+]AME\9:K#_ *1,
MI73HW'W(SP9?JW0>V3W%?1M1QQI!&D<:+'&@"JBC 4#@ #M4E?T%EV!IY=AH
MX>GTW?=]6?SKF685<SQ,L15Z[+LNB_KJ%<-\</\ DDOB?_KT/\Q7<UPWQP_Y
M)+XG_P"O0_S%7C_]TK?X9?DS/+O]]H_XH_FC,_9M_P"2*^'?^WG_ -*9:X[]
MK0!M+\)@C(.HG(_X"*[']FW_ )(KX=_[>?\ TIEKC_VM/^0;X2_[")_]!%?-
MXK_DG8_X(?\ MI]1A/\ DI9?]?*G_MQC:+?0_L\?&35-,O','A+6HC=0/_#$
M1N90/H=T>.I!0FN(U32[GQYX)^(/Q*U6(AII8;;3XVY\M?M$0)'^ZFU >^7K
MZ9^)7PIT7XIV-G;ZLUS ;60R13VC*L@R,,N65A@X!Z?PBN2^-7AVR\(_L[ZI
MH^G(R6=G':Q1[B"S?Z3$2QQW)R3QU)KBQF4UJ=*O&37L(1G*"\W';TCJUZG;
M@<WHU:M"44_K%25.,W_=4EKZR5D_0\T\+_\ (M:3_P!>D/\ Z **/"__ "+6
MD_\ 7I#_ .@"BO-I?PX^B/6K?Q)>K/JNBBBOU(_) HHHH **** "BBB@ HHH
MH *X+XV>.?\ A ?AYJ-_%)LOIQ]EM.>?-<$9'^Z-S?\  :[VOC[]JSQS_;_C
M2'0K>3=9Z0F)-IX:=P"W_?(VCV.ZOG\^QW]GX&=2+]YZ+U?^2U/H^'\O_M''
MPIR7NQ]Y^B_S=D>(=:***_ C^A0HHHH ZCX9^#9/'WCC2M%0'RII=UPPXVPK
M\SG/8[00/<BOT#@@CM8(X8D6**-0B(HP%4#  'IBOGW]D;P/]AT74/%-Q'B:
M])M;4D=(E.78>Q8 ?]LZ^AZ_:>%<#]5P7MI+WJFORZ?Y_,_#^+<P^MX[V$7[
MM/3Y]?\ +Y!7SQ^USX'^W:+I_BFWCS-9$6MT0.L3'*,?8,2/^VE?0]9OB/0K
M;Q-H-_I-XNZVO(6A?U (QD>XZCW%?09G@UF&$J8=[M:>O3\3YS*\=++L93Q*
MV3U]'O\ @?G#16AX@T.Y\-:Y?Z5>+MNK.9X)/0E3C(]CU!]#6?7\\2BX2<9*
MS1_2,9*<5*+NF%%%%24>W_LI^.?[ \:3:%<2;;/5TQ'N/"SH"5_[Z&X>YVU]
M@U^:^GWT^EW]M>6LAAN;>198I%ZJRG(/YBOT*\#>*H/&WA/2];M\!+N$.R*?
MN..'7\&!'X5^M<(8_P!I0E@YO6&J]'O]S_,_'^,\O]E7AC8+2>C]5M]Z_(WJ
M***_0S\W"BBB@ HHHH **** "BBB@ HHHH ***X+XR?$Z#X7^$I+P;9-3N28
M;&!OXGQRQ']U1R?P'>N?$5Z>%I2K57:,=6=&'P]3%5HT**O*3LCFOCM\=(OA
MU:G2=(:.X\13+SGYEM$(X=AW8\84_4\8!^.+Z^N-2O)KN[GDN;F9B\DTK%F=
MCU))ZT[4M2NM8U"XOKV=[F[N',DLTARSL3DDU6K\'S;-JV:UN>>D%LNW_![G
M]!9/D]'**')#6;^)]_\ @=@HHHKPCW@HHHH ***LZ?IMYJURMO8VL][<-TAM
MXS(Y_ #--)R=D)M15V]"M17HNC_L]^/M:4/'H$MK&?XKV1(<?\!8[OTKK]/_
M &0O%=P UWJ>DV@]%DDD8?AL _6O7I9/F%;6%"7W6_.QX];.LNH:3KQ^^_Y7
M/"Z*^C8/V-;UMGG>*((^?F\NS9L?3+C-6)/V,G6,F/Q<K/V#:=@?GYIKM7#>
M:M7]C^,?\S@?$^4)V]O_ .2R_P CYJHKZ&NOV.=70?Z-XBLICC_EM \?.?8M
M7-ZI^RGXYL%)@33]2Q_#;76TG_OX%K"ID.9TU>5!_+7\KG13X@RNKI&NOGI^
M=CQVBNG\0?#'Q9X75GU/P_?VT2]9A"7C'U=<K^M<Q7C5*-2C+EJ1<7YJQ[=.
MM3K1YJ4E)>3N%%%%9&H4444 %>F_!GXVZA\,=06VG,EYX>F?,]IG)C)ZR1^A
M]1T/Y$>945U87%5<'55:A*TD<N*PM'&TI4*\;Q?]?>?I'H^KVFO:7;:CI]PE
MU9W*"2*:,\,I_P ].U7:^-OV=?C$W@?6ET/5)_\ B0W\@"LYXM93P']E/ ;T
MX/8Y^R:_>,HS2GFN'56.DEI)=G_D^A_/^<Y54RG$NE+6+UB^Z_S74*^*OVFO
M!/\ PBOQ&FO88]ECK"_:T(& ),XE'UW8;_@8K[5KR?\ :4\%?\)9\-[JYAC#
M7NDG[9&<<F,#]XO_ 'S\WU05Q\18'Z[@)\J]Z'O+Y;_@=G#6/^HYC#F?NS]U
M_/;\;?*Y\3T445^$G[\%%%% 'V+^ROXU_P"$@\!OH\\FZ[T>3RU!/)A;)0_@
M=R_0"O:Z^&/V??&W_"%_$K3WE?98ZA_H-QD\ .1M;\'"\^F:^YZ_<N&<=]<P
M$8R?O0]U_I^&GR/P;BC ?4LPE**]VI[R]>OXZ_,****^K/D HHHH **** "B
MBB@ HHHH **** "OE']KGQM_:'B#3_#-O)F'3T^T7('0S./E!_W4Y_[:&OJ#
M6M6MM T>]U*\?R[6TA:>5O15&3CWXK\[_$NO7/BCQ!J.KW9S<7L[3.,Y"Y.0
MH]@, >PKX+B['>QPL<+%ZS>OHO\ -V_$_0N#<![?%RQ<EI36GJ_\E?\  S:*
M**_'S]F"BBMOP5X8G\9^*]+T2WR)+R=8RP_@3J[?@H)_"KITY59J$%=MV7S(
MJ5(TH.I-V25WZ(^K/V5_!9\.^ 7U:9-MWK$GFC(Y$*Y$8_'YV^C"O::KV-C#
MIMC;V=L@BM[>-8HD'154  ?D*L5_1F!PL<%AJ>'C]E?CU?S9_-./Q<L=BJF)
ME]I_AT7R04445W' %>*?M)?"3_A--!_M[3(=VMZ=&=Z(,M<0#DK[LO)'XCN*
M]KHKAQN#I8^A+#U5H_P\_D=^!QM7+\1'$47K'\5U3]3\SZ*]I_:2^$O_  A>
MO?V[ID&W1-1<ED1?EMYCR5]E;DC\1V%>+5_/N-P=7 UY8>JM5^/G\S^B\#C*
M688>.)HO27X=T_0****XCN)K*\GTZ\@N[65H+F!UEBE0X9&!R"#Z@BONSX-?
M$^#XG^$X[MBL>JVV(KZ!?X7QPX']UNH_$=J^#:Z_X6_$2[^&GBVVU6#=);-^
MZN[<'B6(GD?4=0?4>F:^FR'-GE>)]]_NY:2_S^7Y'R_$&3K-L-[B_>1UC_E\
M_P S] :*I:/K%IK^EVNHV$RW%G=1B6*1>A4C]#[=JNU^ZQDI)2B[IGX#*+BW
M&2LT%%%%42%%%% !1110 5\N?M2?%HWEPW@W2IOW$)#:E(A^^XY6+Z#@GWP.
MQKUKXY?%2/X9^%&:W=3K=\&BLXSSM_O2$>BY_$D>]?#<TTEQ,\LKM)*[%G=C
MDL2<DD^M?G7%6;^RA]0HOWG\7DNWSZ^7J?I?"63>VG_:%=>['X?-]_ET\_09
M1117Y.?KH4444 :7ASP_?>*M<L])TZ(S7MW((XU[>Y)[ #))[ &OOCX>>!;'
MX=^%;31K$;O+&^:;&#-*?O.?Z>@ ':O-?V:/A+_PB.A_\)%J<.W6-2C'E1N.
M;> X('LS<$^@P..:]PK]EX9RCZG1^M5E^\G^"_S?4_$^*LY^O5_JE%_NX/7S
M?^2V7S"BBBON#X,*KWUA;:I:RVMY;Q7=M*NV2&= Z./0J>"*L44FDU9C3<7=
M%33=+L]&LXK/3[2"QM(\[+>VC6.-<DDX50 ,DD_4U#JWA_2]?6)=4TVSU)86
MWQK=P)*$;U7<#@_2M&BH]G%QY&M.W0I5)J7.GKWZA534M+L]9LY;/4+2"^M)
M,;[>YC62-L$$95@0<$ _45;HJY14E9[$QDXM-.S1DQ>$]#AC2./1=/CC0!51
M;5 % Z #'2BM:BL_94_Y5]QK[:I_,_O"BBBM3$**** "BBB@ HHHH **** ,
M'QSXJ@\$^$]4UNXP4M(2ZHQ^^YX1?Q8@?C7YZZA?3ZI?W-Y=2&:YN)&EED;J
MS,<D_F:^C/VO/'&Z33/"EM)D+_IMWM/?D1J?PW,1[J:^:Z_&>+,?]8QBP\7[
MM/\ -[_=HOO/VWA#+_JN#>)FO>J?DMOOU?W!1117Q!]V%:'A_0[GQ+KEAI5F
MNZZO)D@C] 6.,GV'4GT%9]?0?[(_@;[?KE_XHN(\PV*FVM6;_GLP^=A]$./^
MVE>GEF#EF&+IX==7KZ=?P/+S3'1R[!U,2]TM/7I^)]-^'-"MO#.@V&DV:[;:
MSA6%/4@#&3[GJ?<UI445_1$8J$5&*LD?S;*4IR<Y.[844451)\I?M<>!OL&N
M6'BBWCQ#?*+:Z9?^>RCY&/U08_[9U\^5^@OQ/\&Q^/O ^JZ,54SS1;[=F_AF
M7E#GMR,'V)K\_9H7MYGBE0QR1L596&""#@@_C7XKQ5@?JN-]M%>[4U^?7_/Y
MG[CPEF'UO ^PD_>IZ?+I_E\AE%%%?&'VX5]*?LA^.-LFI^%+F3 ;_3;3<>_
MD4?AM8#V8U\UUL^#?$]QX,\5:9K=KS+9S+)MSC>O1E^A4D?C7K93C7E^,IU^
MB>OH]SQ\WP*S+!5,/U:T]5M_78_1>BJNEZE;ZQIMK?VD@EM;J)9HI!_$K $'
M\C5JOZ&34E=;'\X23BVGN%%%%,04444 %%%% !1110 4444 ,=UC1G=@JJ,E
MF. !ZU\&_&CXB/\ $CQQ=WZ.W]FP?Z/9(>,1@_>QZL<M^(':OJ']I#QDWA+X
M9WD<+[+S5&%C$1U"L"9#_P!\!A]6%?$=?EO&&8-RA@8/3>7Z+]?N/UC@O+TH
MSQ\UJ_=C^K_3[PHHHK\T/U **** "NQ^'_PF\2?$BXQI-GMM%;;)?7!*0)_P
M+')]E!/->H? W]G,^(X;?Q!XIC>+3&P]MI_*M<#L[GJ$/8=3UX'7ZHL[*WTZ
MUBM;2".VMHE"1PPH%1%'0 #H*^]R?A>>+BJ^+?+![+J_\E^)^?9UQ73P<GA\
M&E*:W?1?YO\ #U/%O!7[*?AK0E2;7)9=?NQR4;,4 _X"#D_B<''2O8=)T/3M
M!M!;:98VVGVX_P"65K$L:_7 %7Z*_4,+E^%P,>7#TU'\_OW/RG&9CB\?+FQ-
M1R_+[M@HHHKT#S@HHHH **** "N,\6?"'PCXU$C:GHEN;A^MU;CRIL^I9<$_
M\"R*[.BL*U"EB(\E:*DNS5S>C7JX>7/1DXONG8^4?'W[)>I:6DMWX6O?[5@7
M+?8KK"3@>BMPKG_OG\:\$OK"YTN\EM+RWEM;J)MLD,R%'0^A!Z5^E-<5\2?A
M-H7Q.T\Q:C (;Y%Q!J$(Q+$>P/\ >7_9/'I@\U\%F?"=*HG4P+Y9?RO9^G;\
MO0_0LJXPK4FJ6/7-'^9;KU77\_4^!**ZCXA_#O5OAKKSZ9JD>0?F@N8P?+G3
M^\I_F.H_*N7K\KJTIT)NG55I+='ZU2JTZ]-5:4KQ>S"BBBLC4*^SOV:?B4?&
MG@_^R[V7?JND!8F9C\TL.,1O[D8*GZ GK7QC7=_!+QLW@3XC:7?.^RSG;[)=
M<X'E.0,GV5MK?\!KZ+(<P>7XV,F_<EI+T?7Y;GS?$&6K,L#.*7OQUCZKI\UI
M]Q]ZTR2-9HWC=0Z,"K*PR"#U%/HK][/Y[/SX^)W@U_ ?CG5M&*L(89=UNS?Q
M0M\R'/?@@'W!KEJ^I/VO/!/VG3-,\46\>9+9OL=R0/\ EFQ)1C[!LC_@8KY;
MK^?,YP/]GXVI17P[KT>WW;?(_HS)<?\ VC@*==OWMGZK?[]_F%%%%>*>X*"5
M((.".1BOOKX.^-!X\^'NE:F[[[M8_L]USD^<G#$_[W#?1A7P)7O_ .R/XT_L
MWQ)?^&IY,0:@GGVX)Z3(.0/JF3_P 5]CPMCOJN.5*3]VII\^G^7S/B^+,#];
MP#JQ7O4]?EU_S^1]8T445^V'X6%%%% !1110 4444 %%%% !1110!X/^UEXV
M_L?PA:>'X),7&JR;IL'D0QD''MEMOX*PKY'KO/C=XV_X3KXC:G?1/YEE WV2
MU.<@QH2-P]F;<W_ JX.OP+/<=]?Q\ZB?NK1>B_S=W\S^A\@P']GY?3IR7O/W
MGZO_ "5E\@HHHKY\^A"OH_\ 9#\%^=?:IXIN$^2$?8K4D<;B TC?@-H_X$:^
M<HHGFD2.-2\CD*JJ,DD] *_0;X9^#T\">!])T90/-MX09V'.Z5OF<Y]-Q./8
M"OM>%,#]9QOMY+W:>OS>WZOY'P_%V.^JX'V$7[U33Y+?]%\SJ****_:#\/"B
MBB@ HHHH RO$WANQ\7:#>Z1J,7FV=U&4<=QW##T(."#ZBO@;Q]X(OOA[XHO-
M&OAN>$[HI@,+-&?NN/K^A!':OT.KR[X]_"E?B3X6,MG&/[=T]6DM6[RCJT1^
MN./0@=,FOC^(\H_M&A[6DOWD-O-=O\O^"?9\,YS_ &;B/8U7^ZGOY/H_T?EZ
M'Q!13I(WAD9'5DD4E61A@@CJ"*;7XD?NH4444 >^?LP_%S_A']47PIJL^--O
M9,V<CGB&8G[GLKG_ ,>^IKZTK\T%8HP8$A@<@CM7VI^SW\6A\0O#?]GZA+G7
MM.0+-NZSQ]%E^O0-[\]Z_4^%<XYU]0KO5?#Z=OET\C\GXNR7D?\ :-!:/XEY
M]_GU\_4];HHHK]*/R\**** "L[Q!KUEX7T6\U749A!96L9DD<^GH/4DX '<D
M5HU\A_M-?%K_ (2G6CX9TR;.DZ?)_I$B'B><<$>ZIR/<Y/8&O%S?,H97AG6?
MQ/2*[O\ R74]S)LKGFV*5&.D5K)]E_F]D>9?$;QY>_$;Q5=ZS>917.R"WW9$
M,0^Z@_F?4DFN8HHK\!JU9UZDJM1WD]6S^AZ5*%"G&E35HQ5D@HHHK(U"O9?V
M;_A+_P )QX@_MK4H=VB:;(#L8<7$PY">ZC@G\!W./.O O@N_\?\ BBST73U_
M>SMEY"/EBC'WG;V _,X'>OOGPKX8L/!OA^RT?38_+M+5-B_WF/4L?<G)/N:^
MVX9RCZ]6^LUE^[A^+[?+=_<?#<49S]0H?5J+_>3_  7?U>R^;->BBBOV<_$
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MK\\/$WA^Y\*^(-1TB['^D64[0L<8#8/##V(P1[&OR+B_ ^RQ$<7%:3T?JO\
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MR/R+C3'^TK0P47I'5^KV^Y?F%%%%?HI^:!1110 4444 %%%% !1110 4444
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M^G*+BY Z&9Q\H/\ NH?_ !\^E?3GB;Q!;>%?#^H:O>'%M9PM,PZ%L#A1[DX
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M\[****_FD_J **** /H[]C7_ )"7BG_KC;_^A25]15\N_L:_\A+Q3_UQM_\
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M6C7I.THO^OO.7%86GC*$\/65XR5OZ]#]+E99%5E(96&00<@BG5X+^R[\5/\
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MYJZ:L_F:4ZDJ,XU(.S3NO5'YJ7=K-8W4UM<1F*XA=HY(VZJP."#]"*BKV/\
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M<![#"O%36L]O1?YO]#\8XQS#ZQBHX2#]VGO_ (G_ )*WXA1117WI^?!1110
MUF"*68@*!DD]!7XE?M6_&)OCC\<?$/B**4R:3')]@TL9.!:Q$A&&>F\[I,=C
M(:_27]OCXR_\*F^ FI6EI/Y6N>)2=)M-K89(V7]_(._$>5R.C2(:_'ZOJ\EP
M]E*O+T7ZG@9E6NU27JPHHHKZ@\,**** "OV(_80^,O\ PMWX":7'>3^;KGAX
MC2;W<V6=44>3(<\G='M!)ZLCU^.]?3?_  3Y^,P^%GQVM=*O9_*T3Q0JZ9<;
MCA4GSFW<_P# R4]A*3VKR<SP_M\.[;QU._!5O95E?9Z'Z\4445\$?6!1110
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MC"/#3?O4_P GM]SO^!^+<89?]7Q:Q4%[M3?_ !+?[U9_>7****^Z/@ HHHH
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M/X/HG_H6?05X'7XYQ1FWUNO]4I/W(;^<O^!M]Y^U<*91]3H?6ZR]^:T\H_\
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M*^8/J0KW#]F/XJ?\(KX@_P"$<U&;;I.IR#R6<\0W!P ?8-PI]]OO7A]'2N_
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M,_9.#<O]CAI8R:UGHO1?YO\ )!1117Y^?H@5);V\EW<100HTLTC!$11DLQ.
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MK[B/[/H=F?EG_P .LOBO_P!#!X-_\#;O_P"1:/\ AUE\5_\ H8/!O_@;=_\
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M:<8'EN2=H]E;<O\ P&OO.O$?VJO W_"0>"8M;MTW7FCN6; Y:!\!_P CM;V
M:OD>)L#]<P+G%>]3U7IU_#7Y'V/"N8?4L>J<G[M3W7Z]']^GS/CVBBBOQ _=
MPHHHH ^V_P!G#QT?&7PYMH)Y-]_I1%G-D_,5 _=M^*\9[E37JM?$O[-OCC_A
M#_B-;VLTFRPU8"SER> Y/[IO^^OE^CFOMJOW;AW'_7L!'F?O0]U_+9_=^-S\
M!XER_P"H9A+E7NS]Y?/=?)_A8****^G/E3\]?B?_ ,E*\6_]A>[_ /1SUS-=
M-\3_ /DI7BW_ +"]W_Z.>N9K^:\5_O%3U?YG]/87_=Z?^%?D@HHHKF.H****
M "BBB@#J?!_Q0\3^!6']C:O<6T(.3:L?,A/K\C97\0 ?>O9O#/[8=U$J1Z_H
M,<_&&N-/D*'_ +X;()_X$*^<**]C"9OCL#I0JM+MNON9XV,R? 8_6O23?=:/
M[U^I]LZ-^TYX"U95\W4;C3)&Z)>VSC\RFY1^===8?%#PAJ2@VWB?27)_A:\C
M5O\ ODD'OZ5^?%%?34N,L9%6J4XR^]?JSY6MP5@I.]*I*/W/]$?I%#KFFW )
MBU"UE .#LF4X_6I/[4LO^?N#_OZO^-?FS17;_KK+KA__ ";_ (!P_P"H\.F(
M_P#)?_MC]&KGQ7HEGG[1K&GP8.#YETB\_B:P-1^-'@;2U+3>*--<#G_1YA/^
MB;J^!**QJ<:5W_#HI>K;_P C>GP1AU_$K2?HDO\ ,^Q=<_:R\&Z:&6PBO]7D
M_A,4/E(?J7((_P"^:\N\4_M;>)=55XM&L;71(VZ2-_I$P^A8!?\ QTUX717A
MXGB7,L0K<_*O[JM^._XGOX7A?*\*[^SYW_>=_P -OP-+7O$FJ^*+TW>K:A<:
MC<G_ ):7$A? ]!GH/8<5FT45\Q*4IMRD[MGU,8QA%1@K)!1114E!1110 ^&&
M2XF2*)&DE=@J(HR6).  /6ONSX(_#=?AKX)@M)U7^U;H_:+UASAR.$SZ*,#Z
MY/>O+/V:?@FUL;?QAKL&UR-^FVL@Y7/_ "V8?^@_GZ5]*5^M\+9.\/'Z[75I
M27NKLN_S_+U/Q[BS.HXF7U'#N\8OWGW?;T7Y^@4445^A'YP%%%% !1110 44
M44 %%%% 'R/^UIX)_L?Q;:>(;>/;;ZI'LFP.!.@ S_P)=O\ WRU>#U]Z_&SP
M5_PGGPYU2PCCWWL*_:K7CGS4YP/=AN7_ (%7P57XCQ1@?JF.=2*]VIK\^OXZ
M_,_=N%<?]<R]4Y/WJ>GRZ?AI\@HHHKY ^R"BBB@ KZY_9-\%_P!C^#[KQ!/'
MBYU63;$6'(A0D#\VW?DM?+'AK0;GQ1X@T[2+09N+V=84.,A<G!8^P&2?85^B
M&BZ3;Z#I-EIMHFRULX4@B7_94 #\>*_0.$,#[7$2Q<EI#1>K_P E^9^=\98[
MV.&AA(O6>K]%_F_R+U%%%?KI^-A1110 4444 %%%% !1110 4444 %%%<!\:
M/B9%\,_!TUVC*VJ7.8+&(\YDQRY']U1R?P'>N?$5Z>%I2K57:,5=G3AL/4Q=
M:-"DKRD[(\:_:H^*AO+H>#M-F_T>$K)J#H?OR=5B^B\,??']VOG.I+FXEO+B
M6>>1III6+O(YRS,3DDGN2:CK^?<RQU3,<3+$5.NR[+HC^B\MR^GEF%CAJ?3=
M]WU?]= HHHKS#U K;\%^$;[QSXFL=%T],SW+X+XRL:#EG/L!D_I6)7V/^S3\
M+/\ A#?#/]N7\.W6-4C#*&'S0P'E5]BW#'_@([5[N2Y;+-,4J7V5K)^7^;V/
M SO-(Y5A'5^V](KS_P EO^!ZEX5\-67@_P /6.CZ?'Y=I:1B-<]6/4L?<G)/
MN:UZ**_?80C3BH05DM$?SS.<JDG.;NWJPHHHJR HHHH **** /)/VB?A;_PG
MWA,WUC%OUK3%:6$*/FFCZO'[GN/<8[U\55^F%?&W[2WPM_X0SQ-_;=A#LT?5
M7+%5'RPS]67V#?>'_ AVK\RXLRFZ_M"DO*7Z/]'\C]3X/S>S_LZL_./ZK]5\
MSQBBBBOR\_50IT4KP2))&[1R(0RNIP5(Z$'L:;10!]U? WXG)\3/!\<L[J-8
MLML-['TRV/ED ]& )^H8=J]&KX ^%/Q"N/AIXPM=5CW26C?NKR!3_K8B>1]1
MPP]Q]:^]=-U"WU;3[:^LY5GM+B-98I4.0RL,@C\*_<N'<U_M+#<E1_O(:/S[
M/_/S/P7B3*/[,Q7/37[N>J\NZ_R\BU1117U9\B%%%% !1110 4444 %%%% !
M7Q+^TEXX_P"$P^(UQ:PR;[#20;.+!X+@_O6_[Z^7Z(*^J?BUXV7X?^ ]4U8,
M!=!/)M5/>9N%_+EC[*:^ G=I'9W8L[')9CDDU^;<88_EA#!0>^K].B^_7Y(_
M3^"\OYISQTUM[L?7J_NT^;&T445^5GZR%%%;W@/PI/XW\7Z5HD&0;N8([C^"
M,<NWX*"?PK2G3E5G&G!7;=E\S.I4C1A*I-V25WZ(^H_V5? __"/^")=<N(]M
MWK#[DW#!6!"0GYG<WN"M>WU7L;&#3;*WL[:,16]O&L44:]%50 !^ %6*_HK
M82.!PT,/'[*_'J_FS^:\PQDL?BJF)G]I_AT7R04445WGGA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !5>^L8-2LKBSN8Q+;W$;12QMT96
M!!'X@U8HI-)JS&FXNZ/SM\>>%)_!'B_5=$GR3:3%$<_QQGE&_%2#^-8-?3G[
M7G@?S(--\5VZ?-'_ *%=D?W228V/T.X?BM?,=?SWF^!>7XV=#INO1[?Y']'9
M/CUF6!IXCKL_5;_Y_,****\<]D<CM&ZNC%74Y#*<$&OOWX2^-E^('@/2]6+
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M/#1J_"M?=EOUZ=SY>HKZA_X8UL_^AIG_ / )?_BZ/^&-;/\ Z&F?_P  E_\
MBZ\[_5C-?^?7_DT?\ST_]:LH_P"?O_DLO\CY>KZI_93^&,^CV=QXLU& Q37D
M?DV*.,,(<Y:3'^T0,>P)Z$5T_@O]F'PCX5NH[N[$VNW2'*_;<>2I]?+ P?\
M@1(KU_IP.!7UV1<-5,'66*Q;5ULEKKW?Z?>?&Y_Q/3QE!X3!IV>[>FG9?K?T
ML+1117Z*?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/XN\-6WC#PSJ6BW?\ J+R%HBV,E#U5A[A@"/I7Y^^*O"^H>#=>
MN](U2 P7=NVUA_"P[,I[J1R#7Z-5R_CCX;>'_B)9I;ZW8K.T8(BN$.R:+/\
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MX'Z]CX1DO=C[S^7^;LCYKB+'_P!GY?.47[TO=7J_\E=GME%%%?O1_/@4444
M%%%% !1110 4444 %%%% !7%_%CXBV_PT\'W.IR%7O7_ '5G W_+24CCC^Z.
MI]ACN*[2O)OBM\"9/BKK<-[=^(Y;.VMX_+@LX[4,L>?O-G>,DGOCH .U>;F,
ML5'#2^IQO4>BU2MYZ]CT\MCA98J/UV7+36KT;OY:=_R/C#4-0N=5OKB]NYFN
M+JXD:665SEG8G))_&J]?4/\ PQK9_P#0TS_^ 2__ !='_#&MG_T-,_\ X!+_
M /%U^/OAG-I.[I_^31_S/VA<4Y/%6573_#+_ "/EZBOJ'_AC6S_Z&F?_ , E
M_P#BZ/\ AC6S_P"AIG_\ E_^+I?ZL9K_ ,^O_)H_YC_UJRC_ )^_^2R_R/EZ
MOK+]E_X2R>'=/?Q3JUN8]0O$V6<4BX:&$]7QV+\?@/\ :-=)X'_9I\)>#[R.
M]F2;6[V,[D:^*F-#V(0#&?KFO6J^PR+AN>#JK%8RW,MDM;>;\^WWGQ>?\3PQ
MM%X3!WY7NWI==EY=_N"BBBOT,_-PHHHH **** "BBB@ HHHH **** &LJR*R
ML RL,$$9!%?#_P >/A3+\-_%4DUI"W]@7S&2TD'*QGJT1/8CMZC'H:^XJH:U
MHMAXBTV?3]3M(KZRF&'AF4,I]/H1U!ZBO SG*89M0]FW:2U3_3T9]#DF<3R?
M$>T2O"6DE^OJO^ ?F]17UMKW[(?AV^N6ETO5;W2D8Y\EU$Z+[+G#8^I-97_#
M&MG_ -#3/_X!+_\ %U^6RX6S2,FE!/SYE^K1^L0XLRF44W4:\G%_HFCY>HKZ
MA_X8UL_^AIG_ / )?_BZ/^&-;/\ Z&F?_P  E_\ BZG_ %8S7_GU_P"31_S+
M_P!:LH_Y^_\ DLO\CQSX*_$R7X9^,8;N1F.E76(;Z(<Y3/#@?WE)R/;([U]V
MV]Q%>6\5Q!(LT,JATD0Y5E(R"#W!%?.O_#&MG_T-,_\ X!+_ /%U[-\./!MQ
MX!\+P:+-JTFKQ6[-Y$LD0C9(SR$ZG(!SCV..U?><.87,<O4L/BH6ANG=.SZK
M1[/\_4_/^)L7EF8N.)PE2]39JS5UT>JW7Y>AU-%%%?;GP84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHK[H^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?GK\3_^2E>+?^PO=_\ HYZY
MFNF^)_\ R4KQ;_V%[O\ ]'/7,U_->*_WBIZO\S^GL+_N]/\ PK\D%%%%<QU'
MH7[/W_)8O#7_ %VD_P#13U]W5\(_L_?\EB\-?]=I/_13U]W5^P<&_P"XU/\
M&_R1^,\;?[_3_P "_-A1117WI^>A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\-_M)?\EJ\1?\ ;M_Z315]R5\-_M)?\EJ\1?\
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MBBOK#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[QJ7(N "Q"C)  SV%<O_ ,/3?BO_ -"_X-_\ KO_ .2:^>?VBO\ DX+XG?\
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MO':^]HX'#2I1;@KV1\I4Q593DE+J?8__  ]-^*__ $+_ (-_\ KO_P"2:/\
MAZ;\5_\ H7_!O_@%=_\ R37QQ16WU#"_\^T9?6Z_\[/L?_AZ;\5_^A?\&_\
M@%=__)-3V?\ P50^)L<V;OPSX3GC_NPV]U&?S,[?RKXQHH_L_"_\^T'UNO\
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MB5%,L3'WRC(/^NAKLS/#JM0<K:QU_P SGP-9TJJ71Z'ZVT445\&?5A7YZ_\
M!6G_ )I5_P!Q7_VSK]"J_/7_ (*T_P#-*O\ N*_^V=>KE?\ O</G^3.#'?[O
M+Y?FC\]J^Q_^"67_ "<%X@_[%>X_]*[2OCBOL?\ X)9?\G!>(/\ L5[C_P!*
M[2OKLP_W6IZ'SV$_CP/U,HHHK\\/L KQ#]K[X]_\,_?!V_UBS>/_ (2*_;[!
MI,;@'$S YE(/41J"W(P2%!^]7M]?E=_P4[^(4GB3XY6'A=)";/PWIZ!H\Y N
M)P)7;VS'Y _#WKT<OPZQ&(C&6RU9Q8RJZ-%R6^Q\A7U]<:G>W%Y>7$EU=W$C
M333S,7>1V)+,S'DDDDDGKFHJ*^J_^">_[/\ 9_&#XH76O:[;+=>'?# CG>WE
M7*7-TY/DHP[J-C.1_LJ#PU?=UJL</3=26R/EJ=.56:A'=F[^S/\ \$[=;^*6
MFV?B7QU>7'A?P[<!9;>QA0?;KN,X(;YAB)2#P2&)_N@$&OMKPO\ L3_!7PG:
MK#!X#T^_8+M:;5&>[=_<^8Q /^Z *]QHKX2OF&(KRNY679'U5+"4J2LE=^9X
MMX@_8U^"WB2T:"Y^'NDVZD8#Z>K6CCWW1,IKY!_:,_X)J7GA?3;K7_A?=W6N
M6T*F2;0;TJUT%&23"X $F/[A&[ X+'@_I/14T<=B*$KJ5UV>HZF%HU59QMZ'
M\]CHT;,CJ4=3@JPP0?2EAF>WE26)VCD1@RNAP5(Y!![&OM?_ (*4_L]VW@CQ
M79?$;0[9;?3/$$S0ZG#&N$COL%A(,=/-4,3_ +2,?XJ^)Z^[P]:.)I*I'J?*
MUJ3HS<)=#]D/V)OV@G^/?PAAEU.<2^*=$9;'5.?FEXS%.1_TT4'/^TCXXQ7T
M'7Y"_P#!//XGO\/_ -HK2]-EFV:9XEB;2IU).WS"-\#8]?,4(/:1J_7JOB<Q
MPZP]=J.SU1]/@ZSK4DWNM HHHKRSN"BBB@#D_BKX^M?A;\-_$GBR\VM#I-C+
M="-CCS' ^2/ZLY51[M7X1:QJUUKVK7NIWTS7%[>SO<SS-U>1V+,Q^I)K])_^
M"I'Q3_L7X?\ A_P':38NM;N?MUXBGD6T)&Q6'HTI!'_7$U^9U?9Y/1Y*+JO>
M7Y(^:S*IS5%!= HKH=#\ :SXA\(^)?$ME;&72/#PMOM\V#^[\^3RX^W=@?RK
MGJ]Y23NET/*LS]GOV*?BI_PMC]G?PS>SS>=J>EQ_V1?$MN;S80%5F/JT9B<Y
M[L:]UK\Q_P#@ES\4O[!^)&O>!;J;%MKUK]KLT8G'VF $LJCU:(N2?^F0K].*
M_/L?1]AB)16SU7S/KL)5]K1B^NP4445YYV!1110!\D?\%.O^3;[7_L/6O_HN
M:ORCK]7/^"G7_)M]K_V'K7_T7-7Y1U]OD_\ NWS9\OF/\?Y'NG[#O_)U7P^_
MZ^IO_2:6OV?K\8/V'?\ DZKX??\ 7U-_Z32U^S]>1G7\>/I^K/1RS^%+U_1!
M1117SYZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?A;^T5_R<%\3O\ L9]4_P#2N6O/J]!_:*_Y."^)
MW_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZA0K%&#*2K Y!'45[S\1/@BMK^RK\*OB
MAID&%NC>Z7J^Q?XQ?7)@F/U4&,D_W8QWKP:G3J1JIN/1M?<*<'!I/R?WG[4_
MLA_&@?'+X':)K5S/Y^N6:_V=JN?O&XC !<_[ZE'^KD=J]JK\G?\ @G+\;/\
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MN<8RQ4$U=K.\._\ (OZ7_P!>L7_H K1K\Y>Y]DM@HHHI#/Q._;&_Y.<^(O\
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M_>:GJSZS"_P8>@4445Q'2?B=^V-_R<Y\1?\ L*-_Z"M>.U[%^V-_R<Y\1?\
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M97/B?(_?BQM%L;&WMD8LD,:QJS=2 ,<_E5BBBORT^Z"OSU_X*T_\TJ_[BO\
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M_!AZ+\CXJM_$EZL_6S_@FQ_R;#8_]A2[_P#0A7U/7RQ_P38_Y-AL?^PI=_\
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M*7D89X!VJ0,]R.O2OT>4HTH-O1(^,BG.5ENSSNBOTZ_X=4_#[_H;O$WYV_\
M\:H_X=4_#[_H;O$WYV__ ,:KRO[6PO=_<>A_9]?M^)^8M%?IU_PZI^'W_0W>
M)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU1_:V%[O[@_L^OV_$_,6BOTZ_X=4_#[
M_H;O$WYV_P#\:KX]_;"_9M@_9K^(&G:5IM[=:GHFI6(NK:ZO OF;PQ62,[0
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MJ]!_:*_Y."^)W_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZG[&_P#!/_\ Y-&\!_\
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M,E9:16W^9]/A,*L/&[^)A1117E'>%?GK_P %:?\ FE7_ '%?_;.OT*K\]?\
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MOP-:I.LHRDVC[9HHHKXT^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6*W\[^]A[&G_ "K[CQO_ (8[^"W_ $3K1O\ OVW_ ,51_P ,=_!;_HG6C?\
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M?C-XLC\-^%=9N+[5I(7G6*2PFA&Q!ECN90.]>T5^2/\ P39_Y.>L?^P7=_\
MH(K];JK,,/#"UO9PVL3A*TJ]/GEO<****\T[0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBOG+]LC]J/5/V9=-\+W.F:)9ZTVL37$<BW<KH(_
M+6,@C;USO/Y5K2I3K35.&[,ZE2-*+G+9'T;17P7\$/\ @HUXC^*WQ8\,>$;O
MPAI=C;:M=BV>YAN)&>,$$Y /!/%?>E:5\/4PTE&HK-D4:T*ZO!A7E?QQ_:3\
M%_L]?V)_PF$]Y#_;'G_9?LEL9L^5Y>_.#Q_K4_6O5*_/7_@K3_S2K_N*_P#M
MG6F"HQQ%>-*>SO\ D1B:DJ-)SCNO\SWWP7^WQ\)_'WBW2/#FDWFJOJ>J7,=I
M;++I[(ID<X7+9X&3UKZ-K\/OV5_^3C_AM_V'K3_T:*_<&NK,<+3PLXQI]488
M+$3Q$&Y] HHHKR#T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:]K5I
MX;T/4-6OW,5C86\EU/(JEBL:*68X')X!X%?/'_#Q+X&_]#+>?^"JY_\ B*]D
M^-'_ "1WQW_V ;__ -)WK\'J]W+<#2Q<9.HWIV/*QF*GAW%0MJ?O;\-_B)H?
MQ8\%Z?XJ\-7+W>BZAYGV>:2)HF;9(T;95@"/F1ASZ5TU?//_  3_ /\ DT;P
M'_V__P#I?<U]#5Y->"IU9P6R;7XGH4I.=.,GU2"BBBL#4*XKXN?%SP]\$_!T
MGB?Q/)<1:5'-' S6T)E?<YPORCMQ7:U\L?\ !2?_ )-AOO\ L*6G_H1KIP]-
M5:T*<MFS&M-TZ<IK=(/^'D_P6_Y_M9_\%K?XU]0VETE[:PW$63',BR)D8.",
MBOY\J_H"\._\B_I?_7K%_P"@"O3S+!4L(H>SOK?]#AP6)GB.;GZ&C1117AGJ
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '\]E?JY_P3%_Y-ONO^P]=?\ HN&ORCK]7/\ @F+_ ,FWW7_8>NO_ $7#
M7W&<?[M\T?,9=_'^1];T445\.?3A1110 45B>-KZ?2_!NOWEK(8;FWL+B6*0
M $JZQL0>?0BOQ[_X;B^./_10;S_P%MO_ (W7HX3 U,8FX-*W<X\1BH8=I26Y
M^S]%?FAK_P#P4L\0:/\ "WPUHOA](]6\9&P4ZOXAU*(;(YB22L<0 #,!C+'Y
M<C&UNM?..O\ [5_QB\2737%W\2/$4,C')&GWSV:?@D.Q1^5=E/)Z\[\S2.:>
M8TH[*Y^WM%?C;\/?V[OC'X!U"*63Q3+XDL@P,ECKJBY609_YZ']XO?HP_&OT
MJ_9E_:>\/?M*>%9;RPC.EZ_8A5U+1Y7W-"3G#HV!OC;!PV 1C! XSRXK+ZV%
M7-+5=T;T,93KOE6C/:***0D*"2< =Z\P[A:*^"?VD/\ @I1%X=U2[\/?"RWM
M=3F@8Q3>(;M2\&X<$0)D;\?WV^4XX##!KX[\0_M:?&/Q-<-/>?$?Q!"[')&G
MWC62_@L&P#\!7M4<IKU8\TO=7GN>95S"E3?*M3]NJ*_%?PC^VA\:/!MQ');>
M/=3U!%(W0ZNPO5<#L3*&;\00?>OO+]E/]O;2/C=J%OX6\5VMOX<\82#;;O$Y
M^QW[?W8]QRC^B$G/9B>*C$977P\>?=>15''4JSY=F?6U%%<O\4M6NM!^&?B[
M4K"8V]]9Z1>7-O,H!*2)"[*P!X." >:\F*YFD>@W97.HHK\8/^&XOCC_ -%!
MO/\ P%MO_C=>^?$+_@I7K.E_#_POH?@Y(K[Q-_8UG_;/B34(@P%X8$,PBBP%
M+!RP+,-N00%(P:]J>48B+25G?\#S(YC1DFW=6/TCHK\0-<_:K^,/B&Z:XNOB
M3XDBD8Y(L=0DM$_!(2JC\J[CX8_M\_%WX>:I#)>Z^_B[2PV9M/UH"4NN>=LV
M/,4XSCD@=U/2M99+64;J2;,XYG2;LT['[#T5SGPZ\72^/? ^B>(9M'OM DU*
MV6X;3=14+/!GLP'YCH<$9 .0/B#]J+_@HW>Z!X@U#PK\+5M6:SD:"Y\1W"+.
MID'#"W0_*0#QO8,#@X&,,?*H86KB*CIP6JW\CT*N(IT8<\GN?H%17X>ZQ^U-
M\7]<N#/<_$KQ-$Y).+/4I;9>?]F(J/TKM_AK^WM\8/A_J4,EUXCD\5:<&S+8
M:VHF\P=\2X\Q3SQAL=,@]*]:62UDKJ2;//CF=-NS3/V+HK\JOCY_P4 \9>)O
M%6EZC\.?$E]X:T>;2X3=:6\$+FWNP\@D7<R'<,;"&'!!' .0/7?^">O[0WQ$
M^,'Q,\1Z9XQ\37&N6-KI!N(8988D"2>=&N[*(#T8C\:Y:F65J=%UI-:=.IT0
MQU.=14XGWQ17D7[5EUXOTOX%>)=7\#ZM/I'B#28AJ"201HYDAC.9DPX(_P!7
MN;IG*BOR]_X;B^./_10;S_P%MO\ XW487+ZF+@YPDM"J^+AAY*,DS]GZ*XKX
M+_$*'XK?"GPKXMB*DZI81S3*G1)@-LJ#_=D5U_"NUKS91<9.+W1VQ:DDT%%>
M%?MH?&.]^"?P'U;6=(NOL6OWD\6GZ;-M#%)7)9F (()$:2$9'4"OS8M_VV_C
MM=3QPP^/;Z6:1@B1I:6Y+,3@ #RNN:]+"Y=5Q4/:1:2\SAKXRG0ER23;/V<H
MKF_ASIVM:3X"\/VGB34'U7Q!%91#4+QPH,EQM!D.% &-Q(&!T KI*\QJS:.Y
M.ZN%%%%(9^0'_!1/_DZOQ+_UZV7_ *31UV?_  2R_P"3@O$'_8KW'_I7:5QG
M_!1/_DZOQ+_UZV7_ *31UV?_  2R_P"3@O$'_8KW'_I7:5]O4_Y%O_;J/EX_
M[[\V?J91117Q!]0%%%% !7YA?\%5O^2Q>$O^P"/_ $HEK]/:_,+_ (*K?\EB
M\)?]@$?^E$M>QE/^]+T9YN8?P'\CCO\ @FS_ ,G/6/\ V"[O_P!!%?K=7Y(_
M\$V?^3GK'_L%W?\ Z"*_6ZM,X_WGY+]2<M_@_,***\S^/7[0'A;]GGP>=;\1
MSM)/,3'8Z9;D&XO) .B@]%&1N8\ $=20#XT(2J24(*[9Z4I*"<I/0],HK\A_
MBA_P4.^+7CZ\F72=3C\&:4Q/EV>DH#*!VW3L"Y;W7:#Z5Y?#^TY\7(+PW*_$
MOQ49#_"^KSLG_?!;;^E>[#):TE>4DCRI9G23LDV?N117Y3_![_@I/\1?!=]!
M;^,O)\:Z+D+(9(T@O(U]4D0!6/LX.<?>'6OTI^%OQ3\.?&3P;9^)_"U^+[3+
M@E""-LD$@QNBD7^%QD9'H01D$$^=BL%6PNLUIW1V4,53Q'PO7L=?17DG[5$_
MB[3O@7XFU7P/JL^D>(M)A&H1RP(CF2*,[ID(=6!_=[R,#.5%?EW_ ,-Q?''_
M **#>?\ @+;?_&ZTPN7U,7!SA):$5\7##R49)G[/T5Q7P7^(4/Q6^%/A7Q;$
M5)U2PCFF5.B3 ;94'^[(KK^%=K7G2BXR<7NCMBU))H**\-_;,^,5W\$O@/K&
MM:5=?8]?NI8M/TR7"DK-(<E@"""5C61AP>5%?FK;_MM_':ZGCAA\>WTLTC!$
MC2TMR68G  'E=<UZ6%R^KBH>TBTEYG#7QE/#RY))MG[.45SOP]TW6='\"Z#9
M^(M0;5=?ALHEU"\8*/-N-H\Q@%  &[.,=L5\C?M2?\%$K7X;ZU>>%/AY;6FN
M:U;$Q7>KW)+VEM(."D:J1YCCN<A01CYN0.6CAZF(J>SI*_Y'14K0HPYYZ'VW
M17XG^(OVQ/C/XGN));KXAZQ;;\C9ITHLU4'L!"%Q]>M9&G_M/?%W2Y/,A^)?
MBIVR#BXU:><<>SL1_C7L+):MM9K\3S?[3IWTBS]QZ*_*#X6_\%)OB?X.OK>/
MQ2UKXUTD$+(ES"EO=!?]B6-0,_[ZMGVZU^E/P@^+WAOXX>"+/Q1X8NOM%E,3
M'+#( LUM, "T4JY.UAD>Q!!!((->9B<#6PNLUIW1VT,53Q&D=SMJ^!?^"L7_
M "+_ ,./^OJ^_P#0(:^N/V@_$FI>#_@?XYUO2+IK'5=/TBXN+:Y10QCD5"58
M @@X/J*_&KXG?'CQY\9(+"'QGXBGUV*P9WMEFBB3RRX 8C8JYR%'7TKORG#2
MJ5573TC_ )'+F%:,8.DUJ_\ ,Z;]CG_DYSX=?]A1?_06K]L:_ 'PIXJU7P/X
MBL->T.\;3]6L)/.MKI%5C&^,9 8$'KW%>O\ _#<7QQ_Z*#>?^ MM_P#&Z]?,
M,OJ8NHIP:5EU//P>+AAX.,DS]GZK7>G6FH;/M5K#<[<[?.C#XSUQGZ#\JLU\
M=_\ !13XU>-?@WHW@>;P9KTVA2W]Q=I<M%%&_F!%B*@[U;IN/3UKY+#T98BJ
MJ<79L^@K5%1@YRV1]:PZ#IEO(LD>G6L<BG*ND"@@^H(%7Z_*W]F7]KCXN>./
MCUX)T'7/&EUJ&DW]^L-S:O;P*)$VL<$K&".G8U^J5:XK"SPLE&;O<SP^(CB(
MN4$%%?%W_!1KXX^.?@S_ ,*]_P"$+\03:%_:7]H_:_)BB?S?+^S;,[U.,>8_
M3UKYM^!?[>GCW1_BAI-[\1/&6H:GX/@CNGO;*.T@+SD6TOE(NU%.3+Y>.0,]
M2!FNFCEM:M1]O!JVNG70QJ8VG3J^RDC]8Z*_)/XN?\%%?BCX^U*=/#EXG@G1
M-Q$5OIZJ]RR]C).P)W?[@0>QZUY+:_M/_%VSO#<Q_$OQ2TA.=LNK32)US]QF
M*_I73#)J\HWE))F$LRI)VBFS]QJ*_,W]G_\ X*6>)=%U:UTKXH+'KNBRL(SK
M-M L5W;=MSH@"R*.,X ;J<L>#^D^EZI::YIMIJ.GW,5[87<2SV]S X>.6-@"
MKJPZ@@@@^]>9B<)5PLK5%\^AW4<13Q"O MT45\W_ +6W[8VE?LWV,&EV%K'K
MGC2^B\VWL)&(AMHR2!-,1S@D'" @M@\KUK"E2G6FH4U=LUJ5(THN4W9'TA17
MXL>,OVTOC/XUNI9KCQWJ6F1N3MM]'8621@]@8@&./4DGWJCX8_:[^,GA.\CN
M+3XB:Y=%&SY>IW1O4;V*S;N*]Q9+6M\2O\SR_P"TZ=_A9^VM%?F1XN_X*0>(
M_&'P3^S6,Q\)?$>UOX2UWI\2O;7EKM<.5$@;8P;9E3GU!Z@>>_"W]LSXSZ]\
M3/".FWWCJ[N+&]U>SM[B%K:W >-YD5E)$>>02.*PCE.(<7*5E8U>84DTE=W/
MUYHHHKQ3TPHHHH XWXT?\D=\=_\ 8!O_ /TG>OP>K]X?C1_R1WQW_P!@&_\
M_2=Z_!ZOK<D^"?JCY_-/BB?L;_P3_P#^31O ?_;_ /\ I?<U]#5\\_\ !/\
M_P"31O ?_;__ .E]S7T-7SF+_P!XJ?XG^9[&'_@P]%^04445RG0%0W5I!>1>
M5<0QSQYSLD0,OY&IJ\)_;6^('B#X8_L\Z[X@\,:E)I.L6]Q:I%=1HCE0\Z*P
MPP(Y!(Z5K2INK4C".[=B*DE3BY/H>R_\([I/_0+L_P#P'3_"M  *  ,"OQA_
MX;B^./\ T4&\_P# 6V_^-U^S]=F+P=3"<OM&G>YS8?$PQ%^16L%%?E1^T=^T
MC\<_@W\:O%7A5?'M\EE:W9DLMUK;G-M( \/)CYPC $^JFO?O^">/[3?B?XOZ
MCXL\-^-=;;6=6MHHM0L9I4C1O)SY<JX15&%8Q'_@9K6IEM6G1]O=-;Z>9G#&
MPG5]E9IGVS1117DGH!17Y'_&#]N[XHWWQ0\42>$_&5QIOAI;^6/3K>&W@91
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MW8[_ '>7]=3Y(_8Y_P"3G/AU_P!A1?\ T%J_;&OQ._8Y_P"3G/AU_P!A1?\
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MY;:?BSBI<F)Q#G5>G]61[5I_["OP.L=)-A_P@MO<(R@--<7=PTS>^_S,J?\
M=P*^-?VT/V%[7X-Z$_C?P-+<S^&(Y%2_TVY?S)+'<0JR*_5HRQ"D'YE)!R03
MM^T/^&XO@;_T4"S_ / 6Y_\ C5<O\4/VN/@5XY^&_BGP])XZL;@:IIEQ:",V
MMP,L\;*N#Y?!R00>Q&:\+#U<=2J*4E)KK=,]2M3PM2#2<4^FQ^:7[.OQFO\
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M*G_DL7BW_L G_P!*(J^8_CK\3I/C)\7/%'C)HF@35+LO!"_WD@11'"K>XC1
M<=P:^G/^"5/_ "6+Q;_V 3_Z415]MB(.GE[@]U%?H?+T9*IC.9;-L_3VO*/V
MI/A;_P +A^!/BSPY%%YNH-:F[L /O?:8CYD8'IN*[#[.:]7HKXFG-TY*<=T?
M42BIQ<7LS^>^&:6SN(Y8G:&:)@Z.IPRL#D$>A!K]6?CG^TE%>_L)Q^,[6X5-
M4\5Z=%I2>6P&VZE!CNE7'0H$N,8_NCI7P=^V5\+?^%2_M#>*-,AB$.F7TO\
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M&T"-;A&UO0;>/2M2M=PWHT:[8Y"/1T56SC&=X_A-?0%<-7-,52J2IR2T\O\
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MGZ5^.=FL+7<"W+,EN742,G4+GDCWQFNG)J,.259K6]C#,JLN94UMN>P_"?\
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MJ<.(_P!]^:_0_9^BBBOBCZ8_&_\ ;^_Y.Y\>?]N'_I!;5[M_P2=_Y&#XC_\
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M^\T_5?F<V)_@S]&?D%7]"=?SV5_0G7NYY_R[^?Z'EY7]OY?J%?C1^W)\*_\
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ML1/$=TO^#^AX$J[J48T>W](_2_\ X)?_  L/AOX6ZUXVNX=EUXBNO(MF8?\
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M:XN/ %K'(3G;:7MU;)_WS%*J_I7:_#O]GOX;_"BX%UX4\'Z9I-X 5%X(S+<
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M/4_$;G6+C<,$(X A7Z>4J-]7-?2=06=G#I]G!:VT206\"+%%%&,*B@8"@=@
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MO4KGQ#K=S=ZE>:A.YEU&Z+.9I %+#<>I 9.!T!7H,5[=^P#_ ,G<^ _^W_\
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M=P=_D>-_9M5.RDK'Y$7?PC\3Z=\+8?B#>Z=)9>&KG48],M)[@%&NI'CED+1
MCYD41$%NF2 ,X;"?!?\ Y+%X$_[#UC_Z4)7Z&_\ !4[4;6S^"'A/25VQS3>(
M(YX8U  \N*VG5L#T!E3\Z_/WX!Z?)JWQS^'EG'G=-XAT]<@9VC[0F3CV&3^%
M>CA\0\3AY59*VYQUJ*HUE33OL?NQ1117Y^?7!1110!QOQH_Y([X[_P"P#?\
M_I.]?@]7[^^*O#\/BSPOK&AW$DD-OJ=G-92218WJLB%"5R,9 :OCS_AU3\/O
M^AN\3?G;_P#QJOH,LQE'"QDJCW/(QV'J5W%P6Q\'^#_VE/B?X!\.VF@^'?&F
MIZ3H]IO\BSMW4)'O=G;&1W9F/XUL?\-C?&C_ **+K/\ W\7_ .)K[8_X=4_#
M[_H;O$WYV_\ \:H_X=4_#[_H;O$WYV__ ,:KTWC\ W=K_P E.%83%I63_$^)
M_P#AL;XT?]%%UG_OXO\ \31_PV-\:/\ HHNL_P#?Q?\ XFOMC_AU3\/O^AN\
M3?G;_P#QJC_AU3\/O^AN\3?G;_\ QJCZ]E_\J_\  1_5<9W_ !.H_P""=?Q0
M\5_%3X7^)=0\6ZY=:[>V^L&"*:Z8%DC\B-MHP!QDD_C6W_P42_Y-5\2_]?5E
M_P"E,==[^SK^SKHO[-OA?4M#T/4K_4[>^O/MKR:ALWJVQ4P-B@8PH_.MOXX?
M!_3?CK\.K_P?J][=:?8WDD4CW%EM\T&.0.,;@1R5':OGI5J2QBJQ^&Z9ZZIS
M^K>SE\5C\*J_H3KXF_X=4_#[_H;O$WYV_P#\:K[9KKS3%TL5R>R>U_T.? X>
MI0YN=;V_4*YWXA>"['XC>!=>\+ZD,V6K64MG(V 2F]2 X]U.&'N!7145X:;B
MTT>HTFK,_G\\2>'[WPGXAU/1-2B\C4--NI+.YB/\$D;E&'Y@U]0?\$V_A7_P
MG7QX/B*ZA\S3?"ML;PDC*FYDS'"I_#S''O$*^N_B]_P3T\"_%[XB:QXONM:U
MG2+S5'66>VL#"(?,"*I8!HR<MMW'GDDFO3OV=?V</#O[-OAK4M(T"ZO-1;4+
MO[5/>7^PRMA JI\B@;5PQ''5VKZK$YI3J89QA\37_#G@4<!.%92E\*_I'K5%
M%%?*'T!\/_\ !0S]E+4/B);Q?$?PC9O>ZW86_DZKI\*EI+JW7)66,#[SH,@K
MU9<8Y7!_-O0=>U/PKK5KJNCW]SI6J6;^9!=VLC1RQ-TR&'([C\<5_0)7@WQ?
M_8G^%7QDO9M1U'1)-%UJ9BTNIZ'(+:61CU+K@QNQ/)9D+'UKZ' YFJ,/8UE=
M'CXK NI+VE)V9\)^&O\ @IA\8O#]C';W?_"/^('1=OVC4[!A(?<^3)&,_AWK
MA_BK^VW\6?BYI<VE:EKZ:5I$Z[)K'181;)*,8(=\F0J>ZEMI]*^J[_\ X)0>
M'Y+@M9?$'4K>#LEQI\<K#D_Q!U'3':NA\)_\$M?AWI5Q'-KOB'7=>V8)@C:.
MUB?CD-A6;'T8'WKN6*RV#YXQU]#E]AC9+ED]/4^(/V3[3XF3?&'2I_A;'(VM
MPL!<2.#]C6W)&\71Z>40.1U) V_,%K]J[?S?L\7V@H9]H\PQ@A=V.<9YQFN?
M\ _#?PO\+=!31O">AV>A:<IR8K6/!=L8W.QRSMC^)B3QUKI:\+'8Q8RHI*-D
MOO\ F>KA<.\/"S=[GYX_\%./$?Q/66RTG[!)9_"]A&_VRQ9G6[N.NVY.!LVG
M[J'Y3][)/"?%7PU^,/C/X/ZLVH>#_$-YH=P^/-2%@T4V.GF1,"CX_P!H&OW:
MU#3;35[&>RO[6&]LYU*2V]Q&)(Y%/4,I&"/8U\S_ ! _X)S_  >\;7<MW96.
MH>$[F0EF&B7(6$MZ^5(KJH]DVBO1P>8T*=+V-:&GWW]3BQ.#JSJ>UIRU/D72
M?^"GWQ>TZU$5Q8^%]5D'_+:[L)E<_P#?J9%_3M7'?$[]O7XN_%#2+K2I]6M-
M TVZ0QSV^AVY@,B$$%3(S-( 0<$!AD=<U],7G_!)_0GF)M?B%J,,6/NS:;'(
MWYB1?Y5L^&_^"5O@2QF1]<\6Z]JRKSY=JD-JK'/?*N<=.A!]ZZUB<L@^>,5?
MT.?V..DN5O3U/S@\&^#-;^('B2RT#P[IEQJ^KWC[(;6V3<Q]2>RJ!R6.  "2
M0*_:S]F_X,P? 7X0Z+X229+J]A5KB^ND&%FN9#ND(_V1PHSSM49YK2^%?P-\
M#?!73WM/!WAVUT@R*%FN@#)<3X_ORL2S#/.,X'8"N\KRL?F#Q=H05HK\3T,)
M@UA_>D[L****\8](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH @N[J#3[6:YN9H[:VA1I)9I6"
MI&H&69F/   ))/3%?"7C;_@I]IVB_&**RT315UGX?6NZWNKU<K=73Y'[Z#)"
MA%QPK??!)RN1C[4\>>!](^)7@_5?#.O0/<Z3J4/DW$<<C1L5R""&4Y!! /X<
MYK\Q/CA_P3C\?^ ;^>\\%H?&WA\L6C6$JE]"OH\1P'[#,>2>NU:]C+J>%J-K
M$/7IV^_N>;C)5XI.BM#[V\'_ +8?P;\:6,=S:_$#1]/++EH-8N!8R(>X(FV\
MCV)'H37&_&;]OKX8?#70KLZ'K=MXS\0;"+6QTE_-A+XX,DX^14!ZX);T%?E/
MK'PS\8>'Y'35?"FN::Z?>6\TZ:(KSCD,HK0\+_!/X@^-+F*#1/!6O:DTF"'A
MT^7RP#T)<KM4<CDD#FO764X6+YY3T]5^9Y[S"O)<JCJ87C'Q;J?CSQ5JWB+6
M9_M.J:G<O=7$G0%V.2 .P'0#L !7Z@_\$V_@W<_#WX/7?B?4[=K?4O%DT=S$
MD@PPLXP1 2.VXO(X]59#7E?[-/\ P39O;?5K/Q%\6# MO RRQ>&;>02F5NH%
MQ(/EVCNB$[N[ 9!_0R.-(8UCC54C4!551@ #H /2N7,\=3G#ZO1=UU[>AO@<
M+.,O;5-Q]?/OQ8_;B^&?P:\9:MX5U^35GUO31&9K>SLMX/F1)*H5BP!^5UZD
M<U]!5^5W[;'P!^)'C;]ISQEK6@>"-<UC2;K[%Y-[9V3R12;;*!&VL!@X96!]
MP:\S 4:5>JXUG96].J.[%U:E*"E35W<\@_:J_:(NOVD/B6VN_99-.T6SA%II
MEC(P+QQ EB[XXWLQ)..@"C)VY/TG_P $L?A2;S7O$_Q#O+<F&RC&DZ?(R\&5
M\/,P]U01KQVE85Y7\*O^"=OQ6\=:M"-?TY/!>B[OWUYJ,B/,5[B.%&+%O][:
M/>OU'^&/PVT/X1^!]+\*>';<V^EZ?'L3><R2L22\CGNS,22??@ 8%>SC\51I
M4/JU!WZ:=$>9A,/5J5?;55_PYU5%%%?*'T 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<91P]#ZMAW=[>B_S'AL/4K5?;5EYG6T445\D?0A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>apyx-20221231_g2.jpg
<TEXT>
begin 644 apyx-20221231_g2.jpg
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M@#\ O^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\
M?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3
M;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J
M9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TE
MV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\
M*AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG
M_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >
MH_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA
M-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\
M@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_
MTEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_
M\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N
M?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J
M_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB
M@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\
M?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3
M;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J
M9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TE
MV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\
M*AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG
M_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >
MH_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA
M-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\
M@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_
MTEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_
M\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N
M?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J
M_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB
M@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\
M?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3
M;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J
M9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TE
MV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\
M*AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG
M_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >
MH_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA
M-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\
M@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_
MTEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_
M\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N
M?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J
M_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB
M@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\
M?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3
M;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J
M9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TE
MV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\
M*AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG
M_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >
MH_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA
M-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\
M@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_
MTEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_
M\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N
M?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J
M_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB
M@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\
M?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3
M;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J
M9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TE
MV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\
M*AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG
M_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >
MH_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA
M-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\
M@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_
MTEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_
M\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N
M?_'J_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J
M_?ZB@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB
M@#\ ?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\
M?^(3;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3
M;_@J9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J
M9_TEV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TE
MV_\ *AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_TEV_\
M*AKG_P >H_XA-O\ @J9_TEV_\J&N?_'J_?ZB@#^3W_@L+_P2[_X*!_\ !'OX
M;>#OB1\2/^"BFN>,8/&.N3Z;;6VAZ_JL#V[Q0B4NQEFP00<8%%?H)_P>\_\
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MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XU7U1_&6E:?+J,VL6
MC+"FYE6V.3^M=!6;XQ_Y%B]_ZX&@"M!;^-9X4G76K,!U# &V/<?6G_8O&_\
MT&[+_P !C_C6EIW_ "#X/^N*_P A4U &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XU5TBX\8ZQ;-=0:O:J%E:,A[;G*G'K715C^!_P#D$2_]?LW_ *%0
M ?8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
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M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
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M4 %%%% !1110 4444 %%%% &/9?\CO>_]>47\S6Q6/9?\CO>_P#7E%_,UL4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5F^,?^18O?^N!K2K-\8_\BQ>_]<#0!<T[_D'P?]<5_D*F
MJ'3O^0?!_P!<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K'\#_\@B7_ *_9O_0JV*Q_ _\
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M._Y!\'_7%?Y"J?C'_D6+W_K@:N:=_P @^#_KBO\ (4 34444 %%%% !1110
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M8O?^N!JYIW_(/@_ZXK_(4 34444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CV7_([WO_ %Y1?S-;
M%8]E_P CO>_]>47\S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !6;XQ_P"18O?^N!K2K-\8_P#(
ML7O_ %P- %S3O^0?!_UQ7^0J:H=._P"0?!_UQ7^0J:@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M?P/_ ,@B7_K]F_\ 0JV*Q_ __((E_P"OV;_T*@#8HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M'\2_\A?1_P#K]/\ Z":V*Q_$O_(7T?\ Z_3_ .@FMB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/
M_)K/P/\ ^R@:C_Z0BB@#S_\ X--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F
M?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ HHHH *\+_X)[_\D3U;_L>]9_\
M2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)H ]THHHH **** "BBB@ HHHH **** "
MBBB@ HHHH S?&/\ R+%[_P!<#5S3O^0?!_UQ7^0JGXQ_Y%B]_P"N!JYIW_(/
M@_ZXK_(4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!CV7_([WO\ UY1?S-;%8]E_R.][_P!>
M47\S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6;XQ_Y%B]_P"N!K2K-\8_\BQ>_P#7 T 7-._Y
M!\'_ %Q7^0J:H=._Y!\'_7%?Y"IJ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_ _P#R")?^OV;_
M -"K8K'\#_\ ((E_Z_9O_0J -BBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q+_R%]'_Z_3_Z
M":V*Q_$O_(7T?_K]/_H)K8H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$44?\'O/_ ":S\#_^R@:C_P"D(HH
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M10 4444 %%%% !1110 4444 9OC'_D6+W_K@:N:=_P @^#_KBO\ (53\8_\
M(L7O_7 U<T[_ )!\'_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,>R_P"1WO?^O*+^
M9K8K'LO^1WO?^O*+^9K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8_\ (L7O_7 UI5F^,?\
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M ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/9?\
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M G[*_AS]I_X7ZI)XF\5_$;PY#/JWB>^@5'LU)_>Z; @+")(ID9)#N+2/%DG
M14^\:_*N,LYAFN8JG334:5UKHV[^\[?)+Y'ZSP7DL\IRUU*C3G5M+35)6]U7
MZ[M_,****^0/L0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]'_Z_3_Z"
M:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!
M_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V
M\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH
M *\+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2: /=****
M "BBB@ HHHH **** "BBB@ HHHH **** ,WQC_R+%[_UP-7-._Y!\'_7%?Y"
MJ?C'_D6+W_K@:N:=_P @^#_KBO\ (4 34444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CV7_ ".]
M[_UY1?S-;%8]E_R.][_UY1?S-;% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OC'_D6+W_K@:TJS
M?&/_ "+%[_UP- %S3O\ D'P?]<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9<
M7$%K ]U=3)'%&A>221@%50,DDGH .]?"/PR@G_X*U_M=0_M ZY \W[/'P9UV
M2+X<V$RGR/&GB2(E9-7=3Q):VYRL.>"W/>:.MS]OWXH>._VN?C3:_P#!*K]F
MKQ'/82ZK9)?_ !T\8V#<^&_#K8_T%&Z"[NU(4*>1&XR"KLR?6WPL^%_@3X*_
M#G1?A-\,?#D&D^'_  ]IT5CI.G6RX6&%%P!GJS'JS')9B6)))->Q3_X3,+[1
M_P 6HO=_NP?VO66T>T;OK%GC5/\ A4Q?LU_"IOWO[TUM'TCO+O*RZ21OUYA^
MS'\?? 'QTTWQ+#X(OQ,?#OB6XL+L%@?, .4G7'6-_FVGOL;TKD?^"CO[1W_#
M//[.E_\ V+?^5X@\3;M+T38V'BWK^^G'<;(R<'L[Q^M? O\ P3B_:._X9Y_:
M+L/[:O\ RO#_ (FVZ7K>]L)%O;]S.>PV2$9/9'D]:\<]D^H_^";1_P"&6_VI
MOC;_ ,$X=1/D:7I.L_\ ">?"Z%N%.@ZF^9[>(?\ /.VNOW?NTCU]J5\6?\%2
MHI?V:_C)\&/^"E>CQM':^ ?$R^&?B3)&.)/#.JL('ED_O"WG971>/GFSVK[1
MBECGC6:&171U#(ZG(8'H0>]>KF?[]4\6O^7B][_''27WZ2_[>/)RO_9W4P;_
M .7;]W_!+6/R6L?^W1U%%%>4>L%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &/XE_Y"^C_P#7Z?\ T$UL5C^)
M?^0OH_\ U^G_ -!-;% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?B#_P>\_\ )K/P/_[*!J/_ *0BBC_@]Y_Y-9^!_P#V4#4?_2$44 >?_P#!
MIM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4
M444 %%%% !1110 5X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
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M\:?A?\=?"L?C/X5^,+35[%L"4P-B2W<C.R6-L-$W^RP![].:ZFO./2"BBB@
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M_P!>47\S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6;XQ_Y%B]_P"N!K2K-\8_\BQ>_P#7 T 7
M-._Y!\'_ %Q7^0J:H=._Y!\'_7%?Y"IJ "BBB@ HHHH **** "BBB@ HHHH
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MM\$A+>V3"!5)4L#@E5CQYA^R#X8\0_\ !1_]IE?^"D_Q>T:YMOAUX3EN-/\
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M_P!!NR_\!C_C0 67_([WO_7E%_,UL5REK:^*3XINHX]4MA<"VC,DA@.TKDX
M%:?V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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MW3WVK6KQ"(^8B6Y!(]C0!T&G?\@^#_KBO\A4U85E9^-#9Q&+6;,+Y2[0;8Y
MQ]:E^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
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ML]A))61L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (TAFQ16/]B\;_\
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M;X=^+_@7Q197&C>)]$M=4TR8VW)@GB61,X/# , 1V(([5T7V+QO_ -!NR_\
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MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_!.']FKXG7.NZ]_P4$_:ZTL)\7/BA;I]FT>4$KX.\/Y#6ND0AN4;;M>;H2^
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M^U/^QS^]\%SW_P 6?AU!][1;R4'Q!H\0[02=+Q%'1"-W 50H!:O7/@E^T/\
M"7]H30&UWX8^*8[IX#MU#39U\J\L7Z%)H6^9#D$9^Z<'!- ';4444 %%%% !
M1110 4444 %%%% !1110 4444 8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7
MZ?\ T$UL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^(/_![S
M_P FL_ __LH&H_\ I"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO
M_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444
M%%%% !7A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*30![I111
M0 4444 %%%% !1110 4444 %%%% !1110!F^,?\ D6+W_K@:N:=_R#X/^N*_
MR%4_&/\ R+%[_P!<#5S3O^0?!_UQ7^0H FHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'LO^1W
MO?\ KRB_F:V*Q[+_ )'>]_Z\HOYFMB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQC_ ,BQ>_\
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M*?MA^!OB;XA;X8>.=%O/ _CRW %UX0\18CED/]ZVD.%N4."05Y(&=N.:]>H
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M*LWQC_R+%[_UP- %S3O^0?!_UQ7^0J:H=._Y!\'_ %Q7^0J:@ HHHH ****
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M^(G@W4DO-(U[2[?4=*NX_NSVT\:R1N/8HRG\:U:^.O\ @CSXHU[P!\//'?[
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M_P!0 4444 %%%% !1110 4444 %>%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\
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M3W9CU=CCEF)8]R:W* &0006L"6MK"D<4:!8XXU 55 P  .@ [4^BB@ HHHH
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M[-?[._PQ_91^"/A_X!?"#1A9:'X=L1!!NP9;B0_-)<2L -TLCEG9N,LQP ,
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M 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/>?\ DUGX'_\ 90-1_P#2$44 >?\
M_!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\ P:;?\I3/VN_^WC_T^3U^_P!0 444
M4 %%%% !1110 4444 %>%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3
MU;_L>]9_]*30![I1110 4444 %%%% !1110 4444 %%%% !1110!F^,?^18O
M?^N!JYIW_(/@_P"N*_R%4_&/_(L7O_7 U<T[_D'P?]<5_D* )J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH Q[+_D=[W_KRB_F:V*Q[+_D=[W_KRB_F:V* "BBB@ HHHH ****
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M>*?B9^UUK?AG4/&-[H?A3X3>&=-LI;S4M;\4WXOKJUMHT+O,43$48506(DZ
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MX+?$76;33?"/Q2UV>T6(_;'V6%[?6:RF>PLKMM@AGD!QYT1F2 /D?6M? ?\
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MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 $-E_R
M.][_ ->47\S6Q7,VGB704\6W=Z^J1")[6-4DSP2"<BM3_A,?#'_0:@_[ZH T
MJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?
M#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?
M]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#
M2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
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M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
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M_P 4;C#1M_M*0:\G_P"$!_:1_9J_?_"769?B%X1B^]X4UVY"ZE91CM;7.,2
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MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
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M/P/_ .R@:C_Z0BB@#S__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\
MV\?^GR>OW^H X?\ :3\1R^&?@7XIN[3POK>M75QH5W;6.E>'M(FO;JZGD@=8
MXU2)3C+8&]MJ+GYF YKY=_X-[OA_\5/@3_P2Q^&W[-/QW^$?B?P9XT\#V^HP
M:[I'B+1I(%_?ZK>W$+PS8,4X,4B$[&)0G#!<C/VU10!\F^$?^"C?[16L?$KQ
MC\&_$O\ P2I^-NGZ]H6O75EX8U.V73YO#_B"T1RL%Z-5EGABME=0)'0AVC5L
M+YK@I7*^+?\ @D)I?Q._X)0_$S]@GQYXCTV+Q3\6-0UKQ7XBUS3XG-C:>*;_
M %-M61X5(#FUM[H01+PKO# "0K.0/MRB@#\U/VD/!O[8?[>O_!,KPY_P2^U3
M]G_Q=X/^)/B*RT'PY\7_ !=K&E%-"T"PL+BV>_U.VOB?(U(7*VI%O!;M))_I
M(\X0['(_1+X<^ ?#/PJ^'N@_"_P58_9=&\-Z-:Z5I%MNSY-K;Q+#$F>^$11^
M%;-% !45]86.J6DFGZG917%O*NV6">,.CCT*G@BI:* ,+_A5WPS_ .B=Z%_X
M*(?_ (FO(?\ @GMING+\$M55=/@ 'CG6  (AP!<$ =.P 'X5[W7A?_!/?_DB
M>K?]CWK/_I2: /;O[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?
M^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.
MT_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"
MIJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^
M?&'_ +]"IJ* ,CQ=8V4?AJ\>.SB5A"<%8P"*MZ?I]@UA 390DF%<DQCT%0^,
M?^18O?\ K@:N:=_R#X/^N*_R% !_9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!
M#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\
M\^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C
M#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U%
M$/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_
M -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!
M#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\
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M#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U%
M$/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_
M -^A1_9VG_\ /C#_ -^A4U% #(K:V@),%NB$]2B 9I]%% 'X@_\ ![S_ ,FL
M_ __ +*!J/\ Z0BBC_@]Y_Y-9^!__90-1_\ 2$44 >?_ /!IM_RE,_:[_P"W
MC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%%
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M[.D?^LG7_=P?:C_AF/XM?%#]_P#M&_M!:E>6TG^L\->#U_LZP [H[C]Y.O\
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M_$+PS%<R0<V6HPDQ75HV<AHI5^9<'G'W21R#7O\ ]JX/,_=S2'O?\_8)<_\
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M_@YGY'=_$_\ :'^"WP<C(^(7Q#T^QN ,KIZR&6Z?TQ#&&<Y]<8]ZX3_AH/\
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MJ?SR;G-_]OR;E\KV\@HHHKRSU0HHHH **** "BBB@ HHHH *S?&/_(L7O_7
MUI5F^,?^18O?^N!H N:=_P @^#_KBO\ (5-4.G?\@^#_ *XK_(5-0 4444 %
M%%% !115#Q5XI\.>!O#&H^-/&&MVVFZ3I-E+>:GJ-Y*$BMK>-"\DCL>%55!)
M/H*:3D[(3:BKL\N_;B_; \'?L4_ 6^^+&OZ=+JVL7-Q'IG@WPO:9:YU[5YLK
M;6<2J"Q+-RQ )5%8@$@ \7_P3D_8_P#&'P$\):Y\=/VBM1BUGXU?%.[75_B)
MK/#"T)'[C2[<@D);VR$(%4D%@<$JJ!?+OV._"OB/_@HQ^TL/^"EWQCT2YMOA
M_P"&'N-._9V\)ZE$5_<[MD_B&:,])IBN(L\JJ@\[(Y&^Y:];%M9?AW@X?&_X
MC_*'I'>7>6GV4>/A$\QQ"QD_@7\->76?K+:/:.OVF%%%%>0>R%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %8_@?\ Y!$O_7[-_P"A5L5C
M^!_^01+_ -?LW_H5 &Q1110 4444 %%%% !1110 4444 ! 8%6&0>H-?%?\
MP3-)_9?_ &D?C9_P3;U(^3IWAO7?^$V^&$+<*WAW5'WR01#^Y;71,9/=Y6K[
M4KXL_P""GZ/^S+\>?@M_P4ITI3%8^#?$0\)?$V5!PWAO5'\KSI3W6VN6611W
M>85ZN5_O_:81_P#+Q:?XXZQ^;UC_ -O'DYI^X]GC%_R[>O\ @EI+Y+27_;I]
MIT4B.DB"2-@RL,JP.012UY1ZP4444 %%%% !1110 4444 %%%% %/7_#V@^*
M](G\/^)M&M=0L;I-EQ9WD"R1R+Z%6!!KQ>\_9Q^)WP.NI/$'[)GC,16!<R7/
M@#Q',\VGS9.3]GD)WV['ZX)(RP Q7NE%>E@,VQF7IP@U*G+XH27-"7K%Z7[2
M5I+HT>9C\HP68RC.HG&I'X9Q?+./I):V[Q=XOJF>5?#+]K#P?XK\0+\.?B1H
MMWX(\8+A6\/Z^0@G)XS;S<).I/3&">P(YKU6N<^)OPD^'/QB\/MX9^)'A.UU
M2UY,1F3$D#'^*.08:-O=2*\J_P"$/_:6_9I_>_#C59_B3X/AY/AW6+@+J]C'
MZ6\^,3@#HC#. %4=Z]#ZIE.:ZX27L:O_ #[F_<;_ +E1[?X:EO\ &WH>?];S
M?*=,9%UJ2_Y>07OK_'36_P#BIW_Z]I:GO%%<+\'_ -HOX7?&N.6T\*ZO);:M
M:Y&H>'M5B^SW]HP^\'B;DX/!9<KVSFOF?_A[[_U;S_Y=O_W)6F7<'<2YK7JT
M<-AVY4[<R;C%KFO;XG&][.S5_P C+,>,^&,IH4JV)Q*4*M^5I2DGRVYO@4K-
M75T[/[F?77B7_D+Z/_U^G_T$UL5\0ZG_ ,%9O[1N[.Z_X4#L^R3&3;_PE6=_
M&,?\>O%7/^'OO_5O/_EV_P#W)7J_\0SXW_Z!/_*E+_Y,\G_B)_ W_07_ .4Z
MO_R!]I45XM^R#^U]_P -6?\ "0_\6\_L'^P?LG_,6^U>?Y_G?],H]NWR??.[
MMCGVFOD\SRS'9/CIX/&0Y:D;75T[72:U3:V:>C/KLKS3 YU@88S!SYZ<[V=F
MKV;B]))/=-:H****X#T HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_
M )-9^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW
M_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH *
M*** "O"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2: /=**
M** "BBB@ HHHH **** "BBB@ HHHH **** ,WQC_ ,BQ>_\ 7 U<T[_D'P?]
M<5_D*I^,?^18O?\ K@:N:=_R#X/^N*_R% $U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\+_P#!?[]M
M[Q9^Q[^Q<OA[X7ZU+IWBSXC:DVBZ?J-O)LFL;,1E[NXC8<A]NR(,,%3<;P05
M%?SGDDG).2>IK]L_^#K;X>^(=5^#GPA^*5G!(VEZ'XCU33;]U^ZDUY!;R0DC
MZ64H!_#O7Y*_LL_"S_A9WQ1MOM]MOTS2<7>H;A\KX/R1G_>;&1_=5J_8>$ZF
M#RSA=XR7]YR[W3:2^ZUEW?F?C/%U/&YIQ4L%'^ZH]K-)M_?>[[+R.:^(OPL\
M4?#'^RO^$EMMG]K::EW#@?<SUC;_ &UXR/\ :%?0/_!(']M_Q;^Q'^VAX8\0
M0:W+'X2\4ZG;:+XWTYI"(9K.:01K<,O3?;L_FJW7"NF0)&SVW[4WPL_X6=\+
MKG[!;;]3TG-WI^T?,^!\\8_WES@=V5:^;/A)^S/\8/B%K^F/I_A2\L[:>^A2
M.ZN5\IG+. !$I^>1CT4*#DX%=.6YY@,\R.?UZ48O6,DVEOM;Y;=;K0YLSR''
MY%GU/ZA&4EI*+2;VW3^>_2SU/ZT*IZ_XB\/^%-*EU[Q3KMGIMC NZ>]O[I(8
MHQZL[D ?B:^%_ G_  5?;]KKX@7WPH^#'QD^&WPJGM+LVLK>.]6#ZS,X_P"?
M:UE$<3N.Z9?H>:][\/?L!_#/5]4A\7_M ^-?$'Q1UA#OCF\47[?8H6_Z8VD9
M$:(?[K;QS7XW6P]?#R2JP<6^Z:_,_::.(P^(3=*:DEV:?Y!KW[?WPZU?59?"
MO[._@?Q#\4-8B;8Z>&+%A8P-V\Z\D C1?]M=XYJG_P ('^WE\<OG^(/Q,T?X
M5:++][1_!\8OM49/[LEV_P D3?[<7ITKWG0O#^@^%M*AT+PSHEGIUC;KM@L[
M"V2&*,>BH@  ^@JY6)L>1?#+]AO]G/X::I_PE#^#W\2:^S!YO$?B^Y.I7DCC
M^/=+E$;W15->N@ # & .@HI))(X8VEED545269C@ #J2:-P%HKRKQQ^V5\#?
M".IGPUHFN7/BO6R2(M$\(6C7\[MZ9C^0'/!!8$>E8O\ PDG[:?Q>^7PQX0T7
MX9Z5)TO]=D&H:F5[,D"_NT/^S)S[U[E+A_,'357$6HP?VJCY;KNH_'+_ +=C
M(\*KQ%ERJ.EA[UYK[--<]GVE+X(_]ORB>RZUKNB>&]-DUGQ%K-K86<(S-=7M
MPL4:#U+,0!^->2:S^VO\/]1U&7PY\$O"NN?$+5(SM:/PY8M]EB;MYERX"*O^
MT-PHT7]BGX>7^I1>)/C5XGUSXA:K&=RR^);YC:Q-W\NV0A%7_9.X5ZWHVAZ+
MX<TZ/1_#VD6MA:0C$-K96ZQ1QCT"J !^%7_QCV!_FQ$O_!=/]9R7_@MF?_&1
MX[^7#Q_\&5/TA%_^#$>-?\(Q^VE\7OF\5^,]&^&FDR==/\/QB_U(K_=>X?\
M=H?]J/\ *MOP-^QO\#/!^J?\)+J^@W'BG6R09=<\7737]P[#H<2?(I!Z$*#[
MUZI16=7B#,73=+#M48/>--<MUV<OCE_V]*1I2X=RY5%5Q"=::VE4?/9]XQ^"
M/_;D8B1QI$BQ1(%50 JJ, #T%+117B'NA1110 4444 %%%% !1110 4444 %
M%%% !1110 5F^,?^18O?^N!K2K-\8_\ (L7O_7 T 7-._P"0?!_UQ7^0J:H=
M._Y!\'_7%?Y"IJ "BBB@ HHHH *^%?VI]=UK_@IO^U)+_P $]/AEJMQ#\)_
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M 'U9#C_>8G]=/[1I15LGG"AZKEJ?^#9.5O\ MV<%Y&?]FU9:YS"I7]'S4O\
MP5%0O_V]";\SZT\#_#?P!\--+&C> /!VG:/;8&Z.PM%CWD=V(&7/NQ)K;KX\
MT+_@M!\ O"&K0>$/VR/A#\1?@3K4TGE)_P )_P"%ICIMQ)Z07ULKQR)P?WC!
M%X/-?3_PP^,?PD^-GAU?%WP=^)V@>*M+;&+_ ,/:O#>1 GL6B9@#['FOFL;A
M<QIS=7$QD^;[3U3_ .WM4_O9]-@<7EM2"I8645R_96C7_;NC7W(Z2BBBN ]
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?&/_(L7O\
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MV*Q_ _\ R")?^OV;_P!"H V**** "BBB@ HHHH **** "BBB@ HHHH ^5_\
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M)K8K[O\ XC7_ -0'_E7_ .YGP/\ Q __ *F'_E+_ .Z'Q;_P2"_YJ'_W"?\
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MGUVQ:0>--5$K"U.&D$V'(YX!;<0.P(KZ/KPO_@GO_P D3U;_ +'O6?\ TI-
M'KGV+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MS/B6T\6IH-T]]JUJ\0B/F(EN02/8U9LK/QH;.(Q:S9A?*7:#;'(&/K5OQC_R
M+%[_ -<#5S3O^0?!_P!<5_D* ,W[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M1]B\;_\ 0;LO_ 8_XUL44 4=*@U^&1SK%_!,I7Y!%%M(-7J** /Q!_X/>?\
MDUGX'_\ 90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\ X--O^4IG[7?_
M &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ HH
MHH *\+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)H ]THHH
MH **** "BBB@ HHHH **** "BBB@ HHHH S?&/\ R+%[_P!<#5S3O^0?!_UQ
M7^0JGXQ_Y%B]_P"N!JYIW_(/@_ZXK_(4 34444 %%%% !1110 4444 %%%%
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MI9Q@XNU>])_WURK_ ,"UB_E)GU[16+X!^)/PZ^*WAV+Q?\+_ ![HOB329_\
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M44 %%%% !1110 4444 ?B#_P>\_\FL_ _P#[*!J/_I"**/\ @]Y_Y-9^!_\
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MW4DE9!1112&%%%% !1110!CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S6Q0
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M5E(P00>H([5\W_&[_@D=^P)\<M7_ .$NOO@39^%O$B2&6V\4^ +A]#OX9?\
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M:7Q-XAM\D>"_#6=MSJ,A4C9,X)CA&0Q9L@JQC)_/+]F+_@Z'^/W@K1KWP_\
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M"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX2:]XZG#%/[5$)L=+C;I\UQ,!DCT"\XX-1_\*9_:A^+G[WXU?'%/#&FR??\
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M/8?V!/GWYH\OK?\ ^1N?5<">W_UAA[/;EES>EO\ Y*Q^F]%%%?B1^Y!1110
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M[MZM^K_1604445Y)ZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5X7_ ,$]_P#DB>K?]CWK/_I2: /=**** "BBB@ HHHH **** "BBB@ HHHH
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M/9?\CO>_]>47\S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6;XQ_Y%B]_ZX&M*LWQC_P BQ>_]
M<#0!<T[_ )!\'_7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\#_\
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MZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
MH4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^
MA0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O
M?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Y2UUS45\4W5TO
MANY9WMHU: ,NY0">36G_ ,)+J_\ T*%[_P!]+19?\CO>_P#7E%_,UL4 8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2
MZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM4?$NO:G<Z#=03>&+J%6B(,KL
MN%]S735F^,?^18O?^N!H J67B/54LXD7PE>,!$H#!EP>.M2_\)+J_P#T*%[_
M -]+6EIW_(/@_P"N*_R%34 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM9GA77-1M=.DCA\-W,X-S(Q=&7 );I^%=76/X'_P"01+_U^S?^A4 '_"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
M]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
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M=K[I<T?1(H_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q17E'K&/_ ,)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%
M[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]
M"A>_]]+1_P )+J__ $*%[_WTM;%% '*:YKFHSZCILDGANYC,=R61&9<R';T%
M:?\ PDNK_P#0H7O_ 'TM'B7_ )"^C_\ 7Z?_ $$UL4 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
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M>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
ME*9^UW_V\?\ I\GK]_J "BBB@ HHHH **** "BBB@ KPO_@GO_R1/5O^Q[UG
M_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4F@#W2BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#-\8_P#(L7O_ %P-7-._Y!\'_7%?Y"J?C'_D6+W_ *X&KFG?
M\@^#_KBO\A0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &/9?\CO>_P#7E%_,UL5CV7_([WO_
M %Y1?S-;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %9OC'_D6+W_ *X&M*LWQC_R+%[_ -<#0!<T
M[_D'P?\ 7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\#_ /((E_Z_
M9O\ T*MBL?P/_P @B7_K]F_]"H V**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /B[_@J[:W/[//COX/\ _!2OP_;R ?"OQ8FD^/C
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?&/_(L7O_7
MUI5F^,?^18O?^N!H N:=_P @^#_KBO\ (5-4.G?\@^#_ *XK_(5-0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6/X'_Y!$O\ U^S?^A5L5C^!_P#D$2_]?LW_ *%0!L4444 %%%%
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M%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?@?\ ]E U'_TA%% 'G_\
MP:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O]0 4444
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M*LWQC_R+%[_UP- %S3O^0?!_UQ7^0J:H=._Y!\'_ %Q7^0J:@ HHHH ****
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MN\JU]J A@&4@@C@BO5S3]_[/%K_EXM?\<=)??I+_ +>/)RO]Q[3!O_EV]/\
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M$:;8XU 2-$50H\T_X)'_  ?\5_L[?\$JM0^,WP/_ &>M%LO''Q8EUSXG:/\
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M!\#=2MTNKXK%XTU6)2;QB2$FV#)[G"C)[G)H ^CZ*Q_^$'TC_GYO?_ MJ/\
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MW_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@
MLO\ D=[W_KRB_F:V*Y2U\*Z=)XINK!I[G9';1LI%PV[))ZFM/_A!](_Y^;W_
M ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W
M_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ
M -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH
M_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V*
M*Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X
M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M@BYD4!+AE& U '5T5C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DT >Z4444 %%%% !1110
M4444 %%%% !1110 4444 9OC'_D6+W_K@:N:=_R#X/\ KBO\A5/QC_R+%[_U
MP-7-._Y!\'_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,>R_Y'>]_Z\HOYFMBL>R_Y
M'>]_Z\HOYFMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "LWQC_R+%[_UP-:59OC'_D6+W_K@: +F
MG?\ (/@_ZXK_ "%35#IW_(/@_P"N*_R%34 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^!_^01+_
M -?LW_H5;%8_@?\ Y!$O_7[-_P"A4 ;%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?%?[?I_X91_;@^"/_  4$L?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8]E_R.][_ ->47\S6Q6/9?\CO>_\ 7E%_,UL4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5F^,?^18O?\ K@:TJS?&/_(L7O\ UP- %S3O^0?!_P!<5_D*FJ'3O^0?
M!_UQ7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L?P/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV
M;_T*@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JIK^@Z/XIT*]\,>(M.BO-/U&TDM;ZTG7*3PR*4=&'<%201Z&K
M=%--IW0FDU9GQM_P2!U[6/A3X?\ B1_P3O\ '.HRS:Q\"/&<MCHLETW[V[\.
M7Q:[TRX.>N4:1<#(51&,]*^R:^*_VQ/^,2/^"DOP;_;3M/\ 1_#7Q'1OA?\
M$>0<1I+.QGTFY?L")U9&D;&V- ,\U]J5ZF:I5:L<4MJJYG_BVG_Y,F_1H\O*
M6Z5*>$EO2?*O\.\/_)6EZIA1117E'JF/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_
M /7Z?_036Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X@_\
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MH Q[+_D=[W_KRB_F:V*Q[+_D=[W_ *\HOYFMB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQC_R
M+%[_ -<#6E6;XQ_Y%B]_ZX&@"YIW_(/@_P"N*_R%35#IW_(/@_ZXK_(5-0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6/X'_Y!$O_ %^S?^A5L5C^!_\ D$2_]?LW_H5 &Q1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!XU_P4$_9DA_:__8]\<_ :$!=4U31VG\.7.[:;?5+<B>TD#=4_?1H"00=K
M,.]5?^"<G[3<W[7/[&O@GXRZP677I=-_L_Q;;2+MD@U>T8V]VKIU0M+&T@4\
MA9%KV^OBO]EO_C$3_@J)\6?V2[G_ $;PM\8;,?$OP!&>(TU$D0:O;+VWLZK.
M$&-L<8]:]7#?[3EU2AUA[\?3137W6EZ19Y.)_P!ES*E7Z3_=R]=7!_?S1]9(
M^U****\H]8Q_$O\ R%]'_P"OT_\ H)K8K'\2_P#(7T?_ *_3_P"@FMB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q!_X/>?^36?@?_V4#4?_
M $A%%'_![S_R:S\#_P#LH&H_^D(HH \__P"#3;_E*9^UW_V\?^GR>OW^K\ ?
M^#3;_E*9^UW_ -O'_I\GK]_J "BBB@#\A/\ @I5^WI^PW^T1_P %';_]AG]I
MG_@IC\8_V<M'^'5C:6FC:I\+/$,V@P>(==O,R7GV[4?LLT2V]M$MK#'YFQ%E
M>[W.-JY^FOVD/B%X>_X(?_\ !'CQU\7_  !\:/'/Q5N_#6F/=^&?%/Q6\7MK
MVHZKJ>I7,=O9&6X"HLEO&\\)"1JB^3$3]YF<_47[2W[+7[/W[87PGU/X(_M)
M_"K1_%OAO5;=XIK'5K19#"S+@30R??@F7JLL95U(!!!%?C3\=_V:?C=J_P#P
M:E?%+X,VVOZCXJTWX7_$75V^'VJ7),DVJ>$-'\3F..Z!'6);>*YF0_=\F)-O
MR!: /I/]JKX;_&#]A+_@DUHG_!2#P#\5?%>K?'OP'H^@^+_'NO:[XGO)X?&(
MN)K;^UM,O;9I# +(QW,WDQ)&OV;R(?)\LJ2?T=^#'Q3\-_'/X/>%/C9X-9SH
M_C'PU8:YI1DQN-M=VZ3Q9QQG9(M?#?\ P6?^,'A76_\ @W<\=_$S0;I+BP\8
M?"O0$T$6_P YNCJ4]A';K&!RY;SU( [<]J^L/V"OA1XD^ _[#/P8^!_C&%H]
M7\&_"CP[H>JQN>4N;33;>"5?P>-A0!ZS1163XZL_&-_X1O[/X?ZQ::?K4D!&
MG7M];F6&&3(PSH/O#&>* -:O"_\ @GO_ ,D3U;_L>]9_]*31_P (#_P4$_Z+
M_P"!/_"4D_\ BJQ/^">-CX\7X&ZDL^NV+2#QIJHE86IPT@FPY'/ +;B!V!%
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M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
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MLO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%?'?\
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M'2H-?AD<ZQ?P3*5^011;2#5Z@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\
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MK?\ 8]ZS_P"E)H ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH S?&/\
MR+%[_P!<#5S3O^0?!_UQ7^0JGXQ_Y%B]_P"N!JYIW_(/@_ZXK_(4 34444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S6Q0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !6;XQ_Y%B]_P"N!K2K-\8_\BQ>_P#7 T 7-._Y!\'_ %Q7^0J:H=._
MY!\'_7%?Y"IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Q_ _P#R")?^OV;_ -"K8K'\#_\ ((E_
MZ_9O_0J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^*_VAQ_PR#_P5;^&?[3$'^C^$_CKIA^'GC=Q
MQ&FM1?OM(N']9),&V!SPB-7VI7@W_!2_]F?4/VK_ -C#QE\,?"ZNGB>TLUUG
MP7<P'$L&L63"XMC&W\+.R>5N[+*U;W["/[3&G_M@?LD>!?VA+4QK=:]HD?\
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M=2.H(((/H:Z"O*::9ZJ::N@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Q[+_D=[W_KRB_F:V*Q[+_D=[W_KRB_F:V* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?&/
M_(L7O_7 UI5F^,?^18O?^N!H N:=_P @^#_KBO\ (5-4.G?\@^#_ *XK_(5-
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6/X'_Y!$O\ U^S?^A5L5C^!_P#D$2_]?LW_ *%0!L44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7\AWQK^'OB'X2_&/Q7\+?%L$D>J>'/$=[INH)+][SH)WC8D
M]\E2<]\YK^O&ORT_X+>?\$0_%O[4'BZY_:Z_9%TVWG\9SVZ+XN\(O,D/]M>6
M@1+JW=R$6X"*JNC$"0*""'!$GVW!.<8;+,;.EB'RQJ):O9-7M?LG=Z^A\/QS
MDV*S3 PJX=<TJ;>BW:=KV[M66GJ?AE173_$+X*?&/X2^(G\(_%+X4^(_#FJ1
MR;'T_6]%GM9MWILD4$Y[8ZU[_P#L0?\ !'_]M#]MSQ;8P:#\,M3\*^$I)5.H
M^-_$^G26UG##GYF@63:UV^. D61DC<R [A^N5\;@\-0]M5J)1[WT^7?Y'X]A
M\#C,57]C2IMS[6U^?;YGZ&_\&I/P]\0Z5\'/B]\4KR"1=+USQ'I>FV#M]UYK
M."XDF('TO8@3^':OUEKSS]E7]F;X9?L>_ 3P[^SQ\([!X=&\/6?EK-.09KR9
MF+S7,I &9))&9SC &< !0 /0Z_ L[Q\<TS6KB8JRD]/1))?@C^@\BR^65932
MPLG=Q6OJVV_Q84445Y1ZP4444 %%%% !1110 4444 %%%% !1110!^(/_![S
M_P FL_ __LH&H_\ I"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO
M_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444
M%%%% !7A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*30![I111
M0 4444 %%%% !1110 4444 %%%% !1110!F^,?\ D6+W_K@:N:=_R#X/^N*_
MR%4_&/\ R+%[_P!<#5S3O^0?!_UQ7^0H FHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'LO^1W
MO?\ KRB_F:V*Q[+_ )'>]_Z\HOYFMB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQC_ ,BQ>_\
M7 UI5F^,?^18O?\ K@: +FG?\@^#_KBO\A4U0Z=_R#X/^N*_R%34 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\ U^S?^A4 ;%%%% !1110
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M_P#1>-$_[ZD_^(H_X;N_9#_Z+QHG_?4G_P 10!ZU17DO_#=W[(?_ $7C1/\
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MZD_^(H ]:HKR7_AN[]D/_HO&B?\ ?4G_ ,11_P -W?LA_P#1>-$_[ZD_^(H
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M_P#1>-$_[ZD_^(H_X;N_9#_Z+QHG_?4G_P 10!ZU17DO_#=W[(?_ $7C1/\
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MZD_^(H ]:HKR7_AN[]D/_HO&B?\ ?4G_ ,11_P -W?LA_P#1>-$_[ZD_^(H
M]:HKR7_AN[]D/_HO&B?]]2?_ !%'_#=W[(?_ $7C1/\ OJ3_ .(H ]:HKR7_
M (;N_9#_ .B\:)_WU)_\11_PW=^R'_T7C1/^^I/_ (B@#UJBO)?^&[OV0_\
MHO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_XB@#UJBO)?^&[OV0_^B\:)_P!]2?\
MQ%'_  W=^R'_ -%XT3_OJ3_XB@#UJBO)?^&[OV0_^B\:)_WU)_\ $4?\-W?L
MA_\ 1>-$_P"^I/\ XB@#UJBO)?\ AN[]D/\ Z+QHG_?4G_Q%'_#=W[(?_1>-
M$_[ZD_\ B* /6J*\E_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T7C1/^^I/_B*
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M  W=^R'_ -%XT3_OJ3_XBC_AN[]D/_HO&B?]]2?_ !% 'K5%>2_\-W?LA_\
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M_P"^I/\ XBC_ (;N_9#_ .B\:)_WU)_\10!ZU17DO_#=W[(?_1>-$_[ZD_\
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M,Z)"_P!MT44 %17UA8ZI:2:?J=E%<6\J[98)XPZ./0J>"*EHH PO^%7?#/\
MZ)WH7_@HA_\ B::_PJ^%\A!D^&^@,0,#.CP'_P!EK?HH Y__ (5-\*_^B:>'
M_P#P30?_ !%'_"IOA7_T33P__P"":#_XBN@HH Y__A4WPK_Z)IX?_P#!-!_\
M11_PJ;X5_P#1-/#_ /X)H/\ XBN@HH Y_P#X5-\*_P#HFGA__P $T'_Q%'_"
MIOA7_P!$T\/_ /@F@_\ B*Z"B@#G_P#A4WPK_P"B:>'_ /P30?\ Q%'_  J;
MX5_]$T\/_P#@F@_^(KH** .?_P"%3?"O_HFGA_\ \$T'_P 11_PJ;X5_]$T\
M/_\ @F@_^(KH** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_
M .(KH** .?\ ^%3?"O\ Z)IX?_\ !-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (BN
M@HH \._;7^&_P[TG]E/QSJ6E> M%MKB'0W:*>WTN%'0[EY#!<@_2NV^&GPL^
M&-Q\./#\\_PXT%W?1+1G=]'@)8F%2225Y-=!\2/A]X<^*O@74_AWXNBE?3=6
MMC!>+!*4<H2#PPZ'BM+1M*M-!T>TT/3U8065M'! ';)"(H5<GN< 4 9'_"IO
MA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!10!S_P#PJ;X5_P#1
M-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%=!10!S_\ PJ;X5_\ 1-/#
M_P#X)H/_ (BC_A4WPK_Z)IX?_P#!-!_\17044 <__P *F^%?_1-/#_\ X)H/
M_B*/^%3?"O\ Z)IX?_\ !-!_\17044 <_P#\*F^%?_1-/#__ ()H/_B*/^%3
M?"O_ *)IX?\ _!-!_P#$5T%% '/_ /"IOA7_ -$T\/\ _@F@_P#B*/\ A4WP
MK_Z)IX?_ /!-!_\ $5T%% '/_P#"IOA7_P!$T\/_ /@F@_\ B*/^%3?"O_HF
MGA__ ,$T'_Q%=!10!S__  J;X5_]$T\/_P#@F@_^(H_X5-\*_P#HFGA__P $
MT'_Q%=!10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17
M044 <_\ \*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFGA_\ \$T'_P 17044
M <__ ,*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\ P30?_$5T%% '/_\
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M5-\*_P#HFGA__P $T'_Q%=!10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\
MHFGA_P#\$T'_ ,17044 <_\ \*F^%?\ T33P_P#^":#_ .(H_P"%3?"O_HFG
MA_\ \$T'_P 17044 <__ ,*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\
MP30?_$5T%% '/_\ "IOA7_T33P__ .":#_XBC_A4WPK_ .B:>'__  30?_$5
MT%% '/\ _"IOA7_T33P__P"":#_XBC_A4WPK_P"B:>'_ /P30?\ Q%=!10!S
M_P#PJ;X5_P#1-/#_ /X)H/\ XBC_ (5-\*_^B:>'_P#P30?_ !%=!10!S_\
MPJ;X5_\ 1-/#_P#X)H/_ (BC_A4WPK_Z)IX?_P#!-!_\17044 <__P *F^%?
M_1-/#_\ X)H/_B*/^%3?"O\ Z)IX?_\ !-!_\17044 <_P#\*F^%?_1-/#__
M ()H/_B*/^%3?"O_ *)IX?\ _!-!_P#$5T%% '/_ /"IOA7_ -$T\/\ _@F@
M_P#B*/\ A4WPK_Z)IX?_ /!-!_\ $5T%% '/_P#"IOA7_P!$T\/_ /@F@_\
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MH D_X5-\*_\ HFGA_P#\$T'_ ,11_P *F^%?_1-/#_\ X)H/_B*Z"B@#G_\
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M** .?_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_ .(KH** .?\
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M%=!10!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17044
M9NA^#?"'AB9[CPWX4TW3Y)5VRO8V,<1<=<$H!D5I444 ?B#_ ,'O/_)K/P/_
M .R@:C_Z0BBC_@]Y_P"36?@?_P!E U'_ -(110!Y_P#\&FW_ "E,_:[_ .WC
M_P!/D]?O]7X _P#!IM_RE,_:[_[>/_3Y/7[_ % !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5X?^VE^V]HO[(6F:)HVA?!/QO\
M%#QUXJ:X_P"$6^'GP\TD76H7L5N(_M%W*SLL5K:PF:!9)Y& #3QJ S,!7N%4
M$\+>'8_%,GC9=&@_M:73TL7U IF7[,CM(L0/9=[LQ ZG&<X& #Y4_P""??\
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M#;W1@_M+7(II3OOFN76*,;0J6\!C4B;S4N' /U"HHHH **** "BBB@ HHHH
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M7?"_BG28=2T+5[,GR[JVE4,C $ J<'!5@&4@JP!! _+_ /X(F_\ !0']FO\
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M_P#!1'X"ZSI45[X4T?X]Z%XIT_3YUW01ZM=2WMS-.%Z>8)["UDS_ 'HEST%
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MM7M(-8VD J+^66XN4W#+1-%)_P M:X__ (*A ?\ #[C_ ()S-CG^V?B7S_W
M[&@#]$Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\/_;2_;>T7]D+3-$T;0O@GXW^*'CKQ4UQ_P (M\//AYI(NM0O
M8K<1_:+N5G98K6UA,T"R3R, &GC4!F8"O<*H)X6\.Q^*9/&RZ-!_:TNGI8OJ
M!3,OV9':18@>R[W9B!U.,YP, 'RI_P $^_\ @K_\)_VY/C'XN_98\5_!/QQ\
M(/C%X'M%OM=^&OQ%T](+M[%F11=V[HQ6:(>;#DX4XE1E#(P:N\^(/[=UM#^T
M7KO[)_[.?P8U?XG^.?!VAVNK^/+72M6L["R\.P708VEO<7-U(J_;+A4=XK=0
M<HI>1XE*LWBWPL^"ME^TM_P7&\7?M[>&+)8_"?PA^$Z_"ZVUF-,+KWB-[^6[
MOQ&X_P!;%8Q2+:N>@N))(P<P.J^7_P#!N3K>J_$OQY^VK\<O%LK2:YK_ .U=
MK=E>/*<O';VB*+>#GG9&DY11V"XH ^S/A1_P4"_9H^+?[)NI_MEZ9XJNM+\)
M>'H;\>++?6+)H]1T"\L6:.\T^ZMDWNMW%(IC\E-Y=BGE[Q(A;YAOO^#@CP3\
M+OBYX5\*?M@?L$_'+X)>"/'>L)I?A+XF?$3P]#!I[W,G,2WJ)*S6)89.UBS*
M 6=5579>%_X(S6^F^(?^"D/_  41^ NLZ5%>^%-'^/>A>*=/T^=-T$>K7,E[
M<S3A>GF">PM9,_WHE)Z"O7O^"Z7P<MOVW_@5X0_X)H>&+1;KQ1\7/'&F7,T\
M<89_#OA_3;N&ZU36G)XC6.,):KG'F37T48SO. #W7]M+]M[1?V0M,T31M"^"
M?C?XH>.O%37'_"+?#SX>:2+K4+V*W$?VB[E9V6*UM83- LD\C !IXU 9F KS
M7_@GW_P5_P#A/^W)\8_%W[+'BOX)^./A!\8O ]HM]KOPU^(NGI!=O8LR*+NW
M=&*S1#S8<G"G$J,H9&#5]46O@_PQ9^(CXNM]$@&J'38]/^WE<RBU1V=8@QY"
M[G9B.YQG.!CXJ^%GP5LOVEO^"XWB[]O;PQ9+'X3^$/PG7X76VLQIA=>\1O?R
MW=^(W'^MBL8I%M7/07$DD8.8'50#[GHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
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MB-712]?<]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMKB.ZMX[J)7"R('421LC $9Y5@"I]B 1WI]%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?'/_!57]JS]L3X26VA?!G]
MDC]C3XI>/?\ A)%\SQEXS\ 1VT<FB:;EE>"REN'"B_EV[1(5(MT?S0'?8M?8
MU% 'PU^Q-^V-^U;XL\>^!_V7O"7_  1Y\;_!#X>Z;;RIJGBCQOJULUGIEC!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^(/_  >\
M_P#)K/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/V
MN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+OB1^UUX&TSQ!X2T"XUGQ3I3ZVDDNCV<$D44C70CW"!_,FB18G(D=I%"*Q-
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MD?32LKJ'1@5(R"#P10 M%%% !1110 4444 %%%% !17XMT5^[?\ $%/^H_\
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MU_:O_:#L[:3XX6/PUT2QO;:Y@0K_ ,)1>QP6Y>6-?D9HI9'FD1<(QA=5P"*
M/O"BOS&_;I^'WQ-_X)>?\$VO#W_!0[X9_$?Q;K/Q<^&$_A[5_BGJ.O>*KVY7
MQ];W=U;VNK65[#+(T(B+7320A44VODH(=@!4];^U;^UY??M<_P#!1C]G3_@G
M#\*/&^KZ5X"\=_#VX^*7Q.OM"U&6RO=6T$0RC3=,%Q RR00SW$>;@(RL\>U
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MP^U;X>7'B?5=&AUBS:UN-1T.:..ZCB;AQ&\B.J%EW(6V[@&)4JP##XA\8_\
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M%?&V'Q2DD4/Q2_9PT76/"5U<=+N/3WT[3IXE;HT@>W9RHY"C=C!S7UU\,/\
M@G;\&/A]X[\(?$'Q-XT\:^/+OX<64EI\-(/'NOK?0^%8GB$+-;*L49FG\D"+
M[5=&>Y";E$H#ONZK]H7]D?X7?M&>(/"GQ!UZ\U?0/&?@.\GN?!7CKPM>);ZI
MHS3Q>5<1QM(DD4L,T>%D@GCEA?:I9"R*0 ?$.F>$]7^+G_!UEJWCWP]"[Z5\
M)OV5;/3?$5V@RD-[?:A--;6SD='>&Y>4 ]5A8]J_2^O-OV=/V5/A/^S);^(;
MSP)!J%_K_C'5_P"U?&OC#Q#?&[U7Q!>B,1K+<SD 82-5CCAC5(8D&V.-!Q79
M^.?#%]XR\+W7AO3O&FK^'Y+I-AU70V@6ZB7N$:>*55)&1NV[AG*E2 0 ?FI_
MP:?Q17'_  3Q^(T,T:NC?M$>)PRL,@CR;'J*\M_X(_?"_P"')_X-?/B]-_PA
M&E^;K?@_XD+J\WV)/,O!!_:*0>8V,MY84;,_<QD8-??'[&7_  2L^!_[ 'PV
M\1?"/]EGXK_$?0/#_B:_GU#4+&Y\06]\8[^9(TDO(7NK:1XI2D2*2IVGJ5+
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MH_\ I"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\
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MP<5)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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E#?X;_ 'Q)X.G\'>)+K4KFYUS4[>=+A);<1!%$0R"",Y-% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332321952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APYX MEDICAL CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2644611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5115 Ulmerton Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Clearwater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APYX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,597,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000719135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332311024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RSM US LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Orlando, Florida<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332443504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,192<span></span>
</td>
<td class="nump">$ 30,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net of allowance of $668 and $430</a></td>
<td class="nump">10,602<span></span>
</td>
<td class="nump">13,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">7,545<span></span>
</td>
<td class="nump">7,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of provision for obsolescence of $457 and $263</a></td>
<td class="nump">11,797<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">42,972<span></span>
</td>
<td class="nump">60,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,761<span></span>
</td>
<td class="nump">6,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">51,775<span></span>
</td>
<td class="nump">68,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,669<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,928<span></span>
</td>
<td class="nump">10,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,850<span></span>
</td>
<td class="nump">13,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">1,408<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,982<span></span>
</td>
<td class="nump">14,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of December&#160;31, 2022, and 34,409,912 issued and outstanding as of December 31, 2021</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">73,282<span></span>
</td>
<td class="nump">66,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(35,735)<span></span>
</td>
<td class="num">(12,551)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">37,582<span></span>
</td>
<td class="nump">53,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">37,793<span></span>
</td>
<td class="nump">54,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 51,775<span></span>
</td>
<td class="nump">$ 68,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,597,822<span></span>
</td>
<td class="nump">34,409,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221337062448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 668<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProvisionForObsolescenceInventory', window );">Provision for obsolescence</a></td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,597,822<span></span>
</td>
<td class="nump">34,409,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,597,822<span></span>
</td>
<td class="nump">34,409,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForObsolescenceInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Obsolescence, Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForObsolescenceInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221333615344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 44,510<span></span>
</td>
<td class="nump">$ 48,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">15,379<span></span>
</td>
<td class="nump">14,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">29,131<span></span>
</td>
<td class="nump">33,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Other costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,544<span></span>
</td>
<td class="nump">4,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">9,044<span></span>
</td>
<td class="nump">7,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related costs</a></td>
<td class="nump">18,621<span></span>
</td>
<td class="nump">17,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">20,484<span></span>
</td>
<td class="nump">18,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total other costs and expenses</a></td>
<td class="nump">52,693<span></span>
</td>
<td class="nump">48,049<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(23,562)<span></span>
</td>
<td class="num">(14,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (losses), net</a></td>
<td class="nump">509<span></span>
</td>
<td class="num">(373)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="nump">651<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(22,911)<span></span>
</td>
<td class="num">(14,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(23,278)<span></span>
</td>
<td class="num">(15,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders</a></td>
<td class="num">$ (23,184)<span></span>
</td>
<td class="num">$ (15,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (in shares)</a></td>
<td class="nump">34,516<span></span>
</td>
<td class="nump">34,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - dilutive (in shares)</a></td>
<td class="nump">34,516<span></span>
</td>
<td class="nump">34,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221333660240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Non-controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 63,859<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 61,066<span></span>
</td>
<td class="nump">$ 2,621<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">5,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(15,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,172)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">54,009<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">66,221<span></span>
</td>
<td class="num">(12,551)<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">6,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(23,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,184)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 37,793<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 73,282<span></span>
</td>
<td class="num">$ (35,735)<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336897424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (23,278)<span></span>
</td>
<td class="num">$ (15,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProvisionForInventoryObsolescence', window );">Provision for inventory obsolescence</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProductWarrantyExpenseNet', window );">Provision for product warranties</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">6,697<span></span>
</td>
<td class="nump">5,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for allowance for doubtful accounts</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in current assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">1,918<span></span>
</td>
<td class="num">(4,901)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(523)<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(5,568)<span></span>
</td>
<td class="num">(2,859)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,208)<span></span>
</td>
<td class="nump">3,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,280)<span></span>
</td>
<td class="num">(10,449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,010)<span></span>
</td>
<td class="num">(723)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,010)<span></span>
</td>
<td class="num">(723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_RepaymentOfFinanceLeaseLiabilities', window );">Repayment of finance lease liabilities</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Contributions from non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(20,678)<span></span>
</td>
<td class="num">(11,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">30,870<span></span>
</td>
<td class="nump">41,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">10,192<span></span>
</td>
<td class="nump">30,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseRecongizedNonCash', window );">Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseRecognizedExecution', window );">Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseDerecognizedExecution', window );">Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_NonCashTransferOfOtherAssetsToFixedAssets', window );">Transfer of right-of-use assets to property and equipment on exercise of purchase option</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseDerecognizedExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Derecognized, Execution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseDerecognizedExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseRecognizedExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Recognized, Execution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseRecognizedExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseRecongizedNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Recongized, Non Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseRecongizedNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NonCashTransferOfOtherAssetsToFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash, Transfer Of Other Assets To Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NonCashTransferOfOtherAssetsToFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProductWarrantyExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Warranty Expense, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProductWarrantyExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForInventoryObsolescence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Inventory Obsolescence</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForInventoryObsolescence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_RepaymentOfFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Finance Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_RepaymentOfFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221338695280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (&#8220;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; and J-Plasma&#174; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its plan to accelerate and fully fund the development of its advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, the Company sold its Core business in 2018 for gross proceeds of $97&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) posted a Safety Communication that warns consumers and health care providers against the use of the Company&#8217;s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#174; Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#174; APR Handpiece for certain skin contraction procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, and July 21, 2022, the FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#174; Dermal handpiece, and the expanded indications for the Renuvion&#174; APR handpieces. The 510(k) clearance for the Renuvion&#174; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.  The 510(k) clearance for the Renuvion&#174; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2023, we announced we had submitted a 510(k) premarket notification (&#8220;510(k) submission&#8221;) for the Renuvion APR Handpiece to the FDA, supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion&#8217;s indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While management expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, the Company continues to experience reduced demand for the adoption and utilization of its technology and management believes that this may have an adverse effect in future periods.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Financial Accounting Standards Board&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company as of the date the condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#8217;s sale of the Core business segment to Symmetry Surgical during 2018, it has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6&#160;million and used $20.3&#160;million of cash in operations. As of December 31, 2022, the Company had cash and cash equivalents of $10.2&#160;million. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100&#160;million. The shelf registration included an embedded ATM facility for up to $40&#160;million. To date the Company has not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25&#160;million, comprised of (i) an initial tranche of $10&#160;million, (ii) a second tranche of $5&#160;million, and (iii) a third tranche of $10&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10&#160;million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the Credit Agreement see Note 20.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, the Company&#8217;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of the Company's facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. Upon the closing of the sale of the Property, the Company will enter into a lease agreement with the Purchaser, pursuant to which the Property will be leased back to the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement see Note 20.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for substantially the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company's U.S. headcount by 14%. </span></div>Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations for a period of at least one year from the date of issuance of these audited consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company's ability to continue as a going concern. These audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334798256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, &#8220;Apyx,&#8221; or the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holdings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December&#160;31, 2022 and 2021, all of the Company&#8217;s investments are in money market funds or in Treasury Bills with original maturities of three months or less and are included in cash and cash equivalents.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's standard credit terms for billings range from net 30 days to net 120 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#8217; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available. Management believes that the allowances for doubtful accounts of approximately $0.7 million and $0.4&#160;million at December&#160;31, 2022 and 2021, respectively, are adequate to provide for probable bad debts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#8217; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2022 and 2021, the Company believes the remaining carrying values of its long-lived assets are recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Warranties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a four year limited warranty on end-user sales of its Renuvion&#174;/J-Plasma&#174; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#174;/J-Plasma&#174;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Product returns are only accepted at the Company's discretion and in accordance with its &#8220;Returned Goods Policy&#8221;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. Recognition of the deferred billings and costs occurs as the Company performs on the accompanying supply arrangements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The amounts of advertising costs, including trade shows, were approximately $2.3 million and $1.3 million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the grant date fair value of such awards. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (Loss) Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are charged to operations as incurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planning strategies.  As of December 31, 2022 and 2021, the Company recorded a valuation allowance on the net deferred tax assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2022 and 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior year to conform to the current year presentation. These reclassifications had no impact on previously reported net income, retained earnings or operating cash flows for the periods presented.</span></div>RECENT ACCOUNTING PRONOUNCEMENTS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">and Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 842) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334765072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, &#8220;Apyx,&#8221; or the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated in consolidation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holdings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December&#160;31, 2022 and 2021, all of the Company&#8217;s investments are in money market funds or in Treasury Bills with original maturities of three months or less and are included in cash and cash equivalents.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's standard credit terms for billings range from net 30 days to net 120 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#8217; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available. Management believes that the allowances for doubtful accounts of approximately $0.7 million and $0.4&#160;million at December&#160;31, 2022 and 2021, respectively, are adequate to provide for probable bad debts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#8217; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2022 and 2021, the Company believes the remaining carrying values of its long-lived assets are recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Warranties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a four year limited warranty on end-user sales of its Renuvion&#174;/J-Plasma&#174; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#174;/J-Plasma&#174;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Product returns are only accepted at the Company's discretion and in accordance with its &#8220;Returned Goods Policy&#8221;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. Recognition of the deferred billings and costs occurs as the Company performs on the accompanying supply arrangements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. The amounts of advertising costs, including trade shows, were approximately $2.3 million and $1.3 million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the grant date fair value of such awards. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (Loss) Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are charged to operations as incurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planning strategies.  As of December 31, 2022 and 2021, the Company recorded a valuation allowance on the net deferred tax assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2022 and 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior year to conform to the current year presentation. These reclassifications had no impact on previously reported net income, retained earnings or operating cash flows for the periods presented.</span></div>RECENT ACCOUNTING PRONOUNCEMENTS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">and Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 842) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221338910768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITION OF THE CORE BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSITION OF THE CORE BUSINESS</a></td>
<td class="text">DISPOSITION OF THE CORE BUSINESS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 30, 2018, the Company closed on a definitive asset purchase agreement (the &#8220;Asset Purchase Agreement&#8221;) with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the Company&#8217;s electrosurgical &#8220;Core&#8221; business segment and related intellectual property, including the Bovie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> brand and trademarks, to Symmetry for gross proceeds of $97 million in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, which expired August 30, 2022, whereby it manufactured certain Core pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ducts and sold them to Symmetry at agreed upon prices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Any activity resulting from this agreement is netted and reported in the Consolidated Statements of Operations as other income (loss). Core activity for 2022 amounted to $0.6&#160;million with cost of sales equivalents of $0.6&#160;million and other related expenses of $0.1&#160;million for net other loss of $0.1&#160;million.  Core activity for 2021 amounted to $6.5&#160;million with cost of sales equivalents of $5.5&#160;million and other related expenses of $1.5&#160;million for net other loss of $0.4&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334715312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">INTEREST IN JOINT VENTURE INVESTMENT</a></td>
<td class="text">INTEREST IN JOINT VENTURE INVESTMENT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier (the &#8220;China JV&#8221;) whereby the Company has a 51% interest. The China JV has been consolidated in these consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Changes in the Company&#8217;s ownership investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:54.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.700%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332289936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334720032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,295&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total depreciation expense was $0.7&#160;million for the years ended December&#160;31, 2022 and 2021. Depreciation expense is included within cost of goods sold and selling, general and administrative expense in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334657008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company&#8217;s lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate, which is indicative of its collateralized borrowing rate. We utilized rates of 1.83% to 6.49% for our outstanding leases at December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the year ended December 31, 2022, the Company&#8217;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the year ended December 31, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the year ended December 31, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the year ended December 31, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s lease costs are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash information related to our leases are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2021<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2021<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company&#8217;s lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate, which is indicative of its collateralized borrowing rate. We utilized rates of 1.83% to 6.49% for our outstanding leases at December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the year ended December 31, 2022, the Company&#8217;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the year ended December 31, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the year ended December 31, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the year ended December 31, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s lease costs are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash information related to our leases are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2021<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2021<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221335504320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:67.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334644720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRODUCT WARRANTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantiesDisclosuresAbstract', window );"><strong>Product Warranties Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">PRODUCT WARRANTIES</a></td>
<td class="text">PRODUCT WARRANTIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product warranty activity consisted of the following for the years ended:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:67.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimate to fulfill prior-year warranty obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantiesDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantiesDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI https://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221335442240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>JOINT AND SEVERAL PAYROLL LIABILITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_JointandSeveralPayrollLiabilityTextBlock', window );">JOINT AND SEVERAL PAYROLL LIABILITY</a></td>
<td class="text">JOINT AND SEVERAL PAYROLL LIABILITYDuring 2018 and 2019, the Company improperly calculated and reported the amount of income to certain employees, and did not collect and remit the correct amount of its employees' portion of income and payroll taxes, related to stock option exercises as required by the IRS. Due to IRS statutory requirements, the Company has joint and several liability for the full amount that was not withheld and remitted to the proper taxing authorities. During 2022, the Company was relieved of approximately $650,000 of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. This adjustment is included in other income (losses), net in the accompany Consolidated Statement of Operations for the year ended December 31, 2022. This amount of the liability was approximately $0.3&#160;million and $1.0&#160;million at December&#160;31, 2022 and 2021, respectively. The Company will be relieved of the remainder of the liability as the statute of limitations on the liability expires, which the Company expects to occur during April 2023, or once the Company can establish that its employees have in fact paid these obligations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointandSeveralPayrollLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint and Several Payroll Liability [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointandSeveralPayrollLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334666000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACT ASSETS AND LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">CONTRACT ASSETS AND LIABILITIES</a></td>
<td class="text">CONTRACT ASSETS AND LIABILITIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts with customers may result in the Company having contract assets and liabilities. These contract assets and liabilities arise primarily from OEM development and supply agreements where the development of the goods does not represent a performance obligation on a standalone basis. The Company defers the development fees billed to customers, and the associated costs, and recognizes them as it completes performance obligations on the supply portion of the agreement. Other contract liabilities may be recognized when a customer prepays for goods or services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, respectively, the Company had recorded approximately $2.3&#160;million and $1.9&#160;million of contract liabilities and $0.6&#160;million and $0.5&#160;million of contract assets related to customer prepayments and the deferral of revenues and expenses under these agreements. At December&#160;31, 2022, $0.9&#160;million of the contract liabilities and $0.1&#160;million of the contract assets are presented as current in the accompanying Consolidated Balance Sheet within accrued expenses and other current liabilities and prepaid expenses and other current assets, respectively. At December&#160;31, 2021,  $0.5&#160;million of the contract liabilities and $0.1&#160;million of the contract assets are presented as current in the accompanying Consolidated Balance Sheet within accrued expenses and other current liabilities and prepaid expenses and other current assets, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company recognized approximately $0.2&#160;million of contract liabilities and $0.1&#160;million of contract assets that existed as of December&#160;31, 2021 in sales and cost of sales, respectively, in the accompanying Consolidated Statement of Operations for the year ended December&#160;31, 2022. During 2021, the Company did not recognize any significant contract liabilities or contract assets that existed as of December&#160;31, 2020 in sales or cost of sales in the accompanying Consolidated Statement of Operations for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334580144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted earnings (loss) per share.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerators:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,184)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334666000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense are as follows:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,131)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of the Company&#8217;s deferred tax assets (liabilities) are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance deductibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory 263A adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all positive and negative evidence regarding the realization of deferred tax assets, including past operating results and future sources of taxable income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the earnings of Apyx Bulgaria, EOOD to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. It has not recorded a deferred tax liability related to the U.S. Federal and State income taxes and foreign withholding taxes on the undistributed earnings of Apyx Bulgaria, EOOD indefinitely invested outside the United States. If it decides to repatriate the foreign earnings, the Company will need to adjust its income tax provision in the period it determines that the earnings will no longer be indefinitely invested outside the United States.&#160; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. As of December 31, 2022 and 2021, the Company has recorded a liability of approximately $1.3 million related to uncertain tax positions and accrued approximately $0.8&#160;million and $0.6&#160;million, respectively, of interest and penalties on these positions. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.093%"><tr><td style="width:1.0%"/><td style="width:58.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Tax Benefits</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of year balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions of tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions of tax positions related to the prior year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Decreases for tax positions related to prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of year balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal and state income tax examination.  The Company&#8217;s 2019 through 2021 U.S. federal income tax returns are subject to examination by the Internal Revenue Service (&#8220;IRS&#8221;).  The Company&#8217;s state income tax returns are subject to examination for the 2018 through 2021 tax years.</span></div>During 2022, the Company was notified by the IRS that it is examining the Company&#8217;s 2018, 2019 and 2020 federal income tax returns. During January 2023, the Company was notified that the examination process was complete and that the Company's tax refunds were approved for substantially the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. In the examination, the Company's uncertain tax positions were accepted by the IRS as submitted on our income tax returns and the Company reversed its uncertain tax position in January 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221338910768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">RETIREMENT PLAN</a></td>
<td class="text">RETIREMENT PLAN<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a tax-qualified profit-sharing retirement plan under section 401(k) of the Internal Revenue Code for the benefit of eligible employees with an accumulation of funds for retirement on a tax-deferred basis and provides for annual discretionary contribution to individual trust funds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All employees are eligible to participate upon completing three months of service. The employees may make voluntary contributions to the plan up to the maximum percentage allowed by the Internal Revenue Code. Vesting in employee matching contributions is graded and depends on the years of service. After three years from their date of hire, the employees are 100% vested. The Company makes matching contributions of 50% of the employee contributions up to a total of 3% of participant payroll. Matching contributions made by the Company totaled approximately $0.4&#160;million for each of the years ended December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221338432816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Tor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">omanova, Mr. Shilev&#8217;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company&#8217;s China joint venture is also a supplie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r of the Company. For the years ended December&#160;31, 2022 and 2021, the Company made purchases from this supplier of approximately $0.6&#160;million and $1.3&#160;million, respectively. At December&#160;31, 2022 and 2021, the Company had net receivables from and payables to this supplier of approximately $8,000 and $1,000, respective</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ly.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221338602176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company has recorded an estimated loss of $250,000 in professional services in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed with the U.S. Securities and Exchange Commission on the Company&#8217;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#8220;Goodwin&#8221;), the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, and Tara Semb (&#8220;Semb&#8221;), the Company&#8217;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#8217;s Advanced Energy products and the impact such usage would have on the Company&#8217;s business, operations and prospects. The Complaint seeks an unspecified amount of damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company has recorded an estimated loss of $475,000 in professional services in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff&#8217;s allegations could be subject to separate deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company has recorded an estimated loss of $1,450,000 in selling, general and administrative expenses associated with the insurance deductibles in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company has purchase commitments for inventories totaling approximately $4.1&#160;million, all of which is expected to be purchased by the end of 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant sales concentrations for the year ended December 31, 2022. Sales to one customer within the Advanced Energy segment represented 11% of total sales for the year ended December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from one customer and two customers within the Advanced Energy segment represented 13% and 22%, respectively, of trade accounts receivable at December 31, 2022 and December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221338910768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTIONS</a></td>
<td class="text">STOCK OPTIONS&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2007, the Company&#8217;s stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan (the &#8220;Plan&#8221;) to increase the maximum aggregate number of shares of common stock reserved for issuance under the Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares. Except for the increase in the number of shares covered by the Plan, the Plan remained otherwise unchanged. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance 1.2 million stock options. Stock options to employees typically have a ten-year life and currently vest over periods between <span style="-sec-ix-hidden:f-617">one</span> and seven years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, the Company&#8217;s stockholders approved the 2012 Share Incentive Plan covering a total of 750,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 170,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, the Company&#8217;s stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 40,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company&#8217;s stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of 3,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 30,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company&#8217;s stockholders approved the 2019 Share Incentive Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022, all 200,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company&#8217;s stockholders approved the 2021 Share Incentive Plan covering a total of 1,375,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022, all 1,375,000 are available to be issued in this plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2023, the Company granted employees appro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ximately 1,400,000 options to purchase common shares of the Company's stock. All options granted were pursuant to the plans noted above. The options ves</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t over a period of three years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the Company&#8217;s stock options is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,397,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,028,867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. Options are valued using the Black-Scholes model. For employee grants, the Company calculates expected life via the simplified method as it does not have sufficient history to determine actual expected life. For non-employee grants, the Company calculates expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior. Inputs used in the valuation models are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:60.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.121%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Grants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.10</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.29</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.51</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $6,697,000 and $5,088,000 in stock-based compensation expense during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is &#8220;in-the-money&#8221;. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation at December 31, 2022 is based on the $2.34 closing stock price of the Company's common stock on December&#160;30, 2022, the last trading day of 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were 6,074,922 stock options outstanding and expected to vest with an aggregate intrinsic value of approximately $160,000. These options have a weighted average exercise price of $6.91 and a weighted average remaining contractual term of approximately 6 years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were 4,292,836 stock options outstanding and exercisable with an aggregate intrinsic value of approximately $160,000. These options have a weighted average exercise price of $5.60 and a weighted average remaining contractual term of approximately 6 years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of in the money options exercised during the years ended December&#160;31, 2022 and 2021, was approximately $900,000 and $1,600,000, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options or other consideration paid. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options granted during the years ended December&#160;31, 2022 and 2021, was approximately $11,350,000 and $5,150,000, respectively. The weighted average fair value of options granted during the years ended December&#160;31, 2022 and 2021, was $6.71 and $5.76, respectively. The total fair value of options vested during the years ended December&#160;31, 2022 and 2021, was approximately $5,260,000 and $4,270,000, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows employees to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. During the years ended December&#160;31, 2022 and 2021, the Company received 125,596 and 111,831 options as payment in the exercise of 81,737 and 107,357 options, respectively.</span></div>As of December&#160;31, 2022, there was approximately $8,430,000 of total unrecognized stock-based compensation expense, related to unvested stock options granted under the plans above. This expense is expected to be recognized over a weighted-average period of approximately 1 year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332289936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC AND SEGMENT INFORMATION</a></td>
<td class="text">GEOGRAPHIC AND SEGMENT INFORMATION&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reportable segments are disclosed as principally organized and managed as</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales in 2022 and 2021, were 29.9% and 32.0% of sales, respectively. Revenue by geographic region, based on the "ship to" location on the invoice are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,510&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,517&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334568048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Execution of Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#8220;Credit Agreement&#8221;), by and among the Company (as borrower) and Apyx China Holding Corp., the Company&#8217;s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for an up to $35&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25&#160;million, comprised of (i) an initial tranche of $10&#160;million, (ii) a second tranche of $5&#160;million, and (iii) a third tranche of $10&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10&#160;million, subject to a borrowing base equal to certain percentages of the Company&#8217;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.  The Credit Agreement matures on February 1, 2028.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Term Loans </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The initial tranche of $10&#160;million was fully funded on February 17, 2023, with approximately $2&#160;million of the proceeds used to pay for transaction fees and other costs incurred in connection with the Credit Agreement. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company&#8217;s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets. The net proceeds of these term loans are to be used for working capital and general corporate purposes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each term loan bears interest at a floating rate based on an Adjusted Term SOFR (as defined in the Credit Agreement), subject to a floor of 2.5%, plus 7.35%. The first twenty-four (24) months of the term loans constitute an interest-only period (with a possible twelve (12) month extension), with interest payable monthly on the first day of each month. Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension of the interest-only period). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment obligations, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of 4% of the total amount funded thereunder. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Revolving Facility </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. The proceeds of the revolving facility may be used for working capital needs and general corporate purposes.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans made under the revolving facility bear interest at a floating rate based on an Adjusted Term SOFR (as defined in the Credit Agreement), subject to a floor of 2.5%, plus 4%. The Company is obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee pursuant to the terms of the Credit Agreement. Terminations and reductions of the commitments are subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10&#160;million under the revolving facility.  If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Collateral </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Covenants </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions set forth in the Credit Agreement. The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49&#160;million, $60&#160;million and $70&#160;million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $10&#160;million in cash and cash equivalents during the duration of the Credit Agreement&#8217;s term. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Events of Default</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreement also contains customary Events of Default (as defined in the Credit Agreement) that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Issuance of Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Company&#8217;s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale Leaseback of Clearwater, FL Real Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company's unencumbered real property. On February 27, 2023 the Company&#8217;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 14, 2023, Apyx Medical Corporation (the &#8220;Company&#8221;) entered into a Purchase and Sale Agreement (the &#8220;Purchase Agreement&#8221;) with VK Acquisitions VI, LLC (the &#8220;Purchaser&#8221;), for the sale of the Company&#8217;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#8220;Property&#8221;) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser within thirty (30) days from the date of execution, during which time the Purchaser retains the right to cancel the Purchase Agreement. The closing shall occur five (5) days following the expiration of the due diligence period. Upon execution of the Purchase Agreement, the Purchaser paid a down payment of $400,000 into escrow, which shall be held in accordance with the Purchase Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the terms of the Purchase Agreement, the transaction is not conditioned upon Purchaser obtaining any form of financing. The Purchase Agreement contains customary representations, warranties and covenants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the &#8220;Lease&#8221;) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (10) years commencing from the closing (the &#8220;Initial Term&#8221;), and a renewal term of five (5) years, exercisable at the Company&#8217;s option. The annual fixed rent will be $619,500 for the first year of the Initial Term, and will be subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The net cash proceeds the Company expects to receive following closing is approximately $6,700,000 after taxes, expenses, and fees. This estimate is subject to the consummation of the transaction and the finalization of the Company&#8217;s obligations associated with the sale. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the &#8220;Stein Suit&#8221;) against individual members of the Company&#8217;s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the &#8220;Pritchard Case&#8221;).  The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing.  The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously.  The outcome of the action is not within the Company&#8217;s control and may not be known for a prolonged period of time.  In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company&#8217;s financial condition, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221333499952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidated Financial Statements</a></td>
<td class="text">Consolidated Financial StatementsThe accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, &#8220;Apyx,&#8221; or the &#8220;Company&#8221;). All significant intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in the Preparation of Financial Statements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in the Preparation of Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsHoldings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December&#160;31, 2022 and 2021, all of the Company&#8217;s investments are in money market funds or in Treasury Bills with original maturities of three months or less and are included in cash and cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's standard credit terms for billings range from net 30 days to net 120 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.</span></div>The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#8217; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. </span></div>The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#8217; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2022 and 2021, the Company believes the remaining carrying values of its long-lived assets are recoverable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Product Warranties</a></td>
<td class="text">Product WarrantiesThe Company provides a four year limited warranty on end-user sales of its Renuvion&#174;/J-Plasma&#174; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#174;/J-Plasma&#174;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.</span></div><div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Product returns are only accepted at the Company's discretion and in accordance with its &#8220;Returned Goods Policy&#8221;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.</span>&#8226;In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. Recognition of the deferred billings and costs occurs as the Company performs on the accompanying supply arrangements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the grant date fair value of such awards. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Litigation Contingencies</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earning (Loss) Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings (Loss) Per Share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development CostsResearch and development expenses are charged to operations as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planning strategies.  As of December 31, 2022 and 2021, the Company recorded a valuation allowance on the net deferred tax assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2022. </span></div>The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text">Foreign Currency TransactionsThe functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2022 and 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior year to conform to the current year presentation. These reclassifications had no impact on previously reported net income, retained earnings or operating cash flows for the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 815), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">and Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Topic 842) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334636544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_NoncontrollingInterestTableTextBlock', window );">Schedule of Noncontrolling Interest</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Changes in the Company&#8217;s ownership investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:54.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.700%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334671856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,797&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334644720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,295&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332429136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease Costs</a></td>
<td class="text">Information about the Company&#8217;s lease costs are as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash information related to our leases are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2021<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company&#8217;s weighted average remaining lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended <br/>December 31, 2021<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Finance Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022 are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334720032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:67.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334755312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRODUCT WARRANTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantiesDisclosuresAbstract', window );"><strong>Product Warranties Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule of Product Warranty Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product warranty activity consisted of the following for the years ended:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:67.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimate to fulfill prior-year warranty obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantiesDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantiesDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334666000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Earnings (Loss) Per Share</a></td>
<td class="text">The following table provides the computation of basic and diluted earnings (loss) per share.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerators:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,184)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221333640400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components Of Provision For Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense are as follows:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,131)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Statutory Federal Income Tax Rate</a></td>
<td class="text">Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive stock compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILTI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets (Liabilities)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of the Company&#8217;s deferred tax assets (liabilities) are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss and credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance deductibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory 263A adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,525&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits Roll-Forward</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.093%"><tr><td style="width:1.0%"/><td style="width:58.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Tax Benefits</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of year balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions of tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions of tax positions related to the prior year </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Decreases for tax positions related to prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of year balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221334597744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options And Stock Awards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of the Company&#8217;s stock options is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,397,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Number of Weighted Average Grant-Date Fair Values of Options</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,692,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,028,867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Option Fair Value Assumptions</a></td>
<td class="text">Inputs used in the valuation models are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:60.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.121%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Grants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.10</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.29</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.51</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221337016384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Reporting Information by Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate (Other)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other losses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of Revenue by Geographic Area</a></td>
<td class="text">Revenue by geographic region, based on the "ship to" location on the invoice are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,510&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,517&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336502048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2023</div></th>
<th class="th"><div>Jan. 19, 2023</div></th>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,562<span></span>
</td>
<td class="nump">$ 14,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,280<span></span>
</td>
<td class="nump">10,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,192<span></span>
</td>
<td class="nump">$ 30,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in headcount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackPurchaseAgreement', window );">Sale leaseback, purchase agreement</a></td>
<td class="nump">$ 7,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Subsequent Event | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Subsequent Event | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Subsequent Event | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Subsequent Event | Credit Agreement | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Subsequent Event | Credit Agreement | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Subsequent Event | Credit Agreement | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apyx_ShelfRegistrationMember', window );">Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SecuritiesRegisteredNewIssues', window );">Securities Registered, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apyx_AtTheMarketFacilityMember', window );">At-The-Market Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SecuritiesRegisteredNewIssues', window );">Securities Registered, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SecuritiesRegisteredNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Registered, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SecuritiesRegisteredNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apyx_ShelfRegistrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apyx_ShelfRegistrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apyx_AtTheMarketFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apyx_AtTheMarketFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336911504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 668<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apyx_ApyxSYMedicalDevicesNingboCoLtdMember', window );">Apyx SY Medical Devices (Ningbo) Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Molds | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Molds | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_RenuvionJPlasmaGeneratorsMember', window );">Renuvion/J-Plasma generators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProductWarranty', window );">Product warranty</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MountingFixturesMember', window );">Mounting Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProductWarranty', window );">Product warranty</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_AccessoriesMember', window );">Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ProductWarranty', window );">Product warranty</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProductWarranty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Warranty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProductWarranty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apyx_ApyxSYMedicalDevicesNingboCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apyx_ApyxSYMedicalDevicesNingboCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_RenuvionJPlasmaGeneratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_RenuvionJPlasmaGeneratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MountingFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_MountingFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_AccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_AccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332379856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSITION OF THE CORE BUSINESS - (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Gross proceeds</a></td>
<td class="nump">$ 97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member', window );">Symmetry Surgical Inc. | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_AssetPurchaseAgreementTerm', window );">Asset purchase agreement, term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Net other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AssetPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AssetPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221337054864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_NoncontrollingInterestRequiredCapitalContribution', window );">Required capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">China joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=apyx_ChineseSupplierMember', window );">Chinese Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestRequiredCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Required Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestRequiredCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apyx_ChineseSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apyx_ChineseSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336987776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">$ 305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">China joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221335991312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 4,979<span></span>
</td>
<td class="nump">$ 3,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">5,115<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross inventories</a></td>
<td class="nump">12,254<span></span>
</td>
<td class="nump">7,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: provision for obsolescence</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 11,797<span></span>
</td>
<td class="nump">$ 6,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336612176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 11,295<span></span>
</td>
<td class="nump">$ 11,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,041)<span></span>
</td>
<td class="num">(5,316)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations', window );">Property and equipment in service</a></td>
<td class="nump">6,254<span></span>
</td>
<td class="nump">5,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Construction in progress</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,761<span></span>
</td>
<td class="nump">6,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">2,613<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Molds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 847<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net property, plant and equipment of continuing and discontinued operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=apyx_ComputerEquipmentandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221337057392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>lease</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">63 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_LesseeOperatingLeaseNumberOfLeasesExtended', window );">Number of leases extended</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_LesseeDiscountRateIncrementalBorrowingRate', window );">Discount rate</a></td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_LesseeDiscountRateIncrementalBorrowingRate', window );">Discount rate</a></td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_LesseeDiscountRateIncrementalBorrowingRate', window );">Discount rate</a></td>
<td class="nump">6.49%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_LesseeDiscountRateIncrementalBorrowingRate', window );">Discount rate</a></td>
<td class="nump">6.49%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LesseeDiscountRateIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Discount Rate, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LesseeDiscountRateIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LesseeOperatingLeaseNumberOfLeasesExtended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Leases Extended</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LesseeOperatingLeaseNumberOfLeasesExtended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332279136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221333982912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Cash and Non-Cash Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_OperatingLeaseCostsAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for lease liabilities</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_FinanceLeasePayments', window );">Cash paid for lease liabilities</a></td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336628432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_OperatingLeaseCostsAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">3.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_FinanceLeaseCostsAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336767792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liabilities</a></td>
<td class="num">(216)<span></span>
</td>
<td class="num">$ (122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less current portion of lease liabilities</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221330010352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued commissions</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Accrued product warranties</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Accrued product liability claim insurance deductibles</a></td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees and legal related contingent liabilities</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ShortTermContractLiabilities', window );">Short-term contract liabilities</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_UncertainTaxPositionsLiability', window );">Uncertain tax positions</a></td>
<td class="nump">2,079<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax payable</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accrued expenses and current liabilities</a></td>
<td class="nump">879<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 8,928<span></span>
</td>
<td class="nump">$ 10,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Accrued Expenses And Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ShortTermContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ShortTermContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_UncertainTaxPositionsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Positions Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_UncertainTaxPositionsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126907644&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221333530336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRODUCT WARRANTIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardProductWarrantyAccrualRollForward', window );"><strong>Movement in Standard Product Warranty Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Beginning balance</a></td>
<td class="nump">$ 593<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued', window );">Provision for product warranties</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease', window );">Change in estimate to fulfill prior-year warranty obligations</a></td>
<td class="num">(198)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrualPayments', window );">Product warranty costs incurred</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Accrued product warranties</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardProductWarrantyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardProductWarrantyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1),(c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the standard product warranty accrual from changes in estimates attributable to preexisting product warranties. Excludes extended product warranties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221333627248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>JOINT AND SEVERAL PAYROLL LIABILITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime', window );">Joint and several payroll liability, eecrease due to lapse of time</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability, Decrease Due To Lapse Of Time</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221335891424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACT ASSETS AND LIABILITIES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liability, current</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets, current</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract liabilities, revenue recognized</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ContractWithCustomerAssetRevenueRecognized', window );">Contract assets, revenue recognized</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ContractWithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ContractWithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221335846784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerators:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders</a></td>
<td class="num">$ (23,184)<span></span>
</td>
<td class="num">$ (15,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">34,516<span></span>
</td>
<td class="nump">34,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">34,516<span></span>
</td>
<td class="nump">34,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options (in shares)</a></td>
<td class="nump">6,520<span></span>
</td>
<td class="nump">5,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221333614480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Provision For Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(4,096)<span></span>
</td>
<td class="num">(2,518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="num">(5,100)<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_IncomeTaxExpenseBenefitValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">3,131<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_IncomeTaxExpenseBenefitValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_IncomeTaxExpenseBenefitValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332561200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the statutory federal income tax rate to our effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax provision</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(22.30%)<span></span>
</td>
<td class="num">(21.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Incentive stock compensation expense</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent', window );">Section 162(m) compensation</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">GILTI</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Total</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Section 162(m) Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336456528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Loss and credit carryforwards</a></td>
<td class="nump">$ 7,476<span></span>
</td>
<td class="nump">$ 4,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">1,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development capitalization</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles', window );">Accrued insurance deductibles</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory 263A adjustment</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses', window );">Accrued bonus</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">12,525<span></span>
</td>
<td class="nump">7,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(12,068)<span></span>
</td>
<td class="num">(6,968)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of valuation allowance</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Accrued Insurance Deductibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221338633408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221338343440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Gross Unrealized Tax Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of year balance</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions of tax positions related to the current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions of tax positions related to the prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases for tax positions related to prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of year balance</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221429243952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT PLAN - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DefinedContributionPlanRequisiteServicePeriod', window );">Service period</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod', window );">Defined contribution plan, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears', window );">Defined contribution plan, vesting percentage after 3 years</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined contribution plan, employer matching contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, percent of employees' gross pay</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company matching contributions</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employers Matching Contribution, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DefinedContributionPlanRequisiteServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Requisite Service Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DefinedContributionPlanRequisiteServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221332369728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Narrative (Details) - Co-venturer - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases from supplier</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to supplier</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221329349824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2023 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_ContractWithInternationalDistributorMember', window );">Contract With International Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Cost accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_ContractWithInternationalDistributorMember', window );">Contract With International Distributor | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_ContractWithInternationalDistributorMember', window );">Contract With International Distributor | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember', window );">Suit Against Goodwin And Simb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Cost accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember', window );">Suit Against Goodwin And Simb | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember', window );">Suit Against Goodwin And Simb | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member', window );">Suits Filed in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of claims | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member', window );">Suits Filed in 2022 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Cost accrued</a></td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | lease</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member', window );">Suits Filed in 2022 | Minimum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member', window );">Suits Filed in 2022 | Maximum | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=apyx_LargestCustomerMember', window );">Largest Customer | Sales | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=apyx_TwoLargestCustomersMember', window );">Two Largest Customers | Accounts Receivable Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=apyx_ContractWithInternationalDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=apyx_ContractWithInternationalDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=apyx_SuitAgainstGoodwinAndSimbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=apyx_SuitsFiledIn2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=apyx_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=apyx_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=apyx_TwoLargestCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=apyx_TwoLargestCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=apyx_AccountsReceivableBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=apyx_AccountsReceivableBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221328150592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2012</div></th>
<th class="th"><div>Oct. 30, 2007</div></th>
<th class="th"><div>Dec. 31, 2001</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,697<span></span>
</td>
<td class="nump">$ 5,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice', window );">Closing stock price for computation of intrinsic value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options outstanding and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,074,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of all stock options outstanding and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding and expected to vest, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options outstanding and exercisable, weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options outstanding and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,292,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of currently exercisable stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Intrinsic value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,350<span></span>
</td>
<td class="nump">$ 5,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.71<span></span>
</td>
<td class="nump">$ 5.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of option shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,260<span></span>
</td>
<td class="nump">$ 4,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived', window );">Shares received in stock swaps (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,596<span></span>
</td>
<td class="nump">111,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwaps', window );">Shares issued in stock swaps (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,737<span></span>
</td>
<td class="nump">107,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2001ExecutiveandEmployeeStockOptionPlanMember', window );">2001 Executive and Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2003ExecutiveandEmployeeStockOptionPlanMember', window );">2003 Executive and Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_TwoThousandTwelveShareIncentivePlanMember', window );">2012 Share Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember', window );">2015 Executive and Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2017ExecutiveandEmployeeStockOptionPlanMember', window );">2017 Executive and Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2019ShareIncentivePlanMember', window );">2019 Share Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=apyx_A2021ShareIncentivePlanMember', window );">2021 Share Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares authorized under common stock option plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2001ExecutiveandEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2001ExecutiveandEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2003ExecutiveandEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2003ExecutiveandEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_TwoThousandTwelveShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_TwoThousandTwelveShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2017ExecutiveandEmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2017ExecutiveandEmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2019ShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2019ShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=apyx_A2021ShareIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=apyx_A2021ShareIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336599248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS - Summary of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">5,397,691<span></span>
</td>
<td class="nump">4,938,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,692,417<span></span>
</td>
<td class="nump">894,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(316,506)<span></span>
</td>
<td class="num">(232,521)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled and forfeited (in shares)</a></td>
<td class="num">(253,158)<span></span>
</td>
<td class="num">(203,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">6,520,444<span></span>
</td>
<td class="nump">5,397,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">10.64<span></span>
</td>
<td class="nump">9.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3.96<span></span>
</td>
<td class="nump">6.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled and forfeited (in dollars per share)</a></td>
<td class="nump">9.59<span></span>
</td>
<td class="nump">8.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share)</a></td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336620112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS - Summary of Nonvested Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Non-vested at beginning of period (in shares)</a></td>
<td class="nump">1,802,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Non-vested, Granted (in shares)</a></td>
<td class="nump">1,692,417<span></span>
</td>
<td class="nump">894,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options Non-vested, Vested (in shares)</a></td>
<td class="num">(1,028,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options Non-vested, Forfeited (in shares)</a></td>
<td class="num">(238,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Non-vested at end of period (in shares)</a></td>
<td class="nump">2,227,608<span></span>
</td>
<td class="nump">1,802,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 5.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options, Granted (in dollars per share)</a></td>
<td class="nump">6.71<span></span>
</td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options, Vested (in dollars per share)</a></td>
<td class="nump">5.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options, Forfeited (in dollars per share)</a></td>
<td class="nump">6.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Non-vested Options at end of period (in dollars per share)</a></td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="nump">$ 5.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221328022496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option value (in dollars per share)</a></td>
<td class="nump">$ 10.64<span></span>
</td>
<td class="nump">$ 9.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility - minimum</a></td>
<td class="nump">69.60%<span></span>
</td>
<td class="nump">68.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility - maximum</a></td>
<td class="nump">78.50%<span></span>
</td>
<td class="nump">70.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option value (in dollars per share)</a></td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="nump">$ 9.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option value (in dollars per share)</a></td>
<td class="nump">$ 10.96<span></span>
</td>
<td class="nump">$ 11.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221335497456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221335928928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 44,510<span></span>
</td>
<td class="nump">$ 48,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(23,562)<span></span>
</td>
<td class="num">(14,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (losses), net</a></td>
<td class="nump">509<span></span>
</td>
<td class="num">(373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Advanced Energy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">36,803<span></span>
</td>
<td class="nump">42,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(4,103)<span></span>
</td>
<td class="nump">2,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | OEM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">7,707<span></span>
</td>
<td class="nump">5,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate (Other)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(21,100)<span></span>
</td>
<td class="num">(18,265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (losses), net</a></td>
<td class="nump">509<span></span>
</td>
<td class="num">(373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221336625360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 44,510<span></span>
</td>
<td class="nump">$ 48,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">31,208<span></span>
</td>
<td class="nump">32,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 13,302<span></span>
</td>
<td class="nump">$ 15,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International | Sales | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">29.90%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140221328457280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($) </div>
<div>numberOfMonthlyPayment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of transaction fees and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne', window );">Debt covenant, 12 month net revenue target, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo', window );">Debt covenant, 12 month net revenue target, year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree', window );">Debt covenant, 12 month net revenue target, year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance', window );">Debt covenant, cash and cash equivalents balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackPurchaseAgreement', window );">Sale leaseback, purchase agreement</a></td>
<td class="nump">$ 7,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackDueDiligencePeriod', window );">Sale leaseback, due diligence period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence', window );">Sale leaseback, completion period after due diligence</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackEscrow', window );">Sale leaseback, escrow</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackTermOfLease', window );">Sale leaseback, term of lease</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackRenewalTerm', window );">Sale leaseback, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackAnnualRentPayment', window );">Sale leaseback. annual rent payment</a></td>
<td class="nump">$ 619,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackAnnualRentIncrease', window );">Sale leaseback, annual rent increase</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackManagementFeeOnRentPayment', window );">Sale leaseback, management fee on rent payment</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_SaleLeasebackNetCashProceeds', window );">Sale leaseback, net cash proceeds</a></td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentDefaultApplicableInterestRate', window );">Default, applicable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentInterestRateFloorPercent', window );">Interest rate floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentPeriodOfInterestOnly', window );">Period of interest only</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentExtensionPeriod', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentNumberOfMonthlyPayments', window );">Number of monthly payments | numberOfMonthlyPayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension', window );">Number of monthly payments, extension | numberOfMonthlyPayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentExitFee', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Secured Debt | Debt Instrument, Prepayment Period, One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Secured Debt | Debt Instrument, Prepayment Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Secured Debt | Debt Instrument, Prepayment Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Secured Debt | Adjusted Term Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Secured Debt | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Secured Debt | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Secured Debt | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Mortgage loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentInterestRateFloorPercent', window );">Interest rate floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentAnnualFeePercent', window );">Annual fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Revolving Credit Facility | Debt Instrument, Termination Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentTerminationFees', window );">Termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent', window );">Borrowing base, minimum balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount', window );">Borrowing base, minimum balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Revolving Credit Facility | Debt Instrument, Termination Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentTerminationFees', window );">Termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Revolving Credit Facility | Debt Instrument, Termination Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apyx_DebtInstrumentTerminationFees', window );">Termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember', window );">Credit Agreement | Line of Credit | Subsequent Event | Revolving Credit Facility | Adjusted Term Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentAnnualFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Fee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentAnnualFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash And Cash Equivalents Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentDefaultApplicableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default, Applicable Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentDefaultApplicableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentInterestRateFloorPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate Floor, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentInterestRateFloorPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentNumberOfMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentNumberOfMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Payments, Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPeriodOfInterestOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest Only</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPeriodOfInterestOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPrepaymentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPrepaymentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Termination Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackAnnualRentIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Annual Rent Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackAnnualRentIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackAnnualRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback. Annual Rent Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackAnnualRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackCompletionPeriodAfterDueDiligence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Completion Period After Due Diligence</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackCompletionPeriodAfterDueDiligence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackDueDiligencePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Due Diligence Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackDueDiligencePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Escrow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackManagementFeeOnRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Management Fee On Rent Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackManagementFeeOnRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackNetCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Net Cash Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackNetCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_SaleLeasebackTermOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback, Term Of Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_SaleLeasebackTermOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=apyx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentPrepaymentPeriodAxis=apyx_DebtInstrumentPrepaymentPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentCovenantsAxis=apyx_DebtInstrumentCovenantTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_DebtInstrumentTerminationPeriodAxis=apyx_DebtInstrumentTerminationPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>apyx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apyx="http://apyxmedical.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="apyx-20221231.xsd" xlink:type="simple"/>
    <context id="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie8e23c6c6eda44beb4d3b5fec9263660_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife4bcfcbe5424292ba030a02e7623b76_I20230315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2023-03-15</instant>
        </period>
    </context>
    <context id="ia7082c9220d542aea74c20a8d84ddd01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75e0b82b58654112a567e39aa1802734_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bae49cc66e64b74871c5922613110b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0719a3bd71c14176a650c4eb12985506_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a6edda2d6904896afa5d78839163c76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib406169147a6431dbc30a2558b1f5e27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i295652f4d94541d6bfe4a8724a96ea47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23cc21664d6348d5bb8761b3ca26250d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57f0820c833a4d97a42d7bf8f8ef0251_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87632d688d4749c9803b3fcc53b01ce8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b220174f25b49019af92cabbeeaab3c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fa2eb62abf14f7192ce12f735e12a77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i758630662d83465d81b8137958c8cefc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a54ae736e074ebfb7dd790dda19e87f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaee3b5a980ce4da3a2b821cfef923265_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i160d1cf15ee840e19f82d1cb22f0d5e8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i387665639f6d4372866cc35427b6f229_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76906bbc37b643fb86fb3fd07b5d57d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id796f312650b4349a1f87ceaf7050569_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e7ebb24b75346f1927c12e624da2d6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08c1ccf4264f41de9fa4a85ef430cc4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d05d6cf479e4b08b903d62cabfaf1b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4d0bcee5be54a1bb6f172bf7c4ee059_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00f94b6a4a7043f7b1bba426285e2789_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id973048cfe784ebca10458b24c0549da_D20221122-20221122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apyx:ShelfRegistrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="i1c4f6946432a43cc9388c670091e059e_D20221122-20221122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apyx:AtTheMarketFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="i9623247cdf6a40419d4a2b011f00d8ed_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i498926f26c67490999cf1e6f231404e1_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="icd920217a5774a4a8e99a083c1cb188c_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="ie91aea3453ae4206b00854b54ccdde12_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i4fbd4462461f48afb157563bd14c45a5_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentCovenantsAxis">apyx:DebtInstrumentCovenantTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i982284b9ef6f4f6f9d69822b5e02cff9_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="idaa97eb75f734241a5adb9df998868da_D20230314-20230314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="i4bf73cd58c774543acd7ca829d302f18_D20230119-20230119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-19</startDate>
            <endDate>2023-01-19</endDate>
        </period>
    </context>
    <context id="ic3257cbd5e38423bac3cb15f13f803cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ApyxSYMedicalDevicesNingboCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7654b3f92f4f47c7a70f057fb31c8385_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieabcc8e7335642cb80a3d0784277b499_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie7cfe454f7084225b0b55f3a129f958b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b1b946daaf54d3297203c790f0eaf01_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6a9f29492d5a4b14a57cb6b526e5dfe3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0b3e3ec5679411f8dd7d36415a88d70_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2a5b5a0b0ccd476e8cc706006cc8fa2e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ecb32d40a164cc78a526b05c7c1ff9f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3c33358a7584267bc50bbb56019e99c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3bf0f938d834033b089a461be19a891_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:RenuvionJPlasmaGeneratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa934ffbea294e0fac514a7ff600cbbd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:MountingFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80078dd0c8b24caca7d3320de6bd5594_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:AccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie2b00095642c4b108229e13776c6580c_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="i8fd4fe74bd604c1db72d55317651b6d4_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iefa166e3072441a1a7435fde8c995859_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab43910064884237bbdef4ac6cc8ff44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a3f56438b0549d9bb1816cb85ae9d4f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0bcfaba8f0c645ee95bc37c4c4f557bc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c3682736d9142f6ac1dda33e04b7f44_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33cd0694a0974259aa4da54d953aa393_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e47e5bd233347f190ad5ea24579801f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28e0bc92d62a40c4b1273fbafc570bd2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7f5ca601b6594ace8b084574b85670b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56987d7ae3fb47dfaaf61b0612cb8a6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibaf70880d8834a4ea7a3ff7705a7d5e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf54c2e8062e464a943af7a1cc6f702e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i292d860f0b124b10b47265b193979452_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bcfa1867b9c4a31a3709fe8a05bbe58_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb15fe17f8554f4bb5cb43cfef473c00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10b4e8b0d165454996fdf3396b1c0d64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id12249f705534e21b3e97868de6b1157_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90034014d4ac40d6b47f2c9dfd2b0b6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee2d3c40f1484004855a884bc75b810d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">apyx:ComputerEquipmentandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c1dff9d0dbb4b90aef7333e20bb5fb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3b3ec8b01964331aded480dad14486f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68358e6c1c414942ab2b1cacdda282a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i243c730de3e94d3283669d4a2661af4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ce8494d2834491ab35f3664a41429db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa25d872e0d140a98af126a2c508757b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie2aaebfd6e5041e3b8fade9ae7be2f4c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad2fb842f9454872b733d0f3ea008372_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if873b957ef9a452fbbc6e871b2410716_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15c65c91210b4634aa8886aa2c04c687_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2be8be05786644b587f7269db8612ba8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1bd31e839574eb0b58cd8ec4b423216_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bafa9f247264d98b3a5973a8aa85489_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81985ec077fa472193067684bf28ef76_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3517b2fe5b464ec5ab2cb6fedcd9c77d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i20512693f6584e7d82c03a312e6156ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:ContractWithInternationalDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9aae6976833242b1b30c6676851c9194_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92b182548e09413c8f592eb9c29abd89_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a58968298ce4c70ab56e29d0ce9450d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitAgainstGoodwinAndSimbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ef0e96305c24e7297840166aa515f96_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9a0b18b016bd448eabc6ee7bdd802e0b_D20230101-20230316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-16</endDate>
        </period>
    </context>
    <context id="i978115ab316f4e03b88b250dc52320f6_I20230316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="i8015e0424ea1487ba240da801ce050f6_I20230316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="i870ddbfe09ce44fab9950cf2896a4dfe_I20230316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">apyx:SuitsFiledIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="iba71a7789d3e40e99df5af434f95f621_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:LargestCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb1a97606daa4ceba9e7e3f4025e9194_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:TwoLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">apyx:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i445e51d03e01407ab9b5e970e37bb25c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">apyx:TwoLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">apyx:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f4cb62a47674f069376423c04bbf511_I20011231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2001ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2001-12-31</instant>
        </period>
    </context>
    <context id="i8ce22e9e74ae4aad81ea9bf903e52593_I20071030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2003ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-10-30</instant>
        </period>
    </context>
    <context id="i853b05ef16534eea839dc217dc64ae1e_I20120731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandTwelveShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-07-31</instant>
        </period>
    </context>
    <context id="ic2118a02b53544ed902dfa41da2fb932_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandTwelveShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5dd72154e8a84a13ba2ec410056e0cc3_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="i13a40b61b75e4a1da2703881874d03b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb85bfecc9fe411fbf5543ebcc203676_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2017ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="if744468335d24182b13e02e0c5cbee45_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2017ExecutiveandEmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac91df8b60954d69a9e1632838aa1f72_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2019ShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="ib635cac0c9b846c38ee05d5e5de8a30e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2019ShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b00dca027564cc4a6278d01e014e129_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2021ShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i627345abf94741d0b8653a012a895db1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">apyx:A2021ShareIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idba9e20874ac40928de8555b5779b796_I20230111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="i54189c6eb13741cab646fd61dc525b97_D20230111-20230111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-11</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="if05944548e154442b75796c157713f6b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4d89fb15b914a8b9464e4d4f665063b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i94da9825cefa47e085dc8967533353fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec7daf90e27a450094b575521306a713_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3fd74d3ecc94c9d852ed481d8155c2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iceb3893cd8fd491f9f46c1f269d3f5e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0dd72b9e18204c609c5668ac31713394_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ide55cc7e04aa4a9dbf8cb858b7ceafaa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b469a871d414d41b9f05c65d751b0f2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i868b6761ce074d338f4b5ce301df99d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ee6627e384748dd93f7c235043736aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i52d35bf44ac044d9b818e2795485ffad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="iaaf38b5907d248938c29ae1623e0a4ae_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i6462edbcc6f3498fb5595ceca9c9b20c_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="idd50214c28b1419d87380a2edcf8c85e_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="ifd8c189ae54b4398bbe43a8016d14d18_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentPrepaymentPeriodAxis">apyx:DebtInstrumentPrepaymentPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i84ace2066c844d0eb08a5d4455fd34f1_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i37bf520b9b2c4b23b71810b3dd058fcf_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i29d6f70a7eab414799e5833f411483ba_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i0ebe1df213944e88b24cf4d7fc508cf9_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="ic06bbd8e6458436597927a368cb238b8_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="if422168e879e462b8d0dc783bdd44842_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="apyx:DebtInstrumentTerminationPeriodAxis">apyx:DebtInstrumentTerminationPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i67955df49b104c96886c90aa72882ab9_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">apyx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i76b8d9c682c84508b0bc8b27676bfeda_I20230314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-14</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lease">
        <measure>apyx:lease</measure>
    </unit>
    <unit id="segment">
        <measure>apyx:segment</measure>
    </unit>
    <unit id="numberofmonthlypayment">
        <measure>apyx:numberOfMonthlyPayment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-30">0000719135</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-32">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-33">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231"
      id="f-617">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-3">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-6">0-12183</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-7">APYX MEDICAL CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-9">11-2644611</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-10">5115 Ulmerton Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-11">Clearwater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-12">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-13">33760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-14">727</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-15">384-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-16">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-17">APYX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-27">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ie8e23c6c6eda44beb4d3b5fec9263660_I20220630"
      decimals="-5"
      id="f-28"
      unitRef="usd">202100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ife4bcfcbe5424292ba030a02e7623b76_I20230315"
      decimals="INF"
      id="f-29"
      unitRef="shares">34597822</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-34">49</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-35">RSM US LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-36">Orlando, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-37"
      unitRef="usd">10192000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-38"
      unitRef="usd">30870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-39"
      unitRef="usd">668000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-40"
      unitRef="usd">430000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-41"
      unitRef="usd">10602000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-42"
      unitRef="usd">13038000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-43"
      unitRef="usd">7545000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-44"
      unitRef="usd">7642000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-45"
      unitRef="usd">99000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-46"
      unitRef="usd">483000</us-gaap:OtherReceivablesNetCurrent>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-47"
      unitRef="usd">457000</apyx:ProvisionForObsolescenceInventory>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-48"
      unitRef="usd">263000</apyx:ProvisionForObsolescenceInventory>
    <us-gaap:InventoryNet
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-49"
      unitRef="usd">11797000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-50"
      unitRef="usd">6778000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-51"
      unitRef="usd">2737000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-52"
      unitRef="usd">1926000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-53"
      unitRef="usd">42972000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-54"
      unitRef="usd">60737000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-55"
      unitRef="usd">6761000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-56"
      unitRef="usd">6575000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-57"
      unitRef="usd">710000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-58"
      unitRef="usd">121000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-59"
      unitRef="usd">115000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-60"
      unitRef="usd">178000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-61"
      unitRef="usd">1217000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-62"
      unitRef="usd">1110000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-63"
      unitRef="usd">51775000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-64"
      unitRef="usd">68721000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-65"
      unitRef="usd">2669000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-66"
      unitRef="usd">2631000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-67"
      unitRef="usd">8928000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-68"
      unitRef="usd">10287000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-69"
      unitRef="usd">216000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-70"
      unitRef="usd">122000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-71"
      unitRef="usd">37000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-72"
      unitRef="usd">165000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-73"
      unitRef="usd">11850000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-74"
      unitRef="usd">13205000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-75"
      unitRef="usd">470000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-76"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-77"
      unitRef="usd">73000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-78"
      unitRef="usd">18000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-79"
      unitRef="usd">1408000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-80"
      unitRef="usd">1323000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-81"
      unitRef="usd">181000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-82"
      unitRef="usd">166000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-83"
      unitRef="usd">13982000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-84"
      unitRef="usd">14712000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      id="f-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      id="f-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-87"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-88"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-89"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-90"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-91"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-92"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-93"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-94"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-6"
      id="f-95"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-6"
      id="f-96"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-97"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-98"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-99"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-100"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-101"
      unitRef="shares">34597822</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-102"
      unitRef="shares">34597822</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-103"
      unitRef="shares">34409912</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-104"
      unitRef="shares">34409912</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-105"
      unitRef="usd">35000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-106"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-107"
      unitRef="usd">73282000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-108"
      unitRef="usd">66221000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-109"
      unitRef="usd">-35735000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-110"
      unitRef="usd">-12551000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-111"
      unitRef="usd">37582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-112"
      unitRef="usd">53704000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-113"
      unitRef="usd">211000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-114"
      unitRef="usd">305000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-115"
      unitRef="usd">37793000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-116"
      unitRef="usd">54009000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-117"
      unitRef="usd">51775000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-118"
      unitRef="usd">68721000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-119"
      unitRef="usd">44510000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-120"
      unitRef="usd">48517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-121"
      unitRef="usd">15379000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-122"
      unitRef="usd">14916000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-123"
      unitRef="usd">29131000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-124"
      unitRef="usd">33601000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-125"
      unitRef="usd">4544000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-126"
      unitRef="usd">4321000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-127"
      unitRef="usd">9044000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-128"
      unitRef="usd">7589000</us-gaap:ProfessionalFees>
    <us-gaap:SalariesAndWages
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-129"
      unitRef="usd">18621000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-130"
      unitRef="usd">17522000</us-gaap:SalariesAndWages>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-131"
      unitRef="usd">20484000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-132"
      unitRef="usd">18617000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-133"
      unitRef="usd">52693000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-134"
      unitRef="usd">48049000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-135"
      unitRef="usd">-23562000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-136"
      unitRef="usd">-14448000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-137"
      unitRef="usd">157000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-138"
      unitRef="usd">11000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-139"
      unitRef="usd">15000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-140"
      unitRef="usd">10000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-141"
      unitRef="usd">509000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-142"
      unitRef="usd">-373000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-143"
      unitRef="usd">651000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-144"
      unitRef="usd">-372000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-145"
      unitRef="usd">-22911000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-146"
      unitRef="usd">-14820000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-147"
      unitRef="usd">367000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-148"
      unitRef="usd">380000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-149"
      unitRef="usd">-23278000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-150"
      unitRef="usd">-15200000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-151"
      unitRef="usd">-94000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-152"
      unitRef="usd">-28000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-153"
      unitRef="usd">-23184000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-154"
      unitRef="usd">-15172000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-155"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-156"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="2"
      id="f-157"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="2"
      id="f-158"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-159"
      unitRef="shares">34516000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-160"
      unitRef="shares">34516000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-161"
      unitRef="shares">34332000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-162"
      unitRef="shares">34332000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="i3bae49cc66e64b74871c5922613110b0_I20201231"
      decimals="-3"
      id="f-163"
      unitRef="shares">34289000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3bae49cc66e64b74871c5922613110b0_I20201231"
      decimals="-3"
      id="f-164"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0719a3bd71c14176a650c4eb12985506_I20201231"
      decimals="-3"
      id="f-165"
      unitRef="usd">61066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a6edda2d6904896afa5d78839163c76_I20201231"
      decimals="-3"
      id="f-166"
      unitRef="usd">2621000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib406169147a6431dbc30a2558b1f5e27_I20201231"
      decimals="-3"
      id="f-167"
      unitRef="usd">138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231"
      decimals="-3"
      id="f-168"
      unitRef="usd">63859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i23cc21664d6348d5bb8761b3ca26250d_D20210101-20211231"
      decimals="-3"
      id="f-169"
      unitRef="usd">195000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-170"
      unitRef="usd">195000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i57f0820c833a4d97a42d7bf8f8ef0251_D20210101-20211231"
      decimals="-3"
      id="f-171"
      unitRef="shares">13000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i87632d688d4749c9803b3fcc53b01ce8_D20210101-20211231"
      decimals="-3"
      id="f-172"
      unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-173"
      unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i87632d688d4749c9803b3fcc53b01ce8_D20210101-20211231"
      decimals="-3"
      id="f-174"
      unitRef="usd">5088000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-175"
      unitRef="usd">5088000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="i57f0820c833a4d97a42d7bf8f8ef0251_D20210101-20211231"
      decimals="-3"
      id="f-176"
      unitRef="shares">108000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i3b220174f25b49019af92cabbeeaab3c_D20210101-20211231"
      decimals="-3"
      id="f-177"
      unitRef="usd">-15172000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i23cc21664d6348d5bb8761b3ca26250d_D20210101-20211231"
      decimals="-3"
      id="f-178"
      unitRef="usd">-28000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-179"
      unitRef="usd">-15200000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i5fa2eb62abf14f7192ce12f735e12a77_I20211231"
      decimals="-3"
      id="f-180"
      unitRef="shares">34410000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fa2eb62abf14f7192ce12f735e12a77_I20211231"
      decimals="-3"
      id="f-181"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i758630662d83465d81b8137958c8cefc_I20211231"
      decimals="-3"
      id="f-182"
      unitRef="usd">66221000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a54ae736e074ebfb7dd790dda19e87f_I20211231"
      decimals="-3"
      id="f-183"
      unitRef="usd">-12551000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaee3b5a980ce4da3a2b821cfef923265_I20211231"
      decimals="-3"
      id="f-184"
      unitRef="usd">305000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-185"
      unitRef="usd">54009000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i160d1cf15ee840e19f82d1cb22f0d5e8_D20220101-20221231"
      decimals="-3"
      id="f-186"
      unitRef="shares">106000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i160d1cf15ee840e19f82d1cb22f0d5e8_D20220101-20221231"
      decimals="-3"
      id="f-187"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i387665639f6d4372866cc35427b6f229_D20220101-20221231"
      decimals="-3"
      id="f-188"
      unitRef="usd">364000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-189"
      unitRef="usd">365000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i387665639f6d4372866cc35427b6f229_D20220101-20221231"
      decimals="-3"
      id="f-190"
      unitRef="usd">6697000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-191"
      unitRef="usd">6697000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="i160d1cf15ee840e19f82d1cb22f0d5e8_D20220101-20221231"
      decimals="-3"
      id="f-192"
      unitRef="shares">82000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i76906bbc37b643fb86fb3fd07b5d57d4_D20220101-20221231"
      decimals="-3"
      id="f-193"
      unitRef="usd">-23184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id796f312650b4349a1f87ceaf7050569_D20220101-20221231"
      decimals="-3"
      id="f-194"
      unitRef="usd">-94000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-195"
      unitRef="usd">-23278000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i1e7ebb24b75346f1927c12e624da2d6f_I20221231"
      decimals="-3"
      id="f-196"
      unitRef="shares">34598000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e7ebb24b75346f1927c12e624da2d6f_I20221231"
      decimals="-3"
      id="f-197"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08c1ccf4264f41de9fa4a85ef430cc4f_I20221231"
      decimals="-3"
      id="f-198"
      unitRef="usd">73282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d05d6cf479e4b08b903d62cabfaf1b2_I20221231"
      decimals="-3"
      id="f-199"
      unitRef="usd">-35735000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4d0bcee5be54a1bb6f172bf7c4ee059_I20221231"
      decimals="-3"
      id="f-200"
      unitRef="usd">211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-201"
      unitRef="usd">37793000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-202"
      unitRef="usd">-23278000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-203"
      unitRef="usd">-15200000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-204"
      unitRef="usd">890000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-205"
      unitRef="usd">903000</us-gaap:DepreciationDepletionAndAmortization>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-206"
      unitRef="usd">240000</apyx:ProvisionForInventoryObsolescence>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-207"
      unitRef="usd">109000</apyx:ProvisionForInventoryObsolescence>
    <apyx:ProductWarrantyExpenseNet
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-208"
      unitRef="usd">-2000</apyx:ProductWarrantyExpenseNet>
    <apyx:ProductWarrantyExpenseNet
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-209"
      unitRef="usd">318000</apyx:ProductWarrantyExpenseNet>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-210"
      unitRef="usd">-75000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-211"
      unitRef="usd">-48000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-212"
      unitRef="usd">6697000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-213"
      unitRef="usd">5088000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-214"
      unitRef="usd">315000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-215"
      unitRef="usd">128000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-216"
      unitRef="usd">-1918000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-217"
      unitRef="usd">4901000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-218"
      unitRef="usd">-97000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-219"
      unitRef="usd">-12000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-220"
      unitRef="usd">523000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-221"
      unitRef="usd">-1355000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-222"
      unitRef="usd">5568000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-223"
      unitRef="usd">2859000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-224"
      unitRef="usd">67000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-225"
      unitRef="usd">1154000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-226"
      unitRef="usd">-1208000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-227"
      unitRef="usd">3396000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-228"
      unitRef="usd">-20280000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-229"
      unitRef="usd">-10449000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-230"
      unitRef="usd">1010000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-231"
      unitRef="usd">723000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-232"
      unitRef="usd">-1010000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-233"
      unitRef="usd">-723000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-234"
      unitRef="usd">365000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-235"
      unitRef="usd">67000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:RepaymentOfFinanceLeaseLiabilities
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-236"
      unitRef="usd">148000</apyx:RepaymentOfFinanceLeaseLiabilities>
    <apyx:RepaymentOfFinanceLeaseLiabilities
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-237"
      unitRef="usd">238000</apyx:RepaymentOfFinanceLeaseLiabilities>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-238"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-239"
      unitRef="usd">195000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-240"
      unitRef="usd">217000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-241"
      unitRef="usd">24000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-242"
      unitRef="usd">395000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-243"
      unitRef="usd">103000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-244"
      unitRef="usd">-20678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-245"
      unitRef="usd">-11045000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-246"
      unitRef="usd">30870000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231"
      decimals="-3"
      id="f-247"
      unitRef="usd">41915000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-248"
      unitRef="usd">10192000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-249"
      unitRef="usd">30870000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-250"
      unitRef="usd">15000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-251"
      unitRef="usd">10000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-252"
      unitRef="usd">128000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-253"
      unitRef="usd">111000</us-gaap:IncomeTaxesPaid>
    <apyx:CapitalizationOfLeaseRecongizedNonCash
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-254"
      unitRef="usd">769000</apyx:CapitalizationOfLeaseRecongizedNonCash>
    <apyx:CapitalizationOfLeaseRecongizedNonCash
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-255"
      unitRef="usd">0</apyx:CapitalizationOfLeaseRecongizedNonCash>
    <apyx:CapitalizationOfLeaseRecognizedExecution
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-256"
      unitRef="usd">103000</apyx:CapitalizationOfLeaseRecognizedExecution>
    <apyx:CapitalizationOfLeaseRecognizedExecution
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-257"
      unitRef="usd">0</apyx:CapitalizationOfLeaseRecognizedExecution>
    <apyx:CapitalizationOfLeaseDerecognizedExecution
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-258"
      unitRef="usd">28000</apyx:CapitalizationOfLeaseDerecognizedExecution>
    <apyx:CapitalizationOfLeaseDerecognizedExecution
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-259"
      unitRef="usd">0</apyx:CapitalizationOfLeaseDerecognizedExecution>
    <apyx:NonCashTransferOfOtherAssetsToFixedAssets
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-260"
      unitRef="usd">0</apyx:NonCashTransferOfOtherAssetsToFixedAssets>
    <apyx:NonCashTransferOfOtherAssetsToFixedAssets
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-261"
      unitRef="usd">43000</apyx:NonCashTransferOfOtherAssetsToFixedAssets>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-262">DESCRIPTION OF BUSINESS&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apyx Medical Corporation (&#x201c;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an advanced energy technology company with a passion for elevating people&#x2019;s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion&#xae; in the cosmetic surgery market and J-Plasma&#xae; in the hospital surgical market. Renuvion&#xae; and J-Plasma&#xae; offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of its plan to accelerate and fully fund the development of its advanced energy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;business, with a focus in the cosmetic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;surgery market, the Company sold its Core business in 2018 for gross proceeds of $97&#160;million.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 14, 2022, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) posted a Safety Communication that warns consumers and health care providers against the use of the Company&#x2019;s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#xae; Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion&#xae; APR Handpiece for certain skin contraction procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2022, and July 21, 2022, the FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion&#xae; Dermal handpiece, and the expanded indications for the Renuvion&#xae; APR handpieces. The 510(k) clearance for the Renuvion&#xae; Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.  The 510(k) clearance for the Renuvion&#xae; APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2023, we announced we had submitted a 510(k) premarket notification (&#x201c;510(k) submission&#x201d;) for the Renuvion APR Handpiece to the FDA, supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion&#x2019;s indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;While management expected that receiving these clearances would materially mitigate the financial effects of the Safety Communication in future periods, the Company continues to experience reduced demand for the adoption and utilization of its technology and management believes that this may have an adverse effect in future periods.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the requirements of the Financial Accounting Standards Board&#x2019;s Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, management must evaluate &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented or are not within control of the Company as of the date the condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company&#x2019;s sale of the Core business segment to Symmetry Surgical during 2018, it has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6&#160;million and used $20.3&#160;million of cash in operations. As of December 31, 2022, the Company had cash and cash equivalents of $10.2&#160;million. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100&#160;million. The shelf registration included an embedded ATM facility for up to $40&#160;million. To date the Company has not utilized this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#x201c;Credit Agreement&#x201d;) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement provides for an up to $35&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25&#160;million, comprised of (i) an initial tranche of $10&#160;million, (ii) a second tranche of $5&#160;million, and (iii) a third tranche of $10&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10&#160;million, subject to a borrowing base equal to certain percentages of the Company&#x2019;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a more in depth description of the terms of the Credit Agreement see Note 20.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 27, 2023, the Company&#x2019;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the &#x201c;Purchase Agreement&#x201d;) with VK Acquisitions VI, LLC (the &#x201c;Purchaser&#x201d;), for the sale of the Company's facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#x201c;Property&#x201d;) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. Upon the closing of the sale of the Property, the Company will enter into a lease agreement with the Purchaser, pursuant to which the Property will be leased back to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For a more in depth description of the terms of the Purchase Agreement see Note 20.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for substantially the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. As of the date of this report, the Company is awaiting receipt of the tax refunds. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also continues to re-assess its operating expenditures and cost structure to be commensurate with expected levels of revenue and management has the ability to reduce or delay expenditures to enhance and preserve liquidity. Management has already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company's U.S. headcount by 14%. &lt;/span&gt;&lt;/div&gt;Management believes that the actions already taken, and additional actions that it intends to take to manage operating expenditures, will enable the Company to meet its obligations for a period of at least one year from the date of issuance of these audited consolidated financial statements. As a result, management believes its plans alleviate substantial doubt about the Company's ability to continue as a going concern. These audited financial statements do not include any adjustments relating to the carrying amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i00f94b6a4a7043f7b1bba426285e2789_D20180101-20181231"
      decimals="-6"
      id="f-263"
      unitRef="usd">97000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-5"
      id="f-264"
      unitRef="usd">-23600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-5"
      id="f-265"
      unitRef="usd">-20300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-266"
      unitRef="usd">10200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <apyx:SecuritiesRegisteredNewIssues
      contextRef="id973048cfe784ebca10458b24c0549da_D20221122-20221122"
      decimals="-6"
      id="f-267"
      unitRef="usd">100000000</apyx:SecuritiesRegisteredNewIssues>
    <apyx:SecuritiesRegisteredNewIssues
      contextRef="i1c4f6946432a43cc9388c670091e059e_D20221122-20221122"
      decimals="-6"
      id="f-268"
      unitRef="usd">40000000</apyx:SecuritiesRegisteredNewIssues>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9623247cdf6a40419d4a2b011f00d8ed_I20230217"
      decimals="-6"
      id="f-269"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i498926f26c67490999cf1e6f231404e1_I20230217"
      decimals="-6"
      id="f-270"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icd920217a5774a4a8e99a083c1cb188c_I20230217"
      decimals="-6"
      id="f-271"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie91aea3453ae4206b00854b54ccdde12_I20230217"
      decimals="-6"
      id="f-272"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4fbd4462461f48afb157563bd14c45a5_I20230217"
      decimals="-6"
      id="f-273"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i982284b9ef6f4f6f9d69822b5e02cff9_I20230217"
      decimals="-6"
      id="f-274"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <apyx:SaleLeasebackPurchaseAgreement
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      decimals="-4"
      id="f-275"
      unitRef="usd">7650000</apyx:SaleLeasebackPurchaseAgreement>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i4bf73cd58c774543acd7ca829d302f18_D20230119-20230119"
      decimals="2"
      id="f-276"
      unitRef="number">0.14</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-277">SIGNIFICANT ACCOUNTING POLICIES&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, &#x201c;Apyx,&#x201d; or the &#x201c;Company&#x201d;). All significant intercompany transactions and balances have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Holdings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December&#160;31, 2022 and 2021, all of the Company&#x2019;s investments are in money market funds or in Treasury Bills with original maturities of three months or less and are included in cash and cash equivalents.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's standard credit terms for billings range from net 30 days to net 120 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#x2019; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available. Management believes that the allowances for doubtful accounts of approximately $0.7 million and $0.4&#160;million at December&#160;31, 2022 and 2021, respectively, are adequate to provide for probable bad debts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#x2019; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2022 and 2021, the Company believes the remaining carrying values of its long-lived assets are recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Warranties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a four year limited warranty on end-user sales of its Renuvion&#xae;/J-Plasma&#xae; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#xae;/J-Plasma&#xae;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Product returns are only accepted at the Company's discretion and in accordance with its &#x201c;Returned Goods Policy&#x201d;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. Recognition of the deferred billings and costs occurs as the Company performs on the accompanying supply arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. The amounts of advertising costs, including trade shows, were approximately $2.3 million and $1.3 million for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the grant date fair value of such awards. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are charged to operations as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;planning strategies.  As of December 31, 2022 and 2021, the Company recorded a valuation allowance on the net deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reclassified certain amounts presented in the prior year to conform to the current year presentation. These reclassifications had no impact on previously reported net income, retained earnings or operating cash flows for the periods presented.&lt;/span&gt;&lt;/div&gt;RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (Topic 326),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; Derivatives and Hedging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Topic 815), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;and Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Topic 842) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-278">Consolidated Financial StatementsThe accompanying consolidated financial statements include the accounts of Apyx, its wholly owned subsidiary, Apyx Bulgaria, EOOD, and its 51% owned subsidiary, Apyx SY Medical Devices (Ningbo) Co., Ltd. (collectively, &#x201c;Apyx,&#x201d; or the &#x201c;Company&#x201d;). All significant intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ic3257cbd5e38423bac3cb15f13f803cc_I20221231"
      decimals="2"
      id="f-279"
      unitRef="number">0.51</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:UseOfEstimates
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-280">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions the Company is required to make.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-281">Cash and Cash EquivalentsHoldings of highly liquid investments with original maturities of three months or less from the date of purchase are considered to be cash equivalents. As of December&#160;31, 2022 and 2021, all of the Company&#x2019;s investments are in money market funds or in Treasury Bills with original maturities of three months or less and are included in cash and cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-282">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of trade accounts receivable. With respect to cash, the Company frequently maintains cash and cash equivalent balances in excess of federally insured limits; it has not experienced any losses in such accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-283">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's standard credit terms for billings range from net 30 days to net 120 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and an allowance is generally recorded for accounts that become three months past due, or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated, and receivables are written off when the Company determines they are not collectible and abandons these collection efforts.&lt;/span&gt;&lt;/div&gt;The Company evaluates the allowance for doubtful accounts on a regular basis for adequacy based upon its periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect its customers&#x2019; ability to pay and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-284"
      unitRef="usd">700000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-5"
      id="f-285"
      unitRef="usd">400000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-286">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to manufactured inventory based upon labor hours. &lt;/span&gt;&lt;/div&gt;The Company monitors inventory usage to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjusts inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-287">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and major improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and routine improvements are expensed as incurred. The estimated useful lives are: buildings and improvements, 39 years; machinery and equipment, 3-10 years; furniture and fixtures, 5-10 years;  computer equipment and software, 3-5 years; and molds, 7-15 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7654b3f92f4f47c7a70f057fb31c8385_D20220101-20221231"
      id="f-288">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ieabcc8e7335642cb80a3d0784277b499_D20220101-20221231"
      id="f-289">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie7cfe454f7084225b0b55f3a129f958b_D20220101-20221231"
      id="f-290">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2b1b946daaf54d3297203c790f0eaf01_D20220101-20221231"
      id="f-291">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6a9f29492d5a4b14a57cb6b526e5dfe3_D20220101-20221231"
      id="f-292">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia0b3e3ec5679411f8dd7d36415a88d70_D20220101-20221231"
      id="f-293">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2a5b5a0b0ccd476e8cc706006cc8fa2e_D20220101-20221231"
      id="f-294">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5ecb32d40a164cc78a526b05c7c1ff9f_D20220101-20221231"
      id="f-295">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id3c33358a7584267bc50bbb56019e99c_D20220101-20221231"
      id="f-296">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-297">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases, an impairment loss is recognized to the extent that the assets&#x2019; carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December&#160;31, 2022 and 2021, the Company believes the remaining carrying values of its long-lived assets are recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:StandardProductWarrantyPolicy
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-298">Product WarrantiesThe Company provides a four year limited warranty on end-user sales of its Renuvion&#xae;/J-Plasma&#xae; generators, a two year warranty on mounting fixtures, and a one-year warranty on certain accessories. The Company estimates and provides for future costs for product warranties in cost of sales at the time revenue is recognized. The Company bases its product warranty costs on related material costs, repair labor costs and shipping costs. The Company estimates the future cost of product warranties by considering historical material, repair labor, and shipping costs, and applying the experience rates to the outstanding warranty period for products sold. It is reasonably possible that actual results could differ from those estimates.</us-gaap:StandardProductWarrantyPolicy>
    <apyx:ProductWarranty
      contextRef="if3bf0f938d834033b089a461be19a891_D20220101-20221231"
      id="f-299">P4Y</apyx:ProductWarranty>
    <apyx:ProductWarranty
      contextRef="ifa934ffbea294e0fac514a7ff600cbbd_D20220101-20221231"
      id="f-300">P2Y</apyx:ProductWarranty>
    <apyx:ProductWarranty
      contextRef="i80078dd0c8b24caca7d3320de6bd5594_D20220101-20221231"
      id="f-301">P1Y</apyx:ProductWarranty>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-302">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the Company expects to receive for those goods or services. To recognize revenue, the Company (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, it satisfies the performance obligation(s). For sales of the Company's Advanced Energy products (Renuvion&#xae;/J-Plasma&#xae;), this is at a point in time when title has been transferred to the customer, which is generally at the time of shipment or receipt by customer for FOB destination terms. For sales of products under its OEM agreements, the Company recognizes revenue over time when no alternative use exists for the manufactured goods and the Company has rights to payment. Presently, the Company does not stock any significant completed goods under its OEM agreements, accordingly, the recognition of revenue under these agreements approximates point in time recognition. The following policies apply to its major categories of revenue transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;The majority of sales to customers are evidenced by firm purchase orders. Generally, title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:63pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Product returns are only accepted at the Company's discretion and in accordance with its &#x201c;Returned Goods Policy&#x201d;. Historically, the level of product returns has not been significant. Accruals for sales returns, rebates and allowances are made as a reduction of revenue based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;The terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.&lt;/span&gt;&#x2022;In connection with the execution of OEM supply agreements, the Company may enter into an accompanying product development agreement. If the Company enters into a product development agreement, and development of the goods does not represent a performance obligation on a standalone basis, the Company defers the development fees billed to customers and the associated costs. Recognition of the deferred billings and costs occurs as the Company performs on the accompanying supply arrangements.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-303">Advertising CostsAdvertising costs are expensed as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-5"
      id="f-304"
      unitRef="usd">2300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-5"
      id="f-305"
      unitRef="usd">1300000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-306">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. FASB ASC 718 requires recognizing compensation expense for all share-based payment awards made to employees, directors and non-employees based upon the grant date fair value of such awards. It accounts for forfeitures as they occur. The standard covers employee stock options, restricted stock and other equity awards. The Company utilizes a Black-Scholes model to estimate the grant date fair value of stock option awards. For employee and director awards, compensation expense is recognized on a straight-line basis over the vesting periods. For  non-employee awards, compensation expense is recorded for non-forfeitable, fully vested awards at the grant date. For other awards granted to non-employees, compensation cost is recognized as services are provided, which approximates a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-307">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance, the Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-308">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company computes basic (loss) earnings attributable to common stockholders per share by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding for the reporting period. Diluted (loss) earnings per share attributable to common stockholders gives effect to all potential dilutive shares outstanding during the period. The number of dilutive shares is calculated using the treasury stock method which reduces the effective number of shares by the amount of shares the Company could purchase with the proceeds of assumed exercises. Anti-dilutive units are excluded from the calculation of diluted shares. In periods of loss, all potentially dilutive units are anti-dilutive and are excluded from the calculation of diluted income (loss) per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-309">Research and Development CostsResearch and development expenses are charged to operations as incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-310">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the deferred taxes reverse.  The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowances is recorded when it is more likely than not that a tax benefit will not be realized.  In determining the need for valuation allowances the Company considers projected future taxable income, the timing of reversals of temporary differences, and the availability of tax &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;planning strategies.  As of December 31, 2022 and 2021, the Company recorded a valuation allowance on the net deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the realizability of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., the Company will continue to record a full valuation allowance on the net deferred tax assets as of December 31, 2022. &lt;/span&gt;&lt;/div&gt;The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority.  An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-311">Foreign Currency TransactionsThe functional currency of Apyx Bulgaria is the U.S.&#160;dollar. The monetary assets and liabilities that are denominated in a currency other than U.S. dollar are remeasured into U.S.&#160;dollars at the exchange rate on the balance sheet date, while nonmonetary items are remeasured at historical rates. Revenue and expenses are remeasured at weighted average exchange rates during the period. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in selling, general and administrative expenses in the Consolidated Statements of Operations and were not material for the years ended December 31, 2022 and 2021.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-312">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reclassified certain amounts presented in the prior year to conform to the current year presentation. These reclassifications had no impact on previously reported net income, retained earnings or operating cash flows for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-313">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (Topic 326),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; Derivatives and Hedging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Topic 815), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;and Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Topic 842) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition and, as a result, will be utilizing the deferred elective date. While the Company is in the process of determining the effects of the adoption of the standard on the consolidated financial statements, it does not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on the Company's consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-314">DISPOSITION OF THE CORE BUSINESS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 30, 2018, the Company closed on a definitive asset purchase agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#x201c;Symmetry&#x201d;), pursuant to which the Company divested and sold the Company&#x2019;s electrosurgical &#x201c;Core&#x201d; business segment and related intellectual property, including the Bovie&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; brand and trademarks, to Symmetry for gross proceeds of $97 million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, which expired August 30, 2022, whereby it manufactured certain Core pro&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ducts and sold them to Symmetry at agreed upon prices.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Any activity resulting from this agreement is netted and reported in the Consolidated Statements of Operations as other income (loss). Core activity for 2022 amounted to $0.6&#160;million with cost of sales equivalents of $0.6&#160;million and other related expenses of $0.1&#160;million for net other loss of $0.1&#160;million.  Core activity for 2021 amounted to $6.5&#160;million with cost of sales equivalents of $5.5&#160;million and other related expenses of $1.5&#160;million for net other loss of $0.4&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ie2b00095642c4b108229e13776c6580c_D20180830-20180830"
      decimals="-6"
      id="f-315"
      unitRef="usd">97000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <apyx:AssetPurchaseAgreementTerm
      contextRef="i8fd4fe74bd604c1db72d55317651b6d4_D20180830-20180830"
      id="f-316">P4Y</apyx:AssetPurchaseAgreementTerm>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231"
      decimals="-5"
      id="f-317"
      unitRef="usd">600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231"
      decimals="-5"
      id="f-318"
      unitRef="usd">600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231"
      decimals="-5"
      id="f-319"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i7ad7af6f006a4f9583d90999ace5809e_D20220101-20221231"
      decimals="-5"
      id="f-320"
      unitRef="usd">-100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="iefa166e3072441a1a7435fde8c995859_D20210101-20211231"
      decimals="-5"
      id="f-321"
      unitRef="usd">6500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="iefa166e3072441a1a7435fde8c995859_D20210101-20211231"
      decimals="-5"
      id="f-322"
      unitRef="usd">5500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="iefa166e3072441a1a7435fde8c995859_D20210101-20211231"
      decimals="-5"
      id="f-323"
      unitRef="usd">1500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="iefa166e3072441a1a7435fde8c995859_D20210101-20211231"
      decimals="-5"
      id="f-324"
      unitRef="usd">-400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-325">INTEREST IN JOINT VENTURE INVESTMENT&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company executed a joint venture agreement with its Chinese supplier (the &#x201c;China JV&#x201d;) whereby the Company has a 51% interest. The China JV has been consolidated in these consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Changes in the Company&#x2019;s ownership investment in the China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="iab43910064884237bbdef4ac6cc8ff44_I20191231"
      decimals="2"
      id="f-326"
      unitRef="number">0.51</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <apyx:NoncontrollingInterestRequiredCapitalContribution
      contextRef="i0a3f56438b0549d9bb1816cb85ae9d4f_I20191231"
      decimals="-3"
      id="f-327"
      unitRef="usd">357000</apyx:NoncontrollingInterestRequiredCapitalContribution>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i0bcfaba8f0c645ee95bc37c4c4f557bc_D20210101-20211231"
      decimals="-3"
      id="f-328"
      unitRef="usd">203000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i6c3682736d9142f6ac1dda33e04b7f44_D20200101-20201231"
      decimals="-3"
      id="f-329"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <apyx:NoncontrollingInterestTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-330">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Changes in the Company&#x2019;s ownership investment in the China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</apyx:NoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="i33cd0694a0974259aa4da54d953aa393_I20211231"
      decimals="-3"
      id="f-331"
      unitRef="usd">317000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i4e47e5bd233347f190ad5ea24579801f_I20201231"
      decimals="-3"
      id="f-332"
      unitRef="usd">144000</us-gaap:MinorityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i28e0bc92d62a40c4b1273fbafc570bd2_D20220101-20221231"
      decimals="-3"
      id="f-333"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i0bcfaba8f0c645ee95bc37c4c4f557bc_D20210101-20211231"
      decimals="-3"
      id="f-334"
      unitRef="usd">203000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i28e0bc92d62a40c4b1273fbafc570bd2_D20220101-20221231"
      decimals="-3"
      id="f-335"
      unitRef="usd">-98000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0bcfaba8f0c645ee95bc37c4c4f557bc_D20210101-20211231"
      decimals="-3"
      id="f-336"
      unitRef="usd">-30000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="i7f5ca601b6594ace8b084574b85670b1_I20221231"
      decimals="-3"
      id="f-337"
      unitRef="usd">219000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i33cd0694a0974259aa4da54d953aa393_I20211231"
      decimals="-3"
      id="f-338"
      unitRef="usd">317000</us-gaap:MinorityInterest>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-339">INVENTORIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-340">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-341"
      unitRef="usd">4979000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-342"
      unitRef="usd">3603000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-343"
      unitRef="usd">2160000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-344"
      unitRef="usd">1441000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-345"
      unitRef="usd">5115000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-346"
      unitRef="usd">1997000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-347"
      unitRef="usd">12254000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-348"
      unitRef="usd">7041000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-349"
      unitRef="usd">457000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-350"
      unitRef="usd">263000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-351"
      unitRef="usd">11797000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-352"
      unitRef="usd">6778000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-353">PROPERTY AND EQUIPMENT&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total depreciation expense was $0.7&#160;million for the years ended December&#160;31, 2022 and 2021. Depreciation expense is included within cost of goods sold and selling, general and administrative expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-354">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i56987d7ae3fb47dfaaf61b0612cb8a6b_I20221231"
      decimals="-3"
      id="f-355"
      unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibaf70880d8834a4ea7a3ff7705a7d5e7_I20211231"
      decimals="-3"
      id="f-356"
      unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idf54c2e8062e464a943af7a1cc6f702e_I20221231"
      decimals="-3"
      id="f-357"
      unitRef="usd">4426000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i292d860f0b124b10b47265b193979452_I20211231"
      decimals="-3"
      id="f-358"
      unitRef="usd">4429000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8bcfa1867b9c4a31a3709fe8a05bbe58_I20221231"
      decimals="-3"
      id="f-359"
      unitRef="usd">2613000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibb15fe17f8554f4bb5cb43cfef473c00_I20211231"
      decimals="-3"
      id="f-360"
      unitRef="usd">2337000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i10b4e8b0d165454996fdf3396b1c0d64_I20221231"
      decimals="-3"
      id="f-361"
      unitRef="usd">211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id12249f705534e21b3e97868de6b1157_I20211231"
      decimals="-3"
      id="f-362"
      unitRef="usd">306000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i90034014d4ac40d6b47f2c9dfd2b0b6d_I20221231"
      decimals="-3"
      id="f-363"
      unitRef="usd">1420000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iee2d3c40f1484004855a884bc75b810d_I20211231"
      decimals="-3"
      id="f-364"
      unitRef="usd">1535000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c1dff9d0dbb4b90aef7333e20bb5fb3_I20221231"
      decimals="-3"
      id="f-365"
      unitRef="usd">178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib3b3ec8b01964331aded480dad14486f_I20211231"
      decimals="-3"
      id="f-366"
      unitRef="usd">171000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i68358e6c1c414942ab2b1cacdda282a7_I20221231"
      decimals="-3"
      id="f-367"
      unitRef="usd">847000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i243c730de3e94d3283669d4a2661af4b_I20211231"
      decimals="-3"
      id="f-368"
      unitRef="usd">859000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-369"
      unitRef="usd">11295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-370"
      unitRef="usd">11237000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-371"
      unitRef="usd">5041000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-372"
      unitRef="usd">5316000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-373"
      unitRef="usd">6254000</apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations>
    <apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-374"
      unitRef="usd">5921000</apyx:Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-375"
      unitRef="usd">507000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-376"
      unitRef="usd">654000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-377"
      unitRef="usd">6761000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-378"
      unitRef="usd">6575000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-5"
      id="f-379"
      unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-5"
      id="f-380"
      unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-381">LEASES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company&#x2019;s lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate, which is indicative of its collateralized borrowing rate. We utilized rates of 1.83% to 6.49% for our outstanding leases at December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the year ended December 31, 2022, the Company&#x2019;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the year ended December 31, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the year ended December 31, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the year ended December 31, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s lease costs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash information related to our leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2021&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2021&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-382">LEASES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company does not recognize leases with terms less than twelve months in duration, or that have variable only payments, in its Consolidated Balance Sheet as right-of-use assets and lease liabilities. The Company has adopted the practical expedient which allows for the Company to not separate lease and non-lease components of contracts. Accordingly, non-lease components are included in the measurement of the Company&#x2019;s lease liabilities and right-of-use assets. If the Company is aware of the implicit rate in leases, the Company determines the operating lease liability using the implicit rate. For those leases where the Company is not aware of the implicit rate in the lease, the Company utilizes an incremental borrowing rate, which is indicative of its collateralized borrowing rate. We utilized rates of 1.83% to 6.49% for our outstanding leases at December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. During the year ended December 31, 2022, the Company&#x2019;s leases on the vehicles in Clearwater, Florida expired and the Company purchased the vehicles at fair value. During the year ended December 31, 2022, the Company entered into a one year extension on one of its leases on computer equipment. This extension resulted in reclassification of the lease from finance to operating. During the year ended December 31, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the year ended December 31, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s lease costs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash information related to our leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2021&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2021&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <apyx:LesseeDiscountRateIncrementalBorrowingRate
      contextRef="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231"
      decimals="4"
      id="f-383"
      unitRef="number">0.0183</apyx:LesseeDiscountRateIncrementalBorrowingRate>
    <apyx:LesseeDiscountRateIncrementalBorrowingRate
      contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231"
      decimals="4"
      id="f-384"
      unitRef="number">0.0649</apyx:LesseeDiscountRateIncrementalBorrowingRate>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7ce8494d2834491ab35f3664a41429db_I20221231"
      id="f-385">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <apyx:LesseeOperatingLeaseNumberOfLeasesExtended
      contextRef="ifa25d872e0d140a98af126a2c508757b_D20220101-20221231"
      decimals="INF"
      id="f-386"
      unitRef="lease">1</apyx:LesseeOperatingLeaseNumberOfLeasesExtended>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie2aaebfd6e5041e3b8fade9ae7be2f4c_I20221231"
      id="f-387">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      id="f-388">P63M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-389">Information about the Company&#x2019;s lease costs are as follows:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash information related to our leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2021&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the Company&#x2019;s weighted average remaining lease terms and discount rate assumptions are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended &lt;br/&gt;December 31, 2021&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-390"
      unitRef="usd">213000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-391"
      unitRef="usd">134000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-392"
      unitRef="usd">138000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-393"
      unitRef="usd">216000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-394"
      unitRef="usd">5000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-395"
      unitRef="usd">12000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-396"
      unitRef="usd">16000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-397"
      unitRef="usd">12000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-398"
      unitRef="usd">372000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-399"
      unitRef="usd">374000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-400"
      unitRef="usd">219000</us-gaap:OperatingLeasePayments>
    <apyx:FinanceLeasePayments
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-401"
      unitRef="usd">153000</apyx:FinanceLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-402"
      unitRef="usd">135000</us-gaap:OperatingLeasePayments>
    <apyx:FinanceLeasePayments
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-403"
      unitRef="usd">228000</apyx:FinanceLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      id="f-404">P4Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      id="f-405">P3Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      id="f-406">P1Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      id="f-407">P0Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="4"
      id="f-408"
      unitRef="number">0.0254</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="4"
      id="f-409"
      unitRef="number">0.0260</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="4"
      id="f-410"
      unitRef="number">0.0398</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="4"
      id="f-411"
      unitRef="number">0.0400</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-412">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-413">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-414"
      unitRef="usd">229000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-415"
      unitRef="usd">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-416"
      unitRef="usd">122000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-417"
      unitRef="usd">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-418"
      unitRef="usd">122000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-419"
      unitRef="usd">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-420"
      unitRef="usd">122000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-421"
      unitRef="usd">21000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-422"
      unitRef="usd">122000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-423"
      unitRef="usd">12000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-424"
      unitRef="usd">717000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-425"
      unitRef="usd">115000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-426"
      unitRef="usd">31000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-427"
      unitRef="usd">5000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-428"
      unitRef="usd">686000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-429"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-430"
      unitRef="usd">216000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-431"
      unitRef="usd">37000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-432"
      unitRef="usd">470000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-433"
      unitRef="usd">73000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-434">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees and legal related contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-435">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees and legal related contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-436"
      unitRef="usd">563000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-437"
      unitRef="usd">546000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-438"
      unitRef="usd">0</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-439"
      unitRef="usd">2117000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-440"
      unitRef="usd">847000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-441"
      unitRef="usd">1656000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-442"
      unitRef="usd">391000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-443"
      unitRef="usd">593000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-444"
      unitRef="usd">1825000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-445"
      unitRef="usd">610000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-446"
      unitRef="usd">901000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-447"
      unitRef="usd">421000</us-gaap:AccruedProfessionalFeesCurrent>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-448"
      unitRef="usd">345000</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-449"
      unitRef="usd">1027000</apyx:JointAndSeveralPayrollLiability>
    <apyx:ShortTermContractLiabilities
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-450"
      unitRef="usd">853000</apyx:ShortTermContractLiabilities>
    <apyx:ShortTermContractLiabilities
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-451"
      unitRef="usd">533000</apyx:ShortTermContractLiabilities>
    <apyx:UncertainTaxPositionsLiability
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-452"
      unitRef="usd">2079000</apyx:UncertainTaxPositionsLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-453"
      unitRef="usd">1863000</apyx:UncertainTaxPositionsLiability>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-454"
      unitRef="usd">245000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-455"
      unitRef="usd">428000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-456"
      unitRef="usd">879000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-457"
      unitRef="usd">493000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-458"
      unitRef="usd">8928000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-459"
      unitRef="usd">10287000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ProductWarrantyDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-460">PRODUCT WARRANTIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product warranty activity consisted of the following for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in estimate to fulfill prior-year warranty obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product warranty costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-461">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product warranty activity consisted of the following for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in estimate to fulfill prior-year warranty obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product warranty costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-462"
      unitRef="usd">593000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231"
      decimals="-3"
      id="f-463"
      unitRef="usd">498000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrualWarrantiesIssued
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-464"
      unitRef="usd">196000</us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:StandardProductWarrantyAccrualWarrantiesIssued
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-465"
      unitRef="usd">318000</us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:StandardProductWarrantyAccrualPreexistingIncreaseDecrease
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-466"
      unitRef="usd">-198000</us-gaap:StandardProductWarrantyAccrualPreexistingIncreaseDecrease>
    <us-gaap:StandardProductWarrantyAccrualPreexistingIncreaseDecrease
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-467"
      unitRef="usd">0</us-gaap:StandardProductWarrantyAccrualPreexistingIncreaseDecrease>
    <us-gaap:StandardProductWarrantyAccrualPayments
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-468"
      unitRef="usd">200000</us-gaap:StandardProductWarrantyAccrualPayments>
    <us-gaap:StandardProductWarrantyAccrualPayments
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-469"
      unitRef="usd">223000</us-gaap:StandardProductWarrantyAccrualPayments>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-470"
      unitRef="usd">391000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-471"
      unitRef="usd">593000</us-gaap:StandardProductWarrantyAccrual>
    <apyx:JointandSeveralPayrollLiabilityTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-472">JOINT AND SEVERAL PAYROLL LIABILITYDuring 2018 and 2019, the Company improperly calculated and reported the amount of income to certain employees, and did not collect and remit the correct amount of its employees' portion of income and payroll taxes, related to stock option exercises as required by the IRS. Due to IRS statutory requirements, the Company has joint and several liability for the full amount that was not withheld and remitted to the proper taxing authorities. During 2022, the Company was relieved of approximately $650,000 of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. This adjustment is included in other income (losses), net in the accompany Consolidated Statement of Operations for the year ended December 31, 2022. This amount of the liability was approximately $0.3&#160;million and $1.0&#160;million at December&#160;31, 2022 and 2021, respectively. The Company will be relieved of the remainder of the liability as the statute of limitations on the liability expires, which the Company expects to occur during April 2023, or once the Company can establish that its employees have in fact paid these obligations.</apyx:JointandSeveralPayrollLiabilityTextBlock>
    <apyx:JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-473"
      unitRef="usd">650000</apyx:JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-474"
      unitRef="usd">300000</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-5"
      id="f-475"
      unitRef="usd">1000000</apyx:JointAndSeveralPayrollLiability>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-476">CONTRACT ASSETS AND LIABILITIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts with customers may result in the Company having contract assets and liabilities. These contract assets and liabilities arise primarily from OEM development and supply agreements where the development of the goods does not represent a performance obligation on a standalone basis. The Company defers the development fees billed to customers, and the associated costs, and recognizes them as it completes performance obligations on the supply portion of the agreement. Other contract liabilities may be recognized when a customer prepays for goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, respectively, the Company had recorded approximately $2.3&#160;million and $1.9&#160;million of contract liabilities and $0.6&#160;million and $0.5&#160;million of contract assets related to customer prepayments and the deferral of revenues and expenses under these agreements. At December&#160;31, 2022, $0.9&#160;million of the contract liabilities and $0.1&#160;million of the contract assets are presented as current in the accompanying Consolidated Balance Sheet within accrued expenses and other current liabilities and prepaid expenses and other current assets, respectively. At December&#160;31, 2021,  $0.5&#160;million of the contract liabilities and $0.1&#160;million of the contract assets are presented as current in the accompanying Consolidated Balance Sheet within accrued expenses and other current liabilities and prepaid expenses and other current assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, the Company recognized approximately $0.2&#160;million of contract liabilities and $0.1&#160;million of contract assets that existed as of December&#160;31, 2021 in sales and cost of sales, respectively, in the accompanying Consolidated Statement of Operations for the year ended December&#160;31, 2022. During 2021, the Company did not recognize any significant contract liabilities or contract assets that existed as of December&#160;31, 2020 in sales or cost of sales in the accompanying Consolidated Statement of Operations for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-477"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-5"
      id="f-478"
      unitRef="usd">1900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-479"
      unitRef="usd">600000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-5"
      id="f-480"
      unitRef="usd">500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-481"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-482"
      unitRef="usd">100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-5"
      id="f-483"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-5"
      id="f-484"
      unitRef="usd">100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-5"
      id="f-485"
      unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <apyx:ContractWithCustomerAssetRevenueRecognized
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-5"
      id="f-486"
      unitRef="usd">100000</apyx:ContractWithCustomerAssetRevenueRecognized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-487">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share (&#x201c;basic EPS&#x201d;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (&#x201c;diluted EPS&#x201d;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted earnings (loss) per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerators:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-488">The following table provides the computation of basic and diluted earnings (loss) per share.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerators:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-489"
      unitRef="usd">-23184000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-490"
      unitRef="usd">-15172000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-491"
      unitRef="shares">34516000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-492"
      unitRef="shares">34516000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-493"
      unitRef="shares">34332000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-494"
      unitRef="shares">34332000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-495"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="2"
      id="f-497"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="2"
      id="f-498"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iad2fb842f9454872b733d0f3ea008372_D20220101-20221231"
      decimals="-3"
      id="f-499"
      unitRef="shares">6520000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if873b957ef9a452fbbc6e871b2410716_D20210101-20211231"
      decimals="-3"
      id="f-500"
      unitRef="shares">5398000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-501">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;GILTI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of the Company&#x2019;s deferred tax assets (liabilities) are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory 263A adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all positive and negative evidence regarding the realization of deferred tax assets, including past operating results and future sources of taxable income. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the earnings of Apyx Bulgaria, EOOD to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. It has not recorded a deferred tax liability related to the U.S. Federal and State income taxes and foreign withholding taxes on the undistributed earnings of Apyx Bulgaria, EOOD indefinitely invested outside the United States. If it decides to repatriate the foreign earnings, the Company will need to adjust its income tax provision in the period it determines that the earnings will no longer be indefinitely invested outside the United States.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. As of December 31, 2022 and 2021, the Company has recorded a liability of approximately $1.3 million related to uncertain tax positions and accrued approximately $0.8&#160;million and $0.6&#160;million, respectively, of interest and penalties on these positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.093%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Tax Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Additions of tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Additions of tax positions related to the prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Decreases for tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal and state income tax examination.  The Company&#x2019;s 2019 through 2021 U.S. federal income tax returns are subject to examination by the Internal Revenue Service (&#x201c;IRS&#x201d;).  The Company&#x2019;s state income tax returns are subject to examination for the 2018 through 2021 tax years.&lt;/span&gt;&lt;/div&gt;During 2022, the Company was notified by the IRS that it is examining the Company&#x2019;s 2018, 2019 and 2020 federal income tax returns. During January 2023, the Company was notified that the examination process was complete and that the Company's tax refunds were approved for substantially the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. In the examination, the Company's uncertain tax positions were accepted by the IRS as submitted on our income tax returns and the Company reversed its uncertain tax position in January 2023.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-502">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-503"
      unitRef="usd">214000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-504"
      unitRef="usd">217000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-505"
      unitRef="usd">29000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-506"
      unitRef="usd">54000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-507"
      unitRef="usd">124000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-508"
      unitRef="usd">109000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-509"
      unitRef="usd">367000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-510"
      unitRef="usd">380000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-511"
      unitRef="usd">-4096000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-512"
      unitRef="usd">-2518000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-513"
      unitRef="usd">-1004000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-514"
      unitRef="usd">-613000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-515"
      unitRef="usd">-5100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-516"
      unitRef="usd">-3131000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <apyx:IncomeTaxExpenseBenefitValuationAllowance
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-517"
      unitRef="usd">-5100000</apyx:IncomeTaxExpenseBenefitValuationAllowance>
    <apyx:IncomeTaxExpenseBenefitValuationAllowance
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-518"
      unitRef="usd">-3131000</apyx:IncomeTaxExpenseBenefitValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-519"
      unitRef="usd">367000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-520"
      unitRef="usd">380000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-521">Below is a reconciliation of the statutory federal income tax rate to the Company's effective tax rate:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incentive stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;GILTI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-522"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="INF"
      id="f-523"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-524"
      unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-525"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-526"
      unitRef="number">-0.223</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-527"
      unitRef="number">-0.211</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-528"
      unitRef="number">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-529"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <apyx:EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-530"
      unitRef="number">-0.011</apyx:EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent>
    <apyx:EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-531"
      unitRef="number">-0.038</apyx:EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-532"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-533"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-534"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-535"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-536"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-537"
      unitRef="number">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-538">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of the Company&#x2019;s deferred tax assets (liabilities) are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss and credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory 263A adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-539"
      unitRef="usd">7476000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-540"
      unitRef="usd">4256000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-541"
      unitRef="usd">2381000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-542"
      unitRef="usd">1701000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-543"
      unitRef="usd">982000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-544"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <apyx:DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-545"
      unitRef="usd">400000</apyx:DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles>
    <apyx:DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-546"
      unitRef="usd">70000</apyx:DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-547"
      unitRef="usd">394000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-548"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-549"
      unitRef="usd">339000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-550"
      unitRef="usd">163000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-551"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-552"
      unitRef="usd">555000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-553"
      unitRef="usd">553000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-554"
      unitRef="usd">653000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-555"
      unitRef="usd">12525000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-556"
      unitRef="usd">7398000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-557"
      unitRef="usd">12068000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-558"
      unitRef="usd">6968000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-559"
      unitRef="usd">457000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-560"
      unitRef="usd">430000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-561"
      unitRef="usd">205000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-562"
      unitRef="usd">205000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-563"
      unitRef="usd">252000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-564"
      unitRef="usd">225000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-565"
      unitRef="usd">457000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-566"
      unitRef="usd">430000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-567"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-568"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-5"
      id="f-569"
      unitRef="usd">1300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-570"
      unitRef="usd">1300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-571"
      unitRef="usd">800000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-5"
      id="f-572"
      unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-573">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.093%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Tax Benefits&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Additions of tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Additions of tax positions related to the prior year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Decreases for tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;End of year balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-574"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231"
      decimals="-3"
      id="f-575"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-576"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-577"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-578"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-579"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-580"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-581"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-582"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="-3"
      id="f-583"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-584">RETIREMENT PLAN&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a tax-qualified profit-sharing retirement plan under section 401(k) of the Internal Revenue Code for the benefit of eligible employees with an accumulation of funds for retirement on a tax-deferred basis and provides for annual discretionary contribution to individual trust funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All employees are eligible to participate upon completing three months of service. The employees may make voluntary contributions to the plan up to the maximum percentage allowed by the Internal Revenue Code. Vesting in employee matching contributions is graded and depends on the years of service. After three years from their date of hire, the employees are 100% vested. The Company makes matching contributions of 50% of the employee contributions up to a total of 3% of participant payroll. Matching contributions made by the Company totaled approximately $0.4&#160;million for each of the years ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <apyx:DefinedContributionPlanRequisiteServicePeriod
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-585">P3M</apyx:DefinedContributionPlanRequisiteServicePeriod>
    <apyx:DefinedContributionPlanEmployersMatchingContributionVestingPeriod
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-586">P3Y</apyx:DefinedContributionPlanEmployersMatchingContributionVestingPeriod>
    <apyx:DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-587"
      unitRef="number">1</apyx:DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-588"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-589"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-5"
      id="f-590"
      unitRef="usd">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-591">RELATED PARTY TRANSACTIONS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several relatives of Nikolay Shilev, Apyx Bulgaria&#x2019;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#x2019;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Tor&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;omanova, Mr. Shilev&#x2019;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#x2019;s son, is a quality manager in the quality assurance department. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The partner in the Company&#x2019;s China joint venture is also a supplie&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r of the Company. For the years ended December&#160;31, 2022 and 2021, the Company made purchases from this supplier of approximately $0.6&#160;million and $1.3&#160;million, respectively. At December&#160;31, 2022 and 2021, the Company had net receivables from and payables to this supplier of approximately $8,000 and $1,000, respective&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ly.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i15c65c91210b4634aa8886aa2c04c687_D20220101-20221231"
      decimals="-5"
      id="f-592"
      unitRef="usd">600000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i2be8be05786644b587f7269db8612ba8_D20210101-20211231"
      decimals="-5"
      id="f-593"
      unitRef="usd">1300000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ie1bd31e839574eb0b58cd8ec4b423216_I20221231"
      decimals="-3"
      id="f-594"
      unitRef="usd">8000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i0bafa9f247264d98b3a5973a8aa85489_I20211231"
      decimals="-3"
      id="f-595"
      unitRef="usd">1000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-596">COMMITMENTS AND CONTINGENCIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#x2019;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#x2019;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#x2019;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company has recorded an estimated loss of $250,000 in professional services in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed with the U.S. Securities and Exchange Commission on the Company&#x2019;s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the &#x201c;Complaint&#x201d;) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (&#x201c;Goodwin&#x201d;), the Company&#x2019;s President and Chief Executive Officer and a member of the Company&#x2019;s Board of Directors, and Tara Semb (&#x201c;Semb&#x201d;), the Company&#x2019;s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company&#x2019;s Advanced Energy products and the impact such usage would have on the Company&#x2019;s business, operations and prospects. The Complaint seeks an unspecified amount of damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company has recorded an estimated loss of $475,000 in professional services in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff&#x2019;s allegations could be subject to separate deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company has recorded an estimated loss of $1,450,000 in selling, general and administrative expenses associated with the insurance deductibles in the accompanying Consolidated Statement of Operations for the year ended December 31, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company has purchase commitments for inventories totaling approximately $4.1&#160;million, all of which is expected to be purchased by the end of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no significant sales concentrations for the year ended December 31, 2022. Sales to one customer within the Advanced Energy segment represented 11% of total sales for the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from one customer and two customers within the Advanced Energy segment represented 13% and 22%, respectively, of trade accounts receivable at December 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i81985ec077fa472193067684bf28ef76_I20220331"
      decimals="-3"
      id="f-597"
      unitRef="usd">250000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i3517b2fe5b464ec5ab2cb6fedcd9c77d_I20220331"
      decimals="-3"
      id="f-598"
      unitRef="usd">1000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i20512693f6584e7d82c03a312e6156ee_I20221231"
      decimals="-3"
      id="f-599"
      unitRef="usd">250000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i9aae6976833242b1b30c6676851c9194_I20221231"
      decimals="-3"
      id="f-600"
      unitRef="usd">475000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i92b182548e09413c8f592eb9c29abd89_I20221231"
      decimals="-3"
      id="f-601"
      unitRef="usd">2500000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i1a58968298ce4c70ab56e29d0ce9450d_I20221231"
      decimals="-3"
      id="f-602"
      unitRef="usd">475000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i6ef0e96305c24e7297840166aa515f96_D20220101-20221231"
      decimals="INF"
      id="f-603"
      unitRef="lease">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i9a0b18b016bd448eabc6ee7bdd802e0b_D20230101-20230316"
      decimals="INF"
      id="f-604"
      unitRef="lease">10</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i978115ab316f4e03b88b250dc52320f6_I20230316"
      decimals="-3"
      id="f-605"
      unitRef="usd">1450000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i8015e0424ea1487ba240da801ce050f6_I20230316"
      decimals="-3"
      id="f-606"
      unitRef="usd">2400000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i870ddbfe09ce44fab9950cf2896a4dfe_I20230316"
      decimals="-3"
      id="f-607"
      unitRef="usd">1450000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PurchaseObligation
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-5"
      id="f-608"
      unitRef="usd">4100000</us-gaap:PurchaseObligation>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iba71a7789d3e40e99df5af434f95f621_D20210101-20211231"
      decimals="2"
      id="f-609"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibb1a97606daa4ceba9e7e3f4025e9194_D20220101-20221231"
      decimals="2"
      id="f-610"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i445e51d03e01407ab9b5e970e37bb25c_D20210101-20211231"
      decimals="2"
      id="f-611"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-612">STOCK OPTIONS&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 30, 2007, the Company&#x2019;s stockholders approved, and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan (the &#x201c;Plan&#x201d;) to increase the maximum aggregate number of shares of common stock reserved for issuance under the Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares. Except for the increase in the number of shares covered by the Plan, the Plan remained otherwise unchanged. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance 1.2 million stock options. Stock options to employees typically have a ten-year life and currently vest over periods between &lt;span style="-sec-ix-hidden:f-617"&gt;one&lt;/span&gt; and seven years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2012, the Company&#x2019;s stockholders approved the 2012 Share Incentive Plan covering a total of 750,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 170,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015, the Company&#x2019;s stockholders approved the 2015 Executive and Employee Stock Option Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 40,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, the Company&#x2019;s stockholders approved the 2017 Executive and Employee Stock Option Plan covering a total of 3,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022 approximately 30,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company&#x2019;s stockholders approved the 2019 Share Incentive Plan covering a total of 2,000,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022, all 200,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company&#x2019;s stockholders approved the 2021 Share Incentive Plan covering a total of 1,375,000 shares of common stock issuable upon exercise of options to be granted under the plan. At December&#160;31, 2022, all 1,375,000 are available to be issued in this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2023, the Company granted employees appro&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ximately 1,400,000 options to purchase common shares of the Company's stock. All options granted were pursuant to the plans noted above. The options ves&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t over a period of three years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The status of the Company&#x2019;s stock options is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,938,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,397,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,520,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,802,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,028,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. Options are valued using the Black-Scholes model. For employee grants, the Company calculates expected life via the simplified method as it does not have sufficient history to determine actual expected life. For non-employee grants, the Company calculates expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior. Inputs used in the valuation models are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized approximately $6,697,000 and $5,088,000 in stock-based compensation expense during the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value of each option share is the difference between the fair value of our common stock and the exercise price of such option share to the extent it is &#x201c;in-the-money&#x201d;. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation at December 31, 2022 is based on the $2.34 closing stock price of the Company's common stock on December&#160;30, 2022, the last trading day of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there were 6,074,922 stock options outstanding and expected to vest with an aggregate intrinsic value of approximately $160,000. These options have a weighted average exercise price of $6.91 and a weighted average remaining contractual term of approximately 6 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there were 4,292,836 stock options outstanding and exercisable with an aggregate intrinsic value of approximately $160,000. These options have a weighted average exercise price of $5.60 and a weighted average remaining contractual term of approximately 6 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of in the money options exercised during the years ended December&#160;31, 2022 and 2021, was approximately $900,000 and $1,600,000, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options or other consideration paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of options granted during the years ended December&#160;31, 2022 and 2021, was approximately $11,350,000 and $5,150,000, respectively. The weighted average fair value of options granted during the years ended December&#160;31, 2022 and 2021, was $6.71 and $5.76, respectively. The total fair value of options vested during the years ended December&#160;31, 2022 and 2021, was approximately $5,260,000 and $4,270,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allows employees to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. During the years ended December&#160;31, 2022 and 2021, the Company received 125,596 and 111,831 options as payment in the exercise of 81,737 and 107,357 options, respectively.&lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2022, there was approximately $8,430,000 of total unrecognized stock-based compensation expense, related to unvested stock options granted under the plans above. This expense is expected to be recognized over a weighted-average period of approximately 1 year.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8f4cb62a47674f069376423c04bbf511_I20011231"
      decimals="-5"
      id="f-613"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8ce22e9e74ae4aad81ea9bf903e52593_I20071030"
      decimals="-5"
      id="f-614"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8f4cb62a47674f069376423c04bbf511_I20011231"
      decimals="-5"
      id="f-615"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-616">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231"
      id="f-618">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i853b05ef16534eea839dc217dc64ae1e_I20120731"
      decimals="0"
      id="f-619"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic2118a02b53544ed902dfa41da2fb932_I20221231"
      decimals="0"
      id="f-620"
      unitRef="shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i5dd72154e8a84a13ba2ec410056e0cc3_I20150731"
      decimals="0"
      id="f-621"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i13a40b61b75e4a1da2703881874d03b7_I20221231"
      decimals="0"
      id="f-622"
      unitRef="shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="icb85bfecc9fe411fbf5543ebcc203676_I20170831"
      decimals="0"
      id="f-623"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if744468335d24182b13e02e0c5cbee45_I20221231"
      decimals="0"
      id="f-624"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iac91df8b60954d69a9e1632838aa1f72_I20190831"
      decimals="0"
      id="f-625"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib635cac0c9b846c38ee05d5e5de8a30e_I20221231"
      decimals="0"
      id="f-626"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i4b00dca027564cc4a6278d01e014e129_I20210831"
      decimals="0"
      id="f-627"
      unitRef="shares">1375000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i627345abf94741d0b8653a012a895db1_I20221231"
      decimals="0"
      id="f-628"
      unitRef="shares">1375000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="idba9e20874ac40928de8555b5779b796_I20230111"
      decimals="0"
      id="f-629"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i54189c6eb13741cab646fd61dc525b97_D20230111-20230111"
      id="f-630">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-631">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The status of the Company&#x2019;s stock options is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,938,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,397,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,520,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231"
      decimals="INF"
      id="f-632"
      unitRef="shares">4938943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i295652f4d94541d6bfe4a8724a96ea47_I20201231"
      decimals="2"
      id="f-633"
      unitRef="usdPerShare">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="INF"
      id="f-634"
      unitRef="shares">894980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="2"
      id="f-635"
      unitRef="usdPerShare">9.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="INF"
      id="f-636"
      unitRef="shares">232521</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="2"
      id="f-637"
      unitRef="usdPerShare">6.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="INF"
      id="f-638"
      unitRef="shares">203711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="2"
      id="f-639"
      unitRef="usdPerShare">8.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-640"
      unitRef="shares">5397691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="2"
      id="f-641"
      unitRef="usdPerShare">5.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-642"
      unitRef="shares">1692417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-643"
      unitRef="usdPerShare">10.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-644"
      unitRef="shares">316506</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-645"
      unitRef="usdPerShare">3.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-646"
      unitRef="shares">253158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-647"
      unitRef="usdPerShare">9.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-648"
      unitRef="shares">6520444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="2"
      id="f-649"
      unitRef="usdPerShare">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-650">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,802,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,692,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,028,867)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,227,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="INF"
      id="f-651"
      unitRef="shares">1802216</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i75e0b82b58654112a567e39aa1802734_I20211231"
      decimals="2"
      id="f-652"
      unitRef="usdPerShare">5.21</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-653"
      unitRef="shares">1692417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-654"
      unitRef="usdPerShare">6.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-655"
      unitRef="shares">1028867</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-656"
      unitRef="usdPerShare">5.11</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-657"
      unitRef="shares">238158</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-658"
      unitRef="usdPerShare">6.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="INF"
      id="f-659"
      unitRef="shares">2227608</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="2"
      id="f-660"
      unitRef="usdPerShare">6.27</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-661">Inputs used in the valuation models are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231"
      decimals="2"
      id="f-662"
      unitRef="usdPerShare">5.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231"
      decimals="2"
      id="f-663"
      unitRef="usdPerShare">10.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if05944548e154442b75796c157713f6b_D20210101-20211231"
      decimals="2"
      id="f-664"
      unitRef="usdPerShare">9.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id4d89fb15b914a8b9464e4d4f665063b_D20210101-20211231"
      decimals="2"
      id="f-665"
      unitRef="usdPerShare">11.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5040845d9f6e4cedb14623ba3d1db98b_D20220101-20221231"
      decimals="3"
      id="f-666"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231"
      decimals="3"
      id="f-667"
      unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if05944548e154442b75796c157713f6b_D20210101-20211231"
      decimals="3"
      id="f-668"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id4d89fb15b914a8b9464e4d4f665063b_D20210101-20211231"
      decimals="3"
      id="f-669"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-670"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="INF"
      id="f-671"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-672"
      unitRef="number">0.696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="3"
      id="f-673"
      unitRef="number">0.785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-674"
      unitRef="number">0.689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="3"
      id="f-675"
      unitRef="number">0.708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-676">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9042ce06b425477c8f537e3e45fe3f33_D20220101-20221231"
      id="f-677">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if05944548e154442b75796c157713f6b_D20210101-20211231"
      id="f-678">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id4d89fb15b914a8b9464e4d4f665063b_D20210101-20211231"
      id="f-679">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-680"
      unitRef="usd">6697000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-681"
      unitRef="usd">5088000</us-gaap:AllocatedShareBasedCompensationExpense>
    <apyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="2"
      id="f-682"
      unitRef="usdPerShare">2.34</apyx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="0"
      id="f-683"
      unitRef="shares">6074922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-684"
      unitRef="usd">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="2"
      id="f-685"
      unitRef="usdPerShare">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-686">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="0"
      id="f-687"
      unitRef="shares">4292836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-688"
      unitRef="usd">160000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="2"
      id="f-689"
      unitRef="usdPerShare">5.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-690">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-691"
      unitRef="usd">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-692"
      unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-693"
      unitRef="usd">11350000</apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-694"
      unitRef="usd">5150000</apyx:ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="2"
      id="f-695"
      unitRef="usdPerShare">6.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="2"
      id="f-696"
      unitRef="usdPerShare">5.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-697"
      unitRef="usd">5260000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-698"
      unitRef="usd">4270000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="0"
      id="f-699"
      unitRef="shares">125596</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="0"
      id="f-700"
      unitRef="shares">111831</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="0"
      id="f-701"
      unitRef="shares">81737</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="0"
      id="f-702"
      unitRef="shares">107357</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ia7082c9220d542aea74c20a8d84ddd01_I20221231"
      decimals="-3"
      id="f-703"
      unitRef="usd">8430000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-704">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-705">GEOGRAPHIC AND SEGMENT INFORMATION&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reportable segments are disclosed as principally organized and managed as&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;two operating segments: Advanced Energy and OEM. "Corporate &amp;amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate (Other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate (Other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International sales in 2022 and 2021, were 29.9% and 32.0% of sales, respectively. Revenue by geographic region, based on the "ship to" location on the invoice are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="INF"
      id="f-706"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-707">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate (Other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate (Other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94da9825cefa47e085dc8967533353fa_D20220101-20221231"
      decimals="-3"
      id="f-708"
      unitRef="usd">36803000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec7daf90e27a450094b575521306a713_D20220101-20221231"
      decimals="-3"
      id="f-709"
      unitRef="usd">7707000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-710"
      unitRef="usd">44510000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i94da9825cefa47e085dc8967533353fa_D20220101-20221231"
      decimals="-3"
      id="f-711"
      unitRef="usd">-4103000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iec7daf90e27a450094b575521306a713_D20220101-20221231"
      decimals="-3"
      id="f-712"
      unitRef="usd">1641000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231"
      decimals="-3"
      id="f-713"
      unitRef="usd">-21100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-714"
      unitRef="usd">-23562000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231"
      decimals="-3"
      id="f-715"
      unitRef="usd">157000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-716"
      unitRef="usd">157000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i94da9825cefa47e085dc8967533353fa_D20220101-20221231"
      decimals="-3"
      id="f-717"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231"
      decimals="-3"
      id="f-718"
      unitRef="usd">15000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-719"
      unitRef="usd">15000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231"
      decimals="-3"
      id="f-720"
      unitRef="usd">509000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231"
      decimals="-3"
      id="f-721"
      unitRef="usd">509000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-722"
      unitRef="usd">509000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i94da9825cefa47e085dc8967533353fa_D20220101-20221231"
      decimals="-3"
      id="f-723"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iec7daf90e27a450094b575521306a713_D20220101-20221231"
      decimals="-3"
      id="f-724"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e651aead0764768bdd32b19a6233cbb_D20220101-20221231"
      decimals="-3"
      id="f-725"
      unitRef="usd">367000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-726"
      unitRef="usd">367000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3fd74d3ecc94c9d852ed481d8155c2d_D20210101-20211231"
      decimals="-3"
      id="f-727"
      unitRef="usd">42985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iceb3893cd8fd491f9f46c1f269d3f5e4_D20210101-20211231"
      decimals="-3"
      id="f-728"
      unitRef="usd">5532000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-729"
      unitRef="usd">48517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia3fd74d3ecc94c9d852ed481d8155c2d_D20210101-20211231"
      decimals="-3"
      id="f-730"
      unitRef="usd">2784000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iceb3893cd8fd491f9f46c1f269d3f5e4_D20210101-20211231"
      decimals="-3"
      id="f-731"
      unitRef="usd">1033000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231"
      decimals="-3"
      id="f-732"
      unitRef="usd">-18265000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-733"
      unitRef="usd">-14448000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231"
      decimals="-3"
      id="f-734"
      unitRef="usd">11000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-735"
      unitRef="usd">11000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231"
      decimals="-3"
      id="f-736"
      unitRef="usd">10000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-737"
      unitRef="usd">10000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231"
      decimals="-3"
      id="f-738"
      unitRef="usd">-373000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-739"
      unitRef="usd">-373000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia3fd74d3ecc94c9d852ed481d8155c2d_D20210101-20211231"
      decimals="-3"
      id="f-740"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iceb3893cd8fd491f9f46c1f269d3f5e4_D20210101-20211231"
      decimals="-3"
      id="f-741"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i89e34643699b475a81cdf2f27d1efc03_D20210101-20211231"
      decimals="-3"
      id="f-742"
      unitRef="usd">380000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-743"
      unitRef="usd">380000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0dd72b9e18204c609c5668ac31713394_D20220101-20221231"
      decimals="3"
      id="f-744"
      unitRef="number">0.299</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ide55cc7e04aa4a9dbf8cb858b7ceafaa_D20210101-20211231"
      decimals="3"
      id="f-745"
      unitRef="number">0.320</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-746">Revenue by geographic region, based on the "ship to" location on the invoice are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b469a871d414d41b9f05c65d751b0f2_D20220101-20221231"
      decimals="-3"
      id="f-747"
      unitRef="usd">31208000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i868b6761ce074d338f4b5ce301df99d1_D20210101-20211231"
      decimals="-3"
      id="f-748"
      unitRef="usd">32980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ee6627e384748dd93f7c235043736aa_D20220101-20221231"
      decimals="-3"
      id="f-749"
      unitRef="usd">13302000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52d35bf44ac044d9b818e2795485ffad_D20210101-20211231"
      decimals="-3"
      id="f-750"
      unitRef="usd">15537000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      decimals="-3"
      id="f-751"
      unitRef="usd">44510000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c45b46201c2405d8af799d9a61bf257_D20210101-20211231"
      decimals="-3"
      id="f-752"
      unitRef="usd">48517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231"
      id="f-753">SUBSEQUENT EVENTS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Execution of Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the &#x201c;Credit Agreement&#x201d;), by and among the Company (as borrower) and Apyx China Holding Corp., the Company&#x2019;s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement provides for an up to $35&#160;million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provides for senior secured term loans of up to $25&#160;million, comprised of (i) an initial tranche of $10&#160;million, (ii) a second tranche of $5&#160;million, and (iii) a third tranche of $10&#160;million. The secured revolving facility provides for loans in an aggregate principal amount of up to $10&#160;million, subject to a borrowing base equal to certain percentages of the Company&#x2019;s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.  The Credit Agreement matures on February 1, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline"&gt;Term Loans &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The initial tranche of $10&#160;million was fully funded on February 17, 2023, with approximately $2&#160;million of the proceeds used to pay for transaction fees and other costs incurred in connection with the Credit Agreement. Subject to certain terms and conditions of the Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company&#x2019;s ability to access these additional tranches is conditioned upon, among other things, the achievement of certain minimum revenue targets. The net proceeds of these term loans are to be used for working capital and general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Each term loan bears interest at a floating rate based on an Adjusted Term SOFR (as defined in the Credit Agreement), subject to a floor of 2.5%, plus 7.35%. The first twenty-four (24) months of the term loans constitute an interest-only period (with a possible twelve (12) month extension), with interest payable monthly on the first day of each month. Subsequent to the interest-only period, the outstanding principal amount of the term loans is repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension of the interest-only period). All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity. The term loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Credit Agreement. Additionally, the term loans are subject to mandatory prepayment obligations, pursuant to the terms of the Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company is also obligated to pay an exit fee of 4% of the total amount funded thereunder. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline"&gt;Revolving Facility &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company may borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility will terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must be repaid. The proceeds of the revolving facility may be used for working capital needs and general corporate purposes.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans made under the revolving facility bear interest at a floating rate based on an Adjusted Term SOFR (as defined in the Credit Agreement), subject to a floor of 2.5%, plus 4%. The Company is obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility is terminated or reduced before maturity, the Company is subject to a deferred origination fee pursuant to the terms of the Credit Agreement. Terminations and reductions of the commitments are subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company is required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10&#160;million under the revolving facility.  If the average outstanding balance for a month is less than the minimum balance, the Company will pay a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees are payable monthly on the first day of each month.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline"&gt;Collateral &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all of its assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline"&gt;Covenants &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions set forth in the Credit Agreement. The Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49&#160;million, $60&#160;million and $70&#160;million for 2023, 2024, and 2025, respectively. Additionally, the Company must maintain a balance of $10&#160;million in cash and cash equivalents during the duration of the Credit Agreement&#x2019;s term. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline"&gt;Events of Default&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreement also contains customary Events of Default (as defined in the Credit Agreement) that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Upon the occurrence and during the continuance of an Event of Default under the Credit Agreement, the respective administrative agent, if requested by the respective lenders, may, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline"&gt;Issuance of Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Company&#x2019;s obligations under the Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sale Leaseback of Clearwater, FL Real Property&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In an effort to improve liquidity and the balance sheet condition of the Company, management has been exploring options to leverage the Company's unencumbered real property. On February 27, 2023 the Company&#x2019;s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 14, 2023, Apyx Medical Corporation (the &#x201c;Company&#x201d;) entered into a Purchase and Sale Agreement (the &#x201c;Purchase Agreement&#x201d;) with VK Acquisitions VI, LLC (the &#x201c;Purchaser&#x201d;), for the sale of the Company&#x2019;s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the &#x201c;Property&#x201d;) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser within thirty (30) days from the date of execution, during which time the Purchaser retains the right to cancel the Purchase Agreement. The closing shall occur five (5) days following the expiration of the due diligence period. Upon execution of the Purchase Agreement, the Purchaser paid a down payment of $400,000 into escrow, which shall be held in accordance with the Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the terms of the Purchase Agreement, the transaction is not conditioned upon Purchaser obtaining any form of financing. The Purchase Agreement contains customary representations, warranties and covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with the terms of the Purchase Agreement, upon the closing of the sale of the Property, the Company will enter into a Single Tenant Industrial Building Lease (the &#x201c;Lease&#x201d;) with the Purchaser, pursuant to which the Property will be leased back to the Company. The Lease will have an initial term of ten (10) years commencing from the closing (the &#x201c;Initial Term&#x201d;), and a renewal term of five (5) years, exercisable at the Company&#x2019;s option. The annual fixed rent will be $619,500 for the first year of the Initial Term, and will be subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The net cash proceeds the Company expects to receive following closing is approximately $6,700,000 after taxes, expenses, and fees. This estimate is subject to the consummation of the transaction and the finalization of the Company&#x2019;s obligations associated with the sale. The Company anticipates that the net cash proceeds will be used to strengthen its balance sheet and provide working capital&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the &#x201c;Stein Suit&#x201d;) against individual members of the Company&#x2019;s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the &#x201c;Pritchard Case&#x201d;).  The Stein Suit seeks unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing.  The Company believes that the claims are subject to procedural and substantive defenses, anticipates defense and indemnity coverage to be made available by the relevant insurer, and expects the individual defendants to defend all of the allegations vigorously.  The outcome of the action is not within the Company&#x2019;s control and may not be known for a prolonged period of time.  In the opinion of management, neither the alleged claims against the individual defendants nor the defense thereof are expected to result in a material, adverse effect on the Company&#x2019;s financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9623247cdf6a40419d4a2b011f00d8ed_I20230217"
      decimals="-6"
      id="f-754"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i498926f26c67490999cf1e6f231404e1_I20230217"
      decimals="-6"
      id="f-755"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icd920217a5774a4a8e99a083c1cb188c_I20230217"
      decimals="-6"
      id="f-756"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie91aea3453ae4206b00854b54ccdde12_I20230217"
      decimals="-6"
      id="f-757"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4fbd4462461f48afb157563bd14c45a5_I20230217"
      decimals="-6"
      id="f-758"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i982284b9ef6f4f6f9d69822b5e02cff9_I20230217"
      decimals="-6"
      id="f-759"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icd920217a5774a4a8e99a083c1cb188c_I20230217"
      decimals="-6"
      id="f-760"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217"
      decimals="-6"
      id="f-761"
      unitRef="usd">2000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <apyx:DebtInstrumentInterestRateFloorPercent
      contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217"
      decimals="3"
      id="f-762"
      unitRef="number">0.025</apyx:DebtInstrumentInterestRateFloorPercent>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iaaf38b5907d248938c29ae1623e0a4ae_D20230217-20230217"
      decimals="4"
      id="f-763"
      unitRef="number">0.0735</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <apyx:DebtInstrumentPeriodOfInterestOnly
      contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217"
      id="f-764">P24M</apyx:DebtInstrumentPeriodOfInterestOnly>
    <apyx:DebtInstrumentExtensionPeriod
      contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217"
      id="f-765">P12M</apyx:DebtInstrumentExtensionPeriod>
    <apyx:DebtInstrumentNumberOfMonthlyPayments
      contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217"
      decimals="INF"
      id="f-766"
      unitRef="numberofmonthlypayment">36</apyx:DebtInstrumentNumberOfMonthlyPayments>
    <apyx:DebtInstrumentNumberOfMonthlyPaymentsExtension
      contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217"
      decimals="INF"
      id="f-767"
      unitRef="numberofmonthlypayment">24</apyx:DebtInstrumentNumberOfMonthlyPaymentsExtension>
    <apyx:DebtInstrumentPrepaymentFeePercent
      contextRef="i6462edbcc6f3498fb5595ceca9c9b20c_D20230217-20230217"
      decimals="2"
      id="f-768"
      unitRef="number">0.03</apyx:DebtInstrumentPrepaymentFeePercent>
    <apyx:DebtInstrumentPrepaymentFeePercent
      contextRef="idd50214c28b1419d87380a2edcf8c85e_D20230217-20230217"
      decimals="2"
      id="f-769"
      unitRef="number">0.02</apyx:DebtInstrumentPrepaymentFeePercent>
    <apyx:DebtInstrumentPrepaymentFeePercent
      contextRef="ifd8c189ae54b4398bbe43a8016d14d18_D20230217-20230217"
      decimals="2"
      id="f-770"
      unitRef="number">0.01</apyx:DebtInstrumentPrepaymentFeePercent>
    <apyx:DebtInstrumentExitFee
      contextRef="ic425c684e2c74dac8335bf30aed7d24c_D20230217-20230217"
      decimals="2"
      id="f-771"
      unitRef="number">0.04</apyx:DebtInstrumentExitFee>
    <apyx:DebtInstrumentInterestRateFloorPercent
      contextRef="i84ace2066c844d0eb08a5d4455fd34f1_D20230217-20230217"
      decimals="3"
      id="f-772"
      unitRef="number">0.025</apyx:DebtInstrumentInterestRateFloorPercent>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i37bf520b9b2c4b23b71810b3dd058fcf_D20230217-20230217"
      decimals="2"
      id="f-773"
      unitRef="number">0.04</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <apyx:DebtInstrumentAnnualFeePercent
      contextRef="i84ace2066c844d0eb08a5d4455fd34f1_D20230217-20230217"
      decimals="3"
      id="f-774"
      unitRef="number">0.005</apyx:DebtInstrumentAnnualFeePercent>
    <apyx:DebtInstrumentTerminationFees
      contextRef="i29d6f70a7eab414799e5833f411483ba_D20230217-20230217"
      decimals="2"
      id="f-775"
      unitRef="number">0.03</apyx:DebtInstrumentTerminationFees>
    <apyx:DebtInstrumentTerminationFees
      contextRef="i0ebe1df213944e88b24cf4d7fc508cf9_D20230217-20230217"
      decimals="2"
      id="f-776"
      unitRef="number">0.02</apyx:DebtInstrumentTerminationFees>
    <apyx:DebtInstrumentTerminationFees
      contextRef="ic06bbd8e6458436597927a368cb238b8_D20230217-20230217"
      decimals="2"
      id="f-777"
      unitRef="number">0.01</apyx:DebtInstrumentTerminationFees>
    <apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent
      contextRef="i29d6f70a7eab414799e5833f411483ba_D20230217-20230217"
      decimals="2"
      id="f-778"
      unitRef="number">0.30</apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent>
    <apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount
      contextRef="if422168e879e462b8d0dc783bdd44842_I20230217"
      decimals="-6"
      id="f-779"
      unitRef="usd">10000000</apyx:DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount>
    <apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne
      contextRef="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217"
      decimals="-6"
      id="f-780"
      unitRef="usd">49000000</apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne>
    <apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo
      contextRef="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217"
      decimals="-6"
      id="f-781"
      unitRef="usd">60000000</apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo>
    <apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree
      contextRef="ib8a75ab131aa49a282692f215843efdb_D20230217-20230217"
      decimals="-6"
      id="f-782"
      unitRef="usd">70000000</apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree>
    <apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance
      contextRef="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217"
      decimals="-6"
      id="f-783"
      unitRef="usd">10000000</apyx:DebtInstrumentCovenantCashAndCashEquivalentsBalance>
    <apyx:DebtInstrumentDefaultApplicableInterestRate
      contextRef="i67955df49b104c96886c90aa72882ab9_D20230217-20230217"
      decimals="2"
      id="f-784"
      unitRef="number">0.02</apyx:DebtInstrumentDefaultApplicableInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217"
      decimals="0"
      id="f-785"
      unitRef="shares">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217"
      decimals="INF"
      id="f-786"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie35e29c54cfd43ed904dff77f3e93ee8_I20230217"
      decimals="2"
      id="f-787"
      unitRef="usdPerShare">3.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <apyx:SaleLeasebackPurchaseAgreement
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      decimals="-4"
      id="f-788"
      unitRef="usd">7650000</apyx:SaleLeasebackPurchaseAgreement>
    <apyx:SaleLeasebackDueDiligencePeriod
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      id="f-789">P30D</apyx:SaleLeasebackDueDiligencePeriod>
    <apyx:SaleLeasebackCompletionPeriodAfterDueDiligence
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      id="f-790">P5Y</apyx:SaleLeasebackCompletionPeriodAfterDueDiligence>
    <apyx:SaleLeasebackEscrow
      contextRef="i76b8d9c682c84508b0bc8b27676bfeda_I20230314"
      decimals="-3"
      id="f-791"
      unitRef="usd">400000</apyx:SaleLeasebackEscrow>
    <apyx:SaleLeasebackTermOfLease
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      id="f-792">P10Y</apyx:SaleLeasebackTermOfLease>
    <apyx:SaleLeasebackRenewalTerm
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      id="f-793">P5Y</apyx:SaleLeasebackRenewalTerm>
    <apyx:SaleLeasebackAnnualRentPayment
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      decimals="-2"
      id="f-794"
      unitRef="usd">619500</apyx:SaleLeasebackAnnualRentPayment>
    <apyx:SaleLeasebackAnnualRentIncrease
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      decimals="2"
      id="f-795"
      unitRef="number">0.04</apyx:SaleLeasebackAnnualRentIncrease>
    <apyx:SaleLeasebackManagementFeeOnRentPayment
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      decimals="2"
      id="f-796"
      unitRef="number">0.03</apyx:SaleLeasebackManagementFeeOnRentPayment>
    <apyx:SaleLeasebackNetCashProceeds
      contextRef="idaa97eb75f734241a5adb9df998868da_D20230314-20230314"
      decimals="-5"
      id="f-797"
      unitRef="usd">6700000</apyx:SaleLeasebackNetCashProceeds>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MXB]H,F>5@6N'T/5H.A[]H>5E-1W84BOS*M(!J94.?K H:C\F8,>@@](41K8
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M]9TWTT>5]<RGX:;(5R_"5S-)MUNW4WU'^0373K'[:I[P%57.-441>X!2YW
M/ZU83;U=K4B^S">CSKB4/,X7%XP&3*@=X/L'SN5F11U@.P%Z^!]02P,$%
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MO="FO-VP,/T4I TP^P<A]&EB#^@Z=/H74$L#!!0    ( .N <%9\E*4/P 8
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M!L%;9[%Q%=:NJ@:P&A-,8IBQU6XXIA7#48BW5GLXO2U.SXGSON13 56=R"6
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M:IKY+,1]*V#GC-@M$VYD<5P+!)EEU:I-"] ,0MDS:U(_)5WZM1BQ/KW(6GG
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M?O/^I0P>@EE0R68\^YXF:GTVB 8H84NZS=0#?_F+[0+RM;^89[+\12\[6V>
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MR:O+#4:\,A("_/F*$/9](+ZA:#[CF?T+4$L#!!0    ( .N <%9L7<#;*@<
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MCP]4D/=SY4OM*WXG=N'KVA?\D9@T@1;@^=+#2=,7.J![2?K5?P!02P,$%
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MTWY0+M!GMZ"\_8( :=$W%=.*!Y\0 D$UML69J^N_<5*6!>_!0">F'-E]\UP
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M47^# G 1=X6&KFDH6(9PY,8X,I0"PFS\"A3C_S E6I;XA7,JHXB1C@@DC6%
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M/HAD^)0$/%AB[8.3,LQEA!>L1E(S\1 L)$H]).,N/8*,OV0'ME-2\6Z;'3%
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MO)4*)LZ./(]^&E=L5^O:=FFS_2>5<AZP+.[09K R7#GH"E*DRJM]0TTB;&E
MMI#@^]Q3D8,O)WSM2JX8$.#2>1W'=Q3DDR$M)&G/ML_OP'Z6:[0?GO&J/$OK
M4B)B*BG',I+$[>0N6<.A+G,$0,,5 F5:%/+^&I5NHDH;Q4,E;DT+["W?"&,?
MNBUL21UY^7O4>@A!H]]R03P/YX8BY'@IDR91)22Q'!$$UE5]B/H<&1##H-9"
MM32M]4U^G3:&95@[1;48'E/)'15=DH5>5%[QNECF5U:C#R2W>&TY+7Y+GC8J
M3PUQU;F;CH3%@COC0*:I7)UNX0'%5D2 .HF\]FRXI!HJ9'1*+D>;P/5-VFE+
M7?/J ?UCZ@U5/\?UR<3PQ+XF%N6'S2=%S /T.:5]3;>KX)"KI13U52?'*CD
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M*5Y1)?WPNEQZODKTE>6:=\S(OG+"C)BT$46CB5SI*A%>ZHC);CF-DSN%DKS
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M\4OGU_S7#V:^Z_R*/]*['K:E 7@^][Z+7VB#].<P7OX_4$L#!!0    ( .N
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M24<CR<;XK$\A9[JV9:7,EM+">H14FDTZ0QLM+4?*>TR7JG9ICOXAM7;,Z.M
MKT7YU8NS)!F=SZ+0W4YHMA.*Q^/S-^B+D-.BXE2K(FQI4;NU3I&H6X,$U2(:
MTXAU.NB#P!<VA@$J]%QEFR3''&]R6Q1;LAL#LKY>>IUI#"2R*UILRY*#.X!'
M\;UN2>Z.=Z3ZXI6O%7P)%K@ZS0\"DL%]'V!%S'I;9/NG C(^/?<41Y2S?F>R
M-0;:W!JB9>VU>$.>US%T NBX4 *N3<!4 T8-Y<IA8+NP[6,[+>I,FW4T>F4?
MM 1[?#H!G!-]^4-M9QCSN +ZXD+G/\8]K<')"V#*G'D)S\M?3S&$BD(BJ0VE
MRN<#1(C03J8=LS%-8O"IA!Z6##;8-3Y8$**;)A8_XM\VY++@ID%G:8HX6*<9
MC*]5#77='LT![.C.V:Q.@P=$52'-G>&V@O8]5/BMW2];5HX 5/;;'/)CI875
M0;4GB1R#[7)+.F (FWJ%P5"+8(J0XP:44F.)&#44]M->'L17A:8/,JHK1*UR
M&FX-:(:0Q(M*H\0Q,W"W2 )7SD(]UWZO>; P'';%Y1@EWA1#&U\#PSJ+!;)
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MOW[S+U85[LIKKJQ5F6NFG.$FA@;@]T0I6[_0!,T=Z,5_4$L#!!0    ( .N
M<%;T*YZ;80,  *('   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*U5
M;8_B-A#^*Z/<ZM1*=),X ;)[@ 0LU5'=[2'8;2M5_6"2 :Q+XISM++O_OF,'
MLER/1:K4+XE?YGGFF?%X/-A+]57O$ T\%WFIA][.F.K6]W6ZPX+K:UEA23L;
MJ0IN:*JVOJX4\LR!BMQG0=#S"RY*;S1P:PLU&LC:Y*+$A0)=%P57+Q/,Y7[H
MA=YQ82FV.V,7_-&@XEM<H7FL%HIF?LN2B0)++60)"C=#;QS>3F)K[PQ^%[C7
M)V.PD:RE_&HG\VSH!580YI@:R\#I]X13S'-+1#*^'3B]UJ4%GHZ/[+^ZV"F6
M-=<XE?D?(C.[H9=XD.&&U[E9ROU'/,33M7RIS+7[PKZQC?L>I+4VLCB 24$A
MRN;/GP]Y. $DP1L =@ PI[MQY%3><<-' R7WH*PUL=F!"]6A29PH[:&LC*)=
M03@S&D^GR\?9'<S^7,SN5[,5C._OX,O#Q]D2IH_+Y>S^ 3[-QY/YI_G#?+8:
M^(9\6J2?'O@G#3][@S]D\%F69J=A5F:8?4_@D]A6,3LJGK"+C'>87D,4=H %
MC%W@B]H,1(XO>H-OP5_X.D<-O,Q@G*:JYKF&O\9K;135S-_G8FX8X_.,]A[=
MZHJG./3HHFA43^B-WK\+>\&'"WKC5F]\B?U_.+&+_.?5_S>G31HQ WRFYJ$/
MN95FAXIJ6BDL#>2"KT4NC*#=5-(EUX8 <@-D!1N94[<0Y?86?A(E+<E:$X7^
M&>CTL5@3S[$"?E@)6^\5?U%$!%?0[47V&_?:O;4L:PWOWR4L9!^ =<*PW^ZE
MLBB$MFU'0Q+W(>STNJ_(2LFL3@WLN5*\=/JCFQ"Z-]$/)L<87R#-N2A E+HF
M3(K4-ZR!<'47=A+6A5X8G.(WZ 3P'#9XR%^.6YHJS+EQ(LEWN?UW*F^"$&+*
MP6]2T(Z%:7Q"1<!C-EY%17&7G >L#ZN=5.87@ZIPO+;NOV--NA%THP@>2;LR
MW!X)?X9*:F%<EE@GZ-_80"C/*VZ#<OO-S0)&?F*6P!=7 /Q<;9RKBH0H8\KJ
M@S0D_RSL[9*Z@J1S0SZO( PZ+.G#N9OGG_3- M76O0ZV'.O2-"VT76T?H''3
M=U_-F]?K,U=;.EXZI U!@^M^UP/5O C-Q,C*=>&U--33W7!'CR@J:T#[&RG-
M<6(=M,_RZ!]02P,$%     @ ZX!P5B<+"P+' @  '08  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&ULC57?3]M #/Y7K PAD#;2I(6UI:W4'TSC@:TJ
M,!ZF/5P3)SEQN>ON+A3^^_DN;2BB5'M);)_]W6<[=@9KI1]-@6CAN132#(/"
MVE4_#$U28,G,F5JAI)-,Z9)94G4>FI5&EOJ@4H1QJW41EHS+8#3PMKD>#51E
M!9<XUV"JLF3Z98)"K8=!%&P-"YX7UAG"T6#%<KQ%>[^::]+"!B7E)4K#E02-
MV3 81_U)Q_E[AU\<UV9'!I?)4JE'IURGPZ#E"*' Q#H$1J\GG*(0#HAH_-U@
M!LV5+G!7WJ)_\[E3+DMF<*K$ T]M,0RZ :28L4K8A5I_QTT^YPXO4<+X)ZQK
MWTX<0%(9J\I-,#$HN:S?['E3AYV ;NN#@'@3$'O>]46>Y8Q9-AIHM0;MO G-
M"3Y5'TWDN'1-N;6:3CG%V=%\\7-V/[V#A_%B,?YQ=WUU.P@MX;K3,-E@3&J,
M^ .,*(8;)6UAX$JFF+X%"(E0PRK>LIK$!Q%GF)Q!._H,<2N.#^"UFRS;'J_]
M499:I55BX8%IS:3E:&#&32*4J33)O\=+8S5]('_V)5]#=_9#NZ'IFQ5+<!C0
M5!C43QB,CC]%%ZW+ \0[#?'.(?3_;,]!C/T,WP/#MDCKND@O]<1P$A)%0V@L
MIJ RL 5"I@1-,Y<Y2=I;7I!I ^CZWX>3:TE&51DF4W,*U$TLEZA]1]\H$\RY
ME YGR023"<(1G/?:].STNH[0$_?3[VY9O:7G>ACU+@BF"]."R1R!2T!C.8TJ
M@E6052+C0E @5_J+(_B:FEH*GC.W%PR<1+WN*1Q_ZL91?/F^"HDRUA!V4FE-
M%3BA=7=*S[A]"N,DT179]E [@G8OVF2S[SL(=T:V1)W[Q63HLDK:>GH;:[/[
MQO7(O[K7B_.&::JB 8$9A;;.OIX'H.ME5"M6K?P"6"I+Z\2+!>UOU,Z!SC.E
M[%9Q%S1_A-$_4$L#!!0    ( .N <%;:8-'D*00  &,)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;*56;6_;-A#^*P>MV M@6+*<I&EF&W!>BGE(
M&\/).A3#/M#4V6)#B2I)Q?&_WQTEV7&;!-CVQ2:EN^>>>^YXU&AC[+W+$3T\
M%KITXRCWOCJ+8R=S+(3KFPI+>K,RMA">MG8=N\JBR()3H>,T24[B0J@RFHS"
ML[F=C$SMM2IQ;L'512'L]ARUV8RC0=0]6*AU[OE!/!E58HVWZ/^HYI9V\0XE
M4P663ID2+*[&T71P=G[$]L'@D\*->[(&SF1IS#UO9MDX2I@0:I2>$03]/> %
M:LU 1.-KBQGM0K+CTW6'_C[D3KDLA<,+H_]4F<_'T6D$&:Y$K?W";'[#-I]C
MQI-&N_ +F\9V>!*!K)TW1>M,# I5-O_BL=7AB<-I\H)#VCJD@7<3*+"\%%Y,
M1M9LP+(UH?$BI!J\B9PJN2BWWM);17Y^\OO-[.,=3#]>PNW5IZO%]!KFT\^+
MF^MKN)Y-SV?7L[O/H]A3(#:/90MZWH"F+X .4OA@2I\[N"HSS X!8F*XHYEV
M-,_35Q$O4?9A..A!FJ3I*WC#7=K#@#=\ 6\NMF*IT8$H,YA*:6NA'?PU73IO
MJ5'^?B[G!O'H>40^/&>N$A+'$9T.A_8!H\F//PQ.DE]?X7NTXWOT&OI_+=/_
M!KVLK2K7I/K@-$A%BW<]\#G"A2DJ46Y!%96E$6'U%J30LM;"8Q9L+5;&\H;-
M16'JTH-9@2JE*1"\ 8G6T]@ +"IMMHBN%_PRE4%I/%!K\]EML0KE Y TUH:G
M>T#O]A _ 0?E\[X/Q0"5V%K" R\>.8[%AB>QH",F[\%4P0D?T4KEN#$<&7VM
ME26KY3:$GBUN^W!9!^ZT)D_A:V_LMK.D8>7=H3PYX7PQJFS2</B 5FC02BR5
M5GX+-%:#_:HF<FU./A<>-N3(*FR4SW/4V5Z&EC=[-=)S4EPE4?O<6.45.N;9
M5BY-#QEM0F9:$96,11(5H3PJ&G!(-7QS<ISTDB3IA/V>>Z?D/H>LD82#:%$Y
M9%_>-/J$K59$7+#$#DCF8-KY]^$N5R1X]H7&'4L(M*/2Z9IF!RW D+GMBOFS
M-H[J\TL/2KJR5(,EI&RSNZ (1JLL5/>60H:B,(4;4JIET(F^16$!>40!#1@L
MEA2F&S(=JUV;'7 .*GZC7-(?-N>]4%J'&X=4>S/H)]\\];M@S8LN8GO T@&W
MIZLPW%<ZR/.D>H0"2SRH(#.CSJ"CE%$"WU$EIO^B&G0$*FIE:N--KF1^T#KT
MBE@Y+K:1LK94^=!DT\HJS=2'/2!I32GQP$\*.ED4?ZF5RYOV/CBT=$H>D&NY
MHME+#:;"S.!&(H]U0[3_W!2-GUQ\!=IUN-X=S0BJ67,'[I[NOB"FS<6Y-V\^
M/SX(NU:DA\85N2;]M\<1V.9*;S;>5.$:71I/EW)8YO05A)8-Z/W*&-]M.,#N
MNVKR#U!+ P04    " #K@'!6?ECR\'0$  "Z#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6SE5TMOXS80_BN$=K$G0Z\\-LW:!FPG10UL-D&<MH>B
M!UH:6\12I):DXKB_OC.4+"N)XRVVZ*D7BZ1FOIGYYB%ZN-'FJRT ''LJI;*C
MH'"NNHPBFQ50<AOJ"A2^66E3<H=;LXYL98#G7JF441K'YU')A0K&0W]V9\9#
M73LI%-P99NNRY&8[!:DWHR )=@?W8ETX.HC&PXJO80'NU^K.X"[J4')1@K)"
M*V9@-0HFR>7TE.2]P&\"-K:W9A3)4NNOM)GGHR FAT!"Y@B!X^,19B E :$;
MWUK,H#-)BOWU#OUG'SO&LN069EK^+G)7C(*+@.6PXK5T]WKS"[3QG!%>IJ7U
MOVS3R)ZAQ:RV3I>M,NY+H9HG?VIYZ"E<Q&\HI*U"ZOUN#'DOK[CCXZ'1&V9(
M&M%HX4/UVNB<4)24A3/X5J">&\]NOSS<3V8/;+)87#\LV.3+%?L\GTSGG^</
M\^O%,')HA$2CK 6<-H#I&X!)RFZT<H5EURJ'_#E A-YU+J8[%Z?I4<0KR$)V
MD@Q8&J?I$;R3+N03CW?R!MY</8)U6%C.#M@5+!WC*F?7WVKAMFP!66V$$V#9
M'Y.E=0;+YL]#+#0V3@_;H%:ZM!7/8!1@KU@PCQ",/[Q+SN-/1R(X[2(X/8;^
M(TG[5X#LH0 VTV7%U?;#NXLT^?C)L@RS3.Q8K%A7M+4*QF)U;K%=+;8%$XJY
MO2HK^*-0ZTZ3<6L!]8E^*?A22$]\2.8L?$^,<2-0JC("IXF06[8RNF2WUS?8
ME(\X;"K*L%>R=57A>[XV #[M;%.  >]:7U:O_-%:Z]RR7*,)I1V&XC-(6*P"
MX^>@RH#II11K[D<+31=F'=KB4BN@,2&:,+K0<5 0-R]-K@"M8$02<N;TGL2!
M=YRD,7B=">Y0(-/6M6\,9'JMQ%_@(4N48L*A0%E)<'AXV%%+GA)HRTBE3>-_
M$WA'4,AN<6_V&>C33NE=PMZ#G-@D G;.8TJ@XEO+T(.63%Q0#XB,LCMQV'49
ME$L4W;6U#PH7N$6R*_"S6FX'+\JG"=S@7&&\JHQ^PMP[E&/OT_ $QZ.4?M(C
MUOLD_*D[P/@.AN(%X_#\N68<GAW4;,O0@/39Z*6KC;BIK5WB?,8-EX1A,.6J
M;BW"$WY1+6YJ')"&9&V/^S<(&I!?SR(B&\>B2MX4WO63H>[QI4U\8D?7QE!1
MMEW+LZPAGGIVAM6CI<A]Z%,N?64M_+6!VE_0]S4S-?3"(S]T4T<M\$LO/6WB
MJ$KCZ_.J.,A0,GB5N?\S0U?X%4.GFM+I-U&O;U^T4!RF_[1CDF,-X@KNT&%A
M6])0Y%6RB$'+98M(@XW$_,G+"?!=KA<.'[L!?HN3KYUU-'Y(<PO<,*#+R.NV
MZA.5/"<J1]J;^=\2QNC4"ERO1,:5.\R0-C]"2+PGQ /T^/A/"4C"0]>1J'>?
MQ/&V]K=F^N+7RC57R^ZTNYA/FOOH7KRYU=]PLQ;HBX05JL;AQ[. F>:FW&R<
MKOSM=*D=SE*_+/#/!1@2P/<KK=UN0P:ZOROCOP%02P,$%     @ ZX!P5L8,
MF/VD P  .0@  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULE59MC^(V
M$/XKH]SI!!)'0GA9R@(2[-+>27=["-J>JJH?3#(AUCIV:CO+[K_OV($<W;)(
M_4+\,O/,,S.>&:8'I1]-CFCAN1#2S(+<VG(2AB;)L6"FJTJ4=),I73!+6[T/
M3:F1I5ZI$&$<1:.P8%P&\ZD_6^OY5%56<(EK#:8J"J9?EBC481;T@M/!AN]S
MZP["^;1D>]RB_:U<:]J%#4K*"Y2&*PD:LUFPZ$V6 R?O!7[G>#!G:W">[)1Z
M=)O/Z2R('"$4F%B'P.CSA'<HA ,B&G\?,8/&I%,\7Y_0?_:^DR\[9O!.B>\\
MM?DL& >08L8J83?J\ F/_@P=7J*$\;]PJ&7[40!)9:PJCLK$H."R_K+G8QS.
M%,9O*<1'A=CSK@UYEO?,LOE4JP-H)TUH;N%=]=I$CDN7E*W5=,M)S\Y7B\W#
MYX=?MM#Z\FV[;<-ZM8'MI\5F-0TMP3NA,#E"+6NH^ VH7@Q?E;2Y@95,,?TW
M0$B\&G+QB=PROHIXCTD7^KT.Q%$<7\'K-\[V/5[_+6>9EESN#:Q1PS9G&N'/
MQ<Y836_CKTL.UW"#RW"N7B:F9 G. BH(@_H)@_F'=[U1='N%[* A.[B&_O\R
M<Q7J,M$W\6')#$\ 3\%J"65,&TJ*F?$Q:WUX-X[CZ';GY5;KK=_W;MO #22J
M*"N+*>Q>(.5//"4,L#F"I [#)5TC* T.TXFXFX,O'5)A3ZBI$X"LBAU94YE#
M*ZAVO5T#U%2,9=)#4C_RRAI+I:T[(8)<I5VXY\(3:!SX+_/T*'+.?4_=P0!F
M&?4+L J8$.#EZ!Q*95%:SL0%*EU8&$_ECEQG\L5%@5._\1Y[/TMEN.]!CK3#
MK:G2A<N&)":=^OB*%7#\&=U^/)'JPJ]D-%."&JL/,ML)8JH5!1UK1G4RF+=-
MT:P31GB0OH[1ZR1WX0^ZJRL9J [19\358HM\L[FJ#.&8#N!S@J4]BW%*;:CM
M*];]1/!0%915J[29P,,I(LQ:S7=539F"37TN><R52%$;> ^MN-_IC0=MM^P-
M.[V;N W?7[^2"S'Z>,'%_J S[(W<I]^/X8O/1T/VD@+9C+JCFW:]&!"+Q7G8
M*;?4,<@I:8WS7E0N1)E618,@3D;.G^\$OI4N$09&G2'%9=CI_S2&2XTB/&OG
M%+N]'UJNLBIIZ\[>G#9S<5&/@Q_B]5#]RO2>^(+ C%2C[LTP %T/JGIC5>F'
MPTY9&C5^F=-L1^T$Z#Y3]":/&V>@^;<P_P=02P,$%     @ ZX!P5N\QS@H.
M"   DQ,  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULG5AK;^,V%OTK
MA)NV#N#8>MB.\P3R:C= IS.89+J[6.P'6J)MSDBD2E))W%^_YY*R(F><S'2!
M1!(I\O ^SGU8IX_:?+$K(1Q[*@MESWHKYZKCT<AF*U%R.]254'BST*;D#D.S
M'-G*")[[364Q2J)H.BJY5+WS4S_WP9R?ZMH54HD/AMFZ++E97XI"/Y[UXMYF
MXJ-<KAQ-C,Y/*[X4=\)]JCX8C$8M2BY+H:S4BAFQ..M=Q,>78UKO%_PAQ:/M
M/#/29*[U%QK<YF>]B 02A<@<(7#<'L25* H"@AA_-IB]]DC:V'W>H/_B=8<N
M<V[%E2[^*7.W.NO->BP7"UX7[J-^_(=H])D07J8+ZZ_L,:Q-TQ[+:NMTV6R&
M!*54X<Z?&CMT-LRB5S8DS8;$RQT.\E)><\?/3XU^9(96 XT>O*I^-X23BIQR
MYPS>2NQSY[>_7[U_=\/N+_YU<W<Z<D"D^5'6[+X,NY-7=L<)>Z>56UEVHW*1
M;P.,($HK3[*1YS)Y$_%:9$.6Q@.61$GR!E[:ZI=ZO/0U_52F2\'N^1.[EC8K
MM*V-8/^YF%MGP(C_[M(Y((YW(U*4'-N*9^*LAS"PPCR(WOE//\33Z.0-><>M
MO..WT+_IC^_?S:YT66DEE+-,+Y@,AG PA'A"2%O!."S!+5OH J%ICUG_5C&W
MTK7E*K?[#*X0Y5P8[XZMP55M#'"/V2\B%X87;(\E\=A?#]F=XTZPY(A-Q@R!
M@[!0+$[&+(Z.6#H]9.DL MI" ")_1NB/!]'1=)_UD\$DGNTW*/UX$$5CS$[C
M%-?)((XBW--!G,;[[ ]>U#S$-FG 52:87\+\ G:O'9!W*+[G!=GSHOB\Q*1E
M'#DFTRJ3A0R@,)I;"68A2>VT6;-%(VL'T9"43ON%9&^NUC];)A8+X;--N^:8
M_5MP$Z)DVY;$<[K$K2EH3V7T@_2)+XF'$?MQ<PMFP0IA65\A9T/(C5ASH<1"
MNGTV'HZQ-!W.<-UEHWZ2#&'.'_$0#V-Z0)3 GR0P$D[VA4$_LE38N+%:/QDF
M?E<\G-']KDFL\33IE_O;>_H-<#\-:W^]_>W^EO6CX5&#X)'>PVR&9B<TP@W7
MX#2LF 8)P_T=_ZR-/^*9T1V;__3##-0[L92//;&\$;FU DO[<.@<7G52@-7_
M-^FOOX8^9K]I"^:HG&5X(QW+N#%KE,I';G(+AAT.QH=3W,>#9#*%]V#< RHB
M^;:YDD$ZBUD\.(QB]A$YA9MLY6%S\0!^5JB"A%U)V$;^%?8<S1+F]4Y.V$66
MF1J@4B&]>1^#9S7<,R] E#$BXC""DQ\ 0T1.IND%X_EGE!>/G!Z-6ZA638.C
M52U8FA[!Q6E[QERKVK;+)Y-)X\;))&53_ <'[G)$C-A.)K!)>C3;34RLB*8S
MBO?!$=U?Q1JPAOP/.V#&DT,V3J-MCW5(<,P^&'0UQJV]C<6?M0P6[B?19+^Y
M-MQ,)@G-)).=PG1 D<$FAUB*@_?9[Q!NEP7V6KL]/]T_TQBD0+>#:+:D#:NT
ME3XH24HEEMP/Q -6D)H&,R:7:NDC 1U92PW89:?-D+B*VN^HN(7Y8 -LP!!U
M#%U,8/*B=E0BK:Y-)D*@\2<.(C5Y;_B*Q"0$B*N YW==5.LG=ED7$%+R ;MY
M__Z:,N6<<""=5-*)8HW!@[ .@J)C)"2/\XE>YB'; 4SY2<2-],A8+TO_QJVX
MVPB<0S:\R! G=L662(8F6.-1%I0<T7<N%C*3Y&C(45+'NW.K$B(/IH )F*U$
M)K&/5057E#<,K!6$]ISQB4A;@I]#?HG.MC7#D-TZMD*V4=KYZF(H_?/='%IC
M1<%)[::>?!K>#=NB0.*$Y/]<?43CL*;(/DJW6NDB,,*_;0Q7JURBW9'SFM"_
MY:._Z1WHB.:"Z)[AO27AC:@XCO.5"LLW\FT.'G0S=_ .F9QVAIP$.-LMLL_%
M4 :%P%NI\W"J$P9M\88+6R0,T)H56BT1RW^?>=M4IRBBOZ"45,@U$IZA_D!X
M*DBLRSPCN(+1,V083A*3"CZ4R1_\BT" &E]5L\;;<[&95[2UVU\($!230;."
MFR5$9KS4-;&8-$9(E##P02&_0*D#S*D#HEN M3 G9, Q=47@-16I^;K)&(5X
MX(3#GX@SO :1#8@X9!==^;N>V*C1F-;1&43LI9)_^?KSFG$L %&++#FM$9D%
MD4D-Y;%@N+D@25JI(8GGZ=<=$Q&?NJ9M,E&L=>+L.;3()Q5X].03!P[=BX<I
M?D\51?AQV0;>;K>%0.--!7R!%*'1VB#1,DQ,-Q,#2JU5: :+]2 TXJ"L]R+6
MH@7@A2\?(5:11]HS _M"HT)6"3TJA@=-@_&B"?J9@H]*U-)05U*KCF-(F:8_
MI-H)8S_7@MT"#7RJ(_@U @H][<O6%:V3W&J=?O7'?E*A$F$Q_>BZ; [M]+F7
M8BD512C)3^#([(4OW'MH@=(X;>\7>=Z8/U2ACC]>Y,HL_"()<)O*VG9'WPU3
M(:^8W2#0'(I1^'N[O(;R!L*-RK^I<3??P-^H*9]!'@+VU6#1J0;V135 1N'(
MA+[F;26NMCE.HO@(:AI=+U?!%5N@7Z4=ZYOEC@R=$S9)Y);( \J@;0WMXAU^
M$$OJY>C8)#JY_7CGG^*3_=U2?:7'=QR^H28TFFUK1 ">L,-=/\9'G0\EI4 R
MI<]!%DT,TFGX9M+.ME^<+L*'EN?EX7/5.^1BM-NL$ MLC8:'DQXSX1-0&#A=
M^<\N<^V<+OWC2G"8FA;@_4)KMQG0 >UWN//_ 5!+ P04    " #K@'!63>%X
MQK(#   ^"   &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R55FUOVS80
M_BL'K1LVH)5DV>F*S#;@I"D68"D"-^L^#/M 2R>+"%]4DK+C?[\[RE;L(@ZV
M#[9%\>ZYYQ[>'3W=6O?H&\0 3UH9/TN:$-K++/-E@UKXU+9H:*>V3HM 2[?.
M?.M05-%)JZS(\_>9%M(D\VE\=^_F4]L%)0W>._"=UL+MKE#9[2P9)8<72[EN
M K_(YM-6K/$+AC_;>T>K;$"II$;CI37@L)XEB]'EU83MH\%7B5M_] R<R<K:
M1U[<5K,D9T*HL R,(.AG@]>H% ,1C6][S&0(R8['SP?T3S%WRF4E/%Y;]9>L
M0C-+/B1082TZ%99V^SON\[E@O-(J'[]AV]N.*6+9^6#UWIG66IK^5SSM=3AR
M^)"?<2CV#D7DW0>*+#^*(.939[?@V)K0^"&F&KV)G#1\*%^"HUU)?F&^O'FX
M7=[<W7Q^@/L_%I^G62!0WLK*/<!5#U"< 1@5<&=-:#S<F JK4X",V R4B@.E
MJ^)5Q(]8IC >O84B+XI7\,9#BN.(-SZ7(@;ID HIP!4:K&7P\/=BY8.CDOCG
MI8Q[O,G+>-PFE[X5)<X2Z@./;H/)_*<?1N_SWUYA.QG83EY#_R\'\K\ X*%!
MN+:Z%68'K;,;6:$' 4$\O?O6"25KB15OD"[O?".<-&OJMD&R5@D#'1TM=?*^
MDR;YZ.?'7\#6$ C[U@1T1BA8X@9-Q\$J!!H7<7?5*\[&J.1:KA0"ZE;9'1*-
MK0P-".[-LM.=$A&>3&L*Z"/&$1/NX4B;F@Z=(];4CI)R,=5S8NPCC*'$H)*^
M9'=K:-I 247JY*J+(8(%:2I)+FP8'/59'S.%A5)'!(7#9][DU0H79"E;$1"Z
MEI!*4E91$!(M- X1=-\,E 17ABPQC2?P#*G%CCZ/"!NK.A.^Y^8Y#"O7"]\>
MEM3S4G<:6G0EJ4$#$X2BD<HR[,X?1 I?T4=ZT@PD""R4#;\\C4QBKIV@+HZ:
M5DB3GXZ!]2+X'0IWFM>BIH#[M/O=VEG-QM)!Q1*1=4/']S8"G*HZRO,?84/<
ML$I/:I2U\><8$N %^>U+;\CGU*@7C6K%!E*#;,?18S@[KFJQ<U:I%.Y>CJ-)
MA8.N!V(1CK5IJ=KH,"A!M8,W>3JAP:P4UQ57'XJR.1#L54$>C$!C#?6*!#N,
MMB@R/8S2E\9&=C33-;IUO+D\T:2:Z<?[\':X'!?]G?!LWM^L=\*M)26EL";7
M//WU(@'7WU;](M@VWA K&^B^B8\-7?#HV(#V:VO#8<$!AK\,\W\!4$L#!!0
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M@4UA9!!_UL644Y4]_5QK%SM$!\@VSAQVS&7$92U">)<]C=CUFS1O)B Z*B[
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M/HY?:M>OQ^_=%])AWX^)1TVP=#AXOM\3+GY#CA?!SOF[;68#,.*?,P6_'+V
MYQ.+XDX7I*#]D'_T7U!+ P04    " #K@'!6%OO:E,4)  !-'@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-2YX;6S-66MSVS86_2L8U>DF,S3-AT1)B>T9
MVTF[Z4YC3YQM/^SL!XB$)$PHD@5)*]I?O^=>D!0ER[&==B?[1>(#N#CWW"?
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MK.=S'6O:WB!YH8W>$".)JI3!SES1"4.-_+NSA$67P0#?AM"J+BF'S70FN5T
MSX5$'>F(GRG@T[FQ,F-LR$V#A: QS9U4NVT@H?>F4XTJ$ Y8M,W1U@1V66;;
MVJ6?@=B#V%-+Z\;-==/;6-<_@H-ZXE@<(681FD=3-YCRK>^.?/%1EY^/YY0?
M#86,[T8O\!)!_$)X]MIS)R\0Z8T.B;[3"7::8J,5'(R39O#FQ?:B&WF7@U2=
MZFHCHJD5-9ZXHQ<BFI!TW.U*9KY>0G5.U(@K#(G$T+7_GWH6PT8J7V36C7?Z
MI:,(T3JV%1 0CU ,)Q.^U4WU/9[Q:01,6JBLM.22?3+8(JE-Z^L,02@Z5SG4
MI$&V;200-80>#4&ZL:5%PP&P.]5QPSX<1DELVFQ<VDBCFD*K)'H^1Y6CW5N[
MD:+'O;1%B:XVN_U#>QRP5ULH ]3["S5E4WVI*'(055BYV>3K[!BOCB%7;9K-
M/@IQMZG?U\,H/F8A[VI=D\X#D--LIN$HG9$*L([2=]N]<]M3 6!_S2Y3+27K
ML^D4XEM0T YH<EU*<8?HXG*1R$U;OGFW2J246(B?<,>4;FA<DT8!D\,SS3FF
M+9$-;YGE#1(/6[#-#WR0>2B%@U/K50W0H\ -AX?7VN]_=@R+BZUPKVWL'E*=
MWL)@S.N!?I .)I1MHB+'&Z-[ -+=$M$_/]G)4_ :WNJO=;7DHZ4'O0)K[T6@
M'W$SR%26JF=D/EU8/](@0=Y1Y*+Q(#P'AF\SZ+U,>P]*U'9\3^%HZ 0H\Y,P
M>I0CQLMM]?>A9^1&WE]*#_F\W;T<@-]4HMV(W0;J-Z3,M2SW29FV^SG*V6BX
M[.U^=GU_(+-V0)HX;Q*K5:<;QO'=;D&L0MP?]B0(]#1V;BS+Y3:'<=M4=5N,
M)IGQ&5H[<_L6THT]$B3^2]1)8]-&(772)WHOP^_M?/X:4K&="T=>OQ;ZHX.\
M$JQ[GO0_07C$+;1%XXZC0T"^QD_31O\U](R<(.JQ@_@?/\A.VW=(;KOZIZ<]
M-^BW%W(M#9V.;N!Z='B:V%." T/:'+(?>FC[*7)M^8[K%1>@NT,)@7OH VNK
M?I^9D%KH-9J=!.C(5"5*554I?XHIVX34X;7-IL[BM$YL1[J;&+>AUZ2(]H5!
M<XH='Z%HM^AOGV^Q?H/>!:,?C)P16E@:YL._)Z'?+0N5BN83D[Z_-YKXSA@;
M9Y[HC1$8XW;BGKT/?3LZZ7WB6RFSX ^95+OKK+)?^[JGW;?2"_N)<#O<?FC]
M59H%S(QL,\=4SQV/!L+8CY?VILH+_F XRZLJ7_'E4DG8@P;@_3S/J_:&%NB^
M()__%U!+ P04    " #K@'!6XB<X\O(%   B#@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6RM5VEOXS80_2N$]H #"+8..W9.P#EV-T!S($E;%$4_
MT!)M$2N1*DG%<7]]'TE9<1(GNR@*6-;!F<>9-P?)PZ54WW7!F"&/52GT45 8
M4^\/!CHK6$5U7]9,8&0N544-7M5BH&O%:.Z4JG*01-'NH*)<!,>'[MN-.CZ4
MC2FY8#>*Z*:JJ%J=L%(NCX(X6'^XY8O"V ^#X\.:+M@=,[_6-PIO@PXEYQ43
MFDM!%)L?!=-X_V1HY9W ;YPM]<8SL9[,I/QN7R[RHR"R!K&29<8B4-P>V"DK
M2PL$,_YN,8-N2JNX^;Q&_^)\AR\SJMFI+'_GN2F.@DE <C:G36ENY?(;:_T9
M6;Q,EMK]DZ6734<!R1IM9-4JPX**"W^GCRT/&PJ3Z V%I%5(G-U^(F?E&37T
M^%#))5%6&FCVP;GJM&$<%S8H=T9AE$//''\]O_YZ.[WY=G%*IE=GY.[\Z^7Y
MU3VYN/IR?7LYO;^XOCH<&,QCI0=9BWGB,9,W,..$7$IA"DW.1<[RYP #&-A9
MF:RM/$G>13QC69^D<4B2*$G>P4L[KU.'E[Z!=\<62"Q#;EDME>%B0?Z<SK11
MR)&_MOGKT8;;T6S=[.N:9NPH0&%HIAY8</SY0[P;';QCZ["S=?@>^G^,T+N8
MVRW^\43DNF:*.KZT9U 3JABABX5B"VI83K@P$L5J::6SDCW)25&N")\34[ 5
M88\%GW%#-*]X215AF12RXAG)"FJ#P!37AF>Z3RY0N'G.704#^4<*H<4GI[*J
MJ5@16FI)(*EYSI1V0W-9H@]9#^90D_C*!:H8 "@N^]D*;;%_WPT(:AKX*^=D
MUFAPJK5O*["/M7-75*"9N>Q"0C694\BY0A<" 33+9",\--SA("8K.)L3V3&;
MLXR[EE?1[TS!8+4Q2$4./JRI-EMM0WMF 'V@H&?&2VY6ULJ<ZTS!.3+G@HJ,
MTQ+N^D[N6J+(G[V[7! VC+#-.G,BJ<HMT)ESP-+E=1Z8MF]],M4:*\<F"-=$
M2 ,.']!! 35;.:@?N FIEFH_@P=I_0%93^.A(U'E "E7S^-=4*_VY <E%:.Z
MC1FUMNH-J#ZY?]+^_&&2Q.,#O35[J0NBSDJI+:K&%!Q\UK1$4+$D4L'_L0,P
MW2> $S)+N>'Q4RI-\P=$ S+G@JG%RJE=GU_V27 J%29')9'/M*H/R#7<4P'X
MS<HF9T@6!LN0L8W S#)S)9=U.ENR(Y,:YB\+GA5DR>"%Y4?7('_.,V<]-4;Q
M6=-&W=+XF@!/%$SL@L0=!5C'.2!R]H#5O>ZB!PH:6UZ-LGZC %UG=4.UDCF*
M@N0*U@G$LBPQ7^D<88_8:FCFV4:^(<B>1^N$#:"F95MF6+JE<Z8S:.W3!N'/
M\$!AHQ3+^^3.[3]<O+:7Q9*; O-;1$/>:&?P'X;Y;H*(_L'0E-QJ1[!6L6J&
ME%ZO5Z2')F8*V6@0H'=>1=_2^A3WG@OY#KF7!F;=68_)1Y+NAI,HQ<,X'$=C
MW%VV)@=D. Q'<41ZOT@-:#@I*U2[DM6:!W0_TAN&<93ND#C<'<:DE\1XC7;P
MD(:CW60'31;]#Q6]UE^#K^_Q:.RN3JYE]I5@+Q[M^#_G18L7$H$>\5)V%.VY
MZ\+/:>CCF[#I[MA=CF6VE>7X_V!YF(1[DQ$>1N$H3398QM $/(_7QO9*1_=+
MGI-P/!F"Y2A-P<(D3'8='<-P.)S\!,NQ_?T$QS9T]L]S;$VQ5;&-XUXZ1MC]
M_P;/,R;8G+\63R>1NYP-PCD%=ES5V672);,M8LMWZ-M)LM??^^0^IDD_^K11
MI6T!H<S+51\[+91[X_KX@LF%HC5:$F06F"-T^VJL,\)U\T 7O$;=!<1U.%N1
M[0C6'<DSYO<</U%]+U+"V>]RQ0<<MIR!$KMQ<!X\=[L;^FBQDFAB'VR"O.0G
M3L,T2E @2)IQFU$?UX799<ZVG>!@8]]>(4O=Z<2V.VP1_!:^^]H=@*9^W_\D
M[D]/EU0M.%*P9'.H1OTQSAO*GTC\BY&U.P7,I,&9PCT6.,0Q904P/I?2K%_L
M!-VQ\/A?4$L#!!0    ( .N <%8L3S0<!!,   0U   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(W+GAM;,U;:7,;.9+]*PB-/2M'4!1%23ZZ;4?(LCWC6;O'
M:[D]$;NQ'\ JD$2[#C90)8G[Z_=E)E"%(HMR=^R7C>BV>!02B3Q>7N#+N]I]
M]VMC&G5?%I5_=;1NFLU/IZ<^6YM2^VF],16^6=:NU W>NM6IWSBC<UY4%J?S
MV>SI::EM=?3Z)7_VV;U^6;=-82OSV2G?EJ5VVS>FJ.]>'9T=Q0^^V-6ZH0].
M7[_<Z)6Y,<VOF\\.[TX[*KDM3>5M72EGEJ^.KLY^>G-!S_,#WZRY\\EK12=9
MU/5W>O,A?W4T(X9,8;*&*&C\N377IBB($-CX/= \ZK:DA>GK2/T]GQUG66AO
MKNOB7S9OUJ^.GA^IW"QU6S1?ZKN_FW">2Z*7U87G?]6=/#M_<:2RUC=U&1:#
M@])6\E??!SDD"Y[/#BR8AP5SYELV8B[?ZD:_?NGJ.^7H:5"C%WQ47@WF;$5*
MN6D<OK58U[R^^?7-S;O_^/7=+U_5NV_X]^;E:0.R].5I%DB\$1+S R3.YNI3
M735KK]Y5N<F'!$[!3\?4/#+U9OX@Q;<FFZKSLXF:S^;S!^B==X<\9WKGAP[9
M+KSYO355H][=XE^O_NMJX1L'D_COL?,*M8MQ:N0F/_F-SLRK(_B!-^[6'+W^
MZU_.GLY^?H#7BX[7BX>H_S&%_$D2ZMV]R5KV@GJIKIW);:.N5LZ8DF3RSTJ]
M-PO7PBG5V3.6^OE$-6NCKNMRHZNMPE,&JY2MFEKI0&&B;D#5V6:K=)6KOV&]
MKO"F)WQ,-/[ZE^?S^>SGW5WYX[.?GTS40M;KLJY6@UV/M5>+VD& QCWA9ZXV
MVWMUO;:55G^OB]QBP77M-M,!MT3Y[-G/7MVMZZ+8GM1W%5CWL &;6SHCT5T)
MM[4# T3YD\VO]4:];RNF^N&;^NK@??PLP*EJ=IX#"U5F=9$\!A&5JJAUI<@F
M;&8B;>*M,/ -Y]5&.X@(GS@#42Y=7:H&(*?PAOY.U5<ZR*Z&-JZ^M;GQ"B@,
MDJK=T()'YY> A*(@O2YU9@NH8J*R&HCI&SH%E.U-9;'&DZ8@A8Y'+S+OOG#F
MMBYN:5&D]$=8.4P=6P<FYQV3Q%NY<=;C47Q_;$FIL"G;D"#ACA5"#GWSZ&S6
MKSFV]!SM49,LDZ<2PG08/,A/-FOK\@/DY%"'#ST\GAS%5L2F7D$$*]T8/&*A
M^@U8ALFV$$E_UI1O&-QO"#V*/4;,F':B$*( 1G3B6L%(&D1.M3$N@W1A:2RZ
M,6LVA5W916$0R#+:UH/]S-A;S9]5Y)R$;;6##< :<T/:L!5[+:]Q.21B$%^:
M-6] W_>[[>CY@/81!B$YK$HA@Q'C.5:0^C^RS&CQPXI5=V!RV<)!\2_%C2'-
M#H:87;V!7NXM=C=X_M&\(Q*XQ[>9,;E7+=D6Y+K16]8@[>VU) !+8\3J:W(_
MV*)O2+DP!8$V\IPJ) N=D/;E<M/K-6I/)$FDR48M43@H6(&J'6N^J]LB5POH
M\5;;@C6Z,,V=,97Z1UL9=3X3<? >B(ZF7. $(4*>=R SM/R'B.HJ4=T%$[@Q
MFR;0E=TN)K POS&<-Q41#W:L4B_$;\C*L\QX3XS PG4N<NCU#UG[7CZ0>+MA
MSV78%Y6 _VKE14(Z6UMS*U8'4491PZ)MV9;DNJ9J<63M5@9I*3-7F:8W!9&_
M-P/,<XRTD D;"ED()8WDEYG>V(9\&J( WAN'U_"93>W8YUN\\@;[O -C"=0O
MC'9D110?$0<T_E-+?,/XRTO)X=FX\?15_ANB!=ZRJ]S\\_T7CAS((J.CCIG,
MDQTP 7TPCO/-IY>/)VI3M%X]FYY?/A8I+*T#)U T@O')LFZ=.IY?/%&EY&C!
M+!.A4,!H;-,V1N!8CG)25W UX)*M :WBA0HR\(Q!H%[<&G5\-@^$E;EO)%5_
M$GRVDPE\D8V/GP/-6DXI;.9P5+!D2*K\ #M8S-8H*C*2[/,D5H(RPS=:8O88
M+N\<U1)H1GY8VA;A^,3;>W5\_O1)P.7(*!XL.5L\)B39E6<'$=W)XX9C[#Z9
MJJNBP.Y4*'%L'N,<AZIASN0+(G$L@5NY%L9!AME6&VWS;H,)'2B'%^B S%W8
M3LY<0L(P>$0ZR$0[2RR1$)@.(_!$X7P4A)";3-B$D7Q1-C*PNU&0\_ X>!&K
M^P!>7G5(4&PGNPHAATSV*$%>4P@3%K?B_0M$/LW[3<@1?:M[T_A!$/O<D1FS
M_)W=.4#@J7,XU?RQ)!5GC_L8TW$D]D6BS0WD[VQ(7,6DMX"$241X>1, &E7S
M$MOOXNI5(XQ1'A@V Q[ $#L)['(^S,YA!+KP=114'P'ASN8> L'!B,9%=Y:F
M;GHW">&7^:.7;JJ^=(G1^Y@8)> O)L49S43\B0_HC'RFF CO,Y)@84=;["4/
M;'9W:TO8RNDPR2 NN4.P5Y+-Z$9R'7*,U(.B1OI#3"BT%ZU\^R,W*BF'7Q@E
M?B$NM!-(QLX27.M@+*EX_8\BRL?@IK"E!R5'H>;_0:2Y>#S(!,CZ]@V/3:[+
M<F=833@(QBK$[A  4OTM=,')Z9ZL^UJ%DX);2'%%<F*90Y1-@KM]GM.O1\51
MVH8!8,_M!L!D#VK9^M[X<H)*"*W-#*564+KID'?/*0>BA.0-)YJU0QY?Z9B2
M_EE$^QI88?@5MP,W@Y0S.?.?@[CQ8Z;D_N]@MV,Z#D9BG5@.A49.\G27YB5V
M<3[K^"R09QH7W^W45N \+3,><JFI^K <V-6827+)'9(<,%Q(CJO%AG?X')H
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ML, "];E'PA8W9I^$37S#@_2+JL?'SE*:=J8=E:&3=16(#+BLX[7<O"#/RKA
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MD.GPRS4\WSAZ -\OZ[J);VB#[H=/K_\74$L#!!0    ( .N <%8#IO#M5!8
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MST0FQR9%"&:@!I 0AS^0)<1(&@Q/4R*A(R; ZK2P8N?T%*J2*"5E=PAY:GJ
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MQZ0*TM>['5*03">265FH $ZB,Z'G%!?YF&SN\Y%>IMDEO.DQQ*6:<BJ^,[Z
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M/S"QTO6"_XP&SR96C?RMB?AK_%,=I_('*KKE\G<^/JIZ01%8J>?8>C)^^OA
M9HO"E\:N^<]5S&S3V!5_I!=E=$T+\'QN;1.^T 'Q#YB\_B]02P,$%     @
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M[?! 3R5*XT#VG1#Z-#$$[>,[_A]02P,$%     @ ZX!P5F#A/K[9 @  )@8
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M:^ORRY4'NIY*M6#5JIH$D;(T5ZIM3H,<M3.@\U0INQ-<@/VO8?074$L#!!0
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MU5UX-B8H=WL_# V!-=*V$Z.[[>;MHATS+^KML/["])[X@L =F4;#FU$ NAV
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M0#MH4(U"-0;5.%3SH)J :A*EU:-=]>7L=QISIXP^H TYJ$:A&H-J'*IY4$U
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MKSNJMI]C;ON!AQUSO:PQW]#.(52C4(U!-0[5/*@FH)I$:?770=5@= :7&GA
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MWCY/PPI[#V03?!98/@O")CWM%-!<J55;80$M@!?7=GH:#L? 1 V''EJ9Y:T
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MB"+%A'[\4Y :Y9P*>-H^LG_5P6,P*RI@SJ(_PT!NQ\:-00)8TRR23VS_#8J
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M7&-\/+_"R#N2I?J,OF(23_RZN04: %<&^'S-F#QVU 3E1=+D/U!+ P04
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M][5@\BV6..'<K!Z6]\OU [A9@6_?90L\+5</C_=+V?$D^V]E"WP%BP"2'>(
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M$)89R-^7E(K7F^P!U5'@Y']02P,$%     @ ZX!P5O!Y0AQ= P  U X  !D
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M:J&J@1:%:ULF0ILFR+TN3-L)TBXPWV="Z)>!W:!N9)-?4$L#!!0    ( .N
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M+MOZ,(FB!1<3Q7/;Q69<Z9YHAZG^:P%A#/3W.>=J.S$!RO^@Z"]02P,$%
M  @ ZX!P5@L\A="+ @  .0<  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N
M>&ULK551;]HP$/XK5E9-K;0V)(&TZT*D JU::=VJLF[/)CF(5<?.; /=O]_9
M"1E00'O@)?'9]WUWW]D^)TNI7G4!8,A;R87N>X4QU;7OZZR DNH+68' E:E4
M)35HJIFO*P4T=Z"2^V&G$_LE9<)+$S?WI-)$S@UG IX4T?.RI.K/ +A<]KW
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M1!KLG&Y8X-L&RCK@^E1*LS)L@/:U3/\"4$L#!!0    ( .N <%:_J?9@G (
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MNBKTH]C<0:-G:/A242C[2S9U[-!S2+I26I0-&"LH&:^?]+79ASU ,#H""!I
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MJ.L;QN3S@5X\JA<+D_\ 4$L#!!0    ( .N <%;02P\GW ,  *<,   9
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MA"E.I Z!U-\!#S&E.I+B^%X%M>IW:L?SZ[?HOQ7BE9@5$GC(Z)]D+7=]*[+
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MU.)RI[XD,-<&ZOF&,?DVT&?5^MLD_A=02P,$%     @ ZX!P5KL)+]0A P
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MI<'YXY8Y?B& L@;X?"VE.6YL@.:;(_D'4$L#!!0    ( .N <%92FC'@=0(
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M,X2:0/&ROL<+KO14J)>9GMLH3((^7W*N'@,S&KHO0?0;4$L#!!0    ( .N
M<%8?S)D3^@(  $4)   9    >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;*U6
M6V_:,!3^*U963:W$" D0H(-(W*8AM5U5Z/8P[<$D![#JV-1VH-VOG^U !C2@
M,NTEON2<[WS?\>6XO>;B22X %'I)*),=9Z'4\MIU9;2 !,LR7P+3?V9<)%CI
MH9B[<BD Q]8IH:Y?J01N@@ESPK:=NQ=AFZ>*$@;W LDT2;!X[0'EZX[C.=N)
M!S)?*#/AANTEGL,8U./R7NB1FZ/$) $F"6=(P*SC=+WK?LO86X/O!-9RIX^,
MDBGG3V8PBCM.Q1 ""I$R"%@W*^@#I09(TWC>8#IY2..XV]^B?[':M98IEM#G
M] >)U:+C-!T4PPRG5#WP]5?8Z*D;O(A3:;]HG=D&@8.B5"J>;)PU@X2PK,4O
MFSSL.'C''/R-@W_H4#OB4-TX5*W0C)F5-< *AVW!UT@8:XUF.C8WUENK(<RL
MXE@)_9=H/Q7VO]U-'KK]">J.Q\/)&'7O!NAFU.V-;D:3T7",+@>@,*'R"GU"
MC^,!NKRX0A>(,'1+*-7K(-NNTC0,F!MM0O:RD/Z1D)Z/;CE3"XF&+(9X'\#5
M_',1_E9$SS^).("HC*I>"?D5WR\@U'^_NW>"3C7/:=7B58_@C=@*I-);7<D2
M&L!4(<QB-'Q.B7I%8XA2010!B7YVIU()O9%_%24QBU$KCF$.][5<X@@ZCCZ]
M$L0*G/#C!R^H?"Y*P'\"VTM'+4]'[11ZV->+;50B2O"44*N]2'"&4K<HYO)9
MA7ZYVG97NSK>VGCE5FZS1Z^>TZN_CQZ6$E0ALPS \W;"5LK! ;5"HWHQMR#G
M%IR7NM>2OA2$T%NKB&=01*%UP+/0Z C/1LZS<4X.3Y)L%,7W#D@VWJSSKLT>
MQV;.L7GV-BSI0K0"EH)N(SYGY/?A?91Q;A9Q]@\XGPS_CV>LE8MKG;< []/5
M.IGF3-;)P.?*<G<J50)B;@NX1!%/F<J*5CZ;OQ&ZMC2Z?\VS!\8M%G/")*(P
MTZZ5<D/+$%G1S@:*+VW=FW*EJZCM+O0[!X0QT/]GG*OMP 3(7T[A'U!+ P04
M    " #K@'!6I.\,NW<#  "."P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6RM5FUOXC@0_BM6KCJUTK9Y@T![$(F^W.U*N]T*MKN?33(0JT[,V0[T
M_OV-G9 -*+"LQ!>([9G'SS,>CV>T$?)-90":O.>\4&,GTWIUY[HJR2"GZD:L
MH,"5A9 YU3B42U>M)-#4.N7<#3PO<G/*"B<>V;D7&8]$J3DKX$425>8YE?_=
M Q>;L>,[VXDI6V;:3+CQ:$67, /]NGJ1.'(;E)3E4"@F"B)A,78F_MV#;QVL
MQ7<&&]7Z)D;*7(@W,_B4CAW/, (.B380%/_6\ "<&R3D\6\-ZC1[&L?V]Q;]
M;RL>Q<RI@@?!?[!49V-GZ) 4%K3D>BHV'Z$6U#=XB>#*_I)-;>LY)"F5%GGM
MC QR5E3_]+T.1,O!CPXX!+5#L._0.^ 0U@ZA%5HQL[(>J:;Q2(H-D<8:T<R'
MC8WU1C6L,,<XTQ)7&?KI^&DR??[T_,^,7'[^.IM=D9>G*9E]G$R?R.4C:,JX
MNB+7Y'7V2"XOKL@%<8G*J 1%6$%>"Z;5A];$MTR4BA8I3E[LC$>N1JYF1S>I
M>=U7O((#O/R ?!&%SA1Y*E)(=P%<%-DH#;9*[X.CB(^0W)#0_T "+P@Z"#V<
M[NX?H1,V@0\M7G@ [[G,05(MI+KKBD[EW.MV-G?[3JUH F,'+Z\"N08G_O,/
M/_+^ZE)V)K =G;U&9^\8>OR,I8@+I0C56K)YJ>F< ]&"8&HG;YG@*<C._*A@
M!Q;6%*-U?!V$_K W<M=M;1UF?M\?!(W9#NM^P[I_E/4/>_TA)72-I[2$;9)C
M(50:,YH52[P66#]80BXQTZOEJRX=U491BV#8Z_O1GHPNJS \H")J5$1G4)$R
M7AJC7^B(3M+19750QZ#1,3BJX[/)GQ7(BMY.X%/!.96MU4[N%?QM.TF\FVBP
MQ[W3JM?KYCYLN ]_CWL[W*>Q'Y[$OM/J$/O;AOWM4?9?5^:Q[;R?1QU_MT*=
M"6Q'H^_]? .]H[5X4FAV;<\%6PI\N)266)T+K0B\)[S$]X<LI,B;H^/;,TU$
MGHOZUG26\7KC,T7I7&B[86JU"OXIR?"K0E&CM&M U ^\O73ML.J'M\.]='5;
MG0V^ETO;\"F,>UGHZNEO9INF<F);J;WY>]-LVH[I)TS5J7ZA<HE'3C@L$-*[
M&6 IEE7S5PVT6-G^:2XT=F/V,\.&&:0QP/6%$'H[,!LT+7C\/U!+ P04
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MHS@0Q[^*Q:U.76E3,(2']))(V61/5VD?JJ:[=V\=XC2^ L[:)FGOT]\84DC
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MI$TPZPLA]$-@^U;_7TO_ E!+ P04    " #K@'!6Y2 \%.,"  ":"   &0
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M:&5E=#8Q+GAM;*V5WV_:,!#'_Y535FVMU)$0?K:#2*4PK=*H$+3;P[0'DUS
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M4NX2JP7*W]^D:?'P0[6"^S3[6F_VY7\!4$L#!!0    ( .N <%8E2),=JP,
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M<C<S)@:*84/WJ?S,CO]"+<C3>!%+1?D?'2M;WS50M!>29;6S8I E>?5+'^M
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MO:&^9HFL_,M>%-^D%=2"*UV/I8]K73*#,!WT]R7GZO!B!BB*\.G_4$L#!!0
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MD.*.[0NSEL=';.H9.%XB"^V?<*Q]![<$DKTVLFR"K8*2B_K-7IM[. N@](T
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M)O=?'I[N1L^3AWMP!I[(BC*!7R("IF0A!U& DVLB<!CQ4_GZ^_0:G'PZ!9]
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MW>9X2N:XN]_;$D<2AB8."0N1, Z"&3+X6QE\;/?C(S5!PD(DC(-@AB;!5I.
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M38^'A^+O-K(EK!I^K*\:6!: 9>%B!7'$XY M_8PNR;D?^E% ";^B-.,&H T
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M@7H'@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WC'YV81 [T"]@T#O0+V#0.] O8-
M[P;U;@CT;E#OYB?U+N/7(9=KS_<:K_^35(_G<_/U\I?E]\[)3;C@7-]6E*>_
M4$L#!!0    ( .N <%;ART;(_0$  #TI   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:34[#,! %X*M4V:+&]6\!43; %EAP 9-,VZA);-D&RNUQ4D "004J
M$F_3J+4];^*1OE7/[IX]Q<FV:_NX*-8I^5/&8K6FSL;2>>KSRM*%SJ;\-:R8
MM]7&KHB)V<RPRO6)^C1-0XWB_.R2EO:A39.K;?XY-JY?%(':6$PN=AN'K$5A
MO6^;RJ:\SA[[^E/*]#6AS"?'/7'=^'B4-Q3LRX1AY?N UW,WCQ1"4]/DUH9T
M;;N\BVU;%M-S2['<7^*+'MURV514N^JART?*Z /9.JZ)4M>6NZ)'^Y-3OF':
M??*#\\<R^P+SSMO@?,P3"_3[N+>1#*>G/A>BD)K]K_B>F$L?_'XT3+NF^H?9
M^7J?7-B,\XAL?!Q^QQ]G_%[_EWT(D#XD2!\*I \-TH<!Z6,.TL<Q2!\G('WP
M&4HC**)R%%(YBJD<!56.HBI'896CN,I18.4HL@H4606*K )%5H$BJT"15:#(
M*E!D%2BR"A19!8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP215:)(JM"D56A
MR*I09%4HLBH4616*K I%5H4BJT*15:'(JE%DU2BR:A19-8JL&D56C2*K1I%5
MH\BJ4635*+(:%%D-BJP&15:#(JM!D=6@R&I09#4HLAH460V*K',46>?_*>N]
M<YL_CA^?96>;_BV?C?^:/'\!4$L! A0#%     @ ZX!P5@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #K@'!6J6-AF.X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #K@'!6F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .N <%:K
MQZ)0 0<   PM   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #K@'!6AUNF1#("  "M!0  &
M    @(%$#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
MZX!P5GR4I0_ !@  *QT  !@              ("!K!$  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( .N <%;<D[/E9@,  *0+   8
M          " @:(8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " #K@'!6FKA(2' %   9%0  &               @($^'   >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ZX!P5KWC1$FX!0  TB,
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M965T,3 N>&UL4$L! A0#%     @ ZX!P5M8J"3%N!   *@H  !D
M     ("![6\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .N <%;T*YZ;80,  *('   9              "
M@>:%  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ZX!P
M5B<+"P+' @  '08  !D              ("!?HD  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " #K@'!6VF#1Y"D$  !C"0  &0
M        @(%\C   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( .N <%9^6/+P= 0  +H,   9              " @=R0  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ ZX!P5L8,F/VD P  .0@
M !D              ("!AY4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " #K@'!6[S'."@X(  "3$P  &0              @(%BF0
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .N <%9-X7C&
ML@,  #X(   9              " @:>A  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ ZX!P5M0B]N.( P  ]P<  !D
M ("!D*4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #K
M@'!6ABOA.@X+  #4'P  &0              @(%/J0  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( .N <%86^]J4Q0D  $T>   9
M          " @92T  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#
M%     @ ZX!P5N(G./+R!0  (@X  !D              ("!D+X  'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #K@'!6+$\T' 03   $
M-0  &0              @(&YQ   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;%!+ 0(4 Q0    ( .N <%8#IO#M5!8  ,Q$   9              " @?37
M  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ ZX!P5A#_
M^XC  @  \04  !D              ("!?^X  'AL+W=O<FMS:&5E=',O<VAE
M970R.2YX;6Q02P$"% ,4    " #K@'!6U$&M>;\"  # !0  &0
M    @(%V\0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M .N <%;GT5$1,P,  .$&   9              " @6ST  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ ZX!P5J0:M(CR P  X0L  !D
M             ("!UO<  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " #K@'!6:$NSDW0#  "(!P  &0              @('_^P  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( .N <%9@X3Z^V0(
M "8&   9              " @:K_  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ ZX!P5DGP] 07 P  D08  !D              ("!
MN@(! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #K@'!6
MSGP^QJD%  !*#@  &0              @($(!@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( .N <%9X)]B^/P0  .\)   9
M      " @>@+ 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ ZX!P5M'^9MW^ P  J@D  !D              ("!7A ! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #K@'!6ZA6761H(  "%80
M&0              @(&3% $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( .N <%;Z,AQ( @8  -0K   9              " @>0< 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ ZX!P5GN0%A$A
M!   5!(  !D              ("!'2,! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " #K@'!67V+=.I<#  !?$@  &0
M@(%U)P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .N
M<%8VV@*VRP,  &$0   9              " @4,K 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ ZX!P5ECHSW+6 @  $@@  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( .N <%:_J?9@G (  'P(   9
M  " @1)! 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
MZX!P5AQ%>:WU P  .!0  !D              ("!Y4,! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    " #K@'!6T$L/)]P#  "G#   &0
M            @($12 $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( .N <%:["2_4(0,  '\(   9              " @21, 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ ZX!P5E*:,>!U @
M%08  !D              ("!?$\! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    " #K@'!6'\R9$_H"  !%"0  &0              @($H
M4@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .N <%:D
M[PR[=P,  (X+   9              " @5E5 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ ZX!P5KZ4_@!8 P  B0L  !D
M     ("!!UD! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .N <%9?&8BST@(  ,T'   9              "
M@4EJ 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ ZX!P
M5J!<>EJ8 @  908  !D              ("!4FT! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    " #K@'!6PI6<P>(&  "200  &0
M        @($A< $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( .N <%:X!.9/J T  )G&   9              " @3IW 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ ZX!P5B5(DQVK P  - T
M !D              ("!&84! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    " #K@'!6J=/^U+(#  "0#P  &0              @('[B $
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( .N <%:J3Y*U
M]P,  )81   9              " @>2, 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ ZX!P5L5;A I! @  MP0  !D
M ("!$I$! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #K
M@'!63 1$<+@$  #"%@  &0              @(&*DP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( .N <%; XREJ7P,  ) -   9
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M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #K@'!6L 4 O38"   <*@
M&@              @ %CL@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " #K@'!6X<M&R/T!   ]*0  $P              @ '1M $
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3P!/ * 5  #_M@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>392</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - DISPOSITION OF THE CORE BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS</Role>
      <ShortName>DISPOSITION OF THE CORE BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - PRODUCT WARRANTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PRODUCTWARRANTIES</Role>
      <ShortName>PRODUCT WARRANTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY</Role>
      <ShortName>JOINT AND SEVERAL PAYROLL LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - CONTRACT ASSETS AND LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIES</Role>
      <ShortName>CONTRACT ASSETS AND LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - RETIREMENT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RETIREMENTPLAN</Role>
      <ShortName>RETIREMENT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - STOCK OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONS</Role>
      <ShortName>STOCK OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/LEASES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - PRODUCT WARRANTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PRODUCTWARRANTIESTables</Role>
      <ShortName>PRODUCT WARRANTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/PRODUCTWARRANTIES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INCOMETAXES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - STOCK OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSTables</Role>
      <ShortName>STOCK OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/STOCKOPTIONS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - DISPOSITION OF THE CORE BUSINESS - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails</Role>
      <ShortName>DISPOSITION OF THE CORE BUSINESS - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails</Role>
      <ShortName>INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIESTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - LEASES - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESLeaseCostDetails</Role>
      <ShortName>LEASES - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - LEASES - Cash and Non-Cash Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails</Role>
      <ShortName>LEASES - Cash and Non-Cash Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails</Role>
      <ShortName>LEASES - Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - PRODUCT WARRANTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/PRODUCTWARRANTIESDetails</Role>
      <ShortName>PRODUCT WARRANTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/PRODUCTWARRANTIESTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails</Role>
      <ShortName>JOINT AND SEVERAL PAYROLL LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - CONTRACT ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails</Role>
      <ShortName>CONTRACT ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIES</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - INCOME TAXES - Components of Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Components of Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - RETIREMENT PLAN - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails</Role>
      <ShortName>RETIREMENT PLAN - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - STOCK OPTIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails</Role>
      <ShortName>STOCK OPTIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - STOCK OPTIONS - Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails</Role>
      <ShortName>STOCK OPTIONS - Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - STOCK OPTIONS - Summary of Nonvested Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails</Role>
      <ShortName>STOCK OPTIONS - Summary of Nonvested Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails</Role>
      <ShortName>STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="apyx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  apyx-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="apyx-20221231.htm">apyx-20221231.htm</File>
    <File>a2022q410-kexhibit311.htm</File>
    <File>a2022q410-kexhibit312.htm</File>
    <File>a2022q410-kexhibit321.htm</File>
    <File>a2022q410-kexhibit322.htm</File>
    <File>apyx-20221231.xsd</File>
    <File>apyx-20221231_cal.xml</File>
    <File>apyx-20221231_def.xml</File>
    <File>apyx-20221231_lab.xml</File>
    <File>apyx-20221231_pre.xml</File>
    <File>listofsubsidiaries.htm</File>
    <File>rsm2022consent.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>apyx-20221231_g1.jpg</File>
    <File>apyx-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="664">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "apyx-20221231.htm": {
   "axisCustom": 3,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 664,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 145,
   "dts": {
    "calculationLink": {
     "local": [
      "apyx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apyx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "apyx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "apyx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apyx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "apyx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 584,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 5
   },
   "keyCustom": 63,
   "keyStandard": 329,
   "memberCustom": 36,
   "memberStandard": 28,
   "nsprefix": "apyx",
   "nsuri": "http://apyxmedical.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://apyxmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - DISPOSITION OF THE CORE BUSINESS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS",
     "shortName": "DISPOSITION OF THE CORE BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://apyxmedical.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://apyxmedical.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - PRODUCT WARRANTIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://apyxmedical.com/role/PRODUCTWARRANTIES",
     "shortName": "PRODUCT WARRANTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:JointandSeveralPayrollLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY",
     "shortName": "JOINT AND SEVERAL PAYROLL LIABILITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:JointandSeveralPayrollLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - CONTRACT ASSETS AND LIABILITIES",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIES",
     "shortName": "CONTRACT ASSETS AND LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://apyxmedical.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://apyxmedical.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - RETIREMENT PLAN",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://apyxmedical.com/role/RETIREMENTPLAN",
     "shortName": "RETIREMENT PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - STOCK OPTIONS",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://apyxmedical.com/role/STOCKOPTIONS",
     "shortName": "STOCK OPTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://apyxmedical.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://apyxmedical.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://apyxmedical.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - PRODUCT WARRANTIES (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://apyxmedical.com/role/PRODUCTWARRANTIESTables",
     "shortName": "PRODUCT WARRANTIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://apyxmedical.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - STOCK OPTIONS (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSTables",
     "shortName": "STOCK OPTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ie2b00095642c4b108229e13776c6580c_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i4bf73cd58c774543acd7ca829d302f18_D20230119-20230119",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "apyx:ProvisionForObsolescenceInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ie2b00095642c4b108229e13776c6580c_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - DISPOSITION OF THE CORE BUSINESS - (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
     "shortName": "DISPOSITION OF THE CORE BUSINESS - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i8fd4fe74bd604c1db72d55317651b6d4_D20180830-20180830",
      "decimals": null,
      "lang": "en-US",
      "name": "apyx:AssetPurchaseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i0a3f56438b0549d9bb1816cb85ae9d4f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i0a3f56438b0549d9bb1816cb85ae9d4f_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i75e0b82b58654112a567e39aa1802734_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
     "shortName": "INTEREST IN JOINT VENTURE INVESTMENT - Changes in Ownership Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:NoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i28e0bc92d62a40c4b1273fbafc570bd2_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - INVENTORIES (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://apyxmedical.com/role/INVENTORIESDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - LEASES - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://apyxmedical.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - LEASES - Lease Cost (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://apyxmedical.com/role/LEASESLeaseCostDetails",
     "shortName": "LEASES - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - LEASES - Cash and Non-Cash Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails",
     "shortName": "LEASES - Cash and Non-Cash Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails",
     "shortName": "LEASES - Lease Terms and Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "LEASES - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i75e0b82b58654112a567e39aa1802734_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StandardProductWarrantyAccrual",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - PRODUCT WARRANTIES (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails",
     "shortName": "PRODUCT WARRANTIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i295652f4d94541d6bfe4a8724a96ea47_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StandardProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "apyx:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:JointAndSeveralPayrollLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - JOINT AND SEVERAL PAYROLL LIABILITY (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails",
     "shortName": "JOINT AND SEVERAL PAYROLL LIABILITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "apyx:JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - CONTRACT ASSETS AND LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails",
     "shortName": "CONTRACT ASSETS AND LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "iad2fb842f9454872b733d0f3ea008372_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - INCOME TAXES - Components of Provision For Income Taxes (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Components of Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails",
     "shortName": "INCOME TAXES - Reconciliation of Statutory Federal Income Tax Rate to Effective Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "INCOME TAXES - Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - INCOME TAXES - Narrative (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i3bae49cc66e64b74871c5922613110b0_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i3bae49cc66e64b74871c5922613110b0_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i75e0b82b58654112a567e39aa1802734_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails",
     "shortName": "INCOME TAXES - Unrecognized Tax Benefits Roll-Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:DefinedContributionPlanRequisiteServicePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - RETIREMENT PLAN - Narrative (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails",
     "shortName": "RETIREMENT PLAN - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:DefinedContributionPlanRequisiteServicePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i15c65c91210b4634aa8886aa2c04c687_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i15c65c91210b4634aa8886aa2c04c687_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - STOCK OPTIONS - Narrative (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
     "shortName": "STOCK OPTIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i75e0b82b58654112a567e39aa1802734_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - STOCK OPTIONS - Summary of Stock Options (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails",
     "shortName": "STOCK OPTIONS - Summary of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i295652f4d94541d6bfe4a8724a96ea47_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i75e0b82b58654112a567e39aa1802734_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - STOCK OPTIONS - Summary of Nonvested Stock Options (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails",
     "shortName": "STOCK OPTIONS - Summary of Nonvested Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails",
     "shortName": "STOCK OPTIONS STOCK OPTIONS - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i94da9825cefa47e085dc8967533353fa_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "i8b469a871d414d41b9f05c65d751b0f2_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ia7082c9220d542aea74c20a8d84ddd01_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "ib8a75ab131aa49a282692f215843efdb_D20230217-20230217",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - DESCRIPTION OF BUSINESS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20221231.htm",
      "contextRef": "if4c7f6272f0f4f0293272c7801718e3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 64,
   "tag": {
    "apyx_A2001ExecutiveandEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2001 Executive and Employee Stock Option Plan [Member]",
        "label": "2001 Executive and Employee Stock Option Plan [Member]",
        "terseLabel": "2001 Executive and Employee Stock Option Plan"
       }
      }
     },
     "localname": "A2001ExecutiveandEmployeeStockOptionPlanMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_A2003ExecutiveandEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2003 Executive and Employee Stock Option Plan [Member]",
        "label": "2003 Executive and Employee Stock Option Plan [Member]",
        "terseLabel": "2003 Executive and Employee Stock Option Plan"
       }
      }
     },
     "localname": "A2003ExecutiveandEmployeeStockOptionPlanMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_A2017ExecutiveandEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Executive and Employee Stock Option Plan [Member]",
        "label": "2017 Executive and Employee Stock Option Plan [Member]",
        "terseLabel": "2017 Executive and Employee Stock Option Plan"
       }
      }
     },
     "localname": "A2017ExecutiveandEmployeeStockOptionPlanMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_A2019ShareIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Share Incentive Plan [Member]",
        "label": "2019 Share Incentive Plan [Member]",
        "terseLabel": "2019 Share Incentive Plan"
       }
      }
     },
     "localname": "A2019ShareIncentivePlanMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_A2021ShareIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Share Incentive Plan",
        "label": "2021 Share Incentive Plan [Member]",
        "terseLabel": "2021 Share Incentive Plan"
       }
      }
     },
     "localname": "A2021ShareIncentivePlanMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AccessoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accessories [Member]",
        "label": "Accessories [Member]",
        "terseLabel": "Accessories"
       }
      }
     },
     "localname": "AccessoriesMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AccountsReceivableBenchmarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable Benchmark",
        "label": "Accounts Receivable Benchmark [Member]",
        "terseLabel": "Accounts Receivable Benchmark"
       }
      }
     },
     "localname": "AccountsReceivableBenchmarkMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Expenses And Other Current Liabilities",
        "label": "Accrued Expenses And Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Term Secured Overnight Financing Rate (SOFR)",
        "label": "Adjusted Term Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "Adjusted Term Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "localname": "AdjustedTermSecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AdvancedEnergyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Energy [Member]",
        "label": "Advanced Energy [Member]",
        "terseLabel": "Advanced Energy"
       }
      }
     },
     "localname": "AdvancedEnergyMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ApyxSYMedicalDevicesNingboCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apyx SY Medical Devices (Ningbo) Co., Ltd",
        "label": "Apyx SY Medical Devices (Ningbo) Co., Ltd [Member]",
        "terseLabel": "Apyx SY Medical Devices (Ningbo) Co., Ltd"
       }
      }
     },
     "localname": "ApyxSYMedicalDevicesNingboCoLtdMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AssetPurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Term",
        "label": "Asset Purchase Agreement, Term",
        "terseLabel": "Asset purchase agreement, term"
       }
      }
     },
     "localname": "AssetPurchaseAgreementTerm",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_AtTheMarketFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Facility",
        "label": "At-The-Market Facility [Member]",
        "terseLabel": "At-The-Market Facility"
       }
      }
     },
     "localname": "AtTheMarketFacilityMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://apyxmedical.com/20221231",
     "xbrltype": "stringItemType"
    },
    "apyx_CapitalizationOfLeaseDerecognizedExecution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalization Of Lease, Derecognized, Execution",
        "label": "Capitalization Of Lease, Derecognized, Execution",
        "terseLabel": "Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification"
       }
      }
     },
     "localname": "CapitalizationOfLeaseDerecognizedExecution",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CapitalizationOfLeaseRecognizedExecution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalization Of Lease, Recognized, Execution",
        "label": "Capitalization Of Lease, Recognized, Execution",
        "terseLabel": "Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease"
       }
      }
     },
     "localname": "CapitalizationOfLeaseRecognizedExecution",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CapitalizationOfLeaseRecongizedNonCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalization Of Lease, Recongized, Non Cash",
        "label": "Capitalization Of Lease, Recongized, Non Cash",
        "terseLabel": "Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification"
       }
      }
     },
     "localname": "CapitalizationOfLeaseRecongizedNonCash",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ChineseSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chinese Supplier",
        "label": "Chinese Supplier [Member]",
        "terseLabel": "Chinese Supplier"
       }
      }
     },
     "localname": "ChineseSupplierMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ComputerEquipmentandSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software [Member]",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentandSoftwareMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ContractWithCustomerAssetRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Revenue Recognized",
        "label": "Contract With Customer, Asset, Revenue Recognized",
        "terseLabel": "Contract assets, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRevenueRecognized",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ContractWithInternationalDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With International Distributor",
        "label": "Contract With International Distributor [Member]",
        "terseLabel": "Contract With International Distributor"
       }
      }
     },
     "localname": "ContractWithInternationalDistributorMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentAnnualFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Fee, Percent",
        "label": "Debt Instrument, Annual Fee, Percent",
        "terseLabel": "Annual fee"
       }
      }
     },
     "localname": "DebtInstrumentAnnualFeePercent",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount",
        "label": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount",
        "terseLabel": "Borrowing base, minimum balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent",
        "label": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent",
        "terseLabel": "Borrowing base, minimum balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash And Cash Equivalents Balance",
        "label": "Debt Instrument, Covenant, Cash And Cash Equivalents Balance",
        "terseLabel": "Debt covenant, cash and cash equivalents balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashAndCashEquivalentsBalance",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Tranche One",
        "label": "Debt Instrument, Covenant, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTrancheOneMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentCovenantTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Tranche Three",
        "label": "Debt Instrument, Covenant, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTrancheThreeMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentCovenantTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Tranche Two",
        "label": "Debt Instrument, Covenant, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTrancheTwoMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One",
        "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One",
        "terseLabel": "Debt covenant, 12 month net revenue target, year one"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three",
        "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three",
        "terseLabel": "Debt covenant, 12 month net revenue target, year three"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two",
        "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two",
        "terseLabel": "Debt covenant, 12 month net revenue target, year two"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DebtInstrumentCovenantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenants",
        "label": "Debt Instrument, Covenants [Axis]",
        "terseLabel": "Debt Instrument, Covenants [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentCovenantsAxis",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_DebtInstrumentCovenantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenants [Domain]",
        "label": "Debt Instrument, Covenants [Domain]",
        "terseLabel": "Debt Instrument, Covenants [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentCovenantsDomain",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentDefaultApplicableInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Default, Applicable Interest Rate",
        "label": "Debt Instrument, Default, Applicable Interest Rate",
        "terseLabel": "Default, applicable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentDefaultApplicableInterestRate",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentExitFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Exit Fee",
        "label": "Debt Instrument, Exit Fee",
        "terseLabel": "Exit fee"
       }
      }
     },
     "localname": "DebtInstrumentExitFee",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Extension Period",
        "label": "Debt Instrument, Extension Period",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "DebtInstrumentExtensionPeriod",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_DebtInstrumentInterestRateFloorPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate Floor, Percent",
        "label": "Debt Instrument, Interest Rate Floor, Percent",
        "terseLabel": "Interest rate floor"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFloorPercent",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentNumberOfMonthlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Monthly Payments",
        "label": "Debt Instrument, Number Of Monthly Payments",
        "terseLabel": "Number of monthly payments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfMonthlyPayments",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Monthly Payments, Extension",
        "label": "Debt Instrument, Number Of Monthly Payments, Extension",
        "terseLabel": "Number of monthly payments, extension"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfMonthlyPaymentsExtension",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "apyx_DebtInstrumentPeriodOfInterestOnly": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Period Of Interest Only",
        "label": "Debt Instrument, Period Of Interest Only",
        "terseLabel": "Period of interest only"
       }
      }
     },
     "localname": "DebtInstrumentPeriodOfInterestOnly",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_DebtInstrumentPrepaymentFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee, Percent",
        "label": "Debt Instrument, Prepayment Fee, Percent",
        "terseLabel": "Prepayment fee"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercent",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period",
        "label": "Debt Instrument, Prepayment Period [Axis]",
        "terseLabel": "Debt Instrument, Prepayment Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodAxis",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period [Domain]",
        "label": "Debt Instrument, Prepayment Period [Domain]",
        "terseLabel": "Debt Instrument, Prepayment Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodDomain",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period One",
        "label": "Debt Instrument, Prepayment Period One [Member]",
        "terseLabel": "Debt Instrument, Prepayment Period, One"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodOneMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period Three",
        "label": "Debt Instrument, Prepayment Period Three [Member]",
        "terseLabel": "Debt Instrument, Prepayment Period Three"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodThreeMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentPrepaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Period Two",
        "label": "Debt Instrument, Prepayment Period Two [Member]",
        "terseLabel": "Debt Instrument, Prepayment Period Two"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPeriodTwoMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentTerminationFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Fees",
        "label": "Debt Instrument, Termination Fees",
        "terseLabel": "Termination fees"
       }
      }
     },
     "localname": "DebtInstrumentTerminationFees",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period",
        "label": "Debt Instrument, Termination Period [Axis]",
        "terseLabel": "Debt Instrument, Termination Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodAxis",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period [Domain]",
        "label": "Debt Instrument, Termination Period [Domain]",
        "terseLabel": "Debt Instrument, Termination Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodDomain",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period One",
        "label": "Debt Instrument, Termination Period One [Member]",
        "terseLabel": "Debt Instrument, Termination Period One"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodOneMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period Three",
        "label": "Debt Instrument, Termination Period Three [Member]",
        "terseLabel": "Debt Instrument, Termination Period Three"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodThreeMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DebtInstrumentTerminationPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination Period Two",
        "label": "Debt Instrument, Termination Period Two [Member]",
        "terseLabel": "Debt Instrument, Termination Period Two"
       }
      }
     },
     "localname": "DebtInstrumentTerminationPeriodTwoMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Accrued Insurance Deductibles",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Accrued Insurance Deductibles",
        "terseLabel": "Accrued insurance deductibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAccruedInsuranceDeductibles",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Vesting Percentage After Three Years",
        "terseLabel": "Defined contribution plan, vesting percentage after 3 years"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionVestingPercentageAfterThreeYears",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_DefinedContributionPlanEmployersMatchingContributionVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employers Matching Contribution, Vesting Period",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Vesting Period",
        "terseLabel": "Defined contribution plan, vesting period"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_DefinedContributionPlanRequisiteServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Requisite Service Period",
        "label": "Defined Contribution Plan, Requisite Service Period",
        "terseLabel": "Service period"
       }
      }
     },
     "localname": "DefinedContributionPlanRequisiteServicePeriod",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Section 162(m) Compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Section 162(m) Compensation, Percent",
        "terseLabel": "Section 162(m) compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSection162mCompensationPercent",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "label": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "terseLabel": "Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement"
       }
      }
     },
     "localname": "ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_FinanceLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Costs [Abstract]",
        "label": "Finance Lease, Costs [Abstract]",
        "terseLabel": "Finance",
        "verboseLabel": "Finance lease costs:"
       }
      }
     },
     "localname": "FinanceLeaseCostsAbstract",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails",
      "http://apyxmedical.com/role/LEASESLeaseCostDetails",
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_FinanceLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Payments",
        "label": "Finance Lease, Payments",
        "terseLabel": "Cash paid for lease liabilities"
       }
      }
     },
     "localname": "FinanceLeasePayments",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_IncomeTaxExpenseBenefitValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense (Benefit), Valuation Allowance",
        "label": "Income Tax Expense (Benefit), Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitValuationAllowance",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointAndSeveralPayrollLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint And Several Payroll Liability",
        "label": "Joint And Several Payroll Liability",
        "terseLabel": "Joint and several payroll liability"
       }
      }
     },
     "localname": "JointAndSeveralPayrollLiability",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint And Several Payroll Liability, Decrease Due To Lapse Of Time",
        "label": "Joint And Several Payroll Liability, Decrease Due To Lapse Of Time",
        "terseLabel": "Joint and several payroll liability, eecrease due to lapse of time"
       }
      }
     },
     "localname": "JointAndSeveralPayrollLiabilityDecreaseDueToLapseOfTime",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointandSeveralPayrollLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint and Several Payroll Liability [Text Block]",
        "label": "Joint and Several Payroll Liability [Text Block]",
        "terseLabel": "JOINT AND SEVERAL PAYROLL LIABILITY"
       }
      }
     },
     "localname": "JointandSeveralPayrollLiabilityTextBlock",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/JOINTANDSEVERALPAYROLLLIABILITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_LargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Largest Customer [Member]",
        "label": "Largest Customer [Member]",
        "terseLabel": "Largest Customer"
       }
      }
     },
     "localname": "LargestCustomerMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_LesseeDiscountRateIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Discount Rate, Incremental Borrowing Rate",
        "label": "Lessee, Discount Rate, Incremental Borrowing Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeDiscountRateIncrementalBorrowingRate",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_LesseeOperatingLeaseNumberOfLeasesExtended": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Leases Extended",
        "label": "Lessee, Operating Lease, Number Of Leases Extended",
        "terseLabel": "Number of leases extended"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfLeasesExtended",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "apyx_MountingFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mounting Fixtures [Member]",
        "label": "Mounting Fixtures [Member]",
        "terseLabel": "Mounting Fixtures"
       }
      }
     },
     "localname": "MountingFixturesMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net property, plant and equipment of continuing and discontinued operations",
        "label": "Net property, plant and equipment of continuing and discontinued operations",
        "totalLabel": "Property and equipment in service"
       }
      }
     },
     "localname": "Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NonCashTransferOfOtherAssetsToFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash, Transfer Of Other Assets To Fixed Assets",
        "label": "Non Cash, Transfer Of Other Assets To Fixed Assets",
        "terseLabel": "Transfer of right-of-use assets to property and equipment on exercise of purchase option"
       }
      }
     },
     "localname": "NonCashTransferOfOtherAssetsToFixedAssets",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestRequiredCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Required Capital Contribution",
        "label": "Noncontrolling Interest, Required Capital Contribution",
        "terseLabel": "Required capital contribution"
       }
      }
     },
     "localname": "NoncontrollingInterestRequiredCapitalContribution",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest Table Text Block",
        "label": "Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestTableTextBlock",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_OEMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OEM [Member]",
        "terseLabel": "OEM"
       }
      }
     },
     "localname": "OEMMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_OperatingLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Costs [Abstract]",
        "label": "Operating Lease, Costs [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseCostsAbstract",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails",
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Expenses And Liabilities, Current",
        "label": "Other Accrued Expenses And Liabilities, Current",
        "terseLabel": "Other accrued expenses and current liabilities"
       }
      }
     },
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "label": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProductWarranty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Warranty",
        "label": "Product Warranty",
        "terseLabel": "Product warranty"
       }
      }
     },
     "localname": "ProductWarranty",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_ProductWarrantyExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Warranty Expense, Net",
        "label": "Product Warranty Expense, Net",
        "terseLabel": "Provision for product warranties"
       }
      }
     },
     "localname": "ProductWarrantyExpenseNet",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForInventoryObsolescence": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Inventory Obsolescence",
        "label": "Provision For Inventory Obsolescence",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "ProvisionForInventoryObsolescence",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForObsolescenceInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Obsolescence, Inventory",
        "label": "Provision For Obsolescence, Inventory",
        "terseLabel": "Provision for obsolescence"
       }
      }
     },
     "localname": "ProvisionForObsolescenceInventory",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_RenuvionJPlasmaGeneratorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Renuvion/J-Plasma Generators [Member]",
        "label": "Renuvion/J-Plasma Generators [Member]",
        "terseLabel": "Renuvion/J-Plasma generators"
       }
      }
     },
     "localname": "RenuvionJPlasmaGeneratorsMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_RepaymentOfFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment Of Finance Lease Liabilities",
        "label": "Repayment Of Finance Lease Liabilities",
        "negatedTerseLabel": "Repayment of finance lease liabilities"
       }
      }
     },
     "localname": "RepaymentOfFinanceLeaseLiabilities",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackAnnualRentIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Annual Rent Increase",
        "label": "Sale Leaseback, Annual Rent Increase",
        "terseLabel": "Sale leaseback, annual rent increase"
       }
      }
     },
     "localname": "SaleLeasebackAnnualRentIncrease",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_SaleLeasebackAnnualRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback. Annual Rent Payment",
        "label": "Sale Leaseback. Annual Rent Payment",
        "terseLabel": "Sale leaseback. annual rent payment"
       }
      }
     },
     "localname": "SaleLeasebackAnnualRentPayment",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackCompletionPeriodAfterDueDiligence": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Completion Period After Due Diligence",
        "label": "Sale Leaseback, Completion Period After Due Diligence",
        "terseLabel": "Sale leaseback, completion period after due diligence"
       }
      }
     },
     "localname": "SaleLeasebackCompletionPeriodAfterDueDiligence",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_SaleLeasebackDueDiligencePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Due Diligence Period",
        "label": "Sale Leaseback, Due Diligence Period",
        "terseLabel": "Sale leaseback, due diligence period"
       }
      }
     },
     "localname": "SaleLeasebackDueDiligencePeriod",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_SaleLeasebackEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Escrow",
        "label": "Sale Leaseback, Escrow",
        "terseLabel": "Sale leaseback, escrow"
       }
      }
     },
     "localname": "SaleLeasebackEscrow",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackManagementFeeOnRentPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Management Fee On Rent Payment",
        "label": "Sale Leaseback, Management Fee On Rent Payment",
        "terseLabel": "Sale leaseback, management fee on rent payment"
       }
      }
     },
     "localname": "SaleLeasebackManagementFeeOnRentPayment",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_SaleLeasebackNetCashProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Net Cash Proceeds",
        "label": "Sale Leaseback, Net Cash Proceeds",
        "terseLabel": "Sale leaseback, net cash proceeds"
       }
      }
     },
     "localname": "SaleLeasebackNetCashProceeds",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Purchase Agreement",
        "label": "Sale Leaseback, Purchase Agreement",
        "terseLabel": "Sale leaseback, purchase agreement"
       }
      }
     },
     "localname": "SaleLeasebackPurchaseAgreement",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SaleLeasebackRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Renewal Term",
        "label": "Sale Leaseback, Renewal Term",
        "terseLabel": "Sale leaseback, renewal term"
       }
      }
     },
     "localname": "SaleLeasebackRenewalTerm",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_SaleLeasebackTermOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Leaseback, Term Of Lease",
        "label": "Sale Leaseback, Term Of Lease",
        "terseLabel": "Sale leaseback, term of lease"
       }
      }
     },
     "localname": "SaleLeasebackTermOfLease",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_SecuritiesRegisteredNewIssues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Registered, New Issues",
        "label": "Securities Registered, New Issues",
        "terseLabel": "Securities Registered, New Issues"
       }
      }
     },
     "localname": "SecuritiesRegisteredNewIssues",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Grants In Period, Fair Value",
        "terseLabel": "Intrinsic value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Intrinsic Value, Closing Stock Price",
        "terseLabel": "Closing stock price for computation of intrinsic value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueClosingStockPrice",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "apyx_ShelfRegistrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration",
        "label": "Shelf Registration [Member]",
        "terseLabel": "Shelf Registration"
       }
      }
     },
     "localname": "ShelfRegistrationMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ShortTermContractLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Contract Liabilities",
        "label": "Short-Term Contract Liabilities",
        "terseLabel": "Short-term contract liabilities"
       }
      }
     },
     "localname": "ShortTermContractLiabilities",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Shares issued in stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "terseLabel": "Shares received in stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockSwapToAcquireOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock swap to acquire options shares.",
        "label": "Stock swap to acquire options, Shares",
        "terseLabel": "Shares issued on net settlement of stock options (in shares)"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsShares",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_SuitAgainstGoodwinAndSimbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suit Against Goodwin And Simb",
        "label": "Suit Against Goodwin And Simb [Member]",
        "terseLabel": "Suit Against Goodwin And Simb"
       }
      }
     },
     "localname": "SuitAgainstGoodwinAndSimbMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_SuitsFiledIn2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suits Filed in 2022",
        "label": "Suits Filed in 2022 [Member]",
        "terseLabel": "Suits Filed in 2022"
       }
      }
     },
     "localname": "SuitsFiledIn2022Member",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_SymmetrySurgicalInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Symmetry Surgical Inc. [Member]",
        "label": "Symmetry Surgical Inc. [Member]",
        "terseLabel": "Symmetry Surgical Inc."
       }
      }
     },
     "localname": "SymmetrySurgicalInc.Member",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TwoLargestCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Largest Customers",
        "label": "Two Largest Customers [Member]",
        "terseLabel": "Two Largest Customers"
       }
      }
     },
     "localname": "TwoLargestCustomersMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2015 Executive and Employee Stock Option Plan [Member]",
        "terseLabel": "2015 Executive and Employee Stock Option Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenExecutiveAndEmployeeStockOptionPlanMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TwoThousandTwelveShareIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2012 Share Incentive Plan [Member]",
        "terseLabel": "2012 Share Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwelveShareIncentivePlanMember",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_UncertainTaxPositionsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain Tax Positions Liability",
        "label": "Uncertain Tax Positions Liability",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositionsLiability",
     "nsuri": "http://apyxmedical.com/20221231",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r211",
      "r247",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r321",
      "r323",
      "r324",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r211",
      "r247",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r321",
      "r323",
      "r324",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r275",
      "r570",
      "r623",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r383",
      "r509",
      "r529",
      "r551",
      "r552",
      "r568",
      "r572",
      "r581",
      "r622",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/LEASESNarrativeDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r383",
      "r509",
      "r529",
      "r551",
      "r552",
      "r568",
      "r572",
      "r581",
      "r622",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/LEASESNarrativeDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r275",
      "r570",
      "r623",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r370",
      "r383",
      "r414",
      "r415",
      "r416",
      "r508",
      "r509",
      "r529",
      "r551",
      "r552",
      "r568",
      "r572",
      "r581",
      "r616",
      "r622",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/LEASESNarrativeDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r370",
      "r383",
      "r414",
      "r415",
      "r416",
      "r508",
      "r509",
      "r529",
      "r551",
      "r552",
      "r568",
      "r572",
      "r581",
      "r616",
      "r622",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/LEASESNarrativeDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r272",
      "r273",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r569",
      "r580",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r272",
      "r273",
      "r536",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r569",
      "r580",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r579"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, net of allowance of $668 and $430"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued product liability claim insurance deductibles"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees and legal related contingent liabilities"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r36",
      "r555"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r36",
      "r555"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r88",
      "r186"
     ],
     "calculation": {
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r579"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r606",
      "r607",
      "r608",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r116",
      "r117",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r189",
      "r281",
      "r285",
      "r286",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r146",
      "r160",
      "r188",
      "r208",
      "r255",
      "r261",
      "r267",
      "r283",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r324",
      "r325",
      "r463",
      "r467",
      "r472",
      "r579",
      "r620",
      "r621",
      "r666"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r181",
      "r192",
      "r208",
      "r283",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r324",
      "r325",
      "r463",
      "r467",
      "r472",
      "r579",
      "r620",
      "r621",
      "r666"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r15",
      "r66",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r62",
      "r184",
      "r553"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r56",
      "r62",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r56",
      "r139"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CoVenturerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.",
        "label": "Co-venturer [Member]",
        "terseLabel": "Co-venturer"
       }
      }
     },
     "localname": "CoVenturerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r154",
      "r165"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 17)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r304",
      "r305",
      "r538",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r606",
      "r607",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r579"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,597,822 issued and outstanding as of December\u00a031, 2022, and 34,409,912 issued and outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r71",
      "r72",
      "r137",
      "r138",
      "r275",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r71",
      "r72",
      "r137",
      "r138",
      "r275",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r71",
      "r72",
      "r137",
      "r138",
      "r275",
      "r537",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r71",
      "r72",
      "r137",
      "r138",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r71",
      "r72",
      "r137",
      "r138",
      "r275",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidated Financial Statements"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r345",
      "r347",
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r345",
      "r347",
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets, current"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r345",
      "r346",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r345",
      "r346",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liability, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r345",
      "r346",
      "r366"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract liabilities, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "China joint venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r80",
      "r260",
      "r261",
      "r262",
      "r263",
      "r269",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate (Other)"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r49",
      "r511"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Other costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r656",
      "r658"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r656"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r124",
      "r447",
      "r455",
      "r604"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r656",
      "r658"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r69",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r147",
      "r149",
      "r159",
      "r211",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r483",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r140",
      "r142",
      "r326",
      "r483",
      "r564",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Mortgage loan, principal amount",
        "verboseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38",
      "r211",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r483",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r657",
      "r658"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r60",
      "r124",
      "r448",
      "r454",
      "r455",
      "r604"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r20",
      "r21",
      "r148",
      "r158",
      "r442"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r604",
      "r657",
      "r658"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r122",
      "r655"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r443"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r122",
      "r655"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development capitalization"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r122",
      "r655"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory 263A adjustment"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r122",
      "r655"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": {
     "auth_ref": [
      "r122",
      "r655"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r122",
      "r655"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r122",
      "r655"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r122",
      "r655"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Company matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined contribution plan, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined contribution plan, employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLANNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r60",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r60",
      "r250"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r388",
      "r419",
      "r420",
      "r422",
      "r427",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK OPTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r8",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "negatedTerseLabel": "Net other loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r9",
      "r90"
     ],
     "calculation": {
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "verboseLabel": "Construction in progress"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r8",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r14",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DISPOSITION OF THE CORE BUSINESS"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r153",
      "r166",
      "r315",
      "r316",
      "r317",
      "r323",
      "r324",
      "r325",
      "r502",
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "verboseLabel": "Due to supplier"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r200",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r225",
      "r227",
      "r229",
      "r230",
      "r231",
      "r235",
      "r470",
      "r471",
      "r524",
      "r527",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Loss per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r200",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r227",
      "r229",
      "r230",
      "r231",
      "r235",
      "r470",
      "r471",
      "r524",
      "r527",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]",
        "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earning (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerators:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of the statutory federal income tax rate to our effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r209",
      "r434",
      "r456"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "auth_ref": [
      "r652"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Incentive stock compensation expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r652",
      "r659"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes (net of federal benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESReconciliationofStatutoryFederalIncomeTaxRatetoEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r106",
      "r177",
      "r196",
      "r197",
      "r198",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r224",
      "r238",
      "r284",
      "r344",
      "r423",
      "r424",
      "r425",
      "r450",
      "r451",
      "r469",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r498",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r486",
      "r489",
      "r578"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r485",
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedTerseLabel": "Less current portion of lease liabilities",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Maturity of Finance Lease Liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r486",
      "r489",
      "r578"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r494",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r493",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r601",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r70",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r47",
      "r208",
      "r255",
      "r260",
      "r266",
      "r269",
      "r283",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r324",
      "r325",
      "r472",
      "r561",
      "r620"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r43",
      "r145",
      "r155",
      "r169",
      "r255",
      "r260",
      "r266",
      "r269",
      "r525",
      "r561"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Statement of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r10",
      "r11",
      "r12",
      "r13",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r435",
      "r440",
      "r446",
      "r452",
      "r457",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r210",
      "r223",
      "r224",
      "r253",
      "r433",
      "r453",
      "r458",
      "r528"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Total income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
      "http://apyxmedical.com/role/INCOMETAXESComponentsofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r195",
      "r431",
      "r432",
      "r440",
      "r441",
      "r445",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r57",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r152",
      "r167",
      "r593"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedTerseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in current assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r141",
      "r157",
      "r199",
      "r249",
      "r482"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r202",
      "r205",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r594"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r597"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r191",
      "r554",
      "r579"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net of provision for obsolescence of $457 and $263",
        "totalLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r183",
      "r190",
      "r237",
      "r289",
      "r290",
      "r291",
      "r510",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r83",
      "r597"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedTerseLabel": "Less: provision for obsolescence"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r595"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r495",
      "r578"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Litigation Contingencies"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease, term of contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r208",
      "r283",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r324",
      "r325",
      "r464",
      "r467",
      "r468",
      "r472",
      "r560",
      "r620",
      "r666",
      "r667"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r151",
      "r163",
      "r579",
      "r603",
      "r613",
      "r661"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r182",
      "r208",
      "r283",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r324",
      "r325",
      "r464",
      "r467",
      "r468",
      "r472",
      "r579",
      "r620",
      "r666",
      "r667"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r306",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Cost accrued"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r307",
      "r308",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of claims"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r42",
      "r150",
      "r162",
      "r208",
      "r283",
      "r313",
      "r316",
      "r317",
      "r318",
      "r324",
      "r325",
      "r472"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending interest in China JV",
        "periodStartLabel": "Beginning interest in China JV",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "INTEREST IN JOINT VENTURE INVESTMENT"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r42",
      "r48",
      "r126",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Movement in Standard Product Warranty Accrual [Roll Forward]",
        "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]"
       }
      }
     },
     "localname": "MovementInStandardProductWarrantyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r56",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r44",
      "r61",
      "r156",
      "r168",
      "r180",
      "r193",
      "r194",
      "r198",
      "r208",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r228",
      "r255",
      "r260",
      "r266",
      "r269",
      "r283",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r324",
      "r325",
      "r471",
      "r472",
      "r561",
      "r620"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to stockholders",
        "totalLabel": "Net loss attributable to stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r129",
      "r133",
      "r193",
      "r194",
      "r223",
      "r224",
      "r599"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to Apyx"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r108",
      "r127",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Contributions from non-controlling interest",
        "verboseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r125",
      "r344",
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total other costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r255",
      "r260",
      "r266",
      "r269",
      "r561"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedLabel": "Operating loss",
        "totalLabel": "Loss from operations",
        "verboseLabel": "(Loss) income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r490",
      "r578"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less current portion of lease liabilities",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r487",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESCashandNonCashInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r494",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r493",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OptionOnSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date.",
        "label": "Option on Securities [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "OptionOnSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (loss), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other income (losses), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of transaction fees and other costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "RETIREMENT PLAN"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RETIREMENTPLAN"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r579"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of December 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r598"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Contributions from non-controlling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantiesDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Warranties Disclosures [Abstract]",
        "terseLabel": "Product Warranties Disclosures [Abstract]"
       }
      }
     },
     "localname": "ProductWarrantiesDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r36",
      "r96",
      "r97"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Accrued product warranties"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Product Warranty Disclosure [Text Block]",
        "terseLabel": "PRODUCT WARRANTIES"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r180",
      "r193",
      "r194",
      "r203",
      "r208",
      "r215",
      "r223",
      "r224",
      "r255",
      "r260",
      "r266",
      "r269",
      "r283",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r324",
      "r325",
      "r462",
      "r465",
      "r466",
      "r471",
      "r472",
      "r525",
      "r561",
      "r576",
      "r577",
      "r599",
      "r620"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails",
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r87",
      "r185"
     ],
     "calculation": {
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "apyx_Netpropertyplantandequipmentofcontinuinganddiscontinuedoperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r89",
      "r164",
      "r526",
      "r579"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESNarrativeDetails",
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r201",
      "r287"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Gross Unrealized Tax Benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r374",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r176",
      "r501",
      "r502",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchases from supplier"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r374",
      "r501",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSITIONOFTHECOREBUSINESSDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTChangesinOwnershipInterestDetails",
      "http://apyxmedical.com/role/INTERESTINJOINTVENTUREINVESTMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r499",
      "r500",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r118",
      "r172",
      "r674"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Reduction in headcount"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r107",
      "r161",
      "r533",
      "r534",
      "r579"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r177",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r224",
      "r284",
      "r423",
      "r424",
      "r425",
      "r450",
      "r451",
      "r469",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r246",
      "r247",
      "r259",
      "r264",
      "r265",
      "r271",
      "r272",
      "r275",
      "r364",
      "r365",
      "r511"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r369",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "CONTRACT ASSETS AND LIABILITIES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONTRACTASSETSANDLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Salaries and related costs"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Sales tax payable"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r275",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components Of Provision For Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Statutory Federal Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r16",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "terseLabel": "Schedule of Product Warranty Activity"
       }
      }
     },
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r46",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Reporting Information by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r385",
      "r387",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r109",
      "r111",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Options And Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Option Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r575",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits Roll-Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r275",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r562",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r255",
      "r258",
      "r263",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Remaining shares for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled and forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of Options Non-vested, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Non-vested Options, Granted (in dollars per share)",
        "verboseLabel": "Weighted average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Number of Weighted Average Grant-Date Fair Values of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Stock options outstanding and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of all stock options outstanding and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Stock options outstanding and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Stock options outstanding and expected to vest, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Option value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r392",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Shares authorized under common stock option plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSTOCKOPTIONSFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of currently exercisable stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of Options Non-vested at end of period (in shares)",
        "periodStartLabel": "Number of Options Non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedTerseLabel": "Number of Options Non-vested, Forfeited (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Non-vested Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average grant date fair value, Non-vested Options at end of period (in dollars per share)",
        "periodStartLabel": "Weighted average grant date fair value, Non-vested Options at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock options outstanding and exercisable, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of option shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedTerseLabel": "Number of Options Non-vested, Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Non-vested Options, Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofNonvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r66",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "verboseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandardProductWarrantyAccrual": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.",
        "label": "Standard Product Warranty Accrual",
        "periodEndLabel": "Accrued product warranties",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyAccrualPayments": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.",
        "label": "Standard Product Warranty Accrual, Decrease for Payments",
        "negatedLabel": "Product warranty costs incurred"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyAccrualPreexistingIncreaseDecrease": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the standard product warranty accrual from changes in estimates attributable to preexisting product warranties. Excludes extended product warranties.",
        "label": "Standard Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties",
        "terseLabel": "Change in estimate to fulfill prior-year warranty obligations"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrualPreexistingIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.",
        "label": "Standard Product Warranty Accrual, Increase for Warranties Issued",
        "terseLabel": "Provision for product warranties"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrualWarrantiesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PRODUCTWARRANTIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "terseLabel": "Product Warranties"
       }
      }
     },
     "localname": "StandardProductWarrantyPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r179",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r275",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r562",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r41",
      "r106",
      "r177",
      "r196",
      "r197",
      "r198",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r224",
      "r238",
      "r284",
      "r344",
      "r423",
      "r424",
      "r425",
      "r450",
      "r451",
      "r469",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r498",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Balance Sheet"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r238",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued on stock options exercises for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r106",
      "r107",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/STOCKOPTIONSSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r106",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued on stock options exercises for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r26",
      "r27",
      "r82",
      "r579",
      "r603",
      "r613",
      "r661"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r125",
      "r126",
      "r132",
      "r177",
      "r178",
      "r197",
      "r212",
      "r213",
      "r214",
      "r216",
      "r222",
      "r284",
      "r344",
      "r423",
      "r424",
      "r425",
      "r450",
      "r451",
      "r469",
      "r474",
      "r475",
      "r479",
      "r498",
      "r531",
      "r532",
      "r603",
      "r613",
      "r661"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r480",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r480",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r480",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r480",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://apyxmedical.com/role/STOCKOPTIONSNarrativeDetails",
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Loss and credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.",
        "label": "Tools, Dies and Molds [Member]",
        "terseLabel": "Molds"
       }
      }
     },
     "localname": "ToolsDiesAndMoldsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r279",
      "r280",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r430",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of year balance",
        "periodStartLabel": "Beginning of year balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails",
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases for tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions of tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions of tax positions related to the prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r239",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates in the Preparation of Financial Statements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r491",
      "r578"
     ],
     "calculation": {
      "http://apyxmedical.com/role/LEASESLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r226",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding - dilutive (in shares)",
        "verboseLabel": "Weighted average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r225",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)",
        "verboseLabel": "Weighted average number of shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(4))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1),(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "https://asc.fasb.org/topic&trid=2155896",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r583": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r585": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r586": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r587": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r588": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r589": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(2))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0000719135-23-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000719135-23-000018-xbrl.zip
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M*I%6V@SWFO[? 9748IY(-1^^'<D$+/L",W:E$YZ^K5J<^)H%(^-@:.6_ +U
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M@J3!>K&V+7#[[=T&+M\=X [JS3[-PRE8G"F,H<^(/P98E9)UQ'.[?17*FF-
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MO6ESV\C5*/S]_@J\RO,DGBI)QM+8-!/=TLCR1,EXN98GD[QUJYYJ=#=$Q"#
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M5=UDQ;D^7J?]E !H]_"C<_5P7\^33*5252E@C/422D>6<5 3 X6/M8B%'#1
MWW_>J;/Q)$?V2+^-*CR+.:+>_UI+>,7K^7?H]?M%S1[J<EK17R1Y#LP!TZ=\
M$\C;%RFBW/:O3.+?::8JBS:DEK+<X]._S5/TXL.'[4_S;Y\0 -J_0-I4S1O0
M90BA]F!SMM,^UU_KMBG[6QW00)Q^"7VE_;M=Y/7<02T]-Q4IUQ.!")3DC"4J
M8=)+_%2)V V\(+#_YY3.+4 &]NS'I<5S8PXK *[:O<A<N=L)3(M,?_Z4L$__
M.%:\GE;JT,BT@]_.WK2/MY?:O_'YY5BH6")2D2B?N<R-W83;GLUM5X5([6%
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MOAUL#&B.I,Q0.P=[AF?RM#CFDZSA^9J *>2@#4KNRB"V610'/.6^#*/(BYW
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MP&44I$F?+@=BG<7JHR1GV)%PA$B9&["4.5+%*6<\\E7*/%L(MCF@>0X[[^'
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M%J9.;'/I*^XR/XPCVTE7?^;+>D#L :>?1 K$9NS*P.7,1I<6,-8TX:GP0QL
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M3.+YF[:TLJ65>X2RPB3U73L!.U&PQ/62T(D<._&DM/TH%>F65M;-H;6EVY=
MMVXL@S2T>:AXPAP6QK'R(\]+F>.PR$OXEFY7D5:6J-?(&S(] NH61?S*G0_H
MY]H2[U,2+ZBDRI&IZW@Q8PIG-S"1,AFFPK<CD<9;XEU%XEU[6GEB]G2[7V\M
MB5?809+(2 4,$TT"/PYC-^1>$ E0GZ-D'=Q!STB\#XQB#^F+VO*3ER![4^:Z
M3A"I*(P5"]PDDK84(:C,$J=P,=<TH-E2[2J0R%9?7@&:G6\W-"3#[V@WI#Q?
MN;'P0?&5S,/FQ$RF:1BFGHH]I:+5)\/GS]E\%, $8>S[,F5QXMA,Q$$4!2*V
M.0_=*')YLDZVR5:@OP2!'@8@PV,11*Z(&-C/B9T(L*C# "ZD2O)NEAA[(7CZ
MW9S$VW/8?3G)Z^SK0:7J<EH)5>L_1XI+VH_,+@Y_@O\Q\/)DF@C&G4@FS'<<
MKM(P$8FC; 8_!>)_L-"B?Z9N9CE !"3YWDBAX_S <_;]2?/C92:;T8%CV_^]
M,W<G[F>/Y]EY<8 5B:J"RPTZY]L;DK*"?>V),L_YI%8'[3]^E%D]R?D,OCD'
M&MVCAWX<\^H<UD[*IBG'![CPA:H:++,PB]!Z^K+94QSO1[Z'VVK@\QO9+FQV
MO$\[?MW(J]<\=Q]PZ]K+]KYS[;5;7NM&[N.\UKO3:U_3253M#2TD)Y@7"<\!
M".H)!Y+P=MI;)EQ*T&,/;,NAN]HE'N'6^V_.H)!!"GB512T"K#_8])\?S?6F
MG!RX5R[>8[OKNPZ=Z6LBH9::K]+T'&G!>?^XC'9QK^T3L/6R.F@73H'Y[*5\
MG.6S@S]]!KY:6^_5I?6I'//B3[LU+^J]&MA5JF^LL_^H Q>VK_^\U% .X3U$
M[0;JCHOX_MO[T\\G;ZRSST>?3\Y^>HU;6*O]GYT<__;I]//IR9EU]/Z-=?*/
MX[\<O?_EQ#K^\.[=Z=G9Z8?WUW[4HW^"<[=/^)W7(\"JIBQVK3?[Q_N6:_LL
MOO>V#W]*JM>'S_>U=P38VP^?WED_@= LRN(]*'%5)BPC6S^IE-P6(DP#-W13
M.V6I[<8>_%N$D>V$3J0\L:SDU"HX*C-290=O2J%M8M M=D@.IWL@9QU[[V\D
MJ_ME#ZU['=;32E:0]ONVEOC+1.M-@LS=#]SK1=E-3]Y\S;<?7EZS$-2 X'%>
M&]]'7M\F1MW)5V3Z0[Z7J_0*(#4,=^[./#%M(DMG=R?&WV$WN*/Z&C*,264<
MTB%;I$.-5H]/@D=%,>7Y)S4IJV;'2LMJS!MX.WP[F!IP5&6>\#POFZ3\VE*J
MNW/XQS_$(0M^7"36>5K]'ATI>#+@/@ZCO0KA*YR6('ST_OUO1[]:GTX^?OCT
MV?KXVZ>SWX[>?[8^?[! :'X&R6@YGO7AD^7XK^0/UH>WUN>_G%@#>=K)TJ/C
MSWC9B3VV! IW)*#'T6Z70*["([@6=,\"B;=E934C9:59#5NR9HI7EBJDDKT$
M^J9/O1%)G^5+GX"K: _WB7:CS+&5 PF_[%$U&CZV)_EL#\]Z3Q4M?_$>=8O'
MTZJ"';XE,/\35K[K+OL-LIW#-TIH!PKV#IAG@KL6+GLM:UQY^_/^INI3[.1.
M D'S\N>BMN4RO*Q>,N@?#4CW5[&>C1E^KF"#&74BNX^:Y1LUBUVO9JV*@K4R
MZM3G3T?OSTY);]H@E6H->-_-.E7348"E/?966I5CZW_P/U93ZG\L8Y,O46%U
M[#N=[7$Y'F<UAFZLMUFNK/=4O'^P-MKJ'3_S$?GS"86@\/#TV;6,-]@YM/<<
MUXF\VY6X>9_R.GFG;G+-Q-%^;-_-/;5<GW$<=@^-YI9CR\;G5ET)G7_30?)_
MSIW]?TW.=RR>-]==6M@4\R=?O^4D7=>;?-UY_2WL_YD9M<M6@\@^J?.L1BG0
MX/BXEM#"G<.CC__\A_7NY,WI\=&OUO&'3R"SCSY30.!V\VG%S_Z.#.[5R5<N
M&CHQJTRMJCLIB]=6/5$"P_G2R@HK:VI+C'@%7_##/3C1W;Q?:\.;/&\_CL('
M]T:[T7[HLH</2N-N']O)O1RKFW*RJ3+[M!"FS3VH/]1T\ECW=CTNI;IJ7M5X
MQZ0J+_ ]O1LG0C=.SB]YI1[#PMJ";AGH/O.OIR9)21#XYG6O>.<01SH&C 7.
M%<_:)@B!Y4ZB5X3$%IA+)=A+E?6O:975,A-D,I4I18VS(=+3K=4Y+[+_T-\_
M/#/&/N_IG>Y_VC_;M\Q<\XJ.:Q[+K/?E_L,+S2>F4/=)*/1(RDK5M?D_S ]U
MNAB]O7/H.XYO_9;#Z@T<ZZ>2RZL.\*?:XS'\\T/UN;SL>#J.@3W.%:\N@9ZJ
MY]L9T?.'ZB,(':#;/LG!W3E\^^O5'(<GVM7'$D1A_O]G$RTGS9Z\G4//"P/[
M[JD7JT =5U@!4<<K\Z6H2D\J./ILPG-+?55BBJ.IX6?@"*K>M?Z33>"<I?IA
MI3]R.0MX]9CA,<262O$Y#&$[AZ$;+N+'#X^)M[^6(%P^CLIBP3GC^("M$=MS
M/?>*>V8M$?:TKJ>J^N,?(M<)?ZRM1N5J@I]MZ6Z<ZXB?U%PD:S)XHS9G5046
M[&1:U5.T:YO2@CM(*CONJ^0'I%7T$A^)YF"EOW8Y!/_X!R>P?[S'QLTOF+[J
MKX0U'KO[0?QMQKBS']K?9HS?8E$'W_SD]=<",/'OEB#^_)ME_G[(HA?F./B<
M-3EYP107(^LXYW7]8BWQSQ7'K5IGLW%2YB_V&-X;ORAAQ,E7,<*)[A:(CLM1
M!K_T\N4^SH%! <'5ZH*5/)PGSP\U,GSFN E19:=_!3KT"! X:TKQ9=?ZKWW;
M=JR/O++^SO/I([O2MI"[%7*&<6B^T8'-Q%JVT%D1NFI9F8Z'+7JL%5R==U8[
M$?+"6O)_6[_D90)&[1E8"J*QWO'JBVJ^(U*]"IKU?>R(:0$X-K0@SCL+HI,/
M:$I8[\&*^C9[XMX)_P^6,DC??5I(=%LJ*YE98J3$%POG5EJ9_LA!A#"K+6Y=
MJCS?^U*4E[!1Q6OX: D7T*C<Q1"B5&E6Z #BIREH5\SVV^,:G"\<V+[U3U7W
M^2-/5^I WUS><]V'/?'']\#]#E#Z&P+IS,!(V_T=><= WN6U#HTG!L8?_^#Z
MWGU,VO6DG:)LX)=_3S-D*TUII9A'55&.9KW<7>%AW*7[BQ((>^?%EH >DX#^
M7N;3HN$5)6Q5=5>,9&\)YS$)YW*D*"*Y0#VOG!^(7*3%\[RCF2$Q)<K< .^;
MIY\YNAG(H*'TQLN8>&M)N I6,-XZJ9109!,[KD6U&;7U"MX'RI-53\$8K$<E
M)L>T.:;-B#>+^[[D]562IX?--_Q@\4):K]P?K!'<FH &!I>3?Z&F!;?3G? ,
M;L*\!C.\:]H#[9'7C17;EN2S>O_QB<(4L^B\<E3Z&]Y,>]IP=@Z!)2T2Q[.Q
MJ'GJ>!X^];Y\=@:]P6P!:0;(99PU#= 7&2A56:!-E\\L!?;=S#I%@X(+BL:]
MX0W7V<L+G*-_QU ,#_773^I\FNO0_MG>9^L5>N'#'UW/W>\4W(S2Y2:8+O?8
M;$3OMV,/JO[A"8A_<))XD(87=,3O;HE_PXC_ENX1F\-&R*[-X7.4Q84 -E)Q
MY 5(66C4%DM_!76^V%MZH1X#_X%5JE9, C&.X11FNZB.P.M B./1G5OG57G9
MC-K+^Z"=*-H;&=%4P$*9!1BM=>$SE^^0KCH_[K:WW7K#M?LS-Y)*LG/-)G<Z
MR]YQDSUWF2O$>G5,1PYFYP_WB;#.!RK7*4G8=?;]X.'[:[C?'$"\I1&&'SU\
MZK'[.+%9/(.[-0/Y]KBD85:K5<C[ZW)J?_YZJX<JA2V?+,BXDO ]>BF0W3"Z
M?)(*P>H8\.*\K&9+8C5T$V&,,#?U81O70_?4$KWD.P)Q*XYL"SZP%\E+SJ[3
MZ+X/S _TK6O0GDI3'AWCS],:5J[K^08M:?95R;VFFG:9"2[K<>_[ZT:>O=O&
MNJ#ZR7*S9(OH]T'T]A!_H3,\;BV[JPB?\KSN,=XGT7Y?9'?<M46VT_0&<WT7
M+.$[!O_03TG>21#'& 5L2FM::U,?3D"W_5K2M**L:*U\AHM?9K T+&L5\'$E
M\OJ+K";Q3J,4>8ZV I8EXLW8MEKR2M86UB%F\KI\:.\57YK-L+]1]'0'??1N
M2/H-#6J>SQ'F^-_D3__C'P+F^N&/%&PS&@4F0*)3B#>-PNI6Q!U (ZP0ARWR
M<XI*=34%O*Y!?N)/+6HI_=+@1T7NX\)4S.#S&7J5"\!>Y')5F5LEG&^WB1:U
M>\5F/AV'V6R0T7_&JX3#R_<^?,W53+NBL'IL_PQ;Z(9N@.G_/^!1]-]M:@62
M'!CM@(#:#51C[9"?X!QPO!4HC[)=).V>3V76F-WMS[NZ-H)R'E$2G8JT.L+C
M*ZNC'JW>YOS\KGU!@[MUK/J.=+3U\V+7(Y7GK82R7BU)R+K6;?O#BTXH>;Y8
MS>.;-8@3=U;RPEO-FG4BH<^ Y/S\',@$Z6A,R:O6!2:.MR0@='9YC=GE%IP4
M99!0;"?%S MXK";9AS]=E"0<,!+;S*Z[&8EOVNA,E$JE(& *H5!<ZFAP!G^
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M:P4LM\M2S(MIK*(L]BKT:5:FH.::LT5G=@E<'!&4:,U$]EHQ.,8TQKT9?-H
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MM1L:@FFZ75L5K=.;%U,PB^Y$L]UX^CJ63KID[[3)-2T;]0K3;RIIFM]04O0
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MS*39]L[HC> VRPGTXV"TIT[QI'$:V%@:48':,>G)/FVVE0YU3(N^=D*/X07
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MT(:2P\,Q,J7;E-Z\YDY@6"581AB2^%>D[BHN8[[U#&&W?(N\\T54AVIQ# ^
M_&O?%OE$Y/>OA;X 6O+L6,[=D'!QTO5..DB#-6&Z1A6MLIH_J#G,(O=86G.*
M.]JZW+DIC'+FX#/O ; #] \F""NBCLVBX@J2<*Y\GK+*X=4(V+\R0R=7:_SD
M@?UEL=:(""[T!X]G 0L,=%\7V;F8NRW3ZO!EKI@>PCDR246CU ZA\D8:U#:J
M[FR!T63C>#D<^Y\ ?&WQ^97R#4]D5&)E,$73SU,-AP=P+14(+ M%%+ NG03+
M?AT$VV6RYE >[1&S(N<]QQ%'QQD][0M*@VI?UFK S=DGB4Q2H-[H. 018<1:
ME,K44U#*_T%!<;&PN-7Q+&H7SC<\P5Q9^8#4LS1-L191N*U8_J^U"A2W>8;M
MM=IH47JM;Q?I9DN87\DC@L]ZH!$GBT Y2R71X-L(,B[_(O#%@A.K8#D8*:C%
M>"TG-ZCW5M8H;LQP;:2=_(N[1[_9"3]1]B8^WI0ZBN7KSX3P$K#1[(^ZV<CS
M!_7Y;W?TWIU*.L:R4[(FP_TR:[)EP4RTYE!(RKP\(QL5'F88:>EI5E3W)G,$
MQ/4^9#@M>1=QL<#G&?VU+H.<?)GYN*4>*'B:=)33D49S-!9-+=\W^,A0TL]D
M%;R-'-!7&8IR!X^T][OR\&Q@[GD_R5<X]R>DM$N*?PIN[2[!IQ8S.ENE.FYC
M8_X1NE:\(NG<E-X!,8YBC[%NHC95U1H.[+"2RXE0E358M8/C$X0+>XI^;?OF
MK*"(#K6M;]@N'+L*%(+]+&Y!E /)@T9I\6!!_8/&,Z?PW<7P@]7U_5\:_.J'
M] *+PX:$&RFU&.=(W^*;V J;%%,R3\%2M/*Q='T??,M3F,PS,%-GBW6+!D75
MPM:*0=T,=[OP\F$,K?_UU;-G(:<.QSDE(U\A;\J%Y!)F1A1R?<3)GY:M$J:+
MF+=Z1"P[/K(V\-/!,@I7A.\E#QZ"L<^H 0 KY,*<O&R;?O7U3Y';?HR\.XVC
M48U?$DY&H]L!4+*>><\BY+B$F18S#1@FU?F6UBDZ+"R0*CNI?LML&XC /%T<
M.'F3G;-V&BU2,DKTC[8H_ZV,C%%N4;V.\JS4(B7%6R5*2C0:TUW\*[TO4P0V
M:3AQ+EN%><F+8LF8,K1+&<6H-I,7 5Z"I^(6  XN7>F6F1Q;\4'K/QI="A]C
M^!2:TED$V;* A^);7F\S%V:?JPP%E Z4%8"L@-81D!IG*5AGW<7+E'HW%B G
MT^HF3I]9 P4;'BE:#_Q&I5GV#@(+/;0,+NTKS%[-C?8FXP'QCC1(#?0+\D P
M;K!)9F>0,&)R'_#E%0Q5S<DW4I@%EZ;;29,Q1ZK_C;1!9;IM8,E66=GP_T(0
M9<F )W[#&=:;!4C^ OB@Y3&<T\6[!,PS[,.&J("9"W7YH[X[K1NCEJF=!\[T
M1%Q-[R06LYRE3U7*I8H/R"E)IO+'X/?";4731OO6QFZ3*H=M<>OZ=+RAUH;*
M> I8.$7>VS= G6;-TL'"^@F]J-Y.@!F8)>Y&PGYD1'"KMA] #S/]-%+*\&1N
M4*^4T]+YT/#2"F3@14&SCKBJZ9$YCN%AAL]B1:^]<^03)AG<+%RF^J-FMA,=
ML):9:QPAE*;HU9_6>.:LK,W7 7@X6O;?L/G8F&$0L"^7A;1&M7 LE<3;I7*>
M%6@I,ZJPO^-D021W?%&2'?O9-A."W0ZGX)R.NQX8<MS<YA[KGN,;9U 6ZV$
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MF#5E<N^;,WE,J0ZSZ="UFQSP"'/(#1*/P*NB/WT.4/-[,,JZ?C/[(XP_&91
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M^L\O=B;0D8KAPP>[D?Y\(^W-_#&YXV_JQ0) V:Y]DCSO3NGIJB)Y_8&BA2]
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M:M]"!A^X&[PN<2$U3&*V\7RN[P '-0=M/C4@ \(+0^)WE"=G_4)UZ</G9B5
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M_KP0UC9.0M$HA3V7O/WME0)/=[B,#=DA.T=HG6BPR)M=^)1]T3H['.X?13@
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M#KE@JG?S_#GGV54T 6IB@)>%+RK0U\2Y<DV,:8\B(-GM9G)YZ+SNIO#S;]6
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M;NE^44R:'N?TX;W#(X;&^3?T"C([T+ ##?^T PW?@&?9@89O/!U94S#*5/T
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MR &'!6]<.W #N0MP[FD+M=Z;C-V/@A9GB<@-N<9>8+"H"G T)[E,G_9KD[S
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M.XCL"7O,/(#RK[P?I0QL.\,FE#>)3:@XGD0FLI1V!C][24.[%;@38;&_PM=
M]#UK/4"?(( /B$X<#V7J7\1W)A_2GXTO'X66^.ZY9VRL?97L=_EW[2X"4&@?
M4$+>P_*/#7I)MBX7:I-EL,,1R'B$&LI_$*;R.V36H2D#-C$HIH2<F8C#280D
M]4;"]8%_]QBWR#"S.) <"B\AK1-DC-',_>&<ZAND5:3G@1X9#[Q0<B]R2 9\
MH4A9_D'$'T+_ ;^4\X_V^E86/QU>+3=IMJ9-#N$V8J3?P\8C0*L>Z6$0#8$S
MS%3VY#L?/%R'[PB12 JK"@^F=($G5H(4B-P%CY,":>&AIX\GCN*1JII(N]SB
MR^3>Y*S%?8.-\6_N".6F]<,H$FXO.L=HJN")P<*0$?IQWJ8OSGPLZ<73U#;[
M2ZQQ($X/7:$R]PC/G_M[#;177([8H%P!'@"^$[ED?&3.(&%K\K89/)]H>ZPR
MOY+M-L+V,  ;EX\!(H!S)_+&Q78Y90!B.2/$G(/B!7HP=7S*)2A3K2-6>X@;
M[+V#WBJ\;*09^O'_VV.AM09 >PJ@KVAX,]?PZ#3\&K*(Q.>Y!_P/["[=]@>R
M\\;@]J!<B;DO4HK4[PJ=98(Y/B#BV%XJ0I<*Y)T?.DR&:\Y@;?2(\:&&]O7;
MB78]$Q,L-3%NLF 6Y2_!^UI@5N3K%A@6?_]_6L\!:UTF*;6_7S86"Z##Z[YD
M3L-"=5]2W9=4]R75?6D7NR^]*.B^?3LK51M1IBTF]3\8^\\B:;GYGJDSEFC
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M.$+&C7B Y"]+.6=R7B)=%G#!OJ+5:8S=7[UXF,/D-1@4\U1X,X$J3L%6 J%
MTC/K@"*V<J*=38+1LX'H@2]$@8R&9)%G%&-9D/Q$NY3A^SS5EO??R)N52.#(
MF\5>2!U;&S)_@CL5]Z3A"9,B/@+-F#U3ZJ8Q50>902#.PI0R*^#NL=RXS#MR
M76/,@\<.W=98+#IV\.2K2A5I$2 OA024A!<ZETVH*U?'XQ#]>*31*5*C&Z]4
M;RKRKI3SI.LV,X;'I'F0K/G$NNY8F# C%OWD(N4M@I^/62&NJ)X?PI%\<?6&
M)Q[&N1I9]Z3'PHOA+'$:W9.DH1RR2R7<<'Y:@E%:XI4P$/6?9,><:+<IO%%L
M8>PS((PLQ80<XK!4YFKS]U!2CO+"&>1(N<_((Z&Z9T0)!HS!OLO@E]<"Q$D\
M"<!.'4C<5,":8C3'J.O<:^C#@@SABRU**D_[*W)OF4P#F21=FTDJ'0Q%Y]GQ
M>2&_[H*7@V^/9"%*5L)<0$D.^4D$W,==#]@#B#$JS 5(X^I_BYWTGPN-]J;D
M5J&I'B8XCUU0.W,B+ N=/U(Z,0VR]SQG@7)YTDF-M\Q"[['L^P80%+41,EB"
M-]6\/:^^FBNE2I,A,$%"(7+M/O7H,S)Y<O[*ZT4R[^'U8ACI <632PC44Y+)
M]J"QM(["J)C2!VKOY[U#"ID;!R#5G\I@9[+$S>V$!5$1-GE1_O1L"R#U49@)
MJRD(L[<A6*1E0I^+I7V.V?]B6 D[L(#K05E\$?L +]$;I:-"PFGZ(8X3I7++
M$T 43C6&/Z$EV]#Z:4+.T-SF&[*YW$* -*;24JYX#3Q [ *VE+UWJB:-FK>&
MB0@V+5>6IET6*WH:4W5PN7=)YQ,2B#S38E!.0HEP[8WD!5 )EZQ>1UQ%^Y))
MW6)ES+Z7PRRRUTB[WE'5U3X<\Z7*P*)6GRHWRQ/  S&J@*Y@P_>QQQ$-+*#[
M,"'5!16_)PTM9#7V7) T6'?G<B G:EG,I6$#[,M'8U"3T:0T!VTW$ 6/7#;(
M+6$-\4SV1(9&H09L]I+.B7:>O1)7RT78XZEPD4<4/8W&*=D F>5"=Z3R'2VU
MH0D<7MN7C/KR@)'A =;?O8=V1CX3XT3[^_SPB,RWDY=')W<'W9)#DB[P2#Q0
M "TK2$*9BF)/9/#%9L4(;W')##\3<H^ZZQ4@Z,V-_! !,'*;Q=ZFH#=3*D7[
M*L+^>4%1U/ZR7.'"'-)&P3B6\S[(I,UOD@KTSW1Y%A78"<^^DFD6NMQ'!F;!
ML*#N0"^,(<'VKR7$<Z)=8%@T1G,E<Q+0;Z*;^[G,F)0-]7Y<W&)EY<2HB./0
M\62+H0E32#HKU*V(UK$Z;5G>WL-+@MAH+<D.0?F1H/Q!>1TOGJ;T)+_+I@:H
MR.F^K[1D@+KS9$L9_]#P&%%L.JFG$<$?V<X@N]LGF9""QB6@EMH>:)#BO-2+
M2:A8C+%,6MS*]J7"^O 2Z>2]Q+TDHLI87VYPPL.]%Q39X15T6*J@HP9[404=
M]=VX*NC8AX*.[WDP2QLRD5#,NAT5RC%YP37,C$;2(+FE :J%V$]JX.S"U\GM
MB:ALR( FE*$,:"RP.H2M4FIUY.W;&:G&^68G^VL8_B[,8VF=E/D7(@M$'D6P
M8,:;Z#VAA='L_4_Y]V#&BA(WDK*+%3[X(#143H0,1");6!_'POHX1NOCF*P/
M>FP,(&-$1"FVF:+.#%GI.-@/_($Z0K$GLM]D".P9;)'B_@O;R8\Q[8843<4%
MP %W*J#([@ON#@"NSZEW?+[K*6<EX<XP(%,<KRWF@:5L4WM!>XO"'0-_SV]8
MW,EH&_\C%>&%#+M@:O.1YS2T>S_L(TFEXS%F>H:"-N,\IRS<>PDH1GW88JJC
MH-%.^9TV+]*8^\"C.$O;9M:_?+Y()HMVW;E'1^VH^8E&UY3)W<G:RTWB?4[N
MB$UEA3//IX_QA"PC4\HAHBILJK=<,9HX-0I(RTDBTQL-*I"CJX:%NU1B#[(;
M4''H2%38 _P9+_CA$>#)?PL?^0/&<EDL(XHB[S,!R( "J8^3D44-;1 1,H5G
MY+,^1;1C3"U3%T !D-(WRJM=Z*P)M!1VO>O%<"\R]?5@<#S=/JP747AZ)(SG
MW3_W'*?;EE"DLLH)KSH=9Q9%+#JH%4 @U!YHB[T9+%!."%BK!/Q=Z(!P$X$,
M0G[?7U(0%PFSSHG-3'1>9=F7J2Y[DVD5MU.WWV]8E&B7EXW9GHN;Z+3HN?]S
M]+H?;+6/Z@'P!8;$W<5WS>YM\[;<R3MUBBD'P/]A#]0LS8NZ"O[@9[^?BUR@
MZ"M(MYZ_4\V']L.+?^XO%UY1%>MK-5Z'%X-L+8Y!KB 0NKE 6"-PV;)4X%(%
M+M\0N*R#U'E!%75.RG4[S:Q 1X]^1V?NG"5L*6=@"BG+B^"MXO+RZOSB']K=
MM38)AEY>?;W^\?WE4+3(21\GX?@S2N6RTR1$V[DPQCE\V +-9^.8?\Y^^.)Z
M\=AGSY^]@/9&7_HBGRXE.+X W#.Z"2Y?0N\3'TO9U.V>=%I-%$])!/]WLQ=+
MR75"DNM3XLY_UFV>Z%9SX<?ZB;'PLY<>:YW8+7NIIWZB'8M= UP0XO]SU#R:
M2&P7O?[/NF:,D\+S7EAJCI]P\3Q:YN 8CM^?[DB+W( >RJEK"2C,]]%S',Y!
MQ+]P9I\/YBA'$,U"M?^J8-J44M&%.R8:M@^T2] GV.$7O;,?<MPB>",W:=_W
MG**_]M4#?^/#S5GO^E?M\ORS]A?OZ7,0!E<I]5>CP F<[@>J)&]@.?:@;=KF
M0!]8 ]WL-N%GQ^[HAFUT>-/YUSD&TG5#-X[Q!\-L&D=:P$8  9=[GWL8P@TC
M?..E>T1&R."X:1V=6MV_?)IZ[>G'&56PF&07XE5*#)0P@%:-/#(MH\MJD1XA
M"K:$\G>U7/02RP6PMHK1TC+!/+7GS92W\;#LA;E//+QS"&UAAYM%<P7BLL$"
MA/T=/*:I[>K.90/K7=V^L4!>;%5,**F_&A*;W:JD_AY:;CN'T,Z,U"]XP&!^
M7D_2=2^UV=]IA0 0V-F-RXD&N[I]<UV%L!$)HA3":EBT]/JX 0IKRV"M;;PH
M]0L- R[^2.D*QIX*?P3$SFY<"/]=W?WN$HSR8O9 _%F+L*B\F!U$J/6R/L,9
M8E^IG=?>*C)K5Q69M=->#,%=>3%[(#\LLSY>C%((ZR+4IIJR)>LXE3VW^]BV
MFF]CWZSNA%[Y(N++5M+#/U&QBJI7/#IMMJNH5\34\OKUBNVFJE?<<KWBVV[#
M+E,]MT<?5L##/;P!M>X%D#=5'%4.I*I/.S^BW<RF1PU#W\UF')7/,=KJ'GOC
MYR?M.W?IMNE9&(TER]8>Y',$1L>Y'GL!]5$1%VG+S; M@CN[$I9-CL^&Q^4S
M)*?ZL$W=&!-S3!>@2_9IH2N5L>=ZC#I??BC,T?JXZ"9[85RYO"Q-[Y[:2#P5
MZ)C<KFP4^RIQ$<07_>KBH38H"84DU)T9XR&-PNA%\<;5^M%I'[)6T&(L]J+K
MV!^I<9VX%$JTL7@ISB:-42 -F!?A,SWJ%S"9MR<'<<>SC\AOB\^,+GL=XK/C
M)V$Y8K%P?S5#[%(@+9F36M7HW/G[,K5A^E_S'OR2_;?*XG=TD[A\8JP<(H9T
MA%TPIUO?2JKYKS]U3,/^$A?:OXK1C#/?\N3( "3:F%KY3LN^V<>5[BAO.X ,
M0D))CM6+<-C!6&CC @D-L/XWFNAK(C%\FU3<&>47%/@UWG5&^$C5]V&*PC[*
M:N*/8E!NQ*?Z1_:QP<?$4*"W22;,!$7VQI)Q?S0B6'8,U&+NI)'H=^>SQXD^
M9N,Q;)P,S2CU>=9I^#X;UY9AYW;R?5QQ\20D'[Y_Y,5Q)H,)%GB@6O#+0B6$
MO=73_+J\0'P9".GB?P('HXD;$A3B?-H=M5&<?"H1)[IU/'*:&4DPD7?@!;BI
M,0=V"NA3SXU"&U<<Q1J)GBMT)?%QR&E@ZD)QC=0RB#AY").IK8",;$DC?X8K
MNQM$$4@); D0P49$P^V<@+(I%Q/R0U4MYD\\ K73E*'@'G@R:Q"(IT(9+D\E
MA;>'9G4@&M@G4>B+,2:3$^1]W*@5VIA%^:A"B8='/L<($EK4;@7-202Z;).S
M].OR)K.9_ABG8#^(QI=2C,CN=C.2A%/':-"S06%PRJQX6>74Q=82CSR784$(
MYHLSS%Y?8PZZ+C*-'%\BZ4$HVKSA.N"NV.K/BW_&"\DU[ZI10NROD'*CR&BS
M6T!^%,K#%5*3QH[C5F3#]ZD&\?(X_(F-:')3@YKU: GVXZ$N\0V-XS <9-3I
MQN[9*/5LJGAVP_B%9CE"LTE0,C\."QN8F>%1:L?0D$UJ=E_H'S)I/$\3DV<[
MJ2.#@54'_\Z\@MK1^WYF!D[-J"_?_._YR'$!Y0(33T8&E4X+*ABD;Z)S-1AS
M)B9H;Z2/H@KO[4)X[YV<#2* LVQ(,-U/T[[3D/AM*2,];RB5CVVG78G1]32:
M.\5&8A1,X. \BM[V\F,&.F!JKDDVER3K+YM9-<LYY,+N8_'T:[&#TK1%/_6Q
MM.+%J_ 3G+"4M>EFR6?M@_%11@B$,LUF/HFA8+F.$1VD:9B0U*Q+!Q+P71_,
MCSA7 WM?R:;'-/>)/&0P]'T?##_2A;)E%34C)@"#&GK*^]_+&2Z3$TH-PA8@
MR VYL#J9C[]Z8L( B*2B?LA;6+]VDH9LKL<0QX\X1SL?$(60H=99_>?B[J3B
M*]\<$4Q#*C(Q%S+F8*[2I(69K94^ -5<4%3>\U@+Y9@2F@4ET%P+LZ^<]_]*
MHW) 6CE@ZL[?T7_7N"T.P8H![GT1NJ'F0L;21-^8\ITGHR&R5HA9X[A\!E=F
M1C(<X8E!QH2)"4@T.4QZ;&5^06$^4MY6C0A4S!UR)##1)F*%.8_P+I_CV-$P
M$(&NB91RY:@/'*U6;$:WQ B+HK\W2"-A3\\='AU7L%HQY"#FPLY8D-E0>A(7
MFIPBB;LH&XG1$(";?#^S&*E#) [VP/FSXA,AQ$#8/'C9T(SW0D!9 [K:N%M@
M9A>PL0:5T9\62;M\"D1&!T5T8G!B-!:(*."2' P1=<VFY4T^S7<G"&H[B)T=
MY#?Q1HK>?/%XPII[7G"6/ Y-(S@<9-%9WJV49<G,6K"7XJYS[<UH1!I(QWL9
M&F*BD4!A!"I&&H.\82:I72(%/H"C)+,0DU1!WY Q#FD<>#$LEOXXKLSZ8(HY
M2(7-4<YGHL9IG '].B49:D$OM5"_KT1=B@&+PMB%-01#'G4@7S_$)M%D[K%1
MB%$V5!3QY\5=>611UC%68'UNMK.R+(_"UI^/C<[XA2*KBET"[ *#QS?;7U;L
M/[?VB[],P<&P3EIX[M^Y#%_2<)DY8I^5T!@LR]E41FBX^X+LJCE#"9-;S#RC
M*&PHX^K4%=H;AJ$[9R*(3K$3PX "2N(, )0A"%\I;F3;J$FD"D-[TG[)&N+2
MTHGZG#?M3A1AOY6P)_2YG*KL/Q>#M%/"IB#49N3.<MBAD1_;QD[7ULWM8\=J
MSZ%GL?C(<(,5"$R,+"J=5#>9E$D#IX!W2/_,M+<7\W<H[.&"9GK&'[,I]L#5
MD;0EJK*/IA.X<[FA,JDU5;V!C</C)$H=<?"9":GY(<EBDG,=18Q!MN">=HT6
M]]14E+H2I;ZH:4;8%9ZRLZ@6:(0X3M(%XDBD\5[Z#!Q&*Z>*,S2-B[XL1NWX
M$W=260CRE?>C%)L1FKK97%8]*+3.HS4W?$15 <.ZJDCFXN9&^5UF[L4/#NA,
ML>8@>O"<R7C4+'0A\V\4DQMC? Z^DSER4Z-(YY.TA8$;#O<>4!@JKJT0O3*O
M[@S1L:3$),/2AHSAIO"=EXFA=,5^WI%+Y0"3B_#BRSAH !U5FGBW +/]U/-=
MRJXK;+X5FX7)Q&4@SK(C\9#[ UD$5:B^I$J)49^[-.@P.8;?C\4D=6W '"&_
M^\_%G'.)R>A1(DQ0Q$3F2]$L$O&R*"O$::"$<&6]O\UZS^J;P.7TXGQF^Z(P
MS^.LCF8.$ 1S9,$K)8*2%RMDRB8I39(AA:DM]#"O,+*[JA+.FL9X*8'_*?[T
M#MU$K^ />2_1UM'IC]OOVF^WVK=O-[,]1>L+J:R&'+Y.\<ZX2&W_'>?QSMA#
M"L*)IO6,Z=%A-H_R;Z'(P^9H;Q^=7D<^L%O8P.OZ$;A72R+_?4#RG8'YH!EM
M*A9OJA*?O,2G4\FUOY8:4[ 7=4';(\^*YJM.MYUO+NAKOXVCG%U?W5Y_NSSO
MW5V<:[_VOO6NSBZTV[]=7-S=OO&"Y7O+B@^7: J%*3S#Q8+5)[20P')GTM :
M\TC^YK*$?7P-1_LP>,#63[K-5N6#!PSSI&6TW_38ES]K-<W-;+:2,0FOME=9
M8G["6UJTE ]6R+L\O+.T(-4W=[]M:M"" M^*X#/6FU.Q9IN0;4"@=WM;U"QO
M:(JRU/2&-Y'4##C7><;JFWSO)G'OK*E%/;6,JHFQVY_K(CLJ?T9%C*SAO_:)
MW:H[6C'WG5\%QP+P!^9/7;^?5L!+G5_7=H&B_[S6$8M'H^Y,M3J;#-=\C40V
M6$L#3P1KTM@]FH[>,%OOF$[7-'6W99F,,]MR3)UUW([ENJYN_.MR$K0!G]$;
M,3_^GZ/C9A;"2>/C>\;&GY&2>H&+_UQ,R*B7G+$HPB+%OS,_!0>3IBPG\-ZG
MY'.0CH[=D%Q1?"PP&8"/$[O)&!!XF8;>,+IF%OG)3G3Z7W\RVOJ7=5"8<>D*
MJ*Q2)2F&VE.&LEM<[W?,?JO3;EF&8;)6V^;-+F-&1S?MID4,96R)H3I'ITV]
MT;'U&C'4%GKL;H>(!(B+_[V+L# ]OW8S2?8WM(!3>0##LK,LZ?7G+<CU7K:!
MKV%TCI66@]27;2/B'_E^2TBM>W3:;G?FZ(RLC54.4A4_O?4@EH[]!.<9YI4>
MD>9J!%PJXG=:#E9&@',XNN*)=$=6%'^60?9$6U_;GB@701NU)Y;U? Z>\"H3
M&!42G@F$UVSHS7EYN#W".S!7][*LJ&[.SUV*C98UT7>:C:J2WP+N=^R)3ZG9
MU?BG>71J-UI6JT9F:]6AR8,GN*KD=B4$9R'!M:TZ!1XJ\I-V15Y?T[7O=47U
M05@\58EJ OF$9^*BO3/'(:VCTVZW1N:,LJ-K*H]7HJHV.-N=9HW(:HL#/Z;J
MH=LDL;=F.S\ ND+L5IQ'IJCA#%WGI49I6)[(8X=O(53%QL]/GV^R[7P-H^O"
M9K*M/Y<0&TZ*:-G;#U&]^0 X-;4]SRUKA*8.PM*LSK61J &1MJJ!V3TZ-8R&
MW9TG/^72[ VA5>?2O)G06OK1:;MAVVM'GI0G\U:"N8GXF'FNN*L=RWO:U#0@
MOZPFRFJ4A[-IB2U1<2$PT0M<,DY[!/VWA79;.#2X83?7EN/*%:HO^54EQS=
M?IA9:'3-=HW(K\K$@M&MC7 OKXJ]"Q/LIKZ^'%^E_'0_N:RRC/$Z_-3$X9^-
MKEU5Y'=I?.Z0T7[ -%I9<GD=&K7 I->KL#G>BT8/H4+^)L*637*R%E92CT7K
MGH GRJ[?O%TO@'_CLR !N^HB@_\;'.86.<QMHT86E3+H:RK&JZ2[-M)=RUZ[
MQJ%^EGRMY?9UWC"0NC=I!);C<'"<BN[ :]KS^\U'E66>,R1\0QS\P,U<#WX#
M%QGA7\(K]M&I;=2IB%V%SFLJH5>EK,[1J6&NK?OK%RROM0P6 X!YQ1+X("R9
MJB2P1,&27$+9RSI9*LI"KJG\78FNVCK0U?JIRO>S@+-^,;!9_C(IOM?*@S#9
M*7>J;/-WK H5\<JK,'#>%+)LX\VKAFFH:I<])KA*"T;7)3C*BQJU\A&K+'O9
MD;QHN8Q^[<#KY9=JIZZ6;XRP\OGW1G94F_M=55@TCTY;1L.N+/9:FZ3O*^Z.
M8D3%B!M-<*_*B)C9[C3L]0-P[\6(^^8?UG;#V9*,KBT29-OM#]@$HL'I<SZO
M<Q?#97>Y7X'F<JOTVV7OU\MOEW>7%[=:[^I<N_B_WR[O_JFZ&>Y$,*@<I5EG
M2M\3HU@\_L;VE!5RW\:><6 W)[(6+-J8/>/=T74BP'MJHNZG%5IU\Z@;03]O
MJ[=LM_"*1[N]A[?=%0/M*0-5W01K/09J$P,UZU12>6#=KP"/4<I?O(-8,*!4
M4NT=%!/BX]L$YF]D+?OHM-/HFG6ZWJL2:_45YM4078?Z:)J=.J5S#\PURMS>
M<1@1^4R-/A=U=.L*](.H<]I,!7/&8L\+.QVUNV 3&76ZMJM*Z&HJME<E+1NK
MZ,PZ]3@^,&.[1#8/IBJ<E:F]I<KF)9C'.#JM[&*MLJ9K2%>;J&Q>@JZP(*U=
MIP;&NYH)/J3ZN:IB,Z^50^PYRU>E2M;VG.TFM?WKM-:N2UT)HSOD$APJB5:E
ME=8G48MF59CZQHLAZ^1:U$07E)/1MS"X/TYX-*H\Q',0!M^&0SS%.PISS-0Z
M.K5J-6U-N1,U%=Q+4%=1C@^\)^X>_X='80G5M7'87 =(^DN-*&^_Z@M?D]35
M!GP.(EZZT8#/BU(:VXG4:>B "L775$BO3EJ8*MVA"^U[9B\C$2#,E:'\KK/
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MAOX:>9FB[& *M,MN\_0O_>C3Z<I?>^_3W0VYQAQL$<&"9T"H%H0)/)U%\.=
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MAL "WEG>%.BJ>, ^QP/N(GC<@$>HQ:,2LR )%PR8U@HC=F@,M9Q)+<?OJ#C
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M)JTJ3K1>_@W_>5J&#]';()9+0%:AQ]( N3[B-"F(;A? LT&P'4?@N$2$J<5
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MD; SK#%/!414D4BN@@CP O,41 \<)@[IA%_U&*\Z9\-TPAL/N3[,&T 0>VK
MSRG!XHX)F^Z6P'CL3!H .S*P'B1@ SJ%9(#-&\-GSAOX)%ZXGU1S,%^K3Z<#
M,'B"U[S1@Z,HU&^Q#$9!Q1=0?,ZBX1DP-:YIF(NB6YA$O,=%/+S*TAP'H(""
M@(MI[J4.%REP][2?BX" ?F ZOFT3DQC4#VR?.KH;@'L6:HZ\US7-/<O^4K[7
M]6F/[9YE1X?9YV%P+V =+N!0;_C[;\,[6;N<7F&#Z!!_?<?SD'?"?<IO^#.]
MN.(Q@4IF[O:_3\M36W-=J;DF;<UU ];2UEPW=^&[J[D^D:N<&]#U!>3+"\*_
MSN]1%*A$O)I-WI98G3R<@37*/I7A:(@6;7XK\W)F^%]QM\^]8*5#)2M'"YL$
MOXFF'K<_O $OH\V:NK<NA:%PI8]7J5GF1B65<&;=VJ[.HKJX*"I9H03HO]>J
M)"ZMN;8.-8AY$CMO<T>C+D"N%+\6UZ8HU^1NKRR/DD:X-.4&"-":]Z\A;8LV
MPW)C(3]L;&'U./("6(EH_Z3/O'>W?(;P^\DPZU]<M,4:2V!GAO>*@-U&\P&[
M]8,!=C\4&&-%X^,=2(X/_# +TFW;T]TIA%B.Z:HV,5R+6';HAB&U+>H13[6H
M[SC3(-T/U[_>7'^&^^GF43F_N+C][>;Q^N97Y0YT_L7UU<,\F.Y#F&WUVG?Y
MAJL$,@W/\4++];30(,RQW="DS#)MQR6!9P=NIU\"*-^#I-1N8NFBIJ'80Z*!
M;+FVIGJ$V#;U H>JOF7Y1#4\3,@W4KCV+#Q%' ,(RX7FM49D9CC"-WP2$)^Z
MFDE(8 9.:-B44,MV#)UYKCLM,I5P25$J\Y!?$EM@VQ^/0;1 ))<2=!,T@NS&
M'3^7DH1P=2)L?9?;!M^?8PQYQ=\Q+8B&011$%!.&' 7_TV3P1).(=I6KV]M+
M85_AM]:+"_B&;MJ^%YC,<(AN>!3VZFEFJ!FAHQJ^7U]./1,.^!H-8ZSLNN:)
MG'1\"VM.TN=H=)>G2C^]WM%DGML/)#2U6;=_WMX?_IQ"^$J5GVZ [%[\,Y@0
MO:[R91STIE,G65<]TE?F3!29Z:D.#\@2*F#"@8591LE$(S7)P.FQXB#-C=TA
M1M\' HND )I@>>A#$<UQA3S7F"X["AKN5RG]EK+;\ K6@%@K:7Z$CCJM5AJI
ML7\3R!7Y^O/,&T<$R>W7>BUXJEH/M=>H2H!5]!=^"#-XT3B;U%! 6\CZ$H[<
M+" ]L6_2]]EH7$3L?QMROX236.@^SK(T ]E(9_PZ] RS*@R6GR%W+1%J953R
M*:EHFQ0]@A)-+'-:YGLH&3!*@6<A)!1K2N=^9SR5.EBE8X)G*^L6)J/;XC49
MCG#6;E;L1DS X+ZL=*C$A@5F&F]J7$"?2CY#4CO(*-R;C;66+__CY/S#&'"U
M34;S+#E'F['DO, W3:I1>!\QG= Q# UN9\,T=>H2-J-R+[(N*_Z7TBOW9L$U
M*6ZUE%K]?\0#S,AP.7N&YX%.$MD>7HZ5Q3S$#)(D>HJ&?"K+..L@X<*=,*:\
MP+N?>9_Q #-=,W&CO 9#PA)DK=@RR375 C?=1B?\M2P[F>55X9^@1.?5FY77
M3T4^'!;)\CDT(KL:8^V!\HCHY9/D5?D4#08;;)>KDX05W2)X%<SK[ZLS<X["
MSOE,HX0W =Z&N3505'A*(2YD5S\*\X?C*@W'Q3TO*^7NH_2OT[5O"FLN*@ZP
M*^MI<H ,4 9YG5#5["B[ 'Z9@EQ&?$'"!$B8-P.@_0.2%PTX=J28-5!3"=I3
M_D#A TMG),N34'RF>N$$YB3B3KP@JA:"L<\5M\('00/I1U:I$;) FF 1)M<Q
MFXZ8O>G'K',=0\!E7'-\L6PV1_#IB9\;=].]GKNR#O8KS(]X G 3WV(KCPQ$
MIO?Y.4P+\\RX/,,G%%YG,,9TXI/ (YH5> ZENAX0?S:DTDCAYT3(\.=PD%FE
M(/D< 69S[.5+S#V$DQS1[L2]GR*UDDI,ODRL1?$8DL3#6G$T'L#O?Y+8L@CO
M8*AP[[_RS!7^$Q[*_]W%@C0F^M.RFD'89PP,7M3\]8KC*->')ZQ<$2ZLAA&F
MJK \,0+[@KX65SW*[@N>;$WEN)#<8KP:O[J' BF<?RHJ^V=Y115/E64+X]Z4
MQQ!PH6H/9"OJHF60QF!N)+BX I!)S'&3<,E88YSG"(O-"DA3@3'$%X!(XT%/
MN>"THKQ 4T1QXJP-.[-P^%"1#$ZF_$0JL,K'H-AQ5)[ D2GKU)RXW!=ZS<F8
MO2J3">K!G])CXKW>TRLY25=IG=#H4L58*1<KH)=XU+.B<8),XQ3!T"%/H"**
M<B(!5CEC!MB0X;_RYHQ F6!%+D^E<F\8+@_PH"/8<^Z*\T/+4J;RIV5VP5$S
MN%'A%0#;)3RR6-R'W1QJ-XW&$UH*,B#ORD #+B$3\%3:Y96!C/0UJS/[1J,!
MSV<#/>,7<=U)$(%9E"\.7XXBQ4T ::%$WQ@O)D>[(XN5%/Z^B'\DF$U.,>(2
MR41JV8Y!(J4"HS:KH!75V/@S(>T@2+A2;JC46/&+BP"RLTWG'6XHRCQ_\#7#
MS@X! I+?>9_C)+OQ9JV#=3N.'-+IJ[W9@7%*&5QFG>W:)E,]1_=,QS*)ING4
MM&QFN)1JCJK;!N';U0ZV71.W.UNT-P6H,U[NWTH[6,;K^8A=+NMB"$4VT13Y
M*8<,\RCB;7L[@R#9KQEZG35]S0T!6=.6I^V[)J6@41TK("&AF%$UK-!Q_3"P
M=,\["LLSVW?$3MB.+&U2*-]QUA[$$07B[P+5C-<] PNCK2B0N3DCH\('?Q +
M:%'EE\P_?@T*<+1HV)5_PYH@?B7V,%<1I<\XZBZ. V'B?8^3O[#4."O6CTI+
MR_*.&51^5P$-S]OY XZBAD7&?)'X:-DC4_VYD,Q!UO\D*K6RV;RESL;R!2W>
M\8S0X76UO)70Y*+:WDVYY/W5!)MM37 #UM+6!#=WX;NK":YUC9;6-$W=]!H)
MJ6YZH6J"?0'VG<<,IH4TM(FIAV$8'/QN7\<O7&JV5/S"EQB,7PP0%'?'),7:
M7[A;\IM0QA:*$E1^97)' O.88_:29J6DF WE1:PXC46,NA]@:R0V>%:'L^#7
M9&DR?KZ\ OQ(YE/!U8B*'TPMWA>*(%A#6&%E3&V!$\!301&XA8GH(F7C[XSE
MX\8%LG#^K7QL7/ZJ.LN@?)>64[FB.EC.?9%[$WU1/.U3=BRO0RRZGO <S]0O
M^8TN4EGT&R@Q"<:;3>B5LVE%:KFH9*[,S2TVA)$7!C[#]V&:I::S#//>RG7W
M:[9G[;9W RQC'0:86.53>^>:\?91F.5Y&S%R3+ZIT[70*_MEV7XY\^>A3SKF
M,MH#;W4$/XQH/KJ)OF#9A9S=5!J1&\AQ<5E]!J+IX4O/< $2A;S )R[$?)(R
MC(@,^%AD&982%2:B.*3R/AQAB#W>SS&H-XD6*>MP4JD;9) 95& &H"R0S# /
MS8&BI,H;1&%>IU)Z4D_YQ,;XN3Q0_$+_C0GCTLNRG!D<*,N0TDI/XZL7CCOP
M/I\?\Q^.VHWA*XPS4=[ED;=<8LE1)&</)Z#'N)(O[XV*V=D")KX$L"P(-(>4
M\*4/BC>)9*J?UT56]K!(6]B623PC='70%<3V;6JK<"';H6=HOF,XYC;:XC>^
MRB] L$J(!;C9_Q!,$FQ!*32(T^D;[K1O)$"M/P(A_6<@5C+%R8NWQJCG^PZS
M#<.TB.Y[CDJ-0+4=HMNV1USWS;:&\&K3.SM;N'+;#QDQ26BKL%JPD53/-'&J
MA>Z&KNEX;[5R5RU#"4T?2CA)AKPWB1]*" \1?4J+=J9[FN<2*Z T-$E@Z*ZM
MJX9ON\!TC(:J]F8[TTJ@6RN=B47=4'>)JP<F)9Y&*)816YZI6\P,0F:\V<KU
M16?"L0<FJ Y+ZAZGO<;A^#LHBL6G0U7/ "/<-RW;!5L^=(+ #@R+:"9UG,!6
MWVR/QKH2HU/3,V'YJN\'Q+:8X_NV:JFJ!1H O SV9BLG-7R5'0Z_8^ ^6R(C
M)O,]0P^(2C6+P#X<"DSFJ:9O^UH8NN&;[07A9]8ZA<#P#="V#K5-T%L6^/NF
MZGF>::F:RUQW*]-SK95C5_V<8SC*<H[K%S0<D RWR664CN*4#F[#+_'PZ0L.
M@CWG5M0\X]P]#N/\]SP#"-85;NV,[TT1FSM=([T<%Q"9W%09X/8'?/NR!AM-
M;EDMD.58HS";^@*_\Y^Q2$-4J4>)/WG!N@Y1%\6K$4KC6>03\\FJO'$CXAR6
M3UTJ/R,;-917%4SUQ%:L85Z$Q0*1\ :W/?LE A>G///&9!&7& E2S+N-9>^P
M*#3![/)$(J+Q7:(?'W#6C\0HZ.O,6X>GH=E!LTWP2X_/\>"UWG+B?9 %*K@M
M/YXF1Y; GMY;MAU<3P@/S_(6Y\/7Z=>QHCP%6X+BT@0N&:^0 9WB.6C@HZ?
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M)Y7E+JC(G_"8,LXU?!D-XE<F8K_Y@&=01: NSO)?EAU);B*C'RHP;$LEN>A
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M!I?4^<@.^!98R;GO@TL%VF3PVJW_/$U8<3/)^^0%/C1)^"62@:3+U?R?OSG
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M%D1*6#H9C(5U O;@ .R**.1W)U(P+&YD)4SB%R44C@=>([F@[)_=F$XI\\+
M8G#):LSPG) &S*7,]AB8^_Z>V<WN]$,T)9;QFR#_M,[)]!&W7-,9!9,*ZUE8
MW5SJ!2F3>/+T7- 0-FCWE%-0YO77EO1HYUU:3=W,\IL)790*JT_=-YE$269
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M8(/;6XFK'?81.33OEGOW?V/MBGNM3M_H:H9VG-S;@.3.\<8;VYCE&VN0W^E
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M0.C3&0XOX<&-:5XPZQ)C]_ZTP*D':#Y-@U&U)7PE;P!)JX]@XU7_ =!>46J
M4*^=[0.E'@V1Y7P/&$NB98Q_#ZI% *D#FM<)'6.2_^#1)K'I<58% W%O\$$X
M#9HCX1^MENU\S9?(P7E[79==V76Y!WN179?[N_'+W79=?E+@SRL(Q-9!$],\
M7W?!=C!\$AA>0(S <]4@\JU75Q!6RD:-T[LLN>.Y;T3A,35$Z83>8DYJT"H"
M93*$A^*GC3C["TWBZ5CYEI!B3)22!J,43G+[P$.@V;1$,5H(APS\;'9A=.9B
M[V/,4%GBAF*QKXSGQZ*4%"-.?J39/8_G@)QB<X)",5V(ORS&25X7^"@8PW?5
ME*&B)7+QW20$S8!;QT%VQQS*/@IBX8G\H(RR>_1>#RJA'A!Q]'3>7=QLF.0Y
MV-]STY(8K'&"5%Q,0"#-33?CX<X$7L6"GFPO+,'ACL0)LIFA<IF5""5,8:Q_
MA@.:;C/XJ]Y?-HE3(="YFQ55_L6)+*AN@Y[ ]!G,\TD+U"A8"O(<A!#<U42@
M02N=!R"6U:Y#<GN+YRDQ(R 3T];X<='UD,<D@<5#EI"HT"A"A0K)#A2-9BX-
MW#/OA3&HQ[4AG"=B&)A0<7#,5Y1D]Z ^_67N:C#G0XP>"LD8CH[9K &;3]7>
M8@/<!/WUQ;)KG&0)SAPKV#$C,=FJ\E!7=\RRGQ!8]:J#%MP;Y./)M:"6%#P3
M"#<99 5J6D61!3$+8; T+4XEM?8V34*X,)R15X.RAF0UU4E@9CM7=7.P'J[5
M()*1ZZS=14>;2&\+64IR0#DE O=!*/-I9:3*:V/#L%BV$8M@)VUM?,'[?)$J
M7TD>C#I2LKE/CX]&HB5F$U6Y-I7&WUXXB'DBTQAV"C?8O3LV>2=)*(N;"4H8
M*G_'J(RP =A[T%58XLRHBGQ(#C1=8 9,,8/$R"_J:6TB[QIVBVV:$:?SS&=Z
M4)V3312@D5O:GO<7LL<I^\'F/DE7\UR+!JKC@(1V=,TS5-NQ7=./=!?4,^&3
M5(VG/'5?8"^-!^3A7&SR*OHFZ!,?6-M/!PJA;JG=/DE F'4.:EB:X^L1Q?)J
MDP86\?7 MR,:!J$7.$[XN@=UA4.R\ZBSF4^SP[_2.7Q #%DK.J!:FFY[1F1;
MKDF=T-4#U2"&IE-;LVQ*5_5)SX&%C3<BR6EY!DS] 3[\G213NC98O$?N/V9U
M#!%8_9Q9B 3"HAU:9A!#DITI.KBN9_@!L*X:KMT>!;$X":(N1V!B!V@RH3@0
M=5;^$'24(*'6FR@Q35<41: .B'?$QLIE03"MA7V*KT1V,&!-[F]';6;!587B
MJ05!@6NI? U:U)R#\XL#ED:GR#KI'6I@P 9#[H-M*0&\C.N: N!C-O\*^>OY
M3W%ES)W+L*D2_PO16^$Z^DXG6<Z4A,^ SXI[_!^@'&"FV%^GH,(Z R&3X'OV
M@5U]0'AJ,L'H[SM\@2C].JL^K0K 6&4.7U)<Y^P,V$],?H&,.@-SH:P1]VL<
MAH")];=PYY\!\H#VJ('S5\11I/P=8VADK)R#P@>"B]R3ASDUE,U[30&E1B2)
M6-0+,18+)S"9 :Z."[:XG#(4([>P=#%3.C10SD;P$&YVJ/R69>$]G*2J=1-_
M5\<==$+[&^A6.+:8CVPY&\4T@LN"RV,CC:]P?"W-N60&W;LRLKI6^IB).3)5
MQHO0RV\(YK3 3^N-X1^/[XKOXW.M"XI]#)0;;*@QS<66KK'!!J9A#QJ] 1 S
M$:QF-M-P4 .(_Q0V!)N]IL*@T]1W_B\BCOF.U-4++3RN<?B4WSJ(<9/]X/L4
M\$%3_6,+?Y)3YI498->A,<F! -NMB*IRILG4!RU=:<VT9'G;=41CP0&:1=$Q
M&%1@9DT+PEE-M=:2"SD-[U#E!^)+:7[[,.LCQ1\(-9P93GS1^T9M7T*=E1-X
M,*^)P^HLIE<T@I338$'ICX*/;Q6#C1&7:]9:ZWD'S#$3(6Z8!R+A(J/R,/#;
MBXM*NPU(*AP%+=65\59QW>7#K"(^ZR=@X@MI05P-0["9 D%^*V@AXZJP"VY3
MS^@_';2"1D/*4)B9W0R#Q@5-\,UW\6V6<WD@7H3QA;JH<(EIOZ9+8[#@TGB&
MW<QB!F@G/P@KF1<GKF(EW],*Y&L9Q[&(OZQL&N..9DSC3BMXT+*8Z_)(-+A:
M_H8#L* \0JCM@<UD&+JI^YIOJ(&--I2E!9[FF1MJT%LQ+&Q5/3HQ'6LK%I0'
MAW-URW2IZIF:$;B1Y>G4]P+=(WXHDCI>[: :F H#ZQ4L*(U8KF>[NN<&U P<
ME?A@-^E>J ;4,RTU?$T+RE;U1^Y?6E#2@NKVYSW1YJ"EX+$8?<BT0B;;N2K)
M1(A/:8KA ^9SJ^L)"T!Z93)Z*&(0#%R(WX]B$+<L!YT;6**50)4G\%C%$J(0
MG:-(FT8J]6Q#M0+=I([N.:ZI:K9-B*59D6>O7\TU1YL [#.F''Q&$^U2%$W-
MUP0"==8U@8N$:1R=E/?9(E'6N?>52MQ*%6!ILBT,Q22(DB4]^(7(Q@#@5\3W
M>)^*);YW3H-(7+DR!GVATN#7N@"/J" J?("Y'YH@+X@?V)0Z?ABZJDY5GUV
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MQRCR!BY+FS&'X?3!^W":X^TU](A]5Y96R&SW9GN'V<]*W3D<%-XH -HC%'9
M>]H%"C\G^?%PL&.C(&>/L,,].C&'DL6];23>*)#9(R3V-F-Q/568VS7XLY.W
M5B^TWY<"_9M6[7A.@^PVY07UDTF>@94$UE+RH#R:/KM=]]GQ@D%XFB19 /L(
MNRU#1-6TH.MV<'&Q_\/ ]IP!P'?!VF.5[NN<^IE6\(N=6@-U>J"Z;O>I8T2_
M+/AQS)@$M@JH7\CJ_N&-"M!^U4.!V5D*34-XMNJFQ-MG5"V5&!SQP - K@)Y
M2GP'"#5<GR[VB9[BM 08%<#D6;$@MEF@)!B);A:\/X42%PR&81Q%-*=I@-T3
MRGM*>=. 9LH+&XDSS?$R6"<-UA<#P3K3,6.":=^L;\9T_D5E)A[%Z6K8BP+>
MC'%%7?V W01&]!C6I0_L(^W#4#F]O<WI+8Z:F3]'3B=PBYBI7C<V@.5'I!3]
M.5AO"Q^/ )R$PDV'BO_ 'AUE24@!5V"#[7?6_3U&A)WGH3X0^Q- 4#T@.H0D
MV*VBS D;H1Z2!URPPD0&E )>Q#[AT^@>\#G1? 2VR9I:)!GKA,$!*>"6<KC!
MBD.EZP:KKAH(U:[680A33C-BHYL4'#RSK0Z9//Q\=D^=B^K@3",XX[!BW326
M%1:X^M&)/C06!Y)W0SIJ=ROY]V(6K>$?<WQ$Y? =++U]_':H'"X_.65$T\U=
M&52 PN_Q/R_1D$W==O]VWI#W- UKA3/#CUJCMB^%SWE-.6>@=%<=<^#IBV.W
ME=GF0EGSMMD.-\ YL<&4<A^7(_A&(4LY(US1YAK39G>QJ#+L_C)JT3#+)M:^
M'?/H!/"X4P=A_!=;0-62 60*4>[G)Z(M2KY78+DO!_DUJ[U<"[N;>8O%7@S!
M.\#9-'-::/JT@-M]=3<_#DP!,K3LYH#YO3K[67/T%0U?'%"Z8/ARO5@*I0,3
M2BT$VE H.4<GYD#W](%K+*8>/2F4ZK?OE3QZ!B&W #XK;[2U(>]*@?,\'OFD
MP/&P%8J]Q)-RV )G)Y+%4]^D9$'CN\Q*0(4.EB8:*LZZ#AJ/P::>J7M2],G?
M^5S:KDBU[A1P@_!\GL;N:4<GGMK-0%_?5]I+B.EL--X2F,VY0Y6+#H]AC=?"
M?R4<AIPZZL>8WTH\(7Q/;$QT:P4EH07_;4"*4>.;8TUT\6/A+N1..K1ZZU\V
MW\+JN9*A:H>76<3P)'>'34@<O@V.-.>3%6"YY<,O]YW[--[#%0AIF22<[5#2
M:K^])NU@SRAM8%A]8SB] I*)H1QM"8SF&0QB\8(.MCN$WJ@GU<'-EO2L);,E
MG\;@9;WAGH?)?801&ZSF+-K#71C\&!\6@UWVG UOUPFVP&36MIP]![F,OL1V
M[HGJUP<XN<RWXZS$C0];6:JR20AK;U_/4RAF%,MVF@'!^R@P5%Q,\QSI-:_#
MAK./5(ZO>=N0_L&<!SS0'4S'+%1[U^6S83,:.MY-VW,,0KROB.9B4@5PAI26
M2D'+,N&-VBJ?4;U?WM0_3H-D&O+._[/>O$:9%S9L]46>)0E@&NY"(7YV1X?*
MIPTY6'L*1*WCO^@<07563T((7+"1'/Q(G,;XP"7VY?4]F13G?TSC\N$B+<I\
MRH#[7>Q];1+T0&O4K8'5T6N4@6D]6#R35;TJ+!Q510U:&[A&A_)1X1[@]81S
MQ HKVP-8^H\Y:P-%.SIQM8%C+ []V1/\6/O$Z(10';"D.HXLT.!1V;28 =F2
M.H+SFSCS8Y(5,3[P/J><]XI1'R+UM?4K,2A$;7Y"_")+IN7RGW1-.GD-Z6;K
M<]!I_7>4-U,";NFQGU/RXYA$L-GW)+DG#\71K[/#7.*T6MPVX.WS9U]ZPBC:
MV0EY C6@4\9].^]Y$E7,TF-);_:BC'*DP'^)'2.,_, DFAOZIJ5IA$:.'_@:
M54WXR [^!Y17-ND'^1FZX"F;A4!64J1>"-,69C?P .NW?_R7\O7\T\79Z1?E
M[.K[MZOOIS<75Y>]W_CEU<WYM7)S!9N^O+[Z<O'I].;\D_+YXO+T\NP"SG)]
M Q]\/;^\N5:.V96P44M=9'5(:G'W7"9#]3R?!H%C6;JIV::O.8Y#?-6P797H
MF%JP4IS]68;KMF*]YT++OZ;Y':C:W7Z%>F ?L\ *YF5O?W^6%>5E5OZ#PN:J
M3/3V)*^UQ9\! G]@&DN,5S0'F$-AFK8RWY]*@$9YB?/5F&DP%0>:4_<K%QKC
M64RSFB0$-2ZNX=^,XJ+.IXZ+F80SG[;3\.'QO!4]/:X\=Q.F'KQXI'1GMRS,
M[RP7'^%S3P=)'143R3J#I,.NXHV7LKJW_+N5%GU[RIBQ7!G#[3(6^Z2&H.GF
MD53AI HG5;A74N%>XW2*Y@T5KDTM_G?7R4;T%CTNW^DDRP%RMY_B NLDIOGB
M.%)'M>;'D48!(9;I6:$-1!.:H"2:FN[9;N2ICJWJ_OPXTM_.KW[[?OKM+Q=G
MRNGE)^7Z_#>\..7B\O/5]Z\"';NK-ONC)C]]YED8Z:[E!Y:M6TX4F:9)T2>C
M1T:D4Z)YKF4=U2.>G]00EDO>SIT^_>9>6B=7$Y;+@2YWCIQB1&V578I.:]!,
M<X:R?%!L]5R6@M(91U7MUBCVXQ)G(,<)R15@_&DV1AH"/1&4;M@='#,H,-U%
MP=)M!CE8^:D?S/JVP0+)ZAP4GM?"1^GB"2+X60:?QFD]3KERIG?L_SW[(B4E
MD!\*&!^')&.R#)H(=[ _*MX-,"8\GJ2@;S9@/PACT-1+   )@FR:\J7A.#$
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M^@F+KG^-T/?E20E8"=C]>E("5@)VOYZ4@)6 W:\G)6 E8/?K20E8"=C]>E(
MMGJD\C]8S FSJ@]G!_/$Y1I[L,9;B'"_^Y(5Q2^8])N-*>^V*O*"LW0A\KV.
MMW(/'9+O7C;B6\"!X5_SKLDZP?Z"W0G>S]JN1PT;O6D=D=V%[)<U<7E??.5[
MB'VO&:[<!L[Q7M+F8B^OS;S=$O'ZR/9L:EL:H214'=MT;-</0T/W-8_8NF$$
MOO^Z;,\X.M$UX'N+$1?)]PX"_;80!]PA^IF ?L; LA>'N;T*^DG;1ZZQ*]NG
M?Y;^OCSY%HS*"TQ?QZ&4PJQ\8W;DLS*7I.(AKTE>TV9V\1:LDUFML&)D7"FL
M=<0NY<\"\[>C@['$KH/!KJTG(:Z!77;?L&MM-69.V=PK-4;TQ]A(C>DX]^&1
MQM;KGRK0GW/(SYKB4?R3AL?_2_.LBU2<6K(_EURZ47:GS'A5L^XP,6XSC6PO
MKFD/;^.%_<)/,(!%0L=YR=;*KK9^H\<A4?$+.W37QAMO+;S9*;]Y"\X@UG5!
M>((&.*1*>H.D(2BO25[3WGF#&">;"Q0*.7-)RPY1HZO[MF'MZ,12O07AV"/'
M@R23OKNUUL<ZO1OK>NO=ZE]4<5^>E("5@-VO)R5@^Y((L9<1!);_4)*?,H;P
M"C$$!/X-^2F4CX\TI5%<KA%+T T92W@#F+?U=/HM8)XI,>\-8-X.PB9+,&\1
MPRQL__CLE *)7?W%KAT$5U;&+KMOV"7U>&D@[=>3$K 2L/OUI 2L!.Q^/2D!
M*P&[7T]*P$K [M>3#+"_LNE_)RL.DY3S!?=L"I[<K)PO^(KS!6GG?$%-SA=<
M[E8]G-%D<KZ@G"\HYPON.1CE?,%Y&2\''!WX@*,U(GG$B$+'# T:!)X9>*%K
MZ30T72UT-<L*])!%\K0JDJ?U8OZ-[AR=F/K <Q=KK7HZ_V9#1B,'E$GZ?8)^
M ^H;KF<$H1N%IJ=%7F3:@1;IMA<:D47-7M*O>W1B#2QCL9N=)%])OOM/OF]B
MOJ!$YK>!S.OD60>FY9NVKFJ!;JI6Z)+(\;S0([;F1[KE]%(6>:!+N@-+VYMA
MMS*:),-T^_6D!*P$['X]*0$K ;M?3TK 2L#NUY,2L!*P^_6D''LAU]AXC;<0
M=!9-"=XE;/+?VQ[Y]YHQV"V,'#+4HQ-]X+AFCWHG;<ES+1%O9\'#;2">AM/^
M5&-QPJ1$O'XCWCK=>5V/&J9M&K;G^:9C$5<+PDB/="?4:!2HQ@J8M[MQ:P8.
MG'0'NOV<7KX2_7J,?EN(5.T0_0Q /W-@FFX_T$^:/7*-79D]_3/R]^7)MV%/
MRFE_LG&XO"9Y32]K%V_!.MET'IMA@O(G)]T?,')M/4MN#>2R>H9<;Z-3[YN>
M]7? D]?D-<EKZK&3:V=:S/(): 9.DU7[,0%-(E0/O:9K(Y33'X1Z"QX7/E(/
MX_>TD"/UI+DEKTE>T]YH*\M"<NM.#3/<HQ/#64Q D,'?@\"T'09_U\8TKT>8
M)D-U,B%[OYZ4@.U+<'DO_;+U!#6?3QMY8Y[9U\Q0?OX<*U.5<ZS> .9M/45Y
M"YBG2<Q[ YBW _?YJC.N3!W, G?1[2FQZV"P:P>^])6QR^@;=DD]7AI(^_6D
M!*P$['X]*0$K ;M?3TK 2L#NUY,2L+L$[.R@+V&]7$['8*L%;/ 7-_I._NSG
MOY[49LQ*4\%>V%C4Z[S@E/7&((E2X+P&)4YQNI"ND#1D8X8&RCW-J;+4KDRG
M.)5HSK14P]#1?8]JKJZ:@:UZ@67;+@D,S=$,PS.?&,Z]8%F>92F.]>!M/+['
MQ8]O-,</R"W5:O/R6&_L2_/H1/>&WH*!^2=VKO4.$U++"@*'JB8A)O%"/W(#
MW[5<WPDHB0AYPDY^_F%PF+T^7+26_Z1D$;^U@9+38D+AXSN:/ RK PK,5)X_
M.'WV!-?!B(;3A%Y%K?:XYS\9,B55:]SBM"SSV)^6-+S)/F<Y(%YZ!M8[?$B+
MCP^_T>PV)Y-1')SFE-S ]CXF6?"C.;7-KR&&Y<-3=(IZE*BV:>NV;1BF"8 W
MT6UA$T>U=4\+@B.% O F2&#Y%.A6[$WQ'Y3;^F4 J%N W4#Q24%#)</)4E0Y
M*D;Q1"FS(P7VP.ZE^B9.[[(XH H!&B"%$F5)DMT7[Q=H?QFMBXE]V(N75RO#
M[\2Q^'OPN$\?[61_I@8Z^M"1L^V&MK[RAEY:"7C2->HM/+H?<Y;8N+SSA7%Y
M<E+><O?YX0S90F$EQY-M"#EM!<C)9@%/ 9)-/$-]XQ,H0*#8!TS;G-&R5\'0
M9_7UWZA]QJJ9FR^XR5YD#[%0DC-TK-X@7C??K_!M2>3L<&:='.;4$M<W;8^X
MCA::F@G_\[U(M0+;"AU+\]5(?\)<?I6I):8#5JDVT-7%%E&/1G%WEPKPQ)@@
M200])P+;]6W'U@*J8IZ?X4:F;P744+4P\KQ0Z^/H'A/+-' ,Y)JI#+LC@EXH
M:?LB-E?3S ZS7&4-RC0HM6W=H89K L:'H6=$3J ;EFH:CF$+!VC?Q)-W=*(9
M T/=UH1'64C50\RT]-"P_,@T2:":9NCYKN92W?$LT[6BB/1R=+"E F;B[-%M
MC7L[&&'RB VFZ4.][])D<<I[Z_*X52Q<\ :<*LRFZ-#';2VWF0]I2N4V(' P
MC&NC(-QK,R[MZ,0T!U9',XS'&=<6;OZ5D\8E%4LJ/I!ILY:^X;39WE&Q3)22
M0)! D$"00-AAHN-<NE([]7'V\U63'X6L-=&:FV1%C+]^G].$8.Y:DWV$@KCU
M*R%VU.8GQ <A,RV7_V0AYOY*29:V.0N+]G]QNRP!S#'"R ],HKFA;UJ:1FCD
M^(&O4=6$C^S@?S3=.:I^-:H'84S(+3WV<TI^'),(COB>)/?DH3CZ=38'+4ZK
M+9DZ]\K. VTI:*)H9Z#A2@!H*AE/A7P/^CC-\2G8$^G-7I11CLK>OSQ]1W!#
M-RQ++XL45-\ ZXH__TI62@1^(11=R%M@*'KZ[1__I7P]_W1Q=OI%.;OZ_NWJ
M^^G-Q=5E[S=^>75S?JW<7,&F+Z^OOEQ\.KTY_Z1\OK@\O3R[@+-<W\ '7\\O
M;ZZ58W8E+)NTBQZ?8E]]3>Q>#A=%5X<*5^D7_[OK!.&I7] _IH :YW=(!8OI
MO98QG]ZKJIYE^T:@6A$0F6YX+OQ3BU1?LTUB!-I\>N_UWSY>G__GW^!RE?/?
M\8I7SLE=>DU=U]N9K_OT7N?.YD:A[A'JN;:&KFG?I XEMF.8Q(N,R%\JN5X7
MC<Y_TF#*LZ&!H^4TC$OE]#:G= R7NAWP]K$LXBI5/E,_GY+\0=&< 99!& .6
M#7Z6C6$_#PKC>314XK3,%") ,U"N 5QY7#ZPM*_?X/<DA3]JB"GO< WLVZ&K
M'^;!R3[6/OPRP/PQ_#T99^GMS%O?D4(!0SO/[FG^"WOF=/+P4SD;Q2E1_I(E
M:&?#P_ED.+-;UBC$^5 H]Z,L21Z.L_L4MEX B<9AC&?$=6_Y;K,<-H K?XW#
M,S)1/H,<Q%4O?E=N<K@4]BPH'6DY]QQL(0UBDK0> Q"-E23#^Z/Y71S0:FW<
M6T)1P!;*A.0 (FQ:1P&4;%YK&6-/I(S]W^'A8MD-WM <$BB3/+N+0XJ%!CG
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M\1V'';I?)SDZ_5AK'H(N6G9PEFD=",<WSI3-V<OJNVT0!_TJ-;8%),\12!C
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M6CQGC*\$] J _BW+POLXE7#>,9S_3I(0UI!PWC&<3],PEVQC]VR#Y@3^>I"
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MZ_'$MY%H@"'<LSBG*P*I$.CST@\8:_>X_2'O"A@FMW!4TB=SAQH'-O  C*:
MLA<"XK# UQQ:78[[)T]-0KFTY-E?A9_<X0?OV*]'5QZ/IIQQYPXYGJ.5]&@.
MC'JZ1$3K;2!<JPQRZ2G18:42'@$G.PWGP1=W+)2R_"E!Z4%W)QWP:GUIH2L5
M^?=K968A9"UE*A6DJ6+6<*UA/ [ J,%= ;X@L!&4$\"R&/# NU/,'I1C$(4<
MT#KD8V3RJ:7"G8E -%"8(:8!Z-XQ<#"X>)+%#H!W'B&V2X3%QTY_^<SLB50?
MY+O&(!PQGJ#%2$.>BWM1D!TN9[*Y(%ANM5E#42CDW#GK'BE#67H #XF.-A"1
M+[P&*.FA1[P8 5FV$@HT@?>6(3^!DB;H 4H<L3/?"=BU-!AD=9MP1*J5J2.D
M F=8'5^<H4$  O96I&P!#QU3O,MV9ZXR'Z=H,O![L'ZD'2>/I(S^J8[@23-_
MCZ7%18#ZS:F+O".X=^T_MR\R!DU+L^Y*>0'LJ VJ)$9.-4;Z+N(S!7TCJ<8,
MCE/6JO3BLJ<OT\N0!=##L)6,3<X+G!ZLZ4O0%%74M2-]+#FPY6UJ;9#"NRO<
M%IG[H!BY#9)0F1GJ$=B5-C.D#OT;F*?:,]N"MR=A"(MZ<XM)O0?7HK-(FZ42
MAHWRQE/>7!VR!;8(!(*J>3%JV^[L)U&T>CC(BM^')(!_;8#>Z3FP(-B=5\,M
MT0;M2=$&&"2IT2+)08;Y$24L]@54##0_Q RN#6_R4YJ!0&8$63:H0[EQ+(0,
M<DN,4,?,@N_ E<-X?I1S1"VX0V92M^:I<E]<RM;X*9$\DEX7%<L J>]&4KY_
M=D-0,KZ@[G(>>;C/<Q\>Q]03[8E"LP[_E/+E>PILY!0BL,[":0J1N<HKR(4,
M0/CG-Y?1'6J-V6:0<'C.6L%5X>!G;@3:R7 *QX<M795\B#DC'+]_!1(8GCYR
M_2,,<M^JZ%FJN<IKN%+)*)B.C6YJ>0KT(>0@(0]T+69QGO(75*.%[>6/JGT8
M3]S6+X$7_\F^)B/04V,!U_]5H+_/_HZ7="7%[Z^)-Y=6/VPNTQY;C<H-7>#M
MX?;5SG3Z2QX  7% _.2_KRY^SMX$3+B+6@JJW\I0K[JZ])J4L9LJZ4I*M!=W
M1JX8Z2Q<D@\EP4;&P T^#2!,T$\JN3KZHQN9]FQ)YTUVF?GX6L_*T091(^FS
M<50F5:MJ 0S/ 2=NY=; KRYE @4IA@2RB"=\1ME!2!GXOF04B7\GDHA+H<'^
MFH#ZXQ,[ RU2XE'.5V]EXB]BJ9=-00!_*3,K&;%ZX'29+=ENK3I=WA/L!_Y1
M9B,NS8=;>I(B"I&VJ;B+QL\<S(\E%RPEKE6"[C>P)B:@_8?OV-?_^0IJ,,AL
M-%O04?0Y\1WT_^#>050[\+*OP!+9642);^<9M[P)"0E30C#)*&DR2LLDH]1@
M+R89I<[)**1[$D^;\+RUDF=A%?(*(X:A=O/+>&2>2>:M\@+3OTYF:,2 ,C;/
M+08??A3Q!$F1?1: ..@)# 6^$4R_51RX@MG*U."B]UEG":?&4,J1B7WJ /@#
M0IH<#CE=,-M#>LXJP9*^HD+]N0KN8>?#))YD7JUT%S(CL7BZ?"BU?"=JUPLO
M+H)O*D0L=^R(,2AXVI''<P$0L@-BW D] X<<2=7W^NR47HUQV=^&UY^&_Q?@
M'=C?5:,B5.=7!&USZ%$=M,W,F4I3AEZ]5$&H3N5=&NQ=L&Z4CR#*A\#\U+L[
M0JA&^VD42T^1:T^X\-C/F TSB6L06QCTEAO#3>D8S8V'K+9[]6G*=IQ*W$BI
MMYB*)(,1J@U7S"YG<9!+<--Y1Q(?RS'6$/MU46*;-'Y4I%<Z(6VP3="BL^#/
M8&#(9'RJ)."W?H!N7\33.>7N<U1D[<!W7!4%^:QBKKV\871L:2MUX1B%:&)V
M&I6V8T_=3&L<DXU.3%VZTF#E)L*FVE&GL]-RF4FI%[>0QF<M7@)N<]ERA99G
MM/@9$#&HNEGHGOSZ%*^1\5^R_/6Z^7AO<9VACD)<*8\Y0F(8(B I?7)!WT_W
MG.8M2M=C&HYQ<RQ(NMR5CUD&:!XJ%EB("SF@]T<4"? =\M=G5Q>EP)FFA\J8
M&8FEM%P'&=A(!6M3<>?D"FXPG@JPR0+MI5J=6S W$A2A67@WLY[D-5WDW#+5
MX=X+U_=%%,1\50J/AO"#XN!!6B^S_O6A:F4@M30YZ[/E0+R_;/\TY.XMN[Z'
MLW-O^SR_WU[.\U4*H=KKLCJB5,8#@6L93[5A*BOYB()4FBYSX0!\*LO3B4H!
M!)F>0K&"7Y:YFXZI"@LH(9I')5_(@IC <BO,!YG*S)<$TS]D:#3*6?.TUQ5A
MC?6R=<AUTCHYZ>&2*I!Q[7J(X__MXQ54;3"7*P3202AWCDXUT3LE!?RBL"?)
M'<(TI71UEG,6+]D+(JO&[7,2J,ICI?%7702)SZH+R+*?=:[8RL36JARJ(K+D
M,EM+N5&EH)7,3E]Y5^QSX'G!?3FY/%K(&%=)^*BV%(]?1HUJ34,C4=5I5<Y(
M[EC*2 (PC BV"AY$LEFV.!$ZB30-_E+:N<H+QEUAOG?@N0X*1#2N"A"U"MGE
MF/X6Q2!O0AFILT7J M4_AV)&YF41W/<55FPY-9_4G"R@[U&V5R'Q/9^#G:]J
M79Z/O;_TEB&G#!H44+*<2:\14IGS*MEE:96$3"<2=^2E2*4")E':7D*:X?#F
M.M-7AZ=G7[Y(FQF4Q;DO2F2LLVUP;[F40R<7G<$O9\$VG2"A6;].@\B>D(8
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MMIZVDJ'F,2HQZ") 94%56GQ&KQ;\NNAQ&\+N@#O)GC3#V<Q#*5RJDZ"K_!J
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MFKZ-@[C@#WHV$4#E%NV\T$)NZKOV_PLYX6'F ;%4!V)/W'$YTG(LI[SK@6?
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MGJ*U$1R4N[Y8EGV.HSBHAXL<WXZCV_5D+?I^,;E-E8SF"[NQL7DZOZNZ.AL
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M*QE !F/J=+9.=[!UC'DFOEHW2=(_/,/DAH><78OIR!@DNZQ>=KJ;>-B,07+
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M=1$\.P VXTK:L!RPW;;Z_6/C2GH!5Y+Q)!E/TJO KF7RDHPGR7B2S!JU7.-
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MA%&+U$;OD6K\8H9$19:L'TC30"O*2;I*&'ZG +6:400SZB5P6L4JFNA[>8L
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M7&M(&NP)[J0;HI=N';'//<(3LQWX6)KGM@,_;WG6$/[I!CWG\_\#4$L#!!0
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M$U)U5I\J[5T&^]>&4F?.X>^M,9Z;D\%D:LST^1!^/8*V$B A9>=5E.U!M<E
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MB\^=@L5'N8 *1!X&QAP6KZX=1HM3*[%6[*&M \M8YU\\HTETM4\?[P]@Q2M
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M7<6#@Z\X3V-Z9'?;KSMH_/[>R&EC8\H,?.@",YKDA2;5$O9>.%2.RVL>R^K
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M>DZ'3>%GQ8B'C-?;,KY$L^;OY\57_QFG%A'M&!8OY'PCZ$5O/$V>$^_1II6
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M535T8*2>?X:QG\Z627S%819;5]0+Q8TDQK(2S]:)>)$]H5PQ)WGVQM0V35?
M."@FM!5S!_;H&4R/_>03<O1+'U?I5]]^FP#:S+=(C^*T_P4ECAREU/D<@R1:
M1T$D_E2RHS0)'HP,EJ-9E6K;*(W1'11/.E)*!T9M@7DT3.4_Q8+[@I(H01N$
M/QY_0Z3S4WG-I$=XN+JA,(BT$HAG$(D(-K.R\H&LO90T G90I*FOBHHICO/3
M>XC7XQEM/\#'_J08Y.D,OL[.+R>]3#DDRSP!4\YRH\XD",H)6HI*<.6C-:I9
M>L1CPQR$RBM+LX/\PC*_\WR,D/K3-S[V!^C<O?-_]*^NKUZ-QN/15R3DL?^,
MOYE^Z_'DK<Y2DY@A$XD(B7<"'7/&M H #!WWRLO#)O@.@C*=*Z:#_,'7$*:G
MP\ET/+LSCFCAZ&IT/9SVP-%D =DL3$GS*=%<:_''1 -%KUZ5+;$R8=9A.2AR
M5!%XQ;2Z[P&]@BE.9UFON,=]@$&I'G \FDS/KHNTSO/[T:0_SWX=]*_ZP_+K
M>8H@?HTXF5[*RG.&AC5(=+-DEH98(0+14EMMO%?>UCY@J0#[H.BU:S56S/";
M[[@HD+<ENRWX^/O[ZW'\A-\??1S#[.2RYVVTS"I#=$@:H2E'/#KQQ!@6LDZ9
M*R6;&3"/CG,0E*@MSRZ2^VYG?3Z>1Z??P?33"/VP$L(!N".+5]\>_O'-G\W3
M6R10W#U])BKFLH"F2%P0C"C<6)T$S9.KGA97$?_.DLFZ6WSVILYGDY:V2K:S
M] ICDLLN!)*XX42ZY(CC%L7J @0&1F?:'3F7P.PM'6UO]%C+TS9JZN(&]W<X
M9_X*O[T<^^'$QZ*=Q7%=$X0=9;4]C6Y/*6YUU+E,DFYTL2?6A"PME'<DENI<
MBE%B0Q*(5#+/@N;HAAX(6Y[*@ML;63900462S*W 3S#(\Q#6>';5:W%$'[2Q
M2F:T_"0O>5N<$L\5)]%'JT443 O>S)Q>/< >[.C*BAA5EF+%@\49IJ/IY2=X
MY\>_P_=0TR()*S+*K0(2N"X)G:[4[2M;938:YQM\8KJ1;M<.<5C:K2/)+A)9
M[P429TM5P*F(XIP;%\I1=H[$E_!S#H(S8]%E9[53F1ZB^.'-R):*Z>*H\!ZB
MQ1O1!%-'%N,J//NQ$=OJZE'5MQ!TY^O% INBD*T#3WR*:-((R8EEBI%,,\0
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M^]2V(;0#(U 7"NDT%-BLX^G<GW8L9V=LP9M*JD)"$2DT%R(507'(R748\=L
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M7<S61EHZW98[2B:ADRRL)%RY60B%(VMK>QF/ 3IT<["^5KJX,;,XA%Q8+ W
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M4L&3\SQ#.)E<ER3JX]%D.NG%F(T*T:!MELK]2A-PBZ24E*QI%Z4TX&J[PH_
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MI/'P@M5=+LD:% KJK!"E@#-0(.M5YN^M^99NA@4 >WU.$HD^..W,]-:QU2M
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M0#>D9SR.)T6IR(S*"S*M5DHIH4R:^DWR*=O/D7;@H^*N.\9$9R=1S@_M!DE
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M>>'&Q:,_>4DO-JLHQ<@9>M_@*F0!^ 91>7@Q&N\"EP]06%>_/_S=^DE0, N
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MVNB1V7=NK4'<2.ZZYF<;:>",GT(_-ZF6[$ *(533SR+X*O822):KX&4U84W
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MB7-\%VK]*Z- \7G<IP<IYXPCYW#2WGV#8D#+*H) A$.!517-IM/$OR^DZ "
M%KECL=:$>(P11;CYW]UI&>-SPAG$][P1Q_^0X5BF8;:^V1%A U=\+SM\_T3@
MV9 +"60/@)-C:"(L(C\,X;BR,H1G#VV#9,]_*='N;$6G*[-5 3R+SO7A3W]
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M:&L*&MYC =B((N/12MTO(XT;M37_I_T;P#[8!Q9@VZ3>AGV#( SC-+%GS)
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M(U&5+&\[%.('_/%]MI;<A=?S&S^P:,8>J8[1],M:)I\[ZHA]WE(!88?WFD-
M+XBU<K9=ELMUMW-QE,^CA=S\"^:9%8]2X>^IW:3G> NZ!/AX\;D4K:3);[2G
M/U9!+[?'F)2FCD(1XNW'GD6>!1)O=(3,C%]R?LT=VWUV"GA:C,M^ML(,@S*E
MY I_2%?BU?QK+QY#7&;+U__%WGM&-;FV6Z-15"PH%I B$A4!I8@T 2D178"(
M&)$2BA 5 0$1$.DD49$B+0("4B321&JD(RWT(FBDA@ZA=Q)*2,])7+NN]UW[
MO-\XXXRQ?WP_;GXP(,^3NUQSSJO=GBE_&]@(@?>P  <0>-ENWM"M=L5\1R+J
MJFK;#W? #,/"5ZSOL4=+P"OH9WZBP*K0)$RE011DURL>83711BJQ3SEE+Z-]
M_\7!F^?]GLN_5*2XGK0S"F3^RLK:BMED;P;L^AJ\J(%2DRNWLE0U8HZYE$>O
M6VN+YXBN-.I+C@O:+"1D2WWBA+.9G]G' ZFD)6V1)YI@CP5 A^37/0,PF"E-
MG PT#-'^1C0PX!_(5HIT"JM)-MGS&*C[C)=6N7VN-B);SC?UDNJ+E0IX.")Q
MVIX2]IWPO%G9NWC;']J^C0T>WUU"=L>K&XKV'EG2Z'Q+[.H]J@+JC=@U")#.
M30]COLRZQ7>Q-4[Y2<$Q^JIEZ7)?G&741FPU>ZK,/I_]E_"+G[^EV<QK ZL8
MFO;V4'4%6^;'4N[5EME._!&P2;/VF5Y)LOF(M_)N3OC#>NP!^W@HGS^'RMN-
MF-Q=9UF8, 6*$"?.1WI:N^SLJ7Q/N3#1<)S^!;/3#HQR3D+/CTZ?9J1%?K0C
MK-2>G(!SO&-RXO4(^TG'7\[C8]1:YFH=)XLSS/^5S3SM AE(\VA5$68T^Y;U
M&!][[-9;>0;F53B]<BN)\.O044"'!@]D?&)?P!&-780=P]Y4S80>N>%GF[@?
M;@>X&=U!',<.CM#*M?QA]I[!6#8:FSV-;B>/2W5I9;U\D<Y82@JH8@H'_)QC
MGZ@19./O3+F:!-)G<CV&B[F?'-X<_;UH*5BN:#%LL-/:("[BU83KC[.BH<X#
M>1OKS(,NQ%CF<>S;8<3+%?NQ;)]G<E=6+N+7Q>^ZP;ST2GFOKTG_JL<SBVSD
M_66A:6UA!2N.:K)4 <3D!Q9 V.H:^6V^#[=QE:WCE+A*O+VNI$!1X?WG?C4/
M9K8EQ$\O;XUC !J24Y$W&K0N] 1H9]UVV9956%*O]N5VT.517%)0.]W&3T,3
ML&U5B!9@")4[7*E\7Z=9J4'<_9G6YH?3DOWF"BA/Y85Y0?BML.)A:&);_,!<
MX.<=/?;6A&!%ZSD!DJ8 >X(JD05H&C.X<W-G0A?C6-H&5=YUAG<G&,+<"]WS
MSN2=[O[).8S!,AX[?*H>0PBBZ]8^.7<Q>PFZ6$X6V=TV;[3UE#C(C^XB-^WR
M:3JUMZ**!="CPMJ6- 0^6!K7_UA?U]N&QM*P"FS<V9C>=BM,P+=%B!. D2\*
M7%3X*M[[MF/:3@048G8Z0%'22>EE6?=,G'3S3R=Y0\6D2O&6*3DFD'MF\ B&
M=$5EV,;X1;R[C,*G%YXS"M'O$%+Q-0XD:R*6?GY\%_-[JB&N2G&_FL:'.[<=
M"$UR]#V0$LB6&3>_R#-AP5 7<1;@2-UMIG/;0\E7S7U-8)_J@"I0$D?)KZG^
M7TC]'R&5\TED?U(8 4P_BSF.MA$DF2\A%K\^<#MT8DYNDJ*ZLA]]&5T"<N+(
MS$9#PG:9JMB$?X9:I:#(ASM[ @F[K)B[H$*X2?J-5]0H+2?IL82:.G_&S_DM
MWB.V3$R"=@>M>P?:Z5IKSGX.)6.QL6Z,D1+@S#'935:J=K$P4CR\Y0I8W 2^
MBEF/X-F1<IZ2(@&'$&RXBZ#_87W%\8J%\P'2(U[MRQVA#(\X3F5X'V%<?<F'
MG /R@B]35LDHR>9!7K1=K[O-EN;LQ@2!P5NRD![&^$7GN9">7ED9]G/<8LZ=
M3_ZLM]>DU*L8A!2D/-]_ 9F,<5X7=C&4;AS8@*UO+7_25#/O8P&FYT6_.\]9
M+M2=]2D&B_CTF@W,C)Y<>O3(;*D(&2= N"O]$3U?,W&*;=ARK%W\Y70J**CN
M;UK<-'6N.X'C.#@:PH1R=DN;YB=T#N@Q:"\LP:"/;J3A$S-;U^9DCNA4/E/-
M^VA$CP[ =?D]0VD5?+$<'$Z+GYLS#3X/;.ZZQK7)9HB3+,!A*S*HD6H?[H*4
M^KD7Z28X/F91E_46% G#'7@ JY.=>ESZ&2/  NQFSP9!XV$4M>[PPT>,)23!
MBK$V\;:$??I7'*;2_@?#OX\[JL;6;E*.!^H,6:7E>5+$N.?BL <#1U&=L<-U
MNX@JH>@:"[3-$C6BSF5V-%CO65.WWB<N .\UZ5[0D_4P%.$C.8,FU6@]+!&_
M$OK=)_494K(2Z DK1H35O,;P3=T?628C'^HSUX#A2VPVQ0+L86"#-I K=)6*
M7(POJ.$%-(]MLCEA'D?2[]>T22:<F'I+=I^:,<C9W^VY^^O8:Y^(^=D$YFY]
M;)%6_YP)Q$S@A#&WI?*B^BTY*NWG?;.3J0IO"-MQT^*NR[\8E\PL^"UNLJF5
M=ONYCS:':)?H)FP9'?X'^X>54<+5J)3$,F^-3L"T:[\J\+:?\$XN,[#>UG%.
MT&?JX@H+P-T/_&D1O.^S]=M4X<)EHC6PZ[^G=_Y/0[H5X20GPCX7BI/ E2_G
M1_SSBP(#V]^PF9D(F^[71_HK!T@3-]N A!2Z'B9)2*/S$'!+^K[HP33U#XB:
MEBB8_"+T8G,E"Y#S0%P0XP=?8D#'*"AH(P6!*]G_G0UEZR";\'5ZXKP2FXP)
MPS<X0M[/=65S$DHVU!*S4"(*]&Y-;(U$1!TPWKA(+5==XX*,>LZ 2N1>(? G
MR/ZGZ<05S,#^JH#M8[;'Y&8,$/7+N+R=.Z?J&0:[!,37P>.(=!KF%.H5\<K#
M[97&6W)C(55U5A@,@6,2J+&< .2G(P93F&8#WC<3A^DWIA@&AYTSAS7;XJU<
MDR5O3G,7>4MEC 7!^<C(9H%Q&>*^[((EC[*?65]&.[P]%#U]3X?+TSO0&-!D
M#E#(JP7/ @1;!M#KE&%WSZY^'VEU7Y]3,UX40F.OTFYG\*XLT" U&+$YCX.C
MVVHG.S</,MC,]O7] 'N:63(Z0+%/LBL^<VG8W)8%D!D,2I7?>A3%37OF#YDW
M]4+M94K8!)PF9^$Q@A;[O'O6!O0?&@<J2<[&:[  9:>NTAR4%VTOLP 6:5(P
M/[\4'[^ZUES4C1UX6$;Z\DGXV>X59>NKGE6]ZP735>6IH.KSS]*B0XKV"-="
M4U"/?P?89D"EV%<8O S97Y9^;+VNNZ/J.K>$S"-3JNUA3M\KFR]S;R^=]<G4
MB5&YEY^OL%_CJ([[].6OK0_G0U)[S-CZ;L/AV2%^C2,2@A]<!1";4.4T2K:.
M)X*O1D#R98!G[I-9\-!T+*P$.!54]UAM_:4;K*'P'B9E^=['@S%9R@X"#AN@
MK"?]07[N>8;C"G^&N:*+%B8 =+;:V:_2['_@<VSGUSH6X'I5QZ1T=!F2EL\W
MWZM5MF,*=\"- [D"/-F6=KVI]NH&9%-N-63HTH:OPAF@/ O@>ZNB+XD!"B12
MP7M5&+-4= =C?O:^8\(RSPN!'3LJZ >L[1/[651WRH-_3[:@+/\5+!?K_NJ3
MA?[P0>^$I:(W0=E?,6M;[).!.<^>18_3>FEP[,2&>0T;L*PS68!N,-0;T@@J
MV:''RQU&X!Q!6\:XL7X:]SX6H))MAT_1H\G84PA,+]O(T0?9[[&3/?^W!LW<
MAKW2T<!F$.G(-_8G&UJ5!4UC*<?H-UB !\LH!E]_L!A9<0L1W1W"5-*$S,&]
MV)]'[T'<_9V*I@?_*V#^LVCG?!-P0RJ+!7!%+-ZFGPC#S+A"F&,L0,_=_PQO
M'+6Q;$$X*Y<U'GB0**PF]BPB\T'@]CZ,9@T"KQ; .RUK]4>"Y$HL?R22J M_
M[-IR$Q0)#X5TL;?HSFO,#/]4'EN(+K8N?*&6/D40B:@=G0"]DP_@18'FH6@_
MU,P. S@.F^>>9A9$^OB"O++GRAF0T0 LV])/2ZZ^NC<\9F#G>;CYR*-4@>.Z
MR_WF(J]!PF%ACB,FPII"5""!!6AQ]YENJ+I3<9)[>/+P.?0?[]B,+' WZ.""
M\YSK$'?KQ 8_H: 9M45S.D"5"0,1FY [D3!%Z*]$717:C;UW,%86U (6H(OI
M_O.RW*4VDZ:M6EQ&/^(=!,GL'>=D&$'Q?4D!"D]K!X KN;MF_E![SY / JWC
MOD*:$:7(2 3^$CG.>P^XJDT?^"C\]"&NQ%/+U6(+Z35KY]M@!KO$!=;!8U!-
M%H"K!Y_"C2L15)/S$MVDN)"9 AJ<*N1&[,1O]O:4$:?!!KT#W%&S PY(S\](
MT>U1!9[U.'"[J^NCO;"W-BXT$%F&+(<O_"C2O5+'/A.&E>T->^N'LQ=>Z6IZ
MV,1":]V8W$NJ^W4-QA-J.&%5,<IF:!$+,"ST9EY@K6V,DQW-V6M;#C_^-D;E
M@UF]2#1F'L4<1CQRW'09\/Q#R@+\8\]I(4;X\PSF'G_(%Y^2EI-:APFKI)(O
M=9U6-SNCQ[ ZVFMM )CS)%#(IYS6)BI>-U"V[T=+[\P9D(R3JHEH_0-X[?(4
M.?D*-0JXM(5:ER1?0L\74TA:TT'%"/245I$IG(VD"VS3G.!QDCTA+<C1/RDM
MKE]#,G>AZE)<[KBEQA7AI.KA+C]5X\"M%5V_UX<?F_X\_GE5V8'IEWY6M>_^
M+V_H; :=K7V^R/00)D)= R0+AYR&7]09SF:^OCE2M,W==^R=7IKRSOI+NIW=
M]/HA\V4OR:?>AS:;[]R^=T2(MQ+TH6$=FLJ_/%&":@&3K]&-&<D(>>L3Q@]B
M3H)D%%_H:X80*LIY";A!PH#+-H]>$1O^O$$-6X@,-M('0/CL@,."KJ[Z\ U@
MV!*&34'WT&YQU!AOT[_2:I,71)Z=1I.OU9U>4HD&)2">:W4X!K9'-U!":+E"
M=9\@#=NKB#*]*!#^'+'+3[9Z#JL'EOWJXSBR%SMY!5UTV.8B-(1X17WYP_Q^
MC%=J. X]G=W.F [:X,"NF)J<7W8-XZI<-91C6C?T!O=Z(@X%"$@B:SRS%O#@
MH9E86"<O/@CNH+;Z[K)F>^&]N@)&C 8O _5IPB=]2@,,;QT?_#IS/61.C#$O
MR''&?(N91)3*?TW'55=O0><KN@@E74TT%:Y[Q?#-'BTTO8(BR@+PZ+L>U!&6
M<4\/,C5Z"9@$2-VZ@%XXC)R_EAYV\:49'%,X2(9>[_.,O.-9UEM*\[VTYO L
MNCG,8I !D"B5G@:1+R:T@LDWZDZ:DT4;84FHM[-CS_GH'0['>,:G_5>@;L4'
M%YJZ?<**/E=]&/CRI=<#QOL3$0$\+E<G%W";*!"^?;A3*\^K]_Q3CYEF+?,,
M;+KN%PQ!>.9".D8_PN1<>KE>2_G,R$,=/M/]C#ML$';DM.5Z,X$7Q[U>S]Y4
MAAZZ=?+T_)R_FOX3:JJ7JN=T.L6V%A8.?3M1#&[5)0.)G==P]JB.[C4H3=VD
MHY$1?X]+GJ1[0))1@A[>?K D=%-*5_OTX0 )QQ"2\FA\#XZ.S:DW([W/W[$\
M\ILY<Q*2N>:QPQ/U$\.6AY%O5Z>[2#RR:S=//_38B&4NL[4LE_)&'/R=\[!X
MQ5LE@]5+1&\KF^N_;G+?O\PIP->*HTQ/&>Z;;Z0RTS)M+EUZ.O\$&L$5^+)I
M,.+8BO/&D4OU_B*WW=TLP0A3IO.&P\KHZ0_^ 3)?8_UZ1[I9@%AZ=S+;J-:C
MTO;Z0U?0TTBR7H"'1+@;N63@1.?]U).>'3?(D9UKMW!A)@.06$?<.^N1F[]&
MM<]UBH2YF;Z?.;9U!@+GYI=A@WTH+('L"55RLR6XM^&='F:3$J:[Z8E44QV/
M\5W$IUJJ!'A"0<,KTA?M:+[YQX&<FGS^7[@MTZO1!?O[ JN<EN<0RB;94HIQ
M:GE**PP.S*1]^/\'@X& Q^;,RSY/BNHW1^$2*ES;RCLP.*8!LV8*:J.*$3D8
M",]F[J5\9:_..A+[M^?TK\'/"N=D<K0["1J2>B$9&6M0];#Z)?C](#\VU"OC
M"@W4OM@DC7MMC9N#^W:ST;@/ 0[Z&S1>'^P'DY!A=U0W"EH10M)+P@QL,&C&
MU( YSFG709;D1[2/HQG5+$#F)_8;+B%C?JOJ>3H,;U[C/LF _)'PA'9?W"@Y
M_:::+EV0BPS1UG&XE^+4:#)7F%1"X<07%"-OJBNMU1I1<KR=E2/[!G#'/A2>
M]8JZ.9+[5?4,8_^7O$$6X$_UJTS<O_2NK1QK#M8X>GE/TV[M;9 TFU2W25-Z
M3P?%'SJAH<$I+ ]&*"$,'KB[MSUTG'I8&L>$03HX/DRWCVW:D[PG#2810HY7
M1RU CS\HA8'"%#>JF%(WZ<Y;4@-+TLOFS\ZXGU?X%'W:3R'ZG5X?9*X ]I$F
M1QYA'G<->?OYA\3RV&EFUW/?RRD?L),*&,)!AD @<33.(3"VQQ)MBAG'B&W:
M*-73;EUN;7$^#<P864,DCM"-B#%DWOJD\I+* U/A=I4:<_84XRCZ._!790KE
M?*1,Q%K+6)3%AYD8_R2J)*F&F#U<9JC82-JP5S>EV?WB1LJ_.I:S<RB6?>SX
M-[-\1TVCJ#]5!EM^-\I@"+1OD?6XMN_S5L3LY#IO6,'1G!!D@ 4);YW=L+X7
M)1IPO>=%FR'I$;C4VOW=V3OF0/2A[8?WK6%0FAA9FJ;>5,$43]4P_ (:6NT0
M";U+;X9!Q9@ Z;&.RR!HV_58FZ5^JMSFR)R/T!J(!MIU+Q>^V>V'V9B8@>WB
MI"YR/*"@CZ__OC]S!POPQ#4,04#77'BZ8C]2Z'3+-M"1DH;,Z%S1TU[S&,1)
MR/&#N:^;AZ%OL@!FE(\?-,3O>_H\7$#[@:D(L1:$(YHM=>/);WS\[R1[Q6:U
M_Y&?/9LZG0;2F=7[9KMH(Z9G*4U9/QV1@VPV. ;Q)E\*GT'H3KJ9%-,U+O>5
M(Z>H& ZD-'H'>:/VP84[B8JM=RVN5BUZD9.H=M/' AL#&7,:O,VDPG,# \[+
M7UQ6IQVS$YO=6P-ENNX N/J2:$V3$TWF<"&?JX=.'AS^V"I1EX@(NZZU !HS
MJJ>#_=ADX3NFM B2Q!A5AL,2L!M:D- 2UY4:\1S,./@FQ1LAUU5!/('_B9K&
M[L'B-T6\&HZ>DC1M'&G/V'_M=/51]1/0O4[#IN,A.=:..[_*:F=+(_F*5$P?
MN#EOQ=>Y,G+K3C)RQP+LLF\DIATZ^2E4:^.%!>(('\UE2YE$-W[/>(3$74#[
MG:*T,;EG/?"J8%4?)Q;@7CYCJ%:#39.Y-XLV&'Q&T'? XM_'^C'\!X(?A%<B
MX$@2:5=6'0RNI7V@]S9T0T?1!Q&3DK7^.G!/'[D6W/@^HFQ467;=2+A#QW6W
MXK/XZ-K0=H;S^OH!<FI;JXUHT8#2HD:GU9<F=&YJ$+A2C7L16DKXZ;*] NI?
MPHS?8&OW3H>--3BP14VO3QYHGHEA4Y!MJ"8.6X1F6_5AX)&_RZ+\+?2P/K26
MKV1@ _5SA1;OT$,))=O(#5%.R33D!E2.B4M5VWQ6NG[02G^C>>_LH#%=[YPR
M2/M;$;,GB5@2\+R38(S&V2V16 #%D8ZOO IMQFDD;W@X8H."NCH^;OAE'.SM
M(6;HKA$I$R/?86\; ^Z+O=NM@]"Z,E(-RCBN;\&)B=HG!&^=0O$Y4^'1]M^^
MU7Q\>$=AWYU#P <*X*_H7ZO<?Y03QM_:9@T5CCBKFNUO6 X2[-C1! _4V3.B
M WA)/VPY[6X0U27[!OJB&Z)#?C:-7N1B[G->2F($OG$3;3I(-+;$NNHP7;=
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MK>_GAVS=X#C'5N[XF8\90U;/.6=V_2H1.)Q7/T%XYR,A^VQ,Q>;)FL57M2?
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MGH_ZW4DYW/9EM^G31+W@]0"QJ4.K0"-D9W7IN];I$F\>3>T]QU9T[' X8)E
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M?<S3(2&$)YY/%POI,^#M_,Z_:<U/R9MZVL\"=$[0XT$S\-1*Z 7HQCP+()%
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MTIA NH'G+SHI'7,=\9=_4$(T?B5X,PY: IF''K+IK3-P6_$8"P!*&/V!P06
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M1;L&;]G^*%%K<CC7U!RY]'I+5 (;N[ASXLRE,^&A]'06Z%40LZT/S$9WM9W
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M5=GX&52'XS\!(M>QP'>/Q<'6GEN? 3I@/<D"Z2Q++19R;IDG!W?80%#[-J\
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M .Q 1%W DPI,-R9E\X.Y:FTTRAKSK_'R@!4P]=(&+&HM%A<B:XHH^3V"?Q]
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MZP!:A$+^Q)BR+W$;5T:08UFSNQ"S698*W:W@D6)K!H#\PTAJ F3<BHIE!D4
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M%,K_N;?-^1*HR"A/OX]?N.ZXVIE ZR?B^RPX<OJ2.@?5>0RXTKV5'*FGF.P
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MA2VKV#:F,_<?\SURD#AH9=V!F+7L_'I4*[FJF*^2J)%@V82V=_R, =&= &Q
MS&L/F"M0N;#<K GU8 :DQ$0/TVN^70[@"U%\$%H+/IM7$Q6'@S<]X YA7D?Y
M33FY&W=5]Y'+R5 J!\V"@BWPCFU]9]YBA$LGS-;C7_R.&,B0%,03BJ!_7+[E
M>1KHU&.G/*L_NA9]]VTFRL$;I4D@M[G+(!-"JACY=Z'OM=]2&H9^?:QYQ1UJ
MKV";@A(IK'1JUQ>DQV O_DZ#(X>!*5#-ZB5=S PGQC(BHB3MSY:8E5^W,*R8
MYJ<N'G-Y$-69CG(Q#!+465GQ2U5<&'LE2R>?@EZ&@_QN]3N21)%VLG=S'4:3
MXA'. ED]ET<?70TMI9SG.@W%U3DMD]>*/C@#.M9F]>HCL8@VXU8A%3*?,_V?
M"OZX4/A';Y6C(0^;^!2+$]ES) B 2?'BIY71J/#WYR^]_5=Y:1C FH<:1>7C
M4YX^MA_CB)^';'@SX^[S^()^]2S^R,=TI=$!E_9XT?1^<C#IA#F:UFU63V4E
M"[9D[_5W?2.;DRN!:(YQI@5(+>M1-U5*O2 8'IA2N^9*X:T6#]7W/H?:'_B?
M=YY1S/K:I1A=Z/E(P=$&,EZ?=90QVF/K.KABRKA"H87B)8DV<]@0TE77!^L1
M;!MF$_DR(!N$7)Q*>D<XN"X=-8=L@X\YSMN01($3SYHE-<7CLM<9WT-13G0]
MC\-C5P6N2O290P^TYCTWS6-L,U_]B-"HBW3*^_XFQE?"<+G<-UZ@TUY,HT'W
MX.M+7RF0-'PV%\$,JJCSF$.<,];X)A6F/WQW!'S1*_(JN*8MD6<0$T5I/#U,
MW,HT(?I$YLK1A%D 8YE'=)RB-L_+%)RKJ$J[$U==]T)PBYKB'9@)'A)FFI@Q
M(KX8#YC6![@_S?[#]9TDNJ="H8W (2E7(1^/$\(=TB=]YJ%U3UM<Q,SOA.WU
M!%ENG>4Z% 7ES++(3F!ET&M>NB> B1+8M,P1WT:-<#I*^/BT=N:YG7,4.J$3
M@)#!/.1XO_0$,/AV_3=UM,,GSAF24V"V/O.FS%HEPUM;Y8=#23<>@^*O9H8^
M;;8\E])"8[9<S_POO^WU.P,[BV?:Y%S@[KM,<-A]7H*J*/956ARQBGD8#N5W
M_D*GO.)N93;6('],^:@R3M;BP<PM&2@^S0:-6FT<UBJ&_WWP^,D)X(=&,^2P
MM_T_3Q[C:2B!XI?A6!D@R3T'WER .JTRT3B+)5T^K3)A!)H;A9QF5#?'.5(N
M4LWOCIB3L>@.2:MVH8XZ8'#[CB&@O=N>4,K1K]-#X8?HC5V\"'&!J1'!0&C6
MJ:@J18W<BE$SKYA>NF5H>G&Z)2U4-HET1+T30]AIA8:/C6@"-U7Z=%0<7R ^
M)#T8IEPAL>+0'_<_;]YU4[C+R9=DS&X3&/9\ZT&\GE#0#5W7I)W="Q]U,2.;
M/GL;'N:4LM_DBDW+P?Q=>@I=X>E<:H(<G $>:XOYI6&6V4FLQA0-]D_HC;.@
MO72C]MLG &^S\*%[E'-'USU(S#84+>]V*IC CR\A1]=(T?]N_=#(!K@-$CB.
MC3\!T"Q+?^.-?WW6/P;\!/(94J'21D1' 3DJ4M__WLXP[ACU_NL\J60BXTHF
MD\$CUZVQU0M^E7Z#:7S)39 RJB:X\7(Z\:[%@$,\NUG.-J>28T,Q*-"/&V.M
MH:3HC?2-?/<[X] 6J;.!'4,?<%00>M.%(DC.8KWH(![ER&;-2L>[&IO94-6^
M$4L&N@]HR2M> !C6&N+7A#V'+$<6PYMH'1W\U0OZ3:?N=&^C>SI!V];5R$!X
M!:8!?9XDB?OY ?6HM(+2.[A9:"1>.F5ER/MBO 66\C%V:KD&27 XW3=\<8?:
MEVQ4#Q1AP,-;)%MH()PK,(B1?3O4-!2@^9.BLF*S&4CDG_;K3=I/W4IV>Y [
M.ZT]?F>K"+!;N'1.D%,5P!P>9WYQEMN_?)3J_U<6 C'-P(A*GAO5U19S6%;5
M2N:F]B6-C&C'FSQ9'>%$$(SN&'300\Y$,9),R&FD9S_>HL3+1J278F96P%7&
MMLV<+]],!W0 % V_N&U!=VW41NY*:1IU:Y?;)^B[9K5HKJXV?J68&]0''WSK
M$0VZ9;B91TQ<'%ULGF=9K9>ALA_\<<(5%;?S7WJYNAE"M1><XZSXSE_]$TJZ
M2]C'_89\/ %PR.O-"2F_DB)BV K&!381*X%E:Y96?2CHH6S3!F1LTB3OJV&&
MX=FTC)O7_2J.%OXVC 8'OAI4P[A)-8R73@UCV_XT_WEBW*XR?,P(5QHZ\[OV
MYT'"<I2!1':?1NI[.3!! -DR4$"2QP/]MZQ[?X>YB]M?34:4]1W^?W9Q_O^M
M78RF-$+HX7/6?@-)+ E7CFIL@AM''5P8IP>N+H8?'Q5RMCL5FIGBF^?Y$6R*
M=SV1K44] VL).QH AWR W"V=O8@7?JS'U"ETOH- G;F7$(W3S]K87VR@\-+8
M+<.$\T8-ALS81(;L_HB?]5U]:P\O,%96]6X?I^F!#@H@,AK8Q:A2T=VJ@R+J
M+/,T \\+RS_#)8-5*H<=].6F:7I>C0Y,EZS\I04($UJ&S*XIFK'OJ>>M&:6F
M15E*+Y&GV!XX%?UQN/OFU<*3M1Y5@"]TR6DLZ9OAK@ZQ-HUL=P_)8X@0) E3
M+PV%48=[U-N9>Y$K;;++(] @GT2Q3>WC:"YEO=!(Q*-'Z_XIC.TM?Y]E\S_>
MCVT&?D*H?LNE=\M>8Z?G]?GPNP,\HOF^IGTS"F?\[->]*=)? XM.JH*],W\\
M3P!V A:$9:J%=#X-]DCWIV+<ARH0R:XF]3D,"ZHG?!.VX*WVQ3:0FLBY:!N?
MOG'TO,Y;,?>)^&BO2W5#CJD/RJ/91/0:%KR_/&DW8^(N5OA(H8W"<ZTW(Z[?
M)0D/(3:VKXYU$@,\B7_16:GPS$O<(_GFM9-8+!=4/J#NFQ N+C1ZDV0W*FEA
M"84,+MGQ')/?=NL-BL9EO5TGZE8.SIP 8JO_<RWH0J^OJ&MA0N>HT3B%)J3:
M]O7@S[T:$AAS KCRE@L>^EYCDT^_G,J7SU&!WZLKOEH)1 1Q@DM8CYJIX_PF
M07P6_NE8W-\*%QQ44$XK[B#.-E?(\E%8+R3GD4(5\#=:8WT60A!E/PU?802M
MKQ%/ (^#4(ZB*?$B5\&:<$&?5ZO93S4+X;,(;K]N"M<@R8+XV!.H-%J0/OP^
M?_K)ZU\5WZSX30N<X")DR+^) E]*V' ]3<"#6Z<T4?_A>X7?&.9'BFZN5H$N
M_R@BMSU^Z%-N9R?D!=(?/EL V1$G/3P!(/.WR6>YB&NH"]014 +O0.,6*"@D
M>N\2M*<;-#.W2TJ<ICZM1\+^\!'?P:._RPJYG0 LE*A^S@C]#HJ7^S>-:%F*
ME"]()^$.A:4>_NR_GQ2'(-SU7=<,OA@9M1RR&UR[H_V,:\O&_2$=C8O:6?03
MT']-UK9SN ')FEP[ 52P-W?<S;CV5Y+_+SHX^CJ8%]@8#9XS0YWUZP-DC\L0
MRGI;VQ%L"S/8&,4. M7QG^_$_4R>FS3&?I:1\6ZK=>;P>K\N^O%"12[?E@,D
M3?G&Y"W7!IK<?D(%]:OMN+M5<\3/\C2N7G.][L*= =SY\;_*4S_,0=Q-73RG
M:-O\_B#+5Y$)E/Z6W=U=]-"6PG9N_]+2T@E \H@P6@[%,J[+3.AG.1PD!89O
MVSN?_[@<^=?K@NRI*TI^*2> 1G&*@*EG_AQ/]9QQ9Y(';F3--Z5D26SKW/WL
M67POX8J<01NZ*O 3E^.FU<*J?;\*MP940IM\=&?6 Q0F 8KP.21=<XXZ.&P)
MG')/AEY3<42#0+FD]3\EF_H-1.4:H<-)4A\3K?<KE-)RU(#A<N0HK6!<B[-R
MUO1D>@ZG(/J2XCV84AVA B_9XB>&LKF_EA"CR?6H+X[-F<5R_(4(A95H@!]Z
MX<LWBVCA7MU=-B+XO$AUKQR*JXP.8G*((VB8& I(;P^OI\N6J8'<A89/ "4)
M&Y8G@,M7JM+X\#>6?B?.KG-2>M*'Z!4V&LYVA3<$*EUP&7LD="XE^D#_!_7=
M8@FW?;+KR[G,\BWD[@YX7<SF4\T>IIE*/"X2K29'P$ T02< :V!P9;\P_8.D
MJD@5C\0)?5 R)6Y3>GD>O[]D9!)C*]2_T3QW6SEF.6(2= UNBQV?U"4G4VZE
MTFTM$%74:\,VC1PRRAP1C*JW@A^O*5_J<_*^5Z0QBZ:2_EGXF#<5T]2OH1_#
M9_-Y>$(7YH(#]INY$C?V@TL-Y0*3+KJ F!U (B0*0?P4?AH0!SPE5%;\A,QN
MPL3ST?:);6QY>H:J1_BI;OX@MBNQ&#0 34[SE3BCN4"+D81M2@/571YK[1,4
M('6@?VDRCH$Q[ZOT+2-8P&/8TT%)2I+Y< +8/%UXUMB"KMH=4>G_](-@Q"R(
M2-6J@\2D8RZ4*SL%KT,"[RJ$@W 6J^C3B*"OJW1'V10Z >I7\ZE >WP*M-_6
M_]C]F\8R&LHN>,3/YH$007+/9I$5_M2-=&"P)V2VY74"N$N!_UA:@CLN'2/2
MT#@]8"!</%"1U^C9;ZV('-FHPTS_2-!F:0Q\C'6G:B,*+TEA!6_2SI*M#6&%
MBM ?V3,Q?A!>^'293&D\U8-]H"-#R>D4#F2;> #J#N[[XT./^'<'7@VM/6_4
MF!3\W5[X?D8V&_)YOGF[J*_R4B\NZ!)?#F^-2U?8U< XVO=#B[]A[TVYU@J\
MUW=5]@3,Y(@FI.<G@$ =H@*AV3 4(D*!ZF2/7SVLH[*N>P%JC1-!.6,$+ .V
M]!&,$6=AP'DU@5WDSU)CG]$^D&W(MRRAH3N!J'#1A6V"2'9+GRRQB0=0F2!*
MARKS]B^5>;#ZG:;_@Y#\@3.!=,#.N!*JFS6POJ,0KF1U72ZGIE#19N683[4K
M)&LZ\FQ.I] @V@5N(QY$C_.8S?Y$$ADH\(B/APIL3;FZWMH57'1K+@/XLA@L
M16W(X:HH;(A-SKE?0F&]0U+6LKTKU^T_?>3@^V7[7%WEAS115*K3D;Z;[WP$
M2YGD=0!@$5.8JE\;P4JU9L\^WLFR$HGJ)YV6ZHB N?PB^..]P1?&31 $E;H[
ML/@([J6D/>2VR?'7OGC)_GPJ=U>+C^T>J%63,TE/O+QR336S"'+J;AK=^4[R
M?Q;Y>#D^GS\7J7'%/>#A(]8Y15'\><H=O'))D>DU!S?13J254*[7]5J_ N@>
M]$"""HU,)#XJ-()^0/W$RP;WE^.7URA3D[][^+T0#NIM3Q1?A+@IB X6Y9GC
M0EE8ERH180]S75X[,[J9(4:B-XW@&Z(XV7:U!T!<P.04G_!EZ=;IYN<S1%)/
M+M5%G$5)D\M!%CZ0C][,!&S#X%3?7,BB+GK( =(3T^Y,5RJZ_[;[2B8P48V&
MG[EJD^E?V%D<_^S@%X%U 1%$N8W;2Y,M^<7U,]'Y+=^#JG-W\*5%3 F-G>=Y
M6JSK[BB8N(F$OGP)+1Q24!_&5=P<= ;_;%].V%C')YT 9E5:(]A;'\2 QOF^
M/,DUSIV?'^C8?1&Y KBW9Z4S@786<TBOKPJ:IV5[*_B$W^565VGTER=4B8\0
M(5>18TA/A#Y331(ZV&"P.N9)IM*['M?8Q>7K*?N@VO69VK(\D?Z\JK'E;A&Y
M+D0//HIPN[T%BJ8E,0_)RUE*/A$*V6<2F?LZ6U&N43^$29"P&;O:CUFA:40'
M&: Y%84\?1IK8-WVSODF7LIS"4Y!TB]WU*KXY+0-2Z)3W%B/^:C\H(Q3&JW&
MP9LIO!6!/S69=$1=#$ U0>\GZXA>GZ^137PP*Z F9,A$0A,HQ)L];"\P4H,L
MN/!;]>?O3I: HHA(IZZ>.F^,F2%ED9S0BL0.[3W"8[<5*1.^[>LT 2< <\>
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M(S)Y#!$/VQ[]@:0;@4C7HIJ*IVZ/P#P*S)IK!>YL\E:]5I"1B$7 # :!%T\
M5LB@$\#9O@EYB>_*TB]KC?51CN6FT>%7;J!F^7(>?S]D@;^=Q0W #2*P61_7
M/)-Z?6S?&I&3,PC!3$TWKBH*?3-N%?GF$E$#$8T2[^/[>%?R%[+2J]<1]@^4
ML3)4%,&1%._@4"4_IM3X'QRGIHR^5&.3R>L(I#4)?W,1F;"RG/M[I (57-_]
MUJ7P/0CP[];\5OZ9-OIX<@X;8.]WW9/]":XB?-?4</7 >5Q)NDV^7??%]TH
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MY./?W/&%KCH]2LI@LC0TY5$4/;NF,?'2W:;)CXLZ7+[!7N/(X>Z'<%P4P7_
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MMKE-J#C$,Q(A=?@2>XM!BU'N6NFAME8=ZH]9LW]@#SP(6?ZJ+_,]UZ52F\$
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MI)2TS$:E;<K;=^S4T-32WJ]SX/ 1HZ/&QTR.GSYC>=;*VL;6V<7U@IN[AV?
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M,,0?0]-S1[(C)L8LB,@H7@TAY$3.-3UU$HS3:^-%D0\>MA4/-!]F+BES?'K
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M\#W=.5BF$Y^(,I=ZFQJ:D30\>K$WT,JY.SIF<%%Z,E%Z0-KYS)&3$F?. 0<
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MAGRWYU,TQ&-@70Y)*7\,C4Y$;T?I@&[.C"P*1]M&1ZR(?0XU<N9H+Z;ZR4+
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MB34>E,T2A,V RZC9!UB9[Z$/4;>"G:W:ZHI0/M3G3!_?/_G27[^;:IF)O<X
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MQ^QBOF0X?=P4]@[>%"C#&6$#$3D)OIFOO^B 8J\3Y9_:B<N3X-9=>1;MYWM
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MEHH*),X;H^?@8?@OH*_9>_:BL?8E=ZC<>9;,<[V L?#*YYW<&ZDKCU+*BA@
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M6LP?Y"_=7K=Q7AVT(@?GR(;"R-3,P+.5I8L9QP;OC@1I%D^,F3<I* T3?A8
M-^J^"(GUERBG.%-A0]X"01>(>DTU"RUGC!0JLXA?HX.3)0C?K-[O+Z)_GI+J
M1]U!1Z3L/+<1 X?G@CWG>(L$IMZ!R=NQQ?JXKJK+7*:TQ/>F)8L3(M'X'E4-
M2/.$9DEXMNCAB7'+8L,VC=WY )('18J_A4KCDJ7RP3?34^CL]U"D9_/8%$X(
M5>#&CT<(^D&M6%23',4QR&:[SG1>XQ@^-U'2&M9,BJ9I8[9LF*3')^(O198G
MB2JK[D2%QIT\JEA-0YC'W"N7IW:CZM9>HUL<S6]:T">?!AQ^31DM-#0?GCO8
M.NCUEF 8-J,X>F;47C8.0?Z1[:@7\>"KH7&+I(6SX\T@<O \A-E-7^Z(>61K
ME_T68GR1K? <\(.[PM#FQ%KXWPM2_TPRG77+@VP9P,G6==I]Q5V>OXS6%0K_
M7J/]]Q#:P$,KV)QVIK.Y4XST&,">'Z!=X=05(OJC2O(6KH(STD5"6NE8>#"9
M+O18DRYQ=_H"J\S;F,<Q13ON5&X4N8JTU>0*N4A+P=J!HD-(9:KIRQ_K>R?L
M9;(L;]'RS']NDMPSU:E]O&;A(%=K@,JJ-44,9"5+@WMS@HX0U3=F>HYJ+#RI
MI)2EO7*_F7+(,U#AB(ZOV\/$2AX^,2FEU=M&76]7^)@=U6Q=<X%:%;]52N]M
M4#Y5UW68Z$$70CVA;!ILK\NNC0>7:"A<^ER!8%_T00H09Y+<;^<YCCR;&#.;
MN"P:-<,_=/)J5)UTX4- " "*O S_64N3VU#SQ-_MU'_G+.3/WWT&4(']B#V(
M'$0P02P&"OBUWG2DG_E\UFM)XM3[R=HW&PN&M,4OXR>9YX761DDO#;V2CKKO
MXS@=D"E](]S"[:BIOCE&(JB=^47BP94Y5 RBK"&)F2Q$=G?,H\-WDOI"ZCQ=
M9;YIK_\8.?SXCO\=XO99RUJ% -/!))+-,P; [_NSF'-]/^>.2AC*D0&P!U=]
M%CD9T1J@>\=8.*6WPO4+T>8J2[KI1!(N=3"T-=#)J3__^6C2%H*\6MJ@A7X^
ME-9$$8S;R)Z"O*I"D7]8I'0SR<)W^+4_&V:919Y#]F /0A4Z>#&E2X...X1<
M#C23K=K^W*>WEI2$) HGO=MW_9P_IB.5EHUIK:$Q 37]GG3]03O!Q <Q&FAI
M-VHU.47OW:!K QFEX3<:UF2 "2NYSB:/KOCF:)DZT]NS%;".G0J-DL),PILY
M*["S3Q'?#1C &C,IK:XD)P59,GLJE &D1C" ^VA:/::B:%NMI6_[# FUQ<D
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M9=V,33<8\VO>!$-.XI #.,'*=?ZO8<J1CI)DGV1.*_]S3Q'"+&Y[MGB^6C
M*E<@.9B86P:+@=EBHR%<T#TKB; 7!.)6ZPV4O94.$S]7W03FGZDB";JRNPN8
M/1LZ1N_&^L ?HRN20]S''Q+SGN0R03+8G ,V<P=E#:MPU+243)<**+5 @\K7
MF2&[VG[O%WM:FHG%PKD"1/]W(R;Z&QI@:?4'L HK<!:J"I&U6?^TPPQ ]'F5
M-7G++:ZIWW9&R^>X75_M$6>W!O7/V-D*"%!WHN@2GG-2%,_9@@A1'1KP9SX8
M,^4+SU5U;<EXBK"4:3]Y'^77R!?6$PPC-L]#FN"Q&<((OB!A\-5KOR(]%V8^
MTSQ1I_)L=R!OY N657],:AO>4]#3VT,N\1L%SNQ_ N$&9?S'F)"-I1%;,J^A
M%=;.8916FX5XH*HKE?F>\^*_ID#UE[J7OT.,A?$_%_!]S?X+LN@;+/VNOO=/
MZW$6L)4P@ARQG7P)/(JAHL#* GZO5VRC 9,MES)V\/]',O63L? ^G?,&VNMK
M;J[%)=EU=>^UWT2R=YTNY3&\V'$'#NSJ=<9#'E6-PH@FJ(DYR(1EB_*Z[.HV
MT=<R@3-\QV7Q-Z@<Z>!OV36#!0S W'W7WA-]>Q_[01^8(EG8KU?DF%0]QQ?7
M-O3;/!CW,0T4[6N?*S2,<30<*?X1;S<#[U1K6.ORB6, ] .-S.S^NF ;EH)$
MCEHX(*(9 />;J_K2%W5!V*4]2J7Q^]T,PL?^J7")R;V=SB@9(1OI7/G:@C-J
MXN_T?DM)L! -DN#-X C-.1187>MN@DL+>)L9)?-BZ=^\+.BOMM^,%:-8&,"G
MDX@=6AH#N/SZ4-2?-(.:,NWV8Y P"<%\B[N12 6J3 1=!A.F^A43KWY"^M1I
MN\')[O=/YI--J[\W7-H:-[@UVA"T'VS%PR<X9['A#>=!$=<=>-2/8]9&GWCW
M9IEGF6Y,0MH>/;\]_CQN>&C:8M)F4L?>WRWQBCQW\BD#^9IGH=DB^T5C3-M@
M1%V](O3X?#N.'S:;FG'\_7TL>Y#91/O#/6LZ:4T[64H]-6]@J(ZD;"VWD!SV
M-IGA"(K)_V+O/:":VM*^\2 J*B@JTJ1$18I409JT6*DB D*D1D6Z@(KTD"@*
M2#," @)"E"(B)=*E)4H5$) .02 ) M(32@BD_</]_C.C<\O,W)GW_>ZL[ZYU
M]UWKY+@Y^^RSG^?Y_?9^BH54\!N39'B8I<E"D@Q+?I*_=M*35*,9[1:M3$"C
MT#LZ:1)"GM'I^OEI^P]'J"R@G96!7@QY-T WV6BF@LK(-4BOQ"\U8R,)B^T3
M[D#V9F%N1B4=0L\<"I*'%[7#/"&+NOT3R[6=C54RY!,-F"5^%O:;76$"ODF4
MRRPP 005)J"7@V'!0M[.+"3<P,+6N>$,ECPOA#=BB/H*ZZ_A:RR9',92#2-E
MEF 2+-#;+[M0>&UN_>1Z\/"R3:+B8S*X%E6TL<CY%3XS>EY/GIS>,[0<U#^!
M4<Z6*YQW'_8KJV.!_*UK=;^RX?>?3C@P"5.&MXB0G.E1:DS QL554C--2),)
MD-*BL-[MZ@C+R)E4Q03'DN#X?(B CJ@;?/<"S;G@FV55;7YBQ0!:-%V@,&7G
MOCC]?H/K\6U?\G4GV)HM'+4&V*C[8 T@3M!5[A!5>$G2>P2O?P9DNZNN^4L7
M].'>C)J#D%3EDM;#2:U6^@%.?M(+,]PCG/%/N.#8ZF9[5<H'/SB5!]8A*IYD
M0G*J?;6-A(G.?W\-9\>'4RKK". P3=L:X;QSRM=36."E-".!*(9/^C!V#[);
M&3*$P3U&YDRG .\KVQ@KU9\N>6<9Q.F(V+O^0+Q"W:QQ;-*[,N)H/$3$?8SH
MB9@[2? 2<$\']>LH0 ."'1JJ2JO2:^'\3<9G)-$U3P#+!F_O70FUF*[+>/W^
M$L<;"HBQDYTJ3)$D'R,ES0EF82E5)MLI:Q;!Y@W8M(&HA1O]GJ@HFV+;U+GU
MT,]8FVT=X)NGKR@E;F6OP^!PB,%4/(L'H]F_8<HK/IAP8EW@I7KU8X]$!>/Q
M29$K-CX/3/M0A2I11OHK+<D ]RRX5G&FIY2YV([N,#H_BHV>!L>E@79@G*GM
MG%;]Z&-08TK:&W^K*_Y@<TK%>%N:Q\IU!Q;\R A^JZ>6V [$:I6HZ]W=O\W7
M?+$78&GR.)_F ,<+44'A&XVOD 4&; =]YE<K$P5N?*S7X*Y13)>QC@00,913
M<-P+Y ID<QOQ81:29G$=_D'K)M0?P^XCCK0K<N6(43&5X30/>V(<+I;.YM&P
MYWWDALXOAIU4DA6$F(#/GFU, !N"TO7#57_C 3;$?_G]3Y3$GL;<%R/:Y (W
MT@[$LPC/TV*#?:DRH(-"ZM'6[<\@QWP?W+RS7:?,ZY>C:=JI_#$LC:+FR,)9
MS327'Z[<KT<"FO^\__OO<XPWSQ\FBI&O$2\C]_YT&H]5"%5^^-$HS9HH=O']
MC2S%Z!;-<8J8I<,T1 XXG$3&T2M,R! :#Y+LK<-+#.UD?6?.O/%MF5ALFR 3
MD%CEFW)"KE_74'^\[6/]FP%/(84&PK7Y_1,AHV:^B-$UF.'B1WS#I+JM,CT5
MVA.D*[U$36QK'PI 7J!=HS3CO8;6/H"!^V!J4$=B9VBID>?17I_<Q*U.36<D
MQI.%QQ]>LJH"N$\$>5&D@/-(ZHT1G<W]AG[*=DGB7+Z#5PSP@/+ZW78N!1.E
MUD%$J3UU;Z8[E]+U2G?NH7KR"8H=R9!;@-$#W$LSIUI!;YO!.MV#;ZH(N>_T
MCDO$WKV!M=(5XG!/N@%2NM^-?A3^'EF.F=^]2V\<PXNEB1 S7U\FL@1]PB;-
M2;^HSL O)G%*X,.C&W=E['1ZY%@K=7>0U5I"+W^67U)^BAVAP\LY>1S^B!ZM
MJ=OAU0_A"CZ2.G\4NDC # Z3 RC@<7=0%)QHAL3>F1IO;LBZN@$)+QLVUX[)
MB@D1*^XZ)"'5AQ!\*C"(PQL'-87F,T9 PBL?2Y'A]KP],&Y_@^M7"GQV>YL8
MJ#@ !$QWQTW($=6Q%#% +@I,D:-*TS@IVP\NL[1GR.&#695J@8R,IJE+[QS6
MDG/B9=5\I*O!V-K][TCJGRXJYEB"R]MNU.[O4CCGB[]UQ5;8.EL(XE<-\Z@N
MI]MHL8S$G"(. ? /9_ L[AV%USD0<@YGD]2BDU$+9_>$*1X^QK?G=ID?6].X
M/>9'D:]6RDCR!;#%&>!V+8V)P@;'V&OXW\#K3F2[5XA*#0@D1)TA)N1BWOD"
MZZF8V(N!85>#W[P-@&DJYK:$Y1Q#EQL/^04GI7Y^[NEPORUWF?"F:>>\;\*8
MX\BZG$D:")?_V?T6$U#'1B\)XAIB]"W1GI6/,[26D?9]I/9@%MK8QD\::T2R
M&%V=2![M'$5W=%_/9@U#D;+1C/B1+^QD+\7)RP3Y6+R)5KEW([0-TH<6Q;^Y
M2CF[6S?3N#!HJ<4 OM_+OSRMW#=0,W-=LL'60LM9\'J>N?'Y)9L4>07*+1L#
M"51559]5Z %3B!/48.,^CGMP'+]8/W^.$C*F7]2W&N:Q- L3TT-7^3$8TP:[
M1F?X:F6O4 :Y=KMM3H\)I;^=EZ8=W3SNO0O=PV-FGA2@.O\55;QD#1QYI[6=
M0SY[CE@ZOH,<:30Y7[T<^(P)N$["T+?/88@"3$ ,\/N+FZ:VX5;_2/>VSZ)Y
M^FO,LTQ8"X)'!&CZMBHZNR^!D5)R5BG]S<=U2]$&\"<(BTCCHC#%?M$U^F-[
M=81<P)!=4(N6\(:QG2H&*S*/#$ZN.SQ<9T^']SF/HC]D5-VB?++?-QK]Q6MH
M<::*UG'S(N?.: /PJVR/0I277L]7Z"4, (0K1I9 -1F[8 -H+DIGQC BOIX)
MX%.6*.I]Z$ 1PY0R 7:'&32*\)+T4Q:7YHX<8__*!ZSHG/,B<>#/Z-[V)M1J
MZHD>(=+\9]J#'.(J9PZ("3NGRRP8ZEHX2K?N$-NZK[\:5.K2SP0$9 H&-'])
M8A@MT$G.0+*/FP8^KU7';&V<"8@/&KO;-3[&!G*'AP#+=H>,P3HWM]E#:)>;
MM!>=LT</5X<&3AHY'7'!X%QDNM&-X_"-W4-PG"(3<) $1,")ALA!(#D*[;67
M,D[V[2J=]_NT?)VD\+#>92/$&&NN\C+ZXWC1$W4R2I4)"-OW4]16Q]@TL"B'
M=L#=G+0]F6,#L0T:V+.]A/U^%ZCT):?/_CWW30/]"$E]Q2Q07I>/HQJ[,@'W
M=5DXY[I"_N0S^+BIN1UNE0EX[^A59^;<_QN?'AK+!'#OH9<S <ZH%:]A/\9.
M#,&Y!T^ "]%X:TWV#BJM)<RUV$2Y-)O9131[0<!T) B7 WR;-*]]6S2>F$E^
M0J2E5&,2H9H%%[%.64<[N*YCY_3$GOAKLG.MY<],^,]<(C]_WL5P*1-?OET%
MT3S8W7Z+UWEN?=V15GQ1:?V8%2:A:P[X&PO3/N#;;Z_<4P+_-;=-27(Y4>:G
MJX+FK?L(^X"*^[^$Z!45IGQ_;&;6VMD4UB'&5^+$WVKW8ECX/J+ Z$=)3/S>
MD^O2=M!@C1<3<+I:@;8=-*[W_84-+PY(O-0Y+#U+-J*8.V335#]S/$(?\U^^
M=!!8M[A35TWG9:Y!Z'+:'44OP+6CT?J0JNPD_VOE0&XPK[UR;EX%W8YLY+LA
M=T%1/?**X?X\4ZS,1O'":(M/H*@,]2[M- 5#O4J[%<78:4,%47JMLU=#(#0?
M$BR9;XRB5RKYX6 @1KVJ>JM\1X;:UP/.QU9SZA4>SA*]\ LQQ#Q\-CHIRT44
MV)-1U'UWUN;,_AT.E]Z</"E9Z1#7$&=P-&6S3K8DBU&YNU*%:8))^B1Y-/0\
MB;TQ:;& =H$4_;44VX%2M=;]<DKGLF.D[CMVP9O;?3NK!IQ ^XP2U=VXUV[-
MTKIG)=?/WXVI*K^-.[X:D!W9H#!JDK/4G 6>DNP'?XO];5W'.YF>_'\;Z?Z_
M=;_?.=0#:BZ1)G;%+;$K!WMCVXU[\=5^$E55/^8[T?E>L?YP,9AQ3Y'QQ[]+
M:6;LVNE!0 R9D.LI<IL5'L+-R\,OI%YB D*]2?(SZCO.=_OLY,3:&C,!%W!5
MVUIF$T]#O,')C"%@27HHU0;6AE:GIT%/3^3#CGV6*"]-MV@=MN<R\ #12]*.
MQ#/8[(8\CPA ;>U,[H\J,0%<"<@O:0,I>MN=PW,??6@QI_1E TGG1X+GK=95
M?9&_JKC\_6C[Z\G1 W!7T&!%W<8B0NLCS1'OH!8*]7._-92R&V+B5=(^N:'Y
MIED1N()%1^0KJ@?@;_-D:A.PU,?1\D?2%7;O^HPU4%G^S9EYJ_;'^"3_VMV3
MQG<&&F5>3^?YO+'1+&O9J_3^E.5P[T8_\@<U_'>!E[^EI _\5][=)B*]&R8H
M/,M/O) -.WW 1E\E\/]5QSW>"63IVGP>]3BL6?0@9#^C"\A?6LO>>:;_H(V^
M$P:CK;@M_UIV4KI27BG/\KY^]#52SN9;;]M"?Z.\TV<Q))VS!^Z$#$4U('EA
MBO5"[GZW11$.V2<\8AY-0 EG0W8=UP+#@/(-X)QYNY<FZ]D9ZS[Q2Y%>'Y=)
M@HD'0TT<A3I85@V\/,T[)9&4O.HU+T2U8G2 BO4>(![#75!16%!HOF%1N1$U
M^HM=;-_5BE/='6-S3?GGH8VO88-(XB7@L&Z3U6:PWRV:*"7PH[57])C@_#F_
M_:='W7=+Q<<BDL6?/WLFZGL0MPD/A\;P*DF/;0C@N7$BN $NRA!K.T1U;D;&
MK)EI)]2\@='??-K.*W38\H 5K[[0(+C'&CYGA(*:UT8U(,OUFN3TFGG$(HX0
MRY^W7WN)?7L2<%9P]TGA:RP(Q+7;:[YX#DATF!>G=5M&KH1#K#1!$\?)@HEJ
ME&ZR*>.*9LM&9TZ6Q< R4 FJ0.&F'J,X$![X=Y[]K 6AVM/<(NY5DBJB7O$?
MM$R6N*/U*DDU\39[2.K6T$#9J&YT K!$;UZ$>HJ[#-:'.9AJT.7XE<*!GRTK
MJY9<D_=,78OGNJK$G20F75<[53>ZGUAQ?T5?2P77N>?*M+5/,8%31*/O<*3B
MW&O @70IDE\HE"<+73T.W']EVM*43BTX,WTX.LCS^O;@O+AR,<%GEK;S'3;B
M&T?+5_3G,L,_3/1"CEQZ/,\HJ*7;*,'X:/P4"Z+)&5$AB@5.6_-<Z?OE;4\%
MXJYK"!X]&6 STJ*SVC,0:<\82O&**OS:!7=6",6N(1:Z6H5F]7>GIPH%:O>^
M9Z-PB39EL$R%,14,M:=/-2Y&$_TUC9(67439HJ-"<DI&#1(MFSFN2GO;9^!I
MY[>U(YZ[R/? F  &9\S4]*>,FLYC)#ZAO>MW-NXTZ!#MIQA<"2]HZ[;(V&]
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M]N5.]F5O$MUNN&HGB"J1H+!F'9?]-8W%T.^UDB!'$4GHO4S A^N8JYA(#2:
M=FCT*"7O-G&V4>J#)U2&9&(4?[KF/N*<T[L&\8AQM]9F4&BPRJN90,^2:WOR
MLMSVVF&_Z!ZMJ"Q_:B#\.E"I.$X :&K;V3AV#[Y5!^0B6<<$"#'V4;P;RX7T
MC;SV?B../%H>X8HT5*,:A6@>7(\W8[W3"9HLQ?NU,<%DT(\<04DBRIC%G548
MA!XCG/2Z:W5#*S'5I-K92C< *W+95S0J7JH!JI0@.;78O&@9Q^+J-^2AX]PD
M715P4J5"Y:@"$[ %\9)\GI<43CLZ1K3N'$I%[/?GQE?,"[TXW;]\JH8)>.C0
M(/\@K\;L@<O%DSM%#4X*3EO;\[!&T<UHTX!5<]S'N'GMH"SBG!]->D3D0$V)
M6>3$99 W[Y=K>!=JA/ +L111TZBX6DX+R!<HRR2S49(ZI+*?7R7,VZ\@UP:D
M62,JBUHW0-IW74&S4>*)LX2*\.LD.&L:1+^ACW:SC*]Y[C>-+'#BXDJ<A",H
MS0.<+-6J5)J0/-UD^M2+_^X/3H[_JI?H'O=Q8.-B^!B P3>+$81MIJ&1^4L:
MFE=:1]TTI&8Z&OZ6A@9"D:RH SX"E:(:\UCD41HQ?Q8_=-,'PW-%2.$!>F^M
M$ ;/0VR[D94ENJVONRCVBW?1QZT[=RFH$0;@%)F<^4 F8+>L\!=8!VCKZBK\
MP)<F;Z]QS('SK5<>=-MHVH;0+097KI*JZ!/"KOMW9)QZ\V*;A0 @$%QDSN Y
MCFZ!\V6L8:KYWR#R*Y(<75;CM-P@Q-PH"R0Q%^-'[;8^&:CGLN:7I%_D\D.1
M[7^V_0O5+/^^45!X$]JU-1KO5!.$0QSH1 R?![(T&<6(=KSV"*(AD;/$[#['
MVL1#>G8GZ+W,O.&Z)(-3D#C6J 3KT#"9AQ"+&]K&0??04F6D\FB>PX6RN*LJ
MG)9B628WK;[X[64;13^CV)#$ZC "Z(/^<$+G?51C?PS!X^#PY>XI!KV&)/O:
MY"6V7JSH(PH,9/2$9D?:E+4HD$[+@)X'!%L[Q]]C IP:+>NTXZ<0%.<@U-/U
M6A[=U0.F]J:SOX:T!!@L'O@$C6 "(#DL+*I2=.7O?_C'T12/0#]#HTS @U'X
MUWX8!Q,P=*H7OO+0])0H_!>2P4'N@7Z6-J[W9Z%>/P\3=A^188D,CJ7QELZM
M>E%%5Y'T8\IL"T]_HU2TTR^&"5^F_45N5+X3FQ<[7__:$D#MI;]A/3D#4AP^
M=[?+!<D'$Y/KC%A4+4S >>TYY;/;DSZ\<-0WUC')[[RKZF$M3U0L^@0#"ZP
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M?+0MDGIU%???\+UY7'M6CR6519 Z=SL++0N2SN)ETD(YRZ2Z4-"KA:;<MY[
M\RQ6S(1$RV97+IL\NOWV0<Y#TY?\W2DE[B6IGEFUPBE+\L*:]Y_W77!(/.)>
MH/<I?N%%7 [_9 8RF3<A(3'5520LS96W9I_4E9=AQQ]%:@ X )=+3>V%/*I+
M1O[._U^ _'U]/X<A^,=%%C.U-X6?L/GGD@!8^D5IB>"!HM_,*3;-.GP]/@5*
MT[Y?IK%ET7['#;4/GF2SI)UWZ3)6X[\K\30AO;D%IL.""/*,)NN<1]DLGOW>
M1<N":-.HT$IY@.>/<.H6$GORZ@M?Q5#ZFZ+"TV(J$4S KA(&IQI5&<H$<&%<
M@  H[/,A:A6H05OX6^!G1.EM.VP\%XH),):<G88X=]D_]88Z(.2<WLCWV(YY
MPY;6E0/B6HB&MKWFKZ@?ENC30:C)9-)S(/&*G21^ZW06; Q4S-^P&.+-L5.U
MUB^SO )/'&KBN51D.>H]#3RSQWT:& (JXYZ;IAI, X?A;#IJ_@Z-;[=R2W\+
M;#!O ZPDBGN01/7VO F8MFMLK.&_I%W0>^RHV6$#L=C3EF;'3W.\%BN#CI&J
M&3M%J%N@=_J8 +P\FL+CC/?:?S3,QNL 90M^19/BR 2DORS8)8:AFHGUD)-U
MQ0@/<W5(T*[-XQ-7^-?%STCGY]<8.YO>S(NW*-!V'6MD+3/.WHV+D91ZAL P
M8Y<?59W%L<C&K&E]H#<^(L&]*KJ'0L],G7048>OS.%4I*>S@]I@).,L0O4:]
M1 ,P >?HU7#<<[3ZYWP\P4L(*I\"XG'=%M0N?<[279^.# KRUB/;SLR&Y1Y,
M-\!"*%SY8_3JVRP$7)?X[,V=G,F^\4T$/ T?[M?IS*B!D/U8SXV -6#*(/'N
MQ!/D6&('ZK7)O92C:TB'7N]ILE&L<#-']$.QT=J,=S*74.%(\2OOT.W*3  /
M^O&1, FDMF"N_/0K#.#[O#M0EJANVRP&^X[&Q_K_38K3@!ZFVR02"B^P3BX%
M[; >V1%R-@[C5I6T^VO]N[TOCKD*ZIO>ZT ^0;+@)XZ I!P;:)"S#ZKE).B%
M0V6NG;B=Y0+;5YJX%S,RYA_?"F,94.FUI<(#[<MN.M@XTP=#+5A&HC%MWF%J
MV5.N92F0T91W)V7DO/UHA2L4Y;TA\[<ZIE^1FP53.$F:3;#C72!<*J98M=2#
M(0'5*W&%&A.$H+$XS&YGCX[,PV:J%W#/\()<5L6[BJ*1G0I#48P]X10ZKN#@
M6CT34,9=)P)LVJZMY#7GX7P*.+0&<K\RW&KS;*G+@$?]O%.T[L?L9SMW[((;
M8'!)H!*+@?K.4#5XF60CA'_0OX* ;+K/\:C&F= FV.^BE7M)NQ#I,F,8=>6(
MH\4NP_CG^U]NF8:(-Q!71J WS=UQ-KE&U8PY/U?L0FO_S8XPOS""NK2 H#*R
MB7P;X4B?OIGBV;JPID_&#-63 RF.5&D:#Y&U[D /#TH5?:[1O%Y.;AU48EG[
M0(.)J]O7;]SIF!_Y/UF"I% IN68^;B?;1RI\J>7!VAJWLHW/[&J1$1\ZE!$I
MS?DO)SS[?9Z-FTW&W5HU@: MNEB/G7\(]E4C=]N,6G=4Q[FD&58=7]@5MV-%
MA;1(VR]DU:?#?87&>I<0;TKGI40[$YQ7],2#^F([U1O5Q/X7UHL74R43#VE%
MWG[RH,UV!54\2\ ,&S$491B[9(@0,JZ$"= C3CUN@RI0$@[A#]@6I1I6PNH]
MZHIK8KIXP5H#>4GP4K.\AW!7;SW:I6H(-"!SINOK)&1NU=6!?Q!:S 1LG4..
MR%L%2@3GGC\ _N6 ]S_3Z/V3:?1D)CNQU8Q=**HXK#6P9HQ[$6KL-PX1>8.)
MQW&S#<-=9DX_W0\EAK>5L><%Y.?S3^X:1"&@YZEZ\ _&<%QF50-C'U'+.KP>
MM=/@\&/X;J@"VD!%+9I%PM8>'84<^9QP^%ZYY1>E:+;)VH-6'L[&%H5]ZMK/
M*^!X1*/"Y8*1S/:\Y"X+$>F=O2DC>HZ,8R!?G9BQ8F<L2Z[U: >JR6;T>)\;
M1,DHZ#5O@HFPW7'C$_C.$-F.W$*[5EV+;35Z:^<>GTYX(GH[/8'4V8 8%B+3
MZ,4UIT:W?"Z3P3S8X.T_XZ^ ?V+GU511=)<),$!#5CS$3;8^U8%*'NX*#9R:
M^\!:2EY$8)W=+G=D1$I?>JR[;^AJFE"=4HL0A'U9'=,[*3$S;] FT"8M<^/5
MMB!/!&F*?(FRTYUE2"O( <206;_9GC.4X.S@W*_7FJ:=( F/OEFE/?-#&6W3
M]7F%3\"/&,A-B0<%+,WN4#AYTJ9*ZY./BVE(NONC&/7:E_SNZ]ZN)S%2K\=*
MM/C)EUFR9$8)?Q\A7_P92U.T,_)V&ZC27B.CHLKLF #X?."G]\^B;BS8W"I2
M\_^ RM7B)'J1[>E/:D 295FN@0KA9T/D5^GVT\8C;:(VP0T-U7$!@WN4_*W?
MCU'=-[D&6#2"6**71$%ZYN8I(3T/7T!D'M/IR\,#!ZMQ"[%Y"I$UT"K$8Y\/
M(=B*:"]C/$<AGP0=6QBX)0MA_88B*Z[Q^)5SU!3R2@_]:ZWP0BZ*ZFM>L11_
M5B@ZU]BLE?C\R;0TLAKQ)C1-EPEH%("L1\\BAX7]"?@5Y! *+U$[GEM_@-&W
M-U5$7G5ZV?;"=OT5S@YU%2#M&!(;3IA:A*E ;YMPN18',P%[:#K1#1,FQ-JO
MR=#Q$(!T0&.01UE964*5M=5PEJGN2X?(H[M>9[X W-JF4\3 OGS8HU#?E,IP
MA2W!H4E'8+<?6B]XT",>-;D_(XB;PH^"_$P6HJ;BEIY^13H\I$!8L&<?!72H
MEFAR[^8XIF.J#\7VKMI7VZ;C20E7NKX91YG?75-[71G^R*9^G]N\PE\W6LH9
MY" !6U$>]O-F]>;11ZK.'T5_98FL=]KA7U(VVDFTQVN8U0G^91:?_0$)_BH[
M_*WFWSF_C[4\2?1(D!M&8WP<-3>&3W-BW%SL)Q13)3*1D++A9U-K3;0@<!20
M(N$\KT+DI"N0-SU.HOUGZ_N?+'.$H"7/ R-*@VM?1+S:8J._<2=U&*4U,+0"
M#A;N$=$5CO1#++5V(T9D,CL+$J[*=&+5K2'M0DT0RH&;##)<'%3F/+^3=);\
MBOX":DSJ'.>K]GCMOC'ZPOA3_XZ6FQ$"^_2$=S4D1)CR7MY_$=!R- Y*K@63
M1^EI6D9424:_J"9E)R%81U_H-(FWSG7QR%7;P6I!.6<(^<;]<;C'X,SN  OX
MV6MV'*$/,CV-9&S<;8R@B"DMZ\(B"U[WY9%E2-"8#:T.XP_"#71B91HP^S&.
MW +0K23YE^+=4 W2 87,&E3\MIB-MB/O04-6N$H6IK*[_7D7#8@:!5)4ELEW
M20KU)D.@QLWH+J.<%C?,OIKSNURFI:]V.EPM;BI!D*T#%B[!!V17CJ AC[7#
MR5O7UR81"@5,P+H0TN)]^AC]6GC)<*+M:"*+_N?#4KO.\U)BJ4]^3UZOWY%C
MYJ\;$ C&&+!$+F?^/O4P998,OQ457.!2N+&[OGRL9.96K'96:M5KGF91?;$)
M6<V!MZ;6GPO,N:U57*L-Y51FRG0MOO4TF"9(1Y+B7#>T!?$0HC$2Z[9(+J5'
MU_"3G!MD9PG*;S7 T1ZO[(H_Y T5553MJ;U4\O+IL:^R>?:S$%Y&.X3T"$*T
M $;"B_N:-]1"=51=QPEZ]_>2#KJU4=/LAX($A5^_>T\M:M)VGS><;9?JR8ZZ
MDU6P,UMJP\@&/EQ(6M43!5MGVQZ) 0=\>&?4KP%AC%HF9>[Z:_:XG^5H_3.;
MW*]EDQ-3>I/HM.DZ.7V*\SPTF6J\N3$.9W&=^P,#, [*94^TM'_3R">3#'_5
M&^Z:5O!*G]=J"X=/;CU@?O1%=(#/LE^#"#MCES'59]H#!>L=XU]AO06(LY %
M; Y,IL'EDWB_2E+$$R)'QQ+-=$Y_/4,/#;RLA.V32##QI<JHJ4UO*ZQ5N$%-
M]X!VQ*BKF8R6+TR?AD=Z&6M@YWUUTNAY(!P*4VPRUYEG!]7Y[%.-?(0^^4!J
ME)NHVI8K!]&$=R_<.51RJ6'[,C!P2G,W%.5',*'(@&F\A['8[@ T'TVS9IPJ
M5J?6Z53<<&K=<]4/HC$E>,._8*_8,9I[-\A)82B(?(5R_II7-JP-5"*:2S(Q
MJ_!*:DBAA[ABA97NL<7N/[7OF<?61<LGX^&H[$P*-U4/:A%CTLS]&#FHX2#%
M40_D/J+ZFI\:<Q?WL5Z8]X/(+?=O?-;%(^[J^+' =#HD02KG(]7[Z, R4E.V
M?3+0U*Q!OI?>"M(H=D_SF_"D7X6.$9&,G1-4 *,AY8(O4@CJGN.V\=+'CXA.
M?%S4)G4T)YGK_(+G,[Y#!K>^[KUUBG=%_CY)87PL^NXC+16J,JR=#.,BT@R*
M>\"DYV=:I5@H\)7E<6A]K^AE4JQ]#!%#OD.1(=[:"64C,IKZ%],VGGYTKKX3
M&*\<BDQ_MY7;;3XOI-#AZ:774X9/\WH9@9TF$&=^)B#[HOO'Q>S$*=[IUY9Y
M!P\,#&:4K?@<Q:P\.[V>+NY%%>D<;^FY3,]F''='JST]#I_SGU ]:"V:R4>,
M?8=8Y!-L/E(+^<#82H34SXO?56#W-S?IEAT ?ML(SCB7M9'VPE-GZFA_&>^4
M@W=TV_&04#=$K >ORX? ,\?.0V.GKQ;?K%!(S=5-F0IJ'S6'E<3?@:NRK%5
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MOK^I][>1_!2W]_UH2G_0_?\GX/7/OO_[?:W2>0=4A.PT]/'$D4^X+Q\;NY(
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MY<)E&7$8.,C/#IQI?2)5,.SQ"4X-N>%D:SI2;R;]]93.#IH-,:<9\V!4@#*
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M<72L_D$B%#@?8.'5.2N5=J$Z9Z;<FYBH,E>/UV]*[$9V)PILN1SQ(:BRN7H
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MG9Y8%JZT=[1OT'.-,SZZ>/?3WE2H^(]AUMX:K =+[-<)0*0A<)*TOJNK=(7
MKZ\60(1$Y_#61)X>#0B].&9N;H\8#JOH%BM*J;?-K<TX8^4L#[HOTNF+MZ2Y
M =?H\M.HZ5D5H,@)PT.B-$O+1'=2=J?JE1P9%)]N#_-)^:)^+J5[]Y=@H;MI
M<<3F(VQV@I-AP%.V627UK"G2]1!%I-- [9 1!7^)JLE,[PRJ*Q').='47W5^
M&W1C1%JRT7!^\+VN<J'QM_ZW$(H-+NQ^YNI3MKG\P8S $9^MD3G1^9!D RX*
M(7X]3]ZX./2YZ/E\R ^7C:;SK^X'FS&GOO<#NNN=NM%A4.+35FF@C51L!SF
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M:70MW.S74J8J*CB1*L!IQ+\TD+\@1,-Z_532P]I#QF>$?O"PK;,!VZ(1&68
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M0\D0T6#G=CNKKO21U)4+7RM>V@5?/E9_;S6^4KTO\W3RTWL<J_XV'-1LVDM
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MGE:%5\'$9#ZELOF*H^-T4WC1EWCS1LN.>QP_7Q@C@E93BI%0@(^^"Q#I(1Q
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MJX,>+)?=ASMZ[M++L->'.1?CE'I0$B@"IA+:A8X+A.]$'J&B=/3M7R^MH5\
MZ$YQS:\I?J5VAS]<MRW;/,9LE,$=#T$?/\.8[-%\3E5C[75EB\LV"#@UMWZ
MH0JDT!T0$A>H7 ^K>1+=NW0M5SSE&T\]XS<63/27FY9!JWND.-V3#TPYHR1@
M*+U@C*02L8 2E"%@0U9".*KM8DUM@\#8+]2DE-#7B]:#*^^J-!.?-V]IVVAT
M3X3HO(P;(SW]NO-&L+)&O5,MU 4+'%%<5:$'WFJ<?4"79PT;B%-;7Y &)&R'
M-QMF5&42:@>/Q;F8(()N(D=XI4TE*HU!(:%"GZ%LA?%5FX02=S>]!MS)05V/
MP^D=M+NSB"R"V2 VP"@7;UJ0A[FL=>GC">#I:==48G?!Z1NF.\>BDZ'>L$D!
M4O3;;+6I$#+7F@HQ48GTM>AVVI+C\2:J0OV;$;Z12IY@(S+I"6>-W'1?..A0
MV"G=.$I_-)1B"9E0)(]WI5 T2 MK%B0+\RX,)<J8W'#"I=DE54K65*[>_JG8
MZ!6YS^:291(ILMVDR1T;9L1DX A\U9@*[F:)4+BB#/3L)0B2S<5$\S*C<ZV5
MPXR+@PEOAM7*9<P=C!*<5[_U-LF)_;KOK56-F<L6S2IH57\;!#B,8R/!F[PF
M#JE@C8Z?.15S+?<=Q)=ME9&O1KV521YSOEHV*4\_N^RKB$GGGEX5>3V*11.S
MMT%\[!Y>M>ZG-B+]WXR@/>#[D= 1_S*1=CN;>(64LNJG>W("&RMBX\X"R(AC
MYVZ\)27<?0SZF16W 4L@U()75RC@3F[B>BST@)1F][#$%31X\;[F%^RK#B?1
MXN;4H7:QPCC\'=>-&6']8HG*/86>Z-K,U<125G\LW=:6-93#O0V*]* \A9)T
MLCL#J9[%44<O%P7M3>7:M>^V4=2N\U'D7WS]D=;)-EG7T(#">,0)+)<7ZBBS
MIEGDIM?<(C^:Q^)NP-'X&&F;2,6TSWVE*O+WCGZ 9B16Q#@)IFP.539&G]ME
M^DZ&8@Q2^7-8)@34&:/6MD$'+%EYVZ!OF=L@_U^'\F)(VZ KVR!&R39HNG_J
MO!+5!W>1S:$<^#?WU@/;H/IHUC-5K\] 3T?_=W/E*(T5@^&L6\*?YV?5@W#Z
MN(RQ.H?^<B*.#S?&&$) 7]-5;4\2,-F>Y[3JY-%96SB+9,^7<4H;EIO$EW$_
M/K#VSN69LU7"<JXH81,CX/7S4 T)^I!MV)"G2@&O3IO[KC/IWPN?GNKD+ZVM
M[&:8\?/GLQU>.+<@QZ:WT(]=%'L:,K.+S1G?P#2Z/W8MD=K4M@T2/L$&EMHY
M:M #/3UHOH^IR\(5,-V"KN>CC(S4TTIG4ZH=80=;+V@IK:@!\K"U[U0P+9)M
M@\XR])FUZ-L5*E'8N_F.&/X5X2S)CW5WIN#7[<I?WJA-3/"2OU-:_CY<\T,]
MC_0Q#IJ#T-P2/13U3@/UT1I3&YG9S=1=)SDL/'.B]B66=76%RVN8[ZLTI79W
M'QZR54C,O_-*S%!1N6%Z#.T%F5PX ^B1L,E!< $5=TI=XL'*M+;QJ8#JK7LK
M!*_H_MJD]U,[@[]^3E5^5V$L<=+8#1\I#[JO(/3EU^V^7H3)_KE8ZE7T_E8%
M(^79W7SH=B_/UTM;NM[=X2Z)\U;-4=]T\FM]5;7N51ZM+!<-$Q6()J*!PR*K
M:50!,CBR59AM!A+F[*G]4^ ':]_5]BU;'T<DZ:CD-V9X&X1D(\@MD3=B/VN<
M69>>/D!0_\PYZ8%5!'[0[Z(^H*ND9F8QU&QRZL3UI<8;(S7Q#GHF+2/S0ZMF
M-^J"8EWW];G[=$ER%W)+"-X17=/Y$<+BJ2(G1T&JM1D'5LA%/;"'4"'%T6IG
MXL1W]#Y$?%N.2GW4V'>+CTH97F96JGDRC2>N1%^ZMS=*$A2Z88QB>X6V^_HJ
MWB'L<& 2\.LY[G5_YCDKDDC8J?)RJ56FJ:;NJ2K\(ON'"CG=J=%2XLT.E]"'
MJ4UF\JP&-II%EM&OLSO0U<3BU\FN/U$#\&J;3C@O\N1@V8T:2F9XJQC0:B&F
M]G6?DWDB[%*6T(;B([V8@V$8584ZSV-])R>)$,HYN!AK %<%70/3[5AOH1"6
MP0K;4+"D6?VZA=$A1*PTT+I4'L#C#;TR_ 7G)?85K/%$QO8>],'#)WL38G(A
M!8(V7WP9 K[MK4ILV6I'=;>J,W$H#:01-3"1C(O-41AW!D[ZY2%>T[H,I)<R
M_'I=B^(/E\W;/ES1YS?7[[*=%JBT& Q+_]*XP!"!SN$2H,1P VYFGKZ*GV<1
M$DG=!B65M?+UH&IC!FV!]*+4(S5\>R2")&SMYBTEA#U3 M-%92#8QS9?>AB"
M87ATFPA+G"'/K&%Q(PA=F;H^T521\Y2%[D5],W+3C"FBXPS.)H[,6KW^GE2S
MI\CV2QSI3&5FJCJR<-(!U@U/;"2L%;!CH:*:7SO^&/[E#.@^ R'D(5])I/EP
M=>@5KT-4K3*_4\U:X@$?W^B^\Y:-FE=-.!U^8>%VW'+8 3#N%38"ZH)+8LG_
M.IQ%Q&+8^):8+MX?&Z!B\O8GMB-$+1:ZQWFLYHC/P@#),S+G18'\AH:9 BX'
MJ\]7(2MX3<[RC2P6S]*@!$;.;8-X'1#FG?&!M[$"+H0;(T553\!7LV:&3/L;
MWQAL<A0;HZS1;=5P]A?F.%L/L88A-= U*;*#M3?7W.ZF_&F@B1S4&8\O\=8X
M7Q/USE@L9"5BWQZQF7@B__7Y9%"H%QD'J( 9_&Q'PKL)BV]58-8BQ;BBD29H
M/\\7RY>GS0\W>X5$^)YXE=+]Z<:UQR_J\9\7\I[%@7[>C_O",*%&DZ 1+&$8
MM:<+RE^M FW+F#J_G :\7K>*.W5*^2EG6?\43S#JFO45B,[!*(T4> ;;:EU=
MGU*D(0'\K].'S!A5-E?/4Z$,>0@%YU\[@M0L+:\K, XHU.'E7;7S_MDE."@F
ML..KZ!/^,T_W&^:"Q]XK]1MHLY$7!]3]VMJJ@1*P5.;[=;6@N6ZPNN70NN6(
M?'7, Y6!ZLHX3\9#Y1=?)N=?W!![(-OP%$U\B:E01_4%$FJE<&L"+QP8QQH>
M]6R#N,N?+UR?P-<K7/.1EG>^;14UQO_P:.>1C@-[N*H''14"V%2*,^-+64*
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MB,G"&7]P74+@/@(++!$80WB%E9!'7&!)QN* .(HO<&2]!PHHI=>M"E&/JB5
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M>!L6]P^N6,NYA8Y^SELB$ $21<](<@L#EC>3?3:M'[=<YP0[7GHZR4PJMS[
MA"XS2<,R!"1HUA$T&#-]K5K%G$1[3D(+(/"=]XL2&;XOEFXBLWGMK1M"&FZ/
M8-]_\)+H<"MM%JR^HE0&*-'E$.9$FW@#6<1Z!Y0?Z5SL!1&H.3&"-'Z%B+ ,
M_V9:_O^T]UU1375=N^$%I1-Z58*"@-*4(BHE*-)$B%(%A* H182H"(*$1%&Z
M@,(KJ"A!BHB 2$=:Z%$1D5XE#<$29,<2MF8GG,TWSG_SG^^,\9US[LYX+W:N
MDI6YYIIS/L]<>ZTYW01P<G[?;LAH7=RUW?:&F)#RK;/-B(-<0>@P[QY_%W^
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MV^(KP]1W'CF<?N11>85;U^YJP(\ONI-KQ1\FU:XC4LFGT$DH6<+V,+(D'J/
M.I!U^P\D=_3V@GY&G+RWL9_IB#[#_D/C=Z3NL7I%!#3-Q@Q(.CCPKL$!F"S.
MU_QRGBS9[LU<E8 9TL4=3,8DPUFAF3_4^%+G8ZCEE+$\,9>G<B([-[L*36OQ
MW9MMM$+B"H!9"=9R"1%<ESD_OP5CI/&^LC15Q]YHL2'YPUD?E48[EKU@T[$A
M#! ,>#<CB+2')-D&JZA^HL3E;'TP>"Q@PI8::J#.%)_U'TC;97IV<?;MR94[
M)5H#^%;F*IF61*S+SDCIK<R^152S/A#+7Z/C4K=/0-N>@6V,7U!^3,[A(EM5
M%X&T(H_ FDY!^;<CE$X'F:)CR.V\NY:># SLY8 O<4Z/MIR*/C>LC+=B/[E[
MD6X.+*0]]OGDMO<Q_6G#W3T-V-D'$?/)^\I?YGC+&!?%?^]WNA2^@#Y= ^HL
ML^*Y2GX0'G2AUV1T;F<_(3%YE[!R>-\1@L9\V&A8*W[VEHE93^J*?G5$-?.!
M1,/MVS%]+W)D5,R-5@;A%?7BI1-QV2@PG&G4]Q0?1,>A8EU?ZS>04K%(R-NP
MH%KM\+OILRW;,?LDAU(NG%&;DQ*4OAJ?#>X@L2A(UI6+7"DP $9"5:7$7WZ3
M;6R7=W<9<<1&O)/I/9/.QPF[<\)S]WC(GKGV6;6/>-FR%0%]@S5]=(A.G/ZQ
MD>$,L^ZR1S$*KX'XOML;55)8<I6Q0W<BMC6];,E=::*[G@QPBO1<"0B6%?>K
ML'8LA/J(H7K+Y#G8G*H!.0X$D*ZW:W)MP/S^)71*Z_R!J10<M+^*\B3 H:)?
M_=4J'MSN[20?J7'XN/G>E?L><]\*%=Y_LS2C#QHA/X#9QR86ZYM/%+A/^.Y]
M^7)V3Z>MZO8\JU?'"SM"!0_]SP-9R)W@2P851GI[=L8,7AFTH[N$'%9DWUN-
M3DA863*6^5%A(])EA;RZ1*2?(G;;D3]]V&B@D729!+G$?Y07H!&!%V1:,?5G
M)!\!6VLK9H/@G\ "QW%_S(D((MU?9R/;^>WY*\+;Y7U#VR/<B8ZLV=%W'Y9;
M6^Z_N&.?[O,H.Q"AQ=,5I!F!NMB5LUR/6'?Z&!X)EM%PXK%7L8JSN7J??.?S
MO5%G'-3&$Q%VMS/OHV.%$=&:]$P=S_$& [<YOY'5,TUM]2U.*Y';SUNZ:6[V
M=I].%$ =626'([-]\U<TV51_L.SRJ$%9/^5.B=_K=82^?LF;GGLLQ]]SO/*@
MA?:E:^CC! '^!+EIF0+C40Q6FH^"E #%LA!-L_8?KQE.@;<Q*"EU8V0>1F(S
MYLV;@QI3,+"(B_/%8*IKOTI#0GH;;4_"%]&@%G9EZSI"C,K<2NDVDL&R1BV#
MLE_$97[O?5KT>\_G)>UC:_K;%?Y<M%$7_C<#A,)Z38)9(YRYEEP!A/D*HT2V
MV>K?QX3W -F>8$U5['XC@@GH[3S26']1(V?0L=-<.K7[M_)^Q&)622/A(K%[
M,D;F"[D.QUHK&XRRU(OB^L>Z:3^8C$GWD#Q5F?CJ:^(MD]N]MR_8$8J]WV&;
M4R Y.9H1)!\I*>C(*X4BF/<O9XN'7PRW1KV'T#5/2+B0"OM;:3$2QW[7Z'I?
M*/N0N!KQ^,J6:W@9K@MD])Y(NX<&3F2GD!J]5VKCJ_"^X":VP./W>'%F=KKO
MQ+M&H^YA.6#DWL+GV7T1W\1P/]ZD'#59105K8R_ O+XBW07V2D>PX***1$9U
M;-A:E@UVI<TPZO,P]BI7G)G/2@)R.46\>]$U,R:</.?5K;%!?:I1ON>:5><.
MY>= _#/NPLWI.YR* S.WI%^_85]U9:\331]-RZ/6PVJLS>K@"N /L1VR\#B
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M(F::Y5\.Q*=<*G29?+S'@[K-P-#\FWT6NJ&1".ZH80U0A0GJD H@N9H!*44
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M&_4*'D6Y-S\RE/6[*&TG(Y$H\LY%7F!]YG\ 4$L#!!0    ( .N <%8*JAA
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MEZ46J!+SKLBYG#'&!,J$@#33'CN6^B<BM24GTH0'5,5AE IK9WU@8:?&;8V
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MJ2;INEFJ6J_JIHUF_KXK?I'V]-GP)-2H7P6_0+XF?<^C7Y)KO9_DL)MM35B
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M#L;IQVV?Y>H]+;_>%<MON9#BW<MOI>G9_DN^H NNY[_FJ_Q;W=$[2WA HS2
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M!(:49_KYI!02A"(HM**)0C@4+'7= KP<UM$V\P9 U,Y6O 2C-]AM&W]K[11
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M Z=9?6*S55EE[*8H-H_5+GBS^?VWY=PT8[=DOINIU!_LU^QQ\SC%9I)CB$;
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M7$N%4YI)FOK,+<_V-#9"L$4%[!&<Y7QNCVYM];7^M!:#TF3/G>3S(+M-0(-
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M]M*>ZF+$V*CG;VR^J?9KEQJ4935+V^L\(3_6Z30H;F34-]0]<]3.?/.4[XJ
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M2AEVDJ7M3U:^2Z5))'.!.1)^@H\MO8V-<';&EIN:\/,"U/;Z"C&V0>Q&/<&
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M2".90,0XAE2;B0E),",LQPSK?/I4&OQCS59KM^G)53;Y4,JA93VN'9]+VY\
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M;+W:0N')^+S8W:BVHZWRAZ:?]7L=++='W4!ADCJ(^X6!KSXO,\%)@6()9%G
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MT@12'@<PB6(N@R!-)7?SPV_K;6K3MA82U%+FKJ7$VZ&U/'OT!=C0)XRUG.
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MFYD]PY1&',5<4Y_23(@(A0R)"%+"69#QF#*>N&5^.-.3R]P;)YF#J26]J_L
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M29;*R-P_48B$9DJ&F-3;N33 0H0TP$YFTX7^IL:8^]4R.P1(7T+7SG[RB-G
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M!K9*@)T6@]PW= ?1D[7;08!1#>#N !W:Q#U:ZF F?Z"K9UFLFQ*Z]7D0CW'
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M&E!,3RK9I>4XX90T($D(SA.9."<>=PP!#5YH7*F.M7'V"DG-F$[=H:RF4!K
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M'XZNYI &E"9F0NF%C>8^D4(DXJ,51*!6C$E8+D7MZK9G2%D/.S]4^+P&TYM
MSQ\P_/P%*=_#A_K/<'1U$6!ZG!\54]ULCNA,CIR7NIHRR2\P5*DY61*#1D[:
MG'*N7?F]$8'K(>V'BKYW)Z"6\7>[GQ[7]%GKP 5E2'1)E];(MBQ0$0X!)#<V
M\^IW@AN2N!X&?ZC(?9="^L'JY?;_MG?TV\'9X='!?WPZ//_'PU7L5C2W^N@N
M*^=>7$;]AH@O='MUI@Q!3^6(S&4,<:FMS#22D%0R0D9#>?6\M'4(V[W7]>U+
MSA>]]135F5)O"3#<%U*B81"D2B0G%ZR+-AA5VXY_2$$S+0XK8>%Q&^JM^=U
M:.">^AN.[$\N+B=C*'/9O@W+C#^-/HAQA%$*)>*6B0_>DQQ3@*25K%_\]B)!
MC6!I"TD_!YJ=V=X AE;6\'YRX8=C/(L]=38:8BWH&W_6*OPRQVRB#"F"KXV=
M)PEI!#.["WK5$]R9ZPU 9ZGQP>]0C+N!\\DH(W791HI(%3QQ3&N2F!?6>$5S
M]42J1T3T"YD*@GV^O<067&X )L],S[I=C'69"2LEH5K@+HH&=Y%+@7CI/,O.
MJ0QO-+IL _AT=@E7'S[UN-\ E%:'9MVN@MKLI+>,I$ ID9PAIQP(0H-D"HU
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MR,X1+3WZ<@(H"8YZ)#KDI%4R*:P5)\2G+AD>^-5WH^/!"WM.9^\RXKP]8UM
MPUU#?!F82E:3R+Q#7XQ;$ACE)%#%00COM5YKI.8Z>.@S2+>#L%;%O07G>A;X
M[\-QR?>[BQ!RD;C5EN!* RD:CSB:-:&)>:6<$B:O-4'@%9$_>&G/0M]&9),:
M_.M;\#>)GK>$ XU"*;[(Z91(.,,#BRI'LC$4)#5@_5I9D:\)?OFE_>C_:H+?
MFG\]"_[X3_1B9E^&ES<]H(!R!J4-1PI%W5%'\,!#[6?P9&/!:U!KE2*](O@'
M+^VYPJCK@W][!K>"C%N#.#AF0+%(8E)HQ8;(B!,.OU02<9V,CJN^X6[8Z/-B
M>$?!/27^+;C8NT.('\[^\?M-QMQ[^#I$Q^8(?=PPV9]\G*=;9:<L*"G01P)7
M'"5C 56F3D2'DN?(11D]L)Z3N,[K&L##-I*<=,K6!F+8SVK/C_=YM3GD"#%X
MXH*GI?+;$!^X(]&"4PP,VM2U"WM>IZKG8L->$YVV$TT#8$,S>S)=M,8H=7&S
M^?W6O,W(]Y_AW?7)0@*#[*C67@;BC#-E'SF".\B427\N::<H][7S8C<@K]%$
ME"V1L9HJT)&8&D#@WF@T^=./(WR83-]/KL(\7XWV8BQ!X-DI1!A^76Q;,$%E
M$)H8CCZ 5"F6OCYH1$CKC4\\LE1;Y:U'6:,Y*G5PUX%P&H#<LTS[- -<X,=A
MA@$U#NT"'8EEI=&JUA;WDT$F<FZT<T8X_6;)Q-_):C1_I0[8:HNE;Z,?UY.N
MXOR/4ODRGE\/@G>03$#C5AM)).6)A%PF,^,V$3EQF^EZ/6]7'MQHALINH-B9
M@PWHF;WT%3DSG*%'<O#M$L8S&# 1-;,J$<45.K_!:1*XH$0 _B]1+:.N/;#H
M,16-YJ!4.K)V8WJCY8+O#\].CL\.SP^/CXX_G/_M8/_X].#=I[/#HX.SLQV*
M!-=Y;(W2P(W)KU00^'XXBY.237 %Z;8?T61<DI/P!Y>3F1_]-IU<77XOO4I)
M2Z-M),&9,LP\,Q*D1"U3>,:5X!EJ-Y#:D,1===)-)[#[JK-W?E3,N[,O &4O
M[J6T*-#VHT+6:#(K"1COKA^2@H\87954^*=)OW&SN8F1LL1)4$&5'L 9E;;R
M1#/C/ _>^NH9=V^TM)X'#72(Z%55VB)6&CC6;QL;H+L]ORX=:&?(Y[*8=]?+
M/UG$NJV!X)+-)"0/:*X*ARMSG% '(09KJ<NU^[>N3UV_0&X27(]:6G0BZ<8P
M?!N%%P9B=FAO<9D%D<BUTD,F$P^"<2A9&[KVI+K'5/2+R:[D_0*LMF!^WW[M
MV?7%!<RGUV=7T\_%S,-M^->[,A-NF8;2M#V")Q*2)M8(2:@%40SWQ%?UW7--
M3YY]1SL(V49TD_I\;$R;+.V;Q4:AU$M1"GVYC+RTIL)%<2I)\NBR6XN>GF!O
M<P3VGQOY Y]Y&\NR75C>34B.2= 2$(@Q&2(52[C'J"8A!Q>9MMY [>NL%PEJ
M1['M)/;UX+2%#/H^]@Y&$.?3R9VVOMV6N-V*][64JK[O2TW=30W4\?P+3&^C
MF+.SJ\O+T?7J1#>C@HS!4:*U* /B8B0.&4JBT3GX1+W.>JTCLQOZFD3E-NB9
MM"7*!M1C]Z?14D372%VFE!%&RY R&E%*6E#BI-<*%8@%N5;.>U/AH(\;I;YT
M=BWW(U@5K6*M@6VXSJB/I&/(3AEDO2PYDY(3KRTCH(/VQC/E>>TX4O/35YJ%
MU!:C7#:1;]]VT!Y2/'_4D_,<IA>#DF99>M<1R0,E4J+)&!(>S0Z7E[3,22J_
MEBWS_#M^=@=N-\S5%% #JO$!YUYFW"E\!?S&P(7$L^&*E'%O1.H Q*;%4"2@
MAGGN@NC@!F]#*G]V>Z&.XNQ8^C\6ODL;[=EQ_FTR2;.SR2@-2C*[Y\A97OJQ
M2 ^2."\\898GAZ<&BZIV^&('<OO-4?H)$;\3'GXLZ-\/DKK/Y_&*JP")*$-+
MEW@ XJ@HF8"1)>^0"7:M:MINH+]*;K_95C\A]'?"PP\*_:4!?I+RD+($DE3I
M-LFI(L%H6DX[D5A.UK@>%?^VXQ4[:V3T,V^ +5&QZV2]\TY3'0^/S@].#\[.
M#X_^[1@___O!T?FGTX/#H[_C]W['+VH,1]CX'362('=;6*6,R*/)N  *"1HM
M '133W2?+A9"-"Y&2YCF""/O([$Z&I*=8TD+-"-<[220ERFJ7>!V$\K4+$EO
M!2/)>C26@LK$N22(D2KB9J4LA.IM;I\BI-\(6D4LO%:PMCG;6ZG97]R ABS
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M6YCVC>\==SG0ZG"]!?C<3K _'*\NZ12-S ^3Z9]^F@9&)/"@';' T9P,7)+
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M L2EPUTJ2:621.NBL9V)'#G7/SQ"!]5:%\#\X4A(G'P3U 82DZN)6(S"GB)
M6$7AMS62-V]+N]<Q/-B#X!&.X5UD?N Q?#Q+ UX4U0N2=Z=OC@_I.__ I[2Y
MRGF<N$9W,V]F7XB\^>+KMS>#M\GX@@$9>@/.*5-=+@GHK:KL.Q$X2A=;SXUY
MA)S#6X2M/_H4__H=:R\T/%].BC+2U.%2/@=?/4I1YRF0 8S19%-"3*FU^7B0
MD+'[#[5!P8^ML@Z5>0>1WRT3_Y@O_O5FMNJ!5%^I4@B2A4X@A:V#HD2L@WT=
M,)XQ2B6YQ];)S8<I&;N-T,#0V5_J/6'GU^ELNOR4TZK)Q:2$5"B,E?79R.H,
M#N"#R,"3D](PYZ*70V'G.TK&[MXS,';VEWI/V/EM45_%!_2":,X@$Z_OC2+%
MD()'"$9PF8B9$-JWG;Q+P=A];P;&RNY2WA\C\TL\;XN1/_'\:MT^:ID77_)R
M(JP5V7H.2 $>*.:)DY!J*9E$6U)T7 YF8WZ@9NS&,0-CYS#IM^YAT0!.)YDD
M(UQQB6AF%A,H8QU@B0I8%G7B3O$DG*$ 1.N/W6IE8,CL*N%FQJ9M#/W^]-W[
MX].S?QZ=O#[^WW^\>5^K#&_F5\]OYU?CG=%X!X3:^R_6(B)OQ&JCP'WCZ,%;
MF"I4+H3J&T=6&[%J<G>4BY!4**FHB,D_V]C75D'\UJ/10]0I^"B!9T9Q@HT%
M@K8(PJE2G)7.XU;-#79@?EO:.IWNO1=N[INW0?33@2^^D9M?OI[11ZSJP**1
MHD09P;H<00E?&](Z ;)8F5EA#%GK$H,MR!H7;</@8=MARWLJIV>\58;6Y6,\
M9-JAW@/%K:).*J^7X39!%IP<$'2%Q];^V19D=6K=]H7"ME#;4R\=0.TM>2SK
MPD&&%)L$D@S/A4(55D@R+EC04DM99$IANXY .R#JV^J= F=?Q<Z;2+D#?/QR
M18*;SCZ24&Z^?'/Q>;&^=5S>=,-)&$N1 5@2&510#IS4H@Z\3L[0']&VGI&[
M%6'C)L>'1E5[W70 N-\QUH9+BZ]W!7;3@<(6'H*U%"+K&GI+#T%H!]JCMC;E
M@+KUF?<(.>-FSX<&5RL]= "I7Z\6L]6D$F+EU^G?]:N;S8%8-/-:0N2BEF8Q
M 2AS D\[(['J>S9_K+R9FG%3[$,#JI$6QNZ[\&I^\;G.4KL5#QWM'^;E\B^\
M?8&AG7 ,LP;#R=@J6Q!04%P32W8L,!_%_=K@32WUGEQKW,SZ4) 90M =V*&W
MM5+TT_P\U2E\MW]YX,@FZRJB-1D81]H/$<E'S(:#L2HE3+)VP6[MB6])V[AY
M^<']]"$TU 'RSN;S\^7KZ_&/OU?VUFPH5 I%(;K1K-J@&D!N$J +)5CA9!&Q
M,= VD+(5KNQ+Q54+^7< HXUB>OMM<(#R&GWBP+'V[.<E4WBK.:20HBPA\6@&
MF._W!%7CAH'C9D'W4TW/8%N7:JA<1/$6D'9E[=7EP6NO(,BB:X.ZFEYY+J!M
M7R#S_!FL/?6_+;QV5T8'T#J*\>KB:O4B^W4F(N)TI2?Z^CRO%#9+1Q?SQ>7T
MOU??W\C\A&F,)B '+!2S**$*4&S,H$BIBQ!)4133&(2M:.\T-=8&KJ,H>/Q"
MGNO>=/GR\YJ?SY4?"IOR#3_SLI[!,YU]I.^G.S-YYK=3@":*>2-D<""9JU5P
MM*^=\ $<9SZCX$6Q>P_O-S4*/)243E-LAX%T!"UU4*NXPU2HS=M1.:.*+9YX
MKET4911TSC@-W&N>N)>F?6_!%G1WFMAK8VN?7;%=O$3<R$JM[/.H2\BZ0";R
MR1WR#AQ&#4Q;98L1EC?O:?<8/9TF"0?V3'=51 \V\HZO,E'D8V#&FA&HS?",
M]&3?0P2!.9688O*R^6S0.^MWFNAK9+/V%72G34_?'A]]./[08I[@AD]J44&[
M#9&-RF-7J=OEM_EO+ :)18+5@LR 1@4^,@N^!,F0J>Q"Z^X$WU-PD$/_-B^7
M.:\.U*O9Y2F%"JNN$ZLKD?-?YHO%_"\Z<.OW)RJ;Y)DG1I/5H**5@"(9X*L4
M)<_$:]S*<]]^S7'3'@<H^CMW?" 9=Y#KN.9L):?7>1D7T\]5-]<)1Y%](J$8
M**6.]7 JU@YB D24TOJ@,(76R=I'R!DW(]$ 2:U%/O+$P-/:+7I5,VF<-D$S
M<IYR?187> ''Z ^O@A"&6>G$5A,MGI@5>+O@V#:ED?KFA\JR!P#<W%1I=*H.
M%6)D]D"5$" D'T [[EF=#RUPJ_[5VT!@[-&!>RKKOKKWD-S("O]].IM>7%VL
M";>Q%&XSQ>3*KDR@!0S.0S*1&ZX51[]54><3*O]NT9&5OH_*YBWD-[;B\>\[
MA$?GA?.* <_DW"B>U?7PB9Q-1DED>[?56_.G%']WT7$._V:*WUM^'7B(V[R:
M8$%9ARY K@UG54P, J('3M$R<UD79,_VVF3'UTT#>HQM_82A]-$SQ.[4UV!*
M/(?(@=5.QBH71N922.++R4A<^=)\H,%/\:!I)RCL\:!I%[UT +4?RD9OWMT$
MEX4*"DS,)"9=^_2S;$'7?G4VBN)$ZYK*#:1T"JE]5?Y#:_K#Y=\!C&X>U*RI
M]TE3P,]H:Z7:*3,9!XB99&-\T,A0^>85N=]3T&FY1B/0'"#M#K#RL"/P[:;"
M&%3U(0.D6NJI+))DI-=0A$.N+'F*H;7S] 1)X]95#.4XM=3#V,],=DA(1V&3
MR3H#+[G.90X%/*M5Z48F%C0+QMR#UXM/^C?4\YZW +L(O1L3M2[$F'U<R>XT
MS_)?>'Z6%Q>3Z*TS$3,XK/WUM7;7N0I6HK2";#D%Q8.8J(TD]1C;'0:Q(731
MAYGZGI>3JWJ(ORO7-RK'ZQO=B1<:>; D*%=[HIGZR"\E4;LO9&]-C/'^*?BH
MF=IFS1Z/N69FJKG0NS%3OTYG=6["BI6Z(]Z5U2AEC)=\8C7&5)/Q&26%$3)Y
M"!$5..O1!Z&DL\V;5#Q%U+CE?<.;JE;ZZ+IX9L7=J_E!8X W?%*[XIG'B1RF
M>*:0<R.8C%!2KJ-8*2*COU-L9I@SGB6><NLW@FV*9VX^[7M#6:4W23H545(
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MP!A V'L3_#@%>X1M<',*K@_1+S@]KW[MK_/%;_1O+R<\2<ZD)R.0&,7VS%M
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MAE)8EVGZ8K@W#,DKC!:4C I\O2D)*EOM*0BC@ZS?G;%+16]WGDU#9 ZW6?:
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M)(I4N"UQJQ*]IQ1_=]%Q;E>:*7YO^?621]GGKN;M[8 8LH9&!VT@>NY :<'
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MW;GD*9K&=8;;(N!)>!V@C@[@]0'/\W)]^WR2;^MYLS+)9 -)*U_[!-4.J"X
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M"#HP,7"O4NOA0)MH&7D*[($Z?A0R>PI\[ ?>KVB]Z>71QT7.=]JD%"%DU$:
M%;51<"J)B/<<M' E4]AJE,*G_)+-']\3"O95V[RI##LP'V_GLX_T:1=5/+?Y
M6,&BXDR02((C3ULQ#R0%"@5=YIR7D"@6;&PZ'J)CY!BH]5ESL*@[A,MZ#XF$
M!AT9T,Q]K!W&'01,KD[*SB&HZ()M'5,_3,FX-N9P#3\!F3W$W0-HIK,Z@'UE
M+F]FUT;!K$2*Y86I+U<4IQU5.PQZEV0I&;UN?8'_(Q5]@64?W=Z'RV&"[@ J
M]XWNS2;*,7B'9&UEJ:^GC+. V0M(CCL>C>*J-&]-]3 I(U_4MSZ46@B\3]S<
MMO@I9&Z9A83JIC:\EG*R9'BT+!NOADZS='(Z-5'UT_#90^[] >C&>J;L@D@6
MF)<D&E:?.I4ZV%%K;3 6C*[Y?>A#A'0'G'V4_#AT]I!X!["Y/FM_Q;@:!G7M
M[\7(6,IUOII1H H&0,,I"I19K!JWI^U>>NURF_D#%2/?F+<^I0X4<W= 66\?
MYE(J*6M 7P>&U>G+])4'Z4(63@DO=&OS\A =(U?P'*C;1Z&RAZ [ ,N''*]H
MU1H9W+2_UE8;P2.=S*L17MH *L,AE8#!2"Z3;/]>^QX1/<%D'[W^4&9SB) [
M0,EI_C(__S*=??Q>-&MF;.2H7&90LF:@$"F.S)H,K_;<&A^B\ZW3_X\2-&XR
MKSEZV@E_[*N [Q/CK^9T8N--UV.O,A,^<?+J./EWFOPR)Y@$X]!&CPREO-=]
M:L.%P".+C-P*J)6KTE26G6+BYFVE*L'[1.A6M'G4=0UL$%#(>"IM$B.L'X**
M,;V2MFK< AM[R+1/=)PM<!8_Y7>SO#:"Q@N6D^)@5"263/7B$K>@N8A<BN#-
M0<;C_GK]X64?U3Z-F(/DW#5TSOZ:W[ 41&"%!\B.DP$.@8%'"@58DH%;S"::
M[2ZBMUMO'-]D-.CL)^>^H4,HN-D/(F/D! 5@ DEHW H(D6<0Y-;;S(+DV38
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MI7Z^>_QH^T;Y$:C!CQ_]#U!+ P04    " #K@'!6$7)0?#P#  "(#@  %@
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M5EM/VS 4?M^O. O: *EIKDUOH1)K04-KH6J+JCU-3N*T%JD=.2ZE^_5S[+2
M*#Q-#&EYL'Q\;M^YV0D_#V[ZLY_C"UB*50;CVV_#JSX8IF7-O;YE#68#^#X;
M#<&OVP[,.*(%$811E%G6Q;4!QE*(O&-9F\VFOO'JC"^LV<0J3?E6QEB!ZXE(
MC%Y8GL@5HZ3W*?QLFC!@\7J%J8"88R1P NN"T 7,$US<@6E64GV6;SE9+ 6X
MMNO!G/$[<H\T7Q"1X=[.3FAI.K24DS!BR;87)N0>2')F$-=IVVT[;<<.<ORX
MA5M-ST4-'P=)$$5VVOCEM21*2\IKI4)L,WQFK @UE[@$T'%\/Q?=#4G$LN/8
M]A=#"?;"E%$AW7&IK;?:R M3 C\($V5D03NQQ(NYH75W_)AEC'>.;/5U2XZ9
MHA7)MIWC<TY0=EPK9/+- G.2:G9!?F,)1:)2Y$;C;$KMC%"\QZVP]ADMRFRS
M%*YH@G,L%TE.\((4$HO,_W@=922&\SAF:RK*6EP2OGH>U#[@OPW:/PCZZY$3
MV-W_'<(<0UQ53S 02PR$QHSGC*-R$B': L>IK"&-2Y:2T'6M!*9"#IB:-4E<
M,KXJ=%13LZ4W)]>LKG>>YYENH]6V6S60AZ!HSVNW_2>TZP:-YA/:;KIV (@F
M^R.GW0A<_U2=E0YA:GIPLE<(6@W//2U[\3S?/L ()R1&F1SVQZ DCZVY#$R>
M"$C4#3%"/%Z"$]3495"3S RI1JW24F:)940+IX0B&LODRR)5X1=O>:P!RG.,
M>&E/)9$4<$[I6DI--(@J>>#8YH\WL:>,*SQ;:0[*04M@@&.\BC 'SU'HW3J\
MTE,'KI)W;WF_V2W4"I/I"&ZG,!R./RS<&Y[)-F,UN)1>9/'_*9CG+?I:C3_
MU76X;CM@E9VV76^ZTE?.]*/?T1-WCU\\@SO%B G!5AW[405%<B;7XG65]WH7
M#R?).?1J5ZO^A5 _,[T_4$L! A0#%     @ ZX!P5MY9S*U3"   CRH  !D
M             ( !     &$R,#(R<30Q,"UK97AH:6)I=#,Q,2YH=&U02P$"
M% ,4    " #K@'!6SO>N@4\(  !_*@  &0              @ &*"   83(P
M,C)Q-#$P+6ME>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( .N <%9'EE"-^P0
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M,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ ZX!P5A%R4'P\ P  B X  !8
M             ( !U3,' &QI<W1O9G-U8G-I9&EA<FEE<RYH=&U02P$"% ,4
M    " #K@'!6OL9T . "   G"0  $@              @ %%-P< <G-M,C R
B,F-O;G-E;G0N:'1M4$L%!@     .  X K@,  %4Z!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
